Clustering O 0 8.541127272110316e-07
of O 0 1.486293115249282e-07
missense O 0 9.292691061091318e-07
mutations O 0 9.722546323587267e-09
in O 0 4.317152857424844e-09
the O 0 1.7818499031818646e-07
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
gene O 0 3.639433430180361e-07
in O 0 9.280433310721037e-09
a O 0 1.8643191879164078e-08
sporadic B-Disease 0 3.978329459641827e-06
T I-Disease 0 0.011902733705937862
- I-Disease 1 0.9788016080856323
cell I-Disease 1 0.9999983310699463
leukaemia I-Disease 1 1.0
. O 0 3.3557596907485276e-05

Ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 0.028797144070267677
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 1.7358649628818057e-08
is O 0 4.447086310310766e-10
a O 0 5.978949002560796e-10
recessive B-Disease 0 1.7623198900196257e-08
multi I-Disease 0 3.071163746426464e-06
- I-Disease 1 0.9950280785560608
system I-Disease 0 0.05559983476996422
disorder I-Disease 0 0.08963426202535629
caused O 0 6.884064984724603e-10
by O 0 6.922228415473519e-12
mutations O 0 3.2725700621627496e-11
in O 0 6.717247591492281e-11
the O 0 1.0156616658818507e-09
ATM O 0 5.2624418458435684e-06
gene O 0 2.5454580665495996e-08
at O 0 1.0856513910084686e-07
11q22 O 0 2.056056291621644e-05
- O 0 1.0185440260102041e-05
q23 O 0 2.5945795641746372e-05
( O 0 1.2625951839595473e-08
ref O 0 7.779003112773353e-07
. O 0 2.5110649115589467e-09
3 O 0 6.855991330212419e-08
) O 0 4.527758079575506e-08
. O 0 3.582052556794224e-07

The O 0 1.7429421461656602e-07
risk O 0 6.994613386268611e-07
of O 0 1.3309239932368655e-07
cancer B-Disease 0 1.758256257744506e-05
, O 0 1.7291161835686353e-09
especially O 0 1.4420225014077914e-08
lymphoid B-Disease 0 6.083300104364753e-05
neoplasias I-Disease 0 0.026960857212543488
, O 0 1.0790937032822967e-09
is O 0 2.6269269745582413e-11
substantially O 0 3.770976864103659e-10
elevated O 0 5.975121730728006e-09
in O 0 7.440099092370644e-10
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 0.43213507533073425
and O 0 2.2015356204718728e-09
has O 0 2.586951486360789e-10
long O 0 1.867018067924775e-10
been O 0 1.8715783089984228e-10
associated O 0 8.911769655561841e-10
with O 0 1.2016138084547379e-09
chromosomal O 1 1.0
instability O 1 1.0
. O 0 6.314977781585185e-06

By O 0 3.4741290733109054e-08
analysing O 0 1.3722757330469904e-06
tumour B-Disease 1 1.0
DNA O 0 4.1326723021484213e-07
from O 0 3.149220439979672e-09
patients O 0 2.1823167717371916e-09
with O 0 2.1093944299610534e-11
sporadic B-Disease 0 3.8564181181754975e-08
T I-Disease 0 1.480030164202617e-06
- I-Disease 0 9.899533324642107e-05
cell I-Disease 1 0.9999998807907104
prolymphocytic I-Disease 1 1.0
leukaemia I-Disease 1 1.0
( O 0 1.3132974174823175e-07
T B-Disease 0 3.72540625903639e-06
- I-Disease 0 9.150227015197743e-06
PLL I-Disease 0 7.274145900737494e-05
) O 0 5.486993082115532e-09
, O 0 8.358987946266438e-10
a O 0 1.0553277141056583e-09
rare O 0 6.7159477978862014e-09
clonal B-Disease 0 2.2317070147437335e-07
malignancy I-Disease 0 5.390676847127907e-07
with O 0 4.732912325944305e-11
similarities O 0 3.9038375310163076e-10
to O 0 2.7299063010133295e-10
a O 0 2.8096855952952637e-09
mature B-Disease 0 4.7427878513417454e-08
T I-Disease 0 6.946504527149955e-07
- I-Disease 0 1.7032813275363878e-06
cell I-Disease 0 9.993642015615478e-05
leukaemia I-Disease 0 0.3916088938713074
seen O 0 1.540314986669955e-09
in O 0 3.7898398308477965e-10
A B-Disease 1 0.9987279772758484
- I-Disease 1 0.8844531178474426
T I-Disease 1 0.9999997615814209
, O 0 2.692849054852786e-09
we O 0 2.178418972986762e-10
demonstrate O 0 2.954256006493239e-10
a O 0 8.077903623782134e-11
high O 0 5.554528503814993e-10
frequency O 0 5.352980725348289e-09
of O 0 3.8806104996069735e-09
ATM O 0 6.293064416240668e-06
mutations O 0 2.1047161169462925e-07
in O 0 1.0070205007650657e-06
T B-Disease 0 0.4765683710575104
- I-Disease 1 0.9252031445503235
PLL I-Disease 1 0.7270349264144897
. O 0 2.9723467378062196e-05

In O 0 1.546108485683817e-08
marked O 0 5.810804726280594e-09
contrast O 0 8.004412688222828e-10
to O 0 1.661846771305875e-10
the O 0 1.6117127077386328e-10
ATM O 0 1.3617521688047418e-07
mutation O 0 1.070075472675569e-09
pattern O 0 4.0836556358669895e-10
in O 0 2.2642179242637894e-09
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
, O 0 1.0645043957424605e-08
the O 0 1.6037682293301714e-09
most O 0 1.0565295166520272e-10
frequent O 0 3.129523376554921e-11
nucleotide O 0 5.021411064731751e-10
changes O 0 1.5738520209307438e-10
in O 0 1.9400887840692604e-10
this O 0 1.2556443662603556e-09
leukaemia B-Disease 0 2.370141737628728e-05
were O 0 2.818401867443754e-07
missense O 0 5.098482688481454e-06
mutations O 0 1.0570222457317868e-06
. O 0 1.8698676740314113e-06

These O 0 2.592911663157338e-08
clustered O 0 1.3741804139044689e-08
in O 0 3.139970505827705e-10
the O 0 2.7054661289049875e-10
region O 0 1.5398803343558143e-09
corresponding O 0 1.0365910352305718e-09
to O 0 9.271123313503438e-10
the O 0 3.0335303158324223e-09
kinase O 0 1.848777486657127e-08
domain O 0 2.225079009932074e-09
, O 0 1.847326736026389e-10
which O 0 2.8661373621674535e-11
is O 0 1.0867949769288732e-11
highly O 0 1.649253789093308e-10
conserved O 0 3.690865946204269e-10
in O 0 6.70144661985006e-10
ATM O 0 6.079924901314371e-07
- O 0 1.5964207022989285e-07
related O 0 2.692989120589573e-08
proteins O 0 7.235785304260389e-10
in O 0 1.4279645244030803e-09
mouse O 0 5.460727336981108e-08
, O 0 1.7730202861443445e-09
yeast O 0 7.184386419112343e-08
and O 0 4.515674945082537e-08
Drosophila O 0 2.647418568813009e-06
. O 0 1.926155391629436e-06

The O 0 1.1059664473123121e-07
resulting O 0 2.0411318857327387e-08
amino O 0 1.709631014534807e-08
- O 0 5.791267554400292e-08
acid O 0 3.203993159672791e-08
substitutions O 0 4.862655345050371e-08
are O 0 6.652555728514642e-10
predicted O 0 3.2890199008761556e-08
to O 0 9.628355890356488e-09
interfere O 0 1.8237189181036229e-07
with O 0 5.177392292665672e-09
ATP O 0 8.320718916365877e-05
binding O 0 5.065706076834431e-08
or O 0 1.702481711163273e-08
substrate O 0 9.306689463528528e-08
recognition O 0 1.7613679403893912e-07
. O 0 7.529071126555209e-07

Two O 0 7.231776777416599e-08
of O 0 5.666800007020356e-08
seventeen O 0 1.4065540199226234e-07
mutated O 0 2.8312756583659393e-08
T B-Disease 0 7.141200057958486e-07
- I-Disease 0 2.0314530502218986e-06
PLL I-Disease 0 6.267170101637021e-05
samples O 0 5.569981098574317e-08
had O 0 1.730165344326906e-09
a O 0 4.164738831580195e-10
previously O 0 3.5576606105536257e-09
reported O 0 5.935140379165205e-09
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
allele O 0 1.3730788850807585e-05
. O 0 4.4362359403749e-06

In O 0 4.795290564629795e-08
contrast O 0 1.2686445671761248e-08
, O 0 1.6483991949201027e-09
no O 0 1.7155096232457367e-09
mutations O 0 9.216220564489674e-10
were O 0 2.084391992340784e-09
detected O 0 2.843109081496209e-09
in O 0 2.791490372189287e-10
the O 0 1.3112189112263195e-09
p53 O 0 6.894055104567087e-09
gene O 0 4.516698126622032e-09
, O 0 8.938615403408789e-10
suggesting O 0 3.3251106312803813e-09
that O 0 4.785908475080092e-11
this O 0 1.916996006379179e-10
tumour B-Disease 1 1.0
suppressor O 0 5.97409825786599e-06
is O 0 2.047376157499059e-10
not O 0 1.3105531937451786e-10
frequently O 0 1.8042960181485768e-10
altered O 0 1.2755906331207711e-09
in O 0 1.5412260356839624e-09
this O 0 1.5586509860554543e-08
leukaemia B-Disease 0 0.33393046259880066
. O 0 1.761750468176615e-06

Occasional O 0 2.0492279872996733e-06
missense O 0 8.607952395323082e-07
mutations O 0 1.416777006824077e-08
in O 0 1.4524920155523091e-09
ATM O 0 5.086879355076235e-06
were O 0 4.873109915592977e-08
also O 0 6.570876065481457e-10
found O 0 9.162023223430182e-11
in O 0 2.050572905920589e-10
tumour B-Disease 1 1.0
DNA O 0 1.9041965515498305e-07
from O 0 4.346119020226524e-09
patients O 0 3.590888697502237e-09
with O 0 3.379635460376562e-11
B B-Disease 0 2.3052434698911384e-06
- I-Disease 0 7.09709695456695e-07
cell I-Disease 1 0.9949280023574829
non I-Disease 1 1.0
- I-Disease 1 1.0
Hodgkins I-Disease 1 1.0
lymphomas I-Disease 1 0.9999809265136719
( O 0 8.423540087676429e-09
B B-Disease 0 1.903172517359053e-07
- I-Disease 0 2.061484849491535e-08
NHL I-Disease 0 7.435339455241774e-08
) O 0 5.598221886060628e-10
and O 0 6.372793959208423e-10
a O 0 5.717978535102475e-09
B B-Disease 0 1.76952482888737e-06
- I-Disease 0 3.4533391612967534e-07
NHL I-Disease 0 1.9227600205340423e-06
cell O 0 8.88326576387044e-06
line O 0 6.5271647144982126e-06
. O 0 3.051020712518948e-06

The O 0 5.2902557001743844e-08
evidence O 0 1.7658662088138044e-08
of O 0 2.2772979058061082e-09
a O 0 2.9848581939440066e-10
significant O 0 2.8967120369038923e-10
proportion O 0 2.8525154460723456e-10
of O 0 8.839314280528754e-10
loss O 0 1.5989516377601376e-09
- O 0 1.5491313121174244e-08
of O 0 5.069920305800224e-08
- O 0 1.3423962386127641e-08
function O 0 4.5558903871700807e-10
mutations O 0 3.1846501130639027e-11
and O 0 6.46397779052732e-12
a O 0 7.282093678062651e-11
complete O 0 5.133497182896463e-09
absence O 0 1.41119427254921e-08
of O 0 2.1215902368254547e-09
the O 0 2.1888273138426229e-10
normal O 0 6.95179414034186e-10
copy O 0 1.1089294815747053e-08
of O 0 4.1205248102471614e-09
ATM O 0 1.1581041690078564e-06
in O 0 5.836129357561504e-09
the O 0 1.3062820158893373e-08
majority O 0 9.549943058573263e-10
of O 0 1.0775187853084844e-08
mutated O 0 7.394016421358174e-08
tumours B-Disease 1 0.9997616410255432
establishes O 0 6.847715727786863e-09
somatic O 0 5.4940851867968377e-08
inactivation O 0 5.061707142317573e-08
of O 0 4.8632187166219865e-09
this O 0 1.2615396227655395e-10
gene O 0 1.0716231374496843e-10
in O 0 5.626318508311634e-11
the O 0 6.035320576636138e-10
pathogenesis O 0 1.7808013126341393e-06
of O 0 2.1930123494939835e-08
sporadic B-Disease 0 1.4935625358702964e-06
T I-Disease 0 0.00016016708104871213
- I-Disease 0 0.07479600608348846
PLL I-Disease 1 0.9999303817749023
and O 0 8.122225381157477e-08
suggests O 0 2.743564486706873e-08
that O 0 8.886101576788263e-11
ATM O 0 1.732448851043955e-07
acts O 0 1.043713826476278e-08
as O 0 2.17696332072137e-08
a O 0 1.9454752475667192e-07
tumour B-Disease 1 1.0
suppressor O 0 0.24633972346782684
. O 0 2.1559779270319268e-05

As O 0 1.1609954242430831e-07
constitutional O 0 1.73006796444497e-07
DNA O 0 5.057441754274805e-08
was O 0 1.212393119232047e-08
not O 0 2.5604579567684027e-10
available O 0 2.703852697294451e-09
, O 0 2.938352616776996e-10
a O 0 2.182200198319606e-09
putative O 0 1.1226262586205848e-06
hereditary O 1 0.9999958276748657
predisposition O 1 0.9992700219154358
to O 0 3.386285243323073e-06
T B-Disease 1 0.8654294013977051
- I-Disease 0 0.047660864889621735
PLL I-Disease 0 0.0004245580639690161
will O 0 7.645970967473659e-09
require O 0 4.643357698341788e-09
further O 0 3.158129091573869e-09
investigation O 0 2.859816827793793e-09
. O 0 1.2686155237418006e-08
. O 0 2.5472485276623047e-07

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
protein O 0 1.4241658163882676e-07
kinase O 0 2.6796419305696872e-08
is O 0 1.2713903541072824e-10
involved O 0 2.116230246596018e-10
in O 0 1.9537690909565697e-10
the O 0 2.0966490765772505e-09
modulation O 0 1.8069363250106107e-07
of O 0 1.790311365823527e-08
the O 0 1.621457812461813e-08
Ca2 O 0 7.703436040173983e-07
+ O 0 1.2826587862946326e-06
homeostasis O 0 1.1704275948432041e-06
in O 0 3.9192855183500797e-08
skeletal O 0 1.6201574908336625e-05
muscle O 0 4.51833011538838e-06
cells O 0 1.446576789021492e-05
. O 0 1.9336184777785093e-06

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.10306550562381744
DM B-Disease 1 1.0
) O 0 8.746112456492483e-08
, O 0 1.6197261309969235e-09
the O 0 2.773331564398518e-09
most O 0 5.210202047578605e-09
prevalent O 0 5.907145350647625e-06
muscular B-Disease 0 1.3777826097793877e-05
disorder I-Disease 0 2.067462929744579e-07
in O 0 1.3505564722127161e-10
adults O 0 1.0163394431605965e-10
, O 0 1.2682459249457878e-11
is O 0 4.3793805387659646e-12
caused O 0 9.280814311507513e-11
by O 0 1.7841804422769059e-10
( O 0 2.6729229940514188e-09
CTG O 0 3.1761931040819036e-07
) O 0 6.669796381864046e-10
n O 0 2.692402301107677e-09
- O 0 7.567451554280069e-09
repeat O 0 3.178039387208287e-09
expansion O 0 3.807026249802448e-09
in O 0 4.849572410314806e-10
a O 0 1.2134258875473591e-10
gene O 0 2.8821941361334424e-11
encoding O 0 6.187808598845379e-10
a O 0 2.7366122701266704e-09
protein O 0 6.351319026265401e-09
kinase O 0 1.5903651728876866e-07
( O 0 6.944485164694925e-08
DM B-Disease 1 0.9999982118606567
protein O 0 1.1258947552050813e-07
kinase O 0 9.286705449085275e-08
; O 0 4.812991338809525e-09
DMPK O 0 1.859175790741574e-05
) O 0 7.871061580289052e-10
and O 0 2.729645953714055e-10
involves O 0 1.692402218367306e-09
changes O 0 8.113809624177293e-10
in O 0 1.7794640205792689e-09
cytoarchitecture O 0 6.137740342637699e-07
and O 0 1.7497262305710137e-08
ion O 0 2.611736363178352e-06
homeostasis O 0 0.0006576771847903728
. O 0 2.2014244677848183e-05

To O 0 6.107936911803336e-08
obtain O 0 3.6596199493033055e-07
clues O 0 2.547508586303593e-07
to O 0 9.635497955073902e-10
the O 0 6.753800296799284e-10
normal O 0 3.82855169789309e-09
biological O 0 1.629406831682445e-08
role O 0 6.415507236567919e-09
of O 0 9.692314506537514e-08
DMPK O 1 0.5487808585166931
in O 0 6.029262777929034e-08
cellular O 0 4.2002585587397334e-07
ion O 0 2.764911926078639e-07
homeostasis O 0 2.2738977349945344e-06
, O 0 5.324641172421707e-09
we O 0 2.1022230622946836e-09
have O 0 2.415778410647107e-10
compared O 0 4.3384970616067164e-10
the O 0 6.460742496550154e-10
resting O 0 5.705833672209337e-08
[ O 0 1.3519806607575902e-08
Ca2 O 0 2.291328549119953e-08
+ O 0 3.017667893345788e-08
] O 0 1.953674200194655e-08
i O 0 7.1513661659139416e-09
, O 0 3.778313217850382e-10
the O 0 2.107987950861201e-10
amplitude O 0 2.7009661174304256e-09
and O 0 7.053367334641791e-10
shape O 0 1.1737969707326101e-08
of O 0 5.2759968838245186e-08
depolarization O 0 8.258113837200654e-08
- O 0 1.435958694173678e-07
induced O 0 1.0341609169017829e-07
Ca2 O 0 6.666965646218159e-08
+ O 0 7.335887630688376e-08
transients O 0 8.401482176623176e-08
, O 0 4.0371500586999787e-10
and O 0 1.4046029617187372e-10
the O 0 4.726383173725424e-10
content O 0 1.6162018390275534e-09
of O 0 2.348516270345158e-09
ATP O 0 6.704277097924205e-07
- O 0 9.538209866377656e-08
driven O 0 8.455545952301691e-08
ion O 0 2.0157025915068516e-07
pumps O 0 1.4550417972714058e-06
in O 0 4.1049005972126906e-08
cultured O 0 0.00016610670718364418
skeletal O 0 0.0012207265244796872
muscle O 0 2.4945927634689724e-07
cells O 0 1.037343508869526e-07
of O 0 8.561089615000128e-09
wild O 0 4.209447013181489e-09
- O 0 1.3443845148231048e-08
type O 0 3.188775821172385e-08
and O 0 8.249593008713418e-09
DMPK O 0 0.0003271726018283516
[ O 0 6.578951570190839e-07
- O 0 3.700707793541369e-06
/ O 0 4.580254608299583e-05
- O 0 5.475266516441479e-05
] O 0 6.417409622372361e-06
knockout O 0 4.8822894314071164e-05
mice O 0 1.4567506696039345e-05
. O 0 1.475423232477624e-06

In O 0 3.5198016234971874e-07
vitro O 0 1.5563418855890632e-06
- O 0 6.674987957921985e-07
differentiated O 0 8.72565692588978e-07
DMPK O 0 6.27229965175502e-05
[ O 0 1.5536133446403255e-07
- O 0 4.689741501806566e-07
/ O 0 9.338230029243277e-07
- O 0 1.2323206419750932e-06
] O 0 1.4490620969809243e-07
myotubes O 0 4.141466547480377e-07
exhibit O 0 3.320078878488175e-09
a O 0 2.17942067171073e-10
higher O 0 4.348390980624117e-09
resting O 0 8.620622793387156e-08
[ O 0 3.9830482023717195e-08
Ca2 O 0 1.5958026722273644e-07
+ O 0 2.2999945770152408e-07
] O 0 7.091455245245015e-08
i O 0 2.3704114227030004e-08
than O 0 1.654945624984805e-09
do O 0 4.396913499959965e-09
wild O 0 1.7048700229338465e-08
- O 0 5.6550199190041894e-08
type O 0 7.693357417792868e-08
myotubes O 0 1.3015065860599861e-06
because O 0 5.8937477120935e-10
of O 0 8.946120511055256e-10
an O 0 6.172575645058131e-11
altered O 0 7.711375982211166e-10
open O 0 1.1614761374900695e-09
probability O 0 3.325343889137855e-10
of O 0 2.38167541244394e-10
voltage O 0 4.483207138861189e-09
- O 0 3.006258708637688e-08
dependent O 0 1.82233801382381e-08
l O 0 1.5361935723490205e-08
- O 0 1.645629232882584e-08
type O 0 2.0985424953323673e-08
Ca2 O 0 1.9335008971665957e-07
+ O 0 2.152861782178661e-07
and O 0 1.5972879907621973e-08
Na O 0 1.4744858162885066e-05
+ O 0 5.035351023252588e-06
channels O 0 1.8044755734081264e-06
. O 0 1.0170626865146914e-06

The O 0 1.3569896282206173e-06
mutant O 0 1.4302773934105062e-06
myotubes O 0 6.821054739702959e-06
exhibit O 0 7.599884099818155e-08
smaller O 0 3.2069631394904263e-09
and O 0 2.615974548092481e-09
slower O 0 1.2549249106541538e-07
Ca2 O 0 9.458929639549751e-08
+ O 0 2.5700213512891423e-08
responses O 0 5.550302994983269e-10
upon O 0 4.24958707112566e-10
triggering O 0 2.138907495563558e-09
by O 0 1.1318702919371759e-10
acetylcholine O 0 9.27385102045264e-09
or O 0 8.41393799078105e-09
high O 0 1.3649571428686613e-07
external O 0 3.1483295970247127e-06
K O 0 1.047497607942205e-05
+ O 0 8.522255484422203e-06
. O 0 1.129807174038433e-06

In O 0 3.1016284651741444e-08
addition O 0 1.549740069606287e-08
, O 0 1.1136153110768987e-09
we O 0 8.205852108922329e-10
observed O 0 1.091459700397479e-09
that O 0 5.2808316747254835e-11
these O 0 4.149942056663747e-10
Ca2 O 0 3.296692341336893e-07
+ O 0 6.761925988030271e-07
transients O 0 2.8470998358898214e-07
partially O 0 1.165113339141044e-08
result O 0 3.2409785966081017e-10
from O 0 2.002024934721902e-10
an O 0 4.35046061675326e-11
influx O 0 7.02952862585704e-10
of O 0 5.099183297829768e-10
extracellular O 0 7.468379248365409e-10
Ca2 O 0 9.818857726884289e-09
+ O 0 6.48667564107086e-09
through O 0 5.891061527485419e-10
the O 0 1.4929986136280604e-09
l O 0 7.0067756041680695e-09
- O 0 2.9281618907361917e-08
type O 0 3.192110753502675e-08
Ca2 O 0 3.9354134173663624e-07
+ O 0 9.658364206188708e-07
channel O 0 7.679472560084832e-07
. O 0 7.024856358839315e-07

Neither O 0 3.1007797929305525e-07
the O 0 7.849582317476234e-09
content O 0 4.024780952960327e-09
nor O 0 5.512420298003917e-09
the O 0 4.3781656078323294e-10
activity O 0 4.46771375450794e-09
of O 0 7.582462657751421e-09
Na O 0 2.2633462322119158e-06
+ O 0 1.3472487125909538e-06
/ O 0 1.6253893591056112e-06
K O 0 8.489625429319858e-07
+ O 0 7.005388056313677e-07
ATPase O 0 2.47660614149936e-06
and O 0 8.127742034957919e-08
sarcoplasmic O 0 4.2092746298294514e-05
reticulum O 0 3.2009750157158123e-06
Ca2 O 0 8.894242569112976e-07
+ O 0 3.7820919374098594e-07
- O 0 3.9985388866625726e-07
ATPase O 0 3.8839152693981305e-07
are O 0 1.1358307627773456e-09
affected O 0 2.010034361177304e-09
by O 0 3.5404936760130568e-09
DMPK O 0 0.0009535172721371055
absence O 0 8.428657565673348e-06
. O 0 1.8401357237962657e-06

In O 0 2.673393240115729e-08
conclusion O 0 1.65099596216578e-08
, O 0 1.4946853754693734e-09
our O 0 2.9704509962868997e-09
data O 0 5.234347177918153e-09
suggest O 0 9.886204077602656e-10
that O 0 7.290543863058829e-11
DMPK O 0 1.9254996459494578e-06
is O 0 1.4734720388265288e-10
involved O 0 2.2093799012523618e-10
in O 0 2.3456950271061316e-10
modulating O 0 8.291794273418418e-08
the O 0 4.53186865811972e-09
initial O 0 4.569765454931485e-09
events O 0 7.88515641669818e-10
of O 0 1.699797635978939e-09
excitation O 0 4.4436106350076443e-07
- O 0 3.433947313169483e-06
contraction O 0 1.2402820459556096e-07
coupling O 0 6.962960696910159e-08
in O 0 1.8145998481600145e-08
skeletal O 0 8.555821295885835e-06
muscle O 0 1.9709093521669274e-06
. O 0 4.6207162540667923e-07
. O 0 1.534665443614358e-06

Constitutional O 0 3.2294665288645774e-05
RB1 O 0 0.0004769152728840709
- O 0 9.722078175400384e-06
gene O 0 3.671049952913563e-08
mutations O 0 7.064384632826659e-09
in O 0 1.8145054347940004e-09
patients O 0 1.826555617867598e-08
with O 0 3.080765087482007e-10
isolated O 0 1.1938213617668225e-07
unilateral B-Disease 0 1.6071825257313321e-06
retinoblastoma I-Disease 1 0.521292507648468
. O 0 0.00018321732932236046

In O 0 8.47603658371554e-08
most O 0 1.9545424834177538e-08
patients O 0 8.309728904976055e-09
with O 0 7.205359225936903e-11
isolated O 0 1.0396249194855045e-08
unilateral B-Disease 0 1.5534132558059355e-07
retinoblastoma I-Disease 0 0.00016638475062791258
, O 0 1.6572112571111575e-08
tumor B-Disease 0 3.371224465809064e-06
development O 0 3.7537791541808474e-08
is O 0 1.758101303428461e-10
initiated O 0 2.08657979783311e-09
by O 0 1.5184860313599557e-10
somatic O 0 1.1823843237834808e-07
inactivation O 0 1.9413053564676375e-07
of O 0 3.841471496457416e-08
both O 0 1.96175364841622e-09
alleles O 0 1.0995964139226544e-09
of O 0 4.962060540236735e-09
the O 0 2.0372851849970175e-08
RB1 O 0 5.204612898523919e-05
gene O 0 1.4803913472860586e-07
. O 0 1.403309170200373e-06

However O 0 9.157720626262744e-08
, O 0 4.628732064304586e-09
some O 0 4.918458973435236e-10
of O 0 9.099818676361338e-10
these O 0 3.065256104495262e-10
patients O 0 2.246880459466638e-09
can O 0 6.192436563523529e-10
transmit O 0 1.2482298927807278e-07
retinoblastoma B-Disease 0 1.960286681423895e-05
predisposition O 0 1.334656190010719e-05
to O 0 3.1326698035627487e-07
their O 0 1.8962170997838257e-06
offspring O 0 6.354963988997042e-05
. O 0 1.3273815966385882e-05

To O 0 1.2672805915769914e-08
determine O 0 1.0620356816204435e-09
the O 0 7.467467200150679e-10
frequency O 0 2.92072641627783e-08
and O 0 9.589588012559602e-10
nature O 0 4.885261528642104e-09
of O 0 1.2690947848170708e-08
constitutional O 0 3.7793662954754836e-07
RB1 O 0 1.697928564681206e-05
- O 0 6.489859174507728e-07
gene O 0 8.733205270061717e-09
mutations O 0 2.9289646263919167e-09
in O 0 8.73553451796738e-10
patients O 0 4.593438074351752e-09
with O 0 5.863258489835488e-11
isolated O 0 1.0306731468290309e-08
unilateral B-Disease 0 4.554330956807462e-08
retinoblastoma I-Disease 0 8.317641004396137e-06
, O 0 1.0572038355860514e-08
we O 0 4.74959316321133e-09
analyzed O 0 7.621568265392398e-09
DNA O 0 2.6625391669199416e-08
from O 0 1.3182208213891045e-08
peripheral O 0 0.0018680042121559381
blood O 0 1.4192092976372805e-06
and O 0 2.8571141896804875e-08
from O 0 4.02960750989223e-07
tumor B-Disease 0 0.02873212657868862
tissue O 0 6.719039083691314e-05
. O 0 6.297945219557732e-06

The O 0 4.6081215288040767e-08
analysis O 0 2.1570084385302835e-08
of O 0 3.158944039682865e-08
tumors B-Disease 1 1.0
from O 0 9.808600154315172e-09
54 O 0 3.104824486399593e-08
( O 0 1.2227989731883326e-09
71 O 0 2.9071651752587968e-08
% O 0 3.2060315513504634e-10
) O 0 9.898840080957427e-11
of O 0 8.565168019281089e-10
76 O 0 2.433446688598906e-08
informative O 0 2.068400917210056e-08
patients O 0 6.114182049543615e-09
showed O 0 1.0101941505524792e-09
loss O 0 2.837658996668324e-09
of O 0 3.6236954770174634e-08
constitutional O 0 8.001593414519448e-06
heterozygosity O 1 0.9999970197677612
( O 0 0.00010813758854055777
LOH O 1 1.0
) O 0 1.2813552530133165e-07
at O 0 6.413418418560468e-07
intragenic O 0 4.735529000754468e-05
loci O 0 4.028207513329107e-06
. O 0 1.137580738941324e-06

Three O 0 1.1327379922931868e-07
of O 0 1.189240848020745e-07
13 O 0 7.272193442986463e-07
uninformative O 0 0.0018350842874497175
patients O 0 8.406905749325233e-07
had O 0 7.054248385429673e-08
constitutional O 0 2.033558075709152e-06
deletions O 0 4.574936974677257e-05
. O 0 6.288798431342002e-06

For O 0 1.6018407222873066e-07
39 O 0 2.6551001042207645e-07
randomly O 0 4.078055582112938e-08
selected O 0 7.485227229153679e-07
tumors B-Disease 1 1.0
, O 0 3.534889003731223e-07
SSCP O 1 0.9523235559463501
, O 0 5.382304379963898e-08
hetero O 0 9.778508456292911e-07
- O 0 4.5632262413164426e-08
duplex O 0 1.4154217353734566e-07
analysis O 0 6.813139385997147e-09
, O 0 1.412986672111316e-10
sequencing O 0 2.9887734509514985e-09
, O 0 2.02956901285134e-10
and O 0 3.9816386299129647e-10
Southern O 0 2.794775078029943e-08
blot O 0 5.897216937000849e-08
analysis O 0 1.0365969194126023e-09
were O 0 2.686860733902563e-10
used O 0 7.821749359315788e-10
to O 0 2.101028684364792e-09
identify O 0 5.7536574615824065e-08
mutations O 0 2.003712324949447e-07
. O 0 3.49247784470208e-06

Mutations O 0 4.6597068603659864e-07
were O 0 3.131713199877595e-08
detected O 0 2.490793171716632e-08
in O 0 7.170211091533929e-10
21 O 0 2.3439440610673046e-08
( O 0 2.2100639096578334e-09
91 O 0 5.7654663265793715e-08
% O 0 3.6476155429454593e-10
) O 0 1.690813877797126e-10
of O 0 4.184232516024622e-09
23 O 0 2.4863845737854717e-06
tumors B-Disease 1 1.0
with O 0 1.7633776224101894e-05
LOH O 1 1.0
. O 0 0.00036051819915883243

In O 0 2.6510008410696173e-08
6 O 0 1.1962306700752379e-07
( O 0 4.58002658021428e-09
38 O 0 1.06683977207922e-08
% O 0 2.646082519763837e-10
) O 0 1.5320399116003358e-10
of O 0 2.37889818954784e-09
16 O 0 6.947472002138966e-07
tumors B-Disease 1 1.0
without O 0 0.23672032356262207
LOH O 1 1.0
, O 0 3.7238621075630363e-09
one O 0 1.9502097159396214e-10
mutation O 0 2.4306331947165916e-10
was O 0 6.901774152190399e-10
detected O 0 6.743425817745674e-10
, O 0 3.0378408122366807e-11
and O 0 3.4339437543495777e-11
in O 0 2.756307404538916e-10
9 O 0 3.312705132429983e-08
( O 0 1.90958138190922e-09
56 O 0 5.9382654349349195e-09
% O 0 1.313473496633577e-10
) O 0 6.31249705285164e-11
of O 0 5.768991950816371e-10
the O 0 3.1258828414593154e-08
tumors B-Disease 1 1.0
without O 1 0.9427804946899414
LOH O 1 1.0
, O 0 2.111072028299077e-08
both O 0 4.093233751945036e-09
mutations O 0 5.488029142242112e-09
were O 0 1.0024861829549536e-08
found O 0 1.8627089204414915e-08
. O 0 3.284538081516075e-07

Thus O 0 1.0996435406696037e-07
, O 0 8.176745391885731e-10
a O 0 1.9595126909965899e-10
total O 0 1.5284964960393665e-10
of O 0 3.6657496482739305e-10
45 O 0 2.0600059436048923e-09
mutations O 0 6.970541366335681e-10
were O 0 1.5893675264777585e-09
identified O 0 8.015996755261767e-09
in O 0 2.017563538458944e-08
tumors B-Disease 1 1.0
of O 0 6.281390142248711e-06
36 O 0 4.5217143451736774e-06
patients O 0 1.218857164531073e-06
. O 0 5.459757517201069e-07

Thirty O 0 3.3434364468121203e-06
- O 0 4.7297115202127316e-07
nine O 0 7.967250859053365e-09
of O 0 1.233346647033784e-09
the O 0 4.367273487293488e-10
mutations O 0 3.546480054072987e-10
- O 0 6.446221778588779e-09
including O 0 8.979610388593073e-10
34 O 0 1.2043172681330816e-08
small O 0 3.629017919504207e-10
mutations O 0 7.134414725662452e-10
, O 0 3.4694044859229223e-10
2 O 0 1.9279175589304032e-08
large O 0 8.441747745280281e-09
structural O 0 0.0020459790248423815
alterations O 1 0.9976020455360413
, O 0 1.2480188438246387e-08
and O 0 5.9392961659909815e-09
hypermethylation O 0 1.6791687812656164e-05
in O 0 7.884137787073087e-09
3 O 0 1.0799712981679477e-06
tumors O 1 1.0
- O 0 7.222037083920441e-07
were O 0 1.814098027352884e-08
not O 0 1.704329566365459e-09
detected O 0 4.372993522849811e-09
in O 0 2.408003796361413e-10
the O 0 1.15416654011824e-09
corresponding O 0 1.0207289236063843e-08
peripheral O 0 3.453629688010551e-06
blood O 0 5.580635615842766e-07
DNA O 0 1.3093160760035971e-06
. O 0 2.8725235097226687e-06

In O 0 1.5157299415591297e-08
6 O 0 7.748064234647245e-08
( O 0 1.92701210544044e-09
17 O 0 4.542755505099194e-09
% O 0 1.0953799672863695e-10
) O 0 2.7373664099328288e-11
of O 0 9.261592187614909e-11
the O 0 3.095136091868511e-10
36 O 0 4.015656251965538e-09
patients O 0 1.2552038297641843e-09
, O 0 4.6614202081629585e-11
a O 0 3.0969785069778766e-10
mutation O 0 5.695379168280112e-10
was O 0 3.055970143606146e-09
detected O 0 2.578981472822761e-09
in O 0 3.4072744625746054e-10
constitutional O 0 1.1753024331540018e-08
DNA O 0 1.070290345239755e-08
, O 0 2.507206386948013e-10
and O 0 3.5036784584718816e-10
1 O 0 1.3068152782125253e-08
of O 0 2.279244792902091e-09
these O 0 2.1374460534850925e-10
mutations O 0 2.1238889813535167e-10
is O 0 1.2322166724476613e-11
known O 0 1.5614910753303235e-10
to O 0 1.943065985887671e-10
be O 0 7.909438104469757e-10
associated O 0 1.041335639939689e-08
with O 0 1.1970385793702576e-09
reduced O 0 1.176816340375808e-06
expressivity O 0 2.8945947633474134e-05
. O 0 2.5510682917229133e-06

The O 0 5.446351991622578e-08
presence O 0 1.2800172477511751e-08
of O 0 4.410722453940252e-09
a O 0 5.969810756845106e-10
constitutional O 0 5.544031900228674e-09
mutation O 0 1.1293198598494314e-09
was O 0 2.227821260802898e-10
not O 0 1.6202065730719362e-11
associated O 0 5.3890145818025204e-11
with O 0 1.4562985149388363e-12
an O 0 1.5465427549710142e-11
early O 0 1.283897699266845e-08
age O 0 4.1451344579002125e-09
at O 0 1.8585886607525026e-08
treatment O 0 4.3312587649779744e-07
. O 0 6.347277121676598e-07

In O 0 6.955527709351372e-08
1 O 0 6.087542487875908e-07
patient O 0 8.174645813596726e-07
, O 0 1.7289785603225027e-08
somatic O 0 3.5297263821121305e-05
mosaicism O 0 0.035485778003931046
was O 0 1.7214128433806763e-07
demonstrated O 0 6.970612087542349e-09
by O 0 1.2529882686962424e-10
molecular O 0 1.0771730174496952e-09
analysis O 0 2.830446432788847e-10
of O 0 3.857179298183411e-10
DNA O 0 1.9823434005417084e-09
and O 0 1.009165750964769e-09
RNA O 0 1.771193467448029e-07
from O 0 7.140165791952313e-08
peripheral O 0 0.011589951813220978
blood O 0 2.615856828924734e-05
. O 0 3.919711161870509e-06

In O 0 5.2935664740516586e-08
2 O 0 4.890055720352393e-07
patients O 0 7.733034834700447e-08
without O 0 1.0752851054007806e-08
a O 0 5.52437695588992e-09
detectable O 0 8.246763059105433e-07
mutation O 0 5.232890121220635e-09
in O 0 1.2709545638145414e-09
peripheral O 0 0.0005695209838449955
blood O 0 1.4835722140560392e-05
, O 0 1.5800166508483926e-08
mosaicism O 0 3.0787166906520724e-05
was O 0 8.105027760052508e-09
suggested O 0 4.109220741455033e-10
because O 0 1.2276093336316407e-11
1 O 0 2.4266830767061265e-09
of O 0 2.9398004031122582e-09
the O 0 8.431513265350077e-09
patients O 0 4.637200277102238e-07
showed O 0 1.9949320062551124e-07
multifocal O 1 1.0
tumors B-Disease 1 1.0
and O 0 6.108169259277929e-08
the O 0 4.640048700821353e-08
other O 0 3.334414966360555e-09
later O 0 3.364365497304789e-08
developed O 0 4.1198667588560056e-08
bilateral B-Disease 0 1.5800005712662823e-06
retinoblastoma I-Disease 0 0.0001534918264951557
. O 0 3.5351590668142308e-06

In O 0 1.2985315045455081e-08
conclusion O 0 1.8533107493112766e-08
, O 0 1.554170570017277e-09
our O 0 1.6638933564294689e-09
results O 0 6.10223704899937e-10
emphasize O 0 4.777449547077595e-09
that O 0 5.0871935136642676e-11
the O 0 4.508140527548221e-10
manifestation O 0 4.69024250548955e-08
and O 0 1.9213970414710957e-09
transmissibility O 0 1.40308827667468e-06
of O 0 1.1326274140799342e-08
retinoblastoma B-Disease 0 4.5019756811370826e-08
depend O 0 1.7445801470117317e-09
on O 0 1.6330432561773023e-09
the O 0 3.55643764438085e-10
nature O 0 2.0626352015273852e-10
of O 0 3.12050080220061e-10
the O 0 1.0257222154974599e-10
first O 0 2.90835466820738e-10
mutation O 0 7.283830483206799e-11
, O 0 1.0097749893189789e-11
its O 0 7.946538392589186e-12
time O 0 1.1701030422361924e-10
in O 0 3.5700831180207615e-11
development O 0 2.989484770843376e-10
, O 0 6.819633052712604e-11
and O 0 7.912542149268731e-11
the O 0 2.771944340729249e-10
number O 0 2.5711219264756835e-10
and O 0 6.144149772291385e-11
types O 0 5.706720651588171e-10
of O 0 9.823648561280152e-10
cells O 0 1.6851547934848554e-09
that O 0 3.36726237171181e-11
are O 0 9.163875908102526e-11
affected O 0 2.4295683243025223e-09
. O 0 2.093046091999895e-08
. O 0 7.539187549809867e-07

Hereditary B-Disease 1 1.0
deficiency I-Disease 1 0.9999984502792358
of I-Disease 0 7.773769539198838e-06
the I-Disease 0 1.9896954484011076e-07
fifth I-Disease 0 2.4877979853954457e-07
component I-Disease 0 8.433153730891263e-09
of I-Disease 0 9.370072495684667e-10
complement I-Disease 0 1.2782289893209509e-08
in O 0 1.7616073932913423e-08
man O 0 1.5829219819352147e-06
. O 0 2.766739498838433e-06

I O 0 0.00969705916941166
. O 0 0.00011006784916389734

Clinical O 0 4.4261269067646936e-05
, O 0 4.312677859275027e-08
immunochemical O 0 1.1273982636339497e-05
, O 0 9.092154584777745e-09
and O 0 5.635656830094149e-09
family O 0 1.1316815040629535e-08
studies O 0 2.303520005852988e-07
. O 0 2.5746584242369863e-07

The O 0 1.3226791395481996e-07
first O 0 6.076400183019359e-08
recognized O 0 1.411463390610379e-08
human O 0 4.488734717256193e-09
kindred O 0 2.547430995036848e-06
with O 0 5.74959502230854e-09
hereditary B-Disease 1 1.0
deficiency I-Disease 1 1.0
of I-Disease 1 0.9999575614929199
the I-Disease 0 2.106084593833657e-06
fifth I-Disease 0 1.9718379462574376e-06
component I-Disease 0 4.9148908942697744e-08
of I-Disease 0 9.396708300357659e-09
complement I-Disease 0 1.389467314538706e-07
( O 0 9.270371492675622e-08
C5 O 1 0.9999996423721313
) O 0 2.7922174794525745e-08
is O 0 5.832034410957476e-09
described O 0 1.545746499687084e-07
. O 0 7.384065270343854e-07

The O 0 2.3863756837272376e-07
proband O 0 2.2512056602863595e-05
, O 0 4.9115524980436476e-09
a O 0 9.155389224524413e-10
20 O 0 1.9172674559087e-09
- O 0 8.278090213309497e-09
year O 0 2.320796443910922e-09
- O 0 8.352541414069492e-08
old O 0 2.6262094721118956e-08
black O 0 1.2954294525968635e-08
female O 0 2.190448711303361e-09
with O 0 1.1537747424128497e-09
systemic B-Disease 1 1.0
lupus I-Disease 1 1.0
erythematosus I-Disease 1 1.0
since O 1 0.9971764087677002
age O 0 4.514522515819408e-06
11 O 0 2.2419635570258833e-07
, O 0 6.77261180470623e-09
lacked O 0 4.1255054838984506e-07
serum O 0 6.659708873257841e-08
hemolytic O 0 7.14568315629549e-08
complement O 0 1.3644619656361101e-08
activity O 0 2.2493516382837697e-08
, O 0 1.5245026352417312e-09
even O 0 3.0310955967394193e-09
during O 0 7.376267774361622e-08
remission O 0 5.146724561200244e-06
. O 0 4.1781058257583936e-07

C5 O 0 0.05439871549606323
was O 0 8.627655006421264e-06
undetectable O 0 7.387048299278831e-06
in O 0 5.679338332953421e-09
her O 0 1.5727875668503088e-09
serum O 0 1.4374530010741182e-08
by O 0 1.1279809308817335e-09
both O 0 1.6444495543055382e-08
immunodiffusion O 0 2.629529990372248e-05
and O 0 3.707737334934791e-07
hemolytic O 0 0.001220426638610661
assays O 0 3.150064731016755e-05
. O 0 1.2678999155468773e-05

Other O 0 8.579201349334653e-09
complement O 0 5.419716675447717e-09
components O 0 1.5916800322202107e-08
were O 0 1.4000459680474364e-09
normal O 0 5.690441451378092e-09
during O 0 1.1348741502104076e-08
remission O 0 6.274166821640392e-07
of O 0 6.3874003863872986e-09
lupus O 0 3.5777550237980904e-06
, O 0 2.3750352795559593e-09
but O 0 3.3554623524167937e-09
C1 O 1 0.956390380859375
, O 0 6.957279197195021e-08
C4 O 1 0.9999997615814209
, O 0 3.715524599101627e-07
C2 O 0 8.584226452512667e-05
, O 0 6.12625239426734e-09
and O 0 1.4218284327682795e-08
C3 O 0 0.006788301281630993
levels O 0 9.460403816774487e-06
fell O 0 4.305997663323069e-06
during O 0 2.9781972443743143e-07
exacerbations O 0 0.000319244951242581
. O 0 1.1289477015452576e-06

A O 0 6.712159574817633e-07
younger O 0 4.510037143745649e-08
half O 0 1.3665196085810294e-08
- O 0 1.4860422936635587e-07
sister O 0 2.6899810379177325e-08
, O 0 1.4293978223278714e-09
who O 0 2.65688138156861e-09
had O 0 4.3852885767137195e-09
no O 0 9.224420338682648e-09
underlying O 0 0.23520369827747345
disease O 0 5.01067233926733e-07
, O 0 8.160926795452994e-11
was O 0 4.523094787600712e-09
also O 0 2.0959294300126885e-09
found O 0 3.1936315814107274e-09
to O 0 2.8231921689325645e-08
lack O 0 5.425826020655222e-05
immunochemically O 1 0.8467227816581726
detectable O 0 0.00014598348934669048
C5 O 0 0.00030983472242951393
. O 0 1.242750931851333e-05

By O 0 2.614938807710132e-07
hemolytic O 0 0.0001376786531182006
assay O 0 1.4936124443920562e-06
, O 0 1.6352165843613875e-08
she O 0 9.133796496918478e-10
exhibited O 0 3.384102553738444e-09
1 O 0 1.3874196902463609e-08
- O 0 5.218141652107988e-08
2 O 0 3.093333234005513e-08
% O 0 6.218914272437814e-10
of O 0 4.077024828852416e-10
the O 0 2.1024626484233977e-10
normal O 0 3.6748661891294887e-09
serum O 0 2.88667152403832e-08
C5 O 0 5.199821089263423e-07
level O 0 2.6268907049598056e-08
and O 0 1.444058428390349e-09
normal O 0 7.596055340286512e-09
concentrations O 0 1.553285144950678e-08
of O 0 3.900207712348447e-09
other O 0 9.9045871504444e-10
complement O 0 4.325149660644456e-08
components O 0 2.473622544130194e-06
. O 0 2.4323389880009927e-06

C5 O 0 8.397024794248864e-05
levels O 0 1.7708015320749837e-07
of O 0 6.924628870308425e-09
other O 0 3.1128619126796764e-10
family O 0 5.3170141900427126e-11
members O 0 1.7340223007478173e-11
were O 0 7.90714091425393e-11
either O 0 1.7776076444153688e-10
normal O 0 4.080325410882324e-09
or O 0 8.690828612323287e-10
approximately O 0 2.2036308888750966e-10
half O 0 3.082963606626521e-10
- O 0 1.1196902072185821e-08
normal O 0 2.1267204886044055e-08
, O 0 3.08274761273708e-09
consistent O 0 2.4578897139804212e-08
with O 0 5.858498686173164e-10
autosomal O 0 1.70835235735467e-07
codominant O 0 3.380092437055282e-07
inheritance O 0 7.703015114657319e-09
of O 0 4.451059965049353e-09
the O 0 1.4688540384000248e-09
gene O 0 1.1181408687832572e-08
determining O 0 3.5511247915565036e-06
C5 B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 0.00021959944569971412

Normal O 0 2.076094096992165e-05
hemolytic O 0 7.942737283883616e-05
titers O 0 1.3529886018659454e-05
were O 0 4.512222773200847e-08
restored O 0 2.7935394086853194e-07
to O 0 4.261366814972689e-09
both O 0 8.98794194625907e-09
homozygous O 0 1.6852842236403376e-05
C5 B-Disease 1 1.0
- I-Disease 1 1.0
deficient I-Disease 1 1.0
( O 0 0.007241691928356886
C5D B-Disease 1 1.0
) O 0 1.747925004735862e-08
sera O 0 1.0109717862860634e-07
by O 0 7.660166945200331e-11
addition O 0 3.071946030885897e-10
of O 0 2.982043056931616e-09
highly O 0 3.300268147654606e-08
purified O 0 3.2574737929280673e-07
human O 0 7.781267896689315e-08
C5 O 0 0.0002936641685664654
. O 0 6.2512722251995e-06

In O 0 2.1167497266105784e-07
specific O 0 1.330200802840409e-07
C5 O 0 0.00020345936354715377
titrations O 0 1.1909031854884233e-05
, O 0 3.0069911005625727e-09
however O 0 4.481478244056092e-10
, O 0 1.3548809296715092e-10
it O 0 1.900423221568026e-11
was O 0 8.789232674999425e-10
noted O 0 5.591210272548608e-10
that O 0 5.875693161183637e-12
when O 0 4.0695953551495023e-11
limited O 0 4.933924935279776e-10
amounts O 0 5.705806382927392e-10
of O 0 3.074280385817474e-09
C5 O 0 2.4205005502153654e-06
were O 0 1.5707376732621015e-08
assayed O 0 6.047540779263727e-08
in O 0 5.126625790552453e-10
the O 0 1.2432356255587251e-09
presence O 0 2.0528436728284305e-09
of O 0 4.61337812396323e-09
low O 0 4.7143597470267196e-08
dilutions O 0 1.237058768310817e-06
of O 0 3.365707001989904e-08
either O 0 1.7362894766392856e-07
C5D B-Disease 1 1.0
serum O 0 1.372123961118632e-06
, O 0 3.0927418404047557e-09
curving O 0 1.1936102772835966e-08
rather O 0 5.756439214188447e-10
than O 0 5.544491255005113e-11
linear O 0 1.0005672679280764e-10
dose O 0 1.5961733268454736e-08
- O 0 1.3020433620170024e-08
response O 0 1.331344479105212e-09
plots O 0 2.5007647064256844e-09
were O 0 3.6292757688016763e-09
consistently O 0 4.845191803326543e-09
obtained O 0 3.567744988330901e-09
, O 0 9.957966673468377e-10
suggesting O 0 6.396569052213863e-09
some O 0 5.506154421297538e-10
inhibitory O 0 1.9501956671774678e-07
effect O 0 2.536391150442796e-07
. O 0 2.83262897937675e-06

Further O 0 1.1365739993607349e-07
studies O 0 4.579950285688028e-08
suggested O 0 1.1027810664643312e-08
that O 0 3.765973921598942e-10
low O 0 8.421054076279688e-08
dilutions O 0 8.265728865808342e-06
of O 0 2.400784069322981e-07
C5D B-Disease 1 1.0
serum O 0 6.694489798064751e-07
contain O 0 2.6720767820620495e-09
a O 0 1.7246029604400803e-10
factor O 0 9.329554906400972e-10
( O 0 1.2975942542681196e-10
or O 0 3.7667211016945146e-10
factors O 0 2.5090638455793624e-09
) O 0 2.007684435367807e-10
interfering O 0 8.579561061594632e-09
at O 0 8.544759566575522e-09
some O 0 1.0684133577854027e-09
step O 0 8.010311525197267e-09
in O 0 9.590375160684061e-10
the O 0 3.2750397949143917e-09
hemolytic O 0 1.3923659025749657e-06
assay O 0 1.1435302127438263e-07
of O 0 1.7968152121738967e-07
C5 O 0 8.184100443031639e-05
, O 0 2.7490631993032366e-09
rather O 0 1.6189601881322346e-09
than O 0 4.018826382790053e-10
a O 0 1.3288176115011652e-09
true O 0 1.8039056470797732e-08
C5 O 0 1.7243079128093086e-05
inhibitor O 0 1.7413152590961545e-06
or O 0 1.8713735983055813e-07
inactivator O 0 0.00018030352657660842
. O 0 2.8951549211342353e-06

Of O 0 4.084735394371819e-07
clinical O 0 7.313756782423297e-07
interest O 0 6.863773105436621e-09
are O 0 7.582411781781317e-11
( O 0 2.252801278856964e-10
a O 0 4.618852245119598e-10
) O 0 1.853853182076648e-10
the O 0 9.305918258206702e-10
documentation O 0 2.9637972147611436e-06
of O 0 8.547499987798801e-07
membranous O 1 1.0
glomerulonephritis B-Disease 1 1.0
, O 0 2.235984538856428e-05
vasculitis B-Disease 1 1.0
, O 0 3.399916082003074e-08
and O 0 9.956512059261513e-08
arthritis B-Disease 1 1.0
in O 0 4.900286398878961e-09
an O 0 1.5737230962820092e-10
individual O 0 2.750651095784207e-10
lacking O 0 1.5462611600014498e-06
C5 O 0 0.013358592055737972
( O 0 5.036857597673361e-09
and O 0 1.1454533987986792e-09
its O 0 2.025848377940065e-10
biologic O 0 3.215858512817249e-08
functions O 0 1.2517872294282029e-09
) O 0 9.5145023804033e-11
, O 0 8.557326375280283e-11
and O 0 1.6405068969937986e-10
( O 0 5.808762915116006e-10
b O 0 1.3403544940615575e-08
) O 0 7.54913492828635e-11
a O 0 5.89031989850497e-10
remarkable O 0 9.418707591635211e-09
propensity O 0 2.7764616561398725e-07
to O 0 1.50942032206558e-08
bacterial B-Disease 1 1.0
infections I-Disease 1 0.9999996423721313
in O 0 2.380485530917298e-10
the O 0 4.549638166206904e-10
proband O 0 6.332041380119335e-08
, O 0 1.4247127089195288e-10
even O 0 1.184718018132358e-10
during O 0 5.314786388765924e-10
periods O 0 2.9039937121666526e-09
of O 0 2.4086652117283336e-10
low O 0 1.1410203892836535e-09
- O 0 1.2682229710847537e-09
dose O 0 7.391418144209183e-09
or O 0 5.436818217852135e-10
alternate O 0 4.4892164652310385e-08
- O 0 1.949176294147037e-06
day O 0 1.6065098407125333e-06
corticosteroid O 0 0.1114305853843689
therapy O 0 0.00040465002530254424
. O 0 5.08045275182667e-07

Other O 0 4.0837687009798174e-08
observations O 0 4.9302421700758714e-08
indicate O 0 4.26571711287238e-09
that O 0 7.858787232084552e-11
the O 0 3.115286917321214e-09
C5D B-Disease 1 1.0
state O 0 1.722473719212303e-09
is O 0 1.4281052729270272e-10
compatible O 0 6.5985852337746564e-09
with O 0 1.8894719122641845e-11
normal O 0 6.8572565403712815e-09
coagulation O 0 6.1236820059207275e-09
function O 0 5.813617365291179e-10
and O 0 2.532979381797418e-10
the O 0 9.4212904144797e-10
capacity O 0 9.171858827983215e-09
to O 0 1.4157342853593491e-08
mount O 0 2.2346992409438826e-05
a O 0 3.146424774058687e-07
neutrophilic O 0 0.0011935391230508685
leukocytosis O 0 5.430028977571055e-05
during O 0 4.397504653752549e-06
pyogenic B-Disease 0 0.001488024485297501
infection I-Disease 0 1.091897502192296e-06
. O 0 1.4806152748292334e-08
. O 0 1.9495912795264303e-07

Susceptibility O 0 0.005977950058877468
to O 0 7.40479226806201e-05
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
in O 0 2.596237891339115e-06
twins O 0 2.260120766095497e-07
: O 0 2.6756555304707774e-10
the O 0 1.5493187288662114e-10
role O 0 4.649310658688677e-10
of O 0 4.154553590041132e-09
genes O 0 6.068799685010617e-09
, O 0 3.7449172651804474e-09
HLA O 0 0.023421047255396843
, O 0 1.8408497837185678e-08
and O 0 9.917995313912797e-09
the O 0 1.0885044332553662e-07
environment O 0 3.5321829727763543e-07
. O 0 3.615121784150688e-07

OBJECTIVE O 0 6.163047146401368e-06
To O 0 7.875030405557482e-09
determine O 0 2.9894577924238774e-09
the O 0 1.3854516422995289e-09
relative O 0 3.4539052506943335e-08
effects O 0 6.056682622102016e-08
of O 0 9.692199931521372e-09
genetic O 0 5.038567341131284e-09
and O 0 2.7800931001742413e-10
environmental O 0 9.603774442368262e-10
factors O 0 4.99658092678601e-10
in O 0 1.6057202789632186e-10
susceptibility O 0 2.140827035645998e-07
to O 0 7.706912015237322e-07
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
( O 0 2.5484259822405875e-05
AS B-Disease 1 1.0
) O 0 1.1225046847584963e-07
. O 0 4.471625345559005e-07

METHODS O 0 6.199377367011039e-06
Twins O 0 6.741881861671573e-07
with O 0 5.646585976570861e-10
AS B-Disease 1 0.9954174757003784
were O 0 1.426157192341293e-09
identified O 0 3.5552777388758727e-10
from O 0 1.0973352088106125e-10
the O 0 4.858737856494599e-10
Royal O 0 2.0687541564257117e-06
National O 0 1.971836127268034e-06
Hospital O 1 0.695040762424469
for O 0 9.090251040788644e-08
Rheumatic B-Disease 1 0.9999998807907104
Diseases I-Disease 1 0.9999998807907104
database O 0 1.395793333358597e-06
. O 0 7.652473641428514e-07

Clinical O 0 4.776655259774998e-06
and O 0 9.539225409582741e-09
radiographic O 0 3.5819132335745962e-06
examinations O 0 7.067769161039905e-07
were O 0 1.1671307476035508e-08
performed O 0 8.571186427275279e-09
to O 0 1.060999066382351e-09
establish O 0 2.292028078443309e-08
diagnoses O 0 0.0008763778023421764
, O 0 1.8938106638444197e-09
and O 0 2.8172628674383304e-09
disease O 0 1.3071124271846202e-07
severity O 0 1.0037473430202226e-07
was O 0 5.255395230108206e-09
assessed O 0 7.897985376814631e-09
using O 0 2.1133188532473923e-09
a O 0 1.0826519680762203e-09
combination O 0 1.2785021041850086e-08
of O 0 2.3042440844278644e-08
validated O 0 1.078878568705477e-07
scoring O 0 7.239960808647083e-08
systems O 0 4.7263432634281344e-07
. O 0 4.930919317303051e-07

HLA O 0 0.02687881886959076
typing O 0 2.4629433028167114e-05
for O 0 7.867346596412972e-08
HLA O 0 4.023713700007647e-05
- O 0 1.535410774522461e-05
B27 O 0 8.197261922759935e-05
, O 0 8.995454159332894e-09
HLA O 0 7.354793751801481e-07
- O 0 1.8044084981738706e-07
B60 O 0 2.422909346933011e-06
, O 0 1.6594403628999999e-09
and O 0 1.2293914775085568e-09
HLA O 0 5.323490040609613e-05
- O 0 0.0005796440527774394
DR1 O 1 0.9998019337654114
was O 0 2.2590282355849922e-07
performed O 0 2.4586118030356374e-08
by O 0 9.066278283675899e-10
polymerase O 0 8.721657707155828e-08
chain O 0 5.583561613065058e-09
reaction O 0 2.0010094969880043e-10
with O 0 1.7705581792371028e-11
sequence O 0 1.2713975705569425e-10
- O 0 5.411185277637287e-09
specific O 0 1.0684765294755039e-09
primers O 0 8.29101978183644e-08
, O 0 1.2388043924005387e-09
and O 0 1.1275119726761318e-09
zygosity O 0 7.029776156741718e-07
was O 0 1.9406975582114683e-08
assessed O 0 6.728861734472957e-08
using O 0 4.496654781860343e-08
microsatellite O 0 7.019370968919247e-06
markers O 0 2.532210146455327e-06
. O 0 1.6259939457086148e-06

Genetic O 0 5.177946604817407e-06
and O 0 9.242648424390154e-09
environmental O 0 8.744573065655459e-09
variance O 0 1.2587689779408606e-09
components O 0 6.458429790967557e-09
were O 0 2.6697335453462756e-09
assessed O 0 5.25784171756527e-09
with O 0 7.029109239109488e-11
the O 0 1.0636858061019439e-09
program O 0 3.5441962698001817e-09
Mx O 0 2.8387809436480893e-08
, O 0 9.987483062801061e-11
using O 0 1.8373226551293698e-10
data O 0 2.5772983747174294e-10
from O 0 2.5501486339285506e-11
this O 0 8.900923401111704e-12
and O 0 4.68391506136534e-11
previous O 0 3.0426089425716896e-10
studies O 0 5.420044968396098e-10
of O 0 3.3281863376366516e-10
twins O 0 1.1260510746069485e-08
with O 0 1.4846895934894633e-09
AS B-Disease 1 1.0
. O 0 7.888991603977047e-06

RESULTS O 0 4.053164275319432e-07
Six O 0 4.16570387073989e-08
of O 0 1.7308659394643655e-08
8 O 0 5.639369078380696e-07
monozygotic O 0 2.9608607292175293e-05
( O 0 3.31966305111564e-07
MZ O 0 0.0007971670711413026
) O 0 3.250509550412062e-08
twin O 0 6.475595455412986e-07
pairs O 0 3.908356305259986e-08
were O 0 1.3468770987401513e-07
disease O 0 1.260615221099215e-07
concordant O 0 1.4260627345663579e-08
, O 0 1.180887332363767e-10
compared O 0 7.874331742208085e-11
with O 0 5.629009411367569e-12
4 O 0 8.926403616271728e-09
of O 0 1.540738914229678e-08
15 O 0 4.864176261776265e-08
B27 O 0 1.8545006241765805e-06
- O 0 1.107055027205206e-06
positive O 0 3.5005626841666526e-08
dizygotic O 0 1.1879233170475345e-05
( O 0 1.3394388531651202e-07
DZ O 0 0.006235689856112003
) O 0 1.2422762374342255e-08
twin O 0 1.9595337619193742e-07
pairs O 0 6.146078312951886e-09
( O 0 1.3570746748570173e-09
27 O 0 1.6553283188613932e-08
% O 0 3.072397336545407e-10
) O 0 6.658556345184863e-11
and O 0 1.261638155058975e-10
4 O 0 1.1189302817626867e-08
of O 0 3.091210132311062e-08
32 O 0 1.9711883680884057e-07
DZ O 0 0.00010220868716714904
twin O 0 1.512731273578538e-07
pairs O 0 1.206017619104216e-09
overall O 0 4.641028894525334e-09
( O 0 1.1054467341509167e-09
12 O 0 3.772179901773143e-09
. O 0 6.218783821232421e-10
5 O 0 8.758762604088588e-09
% O 0 2.3065120924314897e-09
) O 0 1.0109385328860299e-08
. O 0 1.4644719215084478e-07

Nonsignificant O 0 3.194986129528843e-05
increases O 0 6.103392458101098e-09
in O 0 1.781738645512121e-10
similarity O 0 1.5155636468033862e-10
with O 0 6.013413725303174e-12
regard O 0 2.5642568068917626e-09
to O 0 1.30325017444477e-09
age O 0 1.2721848463570495e-08
at O 0 1.1968475099877196e-08
disease O 0 1.3743507665253674e-08
onset O 0 4.066133030278252e-08
and O 0 5.636210248516349e-11
all O 0 1.0092036928366355e-10
of O 0 1.3056735692629218e-09
the O 0 1.8379614497021635e-09
disease O 0 5.321057372498217e-09
severity O 0 1.8101499188460934e-09
scores O 0 4.836787081963223e-10
assessed O 0 1.3066999704491877e-09
were O 0 2.5229516253943984e-09
noted O 0 4.300551470493019e-09
in O 0 7.436967930374294e-09
disease O 0 2.8925697392878646e-07
- O 0 6.084936785555328e-07
concordant O 0 6.1663340602535754e-06
MZ O 0 0.00019020373292732984
twins O 0 1.5942678146529943e-06
compared O 0 6.245296901852271e-08
with O 0 4.702162215153294e-09
concordant O 0 4.1094503103522584e-05
DZ O 1 0.9999996423721313
twins O 0 0.0008142262231558561
. O 0 1.993635669350624e-05

HLA O 0 0.0006145797087810934
- O 0 3.065447890548967e-05
B27 O 0 2.239125569758471e-05
and O 0 4.838838219001218e-09
B60 O 0 4.7117799795159954e-07
were O 0 6.202200419913595e-10
associated O 0 2.6180399514963426e-10
with O 0 6.165382874373515e-12
the O 0 1.039212049747107e-09
disease O 0 1.596015053451083e-08
in O 0 9.554657065535821e-11
probands O 0 2.6164806854467315e-07
, O 0 1.3564012413258553e-10
and O 0 2.632651319167678e-10
the O 0 1.9577988119579004e-09
rate O 0 2.6043170464618015e-07
of O 0 9.49178247111604e-09
disease O 0 1.6410655945264807e-08
concordance O 0 7.876682417418124e-09
was O 0 1.2046612596350315e-09
significantly O 0 1.549520511900937e-09
increased O 0 7.890982978153716e-09
among O 0 6.095644433656844e-09
DZ O 0 0.00019072202849201858
twin O 0 3.23631240917166e-07
pairs O 0 1.559128826045253e-09
in O 0 5.340189956903885e-10
which O 0 1.0770677405513851e-10
the O 0 7.975973770335543e-10
co O 0 9.966122149762668e-09
- O 0 1.7032149912665773e-07
twin O 0 1.2912018121369329e-07
was O 0 1.8091292020017136e-08
positive O 0 4.0452510785549123e-10
for O 0 4.669342135166232e-10
both O 0 2.1673089989349137e-09
B27 O 0 1.1878134500875603e-05
and O 0 3.9163415976872784e-07
DR1 O 0 0.14228062331676483
. O 0 1.0699905942601617e-05

Additive O 0 3.7033836974842416e-07
genetic O 0 2.4753347815931193e-08
effects O 0 1.319800801979909e-08
were O 0 1.9473636037048436e-09
estimated O 0 2.1503761271635113e-10
to O 0 1.302034591255108e-10
contribute O 0 8.198608458798162e-10
97 O 0 6.77492693057502e-08
% O 0 3.288339045504074e-10
of O 0 5.164312311123354e-10
the O 0 3.3323599435419737e-10
population O 0 4.6601930647760526e-11
variance O 0 1.7006343000502966e-09
. O 0 5.0713321542161793e-08

CONCLUSION O 0 2.2216804609342944e-06
Susceptibility O 0 2.4803666747175157e-06
to O 0 2.3168704288423214e-08
AS B-Disease 1 0.9999998807907104
is O 0 4.2606573824599536e-10
largely O 0 2.942660004556785e-10
genetically O 0 8.562338338347075e-11
determined O 0 1.0876478884203067e-10
, O 0 1.7833909349285193e-10
and O 0 3.226976463821529e-10
the O 0 8.832085063303907e-10
environmental O 0 1.7587461487167388e-09
trigger O 0 2.862518222457311e-09
for O 0 2.2357175832876663e-10
the O 0 2.695912160177727e-09
disease O 0 4.9812655333880684e-08
is O 0 1.7237775096212715e-10
probably O 0 1.860663623176606e-08
ubiquitous O 0 1.5340742720582057e-06
. O 0 8.801753210718744e-07

HLA O 0 0.0001211204071296379
- O 0 2.868034016501042e-06
B27 O 0 1.785600375114882e-06
accounts O 0 1.4561395422774126e-09
for O 0 6.202859753612344e-11
a O 0 7.526734790985756e-11
minority O 0 1.862794987705918e-11
of O 0 1.6566249760874285e-10
the O 0 2.0606728823313603e-10
overall O 0 1.7571375465763595e-08
genetic O 0 5.9499235760540614e-08
susceptibility O 0 1.8079276742355432e-07
to O 0 7.899856058202204e-08
AS B-Disease 1 1.0
. O 0 0.0007616945076733828

Cell O 0 7.616048378622509e-07
cycle O 0 1.32368356275947e-07
- O 0 3.924110387742985e-07
dependent O 0 1.2459298659450724e-07
colocalization O 0 6.440523975470569e-06
of O 0 1.0837686659215251e-07
BARD1 O 0 0.0003586231032386422
and O 0 3.829342176686623e-08
BRCA1 O 0 2.8107377758601615e-08
proteins O 0 4.431514877278886e-10
in O 0 1.6350099052431233e-09
discrete O 0 1.932331628040629e-08
nuclear O 0 1.0473601150806644e-06
domains O 0 1.5036955574032618e-06
. O 0 1.1378986073395936e-06

Germ O 0 0.00022699357941746712
- O 0 2.8315294002823066e-06
line O 0 1.0324836807740212e-07
mutations O 0 3.5504073014891446e-09
of O 0 1.7840757760012593e-09
the O 0 2.3703288221099683e-09
BRCA1 O 0 3.295236439271321e-08
gene O 0 4.564451483446419e-09
predispose O 0 8.983900556813751e-08
women O 0 6.486796100269032e-10
to O 0 2.0546368773022294e-10
early O 0 7.084106073307339e-06
- O 1 0.9992454051971436
onset O 1 1.0
breast B-Disease 1 1.0
and I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
by O 0 3.683288696265663e-08
compromising O 0 1.7157010745449952e-07
the O 0 1.1388075371598916e-08
genes O 0 3.1763427443820547e-09
presumptive O 0 4.970171474383278e-08
function O 0 3.3414691014144182e-09
as O 0 3.4762817069378116e-09
a O 0 1.3515834673683003e-08
tumor B-Disease 0 3.020025360456202e-06
suppressor O 0 9.750550816534087e-05
. O 0 1.1153865671076346e-05

Although O 0 4.0540339796280023e-07
the O 0 2.4654069008533952e-08
biochemical O 0 3.570661135654518e-07
properties O 0 4.4189263803673384e-08
of O 0 3.9423849074182726e-08
BRCA1 O 0 3.911734580697157e-08
polypeptides O 0 4.237481032731694e-09
are O 0 8.269513546155238e-11
not O 0 2.0898527353097052e-10
understood O 0 2.736915138967788e-09
, O 0 1.9545964846656716e-10
their O 0 2.310777680314402e-10
expression O 0 1.4380335811026157e-09
pattern O 0 4.5760253919446825e-10
and O 0 2.6770338723558496e-10
subcellular O 0 1.1672180022515022e-07
localization O 0 8.19628439785447e-07
suggest O 0 5.048475859581458e-09
a O 0 5.565621297165535e-10
role O 0 8.428068243304665e-10
in O 0 1.0185075005608724e-09
cell O 0 1.8056617534512043e-07
- O 0 3.651497024748096e-07
cycle O 0 5.690497459909238e-07
regulation O 0 1.3580662198364735e-05
. O 0 1.4393262972589582e-06

When O 0 2.967565251310589e-07
resting O 0 1.69273278061155e-06
cells O 0 5.322146279240769e-08
are O 0 1.8422986747257397e-10
induced O 0 1.3518697272729696e-08
to O 0 2.3012859673432473e-10
proliferate O 0 1.2575529062530677e-08
, O 0 4.6502510175905343e-10
the O 0 6.980853117788399e-10
steady O 0 1.3034347823293047e-08
- O 0 1.5589712853980586e-09
state O 0 2.7918726358544532e-11
levels O 0 7.590793549283603e-10
of O 0 1.557098339155516e-10
BRCA1 O 0 6.841628374942843e-10
increase O 0 5.4370334623410344e-11
in O 0 3.2159164220502134e-10
late O 0 1.2630509615974006e-07
G1 O 0 5.1480906648748714e-08
and O 0 3.240533397175227e-10
reach O 0 1.1505838504177746e-09
a O 0 1.645182046150495e-10
maximum O 0 4.970273081994492e-09
during O 0 1.688501605201509e-08
S O 0 3.350703252635867e-07
phase O 0 8.874898753674643e-07
. O 0 2.5966414796130266e-06

Moreover O 0 8.43350903778628e-07
, O 0 1.3035069912348263e-08
in O 0 2.1804444916284638e-09
S O 0 7.191391659944202e-08
phase O 0 6.135398677997728e-08
cells O 0 2.173076723011036e-07
, O 0 2.6181274037639923e-08
BRCA1 O 0 7.590222139697289e-08
polypeptides O 0 6.101718241779963e-08
are O 0 3.5615848048564658e-09
hyperphosphorylated O 0 7.317084964597598e-07
and O 0 8.486903624316255e-09
accumulate O 0 4.8983078926312373e-08
into O 0 1.5745172277092934e-08
discrete O 0 7.504154808657404e-08
subnuclear O 0 4.419231572683202e-06
foci O 0 1.3919622006142163e-06
termed O 0 2.2397688326236675e-07
" O 0 3.3240158359149063e-07
BRCA1 O 0 1.0933073326668818e-06
nuclear O 0 6.865235718578333e-06
dots O 0 1.4853827451588586e-05
. O 0 7.531149549322436e-06

" O 0 1.9575516489567235e-05
BRCA1 O 0 2.079562000290025e-05
associates O 0 3.917439812539669e-07
in O 0 7.813657276756203e-09
vivo O 0 2.55982655517073e-07
with O 0 1.4311429819002797e-10
a O 0 2.312106062163366e-09
structurally O 0 6.228999183122141e-08
related O 0 6.494131099543665e-08
protein O 0 7.388870670865799e-08
termed O 0 3.087974391746684e-06
BARD1 O 1 0.7573530673980713
. O 0 9.029060493048746e-06

Here O 0 1.7288211040522583e-07
we O 0 5.579558592927469e-09
show O 0 9.629581576575674e-10
that O 0 3.947442719920424e-11
the O 0 2.950134303514318e-10
steady O 0 1.2711781849361614e-08
- O 0 4.967325661908717e-09
state O 0 8.054395345125087e-11
levels O 0 2.8909568072776892e-09
of O 0 1.8557716474632002e-09
BARD1 O 0 1.5231394172587898e-06
, O 0 2.9906652154743085e-10
unlike O 0 4.730423830423547e-10
those O 0 9.225449570937627e-11
of O 0 1.5364184369204281e-09
BRCA1 O 0 1.4178475282733416e-08
, O 0 5.074965447882107e-10
remain O 0 5.037952721664851e-09
relatively O 0 1.0287360963090464e-09
constant O 0 1.7396624141241546e-09
during O 0 2.1099357816467545e-09
cell O 0 4.1501756697925885e-08
cycle O 0 1.0070245792803689e-07
progression O 0 1.573957888467703e-06
. O 0 1.2035064855808741e-06

However O 0 2.2457427917288442e-07
, O 0 3.1953636181469847e-08
immunostaining O 0 6.158029918879038e-06
revealed O 0 6.484587800059671e-08
that O 0 8.308045362781513e-10
BARD1 O 0 2.7629621399682947e-05
resides O 0 4.356528648941094e-08
within O 0 2.885371053196195e-09
BRCA1 O 0 5.838890704268351e-09
nuclear O 0 5.343822451209235e-08
dots O 0 3.5556002586645263e-08
during O 0 7.286355696578539e-08
S O 0 1.9925224137296027e-08
phase O 0 4.4011256861153925e-09
of O 0 1.3694516631801434e-09
the O 0 2.540135046746883e-10
cell O 0 1.1769394347993511e-09
cycle O 0 2.406204124838496e-10
, O 0 4.18820464420655e-11
but O 0 3.517362789917655e-11
not O 0 2.1360850588347802e-10
during O 0 1.1540217670358288e-08
the O 0 1.5789380469755088e-08
G1 O 0 1.2408386282913852e-06
phase O 0 1.2642055935430108e-06
. O 0 2.985814944622689e-06

Nevertheless O 0 8.705087566340808e-06
, O 0 9.653810195686674e-08
BARD1 O 0 1.4805107639404014e-05
polypeptides O 0 8.002893281400247e-08
are O 0 4.444941081871434e-10
found O 0 2.6414231912852415e-10
exclusively O 0 3.941358350800783e-10
in O 0 6.82500653215179e-11
the O 0 2.2190468906835292e-10
nuclear O 0 1.6654562173812337e-08
fractions O 0 5.663417823598138e-08
of O 0 1.210941835694257e-08
both O 0 1.65196845092197e-09
G1 O 0 1.5058840574511123e-07
- O 0 1.3837124868132378e-07
and O 0 1.2969374907356723e-08
S O 0 5.430252372207178e-07
- O 0 1.4046827345737256e-07
phase O 0 5.82051313813281e-07
cells O 0 1.2948088397024549e-06
. O 0 6.768274829482834e-07

Therefore O 0 1.653880588037282e-07
, O 0 7.622150022257301e-09
progression O 0 6.59177032957814e-08
to O 0 1.9962225206171524e-09
S O 0 3.747240739926383e-08
phase O 0 2.8709511212809957e-08
is O 0 3.409198756632037e-10
accompanied O 0 1.0079004297836036e-08
by O 0 2.375482865968337e-10
the O 0 7.522978351381937e-10
aggregation O 0 6.481947756320494e-10
of O 0 1.3807426313405813e-09
nuclear O 0 1.422191076017043e-07
BARD1 O 0 1.7672025933279656e-05
polypeptides O 0 1.631621984188314e-07
into O 0 3.090626421453635e-08
BRCA1 O 0 3.098861327544e-07
nuclear O 0 3.258966899011284e-06
dots O 0 9.621393473935314e-06
. O 0 4.6119821490719914e-06

This O 0 4.0264240830367726e-09
cell O 0 2.1179928921810642e-08
cycle O 0 6.7918346502438e-09
- O 0 5.836166039330237e-08
dependent O 0 5.064227792672682e-08
colocalization O 0 1.2996647456020582e-06
of O 0 2.2526014831214525e-08
BARD1 O 0 4.812058250536211e-05
and O 0 1.0501516989336324e-08
BRCA1 O 0 2.3480472677306352e-08
indicates O 0 2.483097949479429e-09
a O 0 2.9154859082503037e-10
role O 0 1.8293507819677757e-09
for O 0 3.926661218400795e-09
BARD1 O 0 0.006934604607522488
in O 0 1.3945715693353122e-07
BRCA1 O 0 4.851038283959497e-06
- O 0 1.0049204320239369e-05
mediated O 0 1.2291514394746628e-05
tumor B-Disease 0 0.0007446329109370708
suppression O 0 0.00254900474101305
. O 0 3.2423472475784365e-06

Ethnic O 0 3.4547881000435154e-08
differences O 0 1.3100496687457053e-08
in O 0 4.260131358790886e-09
the O 0 1.3725850678270035e-08
HFE O 0 4.5547647459898144e-05
codon O 0 2.612476237118244e-06
282 O 0 2.0684483388322406e-06
( O 0 5.857342557646916e-07
Cys O 1 0.9704956412315369
/ O 0 0.001476390054449439
Tyr O 0 0.0007305851322598755
) O 0 2.83542675560966e-07
polymorphism O 0 2.1129702872713096e-05
. O 0 2.546301857364597e-06

Recent O 0 2.1654464887888025e-08
studies O 0 7.15616987889689e-09
have O 0 1.360718066001354e-10
shown O 0 6.973693289502592e-10
that O 0 3.6982599205259703e-09
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
( O 0 3.36491248162929e-05
HH B-Disease 1 0.9025079011917114
) O 0 7.918147248986429e-10
is O 0 3.050533436965708e-11
likely O 0 7.63874796749775e-11
to O 0 7.917841382543145e-11
be O 0 4.1711939458011216e-10
caused O 0 3.1264539845921036e-09
by O 0 2.5521887381252384e-10
homozygosity O 0 1.4546156990036252e-07
for O 0 7.638868426695922e-10
a O 0 1.4769562239891343e-09
Cys282Tyr O 0 2.5844963147392264e-07
mutation O 0 1.2203524857312686e-09
in O 0 4.4084660921761554e-10
the O 0 6.174206923503789e-09
HFE O 0 9.342435077996925e-05
gene O 0 5.584469420227833e-08
located O 0 3.8152425219095676e-08
4 O 0 2.0419904558366397e-06
. O 0 2.3490561034122948e-06

5 O 0 1.6520485587534495e-05
Mb O 0 0.0007080161012709141
telomeric O 0 0.0002868261653929949
to O 0 3.082143166466267e-06
HLA O 0 0.0006985508371144533
- O 0 0.0005662652547471225
A O 0 5.598963252850808e-05
. O 0 4.20874539486249e-06

Population O 0 1.058626342143043e-08
studies O 0 4.291710098414114e-09
of O 0 1.1598467741791296e-09
this O 0 4.725245195125183e-11
polymorphism O 0 7.588438322159163e-09
are O 0 3.198614983990211e-11
facilitated O 0 1.2022534079392244e-09
by O 0 4.962727451207627e-11
the O 0 5.143530601436908e-10
fact O 0 2.378860719520759e-10
that O 0 2.7580519465497666e-11
the O 0 6.951024755785795e-10
Cys282Tyr O 0 6.812335300310224e-07
mutation O 0 4.290179322907761e-09
creates O 0 2.046791403031989e-09
a O 0 6.6426184552881296e-09
Rsal O 0 8.409756446781103e-06
restriction O 0 4.478052062495408e-07
site O 0 4.2140769096477015e-07
. O 0 1.9733155909307243e-07

We O 0 1.1221900564351017e-07
have O 0 5.774454692186737e-09
studied O 0 5.474847952768869e-08
the O 0 8.004049867338381e-09
codon O 0 2.035784376630545e-07
282 O 0 2.660313782598678e-07
( O 0 3.1861168281466234e-07
Cys O 0 0.23045890033245087
/ O 0 0.0002696971350815147
Tyr O 0 6.405523890862241e-05
) O 0 2.552058564475601e-09
polymorphism O 0 1.7937464846795592e-08
in O 0 2.4456536795725015e-10
different O 0 1.669538535198356e-10
ethnic O 0 7.468791696219057e-10
groups O 0 3.9213770008927895e-09
. O 0 9.814647938810594e-08

In O 0 1.1185631976218247e-08
agreement O 0 3.6825000826468113e-09
with O 0 1.5017802279526649e-10
previous O 0 6.440592503764719e-09
observations O 0 1.771675606221379e-08
the O 0 1.8095285270192107e-09
Tyr O 0 2.144997552022687e-06
allele O 0 3.426856665100786e-08
appeared O 0 4.4915267061185205e-09
to O 0 2.087378742077206e-10
be O 0 3.6487846077903896e-10
rare O 0 8.402584406042024e-09
or O 0 5.698935545694894e-09
absent O 0 7.339386343119259e-08
in O 0 1.0463404587213176e-09
Asiatic O 0 3.461113635694346e-07
( O 0 2.1173576225663737e-09
Indian O 0 2.583382840981585e-09
, O 0 4.093864136578418e-10
Chinese O 0 2.8484827829799997e-09
) O 0 1.885902101150805e-09
populations O 0 4.9451576167314215e-09
. O 0 2.7025032878214006e-08

The O 0 6.941902341850437e-08
highest O 0 5.464613650474348e-08
allele O 0 3.691072114619942e-09
frequency O 0 2.1182180454104582e-09
( O 0 1.2626155676542794e-10
7 O 0 1.3547316601858483e-09
. O 0 9.776222192892092e-11
5 O 0 2.0701207414930423e-09
% O 0 2.2396955123848983e-10
) O 0 1.0940999495279158e-10
was O 0 2.1221082668887448e-09
found O 0 9.509246723382603e-10
in O 0 3.1805256206496324e-09
Swedes O 0 7.198361345217563e-06
. O 0 2.6899610929831397e-06

Saamis O 0 0.00035818421747535467
( O 0 2.6807461139810584e-08
2 O 0 7.521622080730594e-08
% O 0 2.2371946517552033e-09
) O 0 2.77402822934647e-10
and O 0 2.4745816507021345e-10
Mordvinians O 0 4.5413759153234423e-07
( O 0 1.598386561996179e-10
1 O 0 2.1501598279627387e-09
. O 0 3.7156513976732697e-10
8 O 0 6.501267080238904e-09
% O 0 4.0415873425736493e-10
) O 0 1.4168241579959329e-10
had O 0 4.5159892492208087e-10
significantly O 0 7.026270676391277e-10
lower O 0 1.8702697168748728e-09
frequencies O 0 9.386462274107998e-09
of O 0 1.0869645628019953e-08
the O 0 1.0589095467139487e-07
Tyr O 0 9.059879812411964e-05
allele O 0 3.045810672119842e-06
. O 0 2.392314627286396e-06

Comparisons O 0 4.2041136794068734e-07
with O 0 1.2693603945734822e-09
allele O 0 1.517754988356046e-08
frequencies O 0 3.228837641700011e-09
based O 0 4.2679776379728196e-10
on O 0 2.7365076871177507e-09
prevalence O 0 1.3504574347678044e-08
estimates O 0 5.649127832185741e-10
of O 0 2.4543280741085027e-09
HH B-Disease 0 0.0003642627561930567
showed O 0 2.2877482308558683e-07
some O 0 4.5821408889423765e-09
disagreements O 0 9.536714529190249e-09
with O 0 3.492629241375056e-10
the O 0 1.025267515331052e-08
RFLP O 0 1.4151303275866667e-06
data O 0 1.2631444334942898e-08
, O 0 6.971778154785113e-10
particularly O 0 6.385427298027935e-09
in O 0 8.26267854137086e-09
Finns O 0 5.779763796454063e-06
. O 0 1.3001197203266202e-06

The O 0 3.000948254339164e-07
newly O 0 1.1835966233775252e-06
described O 0 1.536670453106126e-07
HFE O 0 0.0002093995426548645
marker O 0 7.783656315041299e-07
provides O 0 2.1477049028106876e-09
a O 0 5.892923649053472e-11
new O 0 6.367323335254582e-11
approach O 0 1.2101976087919297e-09
to O 0 1.5211615300714243e-10
the O 0 2.580338165358853e-10
screening O 0 8.463834966221384e-09
of O 0 8.362772696557386e-09
HH B-Disease 0 4.894622634310508e-06
as O 0 3.121151115337284e-09
well O 0 6.748469005835034e-10
as O 0 1.8423618186602653e-10
studies O 0 1.276023037233287e-10
of O 0 1.0478497236565687e-10
the O 0 9.023180119749341e-11
relationship O 0 3.6300819988843713e-11
between O 0 5.468768216054798e-10
the O 0 1.5005504394594027e-08
HFE O 1 0.998941957950592
Tyr O 0 0.00039917544927448034
allele O 0 6.197806357022273e-08
and O 0 2.0812058743047146e-09
different O 0 2.0282628909740197e-08
disorders O 1 0.9999833106994629
including O 0 8.37358402350219e-06
cancer B-Disease 1 0.9998278617858887

Autosomal B-Disease 1 1.0
dominant I-Disease 1 0.999895453453064
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 0 0.14618994295597076
associated O 0 1.266345517336731e-08
with O 0 7.748437308441325e-11
a O 0 1.408789307433267e-09
missense O 0 9.11300972461504e-08
mutation O 0 2.4986763769163645e-09
encoding O 0 2.3975298191203365e-08
Gly23 O 0 2.7594522180152126e-05
- O 0 7.184244896052405e-05
- O 0 0.00019847770454362035
> O 0 8.958453690866008e-05
Val O 0 1.8856926544685848e-06
in O 0 3.502251999520922e-08
neurophysin O 0 0.00012070602679159492
II O 1 1.0
. O 0 2.5044708308996633e-05

Autosomal B-Disease 1 1.0
dominant I-Disease 1 0.9998540878295898
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 1.0
( O 0 2.1759753110472957e-08
ADNDI B-Disease 1 0.99954754114151
) O 0 2.3024551154549044e-09
is O 0 2.4855936753276353e-10
an O 0 1.295833884640274e-09
inherited B-Disease 1 1.0
disease I-Disease 1 1.0
caused O 1 0.582450807094574
by O 0 6.963090992684329e-09
progressive O 1 0.768343448638916
degeneration O 1 1.0
of O 0 4.1388290128452354e-07
the O 0 2.2248425324278287e-08
magnocellular O 0 1.1533394399521057e-06
neurons O 0 3.610215415505991e-08
of O 0 9.591298066879972e-08
the O 0 1.1596465299135161e-07
hypothalamus O 0 1.4314659892988857e-06
leading O 0 1.6110629275090105e-08
to O 0 7.743092833578658e-10
decreased O 0 5.155978310966702e-09
ability O 0 5.942159542193792e-10
to O 0 5.586104356858357e-10
produce O 0 4.638825323866058e-09
the O 0 1.4332771058889193e-07
hormone O 0 2.103168299072422e-06
arginine O 0 8.038321084313793e-07
vasopressin O 0 8.62625711306464e-06
( O 0 2.864268253688351e-07
AVP O 0 0.0001923209783853963
) O 0 2.1582393117114407e-07
. O 0 1.1794971896961215e-06

Affected O 0 7.373088806161832e-08
individuals O 0 3.167985318519584e-10
are O 0 7.223467657357929e-11
not O 0 1.602339511075357e-10
symptomatic O 0 5.40041327212748e-08
at O 0 1.4190967290161893e-09
birth O 0 1.2973481844369417e-08
, O 0 2.332644633007419e-10
but O 0 1.082127096263541e-10
usually O 0 1.8505191823336986e-09
develop O 0 7.040202376629168e-08
diabetes B-Disease 1 0.9999997615814209
insipidus I-Disease 0 1.5313764379243366e-05
at O 0 1.4873148046490314e-08
1 O 0 1.7039931776707817e-07
- O 0 1.0384565030108206e-05
6 O 0 2.0719859094242565e-05
yr O 0 0.00010468583786860108
of O 0 3.157034882406151e-07
age O 0 4.6289508759400633e-07
. O 0 5.177336674933031e-07

The O 0 1.1530145371807521e-07
genetic O 0 4.319988633483263e-08
locus O 0 1.5223299953959213e-08
of O 0 1.4511600809896663e-09
the O 0 3.781393420609902e-09
disease O 0 7.121342093796557e-08
is O 0 3.1519696574999756e-11
the O 0 9.492900909791047e-10
AVP O 1 0.9129316210746765
- O 0 0.00012222984514664859
neurophysin O 1 0.9999990463256836
II O 1 1.0
( O 0 3.6148804838376236e-07
NPII O 0 0.06552616506814957
) O 0 2.19448015315038e-09
gene O 0 1.516235137444255e-09
, O 0 2.262533216335072e-10
and O 0 2.7564753257713903e-10
mutations O 0 1.6110313083572692e-09
that O 0 8.612869445423499e-11
cause O 0 4.8560188758983713e-08
ADNDI B-Disease 0 0.11693897843360901
have O 0 1.4031952266790881e-09
been O 0 1.9936492734462519e-10
found O 0 2.4401730636114394e-11
in O 0 3.1326705118850384e-11
both O 0 7.542341751154424e-11
the O 0 3.6425470972822893e-10
signal O 0 1.3438103074747687e-08
peptide O 0 8.133166140567027e-09
of O 0 1.0608822265112394e-08
the O 0 5.586217000086435e-08
prepro O 1 0.8730317950248718
- O 0 0.0057489569298923016
AVP O 1 0.6382147669792175
- O 0 2.597520870040171e-05
NPII O 0 0.00017488801677245647
precursor O 0 7.744768595330243e-07
and O 0 9.868593053852237e-09
within O 0 2.986689295880751e-08
NPII O 0 8.156022522598505e-05
itself O 0 9.570283054927131e-08
. O 0 1.2345621769327408e-07

An O 0 6.321974055367718e-09
affected O 0 4.952501519994712e-09
girl O 0 8.49524450785566e-09
who O 0 5.6672050385842e-10
presented O 0 1.6114123368993205e-09
at O 0 2.6976814115897696e-09
9 O 0 4.802931385938791e-09
months O 0 4.5423023675716934e-10
of O 0 1.6897629129264402e-10
age O 0 2.8798821660735996e-10
and O 0 1.6184097118010499e-10
her O 0 1.7656691386758183e-10
similarly O 0 6.420278197971641e-10
affected O 0 1.6750532905174254e-10
younger O 0 6.572681288119497e-10
brother O 0 6.0010028057888576e-09
and O 0 1.0738600009219113e-09
father O 0 1.736702692767267e-08
were O 0 6.4251817200045025e-09
all O 0 5.389983459558323e-10
found O 0 2.3028842721650733e-10
to O 0 1.0085513674207292e-10
have O 0 1.0402308875390176e-10
a O 0 2.097747947571449e-10
novel O 0 2.06741779251729e-09
missense O 0 1.8258520029235115e-08
mutation O 0 1.6761215748672953e-09
( O 0 5.609722131261208e-10
G1758 O 0 1.551057948745438e-07
- O 0 9.990620952748941e-08
- O 0 2.2797921417350153e-07
> O 0 5.870652444173174e-07
T O 0 1.1848541703329829e-07
) O 0 2.7441898753366445e-10
encoding O 0 2.022853218264231e-09
the O 0 2.240649443763232e-09
amino O 0 1.7768558846498195e-09
acid O 0 1.5208547754497204e-09
substitution O 0 9.178197046821879e-08
Gly23 O 0 3.054575063288212e-05
- O 0 7.433295832015574e-05
- O 0 0.00012045846233377233
> O 0 8.267040539067239e-05
Val O 0 1.3144946024112869e-05
within O 0 4.2962003021784767e-07
NPII O 0 0.0037757863756269217
. O 0 2.750885414570803e-06

The O 0 3.0334658163155837e-07
mutation O 0 7.388687350839973e-08
was O 0 3.7968760580042726e-08
confirmed O 0 4.9108597188762815e-09
by O 0 1.1823978462999207e-09
restriction O 0 7.530378809406102e-08
endonuclease O 0 9.915905820889748e-07
analysis O 0 1.2368860780043178e-07
. O 0 3.612833552324446e-07

A O 0 9.155070983979385e-06
T1 O 0 0.0001279475400224328
- O 0 3.494230213618721e-06
weighted O 0 3.340541070429026e-07
magnetic O 0 1.7228170179350855e-07
resonance O 0 3.41293741712434e-07
imaging O 0 2.0349982150946744e-05
of O 0 1.1675925861709402e-06
the O 0 7.558556262665661e-06
fathers O 1 0.9901148080825806
pituitary O 0 0.22048799693584442
gland O 0 9.971305189537816e-06
demonstrates O 0 2.3494119716360728e-07
an O 0 3.888946498165069e-09
attenuated O 0 1.0660179441401851e-06
posterior O 0 2.397199750703294e-06
pituitary O 1 0.9883067011833191
bright O 0 0.0001947167475009337
spot O 0 0.0006383795407600701
. O 0 7.938499948068056e-06

This O 0 5.111282774805659e-08
mutation O 0 5.6852154983744185e-08
may O 0 2.8111168948186105e-09
be O 0 4.3284298367751717e-10
valuable O 0 9.409478529676107e-09
for O 0 1.9402737749807386e-10
developing O 0 1.1763715557222554e-09
models O 0 1.9673140894127528e-09
of O 0 2.935586884689201e-09
dominantly B-Disease 0 3.944893251173198e-06
inherited I-Disease 0 3.2927973734331317e-06
neurodegeneration I-Disease 1 1.0
, O 0 4.97064944759984e-10
as O 0 3.733096470837083e-11
the O 0 3.450041641261947e-11
early O 0 1.0185755572322819e-09
age O 0 2.147015482067971e-10
of O 0 4.741335657421075e-10
onset O 0 0.000119125543278642
of O 0 6.17611632947046e-08
symptoms O 0 2.890360292440164e-06
suggests O 0 2.9539983792403746e-09
that O 0 1.1784971436223923e-11
this O 0 6.47598849545794e-11
mutation O 0 2.4910911111675205e-09
may O 0 2.866774595489119e-09
be O 0 3.2821874107469284e-09
particularly O 0 1.558957229974567e-08
deleterious O 0 3.189287056670764e-08
to O 0 1.0093086366680382e-08
the O 0 9.286741686764799e-08
magnocellular O 0 1.6389425582019612e-05
neuron O 0 1.110851712837757e-06
. O 0 1.6785610057468148e-07
. O 0 1.3089165804558434e-06

Frequent O 0 6.851682883279864e-07
inactivation O 0 8.10254095995333e-06
of O 0 6.593419584532967e-06
PTEN O 1 0.9999951124191284
/ O 0 0.09315932542085648
MMAC1 O 1 0.9966846108436584
in O 0 3.494372720069805e-07
primary O 1 0.9999934434890747
prostate B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 2.0844978280365467e-05

Sporadic B-Disease 1 1.0
prostate I-Disease 1 1.0
carcinoma I-Disease 1 1.0
is O 0 1.4458782615633936e-08
the O 0 9.242308585122316e-10
most O 0 1.424041717879021e-10
common O 0 5.221332255445077e-10
male B-Disease 0 7.921481526285135e-11
cancer I-Disease 0 8.408058277398212e-11
in O 0 8.379619914622438e-12
the O 0 1.620850120787054e-10
Western O 0 4.2770928132540575e-08
world O 0 4.926282493045164e-09
, O 0 9.072085443984079e-11
yet O 0 5.149201898202449e-11
many O 0 9.70820819568008e-12
of O 0 3.623247535333718e-11
the O 0 7.647013577916084e-11
major O 0 6.120245421570303e-10
genetic O 0 3.4896327494315926e-10
events O 0 1.9130209569229173e-11
involved O 0 2.1024777405176387e-11
in O 0 2.580809350949398e-11
the O 0 2.6778307349317743e-10
progression O 0 2.982249114324986e-08
of O 0 5.425589422181076e-10
this O 0 9.621883845234436e-11
often O 0 1.1086455087294667e-09
fatal O 0 7.047726313658131e-08
cancer B-Disease 0 5.684325401489332e-07
remain O 0 7.923911482521362e-08
to O 0 3.0801455608298056e-08
be O 0 2.8613359859264165e-07
elucidated O 0 0.00010237635433441028
. O 0 1.1492712474137079e-05

Numerous O 0 2.635787552662805e-07
cytogenetic O 0 5.671109647664707e-06
and O 0 1.4212320209594509e-08
allelotype O 0 1.8932373677671421e-06
studies O 0 7.240827493149027e-09
have O 0 7.70269889538433e-11
reported O 0 6.08834094251165e-11
frequent O 0 1.2453924003175132e-10
loss O 0 8.143407059790775e-10
of O 0 2.968130630165433e-08
heterozygosity O 1 0.9896309971809387
on O 0 3.6334135984361637e-06
chromosomal O 0 1.9688750398927368e-05
arm O 0 4.141063618590124e-05
10q O 0 0.010099506936967373
in O 0 3.185566868069145e-07
sporadic B-Disease 1 1.0
prostate I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 8.151698420988396e-05

Deletion O 0 4.224621534376638e-06
mapping O 0 3.8289377357614285e-07
studies O 0 2.978145374754604e-08
have O 0 4.387662733140729e-10
unambiguously O 0 3.024396511008831e-09
identified O 0 6.147810593937209e-10
a O 0 2.955045097507991e-10
region O 0 3.4093174949845206e-09
of O 0 1.1967974167248485e-08
chromosome O 0 9.224459773804483e-08
10q23 O 0 5.378917080633983e-07
to O 0 4.644311879520302e-10
be O 0 3.0660632366341645e-10
the O 0 9.122914645942615e-10
minimal O 0 2.528628613163164e-07
area O 0 2.0116385002211246e-08
of O 0 2.576617852412255e-08
loss O 0 2.367508926681694e-07
. O 0 9.114640988627798e-07

A O 0 5.404178295975726e-07
new O 0 3.314955421274135e-08
tumor B-Disease 0 5.07615652622917e-07
suppressor O 0 2.762990106930374e-06
gene O 0 5.146362624941503e-08
, O 0 3.172717200072839e-08
PTEN O 1 0.8701689839363098
/ O 0 0.006055690813809633
MMAC1 O 1 0.9968961477279663
, O 0 7.463668794116529e-09
was O 0 2.439236901352615e-08
isolated O 0 7.237983101759937e-09
recently O 0 3.7219854975845124e-10
at O 0 7.880010532979043e-11
this O 0 9.562327492329548e-12
region O 0 5.159969673762532e-10
of O 0 1.0184900700593857e-09
chromosome O 0 8.994356370806145e-09
10q23 O 0 6.87699781565243e-08
and O 0 4.137486186994721e-10
found O 0 2.147482469627704e-10
to O 0 1.2592293874291727e-10
be O 0 1.5913566298042525e-10
inactivated O 0 8.238585813558075e-09
by O 0 3.8206640629034894e-10
mutation O 0 5.033227168382837e-09
in O 0 5.054989316022329e-09
three O 0 1.1482044328658958e-06
prostate B-Disease 1 1.0
cancer I-Disease 1 1.0
cell O 0 4.883158908342011e-06
lines O 0 4.7306002670666203e-07
. O 0 1.6924213923630305e-06

We O 0 1.1997785804851446e-06
screened O 0 1.2761196558130905e-05
80 O 0 3.510896203806624e-05
prostate B-Disease 1 0.9996932744979858
tumors I-Disease 1 1.0
by O 0 6.376262629004259e-09
microsatellite O 0 1.0967989538812617e-07
analysis O 0 3.474571741435284e-09
and O 0 3.99255933869469e-10
found O 0 7.176066962877314e-10
chromosome O 0 9.661763833435089e-09
10q23 O 0 1.311681501192652e-07
to O 0 7.89575183013369e-10
be O 0 1.7042905975372946e-09
deleted O 0 3.595920716747969e-08
in O 0 2.649968022794269e-09
23 O 0 1.1819288658898586e-07
cases O 0 2.0382685761433095e-08
. O 0 1.7091295489990443e-07

We O 0 4.676342868492611e-08
then O 0 1.8671044710316664e-09
proceeded O 0 2.280601485438183e-09
with O 0 9.287361678322892e-12
sequence O 0 2.4327748149310935e-11
analysis O 0 4.8882575071074186e-11
of O 0 1.2053547049362123e-10
the O 0 2.407076482580095e-10
entire O 0 1.584138686894221e-08
PTEN O 0 3.661062510218471e-05
/ O 0 2.483190837665461e-05
MMAC1 O 0 0.0001477596815675497
coding O 0 1.8925712765849312e-06
region O 0 6.436002308873867e-08
and O 0 2.4628770134427214e-09
tested O 0 5.5248619013070766e-09
for O 0 7.192510476095038e-10
homozygous O 0 3.3811862198973586e-09
deletion O 0 4.0268006706867254e-09
with O 0 5.846842454637624e-11
new O 0 5.2261670546727146e-09
intragenic O 0 1.4672506040369626e-05
markers O 0 1.8845474514250782e-08
in O 0 3.2566807584011315e-10
these O 0 9.813680423853555e-11
23 O 0 1.4902160616614424e-09
cases O 0 8.346907887091248e-11
with O 0 8.666854733885287e-11
10q23 O 0 2.048136229859665e-05
loss O 0 5.322988840816834e-07
of O 0 2.039596984104719e-05
heterozygosity O 1 0.9999974966049194
. O 0 5.0448488764232025e-05

The O 0 8.633568526761337e-09
identification O 0 4.411599618947548e-08
of O 0 1.8602733575789898e-08
the O 0 6.6047425306692276e-09
second O 0 5.86261883483985e-08
mutational O 0 1.1028409971913788e-06
event O 0 3.088209021839816e-09
in O 0 4.168887457467463e-10
10 O 0 2.1936932270705256e-09
( O 0 1.0424877627812634e-09
43 O 0 2.0286343271891383e-08
% O 0 3.778956259026245e-09
) O 0 2.6606759462310947e-08
tumors B-Disease 1 1.0
establishes O 0 3.0124117529339856e-06
PTEN O 0 0.3839147090911865
/ O 0 0.000303491426166147
MMAC1 O 0 0.000133452849695459
as O 0 6.0249494282516025e-09
a O 0 4.6162804134830537e-10
main O 0 1.480752853666445e-09
inactivation O 0 8.325879541359882e-09
target O 0 1.1379341913198004e-09
of O 0 1.672914806682968e-09
10q O 0 1.4089506521486328e-06
loss O 0 3.1185582116677324e-08
in O 0 2.0846156800757853e-08
sporadic B-Disease 1 0.9999866485595703
prostate I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 8.927563044380804e-07
. O 0 9.897114523482742e-07

Risk O 0 5.927432084718021e-06
reversals O 0 8.353846396857989e-07
in O 0 4.435187328510892e-09
predictive O 0 9.105035303491604e-08
testing O 0 4.919233376199372e-08
for O 0 6.352751569238535e-08
Huntington B-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 4.967540462530451e-06

The O 0 1.0337783606928497e-07
first O 0 6.4025740265094555e-09
predictive O 0 1.9879026424973745e-08
testing O 0 6.287545151195673e-09
for O 0 8.036510124043161e-09
Huntington B-Disease 1 1.0
disease I-Disease 1 1.0
( O 0 2.987383007635458e-09
HD B-Disease 0 1.1104799568784074e-06
) O 0 4.4902737084129285e-10
was O 0 2.165152057642672e-09
based O 0 3.756203403870728e-10
on O 0 2.4688735500433268e-09
analysis O 0 2.808656862640646e-09
of O 0 2.0962052094120054e-09
linked O 0 4.5652437385967914e-09
polymorphic O 0 4.742450432360101e-09
DNA O 0 8.029187092972734e-09
markers O 0 4.576228285202433e-09
to O 0 7.78532849299296e-10
estimate O 0 2.582210223422976e-09
the O 0 5.251084012058982e-10
likelihood O 0 2.844584345851331e-09
of O 0 4.451450319464811e-09
inheriting O 0 5.734244012955969e-08
the O 0 2.2517724573845044e-08
mutation O 0 2.196176929203375e-08
for O 0 2.828474343630205e-08
HD B-Disease 0 0.00015786499716341496
. O 0 3.7475706449185964e-06

Limits O 0 1.8294220183179277e-07
to O 0 3.02762859227812e-09
accuracy O 0 1.9947391294294903e-08
included O 0 2.1442991826603475e-09
recombination O 0 1.442054808897808e-09
between O 0 7.430027426647001e-11
the O 0 4.397247010956562e-10
DNA O 0 6.317887546458678e-09
markers O 0 9.323334104749392e-09
and O 0 1.5336955039302325e-09
the O 0 1.641046942779667e-08
mutation O 0 1.0632482450034786e-08
, O 0 3.137778925577095e-10
pedigree O 0 3.0090565594775853e-09
structure O 0 4.803047959356377e-10
, O 0 2.0948252854591232e-10
and O 0 5.856116980229586e-11
whether O 0 3.7880889397490236e-11
DNA O 0 1.7687441511426982e-09
samples O 0 1.214104816682493e-09
were O 0 6.051227297021455e-10
available O 0 4.9365533882905765e-09
from O 0 1.3976501067602953e-09
family O 0 2.6097648486711478e-09
members O 0 7.893135922643069e-09
. O 0 1.952329995447144e-07

With O 0 2.8653861505745226e-09
direct O 0 9.1325125239905e-09
tests O 0 9.321390326277879e-10
for O 0 1.554249784430084e-10
the O 0 1.6408518987987009e-09
HD B-Disease 0 2.07786911232688e-06
mutation O 0 4.881405502032976e-09
, O 0 3.9154557374132537e-10
we O 0 6.684825470948397e-10
have O 0 1.1810269429091136e-10
assessed O 0 2.6501296712666544e-09
the O 0 2.918746633273628e-10
accuracy O 0 1.4741650566918452e-08
of O 0 2.049596492526007e-09
results O 0 1.741613658845509e-10
obtained O 0 8.676419027686677e-10
by O 0 5.90444498849152e-11
linkage O 0 3.241474866300109e-09
approaches O 0 2.8172950639060446e-09
when O 0 1.6907236721763752e-10
requested O 0 8.62343085827888e-09
to O 0 8.967304121476616e-10
do O 0 8.278655538873636e-10
so O 0 1.9156362607297694e-10
by O 0 1.3971429568826466e-10
the O 0 9.452753024774552e-10
test O 0 3.3510618724363894e-09
individuals O 0 1.301387220209449e-09
. O 0 1.5220911109281587e-07

For O 0 3.973009654600901e-08
six O 0 4.557300758989413e-09
such O 0 4.1424769170461673e-10
individuals O 0 3.6024509764143176e-11
, O 0 4.4984325292540817e-11
there O 0 3.9087531822357136e-11
was O 0 1.0706838748930636e-09
significant O 0 1.3825373068598878e-09
disparity O 0 6.260822971171365e-09
between O 0 1.009882066860257e-09
the O 0 1.2961608675254865e-08
tests O 0 4.040281353923092e-08
. O 0 2.0259322752735898e-07

Three O 0 5.172618244841942e-08
went O 0 4.31573070613922e-08
from O 0 8.938922935186611e-10
a O 0 2.620237637973588e-10
decreased O 0 2.393325315708239e-09
risk O 0 1.9198280465371198e-10
to O 0 2.237401409976858e-11
an O 0 1.2453797541833733e-11
increased O 0 2.4096946660279173e-10
risk O 0 1.1590639559244664e-09
, O 0 4.6460637420642215e-11
while O 0 6.775925653901282e-11
in O 0 4.937641268076831e-11
another O 0 7.502082982613345e-11
three O 0 4.697226982375291e-11
the O 0 5.254470192284089e-10
risk O 0 1.137639493720144e-08
was O 0 4.01833979424282e-08
decreased O 0 2.8123525908085867e-07
. O 0 1.9244463089762576e-07

Knowledge O 0 1.921832335938234e-06
of O 0 4.851075630085688e-08
the O 0 1.4999631536838365e-09
potential O 0 6.277273145727236e-10
reasons O 0 1.4012214721859095e-09
for O 0 4.921375112987292e-11
these O 0 2.300863492787908e-11
changes O 0 5.427014740377878e-11
in O 0 5.1723143129622784e-11
results O 0 4.365738673350883e-11
and O 0 2.804847847037717e-11
impact O 0 4.509568274357889e-10
of O 0 3.234210677049987e-10
these O 0 4.102859371690748e-11
risk O 0 4.8872811353462e-10
reversals O 0 1.7786701000943594e-09
on O 0 6.755784820455801e-10
both O 0 2.342529226151413e-10
patients O 0 7.67568786308459e-10
and O 0 8.183762001401362e-11
the O 0 1.2975652774471769e-09
counseling O 0 1.7526522455568738e-08
team O 0 5.072950046147717e-11
can O 0 3.464575154543681e-11
assist O 0 2.9329954021051208e-09
in O 0 1.8955803593456722e-10
the O 0 2.8119251371805376e-10
development O 0 7.693629067162533e-10
of O 0 3.910977375287672e-10
strategies O 0 5.841929162642145e-10
for O 0 2.461320036672987e-11
the O 0 5.0048479249831246e-11
prevention O 0 1.2683203820529343e-08
and O 0 4.3277919442585855e-11
, O 0 3.386113264780555e-11
where O 0 3.480776777919914e-11
necessary O 0 1.9926771344103145e-09
, O 0 1.9626583691589872e-10
management O 0 9.468451578342751e-10
of O 0 6.173414002219602e-10
a O 0 3.8377837019432093e-10
risk O 0 1.1122186505119203e-09
reversal O 0 1.2848329067338682e-09
in O 0 1.9971509168659196e-10
any O 0 1.2698975204727958e-10
predictive O 0 2.9370539333939405e-09
testing O 0 1.3986207747507251e-09
program O 0 4.964067379376047e-09
. O 0 1.0012212392496167e-08
. O 0 2.9800270340274437e-07

A O 0 4.3934707605330914e-07
novel O 0 8.303395304665173e-08
common O 0 1.964982665469961e-08
missense O 0 4.151166308474785e-07
mutation O 0 1.4785917379356306e-08
G301C O 0 5.010825248064066e-07
in O 0 2.031878665320619e-09
the O 0 3.305104412376636e-09
N O 0 4.3882529610073107e-08
- O 0 1.1580971204239177e-07
acetylgalactosamine O 0 5.21174388268264e-06
- O 0 6.000753387525037e-07
6 O 0 2.525139507270069e-06
- O 0 9.53914877754869e-06
sulfate O 0 1.106690774577146e-06
sulfatase O 0 8.328388503286988e-06
gene O 0 4.583419510595377e-08
in O 0 5.346636200442845e-08
mucopolysaccharidosis B-Disease 0 0.06640242040157318
IVA I-Disease 1 0.9999935626983643
. O 0 0.00018767961591947824

Mucopolysaccharidosis B-Disease 0 0.19824504852294922
IVA I-Disease 1 1.0
( O 0 0.0006157851312309504
MPS B-Disease 1 1.0
IVA I-Disease 1 1.0
) O 0 3.2105273817251145e-07
is O 0 1.1879096817324353e-08
an O 0 1.522742287818346e-08
autosomal B-Disease 1 0.9999991655349731
recessive I-Disease 1 0.9999995231628418
lysosomal I-Disease 1 1.0
storage I-Disease 1 1.0
disorder I-Disease 1 0.9999998807907104
caused O 0 1.0453674370580757e-08
by O 0 7.245130190236537e-11
a O 0 2.9776339616205405e-08
genetic B-Disease 1 1.0
defect I-Disease 1 1.0
in O 0 4.88236707951728e-07
N O 0 3.406531448035821e-07
- O 0 2.7905520028070896e-07
acetylgalactosamine O 0 7.711419129918795e-06
- O 0 1.4932833209968521e-06
6 O 0 1.2856229659519158e-05
- O 0 0.00018431262287776917
sulfate O 0 2.5756020477274433e-05
sulfatase O 0 7.019869372015819e-05
( O 0 7.83126594683381e-08
GALNS O 0 0.0006666762055829167
) O 0 1.4394646541404654e-07
. O 0 4.328352076754527e-07

In O 0 2.750827121644761e-08
previous O 0 1.4653681823517672e-08
studies O 0 7.970351489916538e-09
, O 0 3.417428007246315e-10
we O 0 1.8822858549594201e-10
have O 0 1.0039240966319696e-10
found O 0 1.1556153256542245e-10
two O 0 6.916887201890987e-11
common O 0 4.68216687643519e-10
mutations O 0 4.849978751941819e-10
in O 0 3.546331284187687e-10
Caucasians O 0 5.8485461806867534e-08
and O 0 1.384173220486673e-09
Japanese O 0 3.490200242595165e-06
, O 0 1.3657274422484988e-08
respectively O 0 1.344010769344095e-07
. O 0 1.3792961794933944e-07

To O 0 1.9469898404622654e-07
characterize O 0 9.834059255808825e-07
the O 0 5.96737947944348e-08
mutational O 0 2.5247849407605827e-05
spectrum O 0 5.45626086534412e-08
in O 0 1.0790685012196377e-10
various O 0 8.653178174000686e-11
ethnic O 0 2.086108195908931e-11
groups O 0 5.979399267386221e-12
, O 0 8.576831952988861e-12
mutations O 0 2.194519566067754e-11
in O 0 5.364544919395087e-11
the O 0 8.961986153188661e-10
GALNS O 0 5.932290150667541e-06
gene O 0 2.433204082663565e-09
in O 0 5.221722609860535e-09
Colombian O 0 0.0002915484656114131
MPS B-Disease 1 1.0
IVA I-Disease 1 1.0
patients O 0 4.7120588533289265e-06
were O 0 6.395129314995529e-09
investigated O 0 4.94231944259127e-09
, O 0 3.723462649318776e-10
and O 0 6.173426214672872e-10
genetic O 0 3.0855300536813957e-09
backgrounds O 0 1.7319417011663063e-09
were O 0 5.4551758665866146e-09
extensively O 0 4.087584937195743e-09
analyzed O 0 1.0389543669830914e-09
to O 0 2.6097088379195554e-10
identify O 0 3.374846180292934e-09
racial O 0 7.193415862971619e-10
origin O 0 1.9408150642163946e-09
, O 0 1.300756169442252e-10
based O 0 1.670047988788781e-10
on O 0 1.1623670914673312e-09
mitochondrial O 0 3.871214460104966e-09
DNA O 0 2.4417225574779877e-08
( O 0 1.5123683638762486e-08
mtDNA O 0 1.7022196630023245e-07
) O 0 2.6863764546192215e-08
lineages O 0 5.957247140031541e-07
. O 0 5.309827315613802e-07

Three O 0 1.925529318214103e-07
novel O 0 3.316176275802718e-07
missense O 0 3.4262143344676588e-06
mutations O 0 7.771582488658169e-08
never O 0 7.399137302854797e-08
identified O 0 1.4699366168713368e-08
previously O 0 2.5714272933186066e-09
in O 0 7.846236160791165e-11
other O 0 1.857221494649952e-11
populations O 0 8.905337404996327e-12
and O 0 7.663012585590323e-12
found O 0 1.2451779191069434e-11
in O 0 4.945218887164593e-11
16 O 0 3.131502834818889e-09
out O 0 2.1431613428379848e-10
of O 0 8.730224543285203e-09
19 O 0 2.834213148616982e-07
Colombian O 0 9.82953224593075e-06
MPS B-Disease 0 0.013824633322656155
IVA I-Disease 1 0.9996659755706787
unrelated O 0 1.6792846224689129e-07
alleles O 0 5.941607650328251e-09
account O 0 2.8590152467700136e-09
for O 0 3.323538333432907e-09
84 O 0 1.1226219385207514e-06
. O 0 7.387192795249575e-07

2 O 0 8.751699738240859e-07
% O 0 1.1185802506474829e-08
of O 0 4.703785805304506e-09
the O 0 1.0665808236609564e-09
alleles O 0 2.899011308787891e-10
in O 0 3.074988597084882e-10
this O 0 8.469677181821567e-10
study O 0 1.4335978626434098e-08
. O 0 9.559428093552924e-08

The O 0 7.674910875721253e-07
G301C O 0 2.7477166440803558e-05
and O 0 2.4988063174191666e-08
S162F O 0 1.9743406483030412e-06
mutations O 0 3.46193651523663e-09
account O 0 1.9381405369500726e-09
for O 0 4.7366741640075816e-09
68 O 0 3.9508718145953026e-06
. O 0 2.4287926407851046e-06

4 O 0 1.9218141460441984e-06
% O 0 3.9242969762653956e-08
and O 0 1.658311532537482e-08
10 O 0 3.617184063386958e-07
. O 0 7.3242551934527e-07

5 O 0 2.688584004317818e-07
% O 0 4.6498453976084875e-09
of O 0 3.2247571279953036e-09
mutations O 0 1.87004145502101e-09
, O 0 4.101531336786479e-10
respectively O 0 2.9270881274356952e-09
, O 0 1.6896953280998162e-10
whereas O 0 1.0949711137797635e-09
the O 0 1.0771606939741218e-09
remaining O 0 8.457464417688243e-08
F69V O 0 1.5441093637491576e-05
is O 0 6.62954025010265e-10
limited O 0 2.1929318361202377e-09
to O 0 2.0645964937671124e-09
a O 0 8.828317632492144e-09
single O 0 2.401833114618057e-07
allele O 0 8.4813302692055e-07
. O 0 1.108322635445802e-06

The O 0 2.186997960507142e-07
skewed O 0 2.1781227133033099e-07
prevalence O 0 1.697134734968131e-07
of O 0 2.981849656080726e-09
G301C O 0 2.7165765459358227e-07
in O 0 1.065537769129321e-09
only O 0 9.979946868909906e-10
Colombian O 0 8.296366615923034e-08
patients O 0 5.504729116978524e-09
and O 0 5.286840965013084e-10
haplotype O 0 1.8873892670967507e-08
analysis O 0 1.0156733232236093e-09
by O 0 1.3513140606491447e-10
restriction O 0 6.230422400221869e-09
fragment O 0 3.6423197791179973e-09
length O 0 3.889804867096558e-10
polymorphisms O 0 8.812636842492338e-09
in O 0 5.987508822080656e-10
the O 0 3.789884850391445e-09
GALNS O 0 4.211961277178489e-05
gene O 0 9.880477769286244e-09
suggest O 0 4.81780437766588e-09
that O 0 1.3419136635217654e-10
G301C O 0 2.1034279029663594e-07
originated O 0 1.0148197837622774e-08
from O 0 7.988870120989588e-10
a O 0 2.336510984690676e-09
common O 0 1.632611201785039e-08
ancestor O 0 1.5146626992645906e-06
. O 0 3.252190765579144e-07

Investigation O 0 1.9763741931910772e-07
of O 0 4.089708127708036e-08
the O 0 5.138826697503873e-09
genetic O 0 4.06573619216033e-09
background O 0 2.0207400197591596e-09
by O 0 1.0995371280131394e-10
means O 0 6.017771614352796e-09
of O 0 9.622151075916463e-09
mtDNA O 0 2.070737714632287e-08
lineages O 0 2.188168757299991e-09
indicate O 0 6.200946423007281e-10
that O 0 1.1012030697032937e-11
all O 0 4.461297303803846e-11
our O 0 1.065407650990835e-09
patients O 0 1.2392700199370665e-09
are O 0 1.4648407486994586e-11
probably O 0 8.785461247384774e-10
of O 0 3.5087228678065685e-09
native O 0 8.363142711687033e-08
American O 0 8.795880603429396e-06
descent O 0 0.000476380082545802

Low O 0 6.05008494858339e-07
frequency O 0 1.3002942012008134e-07
of O 0 5.306262806925588e-08
BRCA1 O 0 2.803087966185558e-07
germline O 0 1.2911639259982621e-06
mutations O 0 3.5075182758248502e-09
in O 0 9.82473546962126e-10
45 O 0 5.638197464463701e-08
German O 1 1.0
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 2.7063106244895607e-06
. O 0 1.7945288846021867e-06

In O 0 1.000728566680209e-08
this O 0 2.4451407565351246e-10
study O 0 3.110648127968574e-10
we O 0 5.7847233947416754e-11
investigated O 0 8.332453060866385e-10
45 O 0 2.3712797059260993e-08
German O 1 0.9999998807907104
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 1.1488212159349587e-08
for O 0 4.441019552103853e-09
germline O 0 2.5872483888633724e-07
mutations O 0 2.4291790801100888e-09
in O 0 3.965883621503963e-09
the O 0 8.919293748022028e-08
BRCA1 O 0 1.190584953292273e-06
gene O 0 3.8603855045948876e-07
. O 0 4.553550752461888e-06

We O 0 4.2272308320434604e-08
identified O 0 2.8078497749106646e-08
four O 0 7.354910014356619e-09
germline O 0 2.2508229449158534e-06
mutations O 0 1.0217047652361089e-08
in O 0 1.4953754901014804e-09
three O 0 3.714953322742076e-08
breast B-Disease 1 0.9999935626983643
cancer I-Disease 0 3.5703105822904035e-06
families O 0 2.2590649836895516e-11
and O 0 4.386606008988103e-11
in O 0 4.821315791048164e-09
one O 0 0.39382731914520264
breast B-Disease 1 1.0
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 0 7.510998898396792e-07
. O 0 1.6865503438268092e-09
among O 0 1.236148544636606e-10
these O 0 2.190588509198843e-11
were O 0 4.724328706018355e-10
one O 0 3.899030542875437e-10
frameshift O 0 5.842191441729483e-08
mutation O 0 4.607152437330342e-09
, O 0 1.2065237697811426e-09
one O 0 2.0394419486535753e-09
nonsense O 0 2.4862515601853374e-07
mutation O 0 8.651800165182522e-09
, O 0 4.803634157113379e-10
one O 0 1.4431271455617178e-10
novel O 0 2.7929190071773746e-09
splice O 0 4.39651337558189e-08
site O 0 7.02413105457822e-09
mutation O 0 8.769422410459526e-10
, O 0 3.1433139424663636e-10
and O 0 1.1686582812586721e-09
one O 0 1.0750635937029074e-08
missense O 0 5.7779061535256915e-06
mutation O 0 8.411300314037362e-07
. O 0 1.4665979506389704e-06

The O 0 3.4677381677283847e-07
missense O 0 3.70873135580041e-06
mutation O 0 3.903275569427933e-08
was O 0 1.96005665031862e-08
also O 0 1.158184326222056e-09
found O 0 5.468997477109383e-10
in O 0 2.337482651881828e-09
2 O 0 2.2095985059422674e-06
. O 0 2.272241545142606e-06

8 O 0 3.0265277928265277e-07
% O 0 3.1195681593487734e-09
of O 0 1.3818175492730234e-09
the O 0 2.2444295033619e-10
general O 0 8.9912299827688e-10
population O 0 2.4158786082750794e-11
, O 0 1.765712055734614e-11
suggesting O 0 1.1098742758175462e-10
that O 0 2.0645499199112294e-12
it O 0 1.0857858882828975e-11
is O 0 7.618828484767803e-11
not O 0 1.41904266115489e-09
disease O 0 6.560813403666543e-08
associated O 0 1.4565659967047395e-07
. O 0 9.9560361377371e-07

The O 0 2.4494189787560572e-08
average O 0 3.259429393054347e-09
age O 0 1.0134150185692192e-09
of O 0 2.6635487149206938e-09
disease O 0 3.2014153106274534e-08
onset O 0 4.415034595695033e-07
in O 0 5.23108112382431e-10
those O 0 8.743268331556919e-10
families O 0 3.0716004739694824e-10
harbouring O 0 1.7061461221601348e-07
causative O 0 1.032162799674552e-07
mutations O 0 1.1620395312661458e-08
was O 0 5.398775826392921e-08
between O 0 1.6242994504978014e-08
32 O 0 2.7722758204618003e-06
. O 0 2.1219389054749627e-06

3 O 0 6.648116595897591e-06
and O 0 6.530164000650984e-07
37 O 0 1.1321778401907068e-05
. O 0 3.6513963550532935e-06

4 O 0 6.664066631856258e-07
years O 0 1.656436943164863e-08
, O 0 1.1676534183990839e-09
whereas O 0 3.1369009612092214e-09
the O 0 1.1545716604999257e-09
family O 0 7.714582861417796e-10
harbouring O 0 2.7406784397498996e-07
the O 0 7.757761544269215e-09
missense O 0 1.9773186465954495e-07
mutation O 0 2.1739083866378905e-09
had O 0 4.329949176984371e-10
an O 0 1.6885538106636844e-11
average O 0 8.215165353542275e-11
age O 0 1.482634154337248e-10
of O 0 1.2694644224708895e-09
onset O 0 9.681207302492112e-07
of O 0 1.5738393699393782e-07
51 O 0 7.425355192935967e-07
. O 0 1.4502360272672377e-06

2 O 0 1.5279583749361336e-05
years O 0 1.1881973023264436e-06
. O 0 2.04894672606315e-06

These O 0 3.417079241785359e-08
findings O 0 1.5575334799677876e-08
show O 0 3.1428719626802604e-09
that O 0 2.736323667651419e-10
BRCA1 O 0 2.8206303070987815e-08
is O 0 3.325165975898159e-10
implicated O 0 9.146435830942323e-10
in O 0 1.225841095298108e-10
a O 0 1.4752211952018257e-10
small O 0 1.0638841890786566e-10
fraction O 0 5.486291865253179e-09
of O 0 4.105021162104094e-06
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 5.244743306320743e-08
suggesting O 0 4.234959938287375e-09
the O 0 3.149741578667431e-10
involvement O 0 7.927289935594217e-10
of O 0 5.660960589182196e-10
another O 0 1.0536220784729267e-09
susceptibility O 0 2.1477468692410184e-08
gene O 0 6.957687759268083e-09
( O 0 9.858964489239952e-08
s O 0 2.022538501478266e-05
) O 0 3.926846147805918e-06

Paternal O 0 0.00028640154050663114
transmission O 0 0.38932904601097107
of O 1 0.9999802112579346
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 1 0.9999874830245972

We O 0 1.8061594175833307e-07
report O 0 1.1182282655397557e-08
a O 0 1.7310631816869204e-09
rare O 0 6.4369696239907626e-09
case O 0 2.9778655097345563e-09
of O 0 3.636560208519768e-08
paternally O 1 0.9999997615814209
transmitted O 1 1.0
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.0007039764313958585
DM B-Disease 1 1.0
) O 0 1.8806497337209294e-06
. O 0 4.631287993106525e-06

The O 0 1.4149897253901145e-07
proband O 0 5.71504870094941e-06
is O 0 3.719075880592726e-10
a O 0 1.764551421645777e-10
23 O 0 2.110370322938593e-09
year O 0 4.158690058986281e-10
old O 0 3.643593515789689e-08
, O 0 2.409416666182551e-08
mentally B-Disease 1 1.0
retarded I-Disease 1 1.0
male O 0 1.6821022654767148e-06
who O 0 4.2590980342538387e-07
suffers O 0 1.2148257155786268e-05
severe O 1 0.6529937386512756
muscular B-Disease 1 1.0
weakness I-Disease 1 1.0
. O 0 0.256611704826355

He O 0 1.0223406832210458e-07
presented O 0 4.0001857826155174e-08
with O 0 5.855798512754973e-09
respiratory O 1 0.9999047517776489
and O 0 8.794620143248721e-09
feeding O 0 3.8947234770603245e-08
difficulties O 0 1.2467578081043484e-08
at O 0 3.6935741576371584e-08
birth O 0 3.847139851131942e-06
. O 0 3.1005099572212202e-06

His O 0 1.6520218650839524e-06
two O 0 2.2904727359218668e-07
sibs O 0 0.0019486472010612488
suffer O 0 6.048250611456751e-07
from O 0 5.559282456601977e-08
childhood O 0 3.605549136409536e-05
onset O 1 1.0
DM B-Disease 1 1.0
. O 0 0.4019518494606018

Their O 0 1.9867654188487904e-08
late O 0 1.9182800770067843e-06
father O 0 7.045601790878209e-08
had O 0 8.268733253657956e-09
the O 0 6.130105867363511e-10
adult O 0 5.167130057159852e-10
type O 0 1.2946036465066868e-09
of O 0 1.828702878015065e-08
DM B-Disease 1 1.0
, O 0 2.521966635526951e-08
with O 0 5.792012980343486e-10
onset O 1 0.9748260378837585
around O 0 9.667588507511482e-09
30 O 0 2.6500147853880662e-08
years O 0 7.988432138006374e-09
. O 0 1.1617519390938469e-07

Only O 0 5.36456354893744e-08
six O 0 2.856022973674044e-09
other O 0 5.880786135836757e-11
cases O 0 1.1683005257667745e-11
of O 0 5.5169376012020876e-11
paternal O 0 3.029126673936844e-07
transmission O 0 0.0021164959762245417
of O 1 0.9999479055404663
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
have O 0 0.0012248881394043565
been O 0 1.4315654084384732e-07
reported O 0 9.270013201501115e-09
recently O 0 4.905890449435901e-08
. O 0 2.4868703007996373e-07

We O 0 7.227308884694139e-08
review O 0 2.3109254954079006e-08
the O 0 1.532011517646481e-09
sex O 0 2.2396484666842298e-10
related O 0 1.445557007428988e-10
effects O 0 2.5252528956798415e-09
on O 0 3.5764657901893315e-09
transmission O 0 2.992088866449194e-06
of O 0 0.030456513166427612
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 1 0.9999994039535522

Decreased O 0 3.901027866959339e-06
fertility O 0 2.0959670621323312e-07
of O 0 1.0632030811308368e-09
males O 0 6.542359709538204e-11
with O 0 9.095038090711771e-12
adult O 0 1.092109958023002e-08
onset O 0 0.016512319445610046
DM B-Disease 1 1.0
and O 0 8.62055671291273e-08
contraction O 0 8.02836410684904e-08
of O 0 1.9197119449643196e-09
the O 0 3.242165702577182e-10
repeat O 0 5.298045890889114e-10
upon O 0 4.20376455867455e-10
male O 0 9.760440372597046e-11
transmission O 0 1.887430489677655e-10
contribute O 0 6.386565581939507e-11
to O 0 1.6379118894516154e-10
the O 0 6.80604406166907e-10
almost O 0 1.8650188060576056e-09
absent O 0 8.079946489658596e-09
occurrence O 0 2.2439681224284413e-09
of O 0 4.006871223705133e-10
paternal O 0 3.3396457865819684e-07
transmission O 0 7.291510428331094e-06
of O 0 2.3392614821204916e-05
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 1 0.999769389629364

Also O 0 6.723268342057054e-08
the O 0 4.83723194832919e-09
fathers O 0 4.399583275471741e-08
of O 0 3.6674507875034124e-09
the O 0 1.290210938087455e-09
reported O 0 1.472247990186304e-09
congenitally O 0 3.814693627646193e-07
affected O 0 5.30284816058213e-10
children O 0 1.6978136951895095e-10
showed O 0 2.3600779663901506e-10
, O 0 8.687526392714418e-11
on O 0 2.642800422947289e-09
average O 0 2.17864859486383e-09
, O 0 8.874418422344377e-10
shorter O 0 2.915245431722724e-07
CTG O 0 2.1285809452820104e-06
repeat O 0 1.6766172450388694e-07
lengths O 0 2.0878432849258388e-07
and O 0 4.526365948720468e-09
hence O 0 7.809187074769852e-09
less O 0 1.6244319223090997e-09
severe O 0 9.698690739412541e-09
clinical O 0 3.1414710832677883e-08
symptoms O 0 1.1094409835266106e-09
than O 0 2.362094547736504e-11
the O 0 1.9424102604137516e-10
mothers O 0 1.11245623823919e-09
of O 0 8.692502828644422e-10
children O 0 3.775829426899691e-09
with O 0 2.955848366070768e-08
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 1 0.9999997615814209

We O 0 8.10024118891306e-08
conclude O 0 1.7876830327168136e-07
that O 0 6.103947902680318e-10
paternal O 0 3.633884375631169e-07
transmission O 0 3.149866824969649e-05
of O 1 0.6722590327262878
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
is O 0 1.9093172909379064e-07
rare O 0 5.709968053935199e-09
and O 0 8.272968421429994e-11
preferentially O 0 1.8385355737837727e-10
occurs O 0 8.235714193949306e-12
with O 0 1.3246983805031975e-12
onset O 0 5.287874955683947e-07
of O 0 1.7466011570377304e-07
DM B-Disease 1 1.0
past O 0 3.483279087390656e-08
30 O 0 5.444126482956335e-09
years O 0 1.0291947849516703e-10
in O 0 5.517463569360004e-11
the O 0 6.450879275199384e-10
father O 0 1.6721564577437675e-08
. O 0 2.091010919968994e-08
. O 0 3.241950139454275e-07

The O 0 2.9500920391001273e-06
RB1 O 0 0.0001538147625979036
gene O 0 1.70172938851465e-07
mutation O 0 9.218264374055707e-09
in O 0 3.0686504448595997e-09
a O 0 3.2660274484896945e-08
child O 0 5.844034944857412e-07
with O 0 1.0910486025750288e-07
ectopic B-Disease 1 1.0
intracranial I-Disease 1 1.0
retinoblastoma I-Disease 1 1.0
. O 0 0.0007418652530759573

The O 0 1.9713152141775936e-06
RB1 O 0 0.0001135960264946334
gene O 0 1.2064833754266147e-07
mutation O 0 1.3565370160506518e-08
was O 0 1.0840308206638838e-08
investigated O 0 5.353174348243783e-09
in O 0 1.7106216443352196e-09
a O 0 1.958972717375218e-08
child O 0 1.8625905795488507e-07
with O 0 6.66041799490813e-09
ectopic B-Disease 0 0.1099681630730629
intracranial I-Disease 1 0.9989977478981018
retinoblastoma I-Disease 0 2.5259873837057967e-06
using O 0 1.0972777353401852e-08
DNA O 0 2.438436652596465e-08
obtained O 0 1.605985211483585e-08
from O 0 5.8745595055142985e-09
both O 0 2.7594646567763448e-09
the O 0 2.6257385599137706e-08
pineal B-Disease 0 0.0067384918220341206
and I-Disease 0 2.540978982779052e-07
retinal I-Disease 1 1.0
tumours I-Disease 1 1.0
of O 0 4.0476043068338186e-06
the O 0 2.6590936386128305e-07
patient O 0 9.40332483878592e-07
. O 0 1.6871599939349835e-07

A O 0 2.046306462943903e-06
nonsense O 0 1.6597234662185656e-06
mutation O 0 3.323425801227131e-08
in O 0 5.73638470058313e-09
exon O 0 7.245562301250175e-07
17 O 0 1.0405081951603279e-07
( O 0 5.761967791784173e-09
codon O 0 4.755296956204802e-08
556 O 0 1.5975682998714547e-08
) O 0 5.883852294275016e-10
of O 0 5.786119583461868e-09
the O 0 1.67242752979746e-08
RB1 O 0 9.04808439372573e-06
gene O 0 4.044581558559912e-09
was O 0 4.623296856465231e-09
found O 0 1.9613859147948887e-10
to O 0 1.8730818285295214e-10
be O 0 3.872822340600379e-10
present O 0 1.1700410640358427e-09
homozygously O 0 7.652145086467499e-07
in O 0 1.9235604220568803e-09
both O 0 1.8368260246148793e-09
the O 0 5.4169060348385756e-09
retinal B-Disease 0 0.00016868524835444987
and I-Disease 0 2.7795931600849144e-07
the I-Disease 0 1.4523907339025754e-05
pineal I-Disease 1 1.0
tumours I-Disease 1 1.0
. O 0 2.1246878532110713e-05

The O 0 3.470440290698207e-08
same O 0 5.058963470361277e-09
mutation O 0 3.63512975276592e-09
was O 0 3.3451168501841266e-09
present O 0 7.516179900690645e-10
heterozygously O 0 2.613517722238612e-07
in O 0 3.7269584640675646e-10
the O 0 3.007196158755221e-10
DNA O 0 2.2441135616446672e-09
from O 0 3.5303365786276686e-10
the O 0 4.0923731070563463e-10
constitutional O 0 4.445519508067264e-09
cells O 0 1.4976018203327612e-09
of O 0 1.937688620667899e-10
the O 0 1.74863026836114e-10
patient O 0 4.3164942731266365e-09
, O 0 1.1846050529396024e-10
proving O 0 4.067240766403302e-09
it O 0 1.6973790428753688e-11
to O 0 1.4460421748907493e-10
be O 0 1.1252517806426e-09
of O 0 4.5279566762701506e-08
germline O 0 1.431425152986776e-05
origin O 0 6.707558100060851e-07
. O 0 9.400061458109121e-07

The O 0 5.4379651004410334e-08
initial O 0 3.171265205992313e-08
mutation O 0 5.092732013878276e-09
was O 0 5.864024821278235e-09
shown O 0 5.862634822051405e-10
to O 0 6.103947902680318e-10
have O 0 3.0220423385962647e-10
occurred O 0 3.737282039395495e-09
in O 0 8.660381300984454e-10
the O 0 5.195218033549054e-09
paternally O 0 1.202650537379668e-06
derived O 0 8.991861477625207e-07
RB1 O 0 0.00019116261682938784
allele O 0 1.2581126611621585e-06
. O 0 7.119657539078617e-07

The O 0 1.478114484143589e-07
mutation O 0 2.9153556013739035e-08
is O 0 8.720114214044727e-11
in O 0 3.935497067120153e-11
an O 0 1.3687869414302778e-11
area O 0 2.2862099713361062e-10
of O 0 4.353650218114069e-10
the O 0 5.991804274962931e-10
gene O 0 3.3225353024413096e-10
that O 0 4.223726576824127e-11
encodes O 0 1.244115088727682e-10
the O 0 2.3674404103779523e-10
protein O 0 2.4035254342358314e-10
- O 0 5.004127334728992e-09
binding O 0 2.1400337057997376e-09
region O 0 7.149457470490006e-09
known O 0 1.4894148137045704e-09
as O 0 1.8585406824644934e-10
the O 0 3.943305959541732e-10
pocket O 0 5.39805159860407e-06
region O 0 1.5170458667057574e-08
and O 0 1.125986082151087e-09
has O 0 1.6918655365572022e-10
been O 0 7.773632432206412e-11
detected O 0 5.005594827522941e-10
in O 0 4.646772897021201e-11
other O 0 9.706713210988482e-11
cases O 0 2.175939844972774e-10
of O 0 5.301020067349782e-09
retinoblastoma B-Disease 0 1.1023163324352936e-06
. O 0 1.2641523028378288e-07
. O 0 1.3462329206959112e-06

Low O 0 1.11889812615118e-06
levels O 0 1.6364584354278122e-08
of O 0 1.4837269191048108e-09
beta O 0 1.921852366137955e-08
hexosaminidase O 0 3.3900093399097386e-07
A O 0 7.410489555326194e-09
in O 0 5.415539683362169e-10
healthy O 0 2.4353026262247113e-09
individuals O 0 2.2108710695523115e-11
with O 0 8.92983534339642e-11
apparent O 0 4.680291567638051e-07
deficiency O 0 0.004373505245894194
of O 0 3.3457039535278454e-05
this O 0 1.3836307743986254e-07
enzyme O 0 7.270133437486948e-07
. O 0 8.491762741869024e-07

Appreciable O 0 3.707461701196735e-06
beta O 0 8.576404866289522e-07
hexosaminidase O 0 5.245261036179727e-06
A O 0 2.1177066855671e-07
( O 0 1.4261143377325425e-08
hex O 0 4.411070051446586e-07
A O 0 2.398365097633359e-07
) O 0 3.6643461598373506e-09
activity O 0 1.6994937013237177e-08
has O 0 1.545402278368968e-10
been O 0 4.583458612650304e-10
detected O 0 1.2042070451911968e-08
in O 0 2.8047077549331334e-08
cultured O 1 1.0
skin O 1 1.0
fibroblasts O 1 1.0
and O 0 9.091502579394728e-05
melanoma B-Disease 1 1.0
tissue O 0 6.826976459706202e-06
from O 0 3.034386741873618e-09
healthy O 0 3.111308322090167e-09
individuals O 0 1.8047219968453376e-11
previously O 0 2.2231350094159552e-10
reported O 0 1.2785737746323633e-10
as O 0 7.217108577428633e-10
having O 0 3.469818210533049e-08
deficiency B-Disease 0 6.067863523639971e-06
of I-Disease 0 3.5193821190659946e-07
hex I-Disease 0 3.351466943968262e-07
A I-Disease 0 1.4201128273327868e-08
activity O 0 2.4740967052849783e-09
indistinguishable O 0 1.050888598363997e-09
from O 0 2.238306415214275e-11
that O 0 2.6770619141608387e-12
of O 0 9.019600344384315e-11
patients O 0 1.70749547834248e-09
with O 0 3.047244900855617e-09
Tay B-Disease 1 1.0
- I-Disease 1 1.0
Sachs I-Disease 1 1.0
disease I-Disease 1 1.0
( O 0 3.309301632725692e-07
TSD B-Disease 0 0.0007896605529822409
) O 0 9.528718436513373e-08
. O 0 6.675248869214556e-07

Identification O 0 3.523315172060393e-06
and O 0 5.771859434844373e-08
quantitation O 0 0.00015737517969682813
of O 0 1.1036142950615613e-06
hex O 0 2.5933748020179337e-06
A O 0 1.835426530760742e-07
, O 0 2.816188393595098e-09
amounting O 0 3.559114958306964e-08
to O 0 6.0513465349743e-09
3 O 0 1.1020409829143318e-06
. O 0 1.7002431604851154e-06

5 O 0 1.919215037560207e-06
% O 0 1.287483399892153e-07
- O 0 2.160975554943434e-06
6 O 0 5.12068800162524e-06
. O 0 2.3615339159732684e-06

9 O 0 3.6889804277961957e-07
% O 0 5.691418003550552e-09
of O 0 2.7952054004742877e-09
total O 0 7.254136180634418e-10
beta O 0 2.0090080710133407e-08
hexosaminidase O 0 1.969979877003425e-07
activity O 0 5.017660953399172e-09
, O 0 3.7395619933988655e-10
has O 0 7.281968777972381e-11
been O 0 9.36992497480027e-11
obtained O 0 2.0533450495463512e-09
by O 0 1.5469365788334244e-09
cellulose O 0 3.6029762213729555e-06
acetate O 0 4.5852451876271516e-05
gel O 0 1.3385057172854431e-05
electrophoresis O 0 9.892282832879573e-07
, O 0 7.194901563423173e-09
DEAE O 0 7.910599379101768e-06
- O 0 1.3175275626053917e-07
cellulose O 0 5.632011266243353e-07
ion O 0 2.7163952154296567e-07
- O 0 2.8487504550867015e-06
exchange O 0 2.3531595161330188e-06
chromatography O 0 5.107694505568361e-06
, O 0 5.107625433709018e-09
radial O 0 4.539535680692097e-08
immunodiffusion O 0 1.9358951703907223e-06
, O 0 6.489843773493931e-09
and O 0 2.7831891458163227e-08
radioimmunoassay O 0 0.00024795637000352144
. O 0 1.798850234990823e-06

Previous O 0 3.094466762831871e-07
family O 0 5.309216621895985e-09
studies O 0 8.220441216622021e-09
suggested O 0 1.263659399342032e-09
that O 0 6.1063406935069064e-12
these O 0 9.166598036181028e-12
individuals O 0 1.5927342777999343e-11
may O 0 1.9711143828260447e-10
be O 0 5.870220975978668e-10
compound O 0 9.649483700968631e-08
heterozygotes O 0 5.0763645731422e-08
for O 0 6.437346766752228e-10
the O 0 1.8715329286322913e-09
common O 0 6.820810583008097e-09
mutant O 0 3.650368540775162e-08
TSD B-Disease 0 1.0407399031464593e-06
gene O 0 2.7534765578707265e-09
and O 0 8.544234209040269e-10
a O 0 8.945835183737927e-09
rare O 0 1.065449310999611e-07
( O 0 1.394886339767254e-08
allelic O 0 3.867932605317037e-07
) O 0 7.404004076505544e-09
mutant O 0 1.8724161066074885e-07
gene O 0 1.4316924534796271e-07
. O 0 1.3903849094276666e-06

Thus O 0 3.098163858794578e-07
, O 0 6.21632034736308e-09
the O 0 1.8887025277081193e-09
postulated O 0 8.082754732186004e-08
rate O 0 6.816024633593543e-09
mutant O 0 3.1630422725470453e-09
gene O 0 8.57355297867457e-10
appears O 0 4.462091252044331e-10
to O 0 1.2615877786892327e-10
code O 0 3.472966358941676e-10
for O 0 3.7472586145170794e-10
the O 0 6.444619837786547e-10
expression O 0 2.088188288951187e-09
of O 0 9.667344702535274e-10
low O 0 3.2047617892771996e-09
amounts O 0 1.1416559919652514e-09
of O 0 4.892525495847622e-09
hex O 0 7.566197837149957e-07
A O 0 2.4950427359726746e-06
. O 0 4.020731012133183e-06

Heterozygotes O 0 0.00010554475011304021
for O 0 4.890270588475687e-08
the O 0 1.0117295445866148e-08
rare O 0 1.652278136532459e-08
mutant O 0 8.38618863241436e-09
may O 0 5.054678897664644e-10
be O 0 7.844590255157158e-11
indistinguishable O 0 3.268356474350753e-09
from O 0 2.4368629336635195e-10
heterozygotes O 0 5.722116469542016e-08
for O 0 1.0463204747068744e-09
the O 0 5.903685096342315e-09
common O 0 1.7665273333022924e-07
TSD B-Disease 0 0.0001835416624089703
mutant O 0 1.0794091167554143e-06
. O 0 4.980458356840245e-07

However O 0 7.161469994798608e-08
, O 0 2.005159815965385e-09
direct O 0 3.1812779077711184e-09
visualization O 0 3.220472137854813e-07
and O 0 1.86699056214934e-09
quantitation O 0 1.832858833950013e-05
of O 0 1.0421328511256434e-07
hex O 0 1.8226043607683096e-07
A O 0 6.897343141076817e-09
by O 0 1.241147740138615e-10
the O 0 3.088366506975859e-10
methods O 0 6.8269017106104e-09
described O 0 2.7757748877199617e-10
may O 0 1.270430427524616e-10
prevent O 0 8.199515511009281e-10
false O 0 1.8703419257803944e-08
- O 0 2.348072456470618e-07
positive O 0 7.606697494111359e-09
prenatal O 0 8.805380389276252e-07
diagnosis O 0 2.0603751238468249e-07
of O 0 7.652960043458279e-09
TSD B-Disease 0 2.2783455278840847e-05
in O 0 8.50990478085123e-09
fetuses O 0 1.1397456489703472e-07
having O 0 1.0783406390046935e-09
the O 0 7.396294132711034e-10
incomplete O 0 4.152463972673104e-08
hex B-Disease 0 4.3386071411077864e-06
A I-Disease 0 4.860911758441944e-06
deficiency I-Disease 0 0.010832776315510273
of O 0 4.472371415431553e-07
the O 0 1.8885307540017493e-08
type O 0 1.4787588042963762e-07
described O 0 2.533173892871332e-09
in O 0 3.805528947520287e-10
the O 0 9.49257916715851e-09
four O 0 7.0032513121987e-08
healthy O 0 4.957224746249267e-07
individuals O 0 6.849390388197207e-08

The O 0 8.985680324258283e-07
tumor B-Disease 0 3.4501240406825673e-06
suppressor O 0 3.698723594425246e-05
gene O 0 4.692139441431209e-07
Smad4 O 0 0.0002019312378251925
/ O 0 1.605886973266024e-05
Dpc4 O 0 1.1220343367313035e-05
is O 0 4.04832306566405e-10
required O 0 7.081270569919695e-10
for O 0 6.552278719595961e-10
gastrulation O 0 1.317475152973202e-06
and O 0 1.1677224742712156e-09
later O 0 1.6073551378781303e-08
for O 0 8.413997831802078e-10
anterior O 0 5.636409561304845e-09
development O 0 1.0162376717914867e-08
of O 0 1.5134707709307804e-08
the O 0 1.6138491432116098e-08
mouse O 0 1.187511387001905e-07
embryo O 0 2.2052735459965334e-07
. O 0 5.731575356549001e-07

Mutations O 0 6.203282509886776e-07
in O 0 3.0819673924042945e-08
the O 0 1.275571008818588e-07
SMAD4 O 1 0.9999512434005737
/ O 0 5.8704183174995705e-05
DPC4 O 0 0.0001987678260775283
tumor B-Disease 0 7.999243507583742e-07
suppressor O 0 2.4908985096772085e-07
gene O 0 2.970598211859965e-09
, O 0 3.764853706567095e-10
a O 0 1.8471481011417268e-09
key O 0 1.86772211918651e-07
signal O 0 1.6589781353104627e-06
transducer O 0 3.6651491086558963e-07
in O 0 4.427521016481251e-09
most O 0 2.0492680885553227e-09
TGFbeta O 0 1.0749589591796394e-06
- O 0 2.926084974319565e-08
related O 0 2.5577795437214945e-09
pathways O 0 1.4447582019627703e-09
, O 0 1.0311512928240507e-11
are O 0 1.3634238052798175e-12
involved O 0 1.329566665098092e-11
in O 0 5.746223982749932e-11
50 O 0 2.21646896392258e-08
% O 0 5.267477565240597e-09
of O 0 2.939138141755393e-07
pancreatic B-Disease 1 1.0
cancers I-Disease 1 1.0
. O 0 0.10694006085395813

Homozygous O 0 2.6934292691294104e-05
Smad4 O 0 3.708004442160018e-05
mutant O 0 8.188573019651813e-07
mice O 0 2.039266604469958e-07
die O 0 9.206688389440387e-08
before O 0 3.1977780423630975e-08
day O 0 3.4494880196689337e-07
7 O 0 3.932842901122058e-06
. O 0 2.0680872694356367e-06

5 O 0 6.159075383038726e-06
of O 0 2.1698804175684927e-06
embryogenesis O 0 0.0007154396153055131
. O 0 1.2626956959138624e-05

Mutant O 0 6.135200578682998e-07
embryos O 0 1.1100854635515134e-07
have O 0 5.373088085569577e-10
reduced O 0 8.2841677961909e-10
size O 0 1.2702177087930977e-09
, O 0 1.8001857782223851e-09
fail O 0 6.8395209495975e-08
to O 0 1.07585540476407e-08
gastrulate O 0 5.344492365111364e-06
or O 0 1.3234963347485973e-08
express O 0 7.910226251794938e-09
a O 0 2.474927374152003e-09
mesodermal O 0 1.6072040125436615e-06
marker O 0 1.3748915250744176e-07
, O 0 3.0358513480877036e-09
and O 0 3.2007361205899088e-09
show O 0 7.018977044026542e-08
abnormal O 0 2.1900618207837397e-07
visceral O 0 3.3598303161852527e-06
endoderm O 0 0.0009994673309847713
development O 0 4.210102360957535e-06
. O 0 2.876256758099771e-06

Growth B-Disease 1 1.0
retardation I-Disease 1 1.0
of O 0 3.885678836468287e-07
the O 0 4.5951317417802784e-08
Smad4 O 0 4.183961937087588e-05
- O 0 6.062225565983681e-07
deficient O 0 1.5969459354892024e-07
embryos O 0 1.6665651969560713e-08
results O 0 3.220483324462009e-10
from O 0 1.9230789183311003e-10
reduced O 0 1.934606030928876e-09
cell O 0 1.4819628191276024e-08
proliferation O 0 9.860017513574348e-08
rather O 0 1.62019575533634e-09
than O 0 4.726906088770022e-10
increased O 0 5.401636471447091e-09
apoptosis O 0 4.888144076176104e-07
. O 0 6.002298391649674e-07

Aggregation O 0 1.204449063152424e-06
of O 0 3.334706661917153e-07
mutant O 0 2.023023853325867e-06
Smad4 O 0 5.582750236499123e-05
ES O 0 0.0002281761699123308
cells O 0 1.1691498258414867e-07
with O 0 5.460398799783661e-10
wild O 0 6.061710422500255e-08
- O 0 2.4195927039727394e-07
type O 0 2.583145999324188e-07
tetraploid O 0 6.827445304224966e-06
morulae O 0 3.6614463169826195e-05
rescues O 0 4.002295099780895e-06
the O 0 2.7844430405821186e-07
gastrulation B-Disease 0 0.0011171811493113637
defect I-Disease 0 0.00017917876539286226
. O 0 3.5738605674850987e-06

These O 0 9.52995407033086e-08
results O 0 2.2754669259938964e-08
indicate O 0 1.7583847267133024e-08
that O 0 3.82948450727838e-10
Smad4 O 0 6.102603720137267e-07
is O 0 1.1712060488111575e-10
initially O 0 3.451754715388944e-10
required O 0 2.100578738728487e-10
for O 0 8.102345877558648e-11
the O 0 3.0782865145795313e-10
differentiation O 0 1.2640964719423664e-08
of O 0 4.947789733478203e-09
the O 0 3.1443709858081093e-09
visceral O 0 1.0181529574992965e-07
endoderm O 0 6.740930984960869e-06
and O 0 1.493710710676055e-09
that O 0 2.2020932299859908e-10
the O 0 2.522624331646739e-09
gastrulation B-Disease 0 3.134381040581502e-05
defect I-Disease 0 3.506731616198522e-07
in O 0 1.670141136500547e-09
the O 0 9.690444002785625e-09
epiblast O 0 4.403447383083403e-05
is O 0 8.707914944672268e-11
secondary O 0 2.5028787931091756e-09
and O 0 5.526882840278802e-10
non O 0 8.151430961333972e-07
- O 0 8.557090609428997e-07
cell O 0 7.978437679412309e-06
autonomous O 0 1.931235601659864e-06
. O 0 2.0452841908991104e-06

Rescued O 0 5.3604999266099185e-05
embryos O 0 2.3702589260210516e-06
show O 0 3.300986861631827e-07
severe O 0 3.266822261593916e-07
anterior O 0 7.350369060077355e-07
truncations O 0 0.4588361084461212
, O 0 4.361425709475952e-08
indicating O 0 3.384220548241501e-08
a O 0 1.0086538271281142e-09
second O 0 2.207603211346054e-09
important O 0 8.608471713245081e-10
role O 0 2.1873758360158035e-09
for O 0 2.0918797805080658e-09
Smad4 O 0 1.009473271551542e-05
in O 0 1.5470112302296002e-08
anterior O 0 2.137036290150718e-06
patterning O 1 0.56912761926651
during O 1 0.9975475668907166
embryogenesis O 1 0.9190934300422668
. O 0 1.3517790193873225e-06

Prevalence O 0 1.6230600522249006e-05
of O 0 8.804374829196604e-08
p16 O 0 7.316177743632579e-07
and O 0 4.357742255933772e-08
CDK4 O 1 0.9979700446128845
germline O 0 0.07710519433021545
mutations O 0 7.845589067301262e-08
in O 0 8.876386736744735e-09
48 O 0 1.2921765346618486e-06
melanoma B-Disease 1 0.9999954700469971
- O 0 3.1708281312603503e-05
prone O 0 5.229395583228325e-07
families O 0 4.950431176098391e-10
in O 0 9.6720842446274e-10
France O 0 3.36776224685309e-07
. O 0 3.6061484820493206e-07

The O 0 4.471084594115382e-06
French O 0 0.00020623223099391907
Familial B-Disease 1 0.8930895328521729
Melanoma I-Disease 1 1.0
Study O 0 6.414115318875702e-07
Group O 0 4.56274733551254e-08
. O 0 1.3529432862924295e-07

Germline O 0 0.00014263733464758843
mutations O 0 1.5222435933992529e-07
in O 0 7.1878236695965825e-09
the O 0 1.0696597385617679e-08
p16 O 0 3.291348775746883e-07
and O 0 2.807114540814837e-09
CDK4 O 0 4.159376476309262e-05
genes O 0 2.1558597129711643e-09
have O 0 1.6610481046175352e-10
been O 0 1.4042761398158632e-10
reported O 0 5.790805682193145e-11
in O 0 3.376040419444948e-11
a O 0 4.966707600750908e-10
subset O 0 3.4919267477562244e-08
of O 0 3.0326351208032065e-08
melanoma B-Disease 1 0.9590489864349365
pedigrees O 0 3.5419517985246785e-07
, O 0 1.384854453334583e-09
but O 0 4.3235121038875945e-10
their O 0 1.685527717398827e-09
prevalence O 0 7.563919268704922e-08
is O 0 2.4154086716854373e-11
not O 0 9.64849519724531e-11
well O 0 3.925927138936913e-09
known O 0 3.0351006330420205e-07
. O 0 1.1230653171878657e-06

We O 0 1.8908343690782203e-07
searched O 0 3.0871626677253516e-07
for O 0 3.7812202258180605e-09
such O 0 1.2572890284445748e-08
germline O 0 8.231405809056014e-05
mutations O 0 8.407653240283253e-08
in O 0 1.425265860888203e-08
48 O 0 6.217449026735267e-07
French O 0 2.5923687644535676e-05
melanoma B-Disease 1 0.9999940395355225
- O 0 3.42705106959329e-06
prone O 0 3.1831731917009165e-08
families O 0 3.3940864008208393e-11
selected O 0 8.010807295288913e-11
according O 0 2.059575600343866e-11
to O 0 1.3095529868834e-11
two O 0 8.395074566069916e-12
major O 0 2.1919731307828982e-10
criteria O 0 4.4254419573341863e-10
families O 0 7.492240335083e-12
with O 0 1.0217106024071332e-12
at O 0 3.6623809540614616e-10
least O 0 1.2586746922504943e-10
three O 0 5.204317532481184e-11
affected O 0 1.7387657980094673e-10
members O 0 3.0942154394253407e-10
( O 0 8.474427826143938e-10
n O 0 1.0108691661514513e-08
= O 0 1.3064714643462594e-08
20 O 0 2.8047490996385704e-09
) O 0 1.3110632024471158e-10
or O 0 1.303547825237672e-10
families O 0 2.0389108804086398e-11
with O 0 3.719895485393421e-12
two O 0 4.240128387289488e-11
affected O 0 1.4338807918790053e-10
members O 0 3.737520362645519e-11
, O 0 1.5088970004017987e-11
one O 0 1.0712711100147043e-11
of O 0 4.758837421348083e-11
them O 0 1.3941662060923399e-11
affected O 0 4.133272196726878e-11
before O 0 1.0091536634115883e-10
the O 0 1.1372153913002947e-10
age O 0 3.440619733563466e-10
of O 0 4.984339607716493e-10
50 O 0 1.5202544778603055e-09
( O 0 2.9803581824694447e-10
n O 0 3.6391256674761507e-09
= O 0 1.3004449961329101e-08
28 O 0 1.0754449775163266e-08
) O 0 5.488245968798822e-10
, O 0 3.506192280955389e-10
and O 0 2.2798522791855902e-10
one O 0 2.2308487002131727e-10
additional O 0 2.8369175897324794e-09
minor O 0 6.037145539039557e-08
criterion O 0 3.1150866561802104e-05
. O 0 1.3417110267255339e-06

Sixteen O 0 2.4234616375906626e-06
different O 0 3.219246380581353e-08
p16 O 0 1.959950168384239e-06
germline O 0 3.751428721443517e-06
mutations O 0 5.895898436136804e-09
were O 0 1.7170679322831006e-09
found O 0 1.8884424579646009e-10
in O 0 8.06407995934677e-11
21 O 0 1.951959704982187e-09
families O 0 5.182485690591321e-11
, O 0 4.824972366090918e-11
while O 0 6.773172994689602e-11
one O 0 2.0889241725274843e-10
germline O 0 7.282742444658652e-07
mutation O 0 8.837161225017098e-09
, O 0 1.3742085247514524e-09
Arg24His O 0 1.0634636964823585e-05
, O 0 3.671160042628685e-09
was O 0 1.1122191168055906e-08
detected O 0 3.205024468044826e-09
in O 0 1.0244362025346732e-09
the O 0 2.0495036778811482e-08
CDK4 O 0 0.0015886431792750955
gene O 0 3.806197526046162e-07
. O 0 2.1844809907634044e-06

The O 0 3.0830722863584015e-08
frequency O 0 4.825992050427885e-08
of O 0 1.0370285963290371e-08
p16 O 0 9.209059470549619e-08
gene O 0 1.868009302796736e-09
mutation O 0 2.9310087690248565e-10
in O 0 1.5642842576824023e-10
our O 0 1.4541828852188132e-09
sample O 0 1.5853860446668477e-09
( O 0 3.0921620819412965e-10
44 O 0 1.2211558431118874e-09
% O 0 1.4014399363215801e-10
) O 0 5.558627516610848e-11
is O 0 7.422176588611773e-12
among O 0 6.0113494043667615e-12
the O 0 2.4179715521488454e-11
highest O 0 9.94437643342394e-10
rates O 0 4.358070293530858e-10
yet O 0 6.02328881216252e-11
reported O 0 1.466764765201134e-10
and O 0 1.594768900270438e-10
the O 0 4.776921080917873e-09
CDK4 O 0 1.0834853128471877e-05
mutation O 0 2.4188642200329014e-09
is O 0 3.9201315804593406e-11
the O 0 1.4139868442786252e-10
second O 0 5.894661203598162e-09
mutation O 0 2.0708632586519116e-09
detected O 0 2.975520496661943e-09
in O 0 2.7636720689727667e-10
this O 0 1.0398663041755185e-09
gene O 0 3.6630552813221584e-08
worldwide O 0 1.6741229558192572e-07
. O 0 4.96303869113035e-07

In O 0 2.0936610667376954e-08
summary O 0 1.0758701307622687e-07
, O 0 4.768306860469806e-10
our O 0 9.734733019683972e-10
results O 0 4.968801481375351e-10
show O 0 4.4688794331726456e-10
frequent O 0 3.2200045407826394e-10
involvement O 0 7.364002740928299e-10
of O 0 1.6773624711419188e-09
the O 0 7.846213456730311e-09
p16 O 0 1.0335057822885574e-06
gene O 0 2.4328851822019715e-08
in O 0 7.706542071161948e-09
familial B-Disease 0 0.00011619578435784206
melanoma I-Disease 1 1.0
and O 0 7.308427640850823e-09
confirm O 0 1.3773739482303426e-08
the O 0 4.005039411225653e-09
role O 0 1.1347962569629999e-08
of O 0 6.09618169278292e-08
the O 0 4.0725367966842896e-08
CDK4 O 0 0.06328700482845306
gene O 0 1.800207272140142e-08
as O 0 4.218899896102357e-09
a O 0 1.8144787006235674e-08
melanoma B-Disease 1 0.9982262253761292
- O 0 1.8820219338522293e-05
predisposing O 0 1.7113365174736828e-05
gene O 0 4.341481485425902e-08
. O 0 5.757104304393579e-08
. O 0 9.320364711129514e-07

Progression O 0 2.6096995497937314e-05
of O 0 1.0294627372786636e-06
somatic O 0 4.3016796553274617e-05
CTG O 0 2.469364153512288e-05
repeat O 0 1.7296407861522312e-07
length O 0 1.3621528793805737e-08
heterogeneity O 0 1.1830978863258679e-08
in O 0 4.884699866813946e-10
the O 0 1.2175230823530114e-09
blood O 0 6.80919010065395e-09
cells O 0 2.110269292643352e-07
of O 0 1.7015586308843922e-06
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 1 0.9999985694885254
. O 0 1.327553854935104e-05

The O 0 4.821373167374077e-08
genetic O 0 1.4963177363824798e-08
basis O 0 3.01426226201329e-08
of O 0 5.568429628510785e-07
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.005433391313999891
DM B-Disease 1 1.0
) O 0 5.727769814001249e-09
is O 0 1.2994567921698064e-10
the O 0 8.615530511235647e-11
expansion O 0 4.512263451772469e-09
of O 0 2.24240226387451e-09
an O 0 2.096272183615966e-10
unstable O 0 1.02590718142892e-08
CTG O 0 3.927210059373465e-07
repeat O 0 9.062478767418725e-09
in O 0 1.8767949416798047e-09
the O 0 4.7586334872562475e-09
34 O 0 3.523115665871046e-08
UTR O 0 5.960786893410841e-06
of O 0 3.210918464446877e-08
the O 0 2.4551814803430716e-08
DM B-Disease 1 0.9957538843154907
protein O 0 3.736414200261606e-08
kinase O 0 6.908405225658498e-08
gene O 0 6.138791253107456e-09
on O 0 6.000867358579853e-08
chromosome O 0 8.467728775940486e-07
19 O 0 7.368023943854496e-06
. O 0 6.338872026390163e-06

One O 0 2.5920513735400164e-08
of O 0 8.2428925907152e-09
the O 0 9.161538749857812e-10
principal O 0 1.250644832140324e-08
features O 0 2.528920850508598e-09
of O 0 6.359271331746186e-09
the O 0 4.8583075340502546e-08
DM B-Disease 1 1.0
mutation O 0 9.743936857375957e-08
is O 0 1.615877431859758e-10
an O 0 5.510248854423416e-11
extraordinarily O 0 6.307183664233662e-09
high O 0 1.6761704912937603e-08
level O 0 5.169244943203921e-08
of O 0 1.8577628324578654e-08
somatic O 0 1.0130840564670507e-05
mosaicism O 0 8.140390491462313e-06
, O 0 5.340251019170239e-10
due O 0 1.4273708881518132e-09
to O 0 2.5852742169263365e-10
an O 0 4.3696376378354884e-11
extremely O 0 1.556925977030943e-10
high O 0 4.523308116954894e-10
degree O 0 9.067077755275932e-09
of O 0 3.773755974378901e-09
somatic O 0 8.249854204223084e-07
instability O 0 6.895294291098253e-08
both O 0 3.2956226636571273e-10
within O 0 6.742396641001847e-10
and O 0 2.1970755770261974e-10
between O 0 1.173652425245919e-10
different O 0 1.511346936489133e-09
tissues O 0 6.911594709890778e-07
. O 0 6.776277245990059e-07

This O 0 5.47739666956204e-08
instability O 0 5.661386808242241e-07
appears O 0 5.9553699749415046e-09
to O 0 2.0232572561784679e-10
be O 0 6.223621618062225e-11
biased O 0 8.382506355708585e-10
towards O 0 4.672245923487139e-10
further O 0 1.347638528548245e-10
expansion O 0 6.659652274088046e-10
and O 0 6.213279196698451e-11
continuous O 0 1.7444137245803404e-09
throughout O 0 1.6304591010651848e-10
the O 0 7.330477891365206e-11
life O 0 2.5726815122695257e-10
of O 0 2.258230408225259e-10
an O 0 1.6793391330316432e-11
individual O 0 2.6995730303958076e-11
, O 0 3.7839724409405306e-11
features O 0 2.0016431567793092e-10
that O 0 3.4743011419202663e-12
could O 0 2.7039634420411574e-11
be O 0 4.391327579345017e-11
associated O 0 4.613190940361278e-10
with O 0 3.7448346507096275e-11
the O 0 2.3749537891859518e-09
progressive O 0 1.7815611386140517e-07
nature O 0 1.5725954982670487e-09
of O 0 1.4103109791108182e-09
the O 0 5.332762231802235e-09
disease O 0 1.0237378944566444e-07
. O 0 1.3208702398515015e-07

Although O 0 8.576915178082345e-08
increasing O 0 6.975027222466679e-09
measured O 0 5.612915021657727e-09
allele O 0 3.258111558324117e-09
size O 0 5.613543518911968e-10
between O 0 2.9492791542296004e-10
patients O 0 2.812282140496336e-08
clearly O 0 4.987544821588585e-10
correlates O 0 1.5257468899410043e-10
with O 0 2.6379768595236053e-12
an O 0 9.850581288162186e-12
increased O 0 2.0986885840290626e-10
severity O 0 8.50889847470171e-09
of O 0 8.475785628903054e-10
symptoms O 0 4.588726731924453e-09
and O 0 4.56936849468903e-11
an O 0 2.5738532832830785e-11
earlier O 0 6.918179917825285e-11
age O 0 1.3885434468896563e-10
of O 0 2.882300231821233e-10
onset O 0 2.0659328470173932e-08
, O 0 3.2628594270889266e-11
this O 0 7.777958832555498e-12
correlation O 0 2.6572129913082776e-11
is O 0 3.3193899018346684e-12
not O 0 3.505789061830633e-11
precise O 0 6.015694165029117e-09
and O 0 3.4670641912981637e-09
measured O 0 1.513753744575297e-08
allele O 0 3.0829652164499066e-09
length O 0 2.8021274189882206e-10
cannot O 0 2.440397883773926e-10
be O 0 9.319448684985687e-11
used O 0 1.0147670481686077e-09
as O 0 4.877978021511353e-10
an O 0 5.432959290785355e-11
accurate O 0 6.277731223747196e-09
predictor O 0 4.365712058529425e-08
of O 0 4.704153955259471e-09
age O 0 2.272465415842362e-08
of O 0 6.918651251908159e-08
onset O 0 0.00010691110219340771
. O 0 6.729503070346254e-07

In O 0 1.5846101319993977e-08
order O 0 3.9686303132668854e-09
to O 0 6.541264752080167e-10
further O 0 9.057186667327244e-10
characterize O 0 2.4457669223210132e-09
the O 0 9.830058989024337e-10
dynamics O 0 1.5300381406291308e-08
of O 0 2.447451379339327e-07
DM B-Disease 1 1.0
CTG O 0 3.6359830119181424e-05
repeat O 0 2.232288096593038e-07
somatic O 0 3.2949524211289827e-06
instability O 0 4.7303569061796225e-08
, O 0 8.3014838059281e-11
we O 0 4.9067905988353644e-11
have O 0 6.37407661374656e-12
studied O 0 1.8080822949961828e-10
repeat O 0 9.665127725932976e-11
length O 0 5.952264375830296e-11
changes O 0 7.125979667454985e-11
over O 0 4.482604218369879e-11
time O 0 6.866598400989687e-10
in O 0 2.063931026086152e-09
111 O 0 2.180164483434055e-05
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 0 7.432822144437523e-07
with O 0 5.022634738671705e-11
varying O 0 1.764155266315015e-09
clinical O 0 3.663509318130309e-08
severity O 0 4.807177234056326e-08
and O 0 2.5057493857616464e-09
CTG O 0 3.990241737028555e-07
repeat O 0 7.482427122340596e-09
size O 0 1.5546181009185034e-09
over O 0 3.034970053050756e-10
time O 0 2.8665433915442406e-10
intervals O 0 3.432125417202059e-10
of O 0 3.9749309399539356e-10
1 O 0 9.472954864975236e-09
- O 0 1.851188073942467e-07
7 O 0 3.724990165210329e-07
years O 0 1.719665334576348e-07
. O 0 5.351334948500153e-07

We O 0 1.3759198225216096e-07
have O 0 1.5006212938928343e-09
found O 0 2.0583630633286276e-10
a O 0 5.3213967954324204e-11
direct O 0 2.984197888800111e-10
progression O 0 1.5867080982445714e-09
of O 0 2.6656310492256807e-10
the O 0 1.8403950585721418e-10
size O 0 3.731467912437836e-10
heterogeneity O 0 5.679630543653502e-09
over O 0 1.7153256592905564e-10
time O 0 7.941742263817275e-10
related O 0 1.7803738483479492e-09
to O 0 8.656070860091347e-10
initial O 0 9.02775010303003e-09
CTG O 0 2.2760903561902524e-07
repeat O 0 3.3356488682301233e-09
size O 0 2.8350824465839253e-10
and O 0 2.4284643740379863e-10
the O 0 8.823750619058046e-10
time O 0 1.6415687698057013e-09
interval O 0 2.939205989704874e-09
and O 0 4.986859813982392e-10
always O 0 2.1757418089407565e-09
biased O 0 4.102409523198958e-09
towards O 0 2.6622584137214744e-09
further O 0 8.873170642687e-09
expansion O 0 3.569282398530049e-07
. O 0 6.374264671649144e-07

Attempts O 0 3.1849046422394167e-07
to O 0 3.955843208558463e-09
mathematically O 0 6.045624001416172e-09
model O 0 2.9202125162441916e-09
the O 0 2.038462065812041e-09
dynamics O 0 1.3327424497333595e-08
have O 0 1.5469189262873329e-09
proved O 0 2.125244513706548e-08
only O 0 4.659431174225404e-10
partially O 0 6.033252120118959e-09
successful O 0 2.243270680324372e-09
suggesting O 0 8.959457065138565e-10
that O 0 7.527966097709005e-12
individual O 0 1.493486931347654e-11
specific O 0 1.4434106687666315e-10
genetic O 0 2.0545829482188083e-09
and O 0 7.954734648762951e-10
/ O 0 2.2366532448359067e-06
or O 0 3.2591558341010796e-09
environmental O 0 2.8957249931238493e-09
factors O 0 5.475375153274342e-10
also O 0 4.545481005480134e-11
play O 0 5.12727083012976e-10
a O 0 7.010689251352176e-10
role O 0 4.289427035786275e-09
in O 0 1.6218971055081965e-08
somatic O 0 2.118508746207226e-05
mosaicism O 0 0.0002122748119290918
. O 0 1.857543878713841e-07
. O 0 1.0053202004201012e-06

Aspartylglucosaminuria B-Disease 1 1.0
among O 0 3.63558285698673e-07
Palestinian O 0 2.333536258447566e-06
Arabs O 0 5.593403784587281e-06
. O 0 5.962186264696356e-07

Aspartylglucosaminuria B-Disease 1 1.0
( O 1 0.7023340463638306
AGU B-Disease 1 1.0
) O 0 6.621155534958234e-08
is O 0 2.2095243412678656e-09
a O 0 8.510196991551311e-09
rare O 0 1.726664231682662e-05
disorder B-Disease 1 0.9999998807907104
of I-Disease 0 4.983229155186564e-05
glycoprotein I-Disease 0 1.1358592928445432e-05
metabolism I-Disease 0 1.9263427475380013e-06
caused O 0 1.302962626681392e-08
by O 0 4.932334540797001e-10
the O 0 1.4843652706986177e-07
deficiency B-Disease 0 0.4162324070930481
of I-Disease 0 0.0006687382701784372
the I-Disease 0 1.121034301831969e-06
lysosomal I-Disease 0 3.010458567587193e-05
enzyme I-Disease 0 8.19234742266417e-08
aspartylglucosaminidase I-Disease 0 5.482660981215304e-06
( O 0 2.1736564548291426e-08
AGA O 0 0.00023879132641013712
) O 0 2.116810264851665e-07
. O 0 1.2357393188722199e-06

AGU B-Disease 1 1.0
is O 0 2.218774568518711e-07
inherited O 0 6.961034614505479e-06
as O 0 1.8093955134190765e-07
an O 0 4.6660524333219655e-08
autosomal O 1 0.9951156377792358
recessive O 0 0.02296268753707409
trait O 0 2.7011745373783924e-07
and O 0 2.682124244923756e-10
occurs O 0 3.5591366659426527e-11
with O 0 5.69972834121163e-13
a O 0 3.022628675131145e-11
high O 0 1.0898911773082887e-09
frequency O 0 7.751638442243802e-09
in O 0 6.316426270913666e-10
Finland O 0 2.584458691501368e-08
because O 0 2.6738905534173796e-10
of O 0 4.291275779166881e-09
a O 0 3.420690175559571e-09
founder O 0 1.2084548473012546e-07
effect O 0 7.392972634079342e-08
. O 0 4.415868204432627e-07

While O 0 8.690388852983233e-08
very O 0 3.308030960269548e-09
few O 0 6.73354572100493e-09
patients O 0 1.4030380413032617e-08
with O 0 5.278518178108982e-10
AGU B-Disease 1 1.0
have O 0 1.7630494397735674e-08
been O 0 1.1248999509660962e-09
reported O 0 1.2259042392326336e-10
from O 0 4.7825868265682914e-11
non O 0 1.5308206258168866e-08
- O 0 1.4131659398231022e-08
Finnish O 0 3.3046525516056136e-08
origin O 0 1.203118160653105e-09
, O 0 1.5791051799496358e-10
we O 0 8.162565068303707e-10
diagnosed O 0 1.3994758774060756e-07
the O 0 1.5811433273782427e-09
disorder O 0 1.1482919717309414e-06
in O 0 2.1769278046868124e-10
8 O 0 2.5276635895465915e-08
patients O 0 1.867638932395721e-09
originating O 0 8.205147672413204e-10
from O 0 1.5449160006841822e-10
3 O 0 3.717758989552067e-09
unrelated O 0 2.518528496864292e-09
families O 0 2.0273559220296278e-10
, O 0 9.017880192585537e-11
all O 0 1.6901109678446602e-10
Palestinian O 0 3.0218838986684204e-08
Arabs O 0 2.9557469360952382e-08
from O 0 1.0028872177159087e-09
the O 0 7.718792272015662e-10
region O 0 4.655870800007733e-09
of O 0 6.0987259686839934e-09
Jerusalem O 0 7.855590411054436e-06
. O 0 4.4243830643608817e-07

The O 0 1.563199276688465e-07
clinical O 0 2.9780455861327937e-06
diagnosis O 1 0.9978349804878235
of O 0 8.185596925613936e-06
AGU B-Disease 1 1.0
is O 0 3.2375204739309993e-09
often O 0 1.0097467306735552e-10
difficult O 0 4.531915814842691e-11
, O 0 6.696200885447645e-12
in O 0 6.392741370986332e-12
particular O 0 2.7624741036347267e-11
early O 0 4.260421460067221e-10
in O 0 1.010678693513789e-11
the O 0 4.756750202061788e-11
course O 0 1.924085113458318e-09
of O 0 4.0110612054000683e-10
the O 0 5.126556956724926e-10
disease O 0 2.2023547430194412e-09
, O 0 1.1991993335846995e-11
and O 0 2.429315602847648e-11
most O 0 4.2199979621848627e-11
of O 0 3.521083147273174e-10
the O 0 6.738719582344288e-10
patients O 0 1.8339204599371328e-09
are O 0 1.138810139938995e-11
diagnosed O 0 4.3302464391992146e-10
after O 0 7.96716650985907e-11
the O 0 2.381439212495451e-10
age O 0 1.926523385265e-09
of O 0 5.944555070414026e-09
5 O 0 8.885911029210547e-08
years O 0 5.373729194957377e-08
. O 0 3.3751092587408493e-07

However O 0 1.8317999206374225e-07
, O 0 5.887919485303428e-09
since O 0 3.224338795959625e-09
these O 0 7.827405945626253e-10
patients O 0 3.5718508151205697e-09
excrete O 0 5.232051680792438e-09
early O 0 3.237396795086056e-09
large O 0 2.673788412899114e-10
amounts O 0 4.665231756462163e-09
of O 0 1.2308937868965586e-08
aspartylglucosamine O 0 6.547707926074509e-06
in O 0 1.9120388827786883e-08
urine O 0 1.4627710598347221e-08
, O 0 2.602590642997171e-10
biochemical O 0 3.488835886855668e-09
screening O 0 1.016817385846025e-08
is O 0 5.856197748954628e-10
easy O 0 2.8460892309567498e-08
by O 0 4.29746815910903e-09
urine O 0 6.413772268842877e-08
chromatography O 0 3.1721398841000337e-07
. O 0 7.368154797404713e-08
. O 0 6.381916364261997e-07

Detection O 0 1.8452374206390232e-05
of O 0 1.0968323493898424e-07
heterozygous O 0 6.677539410304689e-09
carriers O 0 3.1771485442533276e-09
of O 0 7.96548871306868e-09
the O 0 1.2568364127218956e-07
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 1.6620614360363106e-06
ATM O 0 0.00014733914576936513
) O 0 9.941612866271043e-09
gene O 0 2.246083319334957e-09
by O 0 1.7625609860516533e-09
G2 O 0 1.978489081011503e-06
phase O 0 2.3529373720521107e-06
chromosomal O 0 5.116221473144833e-06
radiosensitivity O 0 3.989947435911745e-05
of O 0 4.503675938849483e-07
peripheral O 0 0.001153544639237225
blood O 0 1.1839502803923097e-05
lymphocytes O 0 1.7918030152941355e-06
. O 0 4.715092813967203e-07

In O 0 1.2619591416296316e-06
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 0.7632474899291992
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 4.947622755935299e-08
patients O 0 6.621066717116264e-08
, O 0 7.631859727519341e-11
mutations O 0 5.957215970520124e-11
in O 0 3.9547601304867896e-11
a O 0 1.347155303976777e-10
single O 0 4.416411125696129e-10
gene O 0 2.6921803675250544e-10
, O 0 1.9330188838484474e-10
ATM O 0 1.255140205103089e-07
, O 0 3.2055913479211995e-10
result O 0 2.1747864620280666e-10
in O 0 1.9105359516657927e-09
an O 0 1.732073826588021e-07
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
syndrome I-Disease 1 1.0
that O 0 2.8920486006001056e-09
embraces O 0 6.235625904515985e-10
a O 0 4.396808611639713e-11
variety O 0 9.70356642260306e-11
of O 0 4.088783756017733e-10
clinical O 0 4.626190097667404e-09
features O 0 1.0992189380942818e-09
and O 0 2.509081553636605e-10
manifests O 0 2.0285868540526053e-09
extreme O 0 1.3364410911265168e-08
radiosensitivity O 0 2.1383522152973455e-07
and O 0 6.053421097718115e-10
a O 0 4.902361627756591e-09
strong O 0 2.0079010454310264e-08
pre O 0 0.00034586628316901624
- O 0 1.9352499293745495e-05
disposition O 0 4.216735760564916e-05
to O 0 1.2082675766578177e-06
malignancy B-Disease 1 0.9995682835578918
. O 0 2.5656752313807374e-06

Heterozygotes O 0 9.870121175481472e-06
for O 0 1.845620545282145e-08
the O 0 4.223843497186408e-09
ATM O 0 1.5096959486982087e-06
gene O 0 1.2466104593045202e-08
have O 0 1.1025114154961102e-09
no O 0 1.0716789677900351e-09
clinical O 0 4.151543553376769e-09
expression O 0 4.963080502129458e-10
of O 0 2.0396286881663173e-09
A B-Disease 1 0.9999998807907104
- I-Disease 1 1.0
T I-Disease 1 1.0
but O 0 3.042360807725686e-09
may O 0 4.2232795038898985e-09
be O 0 1.876601540828915e-09
cancer B-Disease 0 3.135245663088426e-08
prone O 0 9.401006639819798e-10
with O 0 9.154419410017933e-12
a O 0 6.529348173245353e-10
moderate O 0 7.363472498411738e-09
increase O 0 5.888680099097598e-10
in O 0 1.5533703212611272e-09
in O 0 3.102841361624087e-08
vitro O 0 6.322106401057681e-06
radiosensitivity O 0 3.8428468542406335e-05
. O 0 2.4821106308081653e-06

We O 0 1.1856657522457681e-07
performed O 0 1.339187178928114e-07
a O 0 3.180745622444192e-08
blind O 0 2.5557065441716986e-07
chromosomal O 0 9.448309157278345e-08
analysis O 0 2.3543840654838277e-08
on O 0 8.080146329803028e-09
G2 O 0 8.775153048645734e-08
- O 0 1.7153338305320176e-08
phase O 0 4.577889356482956e-08
lymphocytes O 0 4.013512189260382e-09
from O 0 6.793589996112459e-11
7 O 0 1.5716060675075028e-09
unrelated O 0 2.1776235925585752e-08
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 3.594850568333641e-05
, O 0 3.370843049133043e-10
13 O 0 1.0983638443207155e-09
obligate O 0 1.7982648259362577e-08
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
heterozygotes O 0 0.00012744659034069628
( O 0 9.378512411117867e-10
parents O 0 9.789002941573699e-11
of O 0 4.3341445016276126e-11
the O 0 4.795841501703535e-11
patients O 0 1.0521796628415458e-10
) O 0 6.019966643233676e-12
, O 0 1.2918989662769054e-11
and O 0 4.6189028296561574e-11
14 O 0 2.8804658658287963e-09
normal O 0 4.625034577543374e-09
controls O 0 8.404859919153296e-09
following O 0 6.964627763395015e-10
X O 0 4.761604799341512e-08
- O 0 1.4060679731642267e-08
irradiation O 0 2.4744190696424084e-08
with O 0 3.5501618311784e-10
1 O 0 9.258832278646878e-08
Gy O 0 7.105370968929492e-06
in O 0 4.385888596747378e-10
order O 0 4.849683432617269e-10
to O 0 3.9455780309616273e-10
evaluate O 0 2.7669699864674158e-09
this O 0 5.952051629343202e-10
cytogenetic O 0 2.58271228403828e-07
method O 0 1.4439408779765017e-08
as O 0 4.3886166922746384e-10
a O 0 2.621752537290689e-10
tool O 0 1.2854758146829681e-08
for O 0 3.219451649716376e-10
detection O 0 2.939757735020976e-07
of O 0 5.952579229528965e-08
ATM O 0 0.0017612206283956766
carriers O 0 1.391327259625541e-05
. O 0 4.83298799736076e-06

Both O 0 3.064751297188195e-07
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
homozygotes O 0 0.10572196543216705
and O 0 5.001362524126307e-08
heterozygotes O 0 3.043345714104362e-06
showed O 0 5.1201394235533826e-09
significantly O 0 4.447620605141367e-10
increased O 0 1.39692174494499e-10
levels O 0 3.894868039200361e-10
of O 0 2.944389176917639e-10
radiation O 0 6.3207867242454085e-06
- O 0 1.5912011122054537e-06
induced O 0 6.696922127957805e-07
chromatid O 0 2.4199479753406195e-07
damage O 0 4.2796550303592085e-08
relative O 0 1.2796388837443828e-08
to O 0 5.920562928807271e-10
that O 0 9.463031747092288e-11
of O 0 7.215322561648918e-09
normal O 0 3.3585382652745466e-07
controls O 0 1.7081174519262277e-06
. O 0 1.549328430883179e-06

These O 0 6.400425522912201e-09
results O 0 2.3886235211989515e-09
show O 0 2.0620343210708825e-09
that O 0 2.0269151634888516e-10
the O 0 1.941311333908402e-09
G2 O 0 1.2444328376659541e-06
- O 0 5.165214247426775e-07
phase O 0 1.126919073612953e-06
chromosomal O 0 7.960514949445496e-07
radiosensitivity O 0 6.606080091842159e-07
assay O 0 4.609051362791661e-09
can O 0 8.422568198440672e-11
be O 0 1.4003757355107727e-11
used O 0 9.314402027449376e-11
for O 0 1.1306895524032523e-11
the O 0 2.0857024440879002e-11
detection O 0 3.7600280222704896e-08
of O 0 4.0683133306629315e-08
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
heterozygotes O 0 0.0029929953161627054
. O 0 6.120559646660695e-06

In O 0 6.927010076651641e-08
combination O 0 4.859994007233581e-08
with O 0 5.471313957450263e-10
molecular O 0 2.0765597241734213e-08
genetic O 0 2.10996398131158e-09
analyses O 0 7.7531125963759e-10
, O 0 3.073439072687201e-11
this O 0 9.597832077712365e-12
test O 0 9.137555989635615e-11
may O 0 2.7631908913750003e-11
be O 0 1.3832955614301312e-11
of O 0 5.31160150585297e-11
value O 0 9.447665566542085e-11
in O 0 3.1421254487185024e-11
studies O 0 5.953391113422413e-10
of O 0 5.725145357793338e-10
familial B-Disease 0 2.0777681797312653e-08
and I-Disease 0 1.9275194773626936e-09
sporadic I-Disease 0 4.3677860617208353e-07
cancers I-Disease 0 1.8575965441414155e-06
aimed O 0 5.157397353627857e-08
at O 0 6.23296569912668e-09
determination O 0 8.38159941451977e-09
of O 0 2.0342294959618812e-08
the O 0 3.6361977873156093e-09
potential O 0 3.217623723017482e-09
involvement O 0 7.62357554862092e-09
of O 0 7.930439416270474e-09
ATM O 0 3.8828144170111045e-05
mutations O 0 1.95738536490353e-08
in O 0 4.0659529076947365e-09
tumor B-Disease 0 1.9847066141664982e-05
risk O 0 5.250588586136473e-08
or O 0 1.2083477551882993e-09
development O 0 8.52927506400647e-09
. O 0 1.8773757659573675e-08
. O 0 2.1438775377191632e-07

Ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
: O 0 1.7345615788144642e-07
identification O 0 2.2836046298380097e-07
and O 0 1.1221183982002003e-09
detection O 0 1.0004271189245628e-06
of O 0 7.715822647469395e-09
founder O 0 3.6015084248219864e-08
- O 0 7.717235739335138e-09
effect O 0 1.7513815953051903e-09
mutations O 0 6.208555891618062e-10
in O 0 3.249222835233212e-10
the O 0 2.3314092878479187e-09
ATM O 0 3.2523473691981053e-06
gene O 0 6.7440466544610445e-09
in O 0 4.324833824398411e-09
ethnic O 0 3.1193538863050208e-09
populations O 0 1.618294120930841e-08
. O 0 7.53266320430157e-08

To O 0 8.080363045337435e-09
facilitate O 0 1.542385597019802e-08
the O 0 6.9828504090097e-10
evaluation O 0 7.453085260067382e-09
of O 0 1.2648030178752379e-08
ATM O 0 0.0013362480094656348
heterozygotes O 0 6.398355253622867e-06
for O 0 4.215625626358133e-09
susceptibility O 0 2.1068650823963253e-07
to O 0 1.2910528202070282e-09
other O 0 1.0858760557397318e-09
diseases O 0 2.4552973627578467e-06
, O 0 7.588502742850167e-11
such O 0 2.6152849330607353e-10
as O 0 1.661385518048064e-08
breast B-Disease 0 0.022860029712319374
cancer I-Disease 0 1.1877911987312473e-07
, O 0 3.8959380166403434e-10
we O 0 6.670891061766326e-10
have O 0 3.0831046049506483e-10
attempted O 0 8.746709134754838e-09
to O 0 4.6045675605732583e-10
define O 0 1.910689162443191e-09
the O 0 1.2356233813903827e-09
most O 0 3.3195390880536024e-10
common O 0 2.1631037239178141e-10
mutations O 0 6.371284055894932e-11
and O 0 1.5145657297765958e-11
their O 0 1.4168106965417593e-10
frequencies O 0 1.4160232986171195e-08
in O 0 4.633767147765866e-09
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 0.00020555728406179696
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 1.4797935321553268e-08
homozygotes O 0 7.148000236156804e-07
from O 0 1.905935409496351e-09
10 O 0 3.70323638421155e-09
ethnic O 0 1.0159213470473105e-09
populations O 0 6.247629524835929e-09
. O 0 8.671695894690856e-08

Both O 0 9.010723545088695e-08
genomic O 0 2.103957541521595e-07
mutations O 0 2.4322668323861762e-09
and O 0 3.6533948089001456e-10
their O 0 6.268826013844375e-10
effects O 0 1.6306444194924552e-08
on O 0 2.0129087729969797e-08
cDNA O 0 3.050085126687918e-07
were O 0 4.959508359547726e-08
characterized O 0 1.0048660925576769e-07
. O 0 3.44236326554892e-07

Protein O 0 1.5328721758578467e-07
- O 0 2.657684206042177e-07
truncation O 0 7.355845923484594e-07
testing O 0 2.0694427504963642e-08
of O 0 3.774835555248046e-09
the O 0 1.339094168884003e-09
entire O 0 4.99699304157275e-09
ATM O 0 3.569694229099696e-07
cDNA O 0 3.222213820208708e-07
detected O 0 4.361201177971452e-08
92 O 0 8.11268776601537e-08
( O 0 2.610626159693652e-09
66 O 0 3.571103235344708e-08
% O 0 1.6960959303702339e-09
) O 0 4.714076351497454e-10
truncating O 0 4.147904419937731e-08
mutations O 0 5.463693941720749e-09
in O 0 2.7815585390555952e-09
140 O 0 9.827704872122922e-08
mutant O 0 1.1537096611391462e-07
alleles O 0 1.4490836086622494e-08
screened O 0 5.78934532313724e-07
. O 0 4.1135799619951285e-06

The O 0 7.6264126391834e-07
haplotyping O 0 9.151257836492732e-05
of O 0 2.2521791720464535e-07
patients O 0 3.082484667515928e-08
with O 0 4.1542089213031375e-11
identical O 0 2.4524751118804033e-09
mutations O 0 6.648131822828418e-09
indicates O 0 3.934187642329334e-09
that O 0 4.3895102830315835e-11
almost O 0 2.3660409742554123e-10
all O 0 8.190211703285044e-11
of O 0 2.7596636087423576e-10
these O 0 6.502649113615533e-11
represent O 0 2.3963844797414424e-10
common O 0 1.290831219691313e-09
ancestry O 0 1.2896794743255668e-09
and O 0 2.7096130894577186e-10
that O 0 9.428979819148253e-11
very O 0 7.480354669020528e-10
few O 0 6.317345313533451e-09
spontaneously O 0 1.905416802117088e-08
recurring O 0 5.8835663452327935e-08
ATM O 0 1.1294235264358576e-05
mutations O 0 2.5032386474777013e-07
exist O 0 9.507365916761046e-07
. O 0 2.7264961772743845e-06

Assays O 0 2.809987563523464e-06
requiring O 0 1.6486491460909747e-07
minimal O 0 3.4995287023775745e-07
amounts O 0 1.4731756259322992e-08
of O 0 8.774212467699272e-09
genomic O 0 2.960181433309117e-08
DNA O 0 1.3184245695185837e-08
were O 0 1.8562212877881734e-09
designed O 0 4.790680740995867e-09
to O 0 7.817469449555858e-10
allow O 0 8.712155441514824e-10
rapid O 0 6.136309238513604e-09
screening O 0 4.544974174791605e-09
for O 0 1.1192839988183323e-09
common O 0 4.5507602131067415e-09
ethnic O 0 1.7648822403515396e-09
mutations O 0 1.3001721477223782e-08
. O 0 1.327457255229092e-07

These O 0 1.3720621439006209e-07
rapid O 0 5.348579747987969e-07
assays O 0 3.016520224718988e-07
detected O 0 9.727706640205724e-08
mutations O 0 1.9066117573629526e-09
in O 0 8.483339031251091e-10
76 O 0 8.854746624820109e-08
% O 0 1.0650379467236348e-09
of O 0 4.162667543994303e-09
Costa O 0 7.418270087100609e-08
Rican O 0 5.579757385021367e-07
patients O 0 2.627191442172716e-08
( O 0 3.0424116004290624e-10
3 O 0 6.0743352570113984e-09
) O 0 6.838705712830517e-10
, O 0 3.799038028606816e-10
50 O 0 2.2416453138163206e-09
% O 0 7.802464230266537e-11
of O 0 1.684716949279519e-10
Norwegian O 0 1.647036107499389e-08
patients O 0 9.071126072512925e-09
( O 0 1.8305820748132362e-10
1 O 0 5.158653948456049e-09
) O 0 5.206404751767479e-10
, O 0 4.5043332952410253e-10
25 O 0 1.5673133901827896e-09
% O 0 9.45653624850884e-11
of O 0 3.105531942715345e-10
Polish O 0 9.097448838701894e-08
patients O 0 1.2786288472454999e-08
( O 0 1.1110901088073888e-10
4 O 0 2.4400406140046016e-09
) O 0 1.4543291571023076e-10
, O 0 1.1150048245811561e-10
and O 0 1.340220295853456e-10
14 O 0 1.4030346884297273e-09
% O 0 6.19777423827017e-11
of O 0 1.073718197686091e-10
Italian O 0 6.258447093898667e-09
patients O 0 2.28363106202778e-09
( O 0 7.340817537171418e-11
1 O 0 2.7946349678842353e-09
) O 0 4.63960175833833e-10
, O 0 1.8792833955671995e-10
as O 0 2.037372631713552e-10
well O 0 1.3584827707191494e-10
as O 0 1.5181181312051706e-10
in O 0 1.2809611704689416e-10
patients O 0 8.09370070964377e-10
of O 0 1.2287491024665087e-09
Amish O 0 1.0855640084628249e-06
/ O 0 6.978149485803442e-06
Mennonite O 0 9.393570508109406e-06
and O 0 4.39830820653242e-08
Irish O 0 3.09074493998196e-07
English O 0 1.7768475402135664e-07
backgrounds O 0 1.9110605364858202e-07
. O 0 5.400283953349572e-07

Additional O 0 4.828956434721476e-07
mutations O 0 2.5639549150469065e-08
were O 0 8.407552876121827e-09
observed O 0 1.3185168512563905e-09
in O 0 2.977108559676367e-10
Japanese O 0 8.199523904295347e-08
, O 0 8.506460535961935e-10
Utah O 0 2.499898066332662e-08
Mormon O 0 4.644467210823677e-08
, O 0 3.0946342710613806e-10
and O 0 8.067330137251361e-10
African O 0 3.540617399266921e-08
American O 0 1.1319442450030692e-07
patients O 0 1.0137445372038201e-07
. O 0 8.452803967884392e-08

These O 0 1.1354631013205108e-08
assays O 0 2.353059613824371e-08
should O 0 8.804937889905773e-10
facilitate O 0 2.1808064243344916e-09
screening O 0 7.144277169857105e-09
for O 0 8.285641506233787e-09
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
heterozygotes O 0 3.1180579753709026e-06
in O 0 1.754490996930258e-09
the O 0 1.1499036167705867e-09
populations O 0 4.820503995972558e-10
studied O 0 6.000384633608746e-09
. O 0 7.625552633783172e-09
. O 0 1.3817437150009937e-07

The O 0 8.348928531631827e-06
von B-Disease 1 0.9984245300292969
Hippel I-Disease 1 0.9951820969581604
- I-Disease 0 0.000964074395596981
Lindau I-Disease 0 0.00039369770092889667
tumor I-Disease 0 7.5703501352109015e-06
suppressor O 0 1.492592787144531e-06
gene O 0 3.307784934847291e-09
is O 0 5.5887020705691626e-11
required O 0 3.29695548639819e-10
for O 0 1.8102284948806613e-10
cell O 0 7.088179820868845e-09
cycle O 0 9.9272874365397e-09
exit O 0 2.5458755104068587e-08
upon O 0 2.325973724737196e-08
serum O 0 3.850046823572484e-07
withdrawal O 0 2.454407876939513e-06
. O 0 3.1709196264273487e-06

The O 0 5.615605118691747e-07
inactivation O 0 7.366955287579913e-06
of O 0 7.376618214038899e-07
the O 0 2.511342245270498e-07
von B-Disease 1 0.9999804496765137
Hippel I-Disease 1 0.9999998807907104
- I-Disease 1 0.9999992847442627
Lindau I-Disease 1 0.9999990463256836
( I-Disease 0 2.318509814358549e-06
VHL I-Disease 0 0.0020035041961818933
) I-Disease 0 1.3075313631816243e-07
tumor I-Disease 0 6.6900493038701825e-06
suppressor O 0 0.00011613487004069611
gene O 0 3.5132657671965717e-07
predisposes O 0 3.095889553605957e-07
affected O 0 1.3033247814320248e-09
individuals O 0 1.586343383042088e-11
to O 0 1.5815646015049367e-10
the O 0 5.672539327150616e-09
human O 0 5.094312200526474e-06
VHL B-Disease 1 1.0
cancer I-Disease 1 1.0
syndrome I-Disease 1 1.0
and O 0 5.172407835374315e-09
is O 0 1.6356266341333026e-10
associated O 0 7.231190646272978e-10
with O 0 1.2012740802092026e-10
sporadic B-Disease 0 7.01662283972837e-05
renal I-Disease 1 1.0
cell I-Disease 1 1.0
carcinomas I-Disease 1 1.0
( O 0 1.8151236872654408e-05
RCC B-Disease 1 0.9999991655349731
) O 0 2.222094934722918e-07
and O 0 9.559898899169639e-07
brain B-Disease 1 0.9999831914901733
hemangioblastomas I-Disease 1 0.9719931483268738
. O 0 9.178350410365965e-06

VHL O 0 0.0009315298520959914
- O 0 2.4028044208534993e-05
negative O 0 3.466706459676061e-07
786 O 0 9.312544534623157e-06
- O 0 1.9983255697297864e-05
0 O 0 1.3471999409375712e-06
RCC B-Disease 0 0.0036195267457515
cells O 0 3.387088145245798e-05
are O 0 2.0256957000697184e-08
tumorigenic O 0 3.480749001028016e-05
in O 0 9.705670578341596e-08
nude O 0 4.20174319515354e-06
mice O 0 8.071278045918007e-08
which O 0 1.926180742684025e-10
is O 0 8.885812918801861e-11
suppressed O 0 1.9063064460311807e-09
by O 0 1.8828388848035615e-10
the O 0 4.482437976349729e-09
reintroduction O 0 4.875239483226324e-07
of O 0 3.508671682084241e-07
VHL B-Disease 0 0.0002518621040508151
. O 0 6.877508894831408e-06

Remarkably O 0 2.8929664495080942e-06
, O 0 1.625618972767029e-09
this O 0 4.4896891759904634e-11
occurs O 0 1.3157226697035895e-10
without O 0 1.989023112880517e-10
affecting O 0 3.5081587634877565e-10
the O 0 1.0550011558807526e-10
growth O 0 4.3853867759402476e-10
rate O 0 2.4651281016474513e-09
and O 0 1.1597886540037905e-10
cell O 0 9.505389364505845e-09
cycle O 0 4.483549531641984e-09
profile O 0 1.124294990439978e-09
of O 0 6.472212765729068e-10
these O 0 1.1506534614014186e-10
cells O 0 3.2425013785086776e-09
in O 0 2.523562914191757e-09
culture O 0 1.6160385030161706e-07
. O 0 6.659709015366388e-07

The O 0 3.72518570657121e-07
786 O 0 3.472729758868809e-06
- O 0 1.7419330333723337e-06
0 O 0 1.218374450218107e-07
cell O 0 7.157591426221188e-07
line O 0 1.0525062066335522e-07
, O 0 3.25460858263682e-09
like O 0 4.791173680018801e-09
many O 0 9.184283333851795e-10
cancer B-Disease 0 1.051296028009574e-08
cells O 0 2.961490164210545e-09
, O 0 6.090260518121227e-10
fails O 0 6.855451761822451e-09
to O 0 2.1497907898293533e-09
exit O 0 4.285070431819804e-08
the O 0 6.106024130758669e-09
cell O 0 3.834253803347565e-08
cycle O 0 6.692891574289206e-09
upon O 0 1.4097254918965518e-08
serum O 0 1.67720401123006e-07
withdrawal O 0 6.532904421874264e-07
. O 0 1.6784822491899831e-06

Here O 0 1.9665804984470014e-07
, O 0 2.3706543395007884e-09
it O 0 5.1215604673915394e-11
is O 0 1.342588713815207e-11
shown O 0 2.8315790684407816e-11
that O 0 5.361852455088023e-12
reintroduction O 0 6.7859562413730146e-09
of O 0 3.846014617892024e-09
the O 0 3.341437349035914e-09
wild O 0 3.065738951590902e-08
- O 0 7.34182279416018e-08
type O 0 9.458894112412963e-08
VHL B-Disease 0 6.6802563196688425e-06
gene O 0 1.4157289562888309e-08
restores O 0 2.1866601684905618e-07
the O 0 1.2844733277006526e-08
ability O 0 1.9465845824129246e-08
of O 0 1.3852414326720464e-07
VHL O 1 0.9955991506576538
- O 0 0.1984306126832962
negative O 0 3.013026912412897e-07
RCC B-Disease 1 0.9929995536804199
cancer I-Disease 0 7.709404599154368e-06
cells O 0 1.3767986750679029e-08
to O 0 9.586571536601696e-10
exit O 0 8.661773520657334e-09
the O 0 2.2574822011733886e-09
cell O 0 1.3039868740349903e-08
cycle O 0 4.5969703599269e-09
and O 0 3.937978831913824e-09
enter O 0 7.212187824734428e-07
G0 O 0 0.00032548175659030676
/ O 0 5.78372273594141e-05
quiescence O 0 6.977217708481476e-06
in O 0 1.280161825434334e-07
low O 0 1.7783472685550805e-06
serum O 0 1.2143079857196426e-06
. O 0 6.480618708337715e-07

Both O 0 2.522251406844589e-06
VHL O 0 0.001571127213537693
- O 0 0.0001557061041239649
positive O 0 1.1986779213657428e-07
and O 0 2.7460355767061628e-08
VHL O 0 0.00017145818856079131
- O 0 2.0866958948317915e-05
negative O 0 6.742119751379505e-08
RCC B-Disease 0 3.7728226743638515e-05
cells O 0 8.759398610891367e-07
exit O 0 1.495413926022593e-07
the O 0 5.088440779843495e-09
cell O 0 2.987794545106226e-08
cycle O 0 5.808123315631519e-09
by O 0 1.4831271766269083e-09
contact O 0 1.2241301305948582e-07
inhibition O 0 5.477453441926627e-07
. O 0 7.251458669088606e-07

The O 0 3.821670361503493e-06
cyclin O 0 1.2294010957702994e-05
- O 0 3.1268186830857303e-06
dependent O 0 4.807599225387094e-07
kinase O 0 6.923033311068139e-07
inhibitor O 0 4.311773409426678e-07
, O 0 1.7777924909978537e-08
p27 O 0 5.771578344138106e-06
, O 0 2.5916542245596474e-09
accumulates O 0 6.725959345033061e-09
upon O 0 9.210140428095315e-10
serum O 0 1.937442917210319e-08
withdrawal O 0 1.843597630113436e-08
, O 0 2.734888704392091e-10
only O 0 5.13940938418056e-11
in O 0 4.908475709219928e-11
the O 0 3.1777588893611153e-10
presence O 0 1.9048016497436038e-09
of O 0 8.930082451286125e-09
VHL B-Disease 0 6.26315795670962e-06
, O 0 1.7929964180041225e-09
as O 0 2.625465678196548e-10
a O 0 1.0160487035060228e-10
result O 0 7.671030477496288e-11
of O 0 3.635842182880822e-10
the O 0 1.743082483907088e-10
stabilization O 0 5.19797652032139e-07
of O 0 1.1433153446205324e-07
the O 0 4.32153761664722e-08
protein O 0 9.761980379607849e-08
. O 0 2.936949954346346e-07

We O 0 4.0163477876831166e-08
propose O 0 2.9744438023726616e-08
that O 0 2.1588171528197364e-10
the O 0 6.529074503269783e-10
loss O 0 7.517804156975672e-09
of O 0 1.5087639582134216e-08
wild O 0 2.0856735005736482e-08
- O 0 3.6769431943639574e-08
type O 0 8.626873437833638e-08
VHL B-Disease 0 3.015372021764051e-05
gene O 0 1.5890469384771677e-08
results O 0 1.6223975496387766e-09
in O 0 1.2584832065343221e-09
a O 0 3.49192519344399e-09
specific O 0 3.761110889399788e-08
cellular O 0 1.8950197045342065e-05
defect O 0 6.997749437687162e-07
in O 0 1.8209959096182615e-09
serum O 0 3.0954463881016636e-08
- O 0 5.732592356366695e-08
dependent O 0 2.2206707583904972e-08
growth O 0 2.9606654905478536e-09
control O 0 1.025468865378798e-08
, O 0 3.1239488773593393e-10
which O 0 8.144365737372539e-11
may O 0 1.2338595700711608e-09
initiate O 0 7.283938430191483e-08
tumor B-Disease 0 1.0080409538204549e-06
formation O 0 1.4598134612242575e-06
. O 0 2.999637445100234e-06

This O 0 1.529498305785637e-08
is O 0 1.077604561139367e-09
corrected O 0 3.538368886779608e-08
by O 0 1.5800087627138026e-10
the O 0 5.369256705911596e-10
reintroduction O 0 4.023508992645475e-08
of O 0 3.6363365651936874e-09
wild O 0 2.944661758874645e-08
- O 0 2.1123956628343876e-07
type O 0 2.1616704088955885e-06
VHL B-Disease 1 0.9993329644203186
, O 0 4.6181037305359496e-07
implicating O 0 0.0001131091921706684
VHL B-Disease 1 0.6552397012710571
as O 0 4.245459450658018e-08
the O 0 5.765958377423885e-09
first O 0 5.875421926759827e-09
tumor B-Disease 0 1.654466785794284e-08
suppressor O 0 7.820219849463683e-08
involved O 0 2.8257429729450223e-10
in O 0 1.3543795251980129e-10
the O 0 1.7182275602323216e-09
regulation O 0 4.83742894630268e-08
of O 0 6.581315048492797e-09
cell O 0 1.494421120185052e-08
cycle O 0 2.3852682051739293e-09
exit O 0 5.43131761787663e-09
, O 0 1.9652654503765632e-10
which O 0 3.1524026444795794e-11
is O 0 1.465986707027689e-11
consistent O 0 2.893150718996651e-10
with O 0 1.0389336092819779e-11
its O 0 3.7853606360549463e-10
gatekeeper O 0 8.742910040382412e-08
function O 0 5.428725802225642e-10
in O 0 5.14498332826463e-10
the O 0 7.736202789487834e-09
kidney O 0 1.6492467693751678e-05
. O 0 1.688888886519635e-07
. O 0 1.0893825219682185e-06

Piebaldism B-Disease 1 1.0
with O 0 6.126527750893729e-06
deafness B-Disease 1 1.0
: O 0 1.1549863287996232e-08
molecular O 0 5.043182760289255e-09
evidence O 0 3.182077379371151e-10
for O 0 3.216098914959886e-11
an O 0 2.46356629540756e-10
expanded O 0 2.130408574885223e-06
syndrome O 1 0.9999996423721313
. O 0 1.5142384654609486e-05

In O 0 6.006109831702133e-09
a O 0 4.45960024464398e-09
South O 0 2.9469877205201556e-08
African O 0 1.9894047298407713e-08
girl O 0 5.582113438151737e-09
of O 0 2.868886017637351e-09
Xhosa O 0 1.4316298120320425e-06
stock O 0 7.79068010103856e-09
with O 0 3.920924349087862e-11
severe O 0 3.8678948044434946e-08
piebaldism B-Disease 0 1.1779384294641204e-05
and O 0 4.648499540849116e-08
profound O 1 0.9999998807907104
congenital O 1 1.0
sensorineural B-Disease 1 1.0
deafness I-Disease 1 1.0
we O 0 1.5959122379172186e-07
identified O 0 4.459073110751888e-09
a O 0 3.015628025071493e-10
novel O 0 7.120493639156678e-10
missense O 0 3.961491135129336e-09
substitution O 0 8.207281076977324e-09
at O 0 7.116003342133581e-09
a O 0 1.1497436336327382e-09
highly O 0 2.2691291068355213e-09
conserved O 0 2.086452566274488e-09
residue O 0 2.4172605250782908e-08
in O 0 2.1751442869089033e-09
the O 0 4.159945277137922e-09
intracellular O 0 2.2350588935182714e-08
kinase O 0 7.898271370265775e-09
domain O 0 1.1449619030656777e-09
of O 0 1.8614649821557805e-09
the O 0 3.652151292499184e-08
KIT O 1 0.9999977350234985
proto O 1 0.9999574422836304
- O 0 0.022467315196990967
oncogene O 0 0.20102789998054504
, O 0 1.3032538959123485e-07
R796G O 0 5.433685873867944e-05
. O 0 1.0308480113963014e-06

Though O 0 3.8299819493659015e-07
auditory B-Disease 0 7.890052802395076e-05
anomalies I-Disease 0 1.0375832971476484e-05
have O 0 2.516070018998562e-09
been O 0 5.347854936665897e-10
observed O 0 5.784593914981428e-10
in O 0 2.411331412321971e-10
mice O 0 7.381472322265381e-09
with O 0 6.486520348625291e-11
dominant O 0 9.023949587572133e-08
white O 0 5.259308366589721e-08
spotting O 0 0.00276855262927711
( O 0 1.3063460357898293e-07
W O 0 0.00046573550207540393
) O 0 1.8583927730020378e-09
due O 0 1.4049850172170864e-08
to O 0 5.992538465449115e-09
KIT O 1 0.9992446899414062
mutations O 0 3.1105498692340916e-06
, O 0 4.2633448060769297e-07
deafness B-Disease 1 1.0
is O 0 2.2363113583168115e-09
not O 0 1.9681876961552547e-10
typical O 0 1.8472043894490753e-09
in O 0 9.546063939325222e-10
human O 0 6.877979075170515e-09
piebaldism B-Disease 0 5.359896931622643e-06
. O 0 6.103873033680429e-07

Thus O 0 1.1035937319547884e-07
, O 0 1.3086154382335735e-09
the O 0 4.858200508550681e-10
occurrence O 0 1.9849169419217105e-08
of O 0 2.7055418172494683e-07
sensorineural B-Disease 1 1.0
deafness I-Disease 1 1.0
in O 0 4.043229637318291e-06
this O 0 5.774752676046546e-09
patient O 0 1.1479976080863707e-08
extends O 0 1.6813334058340956e-10
considerably O 0 1.0800423749790511e-10
the O 0 1.7700930998731934e-10
phenotypic O 0 1.4822052474272596e-09
range O 0 3.158870054420504e-09
of O 0 2.360398987377721e-09
piebaldism B-Disease 0 9.183237921206455e-07
due O 0 3.00640756734083e-08
to O 0 1.2056824871820027e-08
KIT O 0 9.64714345172979e-05
gene O 0 3.4027902273692234e-08
mutation O 0 3.831605255300019e-09
in O 0 6.028395005408527e-10
humans O 0 4.282919352505132e-09
and O 0 4.273826292866545e-10
tightens O 0 4.798584640752779e-08
the O 0 5.702110339456112e-09
clinical O 0 4.2082774598384276e-08
similarity O 0 5.813540204790968e-10
between O 0 1.409468514124157e-10
piebaldism B-Disease 0 1.9708200227341877e-07
and O 0 5.7548366072524e-10
the O 0 5.425402904712939e-10
various O 0 5.308777861756653e-10
forms O 0 2.161298695568803e-09
of O 0 1.383344283567567e-07
Waardenburg B-Disease 1 1.0
syndrome I-Disease 1 0.9999446868896484
. O 0 8.454771460719712e-08
. O 0 4.805041839972546e-07

Cycloheximide O 0 1.4128381735645235e-05
facilitates O 0 7.410945102037658e-08
the O 0 3.188141972643166e-09
identification O 0 8.592322586764567e-08
of O 0 6.809828789755556e-08
aberrant O 0 5.421796913651633e-07
transcripts O 0 2.013137958556399e-07
resulting O 0 4.590521296421457e-09
from O 0 6.887637682417846e-10
a O 0 6.039788669198742e-10
novel O 0 2.7139279712429243e-09
splice O 0 1.1204405581111132e-07
- O 0 4.647409213021092e-08
site O 0 1.3311394653214847e-08
mutation O 0 1.811531480377937e-09
in O 0 6.519119688519481e-10
COL17A1 O 0 2.768767808447592e-05
in O 0 5.721502382982635e-09
a O 0 2.0021721169882767e-08
patient O 0 1.3215205285632692e-07
with O 0 7.056627282508998e-09
generalized O 0 0.41824987530708313
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9999619722366333
. O 0 2.3591350327478722e-05

Patients O 0 1.2459358913474716e-05
with O 0 2.0862225724727068e-08
generalized O 0 2.7772248358814977e-05
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9999136924743652
often O 0 1.3678547183815226e-08
show O 0 1.872232813227015e-09
decreased O 0 3.0664331074348183e-09
expression O 0 5.992181195679791e-10
of O 0 2.7542381708656194e-09
type O 0 3.426608827794553e-07
XVII O 1 0.999998927116394
collagen O 0 4.229312253301032e-05
, O 0 8.25356281097811e-08
a O 0 2.7455589801661517e-08
transmembrane O 0 2.75729856724638e-08
hemidesmosomal O 0 2.2623031270541105e-07
protein O 0 1.5013541521113893e-09
encoded O 0 3.290185235371723e-09
by O 0 8.384876792888463e-09
COL17A1 O 0 0.0010553448228165507
. O 0 7.245455435622716e-06

This O 0 2.9216010943855508e-08
report O 0 1.1340713257368407e-08
documents O 0 1.6957248050175622e-08
a O 0 3.3118947584398484e-09
novel O 0 8.583751487378777e-09
splice O 0 2.7799643476100755e-07
- O 0 6.788780382294135e-08
site O 0 1.20815482063108e-08
mutation O 0 1.4759733435454336e-09
in O 0 3.747108734408755e-10
COL17A1 O 0 2.3150843844632618e-05
in O 0 4.552817678415977e-09
a O 0 1.4807479686851366e-08
patient O 0 1.4102006673510914e-07
with O 0 4.068411829649676e-09
generalized O 0 0.31262460350990295
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9997408986091614
, O 0 6.713988032203133e-09
and O 0 3.7145389542025953e-10
applies O 0 9.912297649350421e-10
a O 0 5.187529225625376e-11
new O 0 1.1775494468402314e-10
methodology O 0 2.365460050057777e-09
to O 0 6.119533768611518e-10
define O 0 4.066464942553694e-09
and O 0 1.936688365233863e-09
characterize O 0 2.278785160569896e-08
the O 0 3.250266056298301e-09
resulting O 0 1.6703641803061942e-09
mRNA O 0 3.607572196528963e-08
splice O 0 7.207918315543793e-07
variants O 0 6.616389214286755e-07
. O 0 6.604215627703525e-07

Mutational O 0 1.5013762094895355e-05
analysis O 0 2.927491671300686e-08
of O 0 1.6576821693092825e-08
COL17A1 O 0 8.217775757657364e-05
identified O 0 2.9458188777198302e-08
a O 0 3.4283715866223474e-09
maternally O 0 1.8080154973176832e-07
inherited O 0 2.6788862328430696e-07
G O 0 1.3463829873217037e-06
- O 0 1.71888632394257e-06
to O 0 9.35058466211558e-08
- O 0 0.011918744072318077
T O 0 1.0344710062781814e-05
transversion O 0 1.1752135833376087e-06
at O 0 1.2230859658401982e-09
the O 0 1.6860991769451772e-10
- O 0 4.509157491838778e-09
1 O 0 1.9508851423211127e-08
position O 0 3.8555061365741494e-08
of O 0 5.426474558589689e-08
exon O 0 4.571904355543666e-06
32 O 0 1.0299763744114898e-06
. O 0 6.700103654111444e-07

This O 0 2.5663718261625945e-08
acceptor O 0 3.565719097764486e-08
splice O 0 1.1520334055603598e-06
- O 0 3.5903426010008843e-07
site O 0 3.3046145375692504e-08
mutation O 0 2.1026642649246696e-09
led O 0 1.097505308855773e-09
to O 0 1.5007951825740662e-10
the O 0 7.651277944553669e-10
formation O 0 9.037656845123365e-09
of O 0 2.5913641010788524e-08
aberrant O 0 1.5079893955771695e-07
transcripts O 0 4.023586370749399e-07
present O 0 6.030284271929531e-09
at O 0 1.1102675756546887e-07
extremely O 0 1.709201313815356e-07
low O 0 1.6091041743493406e-06
levels O 0 5.246754426480038e-07
. O 0 2.646999632816005e-07

Based O 0 1.7733594148694465e-08
on O 0 7.941565627334057e-09
our O 0 3.3258211740161414e-09
recent O 0 8.541122253902245e-10
finding O 0 2.055323911065443e-09
that O 0 9.418626295554233e-11
cycloheximide O 0 4.52295466857322e-07
stabilized O 0 1.0384724191681016e-06
mutant O 0 2.6179856149610714e-07
COL17A1 O 0 1.2058353604516014e-05
transcripts O 0 3.2490598300682905e-07
in O 0 6.3236145209089045e-09
keratinocytes O 0 1.0667023389032693e-06
homozygous O 0 1.1363471053016383e-08
for O 0 3.6754110865899747e-10
a O 0 2.1585628839915216e-09
frameshift O 0 2.3359689294011332e-07
mutation O 0 2.346308924927598e-09
, O 0 1.1846321146258276e-10
the O 0 2.736673387904176e-10
effects O 0 3.289753891522196e-08
of O 0 2.840416613025809e-08
the O 0 4.256427654780737e-09
splice O 0 3.564176154213783e-08
- O 0 1.4890916943954835e-08
site O 0 3.922409508305691e-09
mutation O 0 1.2098923252157334e-10
on O 0 3.5904207384973574e-10
splicing O 0 2.611932714557952e-08
of O 0 2.996880965611126e-08
COL17A1 O 0 1.2940402484673541e-05
transcripts O 0 1.2161338247551612e-07
were O 0 3.155786743036515e-09
determined O 0 9.411448287366397e-10
using O 0 1.9992290045678374e-09
reverse O 0 7.500144505456774e-09
transcriptase O 0 1.6114624301621916e-08
polymerase O 0 7.63877050502515e-09
chain O 0 1.0873870692762466e-09
reaction O 0 1.413601319333324e-10
of O 0 4.046099844057238e-10
total O 0 1.1375168862404195e-10
RNA O 0 2.8751308001062625e-09
from O 0 1.4364874845185227e-09
keratinocytes O 0 4.842709344643481e-08
incubated O 0 8.79441852674745e-09
for O 0 4.044419910087527e-09
2 O 0 4.5748299726255937e-07
. O 0 1.0986672123181052e-06

5 O 0 6.881149943183118e-07
h O 0 1.0287212859338979e-07
in O 0 8.784155069996302e-10
the O 0 4.833246025626181e-10
presence O 0 9.370537679131985e-10
or O 0 1.4789097724232647e-09
absence O 0 3.7575759392893815e-08
of O 0 6.231149285440551e-08
10 O 0 2.1158413687771827e-07
microg O 0 1.174184671981493e-05
cycloheximide O 0 1.2647624316741712e-05
per O 0 6.017332339069981e-07
ml O 0 1.54195095092291e-05
. O 0 1.4732676163475844e-06

Using O 0 9.151678881380576e-08
this O 0 8.963524367189279e-10
approach O 0 1.2823607953293958e-08
, O 0 7.734015650129322e-10
an O 0 1.8902297782563693e-10
abnormally O 0 2.1004527894774583e-08
spliced O 0 3.3218729100781275e-08
transcript O 0 3.952440579269023e-07
was O 0 7.287968628588715e-08
identified O 0 8.61670645946333e-09
that O 0 5.3110540271239515e-11
contains O 0 1.0906225922369117e-10
an O 0 1.6827763141269436e-11
extra O 0 2.758433481631073e-09
264 O 0 1.1665520105452742e-08
bases O 0 1.8999186224277764e-08
upstream O 0 6.214874392895808e-09
from O 0 1.2276715199988075e-09
exon O 0 4.114150087275448e-08
32 O 0 6.594734980325256e-09
, O 0 1.9411434959426543e-10
resulting O 0 2.989649916518289e-10
in O 0 1.5285023247102458e-10
a O 0 4.770162598255467e-10
premature O 0 8.731857015220612e-09
termination O 0 2.9614069418926192e-08
codon O 0 9.173874104817514e-08
27 O 0 1.346965774473574e-07
bp O 0 1.878368465213498e-07
downstream O 0 2.969523471563207e-08
from O 0 1.223037582320785e-08
the O 0 6.864679136242557e-08
cryptic O 0 2.861368102458073e-06
splice O 0 1.1513346180436201e-05
site O 0 2.752260343186208e-06
. O 0 1.048525405167311e-06

Three O 0 2.940890908575966e-07
other O 0 3.21459348029407e-09
splice O 0 2.4536606701985875e-07
variants O 0 2.5453608998304844e-08
, O 0 2.523672382181985e-10
including O 0 1.0531394506463343e-10
one O 0 1.272122164552858e-11
derived O 0 1.4869502851233563e-10
from O 0 7.031294990689219e-11
the O 0 6.086416926009974e-10
skipping O 0 7.558438852584004e-08
of O 0 1.537767779780097e-08
exon O 0 4.58079796317179e-07
32 O 0 5.044878648163831e-08
, O 0 1.5868110159189541e-09
were O 0 7.35123606432353e-09
also O 0 1.0987164955622575e-08
identified O 0 4.052498780993119e-08
. O 0 3.0142629725560255e-07

These O 0 1.7387410622404786e-08
results O 0 3.6667653358080088e-09
indicate O 0 3.5611231741228266e-09
the O 0 8.975825638302126e-10
usefulness O 0 8.178749055787193e-08
of O 0 1.6107762901285128e-09
cycloheximide O 0 1.4581449647721456e-07
treatment O 0 2.305522439627339e-09
in O 0 3.4303632850951615e-11
evaluating O 0 2.35415242855197e-10
the O 0 2.58219418070027e-10
abnormal O 0 3.698746642299966e-09
processing O 0 3.57001361805942e-08
of O 0 3.709827112174935e-08
mRNA O 0 3.221887823201541e-08
due O 0 3.548323945778975e-08
to O 0 1.9898815928343083e-09
splice O 0 3.744433385577395e-08
- O 0 2.518957131769639e-08
site O 0 5.874705166775129e-09
mutations O 0 2.4715390845031493e-10
, O 0 5.933911695343852e-11
because O 0 8.359318792727777e-11
( O 0 9.289390368039108e-10
i O 0 1.9559410091574136e-08
) O 0 1.1371009689398193e-09
aberrant O 0 7.671739687964418e-09
splicing O 0 3.9541856011737764e-08
often O 0 3.604267162504726e-10
generates O 0 9.379794857489188e-11
a O 0 1.1126084775714418e-10
premature O 0 4.827655608607984e-09
termination O 0 5.148764969931108e-09
codon O 0 3.0645225024272804e-08
, O 0 1.203811383909681e-09
( O 0 1.0148327733716656e-09
ii O 0 3.7229660847515333e-06
) O 0 3.267458970057646e-09
transcripts O 0 6.719844947156162e-08
with O 0 1.4435952433444754e-10
premature O 0 2.7468633589933233e-08
termination O 0 4.9374602184570904e-08
codons O 0 1.1560111090602732e-08
can O 0 4.4128239951035653e-10
occur O 0 5.857493379224366e-10
at O 0 3.055427910680919e-09
low O 0 2.7972978600132592e-08
or O 0 1.0504316305670613e-09
undetectable O 0 4.063040037749488e-08
levels O 0 9.549470103564772e-10
due O 0 5.604482433696489e-10
to O 0 8.438169607494217e-10
nonsense O 0 1.4065078879355042e-08
- O 0 4.102174600006947e-09
mediated O 0 1.033507279757373e-09
mRNA O 0 5.249471968227226e-10
decay O 0 2.746704641509723e-09
, O 0 1.0708875453069311e-10
and O 0 1.3826315092835273e-10
( O 0 3.9466618861894176e-10
iii O 0 1.221563934450387e-06
) O 0 7.340583696446856e-10
the O 0 8.248707827895885e-10
levels O 0 2.3102413315712056e-09
of O 0 2.999691606220267e-10
these O 0 7.238969840228648e-11
transcripts O 0 1.1400159038998936e-08
can O 0 1.8494245024314182e-10
be O 0 3.932332515166337e-10
increased O 0 3.5840597156777676e-09
by O 0 6.075980607533893e-09
cycloheximide O 0 2.7169986424269155e-05
. O 0 1.659106260376575e-06

A O 0 2.3202726424642606e-06
deletion O 0 2.1107678094267612e-06
mutation O 0 3.8948869018895493e-08
in O 0 4.525191332760414e-09
COL17A1 O 0 7.88629986345768e-05
in O 0 1.0353545576435863e-08
five O 0 4.278942977720135e-09
Austrian O 0 7.804634094554785e-08
families O 0 2.879663840715807e-09
with O 0 5.147005044392472e-10
generalized O 0 3.383802550160908e-06
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 0 0.33687275648117065
represents O 0 2.0918248466728073e-08
propagation O 0 4.0231603293250373e-07
of O 0 3.981035234801311e-08
an O 0 1.6262928781429764e-08
ancestral O 0 1.2550709470815491e-05
allele O 0 9.263896572520025e-06
. O 0 2.126809476976632e-06

Patients O 0 4.231228740536608e-05
with O 0 3.920107616295354e-08
generalized O 0 7.021495548542589e-05
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9913982152938843
, O 0 1.7773787774899574e-08
a O 0 3.976480034140195e-09
usually O 0 2.178557112486601e-09
nonlethal O 0 2.8144852421974065e-06
form O 0 2.432815549013867e-08
of O 0 2.255085746583063e-06
junctional B-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.999981164932251
, O 0 5.175213502184306e-08
have O 0 3.0427089736662083e-09
generalized O 0 6.235286775790883e-08
blistering B-Disease 0 7.55822895825986e-07
, O 0 4.497375272194404e-08
nail B-Disease 1 1.0
dystrophy I-Disease 1 1.0
, O 0 2.252928061352577e-05
patchy B-Disease 1 1.0
alopecia I-Disease 1 1.0
, O 0 5.851670152878796e-07
and O 0 1.5775851352373138e-05
dental B-Disease 1 1.0
abnormalities I-Disease 1 1.0
. O 0 0.20215386152267456

Skin B-Disease 1 1.0
fragility I-Disease 1 0.7193973064422607
in O 0 5.4696682738608615e-09
most O 0 1.4730505704108054e-10
cases O 0 5.96555877613314e-12
is O 0 1.9619603251058715e-12
due O 0 9.446458892892196e-11
to O 0 4.1625308755399715e-10
mutations O 0 5.010007964045826e-10
in O 0 8.477079593838255e-10
the O 0 4.59152005305441e-09
gene O 0 1.9959027763860604e-09
encoding O 0 2.390470399404876e-08
type O 0 7.4785084507311694e-06
XVII O 1 1.0
collagen O 0 0.0027857462409883738
( O 0 1.0319024568161694e-06
COL17A1 O 0 0.007396366447210312
) O 0 2.2297221846656612e-07
. O 0 8.77792956543999e-07

Recently O 0 4.551382914996793e-07
, O 0 3.723137798061771e-09
we O 0 1.0176628428837375e-09
reported O 0 7.884886077391684e-10
five O 0 3.944780335718434e-10
Austrian O 0 2.8897893855628354e-08
families O 0 1.0703041786186418e-09
with O 0 7.466014473322957e-10
generalized O 0 3.7671850350307068e-06
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9999934434890747
who O 0 1.5075163162237004e-07
share O 0 8.805496776176369e-09
the O 0 6.898921878217834e-09
same O 0 5.964978555539346e-08
COL17A1 O 0 0.2827478349208832
mutation O 0 1.5990078736649593e-06
. O 0 1.1584875210246537e-06

Affected O 0 6.21193763095107e-08
individuals O 0 1.2381826119955974e-10
in O 0 1.3353747274624794e-10
three O 0 8.276614116287107e-11
families O 0 2.924730249653784e-11
are O 0 1.0634292058053774e-11
homozygous O 0 2.310557301044014e-10
for O 0 1.2985598707437873e-10
4003delTC O 0 3.6264612646164096e-08
, O 0 3.591920927359382e-10
whereas O 0 1.467118093678721e-09
those O 0 1.347844197363557e-10
in O 0 1.1461456089767452e-10
two O 0 2.5265428638121534e-10
others O 0 1.6864248886250266e-09
are O 0 3.375952017936612e-10
compound O 0 5.730891530220106e-07
heterozygotes O 0 6.485975973191671e-06
. O 0 8.462295113531582e-07

To O 0 1.732054855096976e-08
determine O 0 1.4787602253818477e-09
if O 0 4.0399150691428076e-10
the O 0 1.239733427027545e-09
occurrence O 0 8.96691432217267e-09
of O 0 1.413132832972508e-09
4003delTC O 0 1.8031348858471574e-08
in O 0 1.0753290619058831e-10
these O 0 4.56298436535274e-11
unrelated O 0 6.229658455758624e-10
families O 0 2.8500776391715554e-11
signifies O 0 8.260609973831379e-10
propagation O 0 4.3153601581025214e-08
of O 0 3.611976717721177e-09
an O 0 6.814123154619267e-10
ancestral O 0 1.8133789581042947e-07
allele O 0 4.825936628094496e-08
or O 0 4.021389443664702e-09
a O 0 1.549740069606287e-08
mutational O 0 6.864042370580137e-05
hot O 0 3.391959035070613e-05
spot O 0 5.658315558321192e-07
, O 0 5.306118655568071e-09
haplotypes O 0 4.581837487194207e-08
were O 0 2.2143844535804647e-09
determined O 0 3.7096059557484296e-09
for O 0 3.161956474428962e-09
polymorphisms O 0 2.3986578412404924e-07
both O 0 5.96344040815211e-09
within O 0 1.7851148115255455e-08
and O 0 5.6259938929770215e-08
flanking O 0 6.571965786861256e-05
COL17A1 O 1 0.9997977614402771
. O 0 1.3843628039467148e-05

Five O 0 1.2856519333581673e-06
intragenic O 0 9.648003469919786e-06
polymorphisms O 0 1.6612278841421357e-06
were O 0 1.8842850835198988e-08
chosen O 0 2.907535101570602e-09
based O 0 2.4950235211207428e-09
on O 0 2.0842737313842008e-08
their O 0 3.120664615607893e-08
informativeness O 0 0.00035064047551713884
. O 0 2.0516724816843634e-06

One O 0 1.1071141337026802e-08
of O 0 1.5424848065492824e-09
these O 0 6.087273046739838e-11
, O 0 6.680462433239498e-11
not O 0 4.456713470490925e-11
previously O 0 3.3980454561266527e-10
reported O 0 9.577939830140991e-11
, O 0 5.487343218701923e-11
was O 0 1.5181566004329738e-09
2988 O 0 3.131251276045077e-07
A O 0 6.001646113418246e-08
or O 0 2.0027909997111237e-08
C O 0 3.6171297779219458e-06
that O 0 1.234047308784625e-10
introduces O 0 1.992992659793913e-09
a O 0 2.6564239696824643e-10
new O 0 1.0800800254173737e-09
restriction O 0 3.264856474061162e-08
site O 0 8.48606163117438e-09
for O 0 3.0532258943338775e-09
Eco0109 O 0 1.357901783194393e-05
I O 0 2.0588953702826984e-05
. O 0 5.4860506679688115e-06

All O 0 8.120242256381971e-08
the O 0 1.953472761329067e-08
4003delTC O 0 4.894577045888582e-07
alleles O 0 5.518226764422707e-09
showed O 0 1.4935681580396931e-09
the O 0 4.0653924671119057e-10
same O 0 7.20151493993626e-10
haplotype O 0 2.596554082856528e-08
for O 0 6.269399444036594e-10
these O 0 9.44172517947095e-10
five O 0 6.2707545822604516e-09
polymorphic O 0 7.394284295969555e-08
markers O 0 8.366666861547856e-07
. O 0 1.7316406228928827e-06

Fourteen O 0 5.204362878430402e-06
microsatellite O 0 4.1222115214623045e-06
polymorphisms O 0 1.296444793297269e-06
were O 0 8.186424871325926e-09
selected O 0 2.7821793757709656e-09
based O 0 2.7905855404242175e-10
on O 0 9.942706657994904e-10
their O 0 8.706125820268085e-10
high O 0 2.7624416532034957e-08
heterozygosity O 0 2.0746595055243233e-06
and O 0 1.9249255522879594e-09
their O 0 1.3967120793267895e-09
location O 0 4.265052311325235e-08
within O 0 1.9541884554996614e-08
10q23 O 0 9.51480797084514e-06
- O 0 2.0670818230428267e-06
q25 O 0 4.2264695366611704e-05
near O 0 6.780137482564896e-06
COL17A1 O 0 0.003308388404548168
. O 0 7.499326784454752e-06

Three O 0 5.8113396761427794e-08
families O 0 1.7838954757820602e-09
shared O 0 5.713345352376109e-09
microsatellite O 0 8.36503147638723e-07
polymorphisms O 0 9.664087201599614e-07
covering O 0 4.1513871451570594e-08
at O 0 3.7155185594883733e-09
most O 0 5.620893195334986e-10
19 O 0 1.4719454988210146e-08
cM O 0 9.331552419666878e-09
, O 0 5.436310290818369e-10
whereas O 0 1.4910833678882796e-09
the O 0 8.516785054979437e-10
others O 0 3.3607916449795994e-09
shared O 0 1.2803705873309923e-09
smaller O 0 1.8111576127743945e-10
regions O 0 3.2853032794211146e-11
consistent O 0 1.2850674691033959e-10
with O 0 2.498791755109475e-12
cross O 0 6.445406430799494e-10
- O 0 2.062877335617941e-08
over O 0 4.023182897938682e-10
events O 0 1.6047740913904818e-10
during O 0 7.206873986476126e-10
passage O 0 7.575361449241313e-10
of O 0 4.1542640855096735e-11
this O 0 5.91982322536988e-12
mutation O 0 7.520593175991408e-11
through O 0 6.644816641365736e-11
several O 0 5.852758833135852e-10
generations O 0 5.9169902755229487e-08
. O 0 4.423151267474168e-07

These O 0 4.9891671238810886e-08
results O 0 1.8765021536637505e-08
indicate O 0 7.865573081744515e-09
that O 0 1.2477438526836693e-10
4003delTC O 0 4.379347728900029e-08
occurs O 0 3.598003006644035e-10
on O 0 7.598485174398206e-10
a O 0 8.188794087260476e-10
single O 0 1.3997530246001588e-08
ancestral O 0 3.9256374861906806e-07
allele O 0 1.692858973001421e-07
. O 0 5.929610225052784e-08
. O 0 8.187143976101652e-07

The O 0 9.258272370971099e-07
haptoglobin O 0 3.2112922781379893e-05
- O 0 2.019421117438469e-06
gene O 0 2.148508926325121e-08
deletion O 0 3.613342869357439e-08
responsible O 0 3.017684946371446e-08
for O 0 2.6278529574597087e-08
anhaptoglobinemia B-Disease 0 0.48405396938323975
. O 0 3.853201633319259e-06

We O 0 1.9132451711811882e-07
have O 0 3.756506217200695e-09
found O 0 9.580393145469657e-10
an O 0 1.6208438757825405e-10
allelic O 0 6.755481507525474e-08
deletion O 0 1.1636624464017586e-07
of O 0 1.3907904872212384e-07
the O 0 1.9735244904950378e-07
haptoglobin O 0 0.00017181201837956905
( O 0 7.656844047687628e-09
Hp O 0 2.7791204004756764e-08
) O 0 4.040878465172426e-10
gene O 0 4.297663058761003e-10
from O 0 6.67230326545365e-10
an O 0 3.6336444964035763e-10
individual O 0 7.912546173827195e-10
with O 0 5.868925789798141e-09
anhaptoglobinemia B-Disease 0 0.008606617338955402
. O 0 6.142088295746362e-06

The O 0 2.9050210059722303e-07
Hp O 0 1.4511282131479675e-07
gene O 0 2.1486881163212956e-09
cluster O 0 1.3809032806122445e-09
consists O 0 3.3828487233655835e-10
of O 0 5.547032833064236e-10
coding O 0 1.3223613848367677e-07
regions O 0 9.623265517788582e-10
of O 0 3.8501837273940964e-09
the O 0 1.4421263072605939e-09
alpha O 0 1.3259017883626711e-08
chain O 0 1.7418139153235757e-09
and O 0 1.8472529061952514e-10
beta O 0 5.4595892251541045e-09
chain O 0 1.907513924592763e-09
of O 0 1.7775441119027846e-09
the O 0 3.5008680399073455e-09
haptoglobin O 0 1.5615603388141608e-06
gene O 0 7.892653641761171e-09
( O 0 1.8028176729245615e-09
Hp O 0 2.2127643717340106e-08
) O 0 4.131019970543548e-10
and O 0 5.620218179736014e-10
of O 0 5.902649036215735e-09
the O 0 1.8333293771988224e-09
alpha O 0 2.79796470437077e-08
chain O 0 3.08314751507055e-09
and O 0 3.87867710172074e-10
beta O 0 1.1552969247929923e-08
chain O 0 2.8726749867757917e-09
of O 0 1.6855533635506958e-09
the O 0 1.2345232613952817e-09
haptoglobin O 0 1.963184956821351e-07
- O 0 5.183956375276466e-08
related O 0 1.9668613404633106e-08
gene O 0 4.6148214138952426e-09
( O 0 2.0201000872077657e-09
Hpr O 0 2.1467357669280318e-07
) O 0 5.771149114153218e-10
, O 0 2.134321469560163e-10
in O 0 1.4641764189970985e-10
tandem O 0 8.403673312784576e-09
from O 0 8.27837076666782e-10
the O 0 5.4033262308905705e-09
5 O 0 2.047769527280252e-07
side O 0 3.886601689373492e-07
. O 0 2.531461632315768e-06

Southern O 0 9.03240197658306e-06
blot O 0 1.0242539246974047e-05
and O 0 2.004694188428857e-08
PCR O 0 2.9341475737965084e-07
analyses O 0 9.635594544477044e-09
have O 0 2.6013299847527094e-10
indicated O 0 3.752823329872257e-10
that O 0 6.178791853161947e-12
the O 0 6.705432042952708e-11
individual O 0 3.025726197369849e-11
with O 0 3.2347641926167015e-11
anhaptoglobinemia B-Disease 0 6.028337793395622e-07
was O 0 1.0695128338511495e-08
homozygous O 0 1.7263613871776329e-09
for O 0 2.725650538604185e-10
the O 0 1.843501684639648e-09
gene O 0 1.7598736912205482e-09
deletion O 0 6.341405178744708e-09
and O 0 3.0225957847740403e-10
that O 0 4.057612579266845e-11
the O 0 3.260689773743053e-10
gene O 0 4.591237112716584e-10
deletion O 0 8.757689018423775e-10
was O 0 1.3524518172047806e-09
included O 0 1.6454150264522127e-09
at O 0 1.1584893044869204e-09
least O 0 1.1809773992066397e-10
from O 0 5.655313717323196e-11
the O 0 3.3081806738444186e-10
promoter O 0 7.3362656394238e-08
region O 0 3.556291972017789e-08
of O 0 7.515126299040276e-08
Hp O 0 1.4536698245137814e-07
to O 0 1.420914852445776e-08
Hpr O 0 2.1668311944722518e-07
alpha O 0 2.4462348591214322e-08
but O 0 9.467657768880144e-10
not O 0 2.8637250348850785e-09
to O 0 1.4073076037846022e-08
Hpr O 0 5.476863407238852e-07
beta O 0 7.730165521024901e-07
( O 0 7.682051972324189e-08
Hpdel O 0 2.7491007131175138e-05
) O 0 1.564663989483961e-07
. O 0 7.913517379165569e-07

In O 0 2.1463954169576027e-08
addition O 0 9.604878670188555e-09
, O 0 5.593888130484004e-10
we O 0 4.384993479433774e-10
found O 0 1.7406705243860898e-10
seven O 0 8.043342381025553e-11
individuals O 0 1.1314100697989993e-11
with O 0 1.1271882732755145e-11
hypohaptoglobinemia B-Disease 0 5.316555871104356e-07
in O 0 6.114458384054444e-10
three O 0 9.822594126962514e-11
families O 0 2.142269521498985e-11
, O 0 1.2426511208918356e-11
and O 0 2.4369079670849558e-11
the O 0 2.2874442617837332e-10
genotypes O 0 1.5569980860163923e-09
of O 0 1.268147920008289e-09
six O 0 4.670464570644128e-10
of O 0 5.782872514181747e-10
the O 0 2.284030603538767e-10
seven O 0 1.9938622974891018e-10
individuals O 0 3.393029347070753e-12
were O 0 1.0675266920445736e-10
found O 0 8.661930200881685e-11
to O 0 8.254782968286634e-10
be O 0 6.573263533482532e-08
Hp2 O 1 0.9998950958251953
/ O 1 0.9999154806137085
Hpdel O 1 0.8082270622253418
. O 0 6.48633431410417e-06

The O 0 2.991399128404737e-07
phenotypes O 0 1.0858212107223153e-07
and O 0 1.631072721330895e-09
genotypes O 0 9.423343882986046e-09
in O 0 2.5286736593521653e-10
one O 0 3.6813725678985776e-11
of O 0 1.2432586904420617e-10
these O 0 1.53156012178135e-11
three O 0 2.0683820975420097e-11
families O 0 1.0572002474840136e-11
showed O 0 3.327987885271e-11
the O 0 1.0757332524757857e-10
father O 0 2.9089550768190975e-09
to O 0 1.3712080360051004e-09
be O 0 5.328908425639156e-09
hypohaptoglobinemic B-Disease 0 0.00014370861754287034
( O 0 3.219405897425531e-08
Hp2 O 0 1.9266040908405557e-05
) O 0 2.3136366156251142e-09
and O 0 3.664003767056556e-09
Hp2 O 0 1.1090035513916519e-05
/ O 0 9.989637419494102e-07
Hpdel O 0 2.5792269298108295e-06
, O 0 6.923886464171858e-10
the O 0 4.372082418324652e-10
mother O 0 5.650572232340778e-10
to O 0 1.339865024485576e-10
be O 0 1.1342671246694636e-10
Hp2 O 0 1.1160957313904873e-07
- O 0 4.215668170104436e-08
1 O 0 7.083343689373578e-08
and O 0 1.6193746787962482e-08
Hp1 O 0 0.00010673530050553381
/ O 0 1.7402062439941801e-06
Hp2 O 0 1.7575182482687524e-06
, O 0 1.6789140910855593e-10
one O 0 1.2445201987010268e-11
of O 0 5.526837668079487e-11
the O 0 4.9520994943597074e-11
two O 0 1.3363625310514049e-11
children O 0 2.8362815568394595e-11
to O 0 2.295353837555858e-11
be O 0 4.678961662563097e-10
hypohaptoglobinemic B-Disease 0 3.1916515581542626e-05
( O 0 2.2507762764689687e-08
Hp2 O 0 6.142263009678572e-05
) O 0 2.9599880324582273e-09
and O 0 3.5937801623475707e-09
Hp2 O 0 0.0005388429271988571
/ O 0 2.8803085569961695e-06
Hpdel O 0 3.3888566122186603e-06
, O 0 2.841768487193974e-10
and O 0 3.0689634861191806e-11
the O 0 1.2366413448816616e-10
other O 0 3.166515660790736e-11
child O 0 3.173966922620508e-10
to O 0 1.3019675615399962e-10
be O 0 7.641914878675493e-10
Hp1 O 0 2.6621639790391782e-06
and O 0 2.785972164076611e-08
Hp1 O 0 0.007985626347362995
/ O 0 2.370141737628728e-05
Hpdel O 0 9.090412277146243e-06
, O 0 2.4481379146124027e-09
showing O 0 1.9714914145652074e-09
an O 0 9.556115621034422e-11
anomalous O 0 7.675841828813645e-08
inheritance O 0 3.530859089551086e-07
of O 0 5.851608875673264e-06
Hp O 0 6.634845703956671e-07
phenotypes O 0 1.4369157419480416e-08
in O 0 4.667952691050914e-10
the O 0 1.4590615382559236e-09
child O 0 1.541985383823885e-08
with O 0 1.431618823488634e-09
Hp1 O 0 0.37528249621391296
. O 0 1.1542545507836621e-05

The O 0 2.014808160311077e-06
Hp2 O 1 0.9731389880180359
/ O 0 0.00013685849262401462
Hpdel O 0 5.420799061539583e-05
individuals O 0 7.636960508428103e-10
had O 0 1.381056047300433e-09
an O 0 5.23280481445898e-11
extremely O 0 3.9425238074208835e-10
low O 0 6.283601194922994e-09
level O 0 1.1273319167059981e-08
of O 0 8.176359145295464e-09
Hp O 0 3.082249477870391e-08
( O 0 1.320182851927143e-09
mean O 0 3.4024185691095e-09
+ O 0 1.2617526579106197e-08
/ O 0 7.16369683573248e-08
- O 0 2.2749618722173182e-07
SD O 0 1.3455794487526873e-06
= O 0 1.0354181512184368e-07
0 O 0 1.5898503846756284e-08
. O 0 2.578096180982925e-09
049 O 0 6.985693516980973e-07
+ O 0 5.523400048446092e-08
/ O 0 1.1098801167008787e-07
- O 0 1.784555649919639e-07
0 O 0 3.028738859711666e-08
. O 0 5.3106949948755755e-09
043 O 0 3.335324890940683e-06
mg O 0 7.729671551715001e-07
/ O 0 2.947421648968884e-07
ml O 0 1.5195472258255904e-07
; O 0 9.24206211561085e-10
n O 0 4.332107117477335e-09
= O 0 6.03490946105012e-09
6 O 0 5.104547451395547e-09
) O 0 1.5364703953579806e-10
, O 0 3.048253316428884e-11
compared O 0 3.470792750426277e-11
with O 0 2.530248580101535e-12
the O 0 9.54467546665505e-11
level O 0 1.4281388294179465e-09
( O 0 6.904733729218293e-11
1 O 0 1.5982503098754819e-09
. O 0 4.126468333698341e-10
64 O 0 1.851313546907818e-09
+ O 0 2.8455993117404432e-09
/ O 0 1.1015911738354589e-08
- O 0 2.5936238046142535e-08
1 O 0 1.1351382944724264e-08
. O 0 2.6004332021045684e-09
07 O 0 1.2300411356136465e-07
mg O 0 1.6092239718545898e-07
/ O 0 1.5104967587831197e-07
ml O 0 7.145015956666612e-08
) O 0 2.3696855588895005e-10
obtained O 0 4.555388510851799e-09
from O 0 1.4580906482208889e-09
52 O 0 2.4911733120802637e-08
healthy O 0 2.6100401839812548e-08
volunteers O 0 1.2662917470152024e-07
having O 0 2.274546950786771e-08
phenotype O 0 2.515457993013115e-07
Hp2 O 0 6.328863037197152e-06
, O 0 4.948903509216507e-09
whereas O 0 8.013306462828496e-09
the O 0 4.954438193038868e-09
serum O 0 2.5143826576368156e-08
Hp O 0 5.176405082352176e-09
level O 0 3.2081863832189583e-09
of O 0 6.525040507909807e-10
an O 0 5.927554280749092e-11
individual O 0 1.8660427369976418e-10
with O 0 5.263136593214313e-10
Hp1 O 0 0.00019482297648210078
/ O 0 3.0161112590576522e-05
Hpdel O 0 3.473248943919316e-05
was O 0 5.414630095401662e-07
0 O 0 1.0150791922569624e-06
. O 0 5.982788593428268e-07

50 O 0 3.364729991517379e-06
mg O 0 5.79843526793411e-06
/ O 0 3.1682354801887413e-06
ml O 0 1.2402352922435966e-06
, O 0 1.9312362820045337e-09
which O 0 5.021714988284742e-11
was O 0 2.7650640110898905e-10
approximately O 0 1.7370015148454598e-11
half O 0 3.157150235688633e-11
the O 0 6.159944082595459e-11
level O 0 2.2251978037957088e-09
of O 0 1.3903461715258914e-09
Hp O 0 4.3793204618225445e-09
in O 0 6.175003841590865e-10
control O 0 2.7621254616860824e-08
sera O 0 8.94401210871365e-08
from O 0 5.343817055525335e-10
the O 0 8.712155441514824e-10
Hp1 O 0 8.815463274913782e-07
phenotype O 0 3.0933438033287075e-09
( O 0 6.943694230709951e-11
1 O 0 1.3572921675475413e-09
. O 0 2.362762485663694e-10
26 O 0 3.481789523362977e-09
+ O 0 6.68926691815841e-09
/ O 0 1.5643871975612456e-08
- O 0 4.8104148220318166e-08
0 O 0 1.17240519514894e-08
. O 0 9.79812453394402e-10
33 O 0 1.0501778113791715e-08
mg O 0 5.582616680044339e-08
/ O 0 6.61079440078538e-08
ml O 0 4.2542954048485626e-08
; O 0 4.835504774369781e-10
n O 0 2.475663896106539e-09
= O 0 3.6448077889161823e-09
9 O 0 4.5495016642860264e-09
) O 0 8.293859488084365e-10
, O 0 8.0844281269421e-10
showing O 0 4.9164636806153794e-09
a O 0 3.960282324300124e-09
gene O 0 1.6642717426407216e-08
- O 0 1.097836616281711e-06
dosage O 0 1.1440713933552615e-05
effect O 0 7.406577537949488e-07
. O 0 1.9188069018127862e-06

The O 0 2.468023296842148e-07
other O 0 2.1045993392476703e-08
allele O 0 8.812355645204661e-08
( O 0 2.4620738781067075e-09
Hp2 O 0 1.4975232716096798e-06
) O 0 2.5770233169630785e-10
of O 0 7.215498198931414e-10
individuals O 0 2.984202121525392e-11
with O 0 1.2273945748653148e-10
Hp2 O 1 0.9298324584960938
/ O 0 0.0001558755902806297
Hpdel O 0 4.566825373331085e-05
was O 0 5.022929983056201e-08
found O 0 7.490134068532939e-10
to O 0 3.6190986318906937e-10
have O 0 3.0728308786365233e-10
, O 0 1.0323089605357438e-10
in O 0 4.605111847411081e-10
all O 0 1.0732129629431597e-09
exons O 0 2.8114401473544604e-08
, O 0 4.2765174734782363e-10
no O 0 1.2016413419857486e-09
mutation O 0 3.445702889681712e-10
, O 0 1.1409913985849229e-10
by O 0 2.409607235964728e-10
DNA O 0 5.5048367642029916e-08
sequencing O 0 1.3388466868491378e-06
. O 0 1.904250666484586e-06

On O 0 6.97814357408788e-08
the O 0 1.1935004096130797e-09
basis O 0 8.619118196939723e-10
of O 0 3.098633016840324e-10
the O 0 1.879982419739079e-10
present O 0 9.576989895565546e-11
study O 0 3.9679620700283635e-10
, O 0 3.124137754051404e-11
the O 0 8.450825456085553e-11
mechanism O 0 1.1143871603280786e-08
of O 0 9.230580744201689e-09
anhaptoglobinemia B-Disease 0 7.379222211056913e-07
and O 0 6.978483346742337e-10
the O 0 1.8591373995846538e-09
mechanism O 0 6.783525918763189e-08
of O 0 1.730707488434291e-08
anomalous O 0 3.714939964538644e-07
inheritance O 0 1.997408816123425e-07
of O 0 3.8668665069963026e-07
Hp O 0 3.5795937947114e-07
phenotypes O 0 6.102020932985397e-08
were O 0 1.0049826748570467e-08
well O 0 1.9299484677048895e-08
explained O 0 4.0038429460764746e-07
. O 0 3.7036556932434905e-07

However O 0 7.60594645043966e-08
, O 0 1.4843554163590511e-09
the O 0 7.628807585646769e-10
mechanism O 0 2.367474394304736e-08
of O 0 2.6914744211126163e-08
hypohaptoglobinemia B-Disease 0 0.0003142566420137882
remains O 0 1.7521446125101647e-06
unknown O 0 1.027149392029969e-05

ATM O 0 0.00017567419854458421
mutations O 0 5.283328619043459e-07
and O 0 1.6926872348221877e-08
phenotypes O 0 1.0596514812277746e-06
in O 0 1.2235385327130643e-07
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
families O 0 2.5363661393384973e-08
in O 0 6.663718465915736e-10
the O 0 6.998771562294337e-10
British O 0 1.5058919444754792e-08
Isles O 0 1.1483551531910052e-07
: O 0 3.4367106382937607e-10
expression O 0 4.729792113522535e-10
of O 0 1.6234243116475255e-10
mutant O 0 7.555995829022777e-10
ATM O 0 6.405728214531337e-08
and O 0 5.53388668222965e-10
the O 0 4.878203618829957e-09
risk O 0 4.3431217022771307e-07
of O 0 4.4414625222088944e-07
leukemia B-Disease 1 1.0
, O 0 4.640749011741718e-06
lymphoma B-Disease 1 1.0
, O 0 0.08918385952711105
and O 1 0.9999960660934448
breast B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 1 0.9853739738464355

We O 0 5.284335813371399e-08
report O 0 2.8648832195443674e-09
the O 0 5.802063274273905e-10
spectrum O 0 6.569801591638225e-09
of O 0 2.289999079252425e-09
59 O 0 7.111539357396168e-09
ATM O 0 3.6114934687248024e-07
mutations O 0 7.045411365425025e-09
observed O 0 5.4887929756830545e-09
in O 0 1.4769569567363305e-08
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 0.999198853969574
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 1.7992597634020058e-08
patients O 0 1.4015616223161942e-08
in O 0 5.660485413727656e-10
the O 0 7.81757769630076e-09
British O 0 1.9781082301051356e-06
Isles O 0 7.100233779055998e-05
. O 0 3.4900938317150576e-06

Of O 0 3.3289693419646937e-06
51 O 0 1.17571698865504e-06
ATM O 0 1.010273535939632e-05
mutations O 0 2.9327004824608593e-08
identified O 0 2.109412644557551e-09
in O 0 2.331746185024741e-10
families O 0 1.0452407689376386e-10
native O 0 4.038304968201345e-10
to O 0 1.9557003239079052e-10
the O 0 2.0820476454019854e-09
British O 0 1.3623508721138933e-07
Isles O 0 7.096277840901166e-07
, O 0 7.564489590272672e-10
11 O 0 2.042431557214286e-09
were O 0 1.266492133389363e-09
founder O 0 1.4002150550140868e-08
mutations O 0 2.7747693032154075e-10
, O 0 3.451074842564239e-11
and O 0 3.321811228862437e-11
2 O 0 3.067526899158679e-09
of O 0 3.397418790740403e-09
these O 0 3.152319794086367e-10
11 O 0 4.462817226880134e-09
conferred O 0 3.636116119309918e-08
a O 0 3.5054583680249607e-09
milder O 0 3.3317654413167475e-08
clinical O 0 6.833311694265376e-09
phenotype O 0 5.344286124753239e-10
with O 0 1.5409158324319883e-11
respect O 0 3.1298428293524694e-09
to O 0 4.9580681782401825e-09
both O 0 3.2122908777409975e-08
cerebellar B-Disease 1 0.9999997615814209
degeneration I-Disease 1 1.0
and O 0 5.632531951960118e-07
cellular O 0 4.52498852610006e-06
features O 0 3.0577677989640506e-07
. O 0 4.350791016349831e-07

We O 0 2.988410230386762e-08
report O 0 1.3888407091044996e-09
, O 0 4.868930952861561e-11
in O 0 3.882776045127656e-11
two O 0 8.991704603111828e-11
A B-Disease 1 0.504787266254425
- I-Disease 1 0.8090084791183472
T I-Disease 1 1.0
families O 0 9.825109614780558e-10
, O 0 8.978064125475527e-11
an O 0 6.26019583394033e-11
ATM O 0 2.2862222976982594e-06
mutation O 0 2.6146141252070265e-08
( O 0 3.516279933890587e-09
7271T O 0 2.0196312107145786e-06
- O 0 1.341447614322533e-06
- O 0 3.6514870771497954e-06
> O 0 3.4168397178291343e-06
G O 0 2.568679065007018e-07
) O 0 1.528866894195957e-10
that O 0 7.218780694734361e-12
may O 0 5.948325859650438e-11
be O 0 4.487403504338516e-11
associated O 0 2.1339917333218494e-10
with O 0 3.212541344055353e-12
an O 0 9.111897000813052e-12
increased O 0 3.1453289972560583e-10
risk O 0 7.643172317273184e-09
of O 0 4.168628819911646e-08
breast B-Disease 1 0.9995527863502502
cancer I-Disease 0 1.119616399591905e-06
in O 0 7.133248214330479e-09
both O 0 2.171191049171739e-08
homozygotes O 0 5.977608907414833e-06
and O 0 2.103993246294067e-08
heterozygotes O 0 3.8130750112941314e-07
( O 0 3.8756675646567373e-10
relative O 0 2.1202311017987086e-09
risk O 0 8.280202634658451e-10
12 O 0 3.186517161246627e-10
. O 0 5.461364693815085e-11
7 O 0 3.803948711578187e-09
; O 0 6.144973418997779e-10
P O 0 5.997149088443621e-08
= O 0 1.1137475830480525e-08
. O 0 5.141903014482807e-10
0025 O 0 5.972332814963011e-07
) O 0 5.918067702559426e-10
, O 0 1.3278035615460482e-10
although O 0 6.672185026701527e-11
there O 0 1.2226927803560272e-11
is O 0 2.981753949651833e-12
a O 0 1.1294609345013917e-11
less O 0 2.3913482305459866e-10
severe O 0 1.982159574254183e-07
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
phenotype O 0 8.048369082302997e-09
in O 0 7.822805597745841e-11
terms O 0 1.0873781736142618e-10
of O 0 1.0295404112570239e-10
the O 0 5.062780750186846e-11
degree O 0 1.2334107957201468e-08
of O 0 3.631694056593915e-08
cerebellar B-Disease 1 0.8216068744659424
degeneration I-Disease 1 1.0
. O 0 7.129303867259296e-06

This O 0 2.411481148101302e-08
mutation O 0 5.230457489346918e-08
( O 0 4.316403678927827e-09
7271T O 0 9.312430506724922e-07
- O 0 3.2565139918006025e-07
- O 0 4.386445482396084e-07
> O 0 6.735255624334968e-07
G O 0 1.8992797379269177e-07
) O 0 3.6648614698542303e-10
also O 0 1.0400087041562145e-10
allows O 0 3.793048514166841e-11
expression O 0 8.319744199125623e-11
of O 0 1.7620559178421757e-10
full O 0 1.4687420168968401e-09
- O 0 7.686005609741642e-09
length O 0 6.992153522844546e-10
ATM O 0 1.0157400254229287e-07
protein O 0 6.189991852423304e-10
at O 0 9.498025699272716e-10
a O 0 4.2402520383788556e-10
level O 0 1.6793856305596933e-09
comparable O 0 4.93112395361095e-09
with O 0 5.406000994079285e-11
that O 0 1.480469635772863e-10
in O 0 1.256866499765863e-09
unaffected O 0 8.970989284762254e-08
individuals O 0 4.5778434376586574e-09
. O 0 2.4203518478316255e-07

In O 0 7.918288247310556e-09
addition O 0 2.133484056088264e-09
, O 0 1.0867540894965444e-10
we O 0 5.450677062479592e-11
have O 0 1.1149702688895147e-11
studied O 0 8.976082099820815e-10
18 O 0 7.82136577726078e-09
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 2.317402277185465e-06
, O 0 7.33934787944257e-11
in O 0 2.1953317635992065e-11
15 O 0 2.863712877942959e-10
families O 0 2.939617993469312e-11
, O 0 1.1905078312057782e-10
who O 0 7.772583132670263e-10
developed O 0 1.1704997149308838e-07
leukemia B-Disease 1 1.0
, O 0 8.047609298955649e-06
lymphoma B-Disease 1 1.0
, O 0 2.3642454834771343e-05
preleukemic O 1 0.9999939203262329
T O 0 7.392022234853357e-05
- O 0 7.85862448537955e-06
cell O 0 2.7112992029287852e-05
proliferation O 1 0.9999440908432007
, O 0 1.0655996618424979e-07
or O 0 0.0021678702905774117
Hodgkin B-Disease 1 1.0
lymphoma I-Disease 1 1.0
, O 0 3.53129649965922e-08
mostly O 0 2.2386927867046325e-09
in O 0 1.158228513098436e-09
childhood O 0 2.1454872012327542e-07
. O 0 1.1058715188028145e-07

A O 0 2.2763103970646625e-06
wide O 0 1.5990856638836703e-07
variety O 0 1.3016808964039228e-08
of O 0 1.4769963918581652e-08
ATM O 0 6.413964911189396e-06
mutation O 0 1.2720076547623194e-08
types O 0 5.427113425326979e-09
, O 0 8.970708065270117e-10
including O 0 4.86246731767892e-09
missense O 0 2.3384386338420882e-07
mutations O 0 2.102692464589495e-09
and O 0 6.511812200571399e-10
in O 0 1.9950046059591386e-09
- O 0 8.23904500180106e-08
frame O 0 1.238154823113291e-07
deletions O 0 1.1479740180675435e-07
, O 0 5.53801560165823e-10
were O 0 5.121318924494744e-10
seen O 0 2.2414348155308517e-10
in O 0 8.286834413118171e-11
these O 0 2.988543856830006e-10
patients O 0 3.531794945388356e-08
. O 0 8.139346618918353e-08

We O 0 1.555936179897799e-08
also O 0 1.1117222697976104e-09
show O 0 1.1477644529245268e-10
that O 0 2.620300244143836e-12
25 O 0 1.4629761291296006e-10
% O 0 2.7007574995852046e-11
of O 0 1.8973492221796562e-10
all O 0 7.657351419609881e-10
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 1.2646638651858666e-06
carried O 0 3.5149720911675786e-09
in O 0 1.5459308277954165e-09
- O 0 2.6878686298914545e-07
frame O 0 1.0695515584302484e-06
deletions O 0 2.802729341055965e-06
or O 0 8.373820747920036e-08
missense O 0 6.866865760457586e-07
mutations O 0 3.791837066557946e-09
, O 0 2.038542668003629e-10
many O 0 3.424107178351399e-11
of O 0 1.5777713857634268e-10
which O 0 1.0222530287540277e-11
were O 0 1.3797600562082124e-10
also O 0 5.245625461780534e-11
associated O 0 1.6410076075779045e-10
with O 0 2.1529030294620277e-11
expression O 0 4.580428480949195e-09
of O 0 2.5832118666357928e-08
mutant O 0 8.315313948514813e-08
ATM O 0 4.926162546325941e-06
protein O 0 3.12497746790541e-07
. O 0 1.813916696846718e-06

The O 0 1.0795192793011665e-06
DMPK O 0 0.00039303943049162626
gene O 0 1.5800398500687152e-07
of O 0 1.243376601678392e-07
severely O 0 0.3834283649921417
affected O 0 0.43495604395866394
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 1 0.9999489784240723
is O 0 2.920563346719973e-09
hypermethylated O 0 3.131505081910291e-07
proximal O 0 3.277444591276435e-07
to O 0 1.2171591734499998e-08
the O 0 2.6994740665031713e-08
largely O 0 1.0537195294091362e-07
expanded O 0 1.8712736959969334e-07
CTG O 0 1.2710621376754716e-05
repeat O 0 2.068148432954331e-06
. O 0 3.870245564030483e-06

Using O 0 8.962529705058842e-07
methylation O 0 7.420332167384913e-06
- O 0 9.951338142855093e-06
sensitive O 0 3.99497730541043e-06
restriction O 0 8.89408369175726e-08
enzymes O 0 2.7878843678053045e-09
, O 0 7.404067636773703e-11
we O 0 6.037850774909259e-11
characterized O 0 5.853469792205246e-11
the O 0 3.205559082064546e-11
methylation O 0 1.5950313292378837e-09
pattern O 0 3.899283118613539e-10
on O 0 7.435120297216713e-10
the O 0 4.312369350500944e-10
5 O 0 4.366758954432726e-09
side O 0 1.4862109321001071e-09
of O 0 5.510906397887538e-09
the O 0 7.072554097931061e-09
CTG O 0 1.049848151524202e-06
repeat O 0 1.1899052410058175e-08
in O 0 2.214173511205786e-09
the O 0 5.980492101542723e-09
DMPK O 0 5.803984095109627e-06
gene O 0 2.5771031975097003e-09
of O 0 9.973438741539553e-10
normal O 0 3.6636054190353207e-09
individuals O 0 2.204104780634264e-11
and O 0 1.2543271976639403e-10
of O 0 6.555269660424301e-09
patients O 0 1.9172574639014783e-08
affected O 0 2.6227291449743007e-09
with O 0 8.381215721442459e-09
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
, O 0 1.483793425904878e-07
showing O 0 7.514149302778605e-09
expansions O 0 5.9534506213765326e-09
of O 0 8.558575181893957e-09
the O 0 5.433307137536758e-09
repetitive O 0 3.4931524339754105e-08
sequence O 0 9.796035982390094e-09
. O 0 3.4144056826335145e-07

The O 0 2.6621589199748996e-07
gene O 0 1.232420743235707e-08
segment O 0 1.3393144371320886e-08
analyzed O 0 5.970621774764595e-09
corresponds O 0 1.7061639878690471e-09
to O 0 2.1701382912908684e-09
the O 0 7.363360143841646e-09
genomic O 0 6.616205610043835e-07
SacI O 0 5.993157174088992e-06
- O 0 2.523526347886218e-07
HindIII O 0 8.019600272746175e-07
fragment O 0 5.021588478371086e-08
carrying O 0 1.6033531835546455e-08
exons O 0 1.1882499961757276e-07
11 O 0 5.699644844980867e-08
- O 0 8.817758612167381e-07
15 O 0 1.709530351945432e-06
. O 0 1.4186841781338444e-06

There O 0 1.19901187645155e-07
is O 0 4.748596182935216e-09
constitutive O 0 4.5513439772548736e-07
methylation O 0 1.6537322835574741e-06
in O 0 1.335054378159839e-07
intron O 0 6.493546243291348e-05
12 O 0 3.5725514635487343e-07
at O 0 6.33798649118944e-08
restriction O 0 6.653120010469138e-08
sites O 0 5.782522904951293e-09
of O 0 1.5272849651637443e-09
SacII O 0 1.1854265267174924e-06
and O 0 4.5005306148482305e-09
HhaI O 0 2.906926738432958e-06
, O 0 7.193470263899826e-10
localized O 0 6.082404357954374e-09
1 O 0 3.5799876396680474e-09
, O 0 3.3183425451888127e-10
159 O 0 3.847643537113754e-09
- O 0 4.412693854760619e-08
1 O 0 1.4793286595704558e-07
, O 0 1.3007153576438668e-08
232 O 0 1.2770641433235141e-08
bp O 0 2.5381375223787472e-08
upstream O 0 5.902716981864842e-09
of O 0 2.9972451187632032e-09
the O 0 1.0112279014151682e-08
CTG O 0 9.487779607297853e-06
repeat O 0 1.0239526915256647e-07
, O 0 2.70943867342055e-09
whereas O 0 3.0314539767317683e-09
most O 0 8.578292243210939e-11
, O 0 1.201800464700753e-11
if O 0 2.762335932909865e-12
not O 0 1.3160533426925802e-11
all O 0 1.9703464554376993e-11
, O 0 6.053059442567843e-11
of O 0 2.791975262095292e-10
the O 0 1.3633316697791997e-10
other O 0 4.3188449344588875e-11
sites O 0 4.4475190197346137e-10
of O 0 5.715020678920268e-10
SacII O 0 8.349434210686013e-07
, O 0 1.8277185320769718e-09
HhaI O 0 2.558099140514969e-06
, O 0 8.593346034757587e-10
and O 0 4.922448004762714e-10
HpaII O 0 7.020101975285797e-07
in O 0 1.7432687238194688e-10
this O 0 9.019393565345979e-11
region O 0 4.042460588493668e-09
are O 0 2.0558520164026817e-10
unmethylated O 0 3.2957333928607113e-07
, O 0 1.4760064004359918e-10
in O 0 1.2463856335909185e-10
normal O 0 1.8286948622048271e-09
individuals O 0 1.7795234036332985e-11
and O 0 1.2352882605703996e-10
most O 0 5.318842588586392e-10
of O 0 3.756893462991684e-09
the O 0 2.3178692742931162e-08
patients O 0 1.1667528099224e-07
. O 0 2.197308646145757e-07

In O 0 1.399245785904668e-08
a O 0 2.0394030908477134e-09
number O 0 4.161292421756002e-10
of O 0 8.996067224487092e-10
young O 0 5.804531855169159e-10
and O 0 1.665102083991954e-10
severely O 0 5.823300597285197e-08
affected O 0 2.2066015681332374e-09
patients O 0 3.445021157233441e-09
, O 0 5.368434863317617e-11
however O 0 1.0984849141415509e-10
, O 0 7.835468385231081e-11
complete O 0 2.388609754433446e-09
methylation O 0 1.8420966085841428e-08
of O 0 5.272010827894746e-09
these O 0 3.776144674727533e-10
restriction O 0 3.919058855217372e-09
sites O 0 9.154481617201782e-10
was O 0 1.5558581090147072e-09
found O 0 1.983075925693356e-10
in O 0 5.876741315802292e-10
the O 0 7.676365321174217e-09
mutated O 0 2.080991379216357e-07
allele O 0 3.391610050584859e-07
. O 0 4.4884717453896883e-07

In O 0 1.989222475629049e-08
most O 0 1.3030512224787572e-09
of O 0 2.925060749170427e-10
these O 0 2.061847394208005e-11
patients O 0 1.013447381570387e-10
, O 0 2.522283814102022e-12
the O 0 1.7189864115474407e-11
onset O 0 2.2650964126569306e-07
of O 0 1.6494254850840662e-08
the O 0 1.2065456189702672e-07
disease O 1 0.966323733329773
was O 0 0.006017669569700956
congenital O 1 1.0
. O 1 0.5775390267372131

Preliminary O 0 2.7418075205787318e-06
in O 0 4.5311662688618526e-07
vivo O 0 6.843800656497478e-05
footprinting O 0 0.00026533781783655286
data O 0 1.6629635979370505e-07
gave O 0 1.432362495279449e-08
evidence O 0 6.072828906411587e-09
for O 0 2.498832529784778e-10
protein O 0 2.6270685626883505e-10
- O 0 1.634412072348823e-08
DNA O 0 7.954712089031091e-08
contact O 0 7.165856175106455e-08
in O 0 1.3166973067413323e-09
normal O 0 2.572208401829812e-08
genes O 0 1.0562639651823247e-09
at O 0 9.134637046770422e-09
an O 0 1.2118930303728348e-09
Sp1 O 0 1.0906241243446857e-07
consensus O 0 1.280517825108518e-08
binding O 0 1.5315030355012027e-09
site O 0 4.256224706011835e-09
upstream O 0 1.8394975542790348e-09
of O 0 8.970058029689199e-10
the O 0 2.932754705753382e-09
CTG O 0 1.2199898264952935e-06
repeat O 0 1.158357321173753e-08
and O 0 4.738460734898808e-10
for O 0 1.3198245274459453e-10
a O 0 3.4852676300545227e-11
significant O 0 1.8514176303163765e-11
reduction O 0 9.673762901840632e-10
of O 0 2.686763311832152e-10
this O 0 7.985358034534595e-12
interaction O 0 1.787950690279594e-11
in O 0 1.3452084064724534e-11
cells O 0 2.2665198884386228e-10
with O 0 6.845488759177343e-11
a O 0 1.575045871504699e-08
hypermethylated O 0 1.4205607840267476e-05
DMPK O 0 4.832186095882207e-05
gene O 0 3.7166969946156314e-08
. O 0 9.380774201872555e-08
. O 0 1.5227908534143353e-06

The O 0 6.241481605684385e-05
hemochromatosis B-Disease 1 1.0
gene O 0 2.540290893193742e-07
product O 0 1.166084917514354e-08
complexes O 0 8.723084476969234e-09
with O 0 1.7159047793757765e-10
the O 0 1.6870908003951968e-09
transferrin O 0 4.662404862187941e-08
receptor O 0 1.7210811664725156e-09
and O 0 1.2669029159084744e-09
lowers O 0 6.64914949766171e-08
its O 0 1.5161483180037294e-09
affinity O 0 6.96003699118819e-09
for O 0 2.8732229928607467e-09
ligand O 0 5.717534534710467e-08
binding O 0 2.113552284299658e-07
. O 0 1.2165670568720088e-06

We O 0 2.3407702087752114e-07
recently O 0 6.115245554383364e-08
reported O 0 2.9412920987681446e-09
the O 0 1.013328088106391e-09
positional O 0 5.497706752066733e-07
cloning O 0 4.327724312247483e-08
of O 0 6.753645975798861e-10
a O 0 6.174850630813467e-10
candidate O 0 2.2790795917160267e-09
gene O 0 4.418066623657069e-08
for O 0 2.556492063376936e-06
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
called O 1 1.0
HFE O 1 0.9999998807907104
. O 0 1.546812563901767e-05

The O 0 1.0336462707982719e-07
gene O 0 1.9565669084897763e-09
product O 0 5.08581843305933e-10
, O 0 1.5549911358547774e-10
a O 0 2.4074803262053024e-10
member O 0 5.029597294203825e-10
of O 0 6.221634318848146e-09
the O 0 1.0325424071311318e-08
major O 0 3.2477142752895816e-08
histocompatibility O 0 6.565659532498103e-06
complex O 0 3.196143794070849e-08
class O 0 5.714456907668364e-09
I O 0 4.9487741904385985e-08
- O 0 3.948457916180814e-08
like O 0 1.7078960468097648e-09
family O 0 1.9220923463958428e-10
, O 0 4.350692722754346e-11
was O 0 4.78904249590073e-10
found O 0 4.8280469899797396e-11
to O 0 9.15472073148571e-11
have O 0 1.5305533229703627e-10
a O 0 1.5442803702470087e-09
mutation O 0 4.107827855648338e-09
, O 0 1.9580528309859346e-09
Cys O 0 9.00017585081514e-06
- O 0 4.471212832868332e-06
282 O 0 1.1701575886036153e-06
- O 0 2.316667632840108e-05
- O 0 2.035440775216557e-05
> O 0 1.3689604202227201e-05
Tyr O 0 1.8650092897587456e-05
( O 0 1.447516662089754e-09
C282Y O 0 2.508797649625194e-07
) O 0 1.0831285174317529e-10
, O 0 2.9343298624251446e-11
in O 0 6.454039386261101e-11
85 O 0 7.150520620058387e-09
% O 0 5.539294023471086e-10
of O 0 5.226067134600498e-09
patient O 0 6.122516538198397e-08
chromosomes O 0 4.6517769192178093e-07
. O 0 2.3174532088887645e-06

This O 0 2.647332308924888e-08
mutation O 0 1.4622298927235988e-08
eliminates O 0 4.2121641286030354e-08
the O 0 2.9244988652976645e-09
ability O 0 7.4439361341660515e-09
of O 0 3.557173755552867e-08
HFE O 1 0.8636372685432434
to O 0 4.579085910449976e-08
associate O 0 1.6526459489796252e-07
with O 0 5.928586510606237e-10
beta2 O 0 0.0006528840167447925
- O 0 2.30935329454951e-05
microglobulin O 1 0.7788052558898926
( O 0 2.8056602374704198e-08
beta2m O 0 1.2297693501750473e-05
) O 0 1.7115419082003314e-09
and O 0 7.80161990565631e-10
prevents O 0 2.5688682292468457e-09
cell O 0 1.1028740942720106e-07
- O 0 1.001357759378152e-06
surface O 0 7.885387276473921e-07
expression O 0 2.5545350581523962e-06
. O 0 1.464820002183842e-06

A O 0 1.4472738030235632e-06
second O 0 2.3658905945467268e-07
mutation O 0 1.2096259105476292e-08
that O 0 7.184827732764631e-11
has O 0 2.839930374198829e-11
no O 0 3.5206986631619586e-11
effect O 0 5.035241112949507e-10
on O 0 5.997318197614732e-09
beta2m O 0 7.994622137630358e-06
association O 0 7.974183091619125e-09
, O 0 9.885223750671912e-10
H63D O 0 8.951929885370191e-06
, O 0 3.9804998186454554e-10
was O 0 1.1689793577573937e-09
found O 0 5.894520288540761e-11
in O 0 6.476630343144052e-11
eight O 0 2.2006069189117738e-10
out O 0 6.771391086735079e-11
of O 0 6.527032248015985e-10
nine O 0 3.6818541548910844e-09
patients O 0 6.726032508730384e-10
heterozygous O 0 2.768351659021562e-10
for O 0 8.979336163505991e-10
the O 0 9.912911025367066e-08
C282Y O 0 0.00013837225560564548
mutant O 0 2.914154947575298e-06
. O 0 2.6449001779838e-06

In O 0 1.1788676701485201e-08
this O 0 5.753936771490942e-10
report O 0 7.728515605265329e-10
, O 0 1.9986637345148495e-10
we O 0 4.1974348996554056e-10
demonstrate O 0 2.549635613746659e-09
in O 0 1.888475598121886e-09
cultured O 0 1.712490302452352e-06
293 O 0 3.385392517429864e-07
cells O 0 8.653502163724625e-07
overexpressing O 0 2.384438175795367e-06
wild O 0 6.881840164396635e-08
- O 0 2.2554353051873477e-07
type O 0 5.268340146358241e-07
or O 0 9.67934568052442e-08
mutant O 0 2.047351586043078e-07
HFE O 0 2.146665110558388e-06
proteins O 0 2.516807873220728e-10
that O 0 4.5718876601208436e-11
both O 0 2.7534069468870825e-10
the O 0 4.880102100202066e-09
wild O 0 1.3749608740454278e-07
- O 0 4.469199836876214e-07
type O 0 9.775468470252235e-07
and O 0 3.3471710025878565e-07
H63D O 1 0.9874251484870911
HFE O 0 0.0001387378288200125
proteins O 0 1.2056847964458939e-08
form O 0 2.6967450494908007e-09
stable O 0 5.057133378727485e-08
complexes O 0 3.0203497480840724e-09
with O 0 1.9525323025071373e-10
the O 0 3.952585370115003e-09
transferrin O 0 1.500628314943242e-07
receptor O 0 6.786422090954147e-09
( O 0 9.440884518596704e-09
TfR O 0 9.870252142718527e-06
) O 0 6.578130040679753e-08
. O 0 6.004589181429765e-07

The O 0 1.4409550885829958e-06
C282Y O 0 5.536719982046634e-05
mutation O 0 7.568710458372152e-08
nearly O 0 4.257475261226773e-09
completely O 0 6.31642960158274e-09
prevents O 0 9.284394919539807e-10
the O 0 4.931281494258144e-10
association O 0 5.2982405129853305e-09
of O 0 7.63539098613819e-09
the O 0 9.385405341788555e-09
mutant O 0 6.234490257384095e-08
HFE O 0 2.1245530206215335e-06
protein O 0 3.40431394185714e-09
with O 0 7.987818739785268e-10
the O 0 3.494532734293898e-07
TfR O 0 0.0016594146145507693
. O 0 6.784031029383186e-06

Studies O 0 2.4257036557173706e-07
on O 0 1.2772712665309882e-08
cell O 0 4.767930050775249e-08
- O 0 3.008266347137578e-08
associated O 0 6.099109661761304e-09
transferrin O 0 7.532533174980927e-08
at O 0 6.934330443186809e-09
37 O 0 9.908634801547578e-09
degrees O 0 1.0295143226812797e-07
C O 0 3.846890308523143e-07
suggest O 0 2.166209434051325e-09
that O 0 1.1979997549538268e-10
the O 0 5.245020417987689e-09
overexpressed O 0 1.6168676211236743e-06
wild O 0 2.988516030200117e-07
- O 0 6.554715810125344e-07
type O 0 4.454621205240983e-07
HFE O 0 2.11552523978753e-05
protein O 0 2.2174444502809365e-09
decreases O 0 1.304655383727038e-09
the O 0 2.1201168598494746e-10
affinity O 0 2.154963540945687e-09
of O 0 1.4283765281675187e-08
the O 0 4.130228603571595e-08
TfR O 0 1.0004204341385048e-05
for O 0 5.568833927327432e-08
transferrin O 0 8.021022949833423e-06
. O 0 3.2994960292853648e-06

The O 0 3.0998683087091194e-06
overexpressed O 0 0.00012865051394328475
H63D O 0 0.00013210647739470005
protein O 0 1.8306641536014467e-08
does O 0 4.2287426338383227e-10
not O 0 1.0146813944622579e-10
have O 0 2.010695603071877e-11
this O 0 6.017085267540079e-12
effect O 0 2.2202661931203238e-10
, O 0 9.6846877739587e-11
providing O 0 1.0232567015933114e-09
the O 0 1.0729381272334138e-10
first O 0 2.7795840629174506e-10
direct O 0 8.929891270881285e-10
evidence O 0 7.367851884154675e-10
for O 0 1.4956741400951046e-10
a O 0 2.5791718760714843e-10
functional O 0 5.08872188831333e-09
consequence O 0 1.0748380852021455e-08
of O 0 8.83834161413688e-09
the O 0 2.9704581905320993e-08
H63D O 0 0.0006992791313678026
mutation O 0 9.63838942880102e-07
. O 0 6.897417961226893e-07

Addition O 0 1.1864806310768472e-06
of O 0 2.7999541885037615e-07
soluble O 0 5.489758336807427e-07
wild O 0 1.447270818744073e-07
- O 0 2.3986876840353943e-07
type O 0 3.672920684039127e-06
HFE O 1 1.0
/ O 1 1.0
beta2m O 1 0.9999674558639526
heterodimers O 0 1.8589540559332818e-05
to O 0 1.5925149199347288e-08
cultured O 0 1.0203746114711976e-06
cells O 0 4.320128823565028e-07
also O 0 1.6426273674596814e-09
decreased O 0 2.140678745377045e-09
the O 0 1.5639770034603373e-10
apparent O 0 4.3332704091625374e-10
affinity O 0 1.6033522287628443e-09
of O 0 3.773539702933704e-09
the O 0 2.949595678813921e-09
TfR O 0 2.3925284153847315e-07
for O 0 1.5134922481951918e-10
its O 0 2.231754191173163e-11
ligand O 0 8.305985343959321e-10
under O 0 6.03051053538195e-10
steady O 0 7.550107206100165e-09
- O 0 2.79114065193653e-09
state O 0 5.891103577182477e-11
conditions O 0 8.479331015109892e-09
, O 0 2.2897796159160322e-10
both O 0 8.083220898180699e-11
in O 0 2.457277992196083e-10
293 O 0 4.068093861775424e-09
cells O 0 6.907638461228771e-09
and O 0 4.067488568182398e-09
in O 0 4.98896746137234e-08
HeLa O 0 7.061731594149023e-05
cells O 0 3.480315399428946e-06
. O 0 2.6177012841799296e-06

Furthermore O 0 2.3577413799102942e-07
, O 0 2.486614691932232e-09
at O 0 1.2198009269326349e-09
4 O 0 8.705996812352623e-09
degrees O 0 4.1486808299850964e-07
C O 0 2.0888719518552534e-06
, O 0 8.079294455676234e-10
the O 0 2.760749406860441e-09
added O 0 3.8142530911500216e-08
soluble O 0 2.4906031015348162e-08
complex O 0 1.3348896210629846e-08
of O 0 4.1733784428288345e-08
HFE O 0 0.0027111368253827095
/ O 0 3.517525328788906e-05
beta2m O 0 8.037930456339382e-06
inhibited O 0 9.099635889242563e-08
binding O 0 3.226867439920511e-09
of O 0 1.657745585248449e-08
transferrin O 0 1.1939710020669736e-06
to O 0 9.748881524274111e-08
HeLa O 0 7.875387382227927e-05
cell O 0 4.39262157669873e-06
TfR O 0 2.0245543055352755e-06
in O 0 1.3695823364301418e-09
a O 0 1.5449874712913925e-09
concentration O 0 1.3994505820846825e-07
- O 0 1.4071174803120812e-07
dependent O 0 7.492884179782777e-08
manner O 0 3.363006157997006e-07
. O 0 1.2698135378741426e-06

Scatchard O 0 0.0001881241478258744
plots O 0 2.296435042126177e-07
of O 0 1.999878307401559e-08
these O 0 1.0252610982419696e-09
data O 0 4.57638549278272e-09
indicate O 0 1.6414247738794074e-09
that O 0 7.068353541361816e-11
the O 0 1.1826234436185246e-09
added O 0 1.570036900488958e-08
heterodimer O 0 1.0901474389868326e-08
substantially O 0 5.37516164911267e-09
reduced O 0 2.2038171287874775e-09
the O 0 1.5001347941634435e-09
affinity O 0 1.2736925292244905e-08
of O 0 4.85494489055327e-08
TfR O 0 4.4616463128477335e-06
for O 0 4.477509918388023e-08
transferrin O 0 8.495849215250928e-06
. O 0 2.0675884115917142e-06

These O 0 3.50271989191242e-08
results O 0 5.427993166051692e-09
establish O 0 1.0355797108729803e-08
a O 0 2.923137953914079e-09
molecular O 0 3.5461457770225024e-08
link O 0 2.931581910559089e-08
between O 0 2.1177011255701927e-09
HFE O 0 0.47274377942085266
and O 0 3.0138309625726833e-08
a O 0 1.6785474343805618e-08
key O 0 1.266633518071103e-07
protein O 0 7.145581903955645e-10
involved O 0 2.0666481026498928e-10
in O 0 1.9577679755133914e-10
iron O 0 7.238820671773283e-07
transport O 0 9.087924581763218e-07
, O 0 1.6316609174893415e-09
the O 0 1.010598826844955e-09
TfR O 0 5.132898195370217e-07
, O 0 7.622898146042445e-11
and O 0 3.142473087303088e-11
raise O 0 4.358086669320471e-10
the O 0 2.0057515370819345e-10
possibility O 0 5.570421901524014e-10
that O 0 1.5759029498019217e-11
alterations O 0 1.2888090594742607e-09
in O 0 6.981702022068603e-11
this O 0 5.317254882925004e-12
regulatory O 0 8.174246696190934e-11
mechanism O 0 3.551315019834078e-09
may O 0 2.5472235432033585e-10
play O 0 4.915139406591607e-10
a O 0 2.2129689747352188e-10
role O 0 4.38532016255877e-10
in O 0 5.653515433579059e-10
the O 0 4.104695250362056e-09
pathogenesis O 1 0.999995231628418
of O 0 8.152304508257657e-05
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 0 0.20649969577789307
. O 0 1.3957068176750909e-06

Genomic O 0 3.954449312004726e-06
organization O 0 7.077348129769234e-08
of O 0 3.172947415919225e-08
the O 0 9.456675087449185e-08
UBE3A O 1 0.9990780353546143
/ O 0 0.00027727201813831925
E6 O 0 3.8134658097987995e-05
- O 0 6.189937994349748e-05
AP O 0 0.00021592489792965353
gene O 0 2.224308026654853e-08
and O 0 7.566787196822133e-09
related O 0 1.2962837558916362e-07
pseudogenes O 0 4.219838046992663e-06
. O 0 8.925596830522409e-07

The O 0 1.5592597719660262e-06
UBE3A O 0 9.89781619864516e-05
gene O 0 7.966554704808004e-08
encodes O 0 1.8292819703447094e-08
the O 0 1.2088671397236794e-08
E6 O 0 3.4321401471970603e-06
- O 0 3.774125389099936e-06
AP O 0 1.4444759472098667e-05
ubiquitin O 0 2.855948189051105e-08
- O 0 1.2836480323130672e-08
protein O 0 1.8505959265002758e-10
ligase O 0 2.900301776520564e-09
and O 0 6.492391069201631e-10
has O 0 1.2080476896603187e-10
recently O 0 2.3556079309372535e-10
been O 0 4.085694976785348e-11
shown O 0 2.7667665034036837e-11
to O 0 6.547802577916428e-11
be O 0 4.663004982141672e-10
mutated O 0 9.569826175948037e-08
in O 0 4.553025064524263e-06
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 0 0.23619376122951508
who O 0 1.1017677437052953e-08
lack O 0 7.305392557555024e-08
15q11 O 0 1.714440259092953e-05
- O 0 3.2622599519527284e-06
q13 O 0 2.996284092660062e-05
deletions O 0 7.334320457630383e-07
or O 0 6.403345764738333e-08
chromosome O 0 7.867869840083586e-07
15 O 0 1.3759686225967016e-06
paternal O 0 0.0014364710077643394
uniparental B-Disease 1 0.9999982118606567
disomy I-Disease 1 0.9284095168113708
. O 0 1.4273219676397275e-05

Previous O 0 2.6047841856779996e-06
UBE3A O 0 5.68717805435881e-05
cDNA O 0 6.517328756672214e-07
analysis O 0 2.6445817979947606e-08
has O 0 2.355068640103042e-10
shown O 0 8.956479308208642e-11
a O 0 2.255406694740003e-10
coding O 0 2.794807230088736e-08
region O 0 7.004304247715254e-09
of O 0 4.063875458371058e-09
approximately O 0 1.8645065491540436e-09
2 O 0 1.127678572743207e-07
. O 0 3.0696509156769025e-07

6 O 0 1.2379743566270918e-05
kb O 0 8.135260941344313e-06
and O 0 1.4939393722102068e-08
a O 0 1.8262909406985273e-08
3 O 0 3.1746094464324415e-07
- O 0 7.917210496088956e-06
untranslated O 1 0.99994957447052
region O 0 8.6954776179482e-07
( O 0 8.477035073894967e-09
UTR O 0 3.950063182855956e-05
) O 0 3.2128650850893337e-09
of O 0 7.815891933660168e-09
< O 0 6.945756467757747e-07
50 O 0 5.6422102545639063e-08
bp O 0 2.7603716645785425e-08
, O 0 4.0906561471487635e-10
whereas O 0 7.913120159130926e-10
Northern O 0 1.3484001692987135e-09
analysis O 0 5.7196658520553e-10
has O 0 1.5991877960752632e-11
indicated O 0 2.793864792294265e-11
mRNA O 0 1.1819080436570317e-10
sizes O 0 5.748145293082985e-10
of O 0 2.0808090805957136e-09
5 O 0 7.816447578079533e-08
- O 0 2.414932396277436e-06
8 O 0 6.065017259970773e-06
kb O 0 0.00013326997577678412
. O 0 7.879765689722262e-06

We O 0 4.2042259451591235e-07
have O 0 1.2426554008015955e-08
analyzed O 0 2.0481202511746233e-08
additional O 0 1.0955315765670548e-08
cDNA O 0 3.24355511338581e-07
clones O 0 1.1038127212259496e-07
and O 0 1.5553893728537105e-09
provide O 0 3.1851272730420988e-09
evidence O 0 7.921636679952826e-10
for O 0 1.0431992769621701e-10
an O 0 1.438565100375655e-10
additional O 0 1.3289804812188777e-08
0 O 0 6.671023697890632e-07
. O 0 1.499545533079072e-06

5 O 0 1.6222827525780303e-06
kb O 0 2.8483323148975614e-06
of O 0 1.4266413472796557e-07
5 O 0 6.527026243929868e-07
- O 0 3.080280066569685e-06
UTR O 0 0.030381930992007256
and O 0 4.1836674569140087e-08
> O 0 7.748299140075687e-07
2 O 0 1.8184184114033997e-07
kb O 0 9.749213631948805e-07
of O 0 1.56303087806009e-07
3 O 0 6.457726613007253e-06
- O 0 0.00022130344586912543
UTR O 1 0.9996247291564941
. O 0 5.043872079113498e-05

We O 0 1.4122275615591207e-07
have O 0 2.5590678465192696e-09
established O 0 3.0624995872585714e-09
the O 0 1.0368758074363882e-09
genomic O 0 1.6024175764073334e-08
organization O 0 2.1071928646421156e-09
of O 0 3.986990737558926e-09
UBE3A O 0 4.433567028172547e-06
and O 0 4.575268164330737e-09
the O 0 3.4101239609896083e-09
sequence O 0 4.846337997577166e-09
of O 0 4.626536664886771e-08
intron O 0 1.838467869674787e-05
- O 0 2.0546744053717703e-05
exon O 0 3.626058969530277e-05
borders O 0 1.4915269730408909e-06
. O 0 1.2587283890752587e-06

We O 0 5.979268848932406e-07
have O 0 3.0985596310983965e-08
also O 0 1.3461395553804323e-08
mapped O 0 2.9822665226220124e-08
two O 0 1.7937148433233574e-09
highly O 0 8.557661246300086e-09
homologous O 0 1.892334822173325e-08
processed O 0 1.1911477315607044e-07
pseudogenes O 0 2.5158416860904254e-07
, O 0 4.1369836445426245e-09
UBE3AP1 O 0 7.492950317100622e-06
and O 0 4.153856369981668e-09
UBE3AP2 O 0 1.989694283111021e-05
, O 0 9.650285015538884e-10
to O 0 2.0983523252304792e-10
chromosomes O 0 5.772359812361572e-10
2 O 0 1.8793093747859757e-09
and O 0 4.992760649358274e-10
21 O 0 1.584129449838656e-08
, O 0 7.45089268061605e-10
respectively O 0 1.9396013684058744e-09
, O 0 2.0905943642901548e-10
and O 0 1.345116656947809e-10
determined O 0 1.6926928747551528e-09
their O 0 2.849906532986779e-09
genomic O 0 2.933977043539926e-07
organization O 0 2.4826263711474894e-07
. O 0 8.090773349067604e-07

These O 0 1.6616265696711707e-08
results O 0 7.648855437913937e-10
will O 0 2.045284219764909e-10
form O 0 3.5531678294065117e-11
the O 0 6.872018926129542e-11
basis O 0 1.2308079555545248e-10
for O 0 1.3337626142417847e-11
studies O 0 1.3061909887035483e-10
of O 0 2.6853697043804914e-10
mutation O 0 4.88482088112363e-10
and O 0 1.2011051042648546e-09
imprinting O 0 1.3033925824856851e-05
of O 0 3.716826904565096e-05
UBE3A O 1 0.9998806715011597
. O 0 3.2197895052377135e-05

Mutation O 0 3.2042489692685194e-06
spectrum O 0 6.127692131485674e-07
and O 0 1.832718510286213e-08
genotype O 0 1.0156697953789262e-06
- O 0 4.413621809362667e-06
phenotype O 0 1.0565249652927378e-07
analyses O 0 5.3743235639558407e-08
in O 0 9.448108073684125e-09
Cowden B-Disease 1 0.9987539052963257
disease I-Disease 0 2.4695871161384275e-06
and O 0 9.79637260201116e-09
Bannayan B-Disease 1 1.0
- I-Disease 1 1.0
Zonana I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 2.006113319907854e-08
two O 0 1.2660920312157486e-08
hamartoma B-Disease 0 0.16310077905654907
syndromes I-Disease 0 2.45082064793678e-05
with O 0 4.922978646959564e-08
germline O 1 0.9997702240943909
PTEN O 1 0.9999250173568726
mutation O 0 5.266438165563159e-06
. O 0 1.67755729307828e-06

The O 0 9.45275678532198e-06
tumour B-Disease 1 1.0
suppressor O 0 0.01891753077507019
gene O 0 2.1178591396164848e-06
PTEN O 0 4.5089593186276034e-05
, O 0 1.1555592038803297e-08
which O 0 1.144097372396402e-09
maps O 0 9.118243582406649e-08
to O 0 8.26521997510099e-08
10q23 O 0 0.00022732323850505054
. O 0 3.3263067962252535e-06

3 O 0 1.2262478321645176e-06
and O 0 3.319136965274083e-08
encodes O 0 8.324974487550207e-09
a O 0 3.7247855910749195e-09
403 O 0 8.636533266326296e-09
amino O 0 2.7668485280685218e-09
acid O 0 5.9513274308642394e-09
dual O 0 7.066058316240742e-08
specificity O 0 1.6986292905585287e-07
phosphatase O 0 6.177664545248263e-06
( O 0 1.5188728497150805e-08
protein O 0 5.3569233493533375e-09
tyrosine O 0 8.628695979950862e-09
phosphatase O 0 4.146844645447345e-08
; O 0 5.449546924829463e-10
PTPase O 0 7.694074497521797e-07
) O 0 3.1266789157768926e-10
, O 0 9.133548084516718e-11
was O 0 5.004774372707743e-10
shown O 0 1.2791057102390369e-10
recently O 0 6.447939404630176e-10
to O 0 2.239187169017498e-10
play O 0 6.105231875608297e-09
a O 0 3.5133100872997147e-09
broad O 0 5.350204279608306e-09
role O 0 4.776064876921282e-09
in O 0 5.880108400191375e-09
human O 0 4.021767452400127e-08
malignancy B-Disease 0 0.00010220050171483308
. O 0 8.001715627869999e-07

Somatic O 0 0.0013509573182091117
PTEN O 0 0.000471333391033113
deletions O 0 3.950193786295131e-06
and O 0 1.919083203461014e-08
mutations O 0 5.47029399555754e-09
were O 0 1.7216327252711494e-09
observed O 0 6.064919677584157e-10
in O 0 1.8730531015087593e-10
sporadic B-Disease 0 5.554438757826574e-07
breast I-Disease 1 0.9450114965438843
, I-Disease 0 1.5791223972883017e-07
brain I-Disease 1 1.0
, I-Disease 0 0.028122659772634506
prostate I-Disease 1 1.0
and I-Disease 1 1.0
kidney I-Disease 1 1.0
cancer I-Disease 1 1.0
cell O 0 6.019493594067171e-05
lines O 0 1.0919016801835824e-08
and O 0 1.541267224958176e-09
in O 0 2.209262994767869e-09
several O 0 1.178340980345638e-09
primary O 0 9.558279856491936e-08
tumours B-Disease 1 0.9999998807907104
such O 0 1.8258106138091534e-07
as O 0 0.0003401713911443949
endometrial B-Disease 1 1.0
carcinomas I-Disease 1 1.0
, O 1 0.9999985694885254
malignant B-Disease 1 1.0
melanoma I-Disease 1 1.0
and O 1 1.0
thyroid B-Disease 1 1.0
tumours I-Disease 1 1.0
. O 0 0.0004445686936378479

In O 0 4.430691191714686e-08
addition O 0 5.0647976479467616e-08
, O 0 1.4373871870532184e-08
PTEN O 0 1.6671790945110843e-05
was O 0 4.656468632902033e-08
identified O 0 4.9331649876194206e-09
as O 0 4.440746381728644e-10
the O 0 4.3285783291047153e-10
susceptibility O 0 7.044578254067346e-09
gene O 0 7.483108577233111e-10
for O 0 1.4694312433505274e-09
two O 0 2.76115457609194e-07
hamartoma B-Disease 1 1.0
syndromes I-Disease 1 1.0
Cowden B-Disease 1 1.0
disease I-Disease 0 0.21081596612930298
( O 0 1.7539690810863817e-09
CD B-Disease 0 1.4986852875154e-05
; O 0 3.100527834476452e-08
MIM O 0 0.0004562295798677951
158350 O 0 1.0164277227886487e-05
) O 0 5.045992512719977e-09
and O 0 5.112137824170304e-09
Bannayan B-Disease 0 0.00019823599723167717
- I-Disease 0 6.504404154838994e-05
Zonana I-Disease 1 0.6866319179534912
( I-Disease 0 2.12479520200759e-07
BZS I-Disease 0 0.0004274928360246122
) I-Disease 0 1.739756072538512e-08
or I-Disease 0 1.658548853811226e-08
Ruvalcaba I-Disease 0 1.636599699850194e-05
- I-Disease 0 1.9907040041289292e-05
Riley I-Disease 0 0.0001241584395756945
- I-Disease 1 1.0
Smith I-Disease 1 0.9999756813049316
syndrome I-Disease 1 1.0
( O 0 5.249632408776961e-07
MIM O 1 0.9912770986557007
153480 O 0 0.00019160110969096422
) O 0 1.1944214861614455e-07
. O 0 4.3386756942709326e-07

Constitutive O 0 3.102186838077614e-06
DNA O 0 2.6782581130646577e-07
from O 0 1.5045197088170426e-08
37 O 0 6.42538040551699e-08
CD B-Disease 0 4.374336640466936e-06
families O 0 2.4869466486165948e-09
and O 0 1.924778780804104e-09
seven O 0 1.7398988916283997e-08
BZS B-Disease 0 1.6287054677377455e-05
families O 0 1.423358098051608e-09
was O 0 7.691197012604789e-09
screened O 0 4.326222224904086e-08
for O 0 7.962544401607374e-08
germline O 0 0.0002246531512355432
PTEN O 0 0.00099177414085716
mutations O 0 5.487641374202212e-06
. O 0 7.111377726687351e-06

PTEN O 0 0.00028921241755597293
mutations O 0 1.1603478355937114e-07
were O 0 1.5388064156240944e-08
identified O 0 4.694741928545909e-09
in O 0 3.447872543027586e-10
30 O 0 3.415305371845534e-09
of O 0 2.240598151459494e-09
37 O 0 1.1179830394780765e-08
( O 0 1.428547502513311e-09
81 O 0 2.6313839995850685e-08
% O 0 3.573232265630111e-10
) O 0 1.2994022524637217e-10
CD B-Disease 0 2.886606011998083e-07
families O 0 6.748637204623265e-10
, O 0 3.16145415402147e-10
including O 0 1.2080897393573764e-09
missense O 0 1.6057012430792383e-07
and O 0 5.632368793584419e-09
nonsense O 0 8.795896064839326e-07
point O 0 1.8075569130360236e-07
mutations O 0 1.4556016836309027e-08
, O 0 2.6729332081032453e-09
deletions O 0 1.1155530899031874e-07
, O 0 6.322288026439082e-09
insertions O 0 1.7951502684354637e-07
, O 0 3.19463078213289e-09
a O 0 1.0556624019386618e-08
deletion O 0 1.618098622202524e-06
/ O 0 3.8552234400413e-06
insertion O 0 1.3195034398449934e-06
and O 0 9.000846290518894e-08
splice O 0 2.610040428407956e-05
site O 0 1.703380462458881e-06
mutations O 0 2.482673835402238e-07
. O 0 4.5067437781654007e-07

These O 0 5.5320032998906754e-08
mutations O 0 2.7232006871713565e-08
were O 0 7.182629602198176e-09
scattered O 0 2.6569826339084557e-09
over O 0 1.593744164418709e-10
the O 0 3.9193856493646706e-10
entire O 0 1.8614366714686525e-09
length O 0 1.6346481945817004e-09
of O 0 3.78003761625223e-09
PTEN O 0 5.147953174855502e-07
, O 0 3.745015131340068e-10
with O 0 1.1093023201402819e-11
the O 0 3.1848401693679307e-10
exception O 0 8.642642712608506e-10
of O 0 2.1398936789207568e-10
the O 0 1.12503673044273e-10
first O 0 5.32119681651011e-10
, O 0 3.329513331706835e-10
fourth O 0 2.0298264402640598e-08
and O 0 4.278673415569756e-09
last O 0 6.320168211004784e-08
exons O 0 2.203912345066783e-06
. O 0 4.188306945707154e-07

A O 0 5.473669716593577e-06
hot O 0 2.6038700525532477e-05
spot O 0 1.47602270317293e-06
for O 0 2.020077971565115e-08
PTEN O 0 1.2425506611180026e-05
mutation O 0 9.519486532383326e-09
in O 0 6.716110445559309e-10
CD B-Disease 0 1.2958024854015093e-05
was O 0 7.785483546740579e-08
identified O 0 1.0995801602575739e-08
in O 0 2.161257395272287e-09
exon O 0 3.5493468431013753e-07
5 O 0 2.6209852066472195e-08
that O 0 3.490331634825594e-10
contains O 0 9.465455086399288e-10
the O 0 6.060398849427884e-10
PTPase O 0 3.5518391428013274e-07
core O 0 1.897535639727721e-08
motif O 0 3.5908747086921267e-09
, O 0 9.214334850682349e-11
with O 0 8.471640056129104e-12
13 O 0 1.9443018306475324e-09
of O 0 4.021373900542358e-09
30 O 0 1.1992606019362029e-08
( O 0 1.992627840508021e-09
43 O 0 1.65993494505301e-08
% O 0 8.007985385916072e-10
) O 0 8.036230569885561e-10
CD B-Disease 0 1.1364281817805022e-06
mutations O 0 1.5629973759700988e-08
identified O 0 1.7192446577496412e-08
in O 0 5.7038396228392685e-09
this O 0 2.9084906927323573e-08
exon O 0 2.3814951418899e-05
. O 0 4.6272703002614435e-06

Seven O 0 1.0399902805602323e-07
of O 0 1.2500914969848509e-08
30 O 0 1.3456260994360036e-08
( O 0 1.1143144185155052e-09
23 O 0 8.907627524479267e-09
% O 0 2.0729408467534682e-10
) O 0 7.79932507466441e-11
were O 0 1.5455881019477147e-10
within O 0 9.238849962844853e-11
the O 0 1.2362900980722458e-10
core O 0 2.9779960719622522e-09
motif O 0 2.799265486075342e-09
, O 0 7.370969112852066e-11
the O 0 1.918759179320162e-10
majority O 0 1.2923775938311621e-10
( O 0 1.50252796315975e-10
five O 0 1.5198391156712177e-10
of O 0 2.3819024530524757e-10
seven O 0 1.3698636669445818e-10
) O 0 3.7149977538675216e-11
of O 0 2.351675243428275e-10
which O 0 4.1471867606723833e-11
were O 0 2.123890174843268e-09
missense O 0 5.2402835848397444e-08
mutations O 0 1.818614814297348e-09
, O 0 4.3563913587618686e-10
possibly O 0 2.2173738400965703e-08
pointing O 0 1.566752239057223e-08
to O 0 1.7732908474954456e-09
the O 0 2.7264317470354626e-09
functional O 0 6.718214873302486e-09
significance O 0 4.099390604750397e-09
of O 0 9.184913940529782e-10
this O 0 3.327691178167669e-10
region O 0 3.736663600761858e-08
. O 0 1.1464139504369086e-07

Germline O 0 0.003985674120485783
PTEN O 0 0.00011305205407552421
mutations O 0 3.1614273865443465e-08
were O 0 4.019457211512645e-09
identified O 0 1.9639849746511118e-09
in O 0 1.5658245533511916e-10
four O 0 2.537950960501689e-10
of O 0 1.4064052145101869e-09
seven O 0 2.5152735450006958e-09
( O 0 9.014840540721991e-10
57 O 0 3.6363243083314956e-08
% O 0 2.968089329868917e-09
) O 0 4.040364487423176e-09
BZS B-Disease 0 3.270788147347048e-05
families O 0 7.892142050991424e-09
studied O 0 7.789915912326251e-07
. O 0 8.338150792042143e-07

Interestingly O 0 1.504713964095572e-06
, O 0 1.3967207834753026e-08
none O 0 1.0206179901217638e-08
of O 0 1.4421978056233797e-09
these O 0 1.4747542076420928e-10
mutations O 0 1.3072358751031743e-09
was O 0 4.747708892693936e-09
observed O 0 1.4796517344706217e-09
in O 0 2.0332120431731937e-09
the O 0 4.498216199522176e-08
PTPase O 0 5.9638707170961425e-05
core O 0 8.044426067499444e-06
motif O 0 4.857982730754884e-06
. O 0 1.1120027920696884e-06

It O 0 1.086189449495123e-08
is O 0 4.686133703302175e-10
also O 0 1.3850916247282186e-10
worthy O 0 3.6715872564485608e-09
of O 0 3.732879338969042e-09
note O 0 8.178933086355755e-09
that O 0 2.6731138136337762e-11
a O 0 1.6058764040760565e-10
single O 0 1.7288525056002868e-09
nonsense O 0 4.8963464394091716e-08
point O 0 1.206934108211044e-08
mutation O 0 1.4708837481336445e-09
, O 0 2.2272775290765878e-10
R233X O 0 1.3558339162500488e-07
, O 0 4.504719652853595e-10
was O 0 1.9817687491041625e-09
observed O 0 2.3886220779090195e-10
in O 0 1.360481866052865e-10
the O 0 1.2478087452194586e-09
germline O 0 5.41942938525608e-07
DNA O 0 4.950256382585394e-08
from O 0 2.682166710954448e-09
two O 0 2.5698471128876577e-10
unrelated O 0 2.153094147416823e-09
CD B-Disease 0 3.2153025131265167e-06
families O 0 8.655427485848577e-10
and O 0 1.6339436470502733e-09
one O 0 1.717678088652974e-08
BZS B-Disease 0 0.014741974882781506
family O 0 1.831302114396749e-07
. O 0 7.888576192272012e-07

Genotype O 0 3.787451760217664e-06
- O 0 1.3180496125642094e-06
phenotype O 0 1.8609263463531533e-08
studies O 0 5.9760791870644425e-09
were O 0 8.253240313393917e-10
not O 0 1.2922347913946197e-10
performed O 0 2.177070079767418e-09
on O 0 8.897350634029522e-10
this O 0 1.2526918391486674e-10
small O 0 5.344530373818657e-10
group O 0 1.5340407832908909e-09
of O 0 4.246504303750953e-08
BZS B-Disease 0 0.003435877151787281
families O 0 2.2591510173697316e-07
. O 0 1.007474907055439e-06

However O 0 2.9168387527533923e-07
, O 0 1.229565604887739e-08
genotype O 0 2.2855697068280278e-07
- O 0 3.929911542854825e-07
phenotype O 0 4.043619483695693e-08
analysis O 0 8.552504482395307e-09
inthe O 0 3.8977483995950024e-07
group O 0 8.958500052891338e-10
of O 0 9.802609834963505e-10
CD B-Disease 0 0.0001143347835750319
families O 0 2.1321742149638112e-09
revealed O 0 8.437364695801364e-10
two O 0 2.18255604561568e-11
possible O 0 1.4486868649132845e-10
associations O 0 7.32901031530453e-11
worthy O 0 6.4574687819174414e-09
of O 0 8.756139813215214e-09
follow O 0 8.44198932981044e-09
- O 0 4.269610442975136e-08
up O 0 2.4446198398919705e-09
in O 0 1.1818793721474208e-09
independent O 0 2.222330541812312e-09
analyses O 0 8.67429292839006e-08
. O 0 3.077779240356904e-07

The O 0 2.4629533967868156e-08
first O 0 1.1144191347511878e-08
was O 0 6.899238069735247e-09
an O 0 2.1496626700923116e-10
association O 0 4.340094394983396e-10
noted O 0 3.448424878982337e-10
in O 0 7.138058893962906e-11
the O 0 2.700037970981839e-10
group O 0 1.303920860173946e-10
of O 0 7.485592146139197e-10
CD B-Disease 0 0.002716963877901435
families O 0 1.0218450974264215e-08
with O 0 2.562072864975562e-08
breast B-Disease 1 1.0
disease I-Disease 1 0.999998927116394
. O 0 4.6144552470650524e-05

A O 0 1.3154158295947127e-07
correlation O 0 4.627990435324136e-09
was O 0 2.3900954548849995e-09
observed O 0 2.0221500862671604e-10
between O 0 1.1932170529416197e-11
the O 0 1.9224810632323397e-10
presence O 0 3.0154567731699444e-09
/ O 0 2.275251290484448e-06
absence O 0 8.529002570867306e-08
of O 0 2.4249214192195723e-08
a O 0 8.465901757404026e-09
PTEN O 0 1.6561468783038436e-06
mutation O 0 1.2143526184615894e-09
and O 0 8.089853092974053e-11
the O 0 3.392049141570652e-10
type O 0 3.822154681643042e-08
of O 0 3.507029191496258e-07
breast O 1 0.8454810976982117
involvement O 0 2.3008815333014354e-06
( O 0 1.45333856949037e-07
unaffected O 0 4.1930685256375e-05
versus O 0 0.49192795157432556
benign O 0 0.3585255742073059
versus O 0 0.00018105293565895408
malignant O 0 9.183726069750264e-05
) O 0 1.5897191474323336e-07
. O 0 1.1584609183046268e-06

Specifically O 0 1.220480356778353e-07
and O 0 6.164389554363936e-10
more O 0 1.4430933878428753e-11
directly O 0 4.955038115928012e-11
, O 0 2.534423365618821e-11
an O 0 2.298889550944594e-11
association O 0 6.176653077893945e-10
was O 0 1.090688250826588e-08
also O 0 1.0836167518846196e-09
observed O 0 3.7763606131058225e-10
between O 0 2.6724816803991303e-11
the O 0 3.3722322156926055e-10
presence O 0 6.030165811132804e-10
of O 0 2.227337869697976e-09
a O 0 1.0181953058463478e-08
PTEN O 0 0.001056669862009585
mutation O 0 1.554710024720407e-06
and O 0 1.1247341262787813e-06
malignant B-Disease 1 1.0
breast I-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 1.2460594916774426e-05

Secondly O 0 1.3256977808850934e-06
, O 0 1.8182689132117957e-08
there O 0 1.0897747149130055e-09
appeared O 0 8.135804030473537e-09
to O 0 4.2926165400025695e-10
be O 0 1.199999100087723e-09
an O 0 5.610482078921564e-10
interdependent O 0 1.2457148557132314e-07
association O 0 1.00882360243304e-08
between O 0 1.1274259303917233e-09
mutations O 0 1.1927449028448223e-09
upstream O 0 1.372218005890602e-09
and O 0 4.1672337802722836e-10
within O 0 4.9948396529941874e-09
the O 0 7.943700808255016e-09
PTPase O 0 2.103280621668091e-06
core O 0 8.988871513793129e-08
motif O 0 1.9765790781889336e-08
, O 0 2.9968380554912244e-10
the O 0 3.961065642155148e-10
core O 0 1.6986835049692672e-08
motif O 0 1.0993411514448326e-08
containing O 0 8.195575329494886e-10
the O 0 7.388168549171681e-11
majority O 0 2.842574786665608e-11
of O 0 9.796928823746498e-10
missense O 0 9.44411198133821e-08
mutations O 0 1.7060923784839588e-09
, O 0 1.5151646604039115e-10
and O 0 2.3769014534380517e-10
the O 0 3.880588295146481e-09
involvement O 0 1.7202295055085415e-07
of O 0 7.132570800649773e-08
all O 0 1.6088755883103545e-09
major O 0 2.0807267020472864e-08
organ O 1 0.9999573230743408
systems O 1 0.9999845027923584
( O 0 1.5930504559946712e-07
central O 1 0.9999983310699463
nervous O 1 0.9999909400939941
system O 1 0.9999996423721313
, O 0 8.660867933940608e-06
thyroid O 1 1.0
, O 0 3.110259285676875e-06
breast O 1 1.0
, O 0 1.9639035599539056e-05
skin O 1 1.0
and O 1 0.9974954724311829
gastrointestinal O 1 1.0
tract O 0 0.0694606751203537
) O 0 3.066990217348575e-08
. O 0 1.935146514142616e-07

However O 0 4.838379297211759e-08
, O 0 1.7163507282091928e-09
these O 0 6.711612515752918e-11
observations O 0 9.084210605969645e-10
would O 0 1.3617566796408909e-10
need O 0 1.2818709427264707e-09
to O 0 3.1781105525041653e-10
be O 0 3.606275000844761e-10
confirmed O 0 3.199031595180202e-10
by O 0 7.113350186660483e-11
studying O 0 2.7118065570874705e-09
a O 0 1.1167926999844369e-10
larger O 0 9.090584535131896e-11
number O 0 4.6419032506683777e-10
of O 0 1.0479223044868036e-09
CD B-Disease 0 1.5043689018057194e-05
families O 0 2.684624611504205e-08
. O 0 2.92189753281491e-07

Molecular O 0 0.00011087761959061027
defects O 0 0.026052430272102356
leading O 0 1.4626489530655817e-07
to O 0 7.513298871941743e-10
human O 0 2.5482924104203164e-10
complement B-Disease 0 1.4800653502788919e-07
component I-Disease 1 1.0
C6 I-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 7.159172810133896e-09
an O 0 5.749515308295372e-10
African O 0 2.7294145610312626e-08
- O 0 1.6551003056974878e-07
American O 0 3.0646401683043223e-07
family O 0 3.365469325444792e-08
. O 0 1.2142403704729077e-07

Complement B-Disease 0 3.096396767432452e-06
component I-Disease 1 0.9999982118606567
C6 I-Disease 1 1.0
deficiency I-Disease 1 1.0
( O 0 3.4698313555736604e-08
C6D B-Disease 0 0.016860928386449814
) O 0 1.102953062215306e-09
was O 0 9.526970323747719e-09
diagnosed O 0 1.7159228704599627e-08
in O 0 1.0454661442116375e-10
a O 0 1.638111729596048e-10
16 O 0 9.060193151277929e-10
- O 0 3.13641623783667e-09
year O 0 1.4264482928183497e-09
- O 0 4.784692464454565e-08
old O 0 6.31887857593938e-08
African O 0 4.0162561276702036e-08
- O 0 4.703725409171966e-08
American O 0 1.0246418824522152e-08
male O 0 9.511531562367281e-10
with O 0 4.3692399698258555e-10
meningococcal B-Disease 1 1.0
meningitis I-Disease 1 0.9999997615814209
. O 0 1.0917049166891957e-06

The O 0 1.1883044237492868e-07
patients O 0 1.216527181213678e-07
father O 0 4.933183639366234e-09
and O 0 1.0565199826118032e-09
two O 0 8.103895887678902e-10
brothers O 0 5.252296659818967e-07
also O 0 1.5472707559638366e-08
had O 0 9.415582091776287e-09
C6D B-Disease 0 0.005469331983476877
, O 0 7.790468270485462e-10
but O 0 1.256098974833364e-10
gave O 0 1.2683343264541236e-09
no O 0 3.8628189535927504e-10
history O 0 3.780801893782382e-09
of O 0 1.003098226703969e-08
meningitis B-Disease 1 0.9999994039535522
or O 0 3.7177303457980315e-09
other O 0 6.977928013185419e-09
neisserial B-Disease 1 0.9909799695014954
infection I-Disease 0 2.023441447818186e-05
. O 0 4.5890053002040077e-07

By O 0 1.8497475551271236e-08
using O 0 1.2131448734464811e-08
exon O 0 1.272409662078644e-07
- O 0 3.871740617000796e-08
specific O 0 5.191444163443748e-09
polymerase O 0 7.126505607857325e-08
chain O 0 1.0204797895596585e-08
reaction O 0 1.1731337012932386e-09
( O 0 8.952008578866355e-10
PCR O 0 1.5838476485896535e-07
) O 0 1.8569825677161589e-09
/ O 0 5.0709648036217914e-08
single O 0 1.1521127163405254e-08
- O 0 2.5948461157554448e-08
strand O 0 1.7591863965549237e-08
conformation O 0 1.379739655860135e-09
polymorphism O 0 5.756474852347537e-09
as O 0 3.7494893301293075e-10
a O 0 2.1253072912674753e-10
screening O 0 2.4016293398432254e-09
step O 0 2.022482847863216e-09
and O 0 1.912044411689351e-10
nucleotide O 0 4.965317490501775e-09
sequencing O 0 5.54881340875113e-09
of O 0 2.890824468693154e-09
target O 0 6.522269835329553e-09
exons O 0 1.1873749983237758e-08
, O 0 1.3981586721723005e-10
we O 0 1.950388323068708e-10
determined O 0 3.6616545906476006e-10
that O 0 6.796208040782403e-11
the O 0 2.0194761418679263e-09
proband O 0 2.35600464293384e-06
was O 0 3.9333190926527095e-08
a O 0 3.87052034866997e-09
compound O 0 1.5733260738670651e-07
heterozygote O 0 4.096884254067845e-07
for O 0 2.1208863554278423e-09
two O 0 5.3680921929810665e-09
C6 O 0 0.0008191824308596551
gene O 0 8.296657370010507e-07
mutations O 0 3.2209848654929374e-07
. O 0 2.087589336952078e-06

The O 0 1.4106055346019275e-07
first O 0 6.160939136634624e-08
, O 0 1.5762532390439787e-09
1195delC O 0 5.0936282747215955e-08
located O 0 4.823465515890746e-10
in O 0 1.850292419280919e-10
exon O 0 1.0185996757172688e-07
7 O 0 4.774454964717734e-08
, O 0 1.0556779894699275e-09
is O 0 3.2741059863283795e-11
a O 0 2.005945756722305e-11
novel O 0 1.1447363890138007e-10
mutation O 0 7.036782267988428e-11
, O 0 1.0538582159713705e-11
while O 0 2.5442941156694765e-11
the O 0 7.987144279297809e-11
second O 0 2.3716222319336566e-09
, O 0 1.274626931779821e-10
1936delG O 0 4.917551699179512e-09
in O 0 2.1888857393292938e-10
exon O 0 2.955566458240355e-08
12 O 0 6.920060968695907e-09
, O 0 4.806118281130978e-10
has O 0 2.7260129917272558e-11
been O 0 1.706598404260795e-11
described O 0 1.4230417191840594e-11
before O 0 7.882355185229173e-11
to O 0 1.5008581877307137e-10
cause O 0 1.3878855398274936e-08
C6D B-Disease 0 0.00012420392886269838
in O 0 1.0515742721040056e-09
an O 0 3.5388716956852306e-10
unrelated O 0 1.2753552880440111e-08
African O 0 8.657582384330453e-08
- O 0 3.0776502057960897e-07
American O 0 3.630915728081163e-07
individual O 0 2.3904341617253522e-08
. O 0 2.1551994677793118e-07

Both O 0 1.1777746777852371e-07
mutations O 0 3.5397661690694804e-08
result O 0 3.427181649584554e-09
in O 0 5.631047184095905e-09
premature O 0 2.675679411368037e-07
termination O 0 3.381533701940498e-07
codons O 0 1.028562905958097e-06
and O 0 2.0203098927140672e-07
C6 O 0 0.008390283212065697
null O 0 7.930841093184426e-06
alleles O 0 5.834562557538447e-07
. O 0 1.4328509223560104e-06

Allele O 0 3.841090858713869e-07
- O 0 8.27957862270523e-08
specific O 0 5.2569792963197415e-09
PCR O 0 1.4013964744208351e-07
indicated O 0 4.110681128821625e-09
that O 0 3.988432153989585e-11
the O 0 6.351534298509875e-10
probands O 0 1.1280566241111956e-06
two O 0 8.418910568686044e-10
brothers O 0 6.318082768075328e-08
also O 0 1.1551530842979219e-09
inherited O 0 1.639051028234917e-08
the O 0 4.911814954766669e-09
1195delC O 0 7.49225534946163e-08
mutation O 0 3.244070845287439e-10
from O 0 8.239127435860638e-11
their O 0 3.461327335863018e-10
heterozygous O 0 3.495550293663996e-09
mother O 0 8.656087513436717e-10
and O 0 3.052677000070503e-10
the O 0 1.3055888592461429e-09
1936delG O 0 3.8239264199546597e-08
mutation O 0 1.8658825873263396e-10
from O 0 1.2100516422197671e-10
their O 0 8.806129714322708e-10
homozygous O 0 3.982949436931449e-08
father O 0 1.8658990086350968e-07
. O 0 1.927013784097653e-07
. O 0 1.5157174857449718e-06

PAX6 O 0 0.004315710160881281
mutations O 0 8.665164386911783e-06
reviewed O 0 1.739735307637602e-05
. O 0 8.044739843171556e-06

Mutations O 0 9.814514214667724e-07
in O 0 4.3772349300752467e-08
PAX6 O 0 5.408153447206132e-05
are O 0 8.700879461365219e-10
responsible O 0 1.910499536350585e-09
for O 0 6.594907953072493e-10
human O 0 8.799300843520541e-09
aniridia B-Disease 1 1.0
and O 0 1.733396715053459e-08
have O 0 2.3214694611084497e-09
also O 0 3.596095643487729e-10
been O 0 8.091551040312339e-11
found O 0 1.7176033165200444e-11
in O 0 4.45611013366598e-11
patients O 0 8.941735685219498e-10
with O 0 1.1563715957008114e-10
Peters B-Disease 1 1.0
anomaly I-Disease 1 1.0
, O 0 2.7953296566352037e-08
with O 0 2.2161819401844696e-07
congenital B-Disease 1 1.0
cataracts I-Disease 1 1.0
, O 0 1.1428285233705537e-06
with O 0 5.31939612358201e-08
autosomal B-Disease 1 0.9999948740005493
dominant I-Disease 0 0.009147951379418373
keratitis I-Disease 1 1.0
, O 0 1.5216555793173825e-09
and O 0 1.1663667809358458e-09
with O 0 7.836641557901203e-09
isolated B-Disease 1 0.9875784516334534
foveal I-Disease 1 1.0
hypoplasia I-Disease 1 1.0
. O 1 0.9912063479423523

No O 0 7.142017466321704e-07
locus O 0 2.1411619854916353e-07
other O 0 8.527903383459545e-10
than O 0 4.1677108986171163e-10
chromosome O 0 5.440703887416021e-08
11p13 O 0 1.5079677950780024e-06
has O 0 2.4417945443389044e-10
been O 0 3.5545863474872874e-10
implicated O 0 3.088167943587905e-09
in O 0 2.0620343210708825e-09
aniridia B-Disease 1 1.0
, O 0 1.917977954235539e-08
and O 0 1.347274913854335e-08
PAX6 O 1 0.998695433139801
is O 0 8.359068437435724e-10
clearly O 0 4.131886777170024e-10
the O 0 1.4713293083890022e-10
major O 0 1.6188180795850826e-09
, O 0 1.0428650998317579e-10
if O 0 2.529376708082509e-11
not O 0 7.857003936351248e-11
only O 0 1.3420747846382142e-10
, O 0 3.9349509761699153e-10
gene O 0 2.2550721290315323e-09
responsible O 0 8.937788464891128e-08
. O 0 2.869681111405953e-06

Twenty O 0 9.587344038664014e-07
- O 0 5.038417043579102e-07
eight O 0 1.2875541521850664e-08
percent O 0 1.109366931650868e-09
of O 0 2.691291911549598e-10
identified O 0 5.348694376294816e-09
PAX6 O 0 5.750964191975072e-06
mutations O 0 2.7187789797267214e-08
are O 0 2.744065419335584e-09
C O 0 0.00010670170740922913
- O 0 3.955588908866048e-05
T O 0 2.2622027245233767e-05
changes O 0 5.964454885543091e-08
at O 0 9.376641685321374e-08
CpG O 0 3.4490506095608e-07
dinucleotides O 0 6.697592880300363e-07
, O 0 7.330230311630714e-10
20 O 0 1.8545616153886613e-09
% O 0 1.015626333034092e-10
are O 0 1.1092135022983118e-11
splicing O 0 7.339789664939644e-09
errors O 0 3.187803088167129e-08
, O 0 4.542605736013172e-10
and O 0 1.1942011268750719e-10
more O 0 1.4231992320756781e-11
than O 0 2.6124866159271676e-11
30 O 0 5.610278908108057e-10
% O 0 1.3451988134516313e-10
are O 0 8.282457358843587e-11
deletion O 0 6.2475105089276894e-09
or O 0 3.9672678475710654e-09
insertion O 0 1.9706864406998648e-07
events O 0 1.322073757137332e-07
. O 0 4.6938936293372535e-07

There O 0 4.3991978060375914e-08
is O 0 1.0778758996465854e-09
a O 0 1.7890270376241801e-09
noticeably O 0 7.970005100332855e-08
elevated O 0 2.9645434551639482e-08
level O 0 2.4323643099677383e-09
of O 0 4.519418728143876e-10
mutation O 0 2.4344656845975976e-10
in O 0 1.248853381818904e-10
the O 0 1.0772696068528376e-09
paired O 0 2.4807831344730857e-09
domain O 0 1.2231115009697646e-09
compared O 0 1.1160154744782602e-10
with O 0 2.8821871105033647e-12
the O 0 3.1965552427237753e-10
rest O 0 4.709127310320582e-09
of O 0 4.905598149917978e-09
the O 0 7.93522136888214e-09
gene O 0 2.3385005931686464e-08
. O 0 5.619231728815066e-07

Increased O 0 1.3913408736243582e-07
mutation O 0 1.2767620738429741e-08
in O 0 1.0784064752300537e-09
the O 0 2.3032367124642406e-09
homeodomain O 0 2.5225423883057374e-07
is O 0 1.2861710307898733e-10
accounted O 0 1.084119238825565e-09
for O 0 1.2126046000648927e-10
by O 0 2.1997213772717572e-10
the O 0 1.6529273949572598e-08
hypermutable O 0 1.0196401490247808e-05
CpG O 0 1.644357553232112e-06
dinucleotide O 0 7.739091415714938e-06
in O 0 1.4920676960628043e-07
codon O 0 2.3420993784384336e-06
240 O 0 1.7619588561501587e-06
. O 0 8.766820087657834e-07

Very O 0 4.6049144941662234e-08
nearly O 0 4.860214009028141e-09
all O 0 1.6888253295821443e-10
mutations O 0 6.118447970493435e-10
appear O 0 6.118786588515945e-10
to O 0 4.780637552492806e-10
cause O 0 1.4955816141082323e-08
loss O 0 7.924874978471053e-09
of O 0 7.593563999819253e-09
function O 0 1.4700732853256682e-09
of O 0 1.4332689479701344e-09
the O 0 9.237197673428454e-10
mutant O 0 9.337802531206307e-09
allele O 0 1.8808801183212154e-09
, O 0 1.4200572662215194e-10
and O 0 1.249356035293303e-10
more O 0 4.066925962664669e-11
than O 0 5.59683098477759e-11
80 O 0 1.2869666443648953e-09
% O 0 1.9576261445219956e-10
of O 0 2.058662573745096e-09
exonic O 0 4.143548437696154e-07
substitutions O 0 5.107355249833745e-08
result O 0 4.7058947849620836e-09
in O 0 2.207402260978597e-08
nonsense O 0 4.604493824444944e-06
codons O 0 1.249101751454873e-05
. O 0 5.198321105126524e-06

In O 0 3.385046554171822e-08
a O 0 8.124979800072651e-09
gene O 0 1.98210137192234e-09
with O 0 5.313283493735277e-11
such O 0 2.104718621609436e-09
extraordinarily O 0 2.2697408397220897e-08
high O 0 3.880781029863556e-09
sequence O 0 4.2887842582883806e-11
conservation O 0 4.4694761780483816e-10
throughout O 0 6.878601854776178e-11
evolution O 0 3.6922462309796344e-10
, O 0 6.299796101449928e-11
there O 0 4.511923126782058e-11
are O 0 1.6606331587620815e-10
presumed O 0 2.3726691722458781e-07
undiscovered O 0 1.1201034794794396e-05
missense O 0 1.298771280744404e-06
mutations O 0 2.2914159458764516e-08
, O 0 6.264164742475486e-10
these O 0 1.2250184200368608e-10
are O 0 1.2252100722864867e-10
hypothesized O 0 3.775339596501226e-09
to O 0 2.726950609766021e-10
exist O 0 1.08140130183898e-09
in O 0 7.488733522187374e-10
as O 0 5.1662554234610525e-09
- O 0 9.257454536282239e-08
yet O 0 1.2843043073473837e-08
unidentified O 0 7.155093584287897e-08
phenotypes O 0 6.564530252717304e-08
. O 0 2.7046278106013233e-08
. O 0 2.610110527712095e-07

Genetic O 0 2.6101454295712756e-06
heterogeneity O 0 6.024975505170005e-07
and O 0 7.439223459471123e-09
penetrance O 0 2.818184157149517e-07
analysis O 0 7.177986649509194e-09
of O 0 9.67398960938226e-09
the O 0 1.0203844880152246e-08
BRCA1 O 0 1.9269438666924543e-07
and O 0 2.73073723633388e-08
BRCA2 O 0 6.58510941775603e-07
genes O 0 2.5571077699737543e-08
in O 0 2.161704060199554e-07
breast B-Disease 1 1.0
cancer I-Disease 1 0.9999911785125732
families O 0 3.4529969639152114e-07
. O 0 3.2087320960272336e-06

The O 0 0.0029048461001366377
Breast B-Disease 1 1.0
Cancer I-Disease 1 1.0
Linkage O 0 4.5613454858539626e-05
Consortium O 0 3.104060169789591e-06
. O 0 1.1723222996806726e-06

The O 0 1.2814854066789394e-08
contribution O 0 6.148730591348794e-08
of O 0 5.990323614923909e-08
BRCA1 O 0 6.909110084052372e-07
and O 0 6.846255473647034e-08
BRCA2 O 1 0.9992434978485107
to O 0 0.023791396990418434
inherited B-Disease 1 1.0
breast I-Disease 1 1.0
cancer I-Disease 1 1.0
was O 0 0.06562265753746033
assessed O 0 4.2361250507383374e-08
by O 0 6.102166549837307e-10
linkage O 0 2.247653263509619e-08
and O 0 3.4658922953845206e-10
mutation O 0 1.2280197692060568e-10
analysis O 0 2.560901317394393e-11
in O 0 1.629528803559488e-11
237 O 0 1.040238797878068e-10
families O 0 1.3841717702578471e-11
, O 0 8.835530397599545e-12
each O 0 2.2379294598029453e-12
with O 0 3.3722673091485245e-12
at O 0 1.5598754510293134e-09
least O 0 3.28183535902582e-10
four O 0 1.679666683518377e-10
cases O 0 2.8143826158455454e-10
of O 0 2.8337282742540992e-08
breast B-Disease 1 0.9999662637710571
cancer I-Disease 0 1.9168592189089395e-06
, O 0 2.3131954129951282e-09
collected O 0 1.6303955518992552e-08
by O 0 1.3513128394038176e-08
the O 0 0.0001328333019046113
Breast B-Disease 1 1.0
Cancer I-Disease 1 1.0
Linkage O 0 3.8788104575360194e-05
Consortium O 0 2.8139754704170628e-06
. O 0 2.1802579794893973e-06

Families O 0 1.669282134741934e-08
were O 0 2.1829744678569796e-09
included O 0 1.5495263960829675e-09
without O 0 1.264872317996435e-09
regard O 0 5.816548576120795e-09
to O 0 8.815574381593194e-10
the O 0 2.2438868541030388e-09
occurrence O 0 3.117636708793725e-07
of O 0 1.3231601769803092e-06
ovarian B-Disease 1 1.0
or I-Disease 0 0.0014901513932272792
other I-Disease 0 8.177782001439482e-05
cancers I-Disease 1 1.0
. O 0 3.51172020600643e-05

Overall O 0 4.73896716357558e-06
, O 0 9.568311298835397e-08
disease O 0 1.3145481148058025e-07
was O 0 1.8624238817821492e-09
linked O 0 2.785051522735671e-09
to O 0 3.7515210382643716e-10
BRCA1 O 0 1.1216439332883965e-08
in O 0 3.772674672664067e-10
an O 0 7.519947858858345e-11
estimated O 0 1.1185535830904314e-10
52 O 0 2.4339735782419325e-10
% O 0 1.3029207920900454e-11
of O 0 4.379182433345008e-11
families O 0 8.995920328103146e-12
, O 0 3.791428282440279e-11
to O 0 4.5161097084189805e-10
BRCA2 O 0 1.555603645897463e-08
in O 0 2.10037848225042e-10
32 O 0 2.396047360520015e-09
% O 0 6.7128413938633e-11
of O 0 6.128560159357477e-11
families O 0 6.7676814673178765e-12
, O 0 9.03209451674769e-12
and O 0 2.227412178312793e-11
to O 0 1.196346494092282e-10
neither O 0 1.0774894310117134e-09
gene O 0 1.4974096962383499e-10
in O 0 3.3248173658684266e-10
16 O 0 4.894849414682767e-09
% O 0 4.4970022150536693e-10
( O 0 2.446521596422002e-10
95 O 0 1.7576939015384596e-08
% O 0 5.255753054989043e-10
confidence O 0 8.132825080053863e-09
interval O 0 2.174751401184949e-08
[ O 0 1.0680108886162998e-07
CI O 0 1.0245783414575271e-05
] O 0 7.301269278059408e-08
6 O 0 3.0078300738978214e-08
% O 0 1.6950965076034663e-09
- O 0 2.4962055533706007e-08
28 O 0 1.1216182649320672e-08
% O 0 1.0099321379186676e-09
) O 0 4.3505624103268303e-10
, O 0 5.101352673619886e-10
suggesting O 0 5.335448083343408e-09
other O 0 9.775593667882276e-10
predisposition O 0 1.8415930469473096e-07
genes O 0 7.425391146398397e-08
. O 0 9.775897069630446e-07

The O 0 6.379817563129109e-08
majority O 0 1.917735747980487e-09
( O 0 8.349316238387416e-10
81 O 0 6.6094432149554905e-09
% O 0 7.722882056082625e-11
) O 0 1.1568409424844717e-11
of O 0 3.025341088758182e-10
the O 0 3.8635823784716194e-07
breast B-Disease 1 1.0
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 4.859834312753719e-09
were O 0 1.4154906136099044e-09
due O 0 2.1097907865197385e-09
to O 0 1.7371060145876527e-09
BRCA1 O 0 1.2187109099670579e-08
, O 0 3.204564391623421e-10
with O 0 6.297200955129867e-11
most O 0 6.333665814040046e-10
others O 0 8.069931389798057e-10
( O 0 1.622192519201704e-10
14 O 0 1.8598182993656565e-09
% O 0 3.6425262806005776e-10
) O 0 3.9980690980101485e-10
due O 0 5.799477786894158e-09
to O 0 7.530450574222414e-08
BRCA2 O 0 7.616653874720214e-06
. O 0 2.6116890694538597e-06

Conversely O 0 1.7555398699187208e-06
, O 0 6.946058839218949e-09
the O 0 1.6000620828293677e-09
majority O 0 1.0806873451674193e-10
of O 0 3.4358454970018215e-10
families O 0 2.7288222029242526e-11
with O 0 3.820842080226594e-12
male B-Disease 0 2.0083891494326878e-10
and I-Disease 0 5.692978866100873e-10
female I-Disease 0 1.8707456206357165e-07
breast I-Disease 1 0.8403160572052002
cancer I-Disease 0 0.003219465259462595
were O 0 8.853671715769451e-07
due O 0 0.00021789879247080535
to O 0 9.66902280197246e-06
BRCA2 O 0 3.3397841434634756e-06
( O 0 1.1845791014764018e-08
76 O 0 5.796920277134632e-07
% O 0 9.003589873657347e-09
) O 0 1.4395382663678902e-08
. O 0 2.586047003205749e-07

The O 0 8.452546040871312e-08
largest O 0 7.0008847607994085e-09
proportion O 0 1.1292466961521086e-09
( O 0 7.335909102401672e-10
67 O 0 2.0063543715309606e-08
% O 0 1.4035345108354136e-10
) O 0 3.5045587959414704e-11
of O 0 1.3836604084715987e-10
families O 0 4.193663818985449e-11
due O 0 4.1666137207130305e-10
to O 0 2.751322780714105e-10
other O 0 1.388207188091073e-10
genes O 0 1.0941063333103074e-10
was O 0 7.758230724519422e-10
found O 0 1.1485309231451524e-10
in O 0 3.3005778665717855e-11
families O 0 2.0959753030402872e-11
with O 0 3.5025459095561207e-12
four O 0 1.37520952958603e-10
or O 0 1.8869446283265034e-10
five O 0 7.393666928701137e-11
cases O 0 3.191107447730879e-11
of O 0 1.3336776127914618e-09
female O 0 8.009642726847233e-08
breast B-Disease 0 0.0004079142236150801
cancer I-Disease 0 4.5723450057266746e-06
only O 0 2.0921385157635086e-07
. O 0 9.215723366651218e-06

These O 0 1.6454976048407843e-08
estimates O 0 1.467521926201698e-08
were O 0 1.700549923100425e-09
not O 0 7.161733012184257e-11
substantially O 0 1.1926312160071006e-09
affected O 0 8.831288478283739e-11
either O 0 9.541981788041554e-11
by O 0 6.011708492126289e-11
changing O 0 2.152075850858637e-09
the O 0 2.178823343967906e-09
assumed O 0 2.1408757433505343e-08
penetrance O 0 3.5200191206286036e-08
model O 0 2.409319188600989e-09
for O 0 1.9859802691257755e-09
BRCA1 O 0 1.7249863759616346e-08
or O 0 7.721973060981213e-10
by O 0 2.720887404272787e-10
including O 0 2.1825541374198565e-09
or O 0 6.742863156716794e-09
excluding O 0 3.4655195690902474e-07
BRCA1 O 0 3.9685420460955356e-07
mutation O 0 2.0605648742844096e-08
data O 0 9.956075786021756e-08
. O 0 1.9016013652617403e-07

Among O 0 2.8721068190407095e-08
those O 0 6.944850250434342e-10
families O 0 6.301694582822037e-11
with O 0 2.0624257510148958e-11
disease O 0 4.2788692589113e-09
due O 0 4.9810728874888355e-09
to O 0 5.523681956276505e-09
BRCA1 O 0 5.887338261345576e-08
that O 0 7.723137129822533e-10
were O 0 7.981061145301283e-09
tested O 0 2.2720223480376944e-09
by O 0 6.287755038858478e-11
one O 0 7.599612605879713e-11
of O 0 3.436474715901028e-10
the O 0 1.4063937514574576e-10
standard O 0 2.2489083928434184e-09
screening O 0 4.4426357037608e-10
methods O 0 3.1194431482362006e-09
, O 0 3.533907333430619e-10
mutations O 0 5.113188761285414e-10
were O 0 1.199717547528678e-09
detected O 0 2.094354911719165e-09
in O 0 2.1831317309484177e-10
the O 0 1.6415280246206976e-09
coding O 0 5.054124585512909e-08
sequence O 0 1.07410791372331e-09
or O 0 1.059898724342645e-09
splice O 0 1.7364873983183315e-08
sites O 0 9.63650825802631e-10
in O 0 2.8271645441391158e-11
an O 0 1.6588437221076724e-11
estimated O 0 7.225314097025759e-11
63 O 0 1.5793348850934308e-09
% O 0 2.3643312307974895e-10
( O 0 4.711963597081592e-10
95 O 0 7.045521499549068e-08
% O 0 3.3052369730057762e-09
CI O 0 3.2720247418183135e-06
51 O 0 3.364846890008266e-08
% O 0 2.691036726787388e-09
- O 0 1.6735324948058405e-07
77 O 0 9.668183054145629e-08
% O 0 5.389472423900088e-09
) O 0 2.0738839978662327e-08
. O 0 1.9880737056610087e-07

The O 0 7.255983547338474e-08
estimated O 0 6.725882073510547e-09
sensitivity O 0 1.2920167158370077e-08
was O 0 6.62757093650157e-09
identical O 0 3.243179891310177e-10
for O 0 1.69791403159536e-10
direct O 0 9.65549529219345e-10
sequencing O 0 5.725661722522091e-09
and O 0 1.8226324893788615e-09
other O 0 5.9336686675237615e-09
techniques O 0 1.3137101632310078e-05
. O 0 1.5135190096771112e-06

The O 0 5.475223474604718e-07
penetrance O 0 2.5670589820947498e-05
of O 0 1.1260960945946863e-06
BRCA2 O 0 1.8977583522428176e-06
was O 0 1.0224767699185122e-08
estimated O 0 2.0386631272018008e-10
by O 0 1.2434739002364914e-11
maximizing O 0 4.876752335292167e-09
the O 0 4.432582301205912e-09
LOD O 0 0.00034080471959896386
score O 0 4.971357157046441e-07
in O 0 2.389276332337431e-08
BRCA2 O 0 4.710953191988665e-07
- O 0 2.367416414017498e-07
mutation O 0 3.3454548020728225e-09
families O 0 1.636313029518277e-10
, O 0 1.3045677038636683e-10
over O 0 9.11266687109169e-11
all O 0 4.021602217907372e-10
possible O 0 4.073995363285121e-09
penetrance O 0 5.646030558636994e-07
functions O 0 3.1609874895366374e-07
. O 0 6.355750770126178e-07

The O 0 4.388805407984364e-08
estimated O 0 4.003007703090589e-09
cumulative O 0 9.004689438540936e-09
risk O 0 2.413027111458632e-08
of O 0 1.0728967225759334e-07
breast B-Disease 1 0.9999996423721313
cancer I-Disease 0 4.1153605707222596e-05
reached O 0 2.715025004818017e-07
28 O 0 2.3012312055925577e-08
% O 0 4.855661983604875e-10
( O 0 3.176668095239421e-10
95 O 0 3.0761651004240775e-08
% O 0 1.569694707548308e-09
CI O 0 7.798233241373964e-07
9 O 0 1.2787752190490664e-08
% O 0 7.396251944236099e-10
- O 0 8.794384775967501e-09
44 O 0 9.63171209455993e-10
% O 0 3.5905559775395446e-11
) O 0 8.451981302337597e-12
by O 0 6.7080637919381125e-12
age O 0 1.3694351208570765e-10
50 O 0 3.441761875500049e-10
years O 0 3.697882278164144e-11
and O 0 1.0165256136840384e-10
84 O 0 5.947152104113229e-09
% O 0 3.204136400647428e-10
( O 0 4.3059336651829483e-10
95 O 0 3.445929763756794e-08
% O 0 2.1282777762365868e-09
CI O 0 1.066450067810365e-06
43 O 0 1.4838523298976725e-08
% O 0 2.7749383346709067e-10
- O 0 6.7476362275442625e-09
95 O 0 1.1047578851730577e-08
% O 0 1.480469635772863e-10
) O 0 2.8846470351284736e-11
by O 0 5.298315952639854e-11
age O 0 3.6699139283058457e-09
70 O 0 3.6824317817263363e-08
years O 0 2.7835872273840323e-08
. O 0 4.892374363407725e-07

The O 0 1.3583892268798081e-06
corresponding O 1 0.999977707862854
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
risks O 0 2.8472945814428385e-06
were O 0 7.314873329278271e-08
0 O 0 6.895339765833342e-07
. O 0 4.669453801398049e-07

4 O 0 1.1185694575033267e-06
% O 0 1.8581385319293986e-08
( O 0 2.8083035896742103e-09
95 O 0 9.21181779744984e-08
% O 0 2.730272452566851e-09
CI O 0 1.551605578242743e-06
0 O 0 9.464629080468967e-09
% O 0 2.024704987002579e-10
- O 0 2.5187685270822158e-09
1 O 0 4.5918437940883905e-09
% O 0 1.4365278411254678e-10
) O 0 1.363851132724081e-11
by O 0 1.0008797610150388e-11
age O 0 2.1525839444258565e-10
50 O 0 4.639442718890052e-10
years O 0 3.946449070313385e-11
and O 0 7.63542701287534e-11
27 O 0 2.517567931903386e-09
% O 0 2.6010421594335753e-10
( O 0 4.302781186904525e-10
95 O 0 2.8375250593626333e-08
% O 0 9.208840356933479e-10
CI O 0 4.972527563040785e-07
0 O 0 8.298483678004231e-09
% O 0 3.8262940038613635e-10
- O 0 9.48834344427496e-09
47 O 0 4.863496716467353e-09
% O 0 1.07351752487439e-10
) O 0 3.531594114369874e-11
by O 0 5.084225054852176e-11
age O 0 2.7512767619697343e-09
70 O 0 4.055970492800043e-08
years O 0 4.709722389861781e-08
. O 0 4.503285424561909e-07

The O 0 7.452988626255319e-08
lifetime O 0 1.9420608055042976e-07
risk O 0 3.410474391785101e-07
of O 0 7.862769280109205e-07
breast B-Disease 1 1.0
cancer I-Disease 0 0.00021040806313976645
appears O 0 1.4552955507340926e-09
similar O 0 1.3653822517056824e-10
to O 0 5.330999530706038e-10
the O 0 7.092169074240928e-09
risk O 0 1.4909198853274575e-07
in O 0 4.662029429169934e-09
BRCA1 O 0 1.7080663994306633e-08
carriers O 0 3.9183114530771945e-09
, O 0 3.3332242521666444e-10
but O 0 1.0192397620345517e-10
there O 0 1.4936814285437805e-10
was O 0 1.7683662312251158e-09
some O 0 1.0128155258914973e-10
suggestion O 0 2.513777186408106e-09
of O 0 3.341435739212528e-10
a O 0 1.8695374415234056e-10
lower O 0 2.1345789580351493e-09
risk O 0 1.86700499504866e-09
in O 0 7.43797134994395e-10
BRCA2 O 0 4.031075206967216e-08
carriers O 0 4.13335499160894e-09
< O 0 1.2922784264901566e-07
50 O 0 7.320718697911843e-09
years O 0 4.4119485842486483e-10
of O 0 1.513804970265653e-09
age O 0 3.145968108242414e-08
. O 0 1.1773052221997204e-07

Eye B-Disease 1 0.9999456405639648
movement I-Disease 0 5.499128019437194e-05
abnormalities I-Disease 0 5.339301787898876e-05
correlate O 0 6.65336088445656e-08
with O 0 5.408169467813195e-10
genotype O 0 1.0390192528575426e-06
in O 0 4.260056414295832e-07
autosomal O 0 0.49868616461753845
dominant O 0 2.8492413548519835e-05
cerebellar B-Disease 1 0.9999982118606567
ataxia I-Disease 1 0.9999998807907104
type I-Disease 1 1.0
I I-Disease 1 1.0
. O 0 0.001069535850547254

We O 0 3.361656126799062e-07
compared O 0 1.7724978818023374e-07
horizontal O 0 1.3214175851317123e-06
eye O 0 0.0001487003028159961
movements O 0 4.399705346713745e-07
( O 0 1.3327118963957219e-08
visually O 0 5.0471307133648224e-08
guided O 0 1.8059456579067046e-06
saccades O 0 7.223842840176076e-05
, O 0 1.944907168649479e-08
antisaccades O 0 1.314632413595973e-06
, O 0 7.219586595219596e-10
and O 0 2.4173915647018873e-10
smooth O 0 4.230567896001958e-09
pursuit O 0 3.498693246228868e-08
) O 0 1.4877929443990467e-10
in O 0 4.679432188958721e-11
control O 0 4.385757090830111e-09
subjects O 0 5.448897510973438e-08
( O 0 4.4406869847968267e-10
n O 0 2.9816731306198108e-09
= O 0 6.564878862747037e-09
14 O 0 2.8712507926798025e-09
) O 0 3.184008057210974e-10
and O 0 4.1012107598881187e-10
patients O 0 2.5844768547500507e-09
with O 0 1.5439757111712638e-11
three O 0 3.522789282506267e-10
forms O 0 3.4501503876072093e-09
of O 0 1.3821694722082611e-07
autosomal O 0 1.418635747540975e-05
dominant O 0 2.0156114715064177e-06
cerebellar B-Disease 0 0.04367024078965187
ataxias I-Disease 0 0.0003307336592115462
type I-Disease 0 1.2540634998003952e-05
I I-Disease 0 0.00016958737978711724
spinocerebellar B-Disease 1 0.999478280544281
ataxias I-Disease 0 2.747771577560343e-05
1 I-Disease 0 1.1314295278452846e-07
and I-Disease 0 4.962865229884983e-09
2 I-Disease 0 1.7804774188334704e-07
( O 0 1.6498280075438743e-08
SCA1 B-Disease 0 7.069931598380208e-05
, O 0 2.0383685850333677e-09
n O 0 1.906000912654804e-09
= O 0 4.229131711497303e-09
11 O 0 1.2423277961914891e-09
; O 0 6.839344646181189e-10
SCA2 B-Disease 0 3.7501197311939904e-06
, O 0 8.007985385916072e-10
n O 0 1.7510576322266047e-09
= O 0 6.299501364992466e-09
10 O 0 2.7758555454227007e-09
) O 0 1.2956757888815673e-09
and O 0 1.3568942414110552e-08
SCA3 B-Disease 1 1.0
/ O 0 0.06238742545247078
Machado B-Disease 0 3.818872301053489e-06
- I-Disease 0 5.242125553195365e-06
Joseph I-Disease 0 1.1575925782381091e-05
disease I-Disease 0 0.01052981149405241
( O 0 1.6708110450736058e-08
MJD B-Disease 1 1.0
) O 0 8.628663117349333e-09
( O 0 2.7572761851502037e-09
n O 0 1.4875021214777462e-08
= O 0 7.77170114929504e-08
16 O 0 1.1365566621179823e-07
) O 0 6.824990350651206e-08
. O 0 7.069421030792e-07

In O 0 4.06691327725639e-07
SCA1 B-Disease 0 0.0001310821680817753
, O 0 1.8108174515418796e-08
saccade O 0 7.518465849898348e-07
amplitude O 0 2.1964785545947052e-08
was O 0 4.721304236454671e-09
significantly O 0 2.159098233533996e-09
increased O 0 5.633440380847787e-10
, O 0 1.5153583943217086e-10
resulting O 0 9.059467065419824e-10
in O 0 7.073633678800206e-09
hypermetria B-Disease 0 1.3724950804316904e-05
. O 0 1.3101641798130004e-06

The O 0 4.57051697821953e-07
smooth O 0 1.8767152596410597e-06
pursuit O 0 9.143161150859669e-06
gain O 0 1.8696875940804603e-06
was O 0 3.486430557586573e-07
decreased O 0 1.0151179594686255e-06
. O 0 2.9967785053486296e-07

In O 0 8.91420654625108e-07
SCA2 B-Disease 0 0.00016339363355655223
, O 0 7.804172241776541e-08
saccade O 0 3.8044915982027305e-06
velocity O 0 2.6534041808190523e-07
was O 0 1.665391806682237e-07
markedly O 0 8.155583373081754e-07
decreased O 0 1.2839610690207337e-06
. O 0 3.740129272955528e-07

The O 0 6.193505441842717e-08
percentage O 0 5.8187264784237414e-08
of O 0 1.1593653148622707e-08
errors O 0 1.7829208331932023e-07
in O 0 5.5546371946491035e-09
antisaccades O 0 1.6452720501547446e-06
was O 0 5.083299559061061e-09
greatly O 0 4.737107595076395e-09
increased O 0 9.543770218556347e-10
and O 0 8.033499560022861e-11
was O 0 5.138333647458637e-10
significantly O 0 2.5499066746981214e-10
correlated O 0 5.690308224615137e-10
with O 0 5.754493409559913e-11
age O 0 5.425967586347724e-08
at O 0 2.8489088776950666e-07
disease O 0 1.6482041473864228e-06
onset O 0 2.101153222611174e-05
. O 0 1.1907688985957066e-06

In O 0 1.2605378962859959e-08
addition O 0 5.726240370762525e-09
, O 0 3.5570482670443937e-10
a O 0 1.5626530625034718e-10
correlation O 0 1.315045156102812e-10
between O 0 5.768108560233465e-11
smooth O 0 1.4055988373229411e-08
pursuit O 0 2.7737860364140943e-07
gain O 0 3.371283696651517e-08
and O 0 2.709188984262312e-10
the O 0 3.2704813857087345e-10
number O 0 7.432610638069548e-10
of O 0 6.733326785024474e-09
trinucleotide O 0 4.833287221117644e-06
repeats O 0 4.444674317483077e-08
was O 0 1.5353857918398717e-07
found O 0 7.412174340970523e-08
. O 0 7.739740226497815e-07

In O 0 2.086081167362863e-06
SCA3 B-Disease 1 1.0
, O 0 3.278079248048016e-07
gaze B-Disease 0 7.0970413617033046e-06
- I-Disease 0 3.850825123663526e-06
evoked I-Disease 0 8.412928877987724e-07
nystagmus I-Disease 0 2.8553356514748884e-06
was O 0 4.666192765512278e-09
often O 0 8.351160041275563e-11
present O 0 2.1854554624334277e-11
as O 0 1.8113234523386978e-10
was O 0 2.6486692839000625e-09
saccade O 0 5.423721063380071e-07
hypometria O 0 1.0565164529907634e-06
and O 0 8.06491851079727e-09
smooth O 0 4.932829256176774e-07
pursuit O 0 1.0177167496294715e-05
gain O 0 1.99205101125699e-06
was O 0 1.050524716106338e-07
markedly O 0 1.6309250838730804e-07
decreased O 0 2.806013981171418e-07
. O 0 1.7429836418614286e-07

Three O 0 4.0678784785086464e-08
major O 0 2.0168286596344842e-08
criteria O 0 2.1519948489867602e-08
, O 0 1.0621167279012411e-09
saccade O 0 3.9410548424712033e-07
amplitude O 0 1.369556823505036e-08
, O 0 4.862742986055935e-10
saccade O 0 1.1577447622812542e-07
velocity O 0 1.4609086385064529e-08
, O 0 5.328041896568436e-10
and O 0 3.217217325879318e-10
presence O 0 5.950782533403753e-09
of O 0 6.922333994907603e-08
gaze B-Disease 0 5.3018297876405995e-06
- I-Disease 0 3.563517793736537e-06
evoked I-Disease 0 4.50382628969237e-07
nystagmus I-Disease 0 4.873049874731805e-07
, O 0 1.7859236312034454e-10
permitted O 0 5.637911804079465e-10
the O 0 4.8593101764637936e-11
correct O 0 2.16854956214263e-09
assignment O 0 5.4095550261479275e-09
of O 0 9.775127374211934e-10
90 O 0 1.9938861672841313e-09
% O 0 6.338883584700028e-11
of O 0 1.6718741668864112e-10
the O 0 1.9606266610239231e-10
SCA1 B-Disease 0 1.3430180842988193e-06
, O 0 4.283219334766386e-10
90 O 0 1.4143382021103434e-09
% O 0 6.670861779634052e-11
of O 0 2.750509542348567e-10
the O 0 2.35539227011472e-10
SCA2 B-Disease 0 1.3441456303553423e-06
, O 0 3.4558192418820965e-10
and O 0 1.5090820260077464e-10
93 O 0 8.573949550338966e-09
% O 0 6.101279204084875e-11
of O 0 1.2686553196861183e-10
the O 0 1.847344499594783e-10
patients O 0 9.478787754702012e-10
with O 0 6.418426207188688e-11
SCA3 B-Disease 1 1.0
to O 0 3.56448168759016e-08
their O 0 1.5171645273426293e-08
genetically O 0 6.502336447056223e-08
confirmed O 0 8.920872041073835e-09
patient O 0 2.5710166440262583e-08
group O 0 5.412648107494533e-10
and O 0 5.291804217044671e-10
, O 0 4.748159643241934e-10
therefore O 0 1.681270123121692e-09
, O 0 6.369634819591852e-10
may O 0 3.405495885289156e-09
help O 0 1.4380809432168462e-08
orient O 0 4.566937150229933e-06
diagnoses O 0 4.704982347902842e-05
of O 0 8.964421027712888e-08
SCA1 B-Disease 0 0.023349128663539886
, O 0 9.020778790613804e-09
SCA2 B-Disease 0 3.2615309464745224e-05
, O 0 2.6253768048434267e-09
and O 0 3.400102421835527e-09
SCA3 B-Disease 1 1.0
at O 0 3.550355032189145e-08
early O 0 8.265156736797508e-08
clinical O 0 1.0396646210608651e-08
stages O 0 1.1518617171191181e-09
of O 0 8.651730443176575e-10
the O 0 2.547370536731819e-09
diseases O 0 2.0640736693167128e-06
. O 0 1.9472716772384047e-08
. O 0 3.437750990542554e-07

Genetic O 0 5.684781285708596e-07
basis O 0 2.2430279855711888e-08
and O 0 9.82902759183446e-10
molecular O 0 8.857850453125593e-09
mechanism O 0 3.4270209425812936e-07
for O 0 7.382432158919983e-07
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 1.0
fibrillation I-Disease 1 1.0
. O 1 0.9997923970222473

Ventricular B-Disease 1 1.0
fibrillation I-Disease 1 1.0
causes O 0 8.300147555928561e-07
more O 0 1.972024349372603e-10
than O 0 6.53049073151557e-11
300 O 0 6.75368427849321e-10
, O 0 5.608222219954939e-11
000 O 0 1.2988485842413411e-08
sudden O 0 1.048842013240403e-09
deaths O 0 7.974509941277574e-11
each O 0 3.3148978353936265e-12
year O 0 1.0127595290176927e-10
in O 0 5.809316916405294e-10
the O 0 3.0452017796278597e-08
USA O 0 4.320155312598217e-06
alone O 0 4.1882148593685997e-07
. O 0 7.534429755651217e-07

In O 0 1.9617209190414542e-08
approximately O 0 6.818426934174227e-10
5 O 0 3.455814301389637e-09
- O 0 1.9052459165891378e-08
12 O 0 4.936892672446902e-09
% O 0 2.1450997922389803e-10
of O 0 6.515486761227152e-11
these O 0 4.6642099904570244e-12
cases O 0 4.435569966876329e-12
, O 0 4.30205437246256e-12
there O 0 1.3168970254551216e-11
are O 0 7.704550192277893e-11
no O 0 5.644219758238478e-09
demonstrable O 0 9.327311272500083e-05
cardiac O 1 1.0
or O 0 3.0934518235881114e-07
non O 1 0.9985836744308472
- O 1 0.9806923270225525
cardiac O 1 1.0
causes O 0 8.857597322275979e-09
to O 0 7.258824791245289e-11
account O 0 1.0356873691996782e-10
for O 0 3.649353735868388e-11
the O 0 9.144551782469534e-10
episode O 0 9.514621091000208e-09
, O 0 1.344226813193572e-10
which O 0 1.3159579329014015e-11
is O 0 3.646707935622828e-12
therefore O 0 7.045162370156177e-11
classified O 0 2.411360444654065e-09
as O 0 4.991147051214284e-08
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 1.0
fibrillation I-Disease 1 1.0
( O 0 2.2949709091335535e-05
IVF B-Disease 1 1.0
) O 0 6.065596949156316e-07
. O 0 1.060613044501224e-06

A O 0 4.0500501086171425e-07
distinct O 0 8.544759566575522e-09
group O 0 5.120159407567826e-09
of O 0 5.2839229880419225e-08
IVF B-Disease 1 1.0
patients O 0 2.4507435227860697e-05
has O 0 3.6341901710201796e-11
been O 0 1.688724680926068e-11
found O 0 1.6644090619633012e-11
to O 0 8.570802401131061e-11
present O 0 3.605064580192163e-10
with O 0 3.456168407023341e-10
a O 0 1.8100335452686522e-08
characteristic O 0 8.156099084999369e-08
electrocardiographic O 0 5.9408785091363825e-06
pattern O 0 1.0522392557277271e-07
. O 0 3.818533969024429e-07

Because O 0 3.8174047034544856e-08
of O 0 2.3276246707837345e-08
the O 0 2.92563706594251e-09
small O 0 4.792323204938498e-10
size O 0 3.6891137367156546e-10
of O 0 2.223272010937194e-09
most O 0 5.537423852786105e-10
pedigrees O 0 1.0706762587631147e-08
and O 0 1.6560436355561592e-10
the O 0 1.960196727157637e-10
high O 0 2.5125406200032785e-09
incidence O 0 1.443606900686234e-09
of O 0 2.5270827097578774e-10
sudden B-Disease 0 4.311590195982262e-09
death I-Disease 0 6.098039850854775e-09
, O 0 2.450435410139562e-10
however O 0 1.4521310542914279e-10
, O 0 9.470506323605576e-11
molecular O 0 7.948455782447184e-10
genetic O 0 3.834703388161387e-10
studies O 0 4.953963350651236e-10
of O 0 4.989107793562653e-09
IVF B-Disease 1 1.0
have O 0 3.5474763127041342e-09
not O 0 5.859505103344986e-10
yet O 0 1.164452978485997e-09
been O 0 4.333561953728804e-09
done O 0 7.58410010348598e-08
. O 0 8.437507972303138e-07

Because O 0 1.8001097714659409e-06
IVF B-Disease 1 1.0
causes O 0 0.14606642723083496
cardiac O 1 1.0
rhythm O 1 0.9999997615814209
disturbance O 0 2.9230837753857486e-05
, O 0 1.0389563653845357e-09
we O 0 1.0319906040834326e-09
investigated O 0 5.649077206015818e-09
whether O 0 4.169342648907559e-09
malfunction O 0 5.738035270042019e-06
of O 0 3.331524212057957e-08
ion O 0 1.0721949905700967e-07
channels O 0 1.7131888796484418e-08
could O 0 1.4682042248637117e-09
cause O 0 6.1465472711574876e-09
the O 0 2.7634994292924375e-09
disorder O 0 1.4763259947869756e-08
by O 0 5.48466445871032e-11
studying O 0 1.2839411756004893e-09
mutations O 0 5.0090306902284e-11
in O 0 6.150950582206605e-11
the O 0 1.6688037618450835e-09
cardiac O 0 0.06601452827453613
sodium O 0 1.616391159586783e-06
channel O 0 1.6992854057207296e-07
gene O 0 1.2730129128613044e-07
SCN5A O 0 0.0003791898488998413
. O 0 1.1190601981070358e-05

We O 0 1.8618463570874155e-07
have O 0 4.863042413205676e-09
now O 0 1.7581357480978e-09
identified O 0 2.842984514472846e-09
a O 0 2.915704122585794e-09
missense O 0 5.686998747478356e-07
mutation O 0 3.070115894843184e-08
, O 0 1.7241763572428681e-09
a O 0 1.9020860442253706e-09
splice O 0 1.0665512917285014e-07
- O 0 7.037033356027678e-08
donor O 0 4.887398219466377e-08
mutation O 0 4.098506867222795e-09
, O 0 1.2909291691176605e-10
and O 0 1.458201198678566e-10
a O 0 1.1425295154410264e-09
frameshift O 0 2.1964325469525647e-08
mutation O 0 2.2230588203608903e-10
in O 0 1.1312163705756717e-10
the O 0 7.542690916295669e-10
coding O 0 1.721051745562363e-07
region O 0 1.9764998526738964e-08
of O 0 7.151244041381233e-09
SCN5A O 0 1.1374157111276872e-05
in O 0 1.9816552843110458e-09
three O 0 4.891322014088928e-09
IVF B-Disease 1 1.0
families O 0 4.724811120127015e-08
. O 0 2.5005664383570547e-07

We O 0 1.7520315509500506e-07
show O 0 1.31522472912593e-08
that O 0 3.179747576353975e-10
sodium O 0 1.1836170266121826e-08
channels O 0 1.2312476593834276e-09
with O 0 7.151496062007823e-11
the O 0 5.1896718034072364e-09
missense O 0 1.165371031675022e-06
mutation O 0 8.703593579184599e-08
recover O 0 1.6868028751559905e-07
from O 0 9.358521069202652e-09
inactivation O 0 4.0886638430492894e-07
more O 0 4.2828027235763955e-10
rapidly O 0 4.026022848435673e-10
than O 0 7.36250643784686e-12
normal O 0 1.3809500765127325e-10
and O 0 6.749547448725579e-11
that O 0 3.237616078011207e-11
the O 0 9.33514487932996e-10
frameshift O 0 1.0837934638630031e-07
mutation O 0 8.748906599187478e-10
causes O 0 2.1666425598088068e-10
the O 0 2.1118350124194052e-10
sodium O 0 1.3172707369335512e-08
channel O 0 4.183138724300761e-09
to O 0 1.5439859391008781e-09
be O 0 5.631810129358428e-09
non O 0 2.466619207552867e-06
- O 0 6.5809122133941855e-06
functional O 0 3.272726871728082e-06
. O 0 1.636728939047316e-06

Our O 0 1.0148725237968392e-07
results O 0 9.692699087793244e-09
indicate O 0 4.193347891146004e-09
that O 0 6.965952814574905e-11
mutations O 0 4.036033729448718e-10
in O 0 2.290216349898344e-10
cardiac O 0 9.694160780782113e-07
ion O 0 4.948358878209547e-08
- O 0 1.3437971801977255e-06
channel O 0 6.970973487341325e-08
genes O 0 8.817962471319163e-10
contribute O 0 1.0298276675868578e-09
to O 0 5.052828155882594e-10
the O 0 9.927131339182438e-10
risk O 0 1.170802921279801e-08
of O 0 7.690375447566566e-09
developing O 0 2.849104419055948e-07
IVF B-Disease 1 1.0
. O 0 5.452722575682856e-07
. O 0 2.1590597043541493e-06

Molecular O 0 2.6895377231994644e-06
heterogeneity O 0 1.2003405345240026e-06
in O 0 4.5377522184253394e-08
mucopolysaccharidosis B-Disease 0 0.003719753585755825
IVA I-Disease 1 0.9976039528846741
in O 0 1.5823484034171997e-07
Australia O 0 3.653969926631362e-08
and O 0 7.337503937776546e-10
Northern O 0 8.945715279651267e-09
Ireland O 0 3.171354290287809e-09
: O 0 5.920212653443002e-10
nine O 0 6.935041430011779e-10
novel O 0 8.942946938539365e-10
mutations O 0 4.0515982235866943e-10
including O 0 4.546020782036919e-10
T312S O 0 1.9208539470128017e-06
, O 0 2.1526342930400233e-09
a O 0 2.9089219921729637e-09
common O 0 9.033072956299293e-09
allele O 0 1.0366627556379626e-08
that O 0 8.856253924660606e-11
confers O 0 5.848300688171548e-08
a O 0 3.4183308628144005e-08
mild O 0 1.8468357438905514e-06
phenotype O 0 6.950209012757114e-07
. O 0 7.719556833762908e-07

Mucopolysaccharidosis B-Disease 1 0.5119289755821228
IVA I-Disease 1 0.9999998807907104
( O 0 0.0002037919475696981
MPS B-Disease 1 1.0
IVA I-Disease 1 1.0
) O 0 2.55842792284966e-07
is O 0 8.42916580978681e-09
an O 0 8.266052731187301e-09
autosomal B-Disease 1 0.9999880790710449
recessive I-Disease 1 0.9999996423721313
lysosomal I-Disease 1 1.0
storage I-Disease 1 1.0
disorder I-Disease 1 0.9992167949676514
caused O 0 1.1056411786114495e-08
by O 0 1.409170280464167e-10
a O 0 5.0671552287440136e-08
genetic B-Disease 1 1.0
defect I-Disease 1 1.0
in O 0 8.273617595477845e-07
N O 0 3.7316783618734917e-07
- O 0 3.488459299205715e-07
acetylgalactosamine O 0 1.0700396160245873e-05
- O 0 2.2785300188843394e-06
6 O 0 8.234116648964118e-06
- O 0 7.24314886610955e-05
sulfate O 0 1.3028108696744312e-05
sulfatase O 0 4.70203158329241e-05
( O 0 8.137980245237486e-08
GALNS O 0 0.0004043070657644421
) O 0 1.970184797528418e-07
. O 0 1.1855577213282231e-06

Previous O 0 4.4273797072946763e-08
studies O 0 8.350339975038423e-09
of O 0 1.6477831321637382e-09
patients O 0 7.96338772701688e-10
from O 0 3.189628769439956e-11
a O 0 9.335709982849494e-11
British O 0 8.940154394565525e-09
- O 0 1.4745593546194868e-07
Irish O 0 1.336043453648017e-08
population O 0 6.038956834597542e-11
showed O 0 4.520089164072871e-11
that O 0 1.0801051893161162e-12
the O 0 1.3263937170826523e-10
I113F O 0 2.8716448241539183e-07
mutation O 0 1.637669000409403e-09
is O 0 2.1972840213990708e-11
the O 0 1.3025686085299526e-10
most O 0 5.3503618202555003e-11
common O 0 1.3266947263002038e-10
single O 0 1.2584712161256562e-09
mutation O 0 6.542391517427859e-09
among O 0 1.1063964855395625e-08
MPS B-Disease 1 1.0
IVA I-Disease 1 1.0
patients O 0 8.710472320672125e-05
and O 0 4.310512835559166e-09
produces O 0 7.899005338707354e-10
a O 0 2.315888369963659e-09
severe O 0 2.9917558208580886e-07
clinical O 0 2.9395605452009477e-06
phenotype O 0 3.1387793342219084e-07
. O 0 7.394311865027703e-07

We O 0 1.9887905011728435e-07
studied O 0 1.6604866459601908e-07
mutations O 0 4.889269877850211e-09
in O 0 6.527443030535096e-10
the O 0 2.3826762785006395e-09
GALNS O 0 1.0797572940646205e-05
gene O 0 1.1454948101174978e-09
from O 0 5.191797547432486e-10
23 O 0 1.5279121967637366e-08
additional O 0 5.223185439717781e-07
MPS B-Disease 1 1.0
IVA I-Disease 1 1.0
patients O 0 0.00019377237185835838
( O 0 8.033610443547445e-10
15 O 0 1.5071384140696864e-09
from O 0 6.137008123907606e-10
Australia O 0 6.874276703427995e-10
, O 0 4.689975838245708e-11
8 O 0 6.444472733235784e-10
from O 0 3.6475114595369007e-10
Northern O 0 3.6709359996223156e-09
Ireland O 0 2.4305417678505137e-09
) O 0 1.7458108569901043e-10
, O 0 8.716888322268801e-11
with O 0 7.820772675304344e-12
various O 0 9.440609405331202e-10
clinical O 0 2.550403621626174e-07
phenotypes O 0 6.576073019459727e-08
( O 0 1.548285499808344e-09
severe O 0 1.4947266890885658e-07
, O 0 1.2639967961192156e-09
16 O 0 4.25967616735079e-09
cases O 0 9.224763314330531e-11
; O 0 4.6646575491138265e-11
intermediate O 0 4.508916795487039e-09
, O 0 1.641264346652349e-10
4 O 0 3.6773131206757625e-09
cases O 0 1.9528897943210666e-10
; O 0 2.705605461894578e-10
mild O 0 9.653511767737655e-09
, O 0 3.0859875765898437e-10
3 O 0 9.221429841943518e-09
cases O 0 4.72631356274178e-09
) O 0 1.2020636930287765e-08
. O 0 3.2186790122068487e-07

We O 0 6.635668228227587e-07
found O 0 2.3482622069082026e-08
two O 0 4.550106680323296e-10
common O 0 1.3393444131537535e-09
mutations O 0 2.6316623880084933e-10
that O 0 1.0394846441941219e-11
together O 0 1.9498368197812255e-11
accounted O 0 1.6246022305210772e-09
for O 0 2.6587454460269555e-10
32 O 0 3.784712543364321e-09
% O 0 2.700707435465688e-10
of O 0 4.667952691050914e-10
the O 0 6.577220434955677e-10
44 O 0 2.917228458798604e-09
unrelated O 0 2.571770352233216e-09
alleles O 0 5.242517531200974e-10
in O 0 5.222328125498166e-10
these O 0 4.997412261786849e-09
patients O 0 2.4527810182917165e-07
. O 0 2.4934746534199803e-07

One O 0 2.9772932563787435e-08
is O 0 9.35055810558083e-10
the O 0 1.478365430074291e-09
T312S O 0 8.636469033262983e-07
mutation O 0 2.7233548749450165e-09
, O 0 8.193414696711088e-11
a O 0 1.3102782747687058e-10
novel O 0 2.2807320476658788e-09
mutation O 0 1.3569712020711222e-09
found O 0 1.0707281589139583e-10
exclusively O 0 7.980341387714418e-10
in O 0 1.4025182126786717e-09
milder O 0 2.186504616474849e-06
patients O 0 9.510631002740411e-07
. O 0 6.20325238287478e-07

The O 0 5.982422379702257e-08
other O 0 1.7871716329054266e-09
is O 0 1.0172276909692357e-10
the O 0 2.3240380453426468e-10
previously O 0 4.51134285484045e-09
described O 0 2.426085998763483e-09
I113F O 0 1.4621497257394367e-07
that O 0 7.807987589814047e-11
produces O 0 2.3062600440493242e-10
a O 0 2.4939246223709688e-09
severe O 0 5.563094873650698e-07
phenotype O 0 1.333874934061896e-06
. O 0 2.247277507194667e-06

The O 0 1.655630512686912e-06
I113F O 0 5.3892956202616915e-05
and O 0 3.7231679073101986e-08
T312S O 0 4.537230324785924e-06
mutations O 0 4.460995572941329e-09
accounted O 0 1.4976246909270685e-09
for O 0 1.3323801784093092e-10
8 O 0 7.771000731793265e-09
( O 0 4.4356754380636687e-10
18 O 0 1.2147487460367756e-09
% O 0 6.333179813911016e-11
) O 0 2.563295582735936e-11
and O 0 3.9597040923933235e-11
6 O 0 4.059010016987941e-09
( O 0 4.902789285665676e-10
14 O 0 3.1077260764789116e-09
% O 0 1.6230775057302083e-10
) O 0 1.589675890922848e-10
of O 0 6.18595563661728e-10
44 O 0 1.5825432075899926e-09
unrelated O 0 1.9334847056740045e-09
alleles O 0 1.5095261707287477e-09
, O 0 3.299574169446373e-09
respectively O 0 3.358954643317702e-07
. O 0 7.143720495150774e-07

The O 0 4.783351528203639e-07
relatively O 0 3.283974194800976e-07
high O 0 1.4988749796884804e-07
residual O 0 3.122175940006855e-06
GALNS O 0 2.245617906737607e-05
activity O 0 3.3303614088708855e-08
seen O 0 2.181026914627182e-09
when O 0 4.632686734229452e-10
the O 0 2.635662355032764e-09
T312S O 0 4.0511392285225156e-07
mutant O 0 1.5687616539139526e-08
cDNA O 0 1.9653224114790646e-07
is O 0 2.476617799729297e-09
overexpressed O 0 6.613078085138113e-08
in O 0 8.737666701286173e-10
mutant O 0 3.921922786531695e-09
cells O 0 2.3862600784241295e-09
provides O 0 3.3186212111679936e-10
an O 0 1.0113767462405221e-11
explanation O 0 7.195802842474563e-10
for O 0 1.7556216203029607e-10
the O 0 2.8917288563690136e-09
mild O 0 1.0790740390120845e-07
phenotype O 0 3.641597690062781e-09
in O 0 3.2196847965515474e-10
patients O 0 3.853782015728058e-10
with O 0 5.869028787269803e-12
this O 0 8.849740384953009e-10
mutation O 0 3.511596702310271e-08
. O 0 2.006722326086674e-07

The O 0 7.404950874700944e-09
distribution O 0 3.091136235866543e-10
and O 0 6.407197689073385e-11
relative O 0 1.3528156372899502e-09
frequencies O 0 3.187564212581151e-09
of O 0 6.314594958034547e-10
the O 0 2.6216138149237622e-09
I113F O 0 7.442021683345956e-07
and O 0 5.640850897492555e-09
T312S O 0 1.4246361388359219e-06
mutations O 0 3.781956081638782e-09
in O 0 4.782151341586882e-10
Australia O 0 2.1596830990233684e-09
corresponded O 0 3.7095970739642325e-10
to O 0 1.444713515486029e-10
those O 0 1.0051158516599656e-10
observed O 0 3.3421751477469286e-10
in O 0 1.348481881713326e-10
Northern O 0 1.9146508822842634e-09
Ireland O 0 1.049788700413501e-09
and O 0 1.3746849492068947e-10
are O 0 4.617687482388888e-11
unique O 0 1.7577525546208506e-10
to O 0 1.1469021565790882e-10
these O 0 4.401356015759639e-11
two O 0 5.64319146967307e-11
populations O 0 7.442948340985467e-11
, O 0 3.417080507439607e-11
suggesting O 0 1.570290009134112e-10
that O 0 3.826852029709116e-12
both O 0 2.5261754493799415e-11
mutations O 0 1.0073306772051538e-10
were O 0 3.425624506281366e-10
probably O 0 1.4952870053264178e-09
introduced O 0 1.1047195380697872e-09
to O 0 4.3192016629944874e-10
Australia O 0 9.463505534768046e-10
by O 0 7.148958508507164e-11
Irish O 0 3.8688519055085635e-09
migrants O 0 3.2445182096552116e-09
during O 0 1.2027580043039166e-09
the O 0 8.097993386968483e-10
19th O 0 3.2469378652422165e-07
century O 0 2.4800285700621316e-06
. O 0 3.659218634766148e-07

Haplotype O 0 4.34306184615707e-06
analysis O 0 5.8482111597868425e-08
using O 0 7.655079770074735e-08
6 O 0 3.0343773005370167e-07
RFLPs O 0 5.5102909755078144e-06
provides O 0 9.12516462392432e-09
additional O 0 4.9779198540989e-09
data O 0 4.2536441036133965e-09
that O 0 1.0971489688982317e-10
the O 0 2.109839192243612e-09
I113F O 0 1.0348767318646424e-06
mutation O 0 2.5651567536755238e-09
originated O 0 3.199423614930197e-09
from O 0 6.384899831068935e-10
a O 0 2.82657963701638e-09
common O 0 1.5821516541336678e-08
ancestor O 0 8.327564842147694e-07
. O 0 2.547603230595996e-07

The O 0 6.440066613322415e-08
other O 0 1.574954944238982e-09
9 O 0 7.178260652551671e-09
novel O 0 3.5288303390501596e-09
mutations O 0 3.7115999163006563e-10
identified O 0 1.286607625994307e-10
in O 0 3.875052015378522e-11
these O 0 8.462600065151094e-11
23 O 0 1.331035281992854e-08
patients O 0 2.181039349125058e-09
were O 0 1.7312275224501406e-10
each O 0 1.741141258948531e-11
limited O 0 1.209823685677236e-09
to O 0 1.4514645041430185e-09
a O 0 1.0250621684804173e-08
single O 0 3.040268836684845e-07
family O 0 8.310794896715379e-08
. O 0 1.3314157740751398e-06

These O 0 5.6732350373067675e-08
data O 0 2.3400799520345572e-08
provide O 0 9.79812453394402e-10
further O 0 3.0806240891578796e-10
evidence O 0 5.708538641790994e-10
for O 0 1.8377571686656324e-10
extensive O 0 1.1500007168763204e-08
allelic O 0 9.574628023756304e-08
heterogeneity O 0 8.570569320909271e-08
in O 0 5.504962885538589e-08
MPS B-Disease 1 0.9999996423721313
IVA I-Disease 1 1.0
in O 0 5.7768485106635126e-08
British O 0 1.2355390026641544e-06
- O 0 3.2631403428240446e-06
Irish O 0 3.80694835655504e-08
patients O 0 2.094802331598089e-09
and O 0 3.488464725420748e-12
provide O 0 2.4632644882172094e-11
evidence O 0 3.3978625468833457e-11
for O 0 1.9849935931071094e-11
their O 0 2.967255607888575e-10
transmission O 0 2.3259123338448262e-07
to O 0 3.3923488462761497e-09
Australia O 0 7.256450551551552e-09
by O 0 4.665060004960253e-10
British O 0 2.0826492175274325e-07
- O 0 5.715472752854112e-07
Irish O 0 6.573727517888983e-08
migrants O 0 4.326618352479272e-08
. O 0 6.306341671091786e-09
. O 0 5.599337882244981e-08

Identification O 0 6.371405561367283e-06
of O 0 5.522793458112574e-07
constitutional O 0 1.3549279174185358e-05
WT1 O 1 0.8127298355102539
mutations O 0 2.43442684677575e-07
, O 0 1.424026119245525e-09
in O 0 1.0708758324540213e-09
patients O 0 3.996111441750827e-09
with O 0 1.5949970511019984e-10
isolated O 0 8.201179184652574e-07
diffuse B-Disease 1 0.9999994039535522
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
, O 0 7.416303304808025e-08
and O 0 2.1743438161081485e-09
analysis O 0 1.3454824809855381e-08
of O 0 4.3361520596363334e-08
genotype O 0 3.272600395121117e-07
/ O 0 7.337426382036938e-07
phenotype O 0 3.781825963500296e-09
correlations O 0 3.004008708451522e-10
by O 0 6.255361506557477e-11
use O 0 2.255958531094393e-09
of O 0 1.1485188800008928e-08
a O 0 6.137736985323272e-09
computerized O 0 4.0735471884545404e-07
mutation O 0 1.6207776454280065e-08
database O 0 3.7544452879956225e-08
. O 0 2.9115696520420897e-07

Constitutional O 0 3.1150532322499203e-06
mutations O 0 1.0839422515118713e-07
of O 0 2.6026926391864436e-08
the O 0 2.462446069273483e-08
WT1 O 0 1.8055419786833227e-05
gene O 0 1.5044852474943582e-08
, O 0 7.614764374608285e-10
encoding O 0 7.457094497453909e-09
a O 0 1.4669845782577795e-08
zinc O 0 0.295134037733078
- O 0 0.07473185658454895
finger O 0 0.00014775981253478676
transcription O 0 1.7913855117512867e-05
factor O 0 1.8063558115954947e-07
involved O 0 2.9388695921284125e-09
in O 0 5.178676598660559e-09
renal O 1 1.0
and O 0 2.3938437152537517e-06
gonadal O 1 1.0
development O 0 1.089339184545679e-05
, O 0 6.775347505261209e-10
are O 0 3.6936811248500234e-11
found O 0 2.1589315404857423e-11
in O 0 2.7148571585255965e-11
most O 0 1.203135924221499e-10
patients O 0 3.71910446883561e-10
with O 0 1.198152826953347e-10
Denys B-Disease 1 0.9999998807907104
- I-Disease 1 1.0
Drash I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 6.487556447609677e-07
DDS B-Disease 1 1.0
) O 0 1.0821942453276279e-08
, O 0 1.8080589248015144e-09
or O 0 3.281400395849232e-08
diffuse B-Disease 1 0.9999878406524658
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
( O 0 2.162284772566636e-06
DMS B-Disease 1 0.9951722025871277
) O 0 2.4573165724461887e-09
associated O 0 1.0078159640158901e-08
with O 0 6.061138257962284e-10
pseudohermaphroditism B-Disease 1 1.0
and O 0 8.116338108266064e-07
/ O 1 0.9635457396507263
or O 0 3.319053348604939e-06
Wilms B-Disease 1 1.0
tumor I-Disease 1 0.9693100452423096
( O 0 1.7091622339648893e-07
WT B-Disease 1 0.9999978542327881
) O 0 2.0702329095456662e-07
. O 0 4.801615318683616e-07

Most O 0 2.299564698660106e-07
mutations O 0 2.1944165951026662e-07
in O 0 7.081115427354234e-08
DDS B-Disease 1 1.0
patients O 1 0.9996696710586548
lie O 0 1.0143848072630135e-07
in O 0 9.920392285422963e-10
exon O 0 1.9200247436401696e-07
8 O 0 1.2335100052496273e-07
or O 0 1.613590683291477e-08
exon O 0 6.683810624963371e-07
9 O 0 1.1872939609247624e-07
, O 0 5.600424568541484e-09
encoding O 0 1.4428277950173651e-07
zinc O 0 0.1871887743473053
finger O 0 6.649199349340051e-05
2 O 0 3.9881906559458e-06
or O 0 1.4008395510245464e-06
zinc O 1 0.9995552897453308
finger O 0 4.401784281071741e-06
3 O 0 1.1514870834616886e-07
, O 0 1.5620728044396515e-09
respectively O 0 3.0232083503278773e-09
, O 0 4.8967867954941013e-11
with O 0 8.602160650461599e-12
a O 0 8.89366802425684e-10
hot O 0 3.309939131668216e-07
spot O 0 1.0562286689719258e-07
( O 0 6.716088574165724e-09
R394W O 0 1.6287408470816445e-06
) O 0 3.2166604935213172e-09
in O 0 9.771365938604504e-09
exon O 0 3.5107641451759264e-06
9 O 0 4.6988570829853415e-06
. O 0 2.9339482807699824e-06

We O 0 3.33920908701657e-08
analyzed O 0 8.911077209461382e-09
a O 0 3.6796193869648164e-10
series O 0 2.7824112458496586e-10
of O 0 6.086369741531428e-10
24 O 0 6.091878557157315e-09
patients O 0 1.7397353557768724e-09
, O 0 9.241987036778809e-11
10 O 0 1.6615243625395237e-09
with O 0 8.617046520775773e-10
isolated B-Disease 0 3.175189476678497e-06
DMS I-Disease 1 0.999993085861206
( O 0 9.182248277284089e-07
IDMS B-Disease 1 0.9998408555984497
) O 0 7.364484133631777e-09
, O 0 1.4185338459427044e-09
10 O 0 2.812323707246378e-09
with O 0 7.579162297766118e-10
DDS B-Disease 1 1.0
, O 0 1.8470643681212096e-08
and O 0 2.2148618494810535e-09
4 O 0 1.5681924026011984e-07
with O 0 6.594156332084822e-09
urogenital B-Disease 1 0.9997188448905945
abnormalities I-Disease 1 0.9992994070053101
and O 0 1.4001369663674268e-06
/ O 1 0.9999980926513672
or O 0 0.003684591967612505
WT B-Disease 1 1.0
. O 0 2.6562815037323162e-05

We O 0 9.861942089628428e-07
report O 0 1.3633777484756138e-07
WT1 O 0 9.394420339958742e-05
heterozygous O 0 7.709912352993342e-08
mutations O 0 1.4336517528690251e-09
in O 0 3.642269263970377e-10
16 O 0 7.020822145875627e-09
patients O 0 3.2613944878079337e-09
, O 0 5.4292091655749886e-11
4 O 0 5.427247984357564e-09
of O 0 1.3103096385691515e-08
whom O 0 2.7197645025012207e-08
presented O 0 1.2931957371620229e-07
with O 0 8.619290525757606e-08
IDMS B-Disease 1 0.9999997615814209
. O 0 0.00018893521337304264

One O 0 8.77475159200003e-08
male O 0 1.0839873887391605e-08
and O 0 6.738629654279293e-10
two O 0 1.6654839729568494e-09
female O 0 1.0257349636333402e-08
IDMS B-Disease 0 0.3146114945411682
patients O 0 3.877231904425571e-07
with O 0 4.472411774258944e-09
WT1 O 1 0.9998457431793213
mutations O 0 4.547588105197065e-06
underwent O 1 0.9755606651306152
normal O 0 2.7094147299067117e-05
puberty O 0 7.630726031493396e-05
. O 0 2.0075522115803324e-06

Two O 0 8.232620274384317e-08
mutations O 0 7.857704531488707e-08
associated O 0 4.258874142237801e-08
with O 0 1.3280625488221176e-09
IDMS B-Disease 1 0.7521197199821472
are O 0 7.422806813650595e-10
different O 0 9.372248116479298e-11
from O 0 6.538645735965076e-10
those O 0 9.554698143787732e-10
described O 0 1.0503841352260679e-08
in O 0 4.6596664304843216e-08
DDS B-Disease 1 1.0
patients O 0 0.49129924178123474
. O 0 2.2494989480037475e-06

No O 0 9.435337233298924e-06
WT1 O 0 0.00022438725864049047
mutations O 0 2.997641672664031e-07
were O 0 2.3172901819634717e-08
detected O 0 1.628962564836911e-08
in O 0 3.9896816406148616e-10
the O 0 2.2135147048629733e-09
six O 0 1.19256355901598e-08
other O 0 4.18432799520474e-09
IDMS B-Disease 1 1.0
patients O 0 2.037123749687453e-06
, O 0 1.7177885780483848e-09
suggesting O 0 4.160056743529594e-09
genetic O 0 3.98597199691153e-09
heterogeneity O 0 1.3947214050347156e-08
of O 0 2.6360053695384522e-08
this O 0 2.230714812867518e-08
disease O 0 2.847509222192457e-06
. O 0 3.341786793953361e-07

We O 0 1.2528050774562871e-06
analyzed O 0 1.4028100849827752e-06
genotype O 0 4.166791768511757e-06
/ O 0 6.291318186413264e-06
phenotype O 0 3.9038788202105934e-08
correlations O 0 5.003383041213283e-09
, O 0 1.297911084163772e-10
on O 0 1.3788471753262144e-10
the O 0 2.6243528183922393e-11
basis O 0 1.162446319757926e-10
of O 0 9.829041053288634e-11
the O 0 1.226201362669599e-10
constitution O 0 6.393296447804175e-10
of O 0 1.981965258579521e-09
a O 0 2.0521351284941147e-09
WT1 O 0 2.7629348551272415e-06
mutation O 0 7.04237512749728e-09
database O 0 2.714849678397968e-09
of O 0 3.03552116776018e-09
84 O 0 7.141541402688745e-08
germ O 1 0.9887837767601013
- O 0 0.00019771649385802448
line O 0 1.223982394549239e-06
mutations O 0 3.029974271484548e-09
, O 0 1.3676028365328108e-10
to O 0 2.1429161223274207e-10
compare O 0 2.9131195233844664e-09
the O 0 4.778294981910847e-10
distribution O 0 2.5888172161536716e-10
and O 0 1.4344470056215641e-10
type O 0 5.6360760503082474e-09
of O 0 4.638683659408116e-09
mutations O 0 4.6398851427653653e-10
, O 0 1.07126744974817e-10
according O 0 2.2632021257074086e-10
to O 0 5.390415336314902e-10
the O 0 1.4682770554941271e-09
different O 0 5.512756473535774e-09
symptoms O 0 9.520648518446251e-07
. O 0 5.72954206745635e-07

This O 0 1.3434796386491143e-08
demonstrated O 0 5.789411972045855e-08
( O 0 1.4249499358243156e-09
1 O 0 2.1313091735919443e-08
) O 0 1.3541425758489822e-09
the O 0 2.184782355030279e-09
association O 0 1.481984757134569e-09
between O 0 1.449881048554147e-10
mutations O 0 4.925340135741862e-10
in O 0 5.180254558645458e-10
exons O 0 3.030044837259993e-08
8 O 0 6.804074637045687e-09
and O 0 1.0860977672777494e-09
9 O 0 3.5916983165407146e-08
and O 0 8.698378017868436e-09
DMS B-Disease 0 1.1806072507170029e-05
; O 0 3.6031142514048042e-09
( O 0 1.3495683459652241e-09
2 O 0 1.6432080585104814e-08
) O 0 8.343681301425931e-10
among O 0 8.225203851353058e-10
patients O 0 1.797036408568431e-09
with O 0 5.7041493056742e-11
DMS B-Disease 0 8.282735279863118e-07
, O 0 8.171412990698457e-10
a O 0 3.3724381620636734e-10
higher O 0 2.911486385315243e-09
frequency O 0 3.201499065852431e-09
of O 0 1.1557503842851702e-09
exon O 0 5.0898020020895274e-08
8 O 0 3.008340598853465e-08
mutations O 0 4.580725576630584e-09
among O 0 1.3995867798044515e-09
46 O 0 2.44141968863687e-08
, O 0 8.971106524313655e-09
XY O 0 2.0684185074060224e-05
patients O 0 3.375620494239229e-08
with O 0 9.919592924845233e-11
female O 0 2.13034101470555e-09
phenotype O 0 1.4640935130927346e-09
than O 0 1.4264664449648023e-10
among O 0 3.9516859229316026e-10
46 O 0 1.412292949254379e-08
, O 0 1.1426543267134548e-08
XY O 0 3.3424479624954984e-05
patients O 0 4.194910019350573e-08
with O 0 7.447507194280334e-11
sexual O 0 1.7669636864781069e-09
ambiguity O 0 1.6586627182846314e-08
or O 0 9.350902274718464e-09
male O 0 2.1751858092500242e-09
phenotype O 0 3.257774328080387e-10
; O 0 7.812143987262488e-11
and O 0 5.633526423132196e-10
( O 0 1.3156680189752024e-09
3 O 0 4.033359601862685e-08
) O 0 1.6311443307159834e-09
statistically O 0 3.027894379670215e-09
significant O 0 6.041044331439593e-10
evidence O 0 8.263541517727901e-10
that O 0 5.2973157110836055e-11
mutations O 0 7.026485504546542e-10
in O 0 3.331547926421763e-09
exons O 0 1.1641763819625339e-07
8 O 0 3.921633151549031e-08
and O 0 5.960995252962675e-09
9 O 0 4.704990530512987e-08
preferentially O 0 4.867366509841986e-09
affect O 0 1.3606616944272787e-09
amino O 0 6.848064892928107e-10
acids O 0 4.914173512560183e-10
with O 0 1.4093200564890829e-11
different O 0 1.1223619256206518e-10
functions O 0 1.0397637417725036e-08
. O 0 2.208050808860662e-08
. O 0 3.1321948767981667e-07

The O 0 7.663069823138358e-07
185delAG O 0 8.299424735014327e-06
BRCA1 O 0 9.587079148332123e-07
mutation O 0 4.277016962817015e-09
originated O 0 3.9877514623753996e-09
before O 0 8.93001006474492e-10
the O 0 1.268919136432345e-10
dispersion O 0 6.516996720051793e-09
of O 0 1.346989075834415e-09
Jews O 0 1.1303849412058753e-08
in O 0 1.1035542618609284e-10
the O 0 1.0074612671884253e-10
diaspora O 0 1.9307060394879727e-09
and O 0 1.0046366516469618e-10
is O 0 2.3947566152315858e-11
not O 0 1.1508685671124397e-10
limited O 0 9.266319267453582e-09
to O 0 1.6166272587270214e-07
Ashkenazim O 0 0.001606380334123969
. O 0 8.314381375384983e-06

The O 0 1.7333196922209027e-07
185delAG O 0 2.3231555132952053e-06
mutation O 0 4.945481180129718e-08
in O 0 4.559995936403993e-09
BRCA1 O 0 8.194129463845456e-08
is O 0 4.190619795618744e-10
detected O 0 3.3841283109126152e-09
in O 0 4.5901690781668947e-10
Ashkenazi O 0 4.794362666871166e-07
Jews O 0 2.679284172302232e-08
both O 0 1.9778328974595638e-10
in O 0 6.810965680337233e-10
familial B-Disease 1 0.9999312162399292
breast I-Disease 1 1.0
and I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 2.2481333871837705e-05
in O 0 3.0232904180138576e-08
the O 0 9.23297616139962e-09
general O 0 1.8515157407250626e-08
population O 0 6.246077544069806e-10
. O 0 1.1773778396673151e-08

All O 0 4.600358636253077e-07
tested O 0 3.886442527800682e-07
Ashkenazi O 0 9.082102678803494e-07
mutation O 0 4.424785871037784e-09
carriers O 0 1.7605249480467933e-09
share O 0 3.8614783592905155e-10
the O 0 4.0089503938744997e-10
same O 0 7.63496488254134e-10
allelic O 0 1.0686078866228854e-07
pattern O 0 9.033693793014663e-09
at O 0 9.198929973308623e-08
the O 0 1.9061877765125246e-07
BRCA1 O 0 2.1037260466982843e-06
locus O 0 3.786039542319486e-06
. O 0 1.5056800748425303e-06

Our O 0 2.3860934561525937e-07
previous O 0 2.6636007177671672e-08
study O 0 5.675028003082616e-09
showed O 0 7.795105672059321e-10
that O 0 1.052998226808155e-11
this O 0 1.3218652561430844e-10
Ashkenazi O 0 1.2636379551622667e-06
mutation O 0 6.6152070488101344e-09
also O 0 1.5180949552995315e-10
occurs O 0 4.3519708670114454e-11
in O 0 2.431703102767635e-11
Iraqi O 0 5.80536552163835e-09
Jews O 0 1.597434362565764e-08
with O 0 6.425836945878061e-11
a O 0 1.028426122040571e-09
similar O 0 1.7953235564860393e-09
allelic O 0 2.9625405773003877e-07
pattern O 0 1.1811209787992993e-07
. O 0 8.667137763040955e-07

We O 0 7.804693780144589e-08
extended O 0 2.9494957587417048e-08
our O 0 2.339891391756055e-09
analysis O 0 2.679017230278191e-09
to O 0 7.533417778482487e-10
other O 0 6.719301226532082e-10
non O 0 2.706507018501725e-07
- O 0 2.503983580481872e-07
Ashkenazi O 0 1.1403701591916615e-06
subsets O 0 4.721333723978205e-08
354 O 0 2.0482922025166772e-08
of O 0 1.3593181025228773e-09
Moroccan O 0 8.489755032314861e-07
origin O 0 1.1842989700028284e-08
, O 0 1.3980606672348017e-09
200 O 0 2.105358021253778e-08
Yemenites O 0 8.066243140092411e-07
and O 0 1.8514725308449442e-09
150 O 0 2.7230655064158782e-08
Iranian O 0 1.9707786691469664e-07
Jews O 0 1.7244310583919287e-06
. O 0 5.623429615297937e-07

Heteroduplex O 0 3.4304586733924225e-05
analysis O 0 5.1449099203182413e-08
complemented O 0 2.0405012790547516e-08
by O 0 2.496926831963009e-10
direct O 0 1.7412824515616876e-09
DNA O 0 7.406913749008481e-09
sequencing O 0 5.7105811634983183e-08
of O 0 2.5373243062176698e-08
abnormally O 0 1.6110757883325277e-07
migrating O 0 1.4641668322212809e-08
bands O 0 7.637215304612255e-08
were O 0 4.6847976165054206e-08
employed O 0 2.3320990294450894e-06
. O 0 1.7314623619313352e-06

Four O 0 1.0014124995905149e-07
of O 0 2.7162649018919183e-08
Moroccan O 0 1.4252422261051834e-05
origin O 0 6.191577472947074e-09
( O 0 1.6706884486961115e-10
1 O 0 1.5406441677967564e-09
. O 0 1.3946135912767943e-10
1 O 0 5.059648255922866e-09
% O 0 2.40310382704223e-10
) O 0 7.898458970201361e-11
and O 0 1.1494995927341378e-10
none O 0 2.0978572212726476e-09
of O 0 1.0646236114908447e-09
the O 0 3.3570179969188985e-09
Yemenites O 0 7.091549036886136e-07
or O 0 5.63440982759289e-09
Iranians O 0 5.2420126905872166e-08
was O 0 9.981588888763326e-09
a O 0 4.549707277590187e-10
carrier O 0 3.046501273473723e-09
of O 0 3.0043081356012635e-09
the O 0 4.9722168604660055e-09
185delAG O 0 1.4537587276208797e-06
mutation O 0 1.2947839422849938e-07
. O 0 2.712044135932956e-07

BRCA1 O 0 2.216125176346395e-05
allelic O 0 1.3424496501102112e-06
patterns O 0 1.1127327503857032e-08
were O 0 1.6765627774972813e-09
determined O 0 4.5686995853166934e-10
for O 0 1.7411685981905123e-10
four O 0 1.2068683552524107e-10
of O 0 8.997744216365788e-11
these O 0 8.526024504462715e-12
individuals O 0 1.999946649261508e-12
and O 0 1.5619401605437844e-11
for O 0 1.0313268988815238e-10
12 O 0 4.703337275202557e-09
additional O 0 2.0379420817562277e-08
non O 0 6.829170047240041e-07
- O 0 7.501692493860901e-07
Ashkenazi O 0 5.958713131803961e-07
185delAG O 0 7.066934415433934e-08
mutation O 0 1.503434488014932e-09
carriers O 0 3.0802731476597955e-09
who O 0 1.4999468334053745e-08
had O 0 2.8616343115572818e-05
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 1 0.9999927282333374

Six O 0 1.0811274933075765e-06
non O 0 9.492665412835777e-06
- O 0 5.559903911489528e-06
Ashkenazi O 0 4.119205641472945e-06
individuals O 0 3.401183779061512e-10
shared O 0 6.285468256983506e-10
the O 0 4.2204431616177374e-10
common O 0 2.409121346858001e-09
Ashkenazi O 0 1.1429026471887482e-06
haplotype O 0 1.2593835663210484e-07
, O 0 3.0270841389068437e-10
four O 0 5.407200243112698e-10
had O 0 7.806205126748011e-10
a O 0 1.9301012177397325e-10
closely O 0 5.930585189606319e-11
related O 0 2.5512977841479767e-10
pattern O 0 6.059150403636693e-10
, O 0 5.593159962957728e-11
and O 0 2.1053439547280561e-10
the O 0 7.045505068248303e-09
rest O 0 1.4527316238854837e-07
( O 0 2.5117738999824724e-09
n O 0 5.438407946201096e-09
= O 0 1.1415825618144027e-08
6 O 0 1.1936968746795174e-08
) O 0 1.0374059389306467e-09
displayed O 0 1.2293639883864671e-08
a O 0 9.66611324315636e-09
distinct O 0 2.1433598007547516e-08
BRCA1 O 0 1.8596757627165061e-06
allelic O 0 3.126651790807955e-06
pattern O 0 5.248751335784618e-07
. O 0 1.779322701622732e-06

We O 0 5.21200433922786e-08
conclude O 0 1.812274206258735e-07
that O 0 1.2485442679732728e-09
the O 0 7.587714456747108e-09
185delAG O 0 6.906784619786777e-06
BRCA1 O 0 1.4945355815143557e-06
mutation O 0 9.491058605703984e-09
occurs O 0 2.216563738111077e-10
in O 0 1.0875026573708979e-10
some O 0 2.752010286322104e-10
non O 0 5.506799993781897e-07
- O 0 1.2209210353830713e-06
Ashkenazi O 0 1.2561357607410173e-06
populations O 0 4.53335285977019e-10
at O 0 4.3036654101547e-11
rates O 0 1.5247228479786656e-10
comparable O 0 4.729575620032733e-10
with O 0 9.042332854702906e-12
that O 0 3.534297854379531e-10
of O 0 1.970902587800083e-07
Ashkenazim O 0 0.0006422988371923566
. O 0 2.077548060697154e-06

The O 0 2.59452264117499e-07
majority O 0 7.565719606361654e-09
of O 0 9.783599708157453e-09
Jewish O 0 1.1319497161821346e-07
185delAG O 0 1.9598871858761413e-07
mutation O 0 1.6656238610579521e-09
carriers O 0 1.5389055585401934e-09
have O 0 1.9861116917763155e-10
a O 0 5.328448793306961e-10
common O 0 2.0361770047827576e-09
allelic O 0 3.320891295288675e-08
pattern O 0 1.0733706146126565e-09
, O 0 1.8052771777465892e-10
supporting O 0 7.031526472189853e-10
the O 0 1.5938846908980508e-09
founder O 0 6.449704414990265e-08
effect O 0 3.128792336326569e-09
notion O 0 8.433668874374689e-09
, O 0 1.5157629318363064e-10
but O 0 4.347258664161302e-11
dating O 0 1.5842707146163093e-09
the O 0 9.174719317606161e-11
mutations O 0 1.1952676348681024e-10
origin O 0 7.571254734273225e-11
to O 0 6.268798674602394e-11
an O 0 3.254381833461828e-11
earlier O 0 3.1482699780482903e-10
date O 0 1.3565318646158175e-08
than O 0 1.1396674715058452e-09
currently O 0 1.5071612846639937e-09
estimated O 0 2.9976912063744976e-09
. O 0 6.486554582352255e-08

However O 0 5.6283123939238067e-08
, O 0 1.596970444772694e-09
the O 0 4.0884876040259144e-10
different O 0 5.993458507269622e-11
allelic O 0 3.480728594240645e-08
pattern O 0 3.66720587230418e-09
at O 0 1.4747612908649899e-08
the O 0 1.499494750589747e-08
BRCA1 O 0 4.055468707520049e-07
locus O 0 2.6228955007923105e-08
even O 0 7.297419890583967e-10
in O 0 2.337499360738349e-10
some O 0 6.22654289239577e-11
Jewish O 0 3.711976948039819e-09
mutation O 0 1.1224436935464155e-09
carriers O 0 1.3484774408212274e-09
, O 0 3.3407029920162756e-10
might O 0 3.0557192332025807e-09
suggest O 0 2.6866107116774174e-09
that O 0 4.795667335466547e-11
the O 0 8.384297145447306e-10
mutation O 0 1.1294641888426327e-09
arose O 0 2.8024924603187173e-09
independently O 0 4.59190507839935e-09
. O 0 9.875729567454528e-09
. O 0 2.4371632889597095e-07

Crystal O 0 2.202977157139685e-06
structure O 0 2.950326631889766e-07
of O 0 3.719467258633813e-06
the O 0 5.431192676041974e-06
hemochromatosis B-Disease 1 1.0
protein O 0 9.728241820994299e-07
HFE O 0 9.511831012787297e-05
and O 0 1.1167724522920253e-08
characterization O 0 3.4486124178556565e-08
of O 0 1.6234880106935634e-08
its O 0 6.813941078043229e-10
interaction O 0 1.1327023763385569e-09
with O 0 3.1819255563725335e-10
transferrin O 0 3.8860494555592595e-07
receptor O 0 8.09139280022464e-08
. O 0 4.270449380783248e-07

HFE O 1 0.5295312404632568
is O 0 8.737374912470841e-08
an O 0 3.0159630348691735e-09
MHC O 0 8.961521302808251e-07
- O 0 1.9688409338414203e-06
related O 0 8.746229696043883e-08
protein O 0 8.388856276297929e-10
that O 0 8.567643122736612e-12
is O 0 5.060905253900794e-12
mutated O 0 1.5766221661550617e-10
in O 0 2.3285906536330003e-10
the O 0 1.9399870154757082e-08
iron B-Disease 1 1.0
- I-Disease 1 1.0
overload I-Disease 1 1.0
disease I-Disease 1 1.0
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 0 0.0012592598795890808

HFE O 0 0.00017242549802176654
binds O 0 7.005241542401563e-08
to O 0 1.1738640282032975e-08
transferrin O 0 2.0592790406226413e-07
receptor O 0 2.0613590834273054e-08
( O 0 1.0509753067822203e-08
TfR O 0 7.69447251514066e-06
) O 0 2.126244957878498e-09
and O 0 4.359100858053466e-10
reduces O 0 3.128440173583158e-09
its O 0 1.7947131281115247e-10
affinity O 0 4.841709255742899e-09
for O 0 2.564217504996691e-09
iron O 0 1.5714772416686174e-06
- O 0 1.945844360307092e-06
loaded O 0 1.6720214262022637e-06
transferrin O 0 2.5952276700991206e-06
, O 0 1.274147365393219e-07
implicating O 0 6.576244231837336e-06
HFE O 0 0.0021357210353016853
in O 0 1.0302819646312855e-06
iron O 1 0.9999611377716064
metabolism O 1 0.9998266100883484
. O 0 9.94360561890062e-06

The O 0 1.4771126188861672e-06
2 O 0 1.8206172171630897e-05
. O 0 5.470074484037468e-06

6 O 0 6.654047410847852e-06
A O 0 6.468602578024729e-07
crystal O 0 2.430151937460323e-07
structure O 0 4.3736883981182473e-07
of O 0 3.656463377410546e-06
HFE O 1 0.999995231628418
reveals O 0 7.479263075538256e-08
the O 0 2.1669328553741707e-09
locations O 0 1.1979940595097105e-08
of O 0 6.986813616549625e-08
hemochromatosis B-Disease 1 1.0
mutations O 0 7.571959059760047e-08
and O 0 5.975008043890284e-09
a O 0 7.537520474443227e-08
patch O 0 0.0002566442999523133
of O 0 1.013972223518067e-06
histidines O 0 4.2983415369235445e-06
that O 0 9.506122278235551e-11
could O 0 2.7610114194942526e-10
be O 0 2.728157422193789e-10
involved O 0 7.728486184355177e-10
in O 0 1.8028452064555722e-09
pH O 0 1.9378205706743756e-07
- O 0 1.4612686527470942e-07
dependent O 0 1.4161939532186807e-07
interactions O 0 3.9136825336072434e-08
. O 0 1.9448539489985706e-07

We O 0 6.819068971708475e-07
also O 0 5.245343359661092e-08
demonstrate O 0 1.039494463839219e-07
that O 0 5.365410338242782e-09
soluble O 0 8.182171882253897e-07
TfR O 0 5.75646254219464e-06
and O 0 9.736539574589642e-09
HFE O 0 2.0607221813406795e-05
bind O 0 5.228891453157303e-08
tightly O 0 1.2235629753831745e-07
at O 0 3.1758659702063596e-08
the O 0 6.433336530164979e-09
basic O 0 1.5730634572719282e-07
pH O 0 1.5878958592452364e-08
of O 0 4.353932769873836e-10
the O 0 2.3203086674250528e-10
cell O 0 1.0324241905834697e-08
surface O 0 2.49520915041046e-09
, O 0 3.971134254765474e-10
but O 0 2.6619118020931865e-10
not O 0 1.447969411039196e-09
at O 0 2.2949851796738585e-08
the O 0 3.278497828773652e-08
acidic O 0 2.5286843197136477e-07
pH O 0 4.7219506882356654e-07
of O 0 8.624766678622109e-08
intracellular O 0 2.1284995455062017e-06
vesicles O 0 5.397298082243651e-05
. O 0 4.69610677100718e-06

TfR O 0 0.0007269653142429888
HFE O 0 0.0003092279948759824
stoichiometry O 0 2.070380560326157e-06
( O 0 3.167076556565007e-08
2 O 0 6.766958904336207e-08
1 O 0 1.4128835346127744e-07
) O 0 1.0431724817294707e-08
differs O 0 2.115170971705993e-08
from O 0 5.2054343058216546e-09
TfR O 0 4.436403742147377e-07
transferrin O 0 1.5091382365994832e-08
stoichiometry O 0 4.05033295791668e-09
( O 0 3.1093372321322477e-10
2 O 0 4.165551015233859e-09
2 O 0 1.6239679823115694e-08
) O 0 1.5190950719556895e-09
, O 0 5.356164400893704e-10
implying O 0 5.5906266283045625e-09
a O 0 1.3667736387112939e-10
different O 0 1.5834654767954426e-11
mode O 0 3.4844866991790013e-09
of O 0 4.308817469489412e-10
binding O 0 4.1540526574124215e-10
for O 0 2.254607833762634e-09
HFE O 0 3.646052209660411e-05
and O 0 5.3315851289426064e-08
transferrin O 0 1.1277102203166578e-06
to O 0 2.1279703332766076e-08
TfR O 0 1.9828717086056713e-06
, O 0 9.723580829401612e-10
consistent O 0 2.268012888606563e-09
with O 0 3.1188628069056534e-11
our O 0 4.070313863735464e-09
demonstration O 0 2.3616115285562955e-08
that O 0 7.453124228895547e-10
HFE O 0 8.585786417825148e-06
, O 0 1.226808432619464e-08
transferrin O 0 2.6186700097241555e-07
, O 0 9.484706353646288e-09
and O 0 5.906951816569972e-09
TfR O 0 2.5551928501954535e-06
form O 0 4.984447077305276e-09
a O 0 7.527058087930527e-09
ternary O 0 2.917142012393015e-07
complex O 0 2.480174998709117e-06
. O 0 2.133232555934228e-06

Identification O 0 2.0548916381812887e-06
of O 0 1.3744588045483397e-07
three O 0 1.828618256816128e-09
novel O 0 1.470614519050173e-09
mutations O 0 2.3695953532687497e-10
and O 0 3.624650926625783e-11
a O 0 1.1658213283638474e-10
high O 0 1.335026422744079e-09
frequency O 0 1.0187004129136312e-08
of O 0 2.4884936333791075e-09
the O 0 4.951301590949697e-09
Arg778Leu O 0 3.5201410355512053e-06
mutation O 0 1.312282171817003e-09
in O 0 2.762823581026197e-10
Korean O 0 4.2008355194411706e-07
patients O 0 1.53582746520442e-08
with O 0 5.061499552816429e-10
Wilson B-Disease 0 6.372237749019405e-06
disease I-Disease 0 3.1425972792931134e-06
. O 0 4.790153411704523e-07

Four O 0 6.829965570886998e-08
mutations O 0 3.910725965283746e-09
- O 0 4.576082446305918e-08
- O 0 3.244405775149062e-07
R778L O 0 6.4393566390208434e-06
, O 0 1.2971470564338006e-09
A874V O 0 2.35645572388421e-07
, O 0 5.432982952413568e-10
L1083F O 0 1.3092682138449163e-07
, O 0 9.361600383783752e-11
and O 0 1.691400144943067e-11
2304delC O 0 2.824763312148093e-09
- O 0 2.8395323870000766e-09
- O 0 1.6708940009380058e-08
in O 0 1.354865997171828e-09
the O 0 2.4262247766415612e-09
copper O 0 2.14473445225849e-07
- O 0 9.433848902062891e-08
transporting O 0 1.0015347839953392e-07
enzyme O 0 1.9312004440052988e-08
, O 0 2.583303793102232e-09
P O 0 3.947908737700345e-07
- O 0 4.045425328058627e-07
type O 0 1.1609561170189409e-06
ATPase O 0 5.746382521465421e-05
( O 0 2.2961497592177693e-08
ATP7B O 0 0.00016538209456484765
) O 0 5.961913740470948e-10
, O 0 1.2802259252708836e-10
were O 0 2.5318494523141055e-10
identified O 0 3.9008307695098665e-10
in O 0 2.0736209971339292e-10
Korean O 0 4.667953135140124e-07
Patients O 0 3.5456245939258224e-08
with O 0 4.587656921017924e-10
Wilson B-Disease 0 6.965809916437138e-06
disease I-Disease 0 5.491761385201244e-06
. O 0 5.451329343486577e-07

Arg778Leu O 0 8.457054354948923e-05
, O 0 1.3335077930776151e-08
the O 0 2.659401143745299e-09
most O 0 6.635308968938602e-10
frequently O 0 1.9412287055597943e-10
reported O 0 3.0633141856473145e-11
mutation O 0 4.965179656313268e-11
of O 0 1.3757525674229498e-10
this O 0 4.7620879461973686e-11
enzyme O 0 6.968374766103125e-10
, O 0 1.355945911107881e-10
was O 0 2.2089090556676183e-09
found O 0 1.1739323402260027e-10
in O 0 1.004883953825697e-10
six O 0 4.2111800158117774e-10
of O 0 3.1987751336615133e-10
eight O 0 4.1194381239506583e-10
unrelated O 0 1.1240248731780866e-09
patients O 0 5.604695596517217e-10
studied O 0 1.3056038472569753e-09
, O 0 1.5825060706298189e-10
an O 0 1.4388257252306857e-10
allele O 0 2.9806783707897466e-09
frequency O 0 4.7068485997669995e-08
of O 0 1.0757408830386339e-07
37 O 0 2.760609277174808e-06
. O 0 3.204224640285247e-06

5 O 0 1.9477417936286656e-06
% O 0 2.1563174357197568e-08
, O 0 1.0620639923075714e-09
which O 0 5.461677290985456e-11
is O 0 9.027685717033496e-12
considerably O 0 2.0558872659837135e-10
higher O 0 1.0840303099612925e-09
than O 0 7.633286364105984e-11
those O 0 1.2986886566146438e-10
in O 0 5.352916443435163e-10
other O 0 2.0267614253555166e-09
Asian O 0 2.2054922510506003e-07
populations O 0 2.5130498571002136e-08
. O 0 1.22746072861446e-07

The O 0 1.2574825802857958e-07
novel O 0 4.7781810508240596e-08
single O 0 6.170816302386584e-09
nucleotide O 0 1.0258273874796942e-07
deletion O 0 1.1337452576754004e-07
, O 0 9.417246982224015e-10
2304delC O 0 4.7874131325897906e-08
, O 0 4.360231897759803e-10
was O 0 2.00652161552739e-09
found O 0 1.401316979121603e-10
in O 0 2.5642601930719877e-10
one O 0 2.9590283556757413e-09
patient O 0 2.0520819532521273e-07
. O 0 3.7008734921073483e-07

Since O 0 5.31100177170174e-08
a O 0 3.738408693720885e-09
mutation O 0 1.571171415193362e-09
at O 0 2.9146867142060273e-09
cDNA O 0 9.015433732884048e-08
nucleotide O 0 4.035376264255319e-07
2302 O 0 3.762108462979086e-05
( O 0 1.066729993226545e-08
2302insC O 0 1.6560869653403643e-07
) O 0 9.266561407095253e-10
had O 0 1.1070206973329277e-09
been O 0 3.327215170045861e-10
previously O 0 4.163611122542932e-10
described O 0 1.0781138481963382e-10
, O 0 1.0073109013575277e-11
this O 0 4.714889936807687e-12
region O 0 4.313627788299357e-10
of O 0 5.944449932293594e-10
the O 0 5.496605948174249e-10
ATP7B O 0 1.1107818863820285e-05
gene O 0 1.5992015489629807e-09
may O 0 1.1699741175874578e-09
be O 0 1.3007120935881744e-09
susceptible O 0 2.5873735154391397e-08
to O 0 1.1909859765069086e-08
gene O 0 4.7566757643835444e-08
rearrangements O 0 2.89830713882111e-05
causing O 0 1.2458645869628526e-05
Wilson B-Disease 0 8.527108730049804e-05
disease I-Disease 0 4.712162535724929e-06
. O 0 4.074331911851914e-07

Disruption O 0 9.239862265530974e-06
of O 0 1.4939983827844117e-07
splicing O 0 1.745980000578129e-07
regulated O 0 2.8316806677253226e-08
by O 0 8.939041729050246e-10
a O 0 2.2952639788798024e-09
CUG O 0 2.0321913325460628e-06
- O 0 2.5149487825615324e-08
binding O 0 5.208910192067151e-09
protein O 0 3.320238661785879e-08
in O 0 1.1581214209854807e-07
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 0.00023426173720508814

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.011499960906803608
DM B-Disease 1 1.0
) O 0 3.7768543847960245e-08
is O 0 6.345285963327285e-10
caused O 0 8.239555704392387e-10
by O 0 1.0692099289277834e-10
a O 0 1.0510790016127203e-09
CTG O 0 1.1132978272598848e-07
expansion O 0 3.3857681103199866e-09
in O 0 4.11571554614909e-10
the O 0 5.629208210677916e-10
3 O 0 1.0686604490217633e-08
untranslated O 0 2.932001279987162e-06
region O 0 1.8031075299518307e-08
of O 0 1.4566293060624957e-08
the O 0 8.31988273830575e-08
DM B-Disease 1 1.0
gene O 0 2.297472065038164e-06
. O 0 4.1174930629495066e-06

One O 0 1.7576470057178994e-08
model O 0 2.2678756650407195e-08
of O 0 2.585871925475658e-07
DM B-Disease 1 1.0
pathogenesis O 1 1.0
suggests O 0 4.279010212826506e-08
that O 0 2.5870784681192305e-11
RNAs O 0 2.4146371568889435e-09
from O 0 2.696632028786894e-09
the O 0 1.8436527859932994e-09
expanded O 0 6.173099809103633e-09
allele O 0 1.204018107436866e-09
create O 0 1.1375472092067795e-10
a O 0 4.650969609443223e-10
gain O 0 7.933298462603489e-09
- O 0 1.2276042404835152e-08
of O 0 5.0046047306295804e-09
- O 0 7.477005681266746e-09
function O 0 4.3719908249251205e-10
mutation O 0 8.066571716147664e-11
by O 0 2.6105837977463686e-11
the O 0 2.443406310614904e-10
inappropriate O 0 9.43596423219617e-10
binding O 0 3.072116172564421e-10
of O 0 3.2941034344702302e-09
proteins O 0 2.1573436093103027e-10
to O 0 2.0699311154004363e-09
the O 0 4.114197338367376e-08
CUG O 1 0.8977805376052856
repeats O 0 1.3152443898434285e-06
. O 0 2.666887894520187e-06

Data O 0 5.453851485981431e-07
presented O 0 6.675835351188653e-08
here O 0 1.2076388777870761e-08
indicate O 0 6.184838419187599e-09
that O 0 1.5624443405748423e-10
the O 0 4.794920016593096e-10
conserved O 0 3.0395013173034613e-09
heterogeneous O 0 1.679556227429657e-08
nuclear O 0 4.839893108510296e-07
ribonucleoprotein O 0 1.3772893225905136e-06
, O 0 2.2900601415187793e-09
CUG O 0 4.030329989745951e-07
- O 0 3.210145260723607e-09
binding O 0 5.332708163940936e-10
protein O 0 8.017980723806772e-10
( O 0 5.041468353894629e-10
CUG O 0 5.020012849854538e-06
- O 0 3.1418940693583863e-07
BP O 0 1.953251512532006e-06
) O 0 1.6257274415565348e-09
, O 0 7.445579708331707e-10
may O 0 2.9990179228889247e-09
mediate O 0 3.941685733366285e-08
the O 0 2.8205855429064286e-09
trans O 0 7.12874879127412e-08
- O 0 1.2781332259237388e-07
dominant O 0 8.460672162868832e-09
effect O 0 2.30867303052662e-09
of O 0 2.632025264404092e-09
the O 0 2.753812511357978e-09
RNA O 0 4.1732596400834154e-07
. O 0 4.084322426933795e-07

CUG O 0 0.001959798391908407
- O 0 2.3380234779324383e-05
BP O 0 4.922537300444674e-06
was O 0 3.628384703802112e-08
found O 0 5.218922516370128e-10
to O 0 6.340286629047398e-11
bind O 0 1.637074920068926e-10
to O 0 4.163650535460306e-10
the O 0 2.9667706069602673e-09
human O 0 5.013846049450876e-08
cardiac O 1 1.0
troponin O 0 0.22962358593940735
T O 0 4.698704742622795e-06
( O 0 1.516149161773228e-08
cTNT O 0 7.762773179820215e-07
) O 0 9.871242712122807e-10
pre O 0 2.928659910139686e-07
- O 0 7.926208667186074e-08
messenger O 0 5.026657845519367e-08
RNA O 0 2.1776942915607833e-08
and O 0 1.794296600188261e-09
regulate O 0 3.951145632896669e-09
its O 0 8.761932845935405e-10
alternative O 0 9.69732596445283e-08
splicing O 0 1.1856515129693435e-06
. O 0 1.1302997791062808e-06

Splicing O 0 2.00239537662128e-06
of O 0 3.71920094721645e-07
cTNT O 0 3.519897654769011e-05
was O 0 2.3000954740837187e-07
disrupted O 0 1.5318128134822473e-06
in O 0 7.238814703214302e-08
DM B-Disease 1 1.0
striated O 0 0.0677933469414711
muscle O 0 1.8512776023271726e-06
and O 0 3.143711291286877e-09
in O 0 7.617146358107618e-10
normal O 0 1.1171772840157246e-08
cells O 0 1.0935482741558644e-08
expressing O 0 9.18177867070824e-10
transcripts O 0 1.518015579904386e-08
that O 0 4.345992454801717e-10
contain O 0 6.366943949842607e-08
CUG O 0 9.474551916355267e-05
repeats O 0 1.238474169440451e-06
. O 0 2.629626351335901e-06

Altered O 0 1.8112996258423664e-06
expression O 0 1.3682804933523585e-07
of O 0 1.4747977949980395e-08
genes O 0 3.612334875668921e-09
regulated O 0 1.631219781472737e-08
posttranscriptionally O 0 3.6546188653119316e-07
by O 0 3.9004603991088516e-09
CUG O 0 0.0001001497294055298
- O 0 1.2075361155439168e-06
BP O 0 4.006012090940203e-07
therefore O 0 2.7016977544036536e-09
may O 0 1.0339371581125079e-09
contribute O 0 1.1937265398387353e-08
to O 0 7.01933942082178e-08
DM B-Disease 1 1.0
pathogenesis O 1 1.0
. O 0 9.211762517224997e-07
. O 0 1.6407359453296522e-06

Identification O 0 1.3582869087258587e-06
of O 0 6.751282199957132e-08
a O 0 3.4544302973671392e-09
novel O 0 4.410116716258017e-09
nonsense O 0 2.119071851325316e-08
mutation O 0 5.682629367065317e-10
and O 0 1.2104163504833565e-10
a O 0 4.5098777490260034e-10
missense O 0 1.1309047032170838e-08
substitution O 0 1.8198370810296183e-08
in O 0 4.815727816520621e-09
the O 0 9.823615698678623e-09
vasopressin O 0 1.3530171827369486e-06
- O 0 2.9758351161035534e-07
neurophysin O 0 3.823025963356486e-06
II O 1 0.9979197382926941
gene O 0 5.840215866470544e-09
in O 0 9.403087197767945e-10
two O 0 1.5288005306146601e-09
Spanish O 0 1.6668869307068235e-07
kindreds O 0 2.4264450075861532e-06
with O 0 9.30737797943948e-09
familial B-Disease 1 0.9999058246612549
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 1.0
. O 0 6.494950866908766e-06

Familial B-Disease 1 0.9999998807907104
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 1.0
( O 0 3.9668088902544696e-07
FNDI B-Disease 1 1.0
) O 0 2.044943059331672e-08
is O 0 1.5277744624953016e-09
an O 0 2.5033466410917526e-09
autosomal B-Disease 1 0.9999990463256836
dominant I-Disease 1 0.9999990463256836
disease I-Disease 1 0.9999992847442627
caused O 0 7.085709086140923e-08
by O 0 5.15490428121268e-10
deficiency O 0 1.1958519507970777e-07
in O 0 1.2890431833056937e-08
the O 0 1.749241675952362e-07
antidiuretic O 0 1.0534102329984307e-05
hormone O 0 1.736655406148202e-07
arginine O 0 1.0880539491608943e-07
vasopressin O 0 4.6315517465700395e-07
( O 0 8.409092977501587e-09
AVP O 0 1.7394032738593523e-06
) O 0 3.0328517475197714e-10
encoded O 0 4.383831353482748e-10
by O 0 2.6045768319882256e-10
the O 0 1.6304328553928826e-08
AVP O 0 0.0005605638143606484
- O 0 5.584444352280116e-06
neurophysin O 0 0.009417476132512093
II O 1 1.0
( O 0 5.304249270920991e-07
AVP O 0 0.0003723305417224765
- O 0 1.6527152411072166e-06
NPII O 0 3.632080552051775e-05
) O 0 3.5247402774274406e-09
gene O 0 3.2295457419451168e-09
on O 0 4.662049235548693e-08
chromosome O 0 2.168450919270981e-06
20p13 O 0 0.00013590538583230227
. O 0 3.248249413445592e-06

In O 0 7.0403607388414e-09
this O 0 3.4884214961117266e-10
study O 0 1.0053080590211039e-09
, O 0 7.266138385420007e-11
we O 0 1.0751588508384202e-10
analyzed O 0 4.738894832101437e-10
two O 0 5.219566792669106e-11
families O 0 1.5523063390254777e-10
with O 0 1.2201772925379828e-10
FNDI B-Disease 1 1.0
using O 0 1.2314713693228896e-08
direct O 0 7.694131554103478e-09
automated O 0 9.54097600924797e-08
fluorescent O 0 2.7128217894301088e-08
, O 0 2.2527850696008045e-09
solid O 0 9.540790379958253e-09
phase O 0 2.1606895828085726e-08
, O 0 9.892032748481938e-10
single O 0 2.7297673010906465e-09
- O 0 1.0014885809539464e-08
stranded O 0 5.125868440813974e-08
DNA O 0 2.1572541530900935e-09
sequencing O 0 7.424311831982777e-09
of O 0 2.352485140022509e-08
PCR O 0 1.0246212696074508e-05
- O 0 6.540379399666563e-05
amplified O 0 0.0001594759669387713
AVP O 0 0.0007938410271890461
- O 0 1.2015731044812128e-05
NPII O 0 0.00017601523722987622
DNA O 0 2.914952574428753e-06
. O 0 1.0410149116069078e-06

In O 0 1.4289461169880724e-08
one O 0 8.60827464865821e-10
of O 0 5.963710636436304e-10
the O 0 1.801160193215523e-10
families O 0 3.595846884141274e-11
, O 0 1.7249705136501703e-11
affected O 0 2.4095786130273744e-11
individuals O 0 4.094726727826847e-12
presented O 0 2.3825660888654454e-10
a O 0 5.207596576184415e-10
novel O 0 3.5237723849945723e-09
nonsense O 0 9.590452876295785e-09
mutation O 0 2.9007649060552865e-10
in O 0 7.514829036825432e-11
exon O 0 1.0268037087257653e-08
3 O 0 2.2217119255429907e-09
of O 0 1.0046908860417147e-09
the O 0 3.0959038110900394e-10
gene O 0 9.412196716462873e-11
, O 0 3.003136281320984e-11
consisting O 0 1.404195926202334e-10
in O 0 1.089188184089096e-10
a O 0 8.447928467880672e-10
G O 0 1.1625986928720522e-07
to O 0 2.273566579447106e-08
T O 0 9.1909299726467e-07
transition O 0 5.420122306531994e-07
at O 0 9.433848902062891e-08
nucleotide O 0 1.3937088283455523e-07
2101 O 0 8.801627586763061e-07
, O 0 1.2088225975759315e-09
which O 0 2.2602978516639283e-11
produces O 0 1.3102375955031942e-11
a O 0 3.121624139734713e-11
stop O 0 8.832826137172844e-10
signal O 0 6.4262479781973525e-09
in O 0 5.765298460858048e-09
codon O 0 3.157607011416985e-07
82 O 0 6.079066565689573e-07
( O 0 1.2341618571554136e-07
Glu O 0 0.00017599694547243416
) O 0 1.2957869444107928e-07
of O 0 7.1715572858011e-07
NPII O 1 0.6871167421340942
. O 0 1.1310953595966566e-05

The O 0 2.3049284436638118e-07
premature O 0 7.211527872641454e-07
termination O 0 1.8069398777242895e-07
eliminates O 0 9.593346561587168e-08
part O 0 3.1849207715595185e-09
of O 0 1.9259035255458912e-08
the O 0 1.604053601056421e-08
C O 0 1.3161114793547313e-06
- O 0 2.2521161824329283e-08
terminal O 0 1.1022705592722559e-07
domain O 0 4.065309422429664e-09
of O 0 1.7840757760012593e-09
NPII O 0 4.464672656467883e-06
, O 0 3.55916573990811e-10
including O 0 2.1681927087069397e-10
a O 0 1.6809517666693807e-10
cysteine O 0 2.3604471155458384e-10
residue O 0 6.47515552287814e-09
in O 0 6.407542829656165e-10
position O 0 1.6616327869201086e-08
85 O 0 5.1289390512465616e-08
, O 0 1.6152765236476796e-10
which O 0 6.327562172142587e-12
could O 0 1.7148209935369252e-11
be O 0 1.5647370552041018e-11
involved O 0 4.131309877530853e-11
in O 0 1.6745166364628972e-10
the O 0 2.902996953935144e-09
correct O 0 1.7536044083499291e-07
folding O 0 5.020794446863874e-07
of O 0 1.4225356892438867e-07
the O 0 4.3135378291481175e-07
prohormone O 0 0.0019803207833319902
. O 0 3.0339915610966273e-06

In O 0 7.19704251750386e-09
the O 0 3.3465590298931147e-09
second O 0 2.86132433302555e-08
family O 0 4.4170847535163205e-10
, O 0 6.103129807089047e-11
a O 0 7.302874277526072e-11
G279A O 0 6.9861316731589795e-09
substitution O 0 5.7835158884245175e-09
at O 0 1.3771788154315345e-09
position O 0 1.3211223226505808e-09
- O 0 5.577101003240159e-09
1 O 0 1.0786970428000586e-08
of O 0 3.871509779429516e-09
the O 0 7.030883097947083e-10
signal O 0 1.894801471280516e-08
peptide O 0 4.220766847140567e-09
was O 0 2.2650774589294542e-09
observed O 0 5.472785558069404e-10
in O 0 2.015711486613725e-10
all O 0 5.756812804236233e-10
affected O 0 3.316471319791958e-09
individuals O 0 1.891990786262454e-09
. O 0 2.7003605396203056e-07

This O 0 7.912493060757697e-08
missense O 0 3.685344836412696e-06
mutation O 0 6.652764028558522e-08
, O 0 2.732460480103782e-09
which O 0 8.402900042447925e-10
replaces O 0 1.689441205598996e-06
Ala O 1 0.9751062393188477
with O 0 1.873544519526149e-08
Thr O 1 0.9999973773956299
, O 0 6.227261817315366e-09
is O 0 2.1566111396698062e-10
frequent O 0 1.1285876677646911e-09
among O 0 9.066070671970294e-10
FNDI B-Disease 1 1.0
patients O 0 3.7594585933220515e-07
and O 0 5.051835061387067e-10
is O 0 1.299679808219878e-10
thought O 0 5.839199679336105e-10
to O 0 1.514959407922234e-10
reduce O 0 1.5797867458644532e-09
the O 0 9.367284725669833e-10
efficiency O 0 1.2640988700240996e-08
of O 0 1.7068549240661923e-08
cleavage O 0 5.499691813071195e-09
by O 0 1.64822955284194e-09
signal O 0 3.5288999811200483e-07
peptidases O 0 6.19198590356973e-06
. O 0 2.422714544536575e-07
. O 0 1.1166966942255385e-06

Genetic O 0 2.431990878903889e-06
heterogeneity O 0 1.3656019746122183e-06
of O 0 3.473924721220101e-07
Saethre B-Disease 1 1.0
- I-Disease 1 1.0
Chotzen I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 5.733997165968674e-10
due O 0 3.9476275581762366e-09
to O 0 3.8785161748933206e-09
TWIST O 0 5.975630756438477e-06
and O 0 3.7782959338983346e-07
FGFR O 1 0.9999957084655762
mutations O 0 2.2559570425073616e-06
. O 0 1.616192321307608e-06

Thirty O 0 7.88823945185868e-06
- O 0 1.964199782378273e-06
two O 0 1.8561681081052939e-09
unrelated O 0 7.1353163377807505e-09
patients O 0 6.557229759174277e-10
with O 0 2.558741846875323e-12
features O 0 1.527150961244672e-09
of O 0 4.6601289938053014e-08
Saethre B-Disease 1 1.0
- I-Disease 1 1.0
Chotzen I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 1.5239386419452217e-09
a O 0 3.0718947385821593e-09
common O 0 2.755351715677534e-07
autosomal B-Disease 0 0.004622261971235275
dominant I-Disease 0 2.1168557395867538e-06
condition I-Disease 1 0.9960869550704956
of O 0 0.010190914385020733
craniosynostosis B-Disease 1 1.0
and O 0 2.2996705411060248e-06
limb B-Disease 1 1.0
anomalies I-Disease 1 0.9455774426460266
, O 0 1.3076075777718188e-09
were O 0 1.1214679185300724e-09
screened O 0 2.954832156731868e-09
for O 0 7.26949667129162e-10
mutations O 0 4.1258230165652776e-10
in O 0 3.674039072976143e-09
TWIST O 0 0.00033147953217849135
, O 0 5.809987513316628e-08
FGFR2 O 1 0.8910881876945496
, O 0 1.3352893901696916e-08
and O 0 3.0130664185890055e-08
FGFR3 O 1 0.9960512518882751
. O 0 2.2670251382805873e-06

Nine O 0 2.6489368565307814e-07
novel O 0 2.796246789671386e-08
and O 0 1.3607240889612626e-09
three O 0 6.17294326765716e-10
recurrent O 0 4.717688284472388e-08
TWIST O 0 1.1228007679164875e-06
mutations O 0 1.1768187313521139e-08
were O 0 5.993430196582494e-09
found O 0 1.2235362722989862e-09
in O 0 1.0363380154032598e-09
12 O 0 1.1293015234059567e-07
families O 0 1.0121927296324884e-08
. O 0 1.297477325579166e-07

Seven O 0 2.1850418363555946e-08
families O 0 4.883042303838181e-10
were O 0 4.653125662557045e-10
found O 0 1.7650428341120517e-10
to O 0 2.466434279035923e-10
have O 0 5.755363408077585e-10
the O 0 1.277775574237694e-08
FGFR3 O 1 0.8378803133964539
P250R O 0 8.079075996647589e-06
mutation O 0 5.4159761120331495e-09
, O 0 1.2096015855611597e-10
and O 0 1.0687164347933376e-10
one O 0 7.40976099922186e-11
individual O 0 3.106976134703565e-11
was O 0 1.1361276364141304e-09
found O 0 1.3186167435730312e-10
to O 0 3.242845991735521e-10
have O 0 1.231705737403388e-09
an O 0 1.5124081986783722e-09
FGFR2 O 0 6.830669735791162e-05
VV269 O 0 3.681332600535825e-05
- O 0 5.523322670342168e-06
270 O 0 3.3590295061003417e-06
deletion O 0 8.8498491095379e-06
. O 0 1.8618139847603743e-06

To O 0 3.294972472644986e-08
date O 0 4.339792525343e-08
, O 0 1.22338450481152e-09
our O 0 6.990072964896399e-10
detection O 0 3.6647254120225625e-08
rate O 0 1.2585936737252723e-09
for O 0 1.0416881940367162e-10
TWIST O 0 2.0303750147832034e-07
or O 0 4.26183213164677e-08
FGFR O 0 0.0004373166593722999
mutations O 0 9.391923683210734e-09
is O 0 1.1402496308265953e-10
68 O 0 9.279194301825555e-09
% O 0 2.481061189829603e-10
in O 0 1.3417215949385053e-10
our O 0 5.606259900758914e-09
Saethre B-Disease 0 0.07450313121080399
- I-Disease 1 0.9999955892562866
Chotzen I-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 0 1.0053760490791319e-07
, O 0 3.513788912612448e-11
including O 0 5.874665337524121e-11
our O 0 1.7064958335311076e-09
five O 0 3.71090802531171e-09
patients O 0 3.3026594792318065e-09
elsewhere O 0 1.894283840897515e-09
reported O 0 8.28134005814718e-10
with O 0 5.604867125974522e-10
TWIST O 0 0.0002962241414934397
mutations O 0 7.620562428201083e-06
. O 0 1.3669721738551743e-05

More O 0 1.1437663260949193e-08
than O 0 1.7170972421709507e-09
35 O 0 4.322961988378893e-09
different O 0 2.320760111862441e-10
TWIST O 0 2.3314687780384702e-07
mutations O 0 9.202840267619194e-09
are O 0 3.0185454136244516e-10
now O 0 4.480461002209779e-10
known O 0 1.4618610766348183e-09
in O 0 4.2092446195240996e-10
the O 0 3.958258609770837e-09
literature O 0 2.0150086754711083e-07
. O 0 1.5308823719806242e-07

The O 0 2.780457464268693e-07
most O 0 8.776455118209014e-09
common O 0 2.7872675278928227e-09
phenotypic O 0 5.662658786320662e-09
features O 0 7.254108425058803e-10
, O 0 2.3954328104425215e-11
present O 0 1.1921205342324548e-11
in O 0 1.835185128862271e-11
more O 0 4.259515483384657e-12
than O 0 4.1675634297744235e-12
a O 0 2.988041064577729e-11
third O 0 8.640054782738105e-10
of O 0 8.782077287605716e-10
our O 0 4.117036489503789e-09
patients O 0 3.8786791556333355e-09
with O 0 8.958050967677877e-11
TWIST O 0 1.71785393376922e-06
mutations O 0 4.791679231175294e-08
, O 0 4.779272089194819e-09
are O 0 6.518886763728915e-09
coronal B-Disease 0 1.954986510099843e-05
synostosis I-Disease 0 8.860413072397932e-05
, O 0 3.779441470896927e-08
brachycephaly B-Disease 0 3.071923856623471e-05
, O 0 4.5110006396953395e-08
low B-Disease 0 1.0827653568412643e-05
frontal I-Disease 1 0.8297357559204102
hairline I-Disease 1 0.9999985694885254
, O 0 1.4233648926165188e-07
facial B-Disease 1 0.9990525841712952
asymmetry I-Disease 1 0.9999936819076538
, O 0 6.792043905079481e-07
ptosis B-Disease 1 0.9999991655349731
, O 0 2.4708705836928857e-07
hypertelorism B-Disease 0 0.012583291158080101
, O 0 2.317988645472724e-08
broad B-Disease 0 3.5849845403390646e-07
great I-Disease 0 5.683875860995613e-05
toes I-Disease 0 0.00013957724149804562
, O 0 2.0150599411294934e-08
and O 0 4.5260225789434116e-08
clinodactyly B-Disease 0 0.004796280059963465
. O 0 2.0786676486750366e-06

Significant O 0 1.8654468476597685e-06
intra O 0 1.5572204574709758e-05
- O 0 3.5417631352174794e-06
and O 0 3.049142094369017e-08
interfamilial O 0 1.3143268006388098e-05
phenotypic O 0 3.6225344501872314e-08
variability O 0 3.2985298936694107e-09
is O 0 1.2709435934232793e-11
present O 0 9.435127158730072e-12
for O 0 1.5101934980332743e-10
either O 0 7.441976812572193e-09
TWIST O 0 6.39826930637355e-06
mutations O 0 2.6591496293804084e-07
or O 0 2.9874021834075393e-07
FGFR O 0 0.04258302226662636
mutations O 0 9.793458275453304e-07
. O 0 1.3894967878513853e-06

The O 0 1.3841822976701224e-07
overlap O 0 1.2097782331466078e-08
in O 0 1.0622017709849274e-09
clinical O 0 5.51113732427666e-09
features O 0 5.847971551453668e-10
and O 0 6.490233350753272e-11
the O 0 2.0623794338980872e-10
presence O 0 1.843778602017565e-10
, O 0 2.919524691447073e-11
in O 0 1.9169730039458877e-11
the O 0 5.2298311514764606e-11
same O 0 3.4014159544515365e-11
genes O 0 1.2335718557743292e-10
, O 0 4.952883589370849e-11
of O 0 4.641071138511421e-10
mutations O 0 2.3141255578451592e-10
for O 0 1.5842456513315284e-10
more O 0 5.384514015216446e-11
than O 0 1.5508502815286818e-10
one O 0 5.973728733899009e-10
craniosynostotic B-Disease 0 2.6008967779489467e-07
condition I-Disease 0 6.753020187488801e-08
- O 0 3.868145626029218e-08
such O 0 3.6930578595217867e-09
as O 0 7.604927354520896e-09
Saethre B-Disease 0 7.472441666322993e-06
- I-Disease 0 3.2049533160716237e-07
Chotzen I-Disease 0 1.1702663869073149e-05
, I-Disease 0 5.411515235920206e-09
Crouzon I-Disease 0 7.54013453843072e-05
, I-Disease 0 1.2323478237874497e-08
and I-Disease 0 1.682862205143465e-08
Pfeiffer I-Disease 0 2.2127102056401782e-05
syndromes I-Disease 0 0.026181207969784737
- O 0 2.2109645669843303e-06
support O 0 8.436021659008475e-08
the O 0 1.0982555309624331e-08
hypothesis O 0 7.186534922709598e-09
that O 0 1.680883730814653e-11
TWIST O 0 3.617204313854927e-08
and O 0 2.607113191999133e-09
FGFRs O 0 2.583549758128356e-06
are O 0 9.175139120687348e-11
components O 0 3.900705980441899e-09
of O 0 6.304225141917641e-09
the O 0 1.2105415558849586e-09
same O 0 2.020060646534816e-10
molecular O 0 8.756686487032539e-10
pathway O 0 3.779762058897518e-10
involved O 0 2.959544415093163e-11
in O 0 5.534063485246321e-11
the O 0 2.2021531265181693e-09
modulation O 0 0.3119069039821625
of O 0 0.02298925444483757
craniofacial O 1 1.0
and O 0 5.665364005835727e-05
limb O 1 0.999953031539917
development O 0 1.10345268922174e-07
in O 0 3.283859184577409e-09
humans O 0 1.960571704984204e-09
. O 0 9.558198676984375e-10
. O 0 2.6403579767020346e-08

Mutation O 0 1.9752511093429348e-07
analysis O 0 2.8522409323272768e-08
of O 0 1.0955444906812772e-07
UBE3A O 1 1.0
in O 1 0.5711840391159058
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 0 0.054951202124357224
. O 0 3.0439244369517837e-07

Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 1.58375701175828e-06
AS B-Disease 1 1.0
) O 0 1.8415160507601058e-09
is O 0 6.633685267765088e-11
caused O 0 3.971649675804656e-10
by O 0 1.31646568646282e-10
chromosome O 0 1.0380045978308772e-07
15q11 O 0 6.099197889852803e-06
- O 0 4.383770374261076e-06
q13 O 0 1.6031510313041508e-05
deletions O 0 1.8931042689018795e-07
of O 0 5.838356020859692e-09
maternal O 0 7.060440765371823e-08
origin O 0 2.381940200635313e-09
, O 0 1.4055999419948506e-10
by O 0 3.899565670373306e-10
paternal O 0 0.0004867583338636905
uniparental B-Disease 1 1.0
disomy I-Disease 1 1.0
( O 0 2.0684858554886887e-06
UPD B-Disease 1 1.0
) O 0 1.1341773742401529e-08
15 O 0 2.050215286431012e-08
, O 0 7.459965423173287e-10
by O 0 6.090039583739326e-10
imprinting O 0 4.448346226126887e-05
defects O 0 1.7349073459627107e-05
, O 0 1.8372638965757915e-09
and O 0 4.755500992992268e-10
by O 0 3.5266617404161593e-10
mutations O 0 9.152403834811196e-10
in O 0 2.633692375297869e-09
the O 0 8.950855345801756e-08
UBE3A O 0 0.00019664540013764054
gene O 0 3.7770638527945266e-07
. O 0 2.259921075165039e-06

UBE3A O 0 0.0010793930850923061
encodes O 0 5.928162067903031e-07
a O 0 4.9975199090113165e-08
ubiquitin O 0 8.409369911532849e-08
- O 0 7.97830992382842e-08
protein O 0 3.387712554925315e-09
ligase O 0 3.710060525463632e-08
and O 0 7.646905331171183e-09
shows O 0 3.35153664821064e-08
brain O 0 2.432213477732148e-06
- O 0 6.476528255916492e-07
specific O 0 1.985924882319523e-07
imprinting O 0 0.00016511708963662386
. O 0 6.251850209082477e-06

Here O 0 4.028704552183626e-07
we O 0 7.551306424602444e-08
describe O 0 2.1900534363794577e-07
UBE3A O 0 0.00011243463086429983
coding O 0 2.2564072423847392e-05
- O 0 3.968476903537521e-06
region O 0 2.0755804541749967e-07
mutations O 0 8.921434258013505e-09
detected O 0 2.5125310720852667e-09
by O 0 6.94562810044097e-11
SSCP O 0 7.304723226297938e-07
analysis O 0 5.209723208388084e-10
in O 0 2.0103284315009518e-10
13 O 0 9.761531138963164e-09
AS B-Disease 1 0.9873944520950317
individuals O 0 3.4614064392535226e-10
or O 0 4.058328784140031e-09
families O 0 8.433861609091764e-09
. O 0 1.561779185976775e-07

Two O 0 4.6479144089062174e-08
identical O 0 2.9756014541248987e-08
de O 0 6.726410788360226e-07
novo O 0 2.925053479430062e-07
5 O 0 3.2530158478039084e-07
- O 0 1.4418238833968644e-06
bp O 0 6.624015327361121e-07
duplications O 0 9.933595492839231e-07
in O 0 2.839403911991667e-08
exon O 0 2.648736881383229e-06
16 O 0 2.818401867443754e-07
were O 0 1.6788442280812887e-07
found O 0 1.487305496539193e-07
. O 0 5.649144441122189e-07

Among O 0 8.33969480140695e-08
the O 0 3.125869341147336e-09
other O 0 2.5417248861181463e-10
11 O 0 1.7592628465123994e-09
unique O 0 1.1411421807494548e-09
mutations O 0 1.4098322509425998e-09
, O 0 2.1470727973316173e-10
8 O 0 1.0728308019736232e-08
were O 0 8.900053138916064e-09
small O 0 3.724387687142894e-09
deletions O 0 2.254807327517483e-07
or O 0 1.515278924557606e-08
insertions O 0 2.6151485599257285e-07
predicted O 0 1.4710416884611277e-08
to O 0 6.642171812565323e-10
cause O 0 5.327048580028304e-09
frameshifts O 0 2.491946133886813e-07
, O 0 3.2950883688265264e-10
1 O 0 8.019025443672945e-09
was O 0 9.547707513490877e-09
a O 0 4.2876738270969383e-10
mutation O 0 3.1442853876129107e-10
to O 0 1.3871589987779487e-10
a O 0 4.3158990270519837e-10
stop O 0 2.3699491258355465e-09
codon O 0 5.026387306372726e-09
, O 0 3.394146075308413e-10
1 O 0 5.5813678123683985e-09
was O 0 7.447571448437884e-09
a O 0 7.768092280535654e-10
missense O 0 2.3788903291688257e-08
mutation O 0 4.28352159298484e-10
, O 0 3.962310340943631e-11
and O 0 6.635786364839191e-11
1 O 0 8.988558342082342e-09
was O 0 1.6799695856661856e-08
predicted O 0 5.005024394932889e-09
to O 0 2.574522262044354e-10
cause O 0 1.1817666845104213e-09
insertion O 0 1.0801979755115099e-08
of O 0 1.0049615362106579e-08
an O 0 8.541317653154579e-10
isoleucine O 0 1.2021104112136527e-06
in O 0 3.1189255622621204e-09
the O 0 1.1234146057859107e-08
hect O 0 7.045937877592223e-07
domain O 0 4.949507470541903e-09
of O 0 1.6320624851573484e-09
the O 0 1.922364711859359e-09
UBE3A O 0 4.196109330223408e-06
protein O 0 1.8367698473298333e-09
, O 0 2.2820621781161066e-10
which O 0 3.290646227727123e-11
functions O 0 9.217240304337793e-10
in O 0 1.7789278938806774e-09
E2 O 0 1.620118439404905e-07
binding O 0 6.229210036678978e-09
and O 0 9.757155972067721e-09
ubiquitin O 0 2.612326852613478e-07
transfer O 0 2.5425090370845282e-06
. O 0 5.0735266086121555e-06

Eight O 0 2.0256037203125743e-07
of O 0 7.641801857971586e-09
the O 0 5.699627991795353e-10
cases O 0 7.86535558905399e-11
were O 0 3.533617287665436e-10
familial O 0 8.916568816630388e-09
, O 0 5.747727849225726e-10
and O 0 7.321231954016127e-10
five O 0 5.856938045667448e-09
were O 0 2.8823361475360798e-08
sporadic O 0 5.938058507126698e-07
. O 0 6.584066909454123e-07

In O 0 6.56797496390027e-08
two O 0 2.5192778974059138e-09
familial O 0 3.336382192742349e-08
cases O 0 6.789059869838354e-10
and O 0 1.865224363850615e-10
one O 0 2.0978001280536063e-10
sporadic O 0 5.639527955736412e-09
case O 0 1.1330049121127672e-09
, O 0 1.32748512182701e-09
mosaicism O 0 0.0022680743131786585
for O 0 3.930761849346709e-08
UBE3A O 0 0.0001658387918723747
mutations O 0 4.035773937260956e-09
was O 0 2.9514077848347142e-09
detected O 0 5.774617450882147e-10
in O 0 2.0940494130372578e-11
the O 0 1.2505146917973775e-10
mother O 0 2.6045818279918365e-10
of O 0 6.175122080342987e-10
three O 0 2.622162487142532e-10
AS B-Disease 1 0.9999972581863403
sons O 0 1.1395793109159058e-07
, O 0 1.9345386403912812e-10
in O 0 6.026000531900166e-11
the O 0 2.04876685061528e-10
maternal O 0 6.331389101887908e-08
grandfather O 0 7.791188494365997e-08
of O 0 6.779205818929768e-08
two O 0 6.9337486863219056e-09
AS B-Disease 1 1.0
first O 0 1.8366925758073194e-07
cousins O 0 6.049905465488337e-08
, O 0 1.2703141316627864e-10
and O 0 4.715989404546761e-11
in O 0 9.164610043077559e-11
the O 0 3.606591414406779e-10
mother O 0 5.76101999438805e-10
of O 0 3.754429211966226e-09
an O 0 3.472226284273461e-09
AS B-Disease 1 1.0
daughter O 1 0.9997754693031311
. O 0 0.32658374309539795

The O 0 9.472235262819595e-08
frequencies O 0 3.653872582276563e-08
with O 0 1.2886559874747405e-10
which O 0 3.268864345873368e-11
we O 0 3.439609430611057e-10
detected O 0 1.6780088429868556e-09
mutations O 0 3.4626151945715833e-10
were O 0 1.3847646362918908e-09
5 O 0 1.3499320772325518e-08
( O 0 2.212704242054997e-09
14 O 0 6.433495958191315e-09
% O 0 1.7865914303527575e-10
) O 0 4.9923010170260795e-11
of O 0 2.180543107188626e-10
35 O 0 6.151376075180792e-10
in O 0 5.007922201927251e-11
sporadic O 0 1.0240416292717214e-09
cases O 0 2.5843806261693913e-11
and O 0 6.638849886497766e-11
8 O 0 1.1570501889934803e-08
( O 0 1.573693730883008e-09
80 O 0 7.049013373006119e-09
% O 0 9.767257141968244e-11
) O 0 4.5422655220450636e-11
of O 0 2.6491428495312164e-10
10 O 0 9.825934510487855e-10
in O 0 4.2688569346083227e-10
familial O 0 2.3413166516661477e-08
cases O 0 3.5618159532901927e-09
. O 0 1.7235262106396476e-08
. O 0 5.231125896898448e-07

The O 0 1.7275653590331785e-05
hemochromatosis B-Disease 1 1.0
845 O 0 6.846934866189258e-06
G O 0 5.554094286708278e-07
- O 0 1.5605301939558558e-07
- O 0 2.0822022861466394e-07
> O 0 2.2106092956164503e-07
A O 0 9.018886970579842e-09
and O 0 1.8785629996020958e-10
187 O 0 1.4319246899319182e-09
C O 0 7.912900912288023e-08
- O 0 1.3553918165598589e-07
- O 0 2.10211555895512e-06
> O 0 1.8438371625961736e-05
G O 0 8.02881368144881e-06
mutations O 0 2.6335431613233595e-08
: O 0 9.00860164243511e-10
prevalence O 0 1.2560426476682096e-08
in O 0 2.373096164021149e-10
non O 0 1.988293689692e-07
- O 0 9.933756928148796e-07
Caucasian O 0 8.335574079865182e-07
populations O 0 1.1330880056448223e-07
. O 0 8.489157465874086e-08

Hemochromatosis B-Disease 1 0.9999998807907104
, O 0 3.091505220709223e-07
the O 0 2.421016870357562e-05
inherited B-Disease 1 1.0
disorder I-Disease 1 1.0
of I-Disease 1 0.9999997615814209
iron I-Disease 1 1.0
metabolism I-Disease 1 1.0
, O 0 8.751465330192332e-09
leads O 0 2.267239906927898e-08
, O 0 7.333362805894694e-10
if O 0 2.0525618982247806e-09
untreated O 0 2.0940695321769454e-05
, O 0 1.709525743187612e-09
to O 0 1.87069879586943e-08
progressive O 1 0.9999997615814209
iron B-Disease 1 1.0
overload I-Disease 1 1.0
and O 0 7.608856321894564e-06
premature B-Disease 0 0.0003618410846684128
death I-Disease 0 3.828244734904729e-05
. O 0 2.142125140380813e-06

The O 0 1.4518837815558072e-05
hemochromatosis B-Disease 1 1.0
gene O 0 2.8068648134649266e-06
, O 0 4.2270855260539975e-08
HFE O 1 0.9999902248382568
, O 0 4.188714086694745e-08
recently O 0 2.1448894216291592e-08
has O 0 2.3185644376644277e-11
been O 0 1.2480692694605278e-11
identified O 0 3.4234282075829015e-11
, O 0 1.6669665647839338e-11
and O 0 4.217351121105217e-11
characterization O 0 2.3386599323771406e-09
of O 0 2.774516394410398e-09
this O 0 2.645446917082239e-10
gene O 0 1.1183812764770096e-09
has O 0 3.175648979891754e-11
shown O 0 4.162878028401984e-11
that O 0 8.733093241619638e-12
it O 0 7.927191021661617e-12
contains O 0 4.03283031968904e-11
two O 0 1.120004609889147e-11
mutations O 0 3.03418123959176e-11
that O 0 8.419833406880795e-12
result O 0 7.672405766268042e-11
in O 0 6.316715484011581e-10
amino O 0 3.5355454675034537e-10
acid O 0 4.045652146622558e-10
substitutions O 0 3.1682225731799463e-09
- O 0 7.0001235918937255e-09
cDNA O 0 6.536706109727675e-08
nucleotides O 0 2.8935509988059493e-08
845 O 0 6.536543395441186e-08
G O 0 2.8848329947095408e-08
- O 0 3.4308591523313225e-08
- O 0 1.1432575064418415e-07
> O 0 2.783667696348857e-07
A O 0 4.864306646368277e-08
( O 0 1.0999718913495826e-09
C282Y O 0 3.3705001101225207e-07
) O 0 1.8977582005863525e-10
and O 0 1.7355054893197774e-10
187 O 0 7.988492534138913e-09
C O 0 3.042316620849306e-07
- O 0 3.580980205697415e-07
- O 0 9.676587069407105e-06
> O 0 3.675874540931545e-05
G O 0 1.67763682838995e-05
( O 0 1.4018669958204555e-07
H63D O 0 0.00042912911158055067
) O 0 2.42549560880434e-07
. O 0 9.409927770320792e-07

Although O 0 0.0005679798778146505
hemochromatosis B-Disease 1 1.0
is O 0 1.7106421168477937e-08
common O 0 3.5663569875055146e-09
in O 0 6.045366984785971e-10
Caucasians O 0 2.522217528166948e-07
, O 0 2.4042359769715915e-10
affecting O 0 5.631248800597177e-10
> O 0 1.3415617949874559e-08
= O 0 7.180232852732615e-09
1 O 0 1.1793129139903158e-08
/ O 0 1.6837925898016692e-07
300 O 0 7.581711258808355e-09
individuals O 0 5.2707282982566994e-11
of O 0 3.2423883022936195e-10
northern O 0 1.4072746301607708e-09
European O 0 1.1787636422511127e-09
origin O 0 1.1730219018346588e-09
, O 0 7.742380347952604e-11
it O 0 1.2630558057780128e-11
has O 0 4.516501755924551e-12
not O 0 1.1203507739587781e-11
been O 0 5.296386246245177e-11
recognized O 0 3.311766694213958e-10
in O 0 2.812858557188491e-10
other O 0 5.56610979529637e-10
populations O 0 4.55476323324433e-09
. O 0 5.37139257517083e-08

The O 0 1.0586813203872225e-07
present O 0 1.1821212453355656e-08
study O 0 5.2378426040888826e-09
used O 0 3.246009905311098e-09
PCR O 0 7.786048428215508e-08
and O 0 1.5577614753681246e-09
restriction O 0 1.3367596807256632e-08
- O 0 3.5838887413319753e-09
enzyme O 0 2.3129030635171688e-10
digestion O 0 2.985252711695807e-09
to O 0 1.1697191826254283e-10
analyze O 0 6.462775870019755e-10
the O 0 1.7040686917102477e-10
frequency O 0 4.422026744776986e-09
of O 0 1.2584832065343221e-09
the O 0 1.1766946306224213e-09
845 O 0 2.022892608977145e-08
G O 0 3.6057283381296656e-08
- O 0 2.3661925752094248e-08
- O 0 6.651597317386404e-08
> O 0 2.2041614045065216e-07
A O 0 1.1536872790429697e-08
and O 0 2.6096788618978906e-10
187 O 0 1.4813658077983405e-09
C O 0 4.346146198486167e-08
- O 0 5.304623940105557e-08
- O 0 8.362654284610471e-07
> O 0 8.348553819814697e-06
G O 0 3.4910058275272604e-06
mutations O 0 2.077185534687942e-08
in O 0 4.86445239644695e-09
HLA O 0 2.3169648102339124e-06
- O 0 2.430363565508742e-06
typed O 0 1.892046554985427e-07
samples O 0 1.2737702448362143e-08
from O 0 5.378132938993474e-10
non O 0 1.1339626126982694e-07
- O 0 1.7958763010028633e-07
Caucasian O 0 8.644810378655166e-08
populations O 0 3.741461362949394e-09
, O 0 2.36597325065091e-10
comprising O 0 1.4256023028735854e-09
Australian O 0 1.4798895442424964e-08
Aboriginal O 0 1.5392879859632558e-08
, O 0 1.578261965562433e-10
Chinese O 0 1.7324173207100557e-09
, O 0 5.284199189325989e-10
and O 0 1.4329820663405712e-09
Pacific O 0 6.207501996868814e-07
Islanders O 0 6.08205209573498e-06
. O 0 6.359492203955597e-07

Results O 0 1.810444985039794e-07
showed O 0 1.4665704206606733e-08
that O 0 9.802905015510177e-11
the O 0 4.6217604743326035e-10
845 O 0 4.435341693920236e-08
G O 0 1.0020544749522742e-07
- O 0 8.792459738060643e-08
- O 0 1.8870082385546993e-07
> O 0 5.554105086957861e-07
A O 0 2.0533773792408283e-08
mutation O 0 2.219187722474203e-09
was O 0 7.650416966598073e-10
present O 0 5.451696039049381e-11
in O 0 7.997296574968615e-11
these O 0 5.2044566573039575e-11
populations O 0 1.0122052501726486e-10
( O 0 3.7539096831018526e-11
allele O 0 2.0571307157712937e-10
frequency O 0 5.368898103874642e-10
0 O 0 4.0720357641355065e-10
. O 0 9.018361751822468e-11
32 O 0 2.0075476836467487e-09
% O 0 1.2436594809539514e-10
) O 0 6.193189711067859e-11
, O 0 5.3614862549622444e-11
and O 0 4.12446743425221e-11
, O 0 3.656049074596268e-11
furthermore O 0 2.4120214159317754e-10
, O 0 2.2043779995817303e-11
it O 0 1.0780310671920645e-11
was O 0 1.3223803163597836e-09
always O 0 1.0346907775016234e-09
seen O 0 7.873944829484003e-10
in O 0 1.5129728025975453e-10
conjunction O 0 1.843242358745556e-08
with O 0 3.727144815002248e-09
HLA O 0 0.05229480192065239
haplotypes O 0 2.585016318334965e-06
common O 0 1.0974639863547964e-08
in O 0 7.348540664864345e-10
Caucasians O 0 7.166635640487584e-08
, O 0 3.2638819424946064e-10
suggesting O 0 1.1969952806722972e-09
that O 0 2.4328117645411318e-11
845 O 0 1.3047083413653127e-08
G O 0 9.528300637384746e-08
- O 0 4.6018988086871104e-07
- O 0 2.4810574359435122e-06
> O 0 9.241668522008695e-06
A O 0 1.0929564098205446e-07
may O 0 3.296579897948959e-09
have O 0 1.231420798664118e-10
been O 0 5.8149676046559406e-11
introduced O 0 1.5907163086748e-10
into O 0 5.791236934449273e-11
these O 0 2.3134313908990123e-11
populations O 0 1.1089135859565502e-10
by O 0 3.2317931664138655e-10
Caucasian O 0 5.150477022652922e-07
admixture O 0 3.239911848140764e-06
. O 0 1.753607307364291e-06

187 O 0 7.165479587456502e-07
C O 0 8.540060321138299e-07
- O 0 1.3063733206308825e-07
- O 0 2.732566883878462e-07
> O 0 3.2223181278823176e-07
G O 0 1.232719739618915e-07
was O 0 3.426148920127048e-09
present O 0 7.411400659851353e-11
at O 0 2.4832957912224174e-10
an O 0 1.7101696794807886e-11
allele O 0 3.458146546897467e-10
frequency O 0 4.966378419624107e-09
of O 0 1.3754941186050473e-08
2 O 0 2.2955994154472137e-06
. O 0 8.012261787371244e-06

68 O 0 2.8641309199883835e-06
% O 0 4.199887548850256e-09
in O 0 3.3043212610550654e-10
the O 0 3.1804511801958313e-10
two O 0 7.959131964607735e-11
populations O 0 2.418802935721942e-10
analyzed O 0 5.030175387332747e-09
( O 0 5.962121019109645e-09
Australian O 0 3.194593318767147e-07
Aboriginal O 0 1.530429898366492e-07
and O 0 2.4309219082141453e-09
Chinese O 0 6.204264479947597e-08
) O 0 4.8949456044056205e-08
. O 0 2.0805805434065405e-07

In O 0 5.506811362465669e-08
the O 0 4.120141738894745e-08
Australian O 0 2.128855953742459e-07
Aboriginal O 0 5.076906717249585e-08
samples O 0 1.8478422125767224e-09
, O 0 6.822052645016896e-11
187 O 0 7.292438319872474e-10
C O 0 4.187587521187197e-08
- O 0 4.6229995831481574e-08
- O 0 4.097954615644994e-07
> O 0 2.799545200105058e-06
G O 0 5.160487717148499e-07
was O 0 6.6764695993981604e-09
found O 0 2.2356579088000927e-10
to O 0 2.1517301829199198e-10
be O 0 1.2365075630071942e-09
associated O 0 1.0401628713907485e-07
with O 0 1.843207186880136e-08
HLA O 1 0.9999997615814209
haplotypes O 0 3.785465378314257e-05
common O 0 6.228678017805578e-08
in O 0 2.089909578728566e-09
Caucasians O 0 8.320945710238448e-08
, O 0 1.920714420844405e-10
suggesting O 0 4.4580675262473335e-10
that O 0 5.444575346125191e-12
it O 0 6.5690898901071826e-12
was O 0 6.624332193894134e-10
introduced O 0 5.860022245229857e-09
by O 0 1.7296506449326898e-09
recent O 0 2.1858214793724073e-08
admixture O 0 3.750534460777999e-07
. O 0 2.267370149411363e-07

In O 0 9.987835447589077e-09
the O 0 2.175169155904655e-09
Chinese O 0 2.3418735839442206e-09
samples O 0 6.053536560912676e-10
analyzed O 0 1.836754914830152e-10
, O 0 4.0724371791478475e-11
187 O 0 7.351933506427599e-10
C O 0 2.3800611259616744e-08
- O 0 1.07800595117169e-08
- O 0 7.185386863284293e-08
> O 0 5.48029049696197e-07
G O 0 8.901466230781807e-08
was O 0 1.996550036409417e-09
present O 0 5.240155531716084e-11
in O 0 1.499493168521937e-10
association O 0 2.561078293883412e-10
with O 0 1.4607421175427682e-11
a O 0 1.719348885487193e-09
wide O 0 4.2412162670757425e-09
variety O 0 2.0982333648333906e-09
of O 0 1.4686278859699087e-08
HLA O 0 4.91357877763221e-06
haplotypes O 0 1.4766139599942107e-07
, O 0 7.256890088847001e-10
showing O 0 4.922917073990618e-10
this O 0 1.8016541383780726e-11
mutation O 0 4.327899497114096e-11
to O 0 3.555432337432052e-11
be O 0 1.2969658680361817e-10
widespread O 0 3.378876622939231e-10
and O 0 1.2275397365257845e-10
likely O 0 1.2758485379293916e-09
to O 0 7.221873099538811e-10
predate O 0 1.2043361152791476e-07
the O 0 5.676630721040965e-09
more O 0 5.917548118183902e-10
genetically O 0 3.4998197673274944e-09
restricted O 0 3.886706956279795e-09
845 O 0 3.639689793999423e-08
G O 0 2.917740289376525e-07
- O 0 1.3288482705320348e-06
- O 0 2.8210367872816278e-06
> O 0 7.240951617859537e-06
A O 0 6.858566621303908e-07
mutation O 0 2.56953171628993e-07
. O 0 1.4079658683385787e-07

Genotype O 0 2.26384090638021e-05
- O 0 1.9348974092281424e-05
phenotype O 0 4.992999151909316e-07
correlations O 0 5.114808345751953e-07
in O 0 8.315573722939007e-07
attenuated B-Disease 1 0.9999984502792358
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 1.0
. O 0 0.0002159207797376439

Germ O 0 0.1868276596069336
- O 0 3.407082476769574e-05
line O 0 4.4867340420751134e-07
mutations O 0 6.235320260117305e-09
of O 0 6.235582272751117e-09
the O 0 7.191320428034942e-09
tumor B-Disease 0 6.246285693123355e-07
suppressor O 0 6.097523055359488e-06
APC O 0 5.87455019740446e-07
are O 0 2.588522063362575e-09
implicated O 0 9.393934874424303e-08
in O 0 9.413933099722271e-08
attenuated B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 1.0
( O 0 1.0516305337660015e-05
AAPC B-Disease 1 1.0
) O 0 7.838286464334487e-09
, O 0 5.406251002426643e-10
a O 0 4.080852600285567e-10
variant O 0 2.512230992124387e-07
of O 0 1.1987357538600918e-05
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 0 2.266039473397541e-06
FAP B-Disease 0 2.9333348720683716e-05
) O 0 1.0442598608051412e-07
. O 0 6.88914099100657e-07

AAPC B-Disease 1 1.0
is O 0 3.3433515511660516e-08
recognized O 0 3.809365267670728e-09
by O 0 1.5377370210511998e-10
the O 0 3.2341979094852036e-10
occurrence O 0 4.8756731985122315e-09
of O 0 3.152134997463918e-09
< O 0 1.8717944385571172e-06
100 O 0 2.239914067558857e-07
colonic B-Disease 0 7.4386830419825856e-06
adenomas I-Disease 0 4.337328846304445e-06
and O 0 3.1475014261594936e-10
a O 0 4.897630634381755e-10
later O 0 9.766335296035322e-09
onset O 1 0.991074800491333
of O 1 0.9619700908660889
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 1.4066420028768789e-08
age O 0 1.1723649606665276e-08
> O 0 9.942431944409691e-08
40 O 0 1.8278450752973185e-08
years O 0 1.4431058570352207e-09
) O 0 8.839285747797021e-09
. O 0 2.228635764822684e-07

The O 0 5.25177057397741e-08
aim O 0 4.327690916738902e-08
of O 0 2.073788030187984e-09
this O 0 1.2672406179969897e-10
study O 0 6.460939561137025e-10
was O 0 6.45414055533422e-10
to O 0 3.7409386699494007e-10
assess O 0 4.5447510643725764e-08
genotype O 0 7.397295007649518e-07
- O 0 1.3452200619212817e-05
phenotype O 0 5.032092644796649e-07
correlations O 0 3.482907686702674e-07
in O 0 4.989976787328487e-07
AAPC B-Disease 1 1.0
families O 0 6.058693884369859e-07
. O 0 1.2086916285625193e-06

By O 0 7.337199736667799e-09
protein O 0 4.0736534145935366e-09
- O 0 6.852213374486382e-08
truncation O 0 1.1305013458695612e-06
test O 0 1.097778437042507e-07
( O 0 2.5899458577782752e-08
PTT O 0 1.1824265584436944e-06
) O 0 4.431624789358324e-10
assay O 0 5.909430722539355e-09
, O 0 1.9191691291720048e-10
the O 0 2.0499786590466584e-10
entire O 0 1.0270657657684978e-09
coding O 0 5.3225928553501944e-08
region O 0 3.494623479483039e-09
of O 0 2.313133684594959e-09
the O 0 2.117022557257542e-09
APC B-Disease 0 4.340637005384451e-08
gene O 0 1.2097337576122413e-09
was O 0 3.294744477244649e-09
screened O 0 3.880573640202556e-09
in O 0 4.004945819424677e-10
affected O 0 4.1090639224528047e-10
individuals O 0 3.453754990334623e-11
from O 0 1.2812012561980168e-09
11 O 0 3.2571506380918436e-07
AAPC B-Disease 1 1.0
kindreds O 0 4.256781267031329e-06
, O 0 3.872794973602822e-09
and O 0 9.324894190143596e-10
their O 0 1.9364223557971627e-09
phenotypic O 0 2.8577245458905054e-08
differences O 0 3.751694510611969e-09
were O 0 4.184425606013065e-08
examined O 0 7.283895229193149e-07
. O 0 9.823944537856732e-07

Five O 0 4.231296486523206e-07
novel O 0 1.2468890986383485e-07
germ O 0 5.5886303016450256e-05
- O 0 4.191897460259497e-06
line O 0 5.030365173297469e-07
APC B-Disease 0 2.8063567469871487e-07
mutations O 0 2.6012421106003103e-09
were O 0 4.191980540468876e-09
identified O 0 9.45351530390326e-09
in O 0 1.119115911052404e-08
seven O 0 1.2345668665147969e-07
kindreds O 0 1.2539319868665189e-05
. O 0 1.041295831782918e-06

Mutations O 0 5.800785629617167e-07
were O 0 3.318548280617506e-08
located O 0 2.7843503058733177e-09
in O 0 2.0905623066003187e-10
three O 0 4.181946455794616e-11
different O 0 4.926200072863374e-12
regions O 0 4.677326234658885e-11
of O 0 3.5698466405165163e-10
the O 0 6.192637513890986e-10
APC B-Disease 0 2.276552102387086e-08
gene O 0 9.425531466433767e-10
( O 0 4.4068185212076116e-10
1 O 0 2.2229718510402563e-08
) O 0 5.467558628069469e-10
at O 0 2.2158042067843553e-09
the O 0 8.180988109174336e-10
5 O 0 6.301700494759643e-09
end O 0 1.5035329425927557e-08
spanning O 0 6.510710193197156e-09
exons O 0 6.409661246209453e-09
4 O 0 1.4546434057294277e-09
and O 0 4.081841253888996e-10
5 O 0 5.5930584608177014e-09
, O 0 9.455800586977148e-10
( O 0 4.487962224075659e-10
2 O 0 6.213060732562781e-09
) O 0 4.4628487017028817e-10
within O 0 1.0533970362658351e-09
exon O 0 5.893573629123239e-08
9 O 0 6.29771168547677e-09
, O 0 4.670161479758406e-10
and O 0 1.7296562793145398e-10
( O 0 2.689911626774233e-10
3 O 0 2.6274207254317616e-09
) O 0 2.1432514096808575e-10
at O 0 8.27382440338198e-10
the O 0 4.939320619179455e-10
3 O 0 8.513151072975234e-09
distal O 0 5.738467123705959e-08
end O 0 4.461474389927389e-08
of O 0 1.698521501225514e-08
the O 0 2.0193922978251067e-08
gene O 0 5.5744873606045076e-08
. O 0 4.4479520511231385e-07

Variability O 0 5.590692921941809e-07
in O 0 5.469856123596628e-09
the O 0 2.887633687720381e-09
number O 0 9.72946612165515e-09
of O 0 1.3433214007818606e-05
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
was O 0 1.2413356671459042e-06
most O 0 2.0225357499903396e-10
apparent O 0 9.986873134026908e-11
in O 0 8.528024640630516e-12
individuals O 0 9.860991146901088e-13
with O 0 5.967193969849682e-13
mutations O 0 5.762170601775196e-11
in O 0 1.254236298153799e-10
region O 0 1.2920924064019346e-07
1 O 0 2.566674811532721e-05
, O 0 1.4398678693794409e-08
and O 0 4.0979227122761586e-08
upper O 1 1.0
- O 1 1.0
gastrointestinal O 1 1.0
manifestations O 0 1.4293420917965705e-06
were O 0 2.0271944123351204e-09
more O 0 1.1845123493170462e-10
severe O 0 2.6842699174522977e-09
in O 0 6.45904218998794e-10
them O 0 3.155377292785033e-09
. O 0 2.780688248549268e-07

In O 0 1.3489565908741952e-08
individuals O 0 1.561809848116269e-10
with O 0 1.8625533407257144e-11
mutations O 0 1.1252598852706797e-10
in O 0 6.239858629797368e-11
either O 0 6.257847018353857e-10
region O 0 2.2807145061420897e-09
2 O 0 9.646664800300186e-09
or O 0 5.646025869054938e-10
region O 0 1.92563431866688e-09
3 O 0 3.6994380891997025e-09
, O 0 1.4733651798604086e-10
the O 0 9.672928430459748e-11
average O 0 2.137878346575306e-10
number O 0 1.5153930887912281e-10
of O 0 1.363184121139227e-09
adenomas B-Disease 0 8.813413842290174e-06
tended O 0 1.6823424431322564e-08
to O 0 3.7712213907248326e-10
be O 0 3.254296276899993e-10
lower O 0 1.641033420263227e-09
than O 0 1.0180389864444805e-10
those O 0 4.5538548626433695e-11
in O 0 3.1989688675793104e-11
individuals O 0 6.306837864455961e-12
with O 0 2.3394684627031648e-12
mutations O 0 4.365106193171542e-11
in O 0 3.0273481638198874e-11
region O 0 9.573414283536863e-10
1 O 0 8.991611011310852e-09
, O 0 5.557103666120611e-10
although O 0 4.953736865154212e-10
age O 0 1.4436646322835145e-09
at O 0 3.137828441523993e-09
diagnosis O 0 1.4720218644015404e-07
was O 0 1.4002871751017665e-08
similar O 0 2.4939401654933135e-08
. O 0 7.002529400779167e-07

In O 0 1.2520358723122627e-06
all O 0 1.0862929684662959e-06
AAPC B-Disease 1 1.0
kindreds O 0 3.406913674552925e-05
, O 0 1.2503060808910504e-08
a O 0 4.88337947857076e-09
predominance O 0 1.0220020385531825e-06
of O 0 4.853635005019896e-07
right O 1 0.9937506318092346
- O 1 1.0
sided O 1 1.0
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and O 1 0.9996322393417358
rectal B-Disease 1 1.0
polyp I-Disease 0 0.00030708889244124293
sparing O 0 4.169862393155199e-07
was O 0 3.8694150106266534e-08
observed O 0 2.4785803631743875e-08
. O 0 6.866381596637439e-08

No O 0 2.9237977287266403e-05
desmoid B-Disease 1 0.9999829530715942
tumors I-Disease 1 1.0
were O 0 9.828491442931409e-08
found O 0 2.0109967024950492e-09
in O 0 1.7608540181512922e-09
these O 0 6.0422347125665965e-09
kindreds O 0 1.612693267816212e-05
. O 0 9.788611805561231e-07

Our O 0 3.049197800919501e-07
data O 0 6.784741657384075e-08
suggest O 0 4.86913087627272e-09
that O 0 4.7204531949951445e-11
, O 0 2.1534379834875494e-10
in O 0 3.5498182171522785e-09
AAPC B-Disease 1 1.0
families O 0 1.029682228370632e-09
, O 0 8.33360880303502e-11
the O 0 7.225162135249263e-11
location O 0 1.349146350193564e-09
of O 0 2.791640918431426e-09
the O 0 1.0373984338230002e-08
APC B-Disease 0 6.101335543462483e-07
mutation O 0 9.60370538649613e-09
may O 0 4.924948449058775e-09
partially O 0 3.5594268865679624e-08
predict O 0 5.769632771546185e-09
specific O 0 3.0280096208201712e-09
phenotypic O 0 1.2885557509889622e-07
expression O 0 9.969320302616325e-08
. O 0 4.4563250867213355e-07

This O 0 6.249333939223334e-09
should O 0 4.509105977490435e-09
help O 0 1.528211668322399e-09
in O 0 2.344017757671679e-10
the O 0 3.2756314327642144e-10
design O 0 6.904016025544024e-09
of O 0 1.2739306498588121e-08
tailored O 0 1.0093706492853016e-07
clinical O 0 3.161518122851703e-07
- O 0 1.4119918034793955e-07
management O 0 2.8620720016192536e-08
protocols O 0 5.08648838604131e-07
in O 0 7.400273727142803e-10
this O 0 1.0798385102761543e-10
subset O 0 4.778524687054642e-09
of O 0 3.621413391385886e-09
FAP B-Disease 0 1.1204783731955104e-06
patients O 0 7.91187417803485e-08
. O 0 1.1501850138984082e-08
. O 0 2.197558188754556e-07

Wilms B-Disease 1 0.9999998807907104
' I-Disease 0 0.0023437701165676117
tumor I-Disease 0 8.583997987443581e-05
1 O 0 8.147242169798119e-07
and O 0 1.013499044688615e-07
Dax O 1 0.9999904632568359
- O 0 1.5414346989928163e-06
1 O 0 7.354576041507244e-07
modulate O 0 5.342986924006254e-07
the O 0 1.7482451042383218e-08
orphan O 0 6.889798953579884e-08
nuclear O 0 1.1190353177426005e-07
receptor O 0 5.764023480736569e-09
SF O 0 6.785616733395727e-06
- O 0 4.807017148777959e-07
1 O 0 1.0672675898604211e-07
in O 0 5.5357260997368485e-09
sex O 0 1.5738679248755716e-09
- O 0 4.2699830338222e-09
specific O 0 9.689035129767376e-10
gene O 0 3.0888391844285934e-09
expression O 0 1.4358396072111645e-07
. O 0 5.094711923447903e-07

Products O 0 7.75048704326764e-07
of O 0 7.669914481311935e-08
steroidogenic O 0 1.3448582649289165e-05
factor O 0 6.048693990123866e-08
1 O 0 9.715135718124657e-08
( O 0 5.9315867773079844e-09
SF O 0 0.00012006433098576963
- O 0 1.8990366470461595e-06
1 O 0 3.2391778859164333e-07
) O 0 1.1126817689444124e-08
and O 0 1.3215640137786977e-08
Wilms B-Disease 1 0.9998260140419006
tumor I-Disease 0 3.041041964024771e-05
1 O 0 5.51333698695089e-07
( O 0 3.3948552413676225e-08
WT1 O 0 5.954400876362342e-06
) O 0 2.3702655393975647e-09
genes O 0 9.831633285273256e-10
are O 0 6.677761815732097e-11
essential O 0 1.3113846009105146e-08
for O 0 1.222890011476352e-09
mammalian O 0 2.994561612013058e-07
gonadogenesis O 0 1.0215098882326856e-06
prior O 0 9.955601143474269e-08
to O 0 7.2723156385734455e-09
sexual O 0 5.294088722962442e-09
differentiation O 0 8.227471681720999e-08
. O 0 1.8577350147097604e-07

In O 0 8.864108025363748e-08
males O 0 1.9710975962539123e-08
, O 0 3.240275603388909e-09
SF O 0 0.000143186523928307
- O 0 3.3585681649128674e-06
1 O 0 4.082243094671867e-07
participates O 0 1.5022887822624398e-08
in O 0 6.369793026372861e-10
sexual O 0 8.946662161113395e-11
development O 0 3.6856025176223994e-11
by O 0 1.7195175838757848e-11
regulating O 0 1.23703125520791e-09
expression O 0 4.028114286569462e-09
of O 0 8.177747368165456e-09
the O 0 1.459699827677241e-08
polypeptide O 0 6.759946131751349e-07
hormone O 0 8.911693072377602e-08
Mullerian O 0 1.3302227444000891e-06
inhibiting O 0 1.1228731011669879e-07
substance O 0 8.072093748978659e-08
( O 0 5.192050878122245e-08
MIS O 0 0.001619310467503965
) O 0 1.9950994101236574e-07
. O 0 1.031333795253886e-06

Here O 0 3.92664844639512e-07
, O 0 6.24167428853184e-09
we O 0 1.8839749760246605e-09
show O 0 3.769511813800364e-09
that O 0 5.994250651397692e-10
WT1 O 0 1.1353632544341963e-05
- O 0 7.993273356987629e-06
KTS O 0 0.0001380555477226153
isoforms O 0 1.2411257444000512e-07
associate O 0 1.0656524551677649e-07
and O 0 2.5527204794428826e-09
synergize O 0 4.3555405682127457e-07
with O 0 1.9986303723129595e-09
SF O 0 0.02850089967250824
- O 0 6.010139713907847e-06
1 O 0 1.7904227433973574e-06
to O 0 9.714931792359494e-08
promote O 0 1.6289242239508894e-06
MIS O 0 0.004275603219866753
expression O 0 1.0831719237103243e-06
. O 0 9.523300832370296e-07

In O 0 1.422569511078109e-07
contrast O 0 8.67285336880741e-08
, O 0 1.7337535851424946e-08
WT1 O 0 1.797626646293793e-05
missense O 0 1.3879075595468748e-06
mutations O 0 6.941423436046534e-09
, O 0 3.934245429437766e-10
associated O 0 2.224153972107956e-09
with O 0 2.0929401267633096e-10
male B-Disease 0 1.2893358380949849e-08
pseudohermaphroditism I-Disease 1 1.0
in O 0 2.8952181096997265e-08
Denys B-Disease 1 0.9999929666519165
- I-Disease 1 1.0
Drash I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 8.1458653156119e-09
fail O 0 5.477981446233571e-08
to O 0 4.047228774339828e-09
synergize O 0 1.5576159739794093e-06
with O 0 2.6212452652885077e-08
SF O 1 1.0
- O 1 0.9999791383743286
1 O 1 0.999234676361084
. O 0 5.828337089042179e-05

Additionally O 0 4.773467026097933e-07
, O 0 4.495383176816858e-09
the O 0 2.423070855073206e-09
X O 0 7.410392868223425e-07
- O 0 3.827605041806237e-07
linked O 0 1.548191050915193e-07
, O 0 2.556831968369977e-10
candidate O 0 2.725151493354616e-10
dosage O 0 9.9193037783607e-08
- O 0 6.745991498746662e-08
sensitive O 0 6.995694690203891e-08
sex O 0 8.457053946031579e-10
- O 0 2.0674728595793113e-09
reversal O 0 2.749115823874604e-09
gene O 0 3.0719533583578595e-09
, O 0 2.3100166224310215e-09
Dax O 0 0.36192771792411804
- O 0 4.881594577454962e-07
1 O 0 7.748661232653831e-07
, O 0 1.1176077840957532e-08
antagonizes O 0 1.2377262237350806e-07
synergy O 0 1.6069902741833175e-08
between O 0 2.129097786962575e-09
SF O 0 0.0014938418753445148
- O 0 3.1783795293449657e-06
1 O 0 1.0797137974805082e-06
and O 0 9.46864133766212e-08
WT1 O 0 0.0002552635269239545
, O 0 1.8505050825012859e-09
most O 0 1.2570719465365698e-10
likely O 0 6.720502626622604e-11
through O 0 1.650700583166742e-11
a O 0 2.3992370590253387e-11
direct O 0 7.574692956202611e-11
interaction O 0 1.551086897810805e-10
with O 0 2.2604798588510278e-10
SF O 1 0.6497012972831726
- O 0 0.0005901622353121638
1 O 0 0.0002066682354779914
. O 0 1.8937316781375557e-05

We O 0 4.2999795368814375e-07
propose O 0 1.2504549431469059e-06
that O 0 1.372574676139493e-08
WT1 O 0 0.00010056754399556667
and O 0 2.4877883220142394e-07
Dax O 1 0.9817938804626465
- O 0 5.311488280312915e-07
1 O 0 1.433379708259963e-07
functionally O 0 1.8155454029056273e-07
oppose O 0 6.068371138923112e-09
each O 0 1.4503458156678306e-10
other O 0 2.1427690177766578e-10
in O 0 1.0234089131699875e-09
testis O 0 1.535174902755898e-07
development O 0 7.698120474408654e-10
by O 0 3.051588426394858e-10
modulating O 0 2.2530126386755e-07
SF O 0 0.00014037419168744236
- O 0 3.965366886404809e-06
1 O 0 3.045569656023872e-06
- O 0 5.398551365942694e-06
mediated O 0 1.5220954310279922e-06
transactivation O 0 4.435427854332374e-06
. O 0 7.044473449013822e-08
. O 0 2.8099236715206644e-07

A O 0 1.2878459756393568e-06
mouse O 0 2.3527192638539418e-07
model O 0 1.9866440936766594e-08
for O 0 1.8899798703841952e-07
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
imprinting O 1 1.0
- O 1 0.9999517202377319
centre O 0 1.8992224795510992e-05
mutations O 0 6.176458811069097e-08
. O 0 6.032173160974708e-08

Imprinting O 0 1.9950241039623506e-05
in O 0 3.781561375149067e-08
the O 0 3.388186087249778e-08
15q11 O 0 9.461883564654272e-06
- O 0 3.974992353050766e-07
q13 O 0 1.1285892469459213e-06
region O 0 3.257173419868309e-09
involves O 0 4.3926531856364193e-10
an O 0 2.3862167450316996e-11
imprinting O 0 3.2117705472956004e-07
centre O 0 1.6562907489969803e-07
( O 0 9.557906688328899e-10
IC O 0 1.6446462041130872e-06
) O 0 1.1161884749810724e-09
, O 0 1.697603169148465e-10
mapping O 0 1.3381086239050433e-09
in O 0 5.2011124573869694e-11
part O 0 2.746996519142897e-10
to O 0 6.024659104930663e-10
the O 0 3.219465583015335e-09
promoter O 0 2.2724120185557695e-07
and O 0 1.700952978467285e-08
first O 0 2.867351156510267e-07
exon O 0 4.916484613204375e-06
of O 0 8.456067348561191e-07
SNRPN O 0 0.012625829316675663
. O 0 5.6211097216873895e-06

Deletion O 0 3.789442189372494e-06
of O 0 3.80051375259427e-07
this O 0 1.412026318092785e-08
IC O 0 1.1496318620629609e-05
abolishes O 0 3.4826593946490902e-06
local O 0 3.997111974740619e-08
paternally O 0 8.314552957244814e-08
derived O 0 3.236433787634496e-09
gene O 0 6.037393363023114e-10
expression O 0 3.8434755378347063e-10
and O 0 9.844012410775704e-11
results O 0 1.1704271996038074e-09
in O 0 9.786123200683505e-08
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 0.9193891882896423
PWS B-Disease 1 1.0
) O 0 6.665058549515379e-07
. O 0 5.891634486943076e-07

We O 0 1.0567325148258533e-07
have O 0 2.6464574975904043e-09
created O 0 2.9818723046304285e-09
two O 0 1.1297938140586439e-09
deletion O 0 5.6237841050688075e-08
mutations O 0 5.88942450363561e-09
in O 0 4.560761546201775e-09
mice O 0 3.5815472188005515e-07
to O 0 1.1783100717366324e-08
understand O 0 2.0037823560414836e-06
PWS B-Disease 1 1.0
and O 0 1.0789197091298774e-07
the O 0 1.8329771478420298e-08
mechanism O 0 1.2443790353700024e-07
of O 0 2.9338641738263505e-08
this O 0 1.054465048611064e-08
IC O 0 3.2678952265996486e-05
. O 0 6.085248969611712e-06

Mice O 0 0.0005322491633705795
harbouring O 0 3.84963204851374e-05
an O 0 2.6102391359472676e-08
intragenic O 0 4.333828837843612e-05
deletion O 0 1.132768716161081e-06
in O 0 1.5395050567690305e-08
Snrpn O 0 2.961730569950305e-05
are O 0 1.739692279123517e-09
phenotypically O 0 2.2492234563742386e-07
normal O 0 1.8969204873542367e-08
, O 0 8.600232748179337e-10
suggesting O 0 1.4207705012481142e-09
that O 0 4.130569150606611e-11
mutations O 0 1.402751137469238e-09
of O 0 2.1012700912592663e-08
SNRPN O 0 0.00021875790844205767
are O 0 2.46455456043293e-09
not O 0 1.6905503663622312e-09
sufficient O 0 1.77422123215365e-07
to O 0 1.1558859114302322e-07
induce O 0 4.563381662592292e-05
PWS B-Disease 1 1.0
. O 0 0.00023685330234002322

Mice O 0 8.843520845402963e-06
with O 0 1.3983033619879848e-09
a O 0 7.604376683900682e-09
larger O 0 8.236463955313411e-09
deletion O 0 7.912704802492954e-08
involving O 0 3.971773132604994e-09
both O 0 1.9937911321932233e-09
Snrpn O 0 2.029100642175763e-06
and O 0 4.23494395107582e-09
the O 0 1.1661427379294764e-08
putative O 0 1.9053715050176834e-06
PWS O 1 1.0
- O 0 4.542554233921692e-05
IC O 0 8.637089194962755e-05
lack O 0 1.9573351437429665e-06
expression O 0 6.9749210851455246e-09
of O 0 1.257264514720191e-09
the O 0 5.347028375624063e-10
imprinted O 0 1.3285800903872769e-08
genes O 0 9.979457260556046e-09
Zfp127 O 0 6.850579666206613e-06
( O 0 2.330649984116917e-08
mouse O 0 1.3548580568567559e-07
homologue O 0 4.719487947113521e-07
of O 0 5.1544081003385145e-08
ZNF127 O 1 0.9657413363456726
) O 0 4.810295806123577e-08
, O 0 3.942196968864664e-08
Ndn O 0 4.098581848666072e-05
and O 0 8.108975180221023e-08
Ipw O 0 1.276017337659141e-05
, O 0 1.2898819790052585e-08
and O 0 2.222288131292771e-09
manifest O 0 2.995155412577333e-08
several O 0 1.0292385832499917e-09
phenotypes O 0 1.6839988958849972e-08
common O 0 4.387397112282088e-09
to O 0 7.453969885773404e-08
PWS B-Disease 1 1.0
infants O 1 0.9999274015426636
. O 0 1.268669257115107e-05

These O 0 2.4825972388953232e-08
data O 0 1.522443149326591e-08
demonstrate O 0 3.072059051589804e-09
that O 0 2.7146087461238366e-11
both O 0 5.904039063198141e-11
the O 0 2.822284628223315e-10
position O 0 2.6075208658937754e-09
of O 0 2.819983135893267e-09
the O 0 7.649380573404585e-10
IC O 0 1.3494627637555823e-07
and O 0 5.995119400914461e-10
its O 0 1.0005977990612536e-10
role O 0 2.224814776852213e-10
in O 0 8.277640378695494e-11
the O 0 1.936037163918769e-10
coordinate O 0 2.314413327653142e-09
expression O 0 1.9166350728738735e-09
of O 0 1.3595955472567312e-09
genes O 0 6.046393385972237e-10
is O 0 4.668823314069037e-11
conserved O 0 7.281291680705237e-10
between O 0 6.66618482636494e-10
mouse O 0 1.0641048220350058e-07
and O 0 9.76089209459019e-10
human O 0 1.9098291836883163e-09
, O 0 4.068511083588078e-10
and O 0 4.923837448878032e-10
indicate O 0 2.381558505959447e-09
that O 0 5.075543804688998e-11
the O 0 1.5869623393172105e-09
mouse O 0 1.9397131012510727e-08
is O 0 3.404089857217407e-11
a O 0 2.7400252206044584e-11
suitable O 0 4.3340145361447924e-10
model O 0 2.3095263201877714e-10
system O 0 8.10296885145334e-10
in O 0 1.5242983264496246e-10
which O 0 5.3853154574623474e-11
to O 0 2.778402230507737e-10
investigate O 0 1.0650095250142044e-09
the O 0 5.673185810017856e-10
molecular O 0 2.512761110295969e-09
mechanisms O 0 1.6696768412316487e-08
of O 0 2.370898366521601e-09
imprinting O 0 3.929959646598036e-08
in O 0 2.6287627630239285e-10
this O 0 6.993937373689363e-11
region O 0 1.8683834479560346e-09
of O 0 1.3811192189905341e-09
the O 0 5.475636055685129e-10
genome O 0 1.6811451120091192e-09
. O 0 3.2705764763107936e-09
. O 0 1.546877541613867e-07

Mutations O 0 1.4195907738212554e-07
of O 0 3.753013189111698e-08
the O 0 1.7453931633326647e-08
ATM O 0 2.962222060887143e-05
gene O 0 5.839628514081596e-08
detected O 0 5.057673035935295e-08
in O 0 3.389063474301679e-09
Japanese O 1 0.9999980926513672
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
patients O 1 0.9999614953994751
: O 0 3.901634293423939e-10
possible O 0 2.196639814489032e-10
preponderance O 0 3.6446706985771016e-08
of O 0 1.9677945939378105e-09
the O 0 1.386709969075639e-09
two O 0 1.534924631840795e-09
founder O 0 3.3030678991963214e-07
mutations O 0 7.625279607736957e-08
4612del165 O 0 2.4553966795792803e-05
and O 0 2.1668580529876635e-07
7883del5 O 0 0.04638352990150452
. O 0 6.401431164704263e-06

The O 0 1.7251549877528305e-07
ATM O 0 0.0005931718624196947
( O 0 1.2646879667954636e-06
A O 1 1.0
- O 1 1.0
T O 1 1.0
, O 0 3.12904440136208e-08
mutated O 0 6.700912713597518e-09
) O 0 5.233904976087445e-10
gene O 0 1.2704092222648455e-09
on O 0 1.4533185321852216e-08
human O 0 2.2318809911325843e-08
chromosome O 0 8.634838195575867e-07
11q22 O 0 7.012529385974631e-05
. O 0 3.306239932499011e-06

3 O 0 3.5549130643630633e-06
has O 0 6.3008469552983115e-09
recently O 0 1.9287036412407588e-09
been O 0 1.5631926308934396e-10
identified O 0 7.84827133837318e-11
as O 0 2.914294847111698e-11
the O 0 2.7962637413891933e-11
gene O 0 1.685802539230785e-11
responsible O 0 3.7487579013228967e-11
for O 0 6.174365185795949e-11
the O 0 3.508682455688472e-09
human O 0 3.103321262187819e-07
recessive B-Disease 1 0.9999984502792358
disease I-Disease 1 1.0
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 0.9775151610374451
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 9.509306551080954e-07
. O 0 2.01609987016127e-06

In O 0 1.1696177359965532e-08
order O 0 4.54309301289868e-09
to O 0 5.58201485034715e-10
define O 0 1.3945504750978444e-09
the O 0 3.428945460903776e-10
types O 0 2.158484946335193e-09
of O 0 4.695897004580729e-09
disease O 0 1.69382392556372e-08
- O 0 9.395776601195394e-09
causing O 0 1.850964048699666e-09
ATM O 0 1.5119566398880124e-07
mutations O 0 2.990836189820101e-10
in O 0 4.767234385028019e-10
Japanese O 0 1.7572905562701635e-05
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 1.9992496902432322e-07
as O 0 2.628612327804092e-10
well O 0 1.0529645905199558e-10
as O 0 1.2244553981854978e-10
to O 0 2.8912641725220567e-10
look O 0 6.278805808612731e-10
for O 0 7.840404991910077e-10
possible O 0 1.3166126855423954e-08
mutational O 0 3.4292511372768786e-06
hotspots O 0 6.274752877288847e-07
, O 0 3.8002484492594135e-10
reverse O 0 5.519184664848353e-09
- O 0 6.55879617283972e-09
transcribed O 0 5.275752723576943e-09
RNA O 0 2.476410188023692e-09
derived O 0 1.3543957066985968e-09
from O 0 2.1057616761410713e-10
ten O 0 1.4605204823325835e-09
patients O 0 2.4274734999885084e-10
belonging O 0 4.1672973405404434e-10
to O 0 8.190617628578423e-11
eight O 0 3.277131344070483e-10
unrelated O 0 1.9036467957533887e-09
Japanese O 0 2.237971784779802e-06
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
families O 0 4.289418598091288e-09
was O 0 5.47174483500612e-09
analyzed O 0 1.478720701442171e-09
for O 0 1.7398607554675039e-10
mutations O 0 2.3806717708296787e-10
by O 0 6.06465377916976e-10
the O 0 1.1670461042001534e-08
restriction O 0 1.0813775475071452e-07
endonuclease O 0 2.7559744353311544e-07
fingerprinting O 0 3.9013409036670055e-07
method O 0 4.276468814623513e-07
. O 0 4.511086899583461e-07

As O 0 1.0958767404645187e-07
has O 0 4.66277405575255e-10
been O 0 7.746575603206907e-11
reported O 0 1.8530038614628097e-11
by O 0 6.321988505614273e-12
others O 0 1.8263934808970816e-10
, O 0 5.899784133456265e-11
mutations O 0 9.586895166613374e-11
that O 0 3.943183279897511e-11
lead O 0 1.1263819210682868e-08
to O 0 3.5819837762574025e-08
exon O 0 3.154951400574646e-06
skipping O 0 5.697236247215187e-07
or O 0 8.035468290756853e-09
premature O 0 2.0997596550387243e-08
protein O 0 9.396560196606174e-10
truncation O 0 1.0540873773834392e-07
were O 0 5.341730613395157e-09
also O 0 2.011012245617394e-09
predominant O 0 1.658776582758037e-08
in O 0 2.35641794965602e-09
our O 0 4.909943740472045e-08
mutants O 0 1.7184896705657593e-06
. O 0 8.261388870778319e-07

Six O 0 5.4854783826385756e-08
different O 0 2.3239760116311459e-10
mutations O 0 4.777666040567397e-10
were O 0 1.526200971158076e-10
identified O 0 2.5880322884752616e-10
on O 0 8.370874549079588e-10
12 O 0 3.3325648907123195e-09
of O 0 3.841894358203035e-09
the O 0 4.305032330620406e-09
16 O 0 1.4964952299578727e-07
alleles O 0 2.2655539666516233e-08
examined O 0 5.913847758165502e-07
. O 0 1.7438361510357936e-06

Four O 0 1.9058279576711357e-07
were O 0 2.9185267536036008e-08
deletions O 0 7.711913241337243e-08
involving O 0 2.4108912644038583e-09
a O 0 1.3054295422421092e-09
loss O 0 8.645004712093396e-09
of O 0 4.856102364669823e-08
a O 0 1.0538598438358804e-08
single O 0 3.128184999923178e-08
exon O 0 1.1473582617327338e-06
exon O 0 1.2980581232113764e-06
7 O 0 1.210761411130079e-06
, O 0 4.357259797416191e-08
exon O 0 1.7549288031659671e-06
16 O 0 2.0737938655202015e-07
, O 0 1.6287605930642712e-08
exon O 0 2.8098966140532866e-06
33 O 0 5.472550128615694e-07
or O 0 8.729263356599404e-08
exon O 0 2.0061354007339105e-05
35 O 0 7.077326699800324e-06
. O 0 2.5205106339853955e-06

The O 0 1.581313711085386e-07
others O 0 3.63036427586394e-08
were O 0 1.4704919060193333e-08
minute O 0 8.435715415089362e-08
deletions O 0 1.5298462585633388e-07
, O 0 3.3047453662504722e-09
4649delA O 0 1.051025790843596e-07
in O 0 2.2339070593346833e-09
exon O 0 3.061526285819127e-07
33 O 0 1.0234528247110575e-07
and O 0 8.033629761428074e-09
7883del5 O 0 5.3942126214678865e-06
in O 0 4.0209005902624995e-08
exon O 0 2.4611990738776512e-05
55 O 0 5.602506462309975e-06
. O 0 3.3702281143632717e-06

The O 0 6.932097562639683e-07
mutations O 0 5.089108299216605e-07
4612del165 O 0 6.3577122091373894e-06
and O 0 6.91602330959995e-09
7883del5 O 0 1.151743390437332e-06
were O 0 4.600847258728891e-09
found O 0 3.6945427273060716e-10
in O 0 9.070390272203355e-11
more O 0 8.659612957262475e-12
than O 0 6.32013148413324e-12
two O 0 3.4274510313236917e-12
unrelated O 0 5.7197944297593395e-11
families O 0 3.691228312591166e-12
; O 0 9.24466232732346e-12
44 O 0 2.076351868218751e-10
% O 0 3.397758810419482e-11
( O 0 3.3658301840100435e-11
7 O 0 1.344050537532837e-09
of O 0 1.5958925292380854e-09
16 O 0 2.8174884647569343e-09
) O 0 4.536787057141112e-10
of O 0 1.297070340022799e-09
the O 0 6.724288348358698e-10
mutant O 0 2.416590705323074e-09
alleles O 0 3.79759640400934e-10
had O 0 8.976202559018986e-10
one O 0 2.0786025678454223e-10
of O 0 1.7179850875237435e-09
the O 0 4.430689148904321e-09
two O 0 4.9052797379545154e-09
mutations O 0 4.196070335638069e-08
. O 0 2.843349875547574e-07

The O 0 1.684311285998774e-07
4612del165 O 0 2.0883719571429538e-06
mutations O 0 2.0291401892080785e-09
in O 0 1.3159835721143764e-10
three O 0 1.5852121698634036e-11
different O 0 2.3913048190910002e-12
families O 0 6.072912138443964e-12
were O 0 3.5620433685989994e-11
all O 0 2.0679402634726785e-11
ascribed O 0 4.616177218252915e-09
to O 0 5.404550140752917e-10
the O 0 4.1736627487409805e-09
same O 0 5.5723372582860975e-09
T O 0 1.0999204391737294e-07
- O 0 1.994526854787182e-07
- O 0 3.5848412949235353e-07
> O 0 6.440969855248113e-07
A O 0 1.8068256224523793e-08
substitution O 0 5.07859176934744e-08
at O 0 6.305391764271917e-09
the O 0 8.229566472728322e-10
splice O 0 4.5795136571769035e-08
donor O 0 1.3853122204920965e-08
site O 0 2.1518840043199816e-08
in O 0 8.172071908063572e-09
intron O 0 2.5301043933723122e-05
33 O 0 7.3984697337436955e-06
. O 0 3.2218711112363962e-06

Microsatellite O 0 0.00010108462447533384
genotyping O 0 1.0392132026026957e-05
around O 0 1.8604932705557076e-08
the O 0 8.922540040146032e-09
ATM O 0 7.964843462104909e-06
locus O 0 5.501750024450303e-07
also O 0 3.2733848964738854e-09
indicated O 0 2.9378945942681867e-09
that O 0 2.5696691302590224e-11
a O 0 3.240199497600571e-10
common O 0 2.4934632136819346e-09
haplotype O 0 7.39805088301182e-08
was O 0 3.20364956785113e-09
shared O 0 4.6191694913488845e-10
by O 0 7.33519148199413e-11
the O 0 8.76933914373268e-10
mutant O 0 6.3715579479151074e-09
alleles O 0 3.4137015436641605e-10
in O 0 6.635941796062639e-10
both O 0 7.700928783549443e-09
mutations O 0 1.653221488595591e-07
. O 0 1.1579231795622036e-06

This O 0 1.105879476881455e-08
suggests O 0 1.2514965952448165e-08
that O 0 3.01424614435053e-11
these O 0 4.363307978816344e-11
two O 0 1.6145218495466906e-10
founder O 0 7.248513611557428e-08
mutations O 0 1.9491026570506165e-09
may O 0 3.4507030566288677e-09
be O 0 1.923762260602757e-09
predominant O 0 1.1430721968963553e-07
among O 0 7.041756955317169e-09
Japanese O 0 5.805478622278315e-07
ATM O 0 1.3534517165680882e-05
mutant O 0 1.3301745411808952e-06
alleles O 0 9.771145670356418e-08
. O 0 5.199835300118139e-07

W474C O 0 4.506345794652589e-05
amino O 0 1.226907215823303e-07
acid O 0 2.127207388014085e-08
substitution O 0 2.3025791051622946e-08
affects O 0 2.0857997551360086e-09
early O 0 3.572661499973151e-09
processing O 0 9.932211497698518e-09
of O 0 3.362791822780764e-09
the O 0 7.182557326679273e-10
alpha O 0 1.3764513973058001e-09
- O 0 2.2811615096873794e-10
subunit O 0 4.21155749164015e-10
of O 0 5.608994935180078e-10
beta O 0 2.1711869635510084e-08
- O 0 8.041145349579892e-08
hexosaminidase O 0 2.358416850256617e-06
A O 0 2.088257033960872e-08
and O 0 7.562656612059016e-10
is O 0 6.357869786199899e-11
associated O 0 1.0314848974957158e-09
with O 0 2.456111147797202e-10
subacute O 0 0.01854698173701763
G B-Disease 0 8.140280260704458e-05
( I-Disease 0 1.1745610350999414e-07
M2 I-Disease 0 0.0010287645272910595
) I-Disease 0 6.785356276850507e-07
gangliosidosis I-Disease 0 0.0005504016880877316
. O 0 5.46273440704681e-06

Mutations O 0 5.054447456132038e-07
in O 0 3.2711394482021205e-08
the O 0 4.7377788803260046e-08
HEXA O 0 2.3285554561880417e-05
gene O 0 4.081881943562848e-09
, O 0 3.5557323752044567e-10
encoding O 0 8.787238159335686e-10
the O 0 6.632145388429933e-10
alpha O 0 2.9304065840563e-09
- O 0 7.089392961567853e-10
subunit O 0 1.440520702722381e-09
of O 0 1.20890097932147e-09
beta O 0 1.0282422913121536e-08
- O 0 6.977704458677181e-08
hexosaminidase O 0 2.047825319095864e-06
A O 0 4.508901696453904e-08
( O 0 1.9613795032569215e-09
Hex O 0 9.613734164304333e-08
A O 0 2.9019853187151057e-08
) O 0 1.0315693854678898e-09
, O 0 3.996231678904394e-10
that O 0 8.0740067409657e-11
abolish O 0 9.965594216509999e-08
Hex O 0 1.3985726354803774e-07
A O 0 2.3135850568678507e-08
enzyme O 0 6.1208327295503295e-09
activity O 0 2.03261585340897e-08
cause O 0 4.0288745367433876e-05
Tay B-Disease 1 1.0
- I-Disease 1 1.0
Sachs I-Disease 1 1.0
disease I-Disease 1 1.0
( O 0 1.7070892255333092e-08
TSD B-Disease 0 0.00033989359508268535
) O 0 5.419280579843644e-10
, O 0 1.0867602651121189e-10
the O 0 4.782279017234714e-10
fatal O 0 5.809322800587324e-08
infantile B-Disease 0 1.1323351145620109e-07
form I-Disease 0 1.6532607505226338e-09
of I-Disease 0 5.971547238914354e-07
G I-Disease 0 1.1633095709839836e-05
( I-Disease 0 1.62788182933582e-08
M2 I-Disease 0 6.349411250994308e-06
) I-Disease 0 1.3695933276380856e-08
gangliosidosis I-Disease 0 1.969734967133263e-06
, I-Disease 0 4.575713141719007e-09
Type I-Disease 0 1.1637090580052245e-07
1 I-Disease 0 6.798798040108522e-06
. O 0 4.74030093755573e-06

Less O 0 5.784522159046901e-07
severe O 0 5.412439350038767e-06
, O 0 1.654716008658852e-08
subacute O 0 6.706952990498394e-05
( O 0 2.709237056919278e-09
juvenile O 0 9.213704288413282e-07
- O 0 1.8413013549434254e-06
onset O 1 1.0
) O 0 4.796879782276164e-09
and O 0 1.8782353450319533e-08
chronic O 1 1.0
( O 0 1.4258634273289772e-09
adult O 0 2.186388492475544e-08
- O 0 7.886803388146291e-08
onset O 0 0.0005504594882950187
) O 0 9.068353290508924e-10
variants O 0 3.198075582133697e-09
are O 0 7.687259162558746e-11
characterized O 0 8.156304798223601e-11
by O 0 2.103271896924941e-11
a O 0 4.1562159269759036e-10
broad O 0 3.3425082701654674e-09
spectrum O 0 9.971161674116047e-09
of O 0 8.957098951434261e-10
clinical O 0 8.085558000914261e-09
manifestations O 0 1.6914373235366043e-09
and O 0 1.1606075128733906e-10
are O 0 3.724682368089205e-11
associated O 0 4.999774483316344e-10
with O 0 3.1962731072976425e-11
residual O 0 5.082735015093931e-07
levels O 0 4.0652304278410156e-07
of O 0 7.245900945918038e-08
Hex O 0 6.764583417862013e-07
A O 0 1.4097716416472394e-07
enzyme O 0 2.7197851082405577e-08
activity O 0 1.4183783036969544e-07
. O 0 4.1225399627364823e-07

We O 0 4.364396488654165e-08
identified O 0 2.731664494604047e-08
a O 0 9.414397261764407e-09
1422 O 0 1.4905068383086473e-05
G O 0 2.092398972308729e-06
- O 0 3.759250148505089e-06
- O 0 5.482640517584514e-06
> O 0 5.7609113355283625e-06
C O 0 2.2657109184365254e-06
( O 0 6.282951381386681e-10
amino O 0 5.779377532100227e-10
acid O 0 4.943787601519034e-10
W474C O 0 1.530715465491994e-08
) O 0 1.7618299180677255e-11
substitution O 0 1.665995674748899e-09
in O 0 1.6219819931606594e-10
the O 0 3.9110670257969105e-10
first O 0 9.167079317862203e-10
position O 0 2.426909784247755e-09
of O 0 3.5316380930794367e-09
exon O 0 9.413035684247006e-08
13 O 0 1.4429661909787228e-08
of O 0 2.90939521363498e-08
HEXA O 0 6.11660216236487e-05
of O 0 1.9875349366316186e-08
a O 0 5.298200100867234e-09
non O 0 5.91839011576667e-07
- O 0 4.452731161563861e-07
Jewish O 0 6.27198289748776e-07
proband O 0 6.807084719184786e-05
who O 0 1.2370036550635177e-08
manifested O 0 2.1404838790317626e-08
a O 0 3.747124832642612e-09
subacute O 0 1.8339287635171786e-06
variant O 0 9.541200824969565e-07
of O 0 3.506227130856132e-06
G B-Disease 0 0.22212989628314972
( I-Disease 0 1.763598334036942e-07
M2 I-Disease 1 0.5595962405204773
) I-Disease 0 4.965907578480255e-07
gangliosidosis I-Disease 0 0.0005040298565290868
. O 0 5.068386144557735e-06

On O 0 5.207413664720661e-07
the O 0 4.7569479022513406e-08
second O 0 3.0100946446509624e-07
maternally O 0 1.406222963851178e-06
inherited O 0 4.3967818896817334e-07
allele O 0 1.4930847669347713e-08
, O 0 1.776268854225549e-10
we O 0 2.039892282867939e-10
identified O 0 1.3995120617948942e-09
the O 0 2.6568205413468604e-09
common O 0 2.305991301909671e-06
infantile O 1 0.9999980926513672
disease O 0 2.622071178848273e-06
- O 0 1.2237508428825095e-07
causing O 0 1.898035861813696e-07
4 O 0 4.567415999190416e-06
- O 0 3.315846697660163e-05
bp O 0 3.348928430568776e-06
insertion O 0 4.0849809579412977e-07
, O 0 2.5708596140816553e-08
+ O 0 1.2135554925407632e-06
TATC O 0 4.8047171731013805e-05
1278 O 0 1.9248211174272e-05
, O 0 1.189405995916104e-08
in O 0 1.0942117434353804e-08
exon O 0 5.95220399191021e-06
11 O 0 2.9156283289921703e-06
. O 0 2.35320885622059e-06

Pulse O 0 3.715409184223972e-05
- O 0 2.652791636137408e-06
chase O 0 2.270901831025185e-07
analysis O 0 2.4176248558660518e-08
using O 0 4.96378618208837e-08
proband O 0 1.7039528756868094e-05
fibroblasts O 0 1.4820606338616926e-05
revealed O 0 1.6181644468815648e-08
that O 0 1.1058846893785557e-10
the O 0 5.053348850481143e-10
W474C O 0 9.289558278169352e-08
- O 0 5.48708722902802e-09
containing O 0 6.651730832807345e-10
alpha O 0 1.0571367115019825e-09
- O 0 6.29414187436339e-10
subunit O 0 1.934997273522754e-09
precursor O 0 1.020349742475446e-07
was O 0 1.4348671584230033e-08
normally O 0 1.0657612570241781e-09
synthesized O 0 3.341783028076861e-08
, O 0 5.522288737402903e-10
but O 0 7.570013366153816e-11
not O 0 2.0250680299316315e-10
phosphorylated O 0 5.8418314630159784e-09
or O 0 3.8450980177628935e-09
secreted O 0 4.009808929339442e-09
, O 0 6.404585750630076e-10
and O 0 1.1061510596377389e-09
the O 0 7.737501306337435e-09
mature O 0 1.9500554060414288e-08
lysosomal O 0 1.6285981985220133e-07
alpha O 0 1.498997193039031e-08
- O 0 1.2003178895270139e-08
subunit O 0 3.3063169979641316e-08
was O 0 6.620852133210064e-08
not O 0 2.040088808996643e-08
detected O 0 1.5562751514153206e-06
. O 0 1.1336094303260325e-06

When O 0 1.3575366608620243e-07
the O 0 3.155270533738985e-08
W474C O 0 7.976329357006762e-07
- O 0 3.0757892233168604e-08
containing O 0 2.3847313013192206e-09
alpha O 0 1.7192045564939917e-09
- O 0 9.628020603003051e-10
subunit O 0 6.4918497244548234e-09
was O 0 1.6155739857026674e-08
transiently O 0 9.55106287392482e-08
co O 0 8.241131332908935e-09
- O 0 4.295323563496822e-08
expressed O 0 7.410584368372497e-10
with O 0 8.815649599203113e-12
the O 0 5.4156502199420586e-11
beta O 0 1.3288346811801688e-10
- O 0 6.543133396208489e-11
subunit O 0 1.5963057264922753e-10
to O 0 7.469899698797633e-11
produce O 0 1.094829116254914e-09
Hex O 0 1.7696469001293735e-07
A O 0 7.365469514297729e-07
( O 0 3.328259268187139e-08
alphabeta O 0 2.6840190912480466e-05
) O 0 1.5832618549538324e-09
in O 0 1.2476707444974977e-09
COS O 0 1.3569637076216168e-06
- O 0 1.9665711192828894e-07
7 O 0 5.357967935992747e-08
cells O 0 1.8994839479091752e-08
, O 0 2.438610979815792e-10
the O 0 1.3787129771181128e-10
mature O 0 1.58901503066744e-10
alpha O 0 5.271253988858859e-10
- O 0 7.817856917391452e-10
subunit O 0 1.6722768725330184e-09
was O 0 1.68774738629196e-09
present O 0 1.4206613663247936e-10
, O 0 1.0401555311512212e-10
but O 0 2.6311189338379393e-11
its O 0 1.1736339330936651e-11
level O 0 5.985316131607021e-10
was O 0 3.2162295049431577e-10
much O 0 9.368048003999263e-11
lower O 0 3.2522673443224903e-10
than O 0 2.1633873512061363e-11
that O 0 3.405730992361855e-12
from O 0 5.395288035781043e-11
normal O 0 1.1233818320022237e-09
alpha O 0 2.5714861351389118e-09
- O 0 1.0010206885624484e-08
subunit O 0 2.4483727045776504e-08
transfections O 0 2.8265120022297197e-07
, O 0 5.502186484207527e-10
although O 0 2.5797869396271267e-10
higher O 0 1.3199084047954557e-09
than O 0 3.0088008473594385e-11
in O 0 5.869994768037401e-11
those O 0 1.1767345431401566e-10
cells O 0 1.7683932096446142e-09
transfected O 0 2.8052639322595496e-08
with O 0 8.391204397995011e-11
an O 0 1.9511547932893336e-10
alpha O 0 7.675897251147035e-09
- O 0 1.401393223687819e-08
subunit O 0 5.355188648081821e-08
associated O 0 3.107979864580557e-07
with O 0 5.047217399578585e-08
infantile O 1 0.8195806741714478
TSD B-Disease 1 0.9698665142059326
. O 0 1.8026721591013484e-05

Furthermore O 0 3.0614151569352543e-07
, O 0 3.380154600662877e-09
the O 0 5.638707833988121e-10
precursor O 0 2.99238571699334e-08
level O 0 1.2448616359961306e-08
of O 0 1.502236446349059e-09
the O 0 1.6413088665956366e-09
W474C O 0 7.590337247620482e-08
alpha O 0 7.421649961258936e-09
- O 0 1.4132945924671958e-09
subunit O 0 4.6086641170006715e-09
was O 0 6.8260685992527215e-09
found O 0 8.02691690893198e-10
to O 0 6.228624838122698e-10
accumulate O 0 1.08264428533289e-08
in O 0 1.4417301796854076e-09
comparison O 0 3.887723032391932e-09
to O 0 8.191606282181851e-10
the O 0 8.572162979447739e-10
normal O 0 3.0268894057883244e-09
alpha O 0 1.278782502112108e-08
- O 0 1.1092955887193057e-08
subunit O 0 2.3085949152346075e-08
precursor O 0 6.690634677397611e-07
levels O 0 8.080579050329106e-07
. O 0 4.992575100004615e-07

We O 0 1.829505258399422e-08
conclude O 0 5.2355680679738725e-08
that O 0 7.397493173577629e-10
the O 0 7.19144388483528e-09
1422 O 0 4.4366195652401075e-05
G O 0 4.297349732951261e-06
- O 0 3.705135895870626e-06
- O 0 3.648270876510651e-06
> O 0 4.448008894541999e-06
C O 0 2.169284471165156e-06
mutation O 0 8.438169607494217e-10
is O 0 5.3470947287970194e-12
the O 0 5.533651661893124e-11
cause O 0 5.347918552445208e-09
of O 0 5.10149398280646e-08
Hex B-Disease 0 4.8212677938863635e-05
A I-Disease 1 0.678408145904541
enzyme I-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 1.3639096607676038e-07
the O 0 2.3997517928364687e-07
proband O 0 0.00013508393021766096
. O 0 5.99929421696288e-07

The O 0 2.0023999525164982e-07
resulting O 0 7.018160630423154e-08
W474C O 0 1.206268848363834e-06
substitution O 0 2.831314418472175e-07
clearly O 0 9.986502291781107e-09
interferes O 0 1.987219278021257e-09
with O 0 5.451040660520157e-11
alpha O 0 5.312366990750661e-09
- O 0 2.364201723281667e-09
subunit O 0 4.639568285114137e-09
processing O 0 1.1132443411554505e-08
, O 0 3.324056585540802e-10
but O 0 7.721261824356063e-11
because O 0 2.449480722421793e-11
the O 0 8.457759492763728e-11
base O 0 1.4766012856881616e-09
substitution O 0 4.870264191936258e-09
falls O 0 1.6148337111943079e-09
at O 0 2.657366549030371e-10
the O 0 1.9775575621494568e-10
first O 0 1.1697822710488026e-09
position O 0 4.782345186526982e-09
of O 0 6.84082301916078e-09
exon O 0 2.0363688690849813e-07
13 O 0 2.286364875203617e-08
, O 0 1.0021434793117123e-09
aberrant O 0 5.2664126393153765e-09
splicing O 0 2.466681436885665e-08
may O 0 2.6384892048980646e-09
also O 0 4.5037745755038827e-10
contribute O 0 1.4620730182102193e-09
to O 0 4.779381779229652e-09
Hex B-Disease 0 1.8469838323653676e-05
A I-Disease 0 0.0002826944401022047
deficiency I-Disease 0 0.0005971233476884663
in O 0 2.3188864162193568e-08
this O 0 8.531145567758358e-09
proband O 0 7.267739420058206e-06
. O 0 5.418210946572799e-08
. O 0 4.2622386331458983e-07

Two O 0 8.191425848735889e-08
frequent O 0 9.598873873528646e-08
missense O 0 1.8731839190877508e-06
mutations O 0 4.779370783580816e-07
in O 0 2.7883941129402956e-06
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 0.0001019656119751744

Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
is O 0 3.6878159193065585e-08
an O 0 4.01531423221968e-07
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
characterized O 0 3.4149468319810694e-06
by O 0 1.653032988269132e-10
early O 0 9.281779398406798e-07
childhood O 1 0.9523168802261353
deafness B-Disease 1 1.0
and O 1 0.9999980926513672
goiter B-Disease 1 1.0
. O 1 0.9999997615814209

A O 0 9.137986722862479e-08
century O 0 6.920407003008222e-08
after O 0 6.782562289586735e-10
its O 0 6.263130639116987e-12
recognition O 0 2.8811020236219065e-10
as O 0 2.116981173694299e-10
a O 0 1.8605633700374824e-09
syndrome O 0 8.124546866383753e-07
by O 0 4.4057260617513805e-10
Vaughan O 0 2.008055844271439e-06
Pendred O 0 6.449036391131813e-06
, O 0 5.381354806210936e-10
the O 0 2.614183758353761e-09
disease O 0 1.5667050945467054e-07
gene O 0 4.061349034856221e-09
( O 0 1.0538436789886418e-08
PDS O 0 0.03435761481523514
) O 0 9.875994244623598e-09
was O 0 1.496358237318418e-07
mapped O 0 6.122352402826436e-08
to O 0 3.316371532946505e-08
chromosome O 0 9.97222855403379e-07
7q22 O 0 0.00013204487913753837
- O 0 4.258605986251496e-05
q31 O 0 0.00026914948830381036
. O 0 2.087561597363674e-06

1 O 0 1.3690040532310377e-06
and O 0 2.7241668476563063e-08
, O 0 9.516000432086003e-09
recently O 0 1.1282461187533954e-08
, O 0 5.844481010264246e-10
found O 0 5.105762479473697e-10
to O 0 1.4108867407713888e-09
encode O 0 5.800243485509782e-08
a O 0 1.399764215648247e-07
putative O 0 1.2121386134822387e-05
sulfate O 0 2.6887559215538204e-05
transporter O 0 6.489734369097278e-05
. O 0 1.17734316518181e-05

We O 0 9.59801340627564e-08
performed O 0 5.012134707271798e-08
mutation O 0 1.5024800292806617e-09
analysis O 0 1.002719018927678e-09
of O 0 1.7591554879459181e-09
the O 0 8.283429053790314e-09
PDS B-Disease 0 5.327302005753154e-06
gene O 0 2.4842490287113606e-09
in O 0 2.6313662360166745e-10
patients O 0 2.655381914351551e-09
from O 0 2.737612914138765e-10
14 O 0 6.497052229548217e-09
Pendred B-Disease 0 4.000327749054122e-07
families O 0 1.312967512490104e-10
originating O 0 2.20960028052275e-09
from O 0 1.577326047552674e-10
seven O 0 1.0967053654109549e-10
countries O 0 2.38366479332619e-11
and O 0 1.31752067589197e-10
identified O 0 1.9086019431568957e-09
all O 0 4.082754134770994e-09
mutations O 0 4.4417081568326466e-08
. O 0 4.4146261757305183e-07

The O 0 3.984522720656969e-07
mutations O 0 2.8487558978440575e-08
include O 0 4.626102168003854e-09
three O 0 1.0629253033300756e-09
single O 0 8.630704151357804e-09
base O 0 1.7577282562797336e-07
deletions O 0 7.352332431764808e-07
, O 0 8.038949061983658e-09
one O 0 3.2123625981483883e-09
splice O 0 3.0874335266162234e-07
site O 0 2.7270573355053784e-08
mutation O 0 3.800757930605414e-09
and O 0 2.093380357948149e-09
10 O 0 2.541412982282054e-07
missense O 0 1.0208699677605182e-05
mutations O 0 1.7061279322660994e-06
. O 0 5.828017037856625e-06

One O 0 4.372770945337834e-07
missense O 0 7.770167030685116e-06
mutation O 0 1.6844366257373622e-07
( O 0 7.744352714667002e-09
L236P O 0 2.092381009788369e-06
) O 0 1.4971248685213823e-09
was O 0 2.2278650035900682e-09
found O 0 8.04383365471395e-11
in O 0 5.24191488826542e-11
a O 0 2.6008439846236797e-10
homozygous O 0 7.324458262125688e-10
state O 0 3.6940898257009636e-11
in O 0 3.9926048578386997e-10
two O 0 3.502689527312697e-10
consanguineous O 0 4.091159411245826e-08
families O 0 4.299234926397055e-11
and O 0 1.3692621689265216e-11
in O 0 4.708367723482709e-11
a O 0 1.2928560999547756e-10
heterozygous O 0 4.4858287223670246e-11
state O 0 1.7916477329515956e-11
in O 0 2.367435969485854e-10
five O 0 3.3075372996016483e-10
additional O 0 4.8304191757608805e-09
non O 0 6.877338591948501e-07
- O 0 2.2956126031203894e-06
consanguineous O 0 8.971193892648444e-06
families O 0 5.8407650271874445e-08
. O 0 4.594014342274022e-07

Another O 0 4.38356806853335e-07
missense O 0 5.118978606333258e-06
mutation O 0 1.0093283009382503e-07
( O 0 6.163546117932128e-09
T416P O 0 1.0082572998726391e-06
) O 0 6.548005471174179e-10
was O 0 1.6492547327828788e-09
found O 0 6.90281096171752e-11
in O 0 2.0173104506304718e-11
a O 0 6.753178571905494e-11
homozygous O 0 2.1973940722563867e-10
state O 0 1.5696392102748646e-11
in O 0 1.0683781637155221e-10
one O 0 1.212063505118266e-10
family O 0 1.55128149909034e-11
and O 0 1.4304490751626542e-11
in O 0 5.509996625630009e-11
a O 0 1.8869157625278632e-10
heterozygous O 0 4.4807407784119846e-11
state O 0 3.1228870184252244e-11
in O 0 7.998872120218437e-10
four O 0 5.845844253116184e-09
families O 0 5.910828715371963e-09
. O 0 1.0157536678434553e-07

Pendred B-Disease 0 0.02176351100206375
patients O 0 8.677707796778122e-07
in O 0 7.731050799542061e-10
three O 0 1.8342762031497983e-10
non O 0 2.4176248558660518e-08
- O 0 2.1704542163547558e-08
consanguineous O 0 2.1123373983300553e-07
families O 0 1.482114014850211e-10
were O 0 2.0294682601118552e-10
shown O 0 1.2896346490709476e-10
to O 0 3.4929290015917047e-10
be O 0 1.757612722030899e-09
compound O 0 3.629315870057326e-07
heterozygotes O 0 3.5489676974975737e-07
for O 0 1.4479867971317617e-08
L236P O 0 6.451976787502645e-06
and O 0 8.383425154079305e-08
T416P O 0 0.00018498887948226184
. O 0 1.5718864005975774e-06

In O 0 9.88330484119615e-09
total O 0 1.7038160882165698e-09
, O 0 4.1851561105588075e-10
one O 0 9.4759998459093e-11
or O 0 2.4673801890529035e-10
both O 0 1.197026644472743e-10
of O 0 4.1052880539460546e-10
these O 0 3.475681548126275e-11
mutations O 0 4.1927763344551394e-11
were O 0 8.399466538966394e-11
found O 0 3.958964059358472e-11
in O 0 4.778775292146875e-11
nine O 0 4.61078980551477e-10
of O 0 3.779826729388702e-10
the O 0 6.237790839414004e-10
14 O 0 1.10555689047942e-08
families O 0 1.5836664202240058e-09
analyzed O 0 1.0210195000581734e-07
. O 0 3.2979218644868524e-07

The O 0 5.383146373105774e-08
identification O 0 2.450393878916657e-07
of O 0 4.5474994436744964e-08
two O 0 4.388760910245537e-09
frequent O 0 1.4579690343907714e-08
PDS B-Disease 0 3.6729062458107364e-07
mutations O 0 8.354827940593168e-10
will O 0 2.132112264519037e-10
facilitate O 0 1.3147205102370663e-08
the O 0 4.9376081001639704e-09
molecular O 0 3.432476773923554e-07
diagnosis O 0 0.06050380691885948
of O 0 2.1462299628183246e-05
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 2.3393440642394125e-05

Insertional O 0 0.00012722695828415453
mutation O 0 7.637302701368753e-08
by O 0 1.4114035495893518e-09
transposable O 0 1.0538194601394935e-06
element O 0 8.907019832804508e-08
, O 0 5.248843581995288e-09
L1 O 0 1.0526222240514471e-06
, O 0 1.943245120372694e-09
in O 0 1.971611540696472e-09
the O 0 5.3710035530230016e-08
DMD B-Disease 1 1.0
gene O 0 1.0602089872691067e-07
results O 0 1.1055104387480696e-08
in O 0 4.918510754237104e-08
X B-Disease 1 0.9999998807907104
- I-Disease 1 0.999995231628418
linked I-Disease 1 0.969334602355957
dilated I-Disease 1 0.997409999370575
cardiomyopathy I-Disease 1 1.0
. O 0 6.944967753952369e-05

X B-Disease 1 0.9999396800994873
- I-Disease 1 0.9999895095825195
linked I-Disease 1 0.9993919134140015
dilated I-Disease 1 1.0
cardiomyopathy I-Disease 1 1.0
( O 0 4.810286782230833e-07
XLDCM B-Disease 1 0.9999711513519287
) O 0 1.6263385083092885e-09
is O 0 8.231258036284217e-11
a O 0 3.3804495314093685e-10
clinical O 0 2.644758367864597e-08
phenotype O 0 2.0307092896132417e-08
of O 0 9.38942079642402e-08
dystrophinopathy B-Disease 0 0.0004063206724822521
which O 0 6.887716508252595e-10
is O 0 5.226799895674539e-11
characterized O 0 1.0777397030370395e-10
by O 0 1.1507762798235177e-10
preferential O 0 1.4446106888499344e-07
myocardial B-Disease 0 0.2736252248287201
involvement I-Disease 0 3.100551992929468e-08
without O 0 2.613745220259034e-09
any O 0 1.1893781515226465e-09
overt O 0 4.895356653378258e-08
clinical O 0 6.509483228001045e-07
signs O 0 3.583658383377042e-07
of O 0 9.364787547383457e-05
skeletal B-Disease 1 1.0
myopathy I-Disease 1 1.0
. O 1 0.9996126294136047

To O 0 2.228911633039843e-08
date O 0 1.05685941775846e-07
, O 0 2.0459482996670886e-09
several O 0 1.1197148069852503e-10
mutations O 0 1.6114576339987252e-10
in O 0 3.551658689371351e-10
the O 0 1.2820994754747517e-07
Duchenne B-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
gene O 0 4.976391574018635e-05
, O 0 3.0903549941285746e-06
DMD O 1 1.0
, O 0 3.022656258622192e-08
have O 0 3.079549115714286e-10
been O 0 1.1889647599794273e-10
identified O 0 8.484564439914521e-11
in O 0 6.126970458764092e-11
patients O 0 7.263883383679115e-10
with O 0 3.343537946509656e-11
XLDCM B-Disease 0 0.0038793468847870827
, O 0 3.493257239028935e-09
but O 0 3.0095487213444017e-10
a O 0 3.731702724607544e-10
pathogenic O 0 8.404887896773516e-10
correlation O 0 3.5209218873788473e-10
of O 0 7.595355455691788e-10
these O 0 3.054354269504955e-10
cardiospecific O 0 6.128469181021501e-07
mutations O 0 5.993658902525567e-09
in O 0 6.905873206619617e-09
DMD O 1 1.0
with O 0 4.041936563226045e-09
the O 0 9.301362524638535e-07
XLDCM B-Disease 1 1.0
phenotype O 0 1.2177122243883787e-07
has O 0 5.325806462508353e-10
remained O 0 1.3077478655532104e-08
to O 0 1.3148803157392308e-09
be O 0 1.2257675763294174e-08
elucidated O 0 1.128547046391759e-05
. O 0 2.7167006919626147e-06

We O 0 8.453964994714624e-08
report O 0 4.529293384791799e-09
here O 0 9.261472699861883e-10
the O 0 3.028874651089808e-10
identification O 0 1.0885953471984067e-08
of O 0 2.8995164047529443e-09
a O 0 9.647690424330335e-10
unique O 0 1.5873103942354305e-09
de O 0 1.4694774108647835e-07
novo O 0 1.0746826006879928e-07
L1 O 0 2.5200006348313764e-07
insertion O 0 5.2916181658702044e-08
in O 0 1.7069907709554855e-09
the O 0 6.85743950512574e-09
muscle O 0 6.83379610677548e-08
exon O 0 1.3742978808295447e-06
1 O 0 6.077038392504619e-07
in O 0 1.662662185708541e-07
DMD O 1 1.0
in O 0 2.1393942972736113e-07
three O 0 4.228649785886773e-08
XLDCM B-Disease 0 0.27672135829925537
patients O 0 2.2494802465189423e-08
from O 0 8.490931291404991e-10
two O 0 2.860726378006717e-10
unrelated O 0 4.719485247051125e-09
Japanese O 0 7.740020464552799e-07
families O 0 2.44557245565602e-08
. O 0 1.8539971335940209e-07

The O 0 8.214644964255058e-08
insertion O 0 2.0036530656852847e-07
was O 0 2.7403951108340152e-08
a O 0 1.153559026079165e-09
5 O 0 8.71560068560484e-09
- O 0 1.9110398596922096e-08
truncated O 0 8.260520267810989e-09
form O 0 3.5046140989258845e-10
of O 0 7.134741131231692e-10
human O 0 2.669375553931985e-10
L1 O 0 6.785619621751948e-09
inversely O 0 1.026936424786129e-09
integrated O 0 9.189193406200502e-09
in O 0 5.152073212499886e-10
the O 0 1.5822866350490017e-09
5 O 0 2.756940986614609e-08
- O 0 3.232617018511519e-07
untranslated O 0 0.0002551331417635083
region O 0 2.014937017236207e-08
in O 0 4.274641751678132e-10
the O 0 6.130784213631557e-10
muscle O 0 4.380431573025589e-09
exon O 0 5.666172953056048e-08
1 O 0 1.023143969547391e-08
, O 0 1.7036169697171033e-10
which O 0 1.2295285449492876e-11
affected O 0 3.814916438305005e-11
the O 0 3.782255411644009e-11
transcription O 0 2.8829998388602007e-09
or O 0 3.9768116577576507e-10
the O 0 8.841540277693127e-10
stability O 0 7.708499651926104e-07
of O 0 5.806583658340969e-09
the O 0 9.339774509342647e-10
muscle O 0 1.4912909795938845e-09
form O 0 2.5033883299663273e-10
of O 0 2.8021076570183823e-09
dystrophin O 0 9.687601476571217e-08
transcripts O 0 3.426987404964166e-08
but O 0 1.456766651752872e-10
not O 0 9.077382595590322e-11
that O 0 2.48078051157119e-11
of O 0 1.2609002730812335e-09
the O 0 2.3830228457200064e-08
brain O 0 0.00010511936852708459
or O 0 2.1082069423528083e-08
Purkinje O 0 0.024572230875492096
cell O 0 1.2107440852560103e-05
form O 0 2.6089934657136382e-09
, O 0 9.37650845855842e-10
probably O 0 1.4877461040896378e-08
due O 0 6.1668270490145005e-09
to O 0 9.167376302521291e-10
its O 0 2.717562841425547e-10
unique O 0 1.5581210766058007e-09
site O 0 4.9084247777386736e-09
of O 0 5.183340423542404e-09
integration O 0 2.454634397963673e-07
. O 0 5.477135118781007e-07

We O 0 1.233491104812856e-07
speculate O 0 1.0040786690979076e-07
that O 0 1.2406813076903944e-10
this O 0 6.427479382065115e-11
insertion O 0 1.1630328700107384e-08
of O 0 5.110334377889103e-09
an O 0 2.226033107843861e-10
L1 O 0 1.111093723693557e-07
sequence O 0 3.0019482455401203e-09
in O 0 1.059026288885434e-08
DMD O 1 1.0
is O 0 9.571150538789652e-10
responsible O 0 6.976433875038879e-10
for O 0 1.7850518285733585e-10
some O 0 1.0144917544918641e-10
of O 0 4.233665640285267e-10
the O 0 1.3954756794554157e-10
population O 0 6.067841108042815e-12
of O 0 3.922615010587549e-11
Japanese O 0 1.1821144951795759e-08
patients O 0 2.5441366791056907e-09
with O 0 1.0691038332399927e-10
XLDCM B-Disease 0 3.310560350655578e-05
. O 0 1.2494554368913668e-07
. O 0 8.607935910731612e-07

Severe O 0 2.395784576947335e-05
early O 1 0.9804401993751526
- O 1 0.9999997615814209
onset O 1 1.0
obesity B-Disease 1 1.0
, O 0 9.383422394648733e-08
adrenal B-Disease 1 1.0
insufficiency I-Disease 1 1.0
and O 0 2.9701409403060097e-06
red O 1 0.9999951124191284
hair O 1 0.9964374303817749
pigmentation O 1 0.9984034895896912
caused O 0 5.968608547846088e-06
by O 0 4.373679729496871e-08
POMC O 0 0.0001914619788294658
mutations O 0 3.941362081150146e-08
in O 0 1.4314611718191372e-08
humans O 0 9.66943645153151e-08
. O 0 9.808847067915849e-08

Sequential O 0 1.1003396593878279e-06
cleavage O 0 3.0644824278169835e-07
of O 0 5.407886405350837e-08
the O 0 3.457423014552319e-09
precursor O 0 1.8008183388928956e-08
protein O 0 2.533288856465532e-10
pre O 0 1.0937405647837295e-07
- O 0 1.8875769569604017e-07
pro O 0 6.456405685639766e-07
- O 0 1.5499698520216043e-06
opiomelanocortin O 0 9.908192623697687e-06
( O 0 1.2751850242409546e-08
POMC O 0 8.276755579572637e-06
) O 0 1.346873390595249e-09
generates O 0 7.894110365391782e-10
the O 0 1.6364138932800643e-09
melanocortin O 0 1.0339423170080408e-05
peptides O 0 2.4956062816272606e-07
adrenocorticotrophin O 0 2.2661954062641598e-05
( O 0 4.439082701424013e-08
ACTH O 0 3.680967347463593e-05
) O 0 6.6279755017717434e-09
, O 0 5.934415625574729e-09
melanocyte O 0 1.2178753422631416e-05
- O 0 8.195391274057329e-06
stimulating O 0 1.045449789671693e-05
hormones O 0 2.3143941234593512e-06
( O 0 6.0284208736050005e-09
MSH O 0 1.4904499948897865e-05
) O 0 8.112912008861883e-10
alpha O 0 6.59445831274752e-09
, O 0 1.5258486141256355e-10
beta O 0 2.9243985011362383e-09
and O 0 2.590615222342052e-10
gamma O 0 2.3165345197639908e-08
as O 0 1.4912909795938845e-09
well O 0 2.2872577165600205e-09
as O 0 1.072126609713564e-09
the O 0 1.3763910011732605e-09
opioid O 0 4.1830691799304986e-08
- O 0 1.2710569485818723e-08
receptor O 0 2.243942587298875e-09
ligand O 0 8.10004010531884e-08
beta O 0 3.1132624371821294e-06
- O 0 2.5708610337460414e-05
endorphin O 0 0.0028908809181302786
. O 0 1.0812649634317495e-05

While O 0 9.351369101295859e-08
a O 0 3.456130714951655e-09
few O 0 1.6130791147261903e-09
cases O 0 2.542408228389803e-10
of O 0 5.497489130590338e-09
isolated O 0 3.3591063584026415e-06
ACTH B-Disease 1 1.0
deficiency I-Disease 0 0.003126316238194704
have O 0 3.270663739840529e-09
been O 0 3.798062309101624e-09
reported O 0 1.8569082937958115e-09
( O 0 4.42844205750248e-09
OMIM O 0 7.792957330821082e-05
201400 O 0 5.630928171740379e-06
) O 0 4.5812846849457856e-09
, O 0 1.9112358362605164e-09
an O 0 1.8009068680768792e-09
inherited O 1 0.83620685338974
POMC O 1 1.0
defect O 1 0.9999990463256836
has O 0 2.898051132405044e-09
not O 0 2.6197230496016743e-10
been O 0 4.1704781295059945e-10
described O 0 7.229342680048489e-10
so O 0 4.774231565640719e-10
far O 0 1.0970810038202217e-08
. O 0 1.3433123058348428e-07

Recent O 0 1.5951195564412046e-07
studies O 0 1.4953419835705972e-08
in O 0 3.228330658355816e-10
animal O 0 3.7311975731313396e-10
models O 0 1.09189650376873e-10
elucidated O 0 8.0510247357779e-09
a O 0 3.9642325533328915e-10
central O 0 3.489667665945717e-09
role O 0 9.667657785428219e-10
of O 0 1.0341624445686648e-08
alpha O 0 5.26734027062048e-07
- O 0 6.853690138086677e-06
MSH O 1 0.8148758411407471
in O 0 3.0073237233807504e-09
the O 0 1.5967146493878204e-09
regulation O 0 9.950793966595484e-09
of O 0 8.500232184793788e-10
food O 0 5.389819146550678e-10
intake O 0 6.994497342427408e-11
by O 0 1.675358311283015e-12
activation O 0 1.197611898540174e-09
of O 0 2.2515951325630112e-09
the O 0 8.109590332594507e-09
brain O 0 4.037986229832313e-07
melanocortin O 0 2.036459591181483e-06
- O 0 1.246886824901594e-07
4 O 0 1.7011305430969514e-07
- O 0 1.9949814600295213e-07
receptor O 0 8.828957120954328e-09
( O 0 6.582055789294827e-09
MC4 O 0 2.674845927685965e-05
- O 0 7.545229436800582e-07
R O 0 1.5071152859036374e-07
; O 0 1.2351639711027929e-09
refs O 0 6.351285719574662e-08
3 O 0 7.883806496522539e-09
- O 0 2.5739801401414297e-08
5 O 0 8.231988424256542e-09
) O 0 3.0367997005953384e-10
and O 0 1.4490544875123135e-10
the O 0 3.729233866156534e-10
linkage O 0 7.337230556458962e-08
of O 0 1.1605644445467078e-08
human O 0 1.934256488311803e-08
obesity B-Disease 1 0.9999983310699463
to O 0 3.530120917805135e-10
chromosome O 0 3.775109558290524e-09
2 O 0 1.2582558106544184e-08
in O 0 3.617657950982789e-09
close O 0 1.0510655457096618e-08
proximity O 0 2.213068306389232e-08
to O 0 3.530405523477498e-09
the O 0 1.985659281444896e-08
POMC O 0 2.726207094383426e-05
locus O 0 4.5338417464790837e-08
, O 0 8.462298084488395e-10
led O 0 1.0671934447259446e-09
to O 0 1.6265361280076718e-10
the O 0 1.0163762886872263e-10
proposal O 0 3.043978957784077e-10
of O 0 5.459784291339531e-10
an O 0 1.1561929191827858e-10
association O 0 1.2704406415764424e-09
of O 0 1.5202349601395326e-08
POMC O 1 0.9903918504714966
with O 0 1.357567303017504e-08
human O 0 1.3773333193967119e-05
obesity B-Disease 1 1.0
. O 0 1.161263980975491e-06

The O 0 6.630759941117503e-08
dual O 0 2.589151506526832e-07
role O 0 2.6106775408152316e-08
of O 0 1.9897581182704016e-07
alpha O 0 2.0158164261374623e-05
- O 0 0.00020795028831344098
MSH O 1 0.9999204874038696
in O 0 9.14195830148401e-09
regulating O 0 3.084442923295683e-08
food O 0 8.400692586008063e-09
intake O 0 4.1422496543930265e-09
and O 0 3.1920588394740435e-10
influencing O 0 5.053874474469922e-07
hair O 0 6.1732948779535946e-06
pigmentation O 0 0.00018628027464728802
predicts O 0 2.2143307631949938e-08
that O 0 3.022674818775606e-11
the O 0 1.3869738690885924e-10
phenotype O 0 7.821376324379514e-10
associated O 0 2.69665123564522e-10
with O 0 2.8134047175276677e-11
a O 0 3.542945936629849e-09
defect O 0 1.9897088066045399e-07
in O 0 1.279433892165116e-08
POMC O 0 2.934706208179705e-05
function O 0 6.425977971957764e-09
would O 0 4.688102350769441e-09
include O 0 1.4103983403401799e-07
obesity B-Disease 1 1.0
, O 0 3.6913465617516295e-09
alteration O 0 8.259482342509727e-07
in O 0 1.0691135088336523e-07
pigmentation O 1 0.9998310804367065
and O 0 6.579697219422087e-05
ACTH B-Disease 1 1.0
deficiency I-Disease 1 0.9999403953552246
. O 0 1.8919987269327976e-05

The O 0 1.1137056077359375e-07
observation O 0 6.97187090281659e-07
of O 0 6.121252837942848e-09
these O 0 1.3929448705596315e-09
symptoms O 0 4.8831491739065314e-08
in O 0 2.1447561782128588e-10
two O 0 3.255475888863657e-10
probands O 0 7.167892022152955e-07
prompted O 0 7.1131944778812795e-09
us O 0 2.0236248232663456e-09
to O 0 9.550471524732984e-10
search O 0 4.353486460217937e-09
for O 0 8.738233470140244e-10
mutations O 0 9.789082877631472e-10
within O 0 3.3512921326916967e-09
their O 0 3.1791806520686805e-08
POMC O 0 0.0001261994184460491
genes O 0 5.145292902852816e-07
. O 0 1.7303498225373914e-06

Patient O 0 2.2086167064117035e-06
1 O 0 1.148682642337917e-07
was O 0 3.570680817688299e-08
found O 0 7.882329788877485e-10
to O 0 4.1787986959640477e-10
be O 0 5.016375648203564e-10
a O 0 9.55837964333739e-10
compound O 0 3.190345765347047e-08
heterozygote O 0 4.7062382435569816e-08
for O 0 2.5008828341555045e-10
two O 0 8.836546078194729e-11
mutations O 0 2.2125089260693898e-10
in O 0 4.377647966347098e-10
exon O 0 1.372916784703193e-07
3 O 0 1.0856513910084686e-07
( O 0 1.2130847437674674e-08
G7013T O 0 3.804208745350479e-06
, O 0 3.2090798907091767e-09
C7133delta O 0 3.1846920478528773e-07
) O 0 2.988270464410192e-10
which O 0 1.6884637785152812e-11
interfere O 0 2.653329778112834e-10
with O 0 8.673150739268998e-12
appropriate O 0 2.2594854875990222e-09
synthesis O 0 1.021740345663602e-07
of O 0 3.0094710723460594e-08
ACTH O 0 4.341823569120606e-06
and O 0 3.410490023725288e-08
alpha O 0 1.0467427273397334e-05
- O 0 0.00021956657292321324
MSH O 1 0.908564031124115
. O 0 1.3675210539076943e-05

Patient O 0 3.7074123611091636e-06
2 O 0 1.947493188936278e-07
was O 0 4.993603752723175e-08
homozygous O 0 5.850306017407547e-09
for O 0 3.7705022437606317e-10
a O 0 1.308742780814498e-09
mutation O 0 1.9147312624312463e-09
in O 0 1.7105890037782956e-09
exon O 0 4.012378269635519e-07
2 O 0 3.5060057257396693e-07
( O 0 5.964592020291093e-08
C3804A O 0 5.012497240386438e-06
) O 0 6.104742933388252e-09
which O 0 3.196630071755635e-09
abolishes O 0 1.6589591496085632e-06
POMC O 0 0.00015963024634402245
translation O 0 3.9481954445363954e-05
. O 0 5.032749413658166e-06

These O 0 3.923765490299047e-08
findings O 0 1.2883353939230346e-08
represent O 0 6.950985342868421e-10
the O 0 7.406655844199861e-10
first O 0 1.2145588978995647e-09
examples O 0 1.9020860442253706e-09
of O 0 1.3858797442978243e-09
a O 0 7.64244312279061e-09
genetic B-Disease 1 0.9999396800994873
defect I-Disease 1 0.9999973773956299
within O 0 2.05723491575327e-08
the O 0 7.381584232746263e-09
POMC O 0 4.734021331387339e-06
gene O 0 1.2980702068787764e-09
and O 0 3.363483103147047e-10
define O 0 3.6795793079136274e-09
a O 0 4.2078096562647715e-09
new O 0 8.703327836201424e-08
monogenic B-Disease 1 1.0
endocrine I-Disease 1 1.0
disorder I-Disease 0 2.1503559764823876e-05
resulting O 0 6.231535842893265e-10
in O 0 1.1631959284663651e-10
early O 0 1.5434912938872003e-06
- O 0 0.005150618962943554
onset O 1 1.0
obesity B-Disease 1 1.0
, O 0 8.643590376777865e-08
adrenal B-Disease 1 1.0
insufficiency I-Disease 1 1.0
and O 0 5.667043751600431e-06
red O 1 0.999961256980896
hair O 1 0.9992485642433167
pigmentation O 1 0.9999964237213135
. O 0 5.010910172131844e-06
. O 0 3.741510454347008e-06

A O 0 9.103729894377466e-07
European O 0 1.9222194680423854e-07
multicenter O 0 1.0412767551315483e-05
study O 0 1.192129701621525e-07
of O 0 4.964165327692172e-07
phenylalanine B-Disease 1 1.0
hydroxylase I-Disease 1 1.0
deficiency I-Disease 1 1.0
: O 0 1.863604559559917e-08
classification O 0 1.0162435337690567e-08
of O 0 3.97492527781651e-09
105 O 0 2.10020445479131e-08
mutations O 0 1.0166206071415829e-10
and O 0 3.787583094383429e-11
a O 0 3.125820158267345e-10
general O 0 4.803288433663511e-09
system O 0 5.660844681898425e-09
for O 0 1.4470583620251887e-09
genotype O 0 1.3819684951954514e-08
- O 0 8.682453511710264e-08
based O 0 2.114368413685952e-08
prediction O 0 6.634320470766397e-07
of O 0 7.332936036164028e-08
metabolic O 0 2.0330118786660023e-05
phenotype O 0 8.059138281168998e-07
. O 0 3.6563545791068464e-07

Phenylketonuria B-Disease 1 0.9999004602432251
( O 0 2.6600475848681526e-06
PKU B-Disease 1 0.9494808316230774
) O 0 9.936061928783602e-08
and O 0 7.17116108717164e-08
mild B-Disease 1 0.6936614513397217
hyperphenylalaninemia I-Disease 1 1.0
( O 0 5.223775588092394e-06
MHP B-Disease 1 1.0
) O 0 3.740735721180499e-08
are O 0 1.7334627955278847e-08
allelic B-Disease 0 2.889920142479241e-05
disorders I-Disease 0 0.0009641745127737522
caused O 0 8.313660870840067e-09
by O 0 1.0704259700844432e-10
mutations O 0 7.603497692576511e-11
in O 0 2.8585939171321684e-10
the O 0 3.82594533832048e-09
gene O 0 2.4389890107556766e-09
encoding O 0 7.565332538206349e-08
phenylalanine O 0 2.463212922521052e-06
hydroxylase O 0 7.254790398292243e-05
( O 0 1.4437983963944134e-06
PAH O 1 1.0
) O 0 1.5130081010283902e-06
. O 0 2.8233537250343943e-06

Previous O 0 2.3656379255498905e-07
studies O 0 6.88068482190829e-08
have O 0 6.724621415266085e-10
suggested O 0 5.85426596089178e-10
that O 0 1.0881348773417177e-11
the O 0 2.855868874718226e-10
highly O 0 1.0948651762987538e-08
variable O 0 2.423802811790665e-07
metabolic O 0 0.18912045657634735
phenotypes O 0 3.476834172033705e-05
of O 0 0.23971453309059143
PAH B-Disease 1 1.0
deficiency I-Disease 1 1.0
correlate O 0 2.0118543034186587e-05
with O 0 2.831190215601964e-07
PAH O 1 1.0
genotypes O 0 0.019320007413625717
. O 0 9.753140147950035e-06

We O 0 4.3559973050832923e-07
identified O 0 7.526602274765537e-08
both O 0 5.229197963529941e-09
causative O 0 2.739074034252553e-07
mutations O 0 2.2931997634145773e-08
in O 0 3.730053599326766e-09
686 O 0 1.3638423297379632e-06
patients O 0 7.746350405568592e-08
from O 0 1.5650369888930982e-09
seven O 0 4.6448280777156015e-09
European O 0 3.2955128403955314e-08
centers O 0 1.986921347452153e-07
. O 0 7.731766515917116e-08

On O 0 5.991466878185747e-08
the O 0 1.4111235513425413e-09
basis O 0 1.4917576063311344e-09
of O 0 6.574022437533245e-10
the O 0 4.0825653968568076e-10
phenotypic O 0 2.7470190566702968e-09
characteristics O 0 1.5268247777200372e-09
of O 0 5.73374858703346e-09
297 O 0 2.5222409050229544e-08
functionally O 0 1.336687631692257e-07
hemizygous O 0 2.46896775024652e-06
patients O 0 1.3158745204577826e-08
, O 0 9.067242096039152e-11
105 O 0 8.624812863899933e-09
of O 0 3.0029103648132605e-09
the O 0 1.4678177562288397e-09
mutations O 0 4.853347723710044e-10
were O 0 8.848558552543295e-10
assigned O 0 2.7786965617337955e-08
to O 0 3.987180807740742e-09
one O 0 2.917000418989346e-09
of O 0 3.530742365143169e-09
four O 0 9.213126928031556e-10
arbitrary O 0 4.389288932316049e-09
phenotype O 0 6.068869407016564e-09
categories O 0 1.628015233734459e-08
. O 0 2.3834303419789649e-07

We O 0 2.357329975666289e-07
proposed O 0 1.6377136091705324e-08
and O 0 3.993414043890198e-09
tested O 0 7.738490737096981e-09
a O 0 2.4496549233532505e-10
simple O 0 3.908963708276758e-10
model O 0 1.7536469498757867e-10
for O 0 1.0038590098071509e-10
correlation O 0 1.993809145561798e-10
between O 0 1.4872537923427132e-10
genotype O 0 1.5599416869349625e-08
and O 0 6.655884288164771e-09
phenotypic O 0 1.2754932754432957e-07
outcome O 0 3.561081314273906e-07
. O 0 3.989598098996794e-06

The O 0 9.99104017296304e-08
observed O 0 2.3412228600250273e-08
phenotype O 0 1.511313030277961e-08
matched O 0 1.2951329786403676e-08
the O 0 1.605589328157464e-09
predicted O 0 8.34795077508943e-09
phenotype O 0 2.122755971001311e-09
in O 0 1.9887576307997534e-10
79 O 0 6.762569171314681e-09
% O 0 6.871311158951343e-11
of O 0 7.98863752926593e-11
the O 0 3.516759106148015e-11
cases O 0 1.376294998106653e-11
, O 0 7.890249217878953e-12
and O 0 1.867373269903716e-11
in O 0 6.120125933817278e-11
only O 0 4.990568028273579e-11
5 O 0 5.833077354466809e-10
of O 0 4.423306998457832e-10
184 O 0 5.1421995550526844e-09
patients O 0 5.220856191812118e-09
was O 0 1.5933802055556612e-09
the O 0 1.2253158487851579e-09
observed O 0 2.4125517139594876e-09
phenotype O 0 5.954151616194281e-10
more O 0 4.333028727487864e-11
than O 0 3.63538955883147e-11
one O 0 2.10262206951084e-11
category O 0 3.1470215322570994e-10
away O 0 3.3950334210608446e-10
from O 0 2.1269376537791373e-10
that O 0 1.6692550119934424e-10
expected O 0 2.077209515505274e-08
. O 0 4.615924069639732e-07

Among O 0 9.889192398304658e-08
the O 0 5.119456414348633e-09
seven O 0 7.489476816502361e-10
contributing O 0 5.658467028268888e-10
centers O 0 5.930044788549083e-10
, O 0 1.538780734777756e-11
the O 0 2.236087530416153e-11
proportion O 0 8.909148419000701e-11
of O 0 3.67113728305668e-10
patients O 0 5.194809027386782e-10
for O 0 6.583768946688551e-11
whom O 0 1.178718567196313e-09
the O 0 1.1625399531922653e-09
observed O 0 2.1250652348925314e-09
phenotype O 0 1.3615651939247186e-09
did O 0 8.89953943872257e-10
not O 0 5.381241563462424e-10
match O 0 8.09598965645364e-09
the O 0 2.1054493704042443e-09
predicted O 0 4.3167576180280776e-09
phenotype O 0 4.5819906202559935e-10
was O 0 4.0621683794483943e-10
4 O 0 1.0666458827301994e-09
% O 0 1.7411952435431033e-10
- O 0 5.032459338139006e-09
23 O 0 6.024375220903266e-09
% O 0 5.268027680749299e-10
( O 0 5.762921251317721e-10
P O 0 3.78155426972171e-08
< O 0 5.172440253886634e-08
. O 0 8.051205258041705e-10
0001 O 0 3.05741104966728e-06
) O 0 1.1232746954803474e-09
, O 0 4.222536487130668e-10
suggesting O 0 2.1080692746977547e-09
that O 0 1.9226341005373904e-11
differences O 0 3.121516933823898e-11
in O 0 4.576983236859178e-11
methods O 0 2.2444477387750794e-09
used O 0 3.525007508109468e-10
for O 0 1.514664782487074e-10
mutation O 0 1.5241246043018464e-09
detection O 0 5.148836521584599e-07
or O 0 4.101111006349356e-09
phenotype O 0 1.2708532892702351e-08
classification O 0 1.6629827515046713e-09
may O 0 3.1399466360326755e-10
account O 0 1.395087240174675e-10
for O 0 5.2830479574383915e-11
a O 0 1.0328269489656705e-10
considerable O 0 1.3924666975029254e-09
proportion O 0 5.256515223095448e-10
of O 0 5.436541439252096e-09
genotype O 0 6.440374136218452e-07
- O 0 2.2688054741593078e-05
phenotype O 0 1.8914670363301411e-06
inconsistencies O 0 3.516085143928649e-06
. O 0 4.649821676139254e-06

Our O 0 4.2910249931082944e-07
data O 0 1.096537474154502e-07
indicate O 0 8.274239071681677e-09
that O 0 2.7693708437581677e-10
the O 0 7.96436339101092e-09
PAH O 1 1.0
- O 0 1.3657707313541323e-05
mutation O 0 1.4829271144378708e-08
genotype O 0 5.524451118787965e-09
is O 0 4.6649153290223566e-11
the O 0 2.6209576176050575e-10
main O 0 6.914915307021374e-09
determinant O 0 2.9508125720667522e-08
of O 0 4.3021618267857775e-08
metabolic O 1 0.9999884366989136
phenotype O 0 4.643501938517147e-08
in O 0 8.424918540583803e-10
most O 0 3.0482913970786285e-09
patients O 0 1.0887826107364162e-07
with O 0 7.261064638441894e-08
PAH B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 1 0.912649929523468

In O 0 1.9777518289743057e-08
the O 0 2.2298374258156173e-09
present O 0 2.072166049860158e-10
study O 0 5.445743300747097e-10
, O 0 3.9473598001382726e-11
the O 0 1.0946573508752167e-10
classification O 0 1.2282570516219948e-09
of O 0 5.585170104183135e-09
105 O 0 1.358359440928325e-06
PAH O 1 1.0
mutations O 0 1.294515517002992e-08
may O 0 1.2193404064220204e-09
allow O 0 1.2376331071095592e-09
the O 0 1.4695266115083427e-09
prediction O 0 2.9186994154883905e-08
of O 0 3.4532445791768396e-09
the O 0 1.199973898025064e-09
biochemical O 0 4.5367656298367365e-08
phenotype O 0 1.8380035271547968e-09
in O 0 1.4419770932860843e-10
> O 0 3.5347600402246826e-08
10 O 0 2.8382436401130917e-09
, O 0 3.68178182386103e-10
000 O 0 3.0566944531074114e-08
genotypes O 0 9.378910093005288e-09
, O 0 1.7564991128260488e-10
which O 0 2.203453218496687e-11
may O 0 4.871002212691877e-11
be O 0 3.104073595383561e-11
useful O 0 5.222776655600114e-10
for O 0 5.4082287259671347e-11
the O 0 7.035242388653273e-10
management O 0 1.864600029932717e-08
of O 0 6.196931678914552e-08
hyperphenylalaninemia B-Disease 1 1.0
in O 0 1.151128046217309e-07
newborns O 0 1.1141256663904642e-06
. O 0 3.5423605027062877e-07

Somatic O 0 4.943485328112729e-05
instability O 0 2.679969838936813e-06
of O 0 1.552613611011111e-07
the O 0 7.227487941463551e-08
CTG O 0 1.8425345842842944e-05
repeat O 0 3.1099278885449166e-07
in O 0 1.7668432050754745e-08
mice O 0 2.95445623521573e-08
transgenic O 0 1.5186410351475388e-08
for O 0 2.0096011521530954e-09
the O 0 1.3960423075332073e-06
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
region O 0 1.2736581993522123e-06
is O 0 1.6057721818896198e-10
age O 0 1.0950604312220946e-10
dependent O 0 9.292185770837236e-11
but O 0 6.410702264175727e-12
not O 0 2.3866035883668424e-11
correlated O 0 5.972270455956163e-10
to O 0 4.458407532048625e-10
the O 0 4.980816648014752e-09
relative O 0 1.9116075122838083e-07
intertissue O 0 1.1346812698320718e-06
transcription O 0 2.048988392289175e-07
levels O 0 9.873963335849112e-08
and O 0 3.310115559429505e-08
proliferative O 0 0.0005636326386593282
capacities O 0 0.00013136118650436401
. O 0 1.1564383385120891e-05

A O 0 2.7087817215942778e-05
( O 0 5.586748557107057e-07
CTG O 0 5.649631566484459e-05
) O 0 1.5261180763559423e-08
nexpansion O 0 8.048362474255555e-07
in O 0 8.109988236526533e-10
the O 0 1.2839631580163768e-09
3 O 0 6.411228525848855e-08
- O 0 1.4090257991483668e-06
untranslated O 0 0.04167045280337334
region O 0 1.8784902522384073e-07
( O 0 5.515838452652133e-09
UTR O 0 2.1310515876393765e-05
) O 0 2.747521987700452e-09
of O 0 8.014636954101206e-09
the O 0 1.6331531682567402e-08
DM O 1 0.9999994039535522
protein O 0 3.1216469409400815e-08
kinase O 0 9.62881898658452e-08
gene O 0 1.9368886938764263e-08
( O 0 4.6497743433349115e-09
DMPK O 0 0.00014097473467700183
) O 0 1.1540916000640777e-09
is O 0 1.3624112948917855e-10
responsible O 0 7.568804472057877e-10
for O 0 1.98315275312666e-09
causing O 0 1.6607273209956475e-05
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.0003504827036522329
DM B-Disease 1 1.0
) O 0 1.4824146319369902e-06
. O 0 4.752178028866183e-06

Major O 0 2.7093371954833856e-06
instability O 0 6.2233975768322125e-06
, O 0 2.3891657541241784e-09
with O 0 8.721245947640455e-11
very O 0 1.829492946026079e-10
large O 0 1.7237282434745538e-10
expansions O 0 4.9304937910221724e-09
between O 0 7.205578494984266e-11
generations O 0 1.060396104257677e-09
and O 0 8.442576499012588e-11
high O 0 1.5335082093059782e-09
levels O 0 1.198608323704775e-09
of O 0 1.429231621941085e-09
somatic O 0 1.1035448324037134e-06
mosaicism O 0 6.103119631006848e-06
, O 0 1.4438656936732741e-09
is O 0 1.7636024585154786e-10
observed O 0 8.556937935999542e-10
in O 0 3.3743055016799417e-09
patients O 0 1.196898296029758e-07
. O 0 1.6966362181847217e-07

There O 0 3.4805825777084465e-08
is O 0 4.993665481123344e-10
a O 0 3.456195052375932e-10
good O 0 4.781512963347723e-10
correlation O 0 1.1906509111980768e-10
between O 0 3.805701240255921e-11
repeat O 0 2.759827921750002e-09
size O 0 1.785600889370187e-09
( O 0 1.1696930091176228e-09
at O 0 4.2521839382914095e-09
least O 0 2.9041305471544376e-10
in O 0 4.063633041173631e-10
leucocytes O 0 2.541076185025304e-07
) O 0 7.044856920046527e-10
, O 0 3.182368812915115e-10
clinical O 0 8.907729664997532e-09
severity O 0 8.28551449671977e-09
and O 0 4.326481950478467e-10
age O 0 7.112638478190547e-09
of O 0 3.9432947573914134e-08
onset O 0 0.00013279402628540993
. O 0 6.625917308156204e-07

The O 0 2.0711249817395583e-06
trinucleotide O 0 0.00026286463253200054
repeat O 0 5.174118200557132e-07
instability O 0 2.5958811988857633e-07
mechanisms O 0 1.253548020940798e-07
involved O 0 4.826790078737986e-09
in O 0 1.8083289532455638e-08
DM B-Disease 1 1.0
and O 0 5.144988790561911e-07
other O 0 1.0848647491457086e-07
human O 0 3.9777037841304264e-07
genetic B-Disease 1 1.0
diseases I-Disease 1 1.0
are O 0 1.6119310053408498e-10
unknown O 0 3.093781586471778e-08
. O 0 5.5388976960557557e-08

We O 0 2.1549465145653812e-07
studied O 0 3.887042794303852e-07
somatic O 0 2.291712235091836e-06
instability O 0 1.0325133104061024e-07
by O 0 5.08723452252724e-10
measuring O 0 7.7815025534278e-09
the O 0 8.760646097449865e-10
CTG O 0 7.957350476317515e-07
repeat O 0 2.9555721425822412e-08
length O 0 2.519787267729612e-09
at O 0 3.0671409856353193e-09
several O 0 1.5112826268204316e-10
ages O 0 1.1699652358032608e-09
in O 0 1.4773443579585432e-10
various O 0 9.946766743595958e-10
tissues O 0 1.6950391312775537e-08
of O 0 3.598746189936719e-09
transgenic O 0 3.685853755541757e-08
mice O 0 7.112502586892333e-09
carrying O 0 4.192652447443379e-09
a O 0 9.404992340478202e-09
( O 0 5.6658272740151006e-08
CTG O 0 1.179610080725979e-05
) O 0 1.66936491297065e-08
55expansion O 0 1.5138250546442578e-06
surrounded O 0 2.493112738477521e-08
by O 0 6.054182710713008e-10
45 O 0 5.925898882708225e-09
kb O 0 1.1708636549201401e-07
of O 0 1.0075833500877707e-08
the O 0 1.3721845881775607e-08
human O 0 5.782746370641689e-08
DM B-Disease 1 1.0
region O 0 4.6527043195965234e-07
, O 0 3.0942937101485768e-09
using O 0 1.5877745340731053e-08
small O 0 2.1282748008388808e-08
- O 0 1.8066174334308016e-06
pool O 0 2.5466586066613672e-06
PCR O 0 1.0180680874327663e-05
. O 0 2.8700917482638033e-06

These O 0 8.796099848495942e-08
mice O 0 8.350773583742921e-08
have O 0 1.295853008231873e-10
been O 0 9.345543783290111e-11
shown O 0 6.828223403365641e-11
to O 0 2.2389991249927021e-10
reproduce O 0 2.23034790636234e-09
the O 0 4.772893191784533e-10
intergenerational O 0 1.0746494361058012e-08
and O 0 2.183124347965304e-09
somatic O 0 7.137999773476622e-07
instability O 0 7.92533114690741e-08
of O 0 8.91490259391503e-09
the O 0 5.569978256403374e-09
55 O 0 6.189702617120929e-08
CTG O 0 1.3494566246663453e-06
repeat O 0 3.1656270493840566e-08
suggesting O 0 1.3300506473967744e-08
that O 0 7.522400757853376e-11
surrounding O 0 1.440882829717438e-10
sequences O 0 5.94182827939882e-11
and O 0 9.71178762410041e-11
the O 0 2.911040852815461e-10
chromatin O 0 2.627200235139071e-09
environment O 0 2.441935542663032e-09
are O 0 5.643740336180869e-11
involved O 0 2.624744588342054e-10
in O 0 6.313547462610813e-10
instability O 0 3.087227469222853e-07
mechanisms O 0 9.767195479071233e-06
. O 0 1.735307364469918e-06

As O 0 3.76609285979157e-08
observed O 0 3.2732598853613126e-09
in O 0 2.192746817453184e-10
some O 0 7.838771298729341e-11
of O 0 3.6229871880344433e-10
the O 0 7.416721126141113e-10
tissues O 0 4.709012912940125e-08
of O 0 1.921497414514306e-07
DM B-Disease 1 1.0
patients O 0 0.0007786062196828425
, O 0 4.476591319857448e-10
there O 0 1.2862347298359111e-10
is O 0 2.1866269211967548e-11
a O 0 8.070357576661635e-11
tendency O 0 3.6565736549754035e-10
for O 0 2.442772650823599e-10
repeat O 0 4.464792091596337e-09
length O 0 2.7144613223839542e-09
and O 0 3.737396170322427e-09
somatic O 0 9.930906799127115e-07
mosaicism O 0 5.193734864405997e-07
to O 0 2.1222044954694042e-10
increase O 0 7.140510405179157e-11
with O 0 1.842585979627831e-11
the O 0 8.934541440019927e-10
age O 0 2.66800248560628e-09
of O 0 2.909410268259194e-09
the O 0 1.649834402428496e-08
mouse O 0 1.0241133168165106e-06
. O 0 4.6683138066327956e-07

Furthermore O 0 6.94457071404031e-07
, O 0 9.58655732574698e-09
we O 0 1.5782627427185503e-09
observed O 0 1.2326504261750415e-09
no O 0 3.73454378532756e-10
correlation O 0 1.9699417097562844e-10
between O 0 9.701215525348417e-11
the O 0 2.6937121422321297e-09
somatic O 0 5.8069126680493355e-06
mutation O 0 4.6105391504625004e-08
rate O 0 1.662120041601156e-07
and O 0 1.9575496779111745e-08
tissue O 0 3.944502168451436e-06
proliferation O 0 0.00044919681386090815
capacity O 0 2.2478604932985036e-06
. O 0 1.5231394172587898e-06

The O 0 4.3956077888651635e-07
somatic O 0 3.092275437666103e-05
mutation O 0 5.1203766560092845e-08
rates O 0 2.101354290573454e-08
in O 0 1.963759155287903e-10
different O 0 1.8521108258173768e-10
tissues O 0 2.5467400632805948e-08
were O 0 3.27657034837614e-09
also O 0 2.3231604140416806e-10
not O 0 4.319058999335823e-11
correlated O 0 2.753601235916392e-10
to O 0 1.9251412963772196e-10
the O 0 9.960929858721101e-10
relative O 0 2.993967029851774e-08
inter O 0 6.344251346490637e-08
- O 0 9.988960982809658e-07
tissue O 0 2.3352784239705215e-07
difference O 0 2.2143338274105417e-09
in O 0 7.841493426807844e-11
transcriptional O 0 4.077460591389581e-10
levels O 0 6.011859898791272e-10
of O 0 1.244969544123009e-10
the O 0 2.890701567004328e-10
three O 0 2.5117583013489764e-10
genes O 0 1.088470202859071e-09
( O 0 2.9322737571391144e-09
DMAHP O 0 7.255731907207519e-05
, O 0 9.6388657055968e-09
DMPK O 0 2.9619339329656214e-05
and O 0 4.071369463787278e-09
59 O 0 5.037935935092719e-08
) O 0 4.236912765076539e-10
surrounding O 0 1.2533808435577498e-09
the O 0 1.179017661279147e-09
repeat O 0 2.4201161963333107e-08
. O 0 2.2450052483691252e-08
. O 0 2.847656617177563e-07

A O 0 9.635504056859645e-07
novel O 0 2.6245001549796143e-07
missense O 0 2.781809598673135e-06
mutation O 0 1.6904674993156732e-08
in O 0 2.1306985065194795e-09
patients O 0 6.450747491726361e-09
from O 0 5.669281155640249e-10
a O 0 3.6526581759233068e-09
retinoblastoma B-Disease 0 4.806751348951366e-06
pedigree O 0 1.3718125728701125e-06
showing O 0 2.9389495281861855e-08
only O 0 2.7922375522848597e-09
mild O 0 1.0645611503434793e-08
expression O 0 1.2185452646917838e-09
of O 0 2.7160771409739937e-09
the O 0 6.397752549958113e-09
tumor B-Disease 0 2.241750507891993e-06
phenotype O 0 2.498890410151944e-07
. O 0 3.5512903195922263e-07

We O 0 3.525654221903096e-07
have O 0 7.820276870518228e-09
used O 0 3.4430833739662603e-09
single O 0 2.244229246883833e-09
strand O 0 7.937052792783561e-09
conformation O 0 3.690204530837349e-10
polymorphism O 0 2.28780772104642e-09
analysis O 0 3.0375063575505123e-10
to O 0 9.069801854000303e-11
study O 0 4.960695743072563e-10
the O 0 6.870004010117725e-10
27 O 0 3.225945732765467e-08
exons O 0 5.1626926733661094e-08
of O 0 2.7181032979939346e-09
the O 0 5.13024733805878e-09
RB1 O 0 2.0168035916867666e-06
gene O 0 1.1006791034162688e-09
in O 0 9.329301914329236e-11
individuals O 0 1.6422467552512643e-11
from O 0 2.9606075924171193e-10
a O 0 1.0760723423430818e-09
family O 0 1.1646528186304295e-09
showing O 0 8.265153894626565e-09
mild O 0 1.919749337275789e-08
expression O 0 2.6856987744849903e-09
of O 0 8.915276517029724e-09
the O 0 3.377900270606915e-08
retinoblastoma B-Disease 0 9.88491956377402e-06
phenotype O 0 1.4848312730464386e-06
. O 0 1.1065968692491879e-06

In O 0 2.380728503226237e-08
this O 0 2.0545594114906862e-09
family O 0 1.1392675691723753e-09
affected O 0 2.8896654513665965e-10
individuals O 0 1.751426607909945e-11
developed O 0 3.1305473768838965e-09
unilateral B-Disease 0 6.330567998702463e-07
tumors I-Disease 1 1.0
and O 0 1.8011654390193144e-08
, O 0 1.1466140259486224e-09
as O 0 3.0713073750909814e-10
a O 0 6.082329084833304e-11
result O 0 5.6520999686116014e-11
of O 0 4.0191636130337827e-10
linkage O 0 1.1712518066531175e-08
analysis O 0 3.3472291605107785e-09
, O 0 9.050037941271682e-10
unaffected O 0 1.2812043870269463e-08
mutation O 0 9.698353231613055e-10
carriers O 0 2.8214357516986865e-09
were O 0 3.23883608821518e-09
also O 0 1.6569796645882207e-09
identified O 0 3.0054543298518865e-09
within O 0 6.5569327745151895e-09
the O 0 3.810878723697897e-08
pedigree O 0 4.661276761908084e-06
. O 0 1.2091309145034757e-06

A O 0 3.2588658882559685e-07
single O 0 3.725959629719e-08
band O 0 1.5331764302572992e-07
shift O 0 4.387106500303162e-08
using O 0 1.7894306481025524e-08
SSCP O 0 6.698195193166612e-06
was O 0 1.1230396168571133e-08
identified O 0 2.8624362879980936e-09
in O 0 4.024356958787223e-10
exon O 0 5.331361307980842e-08
21 O 0 3.878235510512695e-09
which O 0 2.5105450704443477e-11
resulted O 0 9.711602355633175e-11
in O 0 2.4904854220575423e-11
a O 0 1.4019853333824273e-10
missense O 0 9.118135579910813e-09
mutation O 0 2.1585248866085038e-10
converting O 0 5.664462676691073e-09
a O 0 7.3927437505005855e-09
cys O 0 9.00740360521013e-06
- O 0 1.5832551071071066e-05
- O 0 1.905216049635783e-05
> O 0 1.0553850188443903e-05
arg O 0 3.16506452691101e-06
at O 0 1.842943575525169e-08
nucleotide O 0 3.4707252183352466e-08
position O 0 3.208928589515381e-08
28 O 0 6.794662255060757e-08
in O 0 1.1933872556824099e-08
the O 0 8.405007889678018e-08
exon O 0 3.3497904951218516e-05
. O 0 2.5217295842594467e-06

The O 0 1.134908643507515e-06
mutation O 0 3.260724952269811e-07
destroyed O 0 3.1768825010658475e-06
an O 0 1.8750210273310586e-08
NdeI O 0 1.1098881259385962e-05
restriction O 0 2.3430416717928892e-07
enzyme O 0 4.394786401462625e-08
site O 0 2.152619487105767e-07
. O 0 3.15302713715937e-07

Analysis O 0 6.571058008830732e-08
of O 0 1.0396308702809165e-08
all O 0 8.804551532293203e-10
family O 0 2.072553378917874e-10
members O 0 6.324041984528961e-11
demonstrated O 0 8.546026664113526e-10
that O 0 1.8523359929245586e-11
the O 0 8.0205653230081e-10
missense O 0 2.712644118219032e-07
mutation O 0 2.161043965998033e-08
co O 0 4.2415422285557725e-08
- O 0 4.594124675350031e-06
segregated O 0 2.0256248944861e-07
with O 0 4.05172201345394e-10
patients O 0 9.089592367672594e-08
with O 0 4.287314392392716e-10
tumors B-Disease 1 1.0
or O 0 3.4361445955255476e-07
who O 0 8.733588963139027e-09
, O 0 2.3505092316966625e-10
as O 0 2.819744993054485e-10
a O 0 8.006607182808878e-11
result O 0 1.6402627867062591e-10
of O 0 1.5364770566961283e-09
linkage O 0 6.745641822902826e-09
analysis O 0 2.1181050247065514e-09
had O 0 1.8241453902945182e-09
been O 0 4.933783936955649e-10
predicted O 0 1.5808718778487219e-09
to O 0 4.5268383486174457e-10
carry O 0 1.2512556324395518e-08
the O 0 5.043877848720513e-08
predisposing O 0 1.8908567653852515e-05
mutation O 0 4.410682947764144e-07
. O 0 5.502815270119754e-07

These O 0 1.605804555993018e-08
observations O 0 8.4878145401035e-08
point O 0 1.0143805795337357e-08
to O 0 4.200141900945198e-10
another O 0 5.161239768902703e-10
region O 0 2.737948756603714e-09
of O 0 4.814965315347308e-09
the O 0 6.530447738128942e-09
RB1 O 0 3.265824034315301e-06
gene O 0 1.6899959209837334e-09
where O 0 4.3759532109000077e-10
mutations O 0 3.2274319328173817e-10
only O 0 1.761951695655739e-10
modify O 0 2.308827351527043e-09
the O 0 1.0797854832489406e-09
function O 0 6.005167474398831e-10
of O 0 5.47966894082208e-10
the O 0 4.786020468827701e-10
gene O 0 3.7957426091139723e-10
and O 0 3.2039715325282714e-10
raise O 0 5.975224759424691e-09
important O 0 5.093878208128899e-09
questions O 0 2.956461520042808e-09
for O 0 5.652771029041048e-10
genetic O 0 6.600284763180753e-09
counseling O 0 4.384870688767251e-09
in O 0 3.2210224071294036e-11
families O 0 1.798550371134855e-11
with O 0 6.415742503235178e-12
these O 0 2.2482082862040897e-10
distinctive O 0 2.226455642073688e-08
phenotypes O 0 2.599510651180026e-07
. O 0 7.050334716041107e-08
. O 0 9.6213352662744e-07

Maternal B-Disease 0 0.0004663621075451374
disomy I-Disease 0 0.3360142111778259
and O 0 5.4548265325138345e-05
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
consistent O 0 0.0005219261511228979
with O 0 1.0851453069449235e-09
gamete O 0 3.650132214261248e-07
complementation O 0 5.602696546702646e-07
in O 0 8.712686683232107e-10
a O 0 4.942147802111663e-10
case O 0 6.025865917358431e-10
of O 0 2.485770478344307e-09
familial O 0 8.725483979787896e-08
translocation O 0 1.2844701302583417e-07
( O 0 6.421025378067213e-10
3 O 0 6.606166724765217e-09
; O 0 4.257123820128328e-10
15 O 0 1.2646390601389612e-08
) O 0 1.2008897209980773e-09
( O 0 1.5531451680317332e-09
p25 O 0 2.8926305617460457e-07
; O 0 1.5170711353817978e-09
q11 O 0 4.00211320084054e-07
. O 0 1.3894739803177458e-09
2 O 0 7.011738034634618e-08
) O 0 6.071361013937349e-08
. O 0 4.897411258752982e-07

Maternal B-Disease 1 0.9999827146530151
uniparental I-Disease 1 1.0
disomy I-Disease 1 1.0
( I-Disease 0 1.5949513908708468e-05
UPD I-Disease 1 1.0
) I-Disease 0 1.8843712368266097e-08
for I-Disease 0 2.126662845824967e-09
chromosome I-Disease 0 3.910220414127252e-08
15 I-Disease 0 3.0141689144613792e-09
is O 0 1.9332981396336102e-11
responsible O 0 2.9023018363605324e-11
for O 0 2.1114473017225244e-11
an O 0 1.0747134085442589e-11
estimated O 0 6.92731705331795e-11
30 O 0 3.1356134355675636e-10
% O 0 2.737684905163018e-11
of O 0 6.704715949101825e-11
cases O 0 4.548611834409577e-11
of O 0 1.3968326051383428e-08
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.003737399587407708
PWS B-Disease 1 1.0
) O 0 7.434516646753764e-07
. O 0 7.997695661288162e-07

We O 0 6.600337343343199e-08
report O 0 2.1773773895006343e-09
on O 0 7.733735318815604e-10
an O 0 3.055727892942173e-11
unusual O 0 1.531075960459205e-10
case O 0 2.1231802427301716e-10
of O 0 3.418225036355693e-09
maternal B-Disease 0 0.00044372701086103916
disomy I-Disease 0 0.0012091501848772168
15 I-Disease 0 2.985946423450514e-07
in O 0 1.1170711644581388e-07
PWS B-Disease 1 1.0
that O 0 5.730621754906906e-09
is O 0 1.4178974661049892e-10
most O 0 3.477352433778336e-11
consistent O 0 2.3481167010785953e-10
with O 0 3.35421577665751e-12
adjacent O 0 4.715829948764849e-10
- O 0 9.729578032136033e-09
1 O 0 4.691101196385716e-08
segregation O 0 7.883434705036052e-08
of O 0 3.8104772670521925e-09
a O 0 1.7821270015261348e-09
paternal O 0 1.0845833742223476e-07
t O 0 1.5967337674283044e-08
( O 0 2.5768265299319637e-10
3 O 0 1.5883492299195723e-09
; O 0 2.8873073376622926e-10
15 O 0 5.333738783974695e-09
) O 0 5.854500217949976e-10
( O 0 1.0540763817346033e-09
p25 O 0 1.6176096551134833e-07
; O 0 4.475584347574113e-10
q11 O 0 1.1142750366843757e-07
. O 0 2.659851228159482e-10
2 O 0 2.3223729606058896e-09
) O 0 1.5193696301096793e-10
with O 0 6.118515416542181e-11
simultaneous O 0 2.658667064281417e-08
maternal O 0 3.571223032849957e-07
meiotic O 0 3.271631612733472e-06
nondisjunction O 0 4.8840993258636445e-06
for O 0 1.3780939944751935e-08
chromosome O 0 2.9267084755701944e-07
15 O 0 9.230035971086181e-07
. O 0 1.7032423329510493e-06

The O 0 4.4572644242180104e-07
patient O 0 7.655460649402812e-06
( O 0 6.885171544013247e-09
J O 0 9.231505941897922e-07
. O 0 1.41532585651305e-09
B O 0 1.7202295055085415e-07
. O 0 4.89109308610125e-11
) O 0 5.935994057404415e-11
, O 0 3.4866505516095714e-11
a O 0 7.979302635297003e-11
17 O 0 5.184109808098469e-10
- O 0 3.4657883229982644e-09
year O 0 1.5673792264081499e-09
- O 0 8.774350135354325e-08
old O 0 6.346041914184752e-08
white O 0 4.42915171205982e-09
male O 0 7.575650107227716e-10
with O 0 6.177157396702881e-11
PWS B-Disease 1 1.0
, O 0 3.4821345806790305e-09
was O 0 6.358033655118334e-09
found O 0 2.2016312384298686e-10
to O 0 1.8717639937992914e-10
have O 0 4.4280507038862993e-10
47 O 0 5.7477311798947994e-09
chromosomes O 0 9.795807498491627e-10
with O 0 1.5104181794178828e-10
a O 0 2.033244150823066e-08
supernumerary O 1 0.9301640391349792
, O 0 2.19382823019032e-08
paternal O 0 1.3963444871478714e-06
der O 0 0.000431583117460832
( O 0 5.806794156626438e-09
15 O 0 9.960972491285247e-09
) O 0 1.5613452197804634e-10
consisting O 0 9.653028376632733e-10
of O 0 1.6356336285383577e-09
the O 0 1.9249550842204144e-09
short O 0 2.418750177923812e-08
arm O 0 1.0370764869094273e-07
and O 0 7.127454182409565e-09
the O 0 4.052831314993455e-08
proximal O 0 1.5948038708302192e-05
long O 0 4.7255408475166405e-08
arm O 0 8.512635929491807e-08
of O 0 2.5423963379012093e-08
chromosome O 0 5.110444334377462e-08
15 O 0 2.679989563603158e-08
, O 0 4.42530101452121e-09
and O 0 1.4911892165514473e-08
distal O 0 2.9602904760395177e-05
chromosome O 0 0.00010910427226917818
arm O 0 0.001559192780405283
3p O 1 0.9999946355819702
. O 0 3.468313661869615e-05

The O 0 7.834192388145311e-07
t O 0 1.5084654592101288e-07
( O 0 7.4610750910864e-10
3 O 0 1.932621840339266e-09
; O 0 1.2158006545970323e-10
15 O 0 1.1902723251466796e-09
) O 0 6.674628905134483e-11
was O 0 5.086303600521092e-10
present O 0 1.9098892606317364e-11
in O 0 1.6913387357320175e-11
the O 0 2.6079808451706654e-11
balanced O 0 2.0883983431474462e-10
state O 0 2.0056319452455007e-11
in O 0 7.38388655774358e-11
the O 0 5.515004564138337e-10
patients O 0 1.8152946923422064e-09
father O 0 9.934953970613947e-10
and O 0 1.3182351876750431e-09
a O 0 2.6160456911838992e-08
sister O 0 2.650935584824765e-06
. O 0 3.899424882547464e-06

Fluorescent O 0 5.015136594010983e-06
in O 0 4.337326586778545e-08
situ O 0 3.200243838819006e-07
hybridization O 0 4.0272536416807725e-09
analysis O 0 8.70380101325452e-10
demonstrated O 0 9.916099052986738e-10
that O 0 3.16220660767641e-11
the O 0 2.90637092170698e-09
PWS B-Disease 1 1.0
critical O 0 2.8304873467277503e-06
region O 0 1.6338571384721945e-08
resided O 0 2.1861550791868467e-08
on O 0 7.213722952315038e-10
the O 0 7.685265618340154e-11
derivative O 0 1.975843044732528e-09
chromosome O 0 1.3499030782071486e-09
3 O 0 7.435673743394489e-10
and O 0 8.83947845475852e-11
that O 0 2.6805221237102828e-11
there O 0 9.136753853500323e-11
was O 0 2.3058346343418634e-09
no O 0 9.038721437981678e-10
deletion O 0 6.787975515010203e-09
of O 0 2.325192038910018e-09
the O 0 9.598248418285493e-09
PWS B-Disease 1 1.0
region O 0 7.303581384121571e-08
on O 0 4.4690779965606e-09
the O 0 5.436299743699635e-10
normal O 0 7.222221043434729e-09
pair O 0 8.703240794716294e-09
of O 0 1.3432029710713778e-08
15s O 0 2.8574302177730715e-06
present O 0 1.0437098296733893e-08
in O 0 1.593144673961433e-07
J O 0 0.00048005441203713417
. O 0 5.5738873925292864e-06

B O 0 0.019861772656440735
. O 0 1.6167185094673187e-05

Methylation O 0 1.4543397810484748e-06
analysis O 0 1.47906348502147e-07
at O 0 4.675905884710119e-08
exon O 0 2.079969618762334e-07
alpha O 0 4.6896875716129216e-08
of O 0 8.53057535721291e-09
the O 0 4.777413131762387e-09
small O 0 3.4987985841894442e-09
nuclear O 0 2.4626862682453066e-07
ribonucleoprotein O 0 2.084172137983842e-06
- O 0 3.930350089831336e-07
associated O 0 8.271781126722999e-08
polypeptide O 0 9.540611500824525e-08
N O 0 8.97644980568657e-08
( O 0 2.4551101152070487e-09
SNRPN O 0 3.35321396960353e-06
) O 0 3.075154353382459e-09
gene O 0 4.838117906302841e-09
showed O 0 3.81365428125946e-09
a O 0 9.867214822989467e-10
pattern O 0 3.131777503995181e-09
characteristic O 0 3.6481602183613404e-09
of O 0 2.045339675404989e-09
only O 0 3.1902389063809267e-10
the O 0 4.128137554015865e-10
maternal O 0 8.279799601496052e-08
chromosome O 0 3.824342442726447e-08
15 O 0 6.79047715834713e-08
in O 0 1.482216447357132e-07
J O 0 0.0005838513607159257
. O 0 9.294958545069676e-06

B O 0 0.020067457109689713
. O 0 1.7824659153120592e-05

Maternal B-Disease 0 0.00019954868184868246
disomy I-Disease 0 0.00012611965939868242
was O 0 2.2746473860024707e-07
confirmed O 0 7.628229603540149e-09
by O 0 2.8144470087809736e-10
polymerase O 0 4.512325801897532e-08
chain O 0 5.250215373564515e-09
reaction O 0 2.632807027946882e-10
analysis O 0 5.889443932538541e-10
of O 0 2.211531180407178e-09
microsatellite O 0 1.4642594692304556e-07
repeats O 0 1.1122786247597105e-08
at O 0 7.554010750254747e-09
the O 0 2.5087287802705305e-09
gamma O 0 7.470223550853916e-08
- O 0 1.2336370502907812e-07
aminobutyric O 0 9.21920616292482e-07
acid O 0 1.1058436832911411e-08
receptor O 0 2.4079638283325266e-09
beta3 O 0 2.513448293939291e-07
subunit O 0 6.956123854706675e-08
( O 0 2.7575246974720358e-08
GABRB3 O 0 0.0002665520878508687
) O 0 1.309006165683968e-07
locus O 0 3.943756837543333e-06
. O 0 1.22451126571832e-06

A O 0 2.1069799913675524e-05
niece O 0 0.0009740967652760446
( O 0 2.8778325145140116e-07
B O 0 6.024864433129551e-06
. O 0 5.215957110671354e-10
B O 0 3.13775210258882e-08
. O 0 3.827510877685292e-11
) O 0 4.6304054340806644e-11
with O 0 2.2672233881970705e-11
45 O 0 1.4194567743430753e-09
chromosomes O 0 5.713843842514166e-10
and O 0 1.774196622950086e-10
the O 0 4.738777148460827e-10
derivative O 0 4.454193902603265e-09
3 O 0 1.7020230780318002e-09
but O 0 6.743499508798934e-11
without O 0 2.631692364030158e-10
the O 0 6.473842573129218e-10
der O 0 1.345867076452123e-06
( O 0 1.6598233898434955e-09
15 O 0 5.9466978008515525e-09
) O 0 3.7644226624777843e-10
demonstrated O 0 1.8264918466570634e-09
a O 0 3.1620511764529624e-10
phenotype O 0 1.8639092491667952e-09
consistent O 0 7.026834114576275e-10
with O 0 1.3052613677400071e-11
that O 0 3.08733455467447e-11
reported O 0 9.5878825712159e-11
for O 0 1.8727959461006805e-10
haploinsufficiency O 0 6.007183515066572e-07
of O 0 4.761405136832764e-08
distal O 0 5.47133231521002e-06
3 O 0 3.1802974262973294e-05
p O 0 3.9142672903835773e-05
. O 0 1.3795622635370819e-06

Uniparental B-Disease 1 1.0
disomy I-Disease 1 1.0
associated O 0 5.38112317371997e-07
with O 0 8.664181594397746e-10
unbalanced O 0 1.7714535260893172e-07
segregation O 0 7.352619491030055e-07
of O 0 4.813801979253185e-08
non O 0 2.5830252070591087e-06
- O 0 1.3984127917865408e-06
Robertsonian O 0 1.9177723515895195e-05
translocations O 0 3.752430473014101e-07
has O 0 9.681714457920876e-11
been O 0 5.7196525293790046e-11
reported O 0 3.0937301331857014e-11
previously O 0 7.845368105163786e-11
but O 0 1.9887111055161277e-11
has O 0 9.424514987865784e-12
not O 0 1.452570876081527e-11
, O 0 4.212865126196341e-11
to O 0 1.4012206672742167e-10
our O 0 1.326042720073417e-09
knowledge O 0 1.6399203772721194e-08
, O 0 2.4241883500586425e-10
been O 0 1.2987753927884427e-10
observed O 0 6.453534234784897e-11
in O 0 5.677187886465873e-11
a O 0 6.036437460998911e-10
case O 0 6.416755571336807e-09
of O 0 4.437812890500936e-07
PWS B-Disease 1 1.0
. O 0 0.000325272063491866

Furthermore O 0 1.7262375422433252e-06
, O 0 1.892251688673241e-08
our O 0 1.1112332387597235e-08
findings O 0 3.924796487808635e-09
are O 0 1.6047740913904818e-10
best O 0 1.8257813039213033e-09
interpreted O 0 4.891322014088928e-09
as O 0 6.952258213566154e-10
true O 0 3.280103300085102e-09
gamete O 0 1.498217443440808e-07
complementation O 0 6.976160307203827e-07
resulting O 0 2.018568245887309e-08
in O 0 1.3225424311258394e-08
maternal B-Disease 1 0.8508399724960327
UPD I-Disease 1 1.0
15 I-Disease 0 0.0007216831436380744
and O 0 0.0001084942341549322
PWS B-Disease 1 1.0

Schwartz B-Disease 1 0.9921486377716064
- I-Disease 1 1.0
Jampel I-Disease 1 1.0
syndrome I-Disease 1 0.9999995231628418
type I-Disease 0 3.9111534988478525e-07
2 I-Disease 0 6.697184176118753e-07
and O 0 2.888037364812135e-08
Stuve B-Disease 1 1.0
- I-Disease 1 1.0
Wiedemann I-Disease 1 1.0
syndrome I-Disease 1 1.0
: O 0 1.4879724119509774e-09
a O 0 3.835214923419983e-10
case O 0 2.0708780523737147e-10
for O 0 3.0307353848790797e-10
" O 0 1.8936454182494344e-08
lumping O 0 2.1504793323856575e-07
" O 0 9.349957394988451e-07
. O 0 1.0153435141546652e-06

Recent O 0 6.748706482540001e-08
studies O 0 1.4764781397502702e-08
demonstrated O 0 2.147454880585542e-09
the O 0 9.455092958576827e-11
existence O 0 3.22455229184726e-10
of O 0 2.3049233355276755e-10
a O 0 2.1264263960762975e-10
genetically O 0 6.784205419663181e-10
distinct O 0 1.1497101187751824e-10
, O 0 6.601801050276634e-11
usually O 0 2.5888454574518605e-11
lethal O 0 4.994722413442787e-10
form O 0 3.574211759893586e-11
of O 0 6.087484405448151e-10
the O 0 2.6988600243527117e-09
Schwartz B-Disease 0 0.0002106419124174863
- I-Disease 1 0.9999984502792358
Jampel I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 5.206837627724781e-08
SJS B-Disease 1 0.964849591255188
) O 0 1.3369229279192041e-08
of O 0 3.255523495226953e-07
myotonia B-Disease 1 1.0
and O 0 1.509895173512632e-05
skeletal B-Disease 1 1.0
dysplasia I-Disease 1 1.0
, O 0 9.342704743176e-08
which O 0 2.550803124279355e-09
we O 0 1.232989710331367e-08
called O 0 1.3765419737410411e-07
SJS B-Disease 0 9.659837087383494e-05
type I-Disease 0 1.8101105524692684e-05
2 I-Disease 0 0.00011938754323637113
. O 0 1.239810444531031e-05

This O 0 2.5388379754076595e-07
disorder O 0 0.0023980126716196537
is O 0 1.8598386719581583e-10
reminiscent O 0 1.4849904417246762e-08
of O 0 1.7838409638315511e-09
another O 0 1.5221898186368321e-09
rare O 0 5.300292205134838e-09
condition O 0 2.411003379165777e-07
, O 0 6.497172799768691e-10
the O 0 1.7355867854007556e-08
Stuve B-Disease 1 1.0
- I-Disease 1 1.0
Wiedemann I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.0002147496707038954
SWS B-Disease 1 1.0
) O 0 9.521079480379058e-10
, O 0 2.218966538292122e-10
which O 0 8.295563541649287e-11
comprises O 0 1.1804059951714407e-09
campomelia B-Disease 0 9.948613524102257e-07
at O 0 2.290244971447919e-08
birth O 0 1.491219791205367e-06
with O 0 2.3841867147211815e-08
skeletal B-Disease 1 1.0
dysplasia I-Disease 1 1.0
, O 0 2.8431981036192155e-07
contractures B-Disease 0 0.0001269551139557734
, O 0 2.5033943806818115e-09
and O 0 8.449604349536344e-10
early B-Disease 0 6.535496481774317e-07
death I-Disease 0 1.4456846884058905e-06
. O 0 2.783880006518302e-07

To O 0 5.801770797120298e-08
test O 0 6.15311579466038e-09
for O 0 3.619436972357448e-10
possible O 0 2.9954736469051113e-09
nosologic O 0 1.8276012951901066e-06
identity O 0 6.667866703224945e-09
between O 0 3.6467528996553256e-10
these O 0 1.11484799170114e-09
disorders O 0 4.0170377246795397e-07
, O 0 4.5777603929764155e-11
we O 0 3.33682283193415e-11
reviewed O 0 5.612612041794307e-10
the O 0 2.3276669480765122e-10
literature O 0 2.2102240038179843e-09
and O 0 7.090241588292301e-11
obtained O 0 3.037610718514827e-10
a O 0 3.052407632209153e-11
follow O 0 9.090515840082247e-11
- O 0 1.413402395122887e-09
up O 0 3.6035111006249565e-10
of O 0 4.973257361484684e-10
the O 0 1.3422436773158353e-10
only O 0 3.53337289982214e-11
two O 0 2.299021042984073e-11
surviving O 0 1.2139300054059277e-07
patients O 0 5.023914617652281e-09
, O 0 5.771299757539872e-11
one O 0 4.5836050233116765e-11
with O 0 1.1584666559372181e-10
SJS B-Disease 0 0.00016761868027970195
type I-Disease 0 3.051642852369696e-05
2 I-Disease 0 1.9409662854741327e-06
at O 0 4.4834319368192155e-08
age O 0 1.7662291629250149e-09
10 O 0 4.465045555512859e-10
years O 0 1.1727530058180946e-10
and O 0 1.7247477057669158e-10
another O 0 9.640810372246733e-10
with O 0 6.539443431208269e-10
SWS B-Disease 0 0.00010997656499966979
at O 0 8.572119014615964e-09
age O 0 7.170570359704698e-09
7 O 0 9.700119107947103e-08
years O 0 5.081421505792605e-08
. O 0 5.982782340652193e-07

Patients O 0 6.727489562763367e-06
reported O 0 5.59602542082871e-09
as O 0 6.577496880488809e-10
having O 0 2.357555262122446e-09
either O 0 7.349724739924568e-08
neonatal O 1 1.0
SJS B-Disease 1 1.0
or O 1 0.5203154683113098
SWS B-Disease 1 0.9670212864875793
presented O 0 8.025696551783312e-09
a O 0 3.867227371667781e-10
combination O 0 7.303017079962615e-10
of O 0 4.3590761555911683e-10
a O 0 3.7837147304209395e-10
severe O 0 8.133072881832959e-09
, O 0 1.9005086393519832e-09
prenatal O 0 4.292238736525178e-05
- O 0 2.6689647711464204e-05
onset O 1 1.0
neuromuscular B-Disease 1 1.0
disorder I-Disease 1 1.0
( O 0 7.775211585681063e-09
with O 0 2.34921202491023e-08
congenital B-Disease 1 1.0
joint I-Disease 1 1.0
contractures I-Disease 1 1.0
, O 1 0.9999997615814209
respiratory O 1 1.0
and O 0 2.6066081773024052e-06
feeding O 0 1.610308390809223e-05
difficulties O 0 3.171653020217491e-07
, O 0 1.7648552619320412e-09
tendency O 0 3.789667690767828e-09
to O 0 2.0996264726846903e-09
hyperthermia B-Disease 0 5.478635284816846e-05
, O 0 1.0376017822721906e-09
and O 0 2.621022565651998e-10
frequent O 0 6.926316742372762e-10
death O 0 1.5922470009144263e-09
in O 0 2.1949435324852828e-10
infancy O 0 1.8866730400191045e-08
) O 0 6.448206552045477e-11
with O 0 1.4498887333791455e-11
a O 0 2.6405129194273513e-09
distinct O 0 1.5755386328919485e-08
campomelic B-Disease 1 0.9999812841415405
- I-Disease 1 0.9999967813491821
metaphyseal I-Disease 1 0.9999998807907104
skeletal I-Disease 1 1.0
dysplasia I-Disease 1 1.0
. O 0 0.0010525936959311366

The O 0 7.973228832724999e-08
similarity O 0 2.8402487473044857e-08
of O 0 2.0966341551797996e-08
the O 0 1.1941249766778128e-08
clinical O 0 1.6408425551617256e-07
and O 0 2.2380142183919816e-09
radiographic O 0 2.3839947971282527e-05
findings O 0 1.5857802182495107e-08
is O 0 1.200543275903243e-10
so O 0 1.2849057928754348e-10
extensive O 0 3.221068745062894e-09
that O 0 6.337155106228565e-11
these O 0 7.529424306262911e-10
disorders O 0 8.865020390658174e-06
appear O 0 2.111824048967037e-09
to O 0 4.753215598896077e-10
be O 0 1.2270183757934205e-09
a O 0 7.4403732064354244e-09
single O 0 4.8989619472195045e-08
entity O 0 1.5435428224463976e-07
. O 0 3.11202143166156e-06

The O 0 1.1142665101715465e-07
follow O 0 7.003344393297084e-08
- O 0 1.3368214979436743e-07
up O 0 4.7855297502508165e-09
observation O 0 1.32016126030976e-07
of O 0 1.2017146167053738e-09
an O 0 5.569462946386494e-11
identical O 0 2.1703194796884873e-10
and O 0 2.702160439849166e-10
unique O 0 2.637291496299099e-09
pattern O 0 1.8767384091233907e-08
of O 0 6.468510491686175e-07
progressive O 1 1.0
bone B-Disease 1 1.0
dysplasia I-Disease 1 1.0
in O 0 1.479810585180985e-08
the O 0 2.15365396627476e-08
two O 0 4.584414181607599e-09
patients O 0 2.3203421406492453e-08
( O 0 1.6490021848003522e-10
one O 0 1.421441991888983e-10
with O 0 9.209854406888596e-11
SJS B-Disease 0 1.4516568626277149e-05
type I-Disease 0 1.975815393961966e-06
2 I-Disease 0 1.566509467920696e-06
, O 0 5.341404651915127e-09
one O 0 1.1917216102830253e-09
with O 0 1.5700092337311844e-09
SWS B-Disease 0 0.45460236072540283
) O 0 4.478438508925819e-09
surviving O 0 5.780220249107515e-07
beyond O 0 1.3396559950251685e-07
infancy O 0 1.4653883795290312e-07
adds O 0 2.7204374308809065e-09
to O 0 3.5507577433868676e-10
the O 0 5.773383993101788e-10
evidence O 0 7.975518023783934e-10
in O 0 2.3338461718758197e-10
favor O 0 4.026715849647644e-09
of O 0 8.699589493232907e-09
identity O 0 6.046998635156342e-08
. O 0 3.145020741612825e-07

The O 0 3.7613125414281967e-07
hypothesis O 0 7.008649163253722e-07
that O 0 6.929094631402677e-09
SWS B-Disease 0 0.004394798073917627
and O 0 2.139291943592525e-08
SJS B-Disease 0 4.826907388633117e-05
type I-Disease 0 1.6312654906869284e-06
2 I-Disease 0 2.65985960368198e-07
are O 0 6.742422176131413e-10
the O 0 2.384508590580481e-09
same O 0 1.1991233783703592e-08
disorder O 0 3.823620886578283e-07
should O 0 1.0183114351747236e-09
be O 0 3.1748145778998094e-10
testable O 0 2.363579554298667e-09
by O 0 6.326684315327569e-11
molecular O 0 1.5146713883140706e-09
methods O 0 1.137266369966028e-08
. O 0 1.14549987273449e-08
. O 0 2.646704331255023e-07

A O 0 2.7743228656618157e-06
mouse O 0 2.481187379999028e-07
model O 0 4.6136072739955125e-09
of O 0 1.7113567452042844e-08
severe O 0 0.43427640199661255
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
: O 0 1.732215787342284e-05
defects O 0 0.00033242168137803674
in O 0 1.347528524320296e-07
hemostasis O 1 0.9995668530464172
and O 0 9.317823241872247e-07
thrombosis B-Disease 1 0.9999996423721313
. O 0 3.978685981564922e-06

von B-Disease 0 0.007978372275829315
Willebrand I-Disease 1 0.9237681031227112
factor I-Disease 0 4.9221944209421054e-05
( I-Disease 0 1.6721378415240906e-06
vWf I-Disease 1 0.9925139546394348
) I-Disease 0 1.4854862456559204e-05
deficiency I-Disease 1 0.9999998807907104
causes O 0 0.02083953656256199
severe O 1 1.0
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
in O 0 0.00015768235607538372
humans O 0 3.906518941221293e-06
. O 0 3.8320973771988065e-07

We O 0 1.1844247893577631e-07
generated O 0 9.931075517499721e-09
a O 0 4.200416459099188e-09
mouse O 0 1.8299694204415573e-08
model O 0 1.4255696623166614e-09
for O 0 3.0719579657834117e-10
this O 0 3.1276572998173435e-10
disease O 0 1.4106176227102196e-09
by O 0 6.634318094889124e-11
using O 0 4.337142645027825e-09
gene O 0 5.893435961468185e-09
targeting O 0 3.1229336627802695e-07
. O 0 2.1998300780978752e-06

vWf B-Disease 0 0.0012487656204029918
- I-Disease 0 0.0715046226978302
deficient I-Disease 0 0.0019845578353852034
mice O 0 2.7493745164974825e-06
appeared O 0 2.153070610688701e-08
normal O 0 1.1188981297038936e-08
at O 0 1.5913907969178354e-09
birth O 0 3.0736062583969215e-09
; O 0 2.910430230151917e-10
they O 0 1.0915013337609025e-09
were O 0 4.766145700330071e-09
viable O 0 2.14406981058346e-07
and O 0 7.321908412905032e-08
fertile O 0 7.166291652538348e-06
. O 0 2.329509243281791e-06

Neither O 0 3.121238842140883e-05
vWf O 0 0.00032907520653679967
nor O 0 6.824730371590704e-05
vWf O 0 0.0003561442717909813
propolypeptide O 0 0.000478893518447876
( O 0 6.645744292654854e-07
von B-Disease 0 0.003245455678552389
Willebrand I-Disease 0 0.4819980561733246
antigen O 0 7.504514087486314e-06
II O 1 1.0
) O 0 1.5038547473977815e-07
were O 0 8.730178535643063e-08
detectable O 0 2.2804118771091453e-07
in O 0 1.0680608619750842e-09
plasma O 0 6.031908128534269e-08
, O 0 2.392576581300432e-09
platelets O 0 4.777803042088635e-07
, O 0 4.987556589952646e-09
or O 0 8.763842096470853e-09
endothelial O 0 5.797345465907711e-07
cells O 0 9.223209929132281e-08
of O 0 2.055454118021771e-08
the O 0 3.3509550689814205e-08
homozygous O 0 3.3042746849787363e-07
mutant O 0 1.179843707177497e-06
mice O 0 2.826948048095801e-06
. O 0 2.757456968538463e-06

The O 0 1.1580743830563733e-06
mutant O 0 3.364694202900864e-05
mice O 0 7.611156888742698e-06
exhibited O 0 2.3254509073922236e-07
defects O 0 1.9359820271347417e-06
in O 0 1.0605787359452279e-08
hemostasis O 0 8.520913979737088e-06
with O 0 1.4094819755783305e-10
a O 0 2.6509285877551747e-09
highly O 0 1.2311853936353145e-07
prolonged O 0 0.00013456211308948696
bleeding O 0 1.0498139090486802e-05
time O 0 2.2604648819424256e-08
and O 0 8.83224160475038e-09
spontaneous O 0 1.27234898172901e-07
bleeding O 0 7.109832722562714e-07
events O 0 5.543775438709986e-10
in O 0 1.5582896084609388e-10
approximately O 0 7.564614906696576e-11
10 O 0 6.45783482244866e-10
% O 0 8.212725499667783e-10
of O 0 1.078666223008895e-08
neonates O 0 7.40293387480051e-07
. O 0 4.971262228536943e-07

As O 0 3.408331039622681e-08
in O 0 1.6967787175303783e-09
the O 0 1.3457384095971747e-09
human O 0 6.688268827659272e-10
disease O 0 8.547543228765164e-10
, O 0 1.5778368195329406e-11
the O 0 2.125274956021883e-10
factor O 0 1.5220861016018716e-08
VIII O 0 0.262565940618515
level O 0 6.579604132639361e-07
in O 0 2.5712652007570114e-09
these O 0 1.8553893976758218e-09
mice O 0 2.19609734841697e-08
was O 0 2.136330445878798e-09
reduced O 0 2.0968089486927965e-09
strongly O 0 1.9965491759865728e-10
as O 0 1.412027578195918e-10
a O 0 6.897060006449962e-11
result O 0 1.137785976546013e-10
of O 0 4.658329277873463e-10
the O 0 3.3608024696540895e-10
lack O 0 3.95546573273009e-09
of O 0 9.389913291357743e-10
protection O 0 5.197041463844698e-09
provided O 0 6.505087579711244e-09
by O 0 4.2000318778434576e-09
vWf O 0 1.2958174011146184e-05
. O 0 2.2920905848877737e-06

Defective O 0 0.26170405745506287
thrombosis B-Disease 1 0.9999978542327881
in O 0 1.5404766884330456e-07
mutant O 0 1.6842402601469075e-06
mice O 0 1.2445819663753355e-07
was O 0 5.523007384766743e-09
also O 0 3.8356248732718257e-10
evident O 0 1.9643597859442252e-09
in O 0 2.7046559436527673e-10
an O 0 4.939676098714152e-11
in O 0 2.525039899392567e-10
vivo O 0 5.820069404194328e-08
model O 0 1.172935260029817e-08
of O 0 2.9141168056412425e-07
vascular B-Disease 1 1.0
injury I-Disease 1 1.0
. O 0 0.00011232188990106806

In O 0 1.5017501908687336e-08
this O 0 4.917455886932487e-10
model O 0 3.1032478808867836e-09
, O 0 1.1460784543615432e-09
the O 0 3.515059354697314e-09
exteriorized O 0 5.066390258434694e-06
mesentery O 0 7.2771445047692396e-06
was O 0 8.762776815274265e-08
superfused O 0 2.4468749870720785e-06
with O 0 3.926601266357466e-09
ferric O 0 0.013778765685856342
chloride O 0 6.713512993883342e-05
and O 0 5.373688338750071e-08
the O 0 4.2675910805201056e-08
accumulation O 0 3.456605099927401e-06
of O 0 5.640234803649946e-07
fluorescently O 0 9.146483535005245e-06
labeled O 0 8.095529580032235e-08
platelets O 0 9.128005018510521e-08
was O 0 1.5195219305041974e-08
observed O 0 5.689084758842e-09
by O 0 3.2962530482905095e-09
intravital O 0 8.152650480042212e-06
microscopy O 0 1.238264849234838e-05
. O 0 2.8443203063943656e-06

We O 0 8.738374646100056e-08
conclude O 0 1.296960334684627e-07
that O 0 5.380369483276581e-10
these O 0 7.255270828565585e-10
mice O 0 2.8162112641894055e-08
very O 0 6.675116015486537e-10
closely O 0 1.27409105488141e-08
mimic O 0 7.983681825862732e-06
severe O 0 5.193462493480183e-05
human O 0 4.398611963551957e-06
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
and O 0 1.3067435133962135e-07
will O 0 4.457389124468136e-09
be O 0 6.52792875310837e-10
very O 0 6.824004555872065e-11
useful O 0 4.993894187066417e-10
for O 0 2.788174031931323e-11
investigating O 0 1.00383597267939e-10
the O 0 1.777861885488008e-10
role O 0 2.8217801428809253e-09
of O 0 1.0831234575903181e-08
vWf O 0 3.988602088611515e-07
in O 0 2.5758204458270484e-09
normal O 0 7.132013024602202e-08
physiology O 0 3.1296895031118765e-07
and O 0 9.523423161184041e-10
in O 0 1.2453644782084439e-09
disease O 0 5.112400724982535e-09
models O 0 2.4987527602604587e-09
. O 0 7.697536830164609e-09
. O 0 2.4705383339096443e-07

Oral O 0 0.002842037472873926
contraceptives O 0 0.0002097966498695314
and O 0 2.5382231871873273e-09
the O 0 3.2070730515698642e-09
risk O 0 6.052202934370143e-07
of O 0 0.00028223343542777
hereditary B-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 1 0.9968760013580322

Hereditary B-Disease 1 1.0
Ovarian I-Disease 1 1.0
Cancer I-Disease 1 1.0
Clinical O 0 2.016427788475994e-05
Study O 0 5.563037674960469e-08
Group O 0 8.849711186087461e-09
. O 0 9.779704868151384e-08

BACKGROUND O 0 1.652681930863764e-05
Women O 0 1.2902584778373694e-08
with O 0 3.850385635328912e-11
mutations O 0 8.359223729881293e-11
in O 0 6.751169762120313e-11
either O 0 5.851430451286888e-10
the O 0 6.321130285869003e-09
BRCA1 O 0 8.175005916655209e-08
or O 0 5.941743541626465e-09
the O 0 2.8142999042302108e-08
BRCA2 O 0 5.872433916920272e-08
gene O 0 3.1825023172338263e-10
have O 0 1.4326669017794558e-10
a O 0 2.468533433219733e-10
high O 0 4.440841472330703e-09
lifetime O 0 3.338928777907313e-08
risk O 0 5.18280501182744e-07
of O 0 0.0002817435597535223
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.002668671077117324

Oral O 1 0.999961256980896
contraceptives O 1 1.0
protect O 0 1.8340899259783328e-05
against O 1 0.9999867677688599
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 3.148105633954401e-07
general O 0 3.249282087836036e-08
, O 0 3.168390272367816e-10
but O 0 1.8385275940557833e-11
it O 0 4.014930315293652e-12
is O 0 1.8955316916785536e-12
not O 0 4.72689248853797e-12
known O 0 1.3641796026142572e-10
whether O 0 1.0218363655223328e-10
they O 0 7.252420886061373e-10
also O 0 5.078628184662648e-09
protect O 0 2.4874271531416525e-08
against O 0 2.5065968856097243e-08
hereditary B-Disease 1 0.999717652797699
forms I-Disease 0 9.255030818167143e-06
of I-Disease 1 0.9999932050704956
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.00011212262324988842

METHODS O 0 1.340650783276942e-06
We O 0 4.0860903993689135e-08
enrolled O 0 1.2249313385837013e-07
207 O 0 1.468824564199167e-07
women O 0 6.362631754797121e-09
with O 0 2.0470345418743818e-08
hereditary B-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 8.575274712541159e-09
161 O 0 2.8246558425593093e-09
of O 0 1.1815030065420729e-09
their O 0 8.712371379893113e-10
sisters O 0 1.4522662183935608e-07
as O 0 2.2421968726149544e-09
controls O 0 1.1007573519350444e-08
in O 0 2.955168887375237e-10
a O 0 8.054138467272765e-10
case O 0 2.547681399178714e-09
- O 0 1.229476964681453e-07
control O 0 6.552940590154321e-07
study O 0 4.2318092141613306e-07
. O 0 2.973590937926929e-07

All O 0 3.175702190105767e-08
the O 0 7.896870712897908e-09
patients O 0 4.243223106215055e-09
carried O 0 2.4025720302134346e-10
a O 0 4.5683661714646107e-11
pathogenic O 0 2.605630433638595e-10
mutation O 0 2.2306190228249534e-10
in O 0 2.6404661790380146e-10
either O 0 1.1160102175722386e-08
BRCA1 O 0 1.8712557903199922e-07
( O 0 1.5351909743444025e-09
179 O 0 2.0024662816808814e-08
women O 0 1.6985887141274247e-09
) O 0 4.5150938543514485e-10
or O 0 8.595809397604626e-09
BRCA2 O 0 2.507907765902928e-07
( O 0 2.441804980435336e-09
28 O 0 9.460499228453045e-08
women O 0 2.2350462813847116e-08
) O 0 2.4507274432039594e-08
. O 0 3.53180894308025e-07

The O 0 1.4291373418018338e-07
control O 0 1.9870994094617345e-07
women O 0 1.95612659403821e-09
were O 0 5.550208070914664e-10
enrolled O 0 1.515379377536874e-09
regardless O 0 3.0221805613628305e-10
of O 0 4.6502332540221403e-10
whether O 0 9.637349251967464e-11
or O 0 4.274299247875035e-10
not O 0 4.0785338994986375e-10
they O 0 4.4756523487343713e-10
had O 0 6.198537239043844e-09
either O 0 1.9286090946479817e-08
mutation O 0 1.5569757749744895e-07
. O 0 6.539062837873644e-07

Lifetime O 0 8.595524150223355e-07
histories O 0 6.253342235140735e-07
of O 0 8.273026708138786e-08
oral O 0 4.450877440831391e-06
- O 0 2.0806480449664377e-07
contraceptive O 0 4.872719614468224e-07
use O 0 4.927351304750971e-10
were O 0 1.5516432583240203e-10
obtained O 0 5.839411176822296e-10
by O 0 3.659222924667915e-11
interview O 0 4.672540132588665e-10
or O 0 4.6930900138297815e-11
by O 0 1.9342423496215844e-11
written O 0 1.7233994786813867e-10
questionnaire O 0 7.609472080227775e-12
and O 0 4.128054668928183e-12
were O 0 5.118201348852658e-11
compared O 0 4.2920250686862005e-11
between O 0 6.379853676602432e-12
patients O 0 9.787733123989284e-11
and O 0 1.4048381381803754e-11
control O 0 5.288194770969312e-09
women O 0 5.351518117535647e-10
, O 0 7.726418116416056e-11
after O 0 1.826713919017564e-10
adjustment O 0 2.331177917369587e-09
for O 0 9.291033914449187e-11
year O 0 2.1114161807833653e-10
of O 0 8.539052798184343e-10
birth O 0 1.4487159916143355e-08
and O 0 8.643916693529263e-09
parity O 0 3.2321347589459037e-06
. O 0 7.21675689874246e-07

RESULTS O 0 1.6758818333073577e-07
The O 0 9.916406362719954e-09
adjusted O 0 5.9039585664777405e-08
odds O 0 3.466331932600042e-08
ratio O 0 9.784163523818279e-08
for O 0 1.0711132745200302e-06
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
associated O 0 1.108373393066131e-08
with O 0 2.6943466555073847e-11
any O 0 3.516398561220768e-10
past O 0 1.3718881586299858e-09
use O 0 4.790717156311075e-09
of O 0 2.9680965241141166e-08
oral O 0 7.490813914046157e-06
contraceptives O 0 1.6014349967008457e-05
was O 0 5.974850836309997e-08
0 O 0 4.117329979180795e-07
. O 0 5.258290798337839e-07

5 O 0 1.4840795756754233e-06
( O 0 6.145869946294624e-08
95 O 0 1.082142489394755e-06
percent O 0 1.4766189160297927e-08
confidence O 0 6.305957089836056e-09
interval O 0 2.7993618534338793e-09
, O 0 1.8395107659330279e-10
0 O 0 4.646030782318178e-10
. O 0 4.189610464111482e-11
3 O 0 1.5032481925913999e-09
to O 0 1.0927594384924078e-09
0 O 0 3.905686440930367e-09
. O 0 1.4731580399995892e-09
8 O 0 1.308455637172301e-07
) O 0 1.0320052723500339e-07
. O 0 8.377030553674558e-07

The O 0 1.0467724109730625e-07
risk O 0 4.042007617499621e-08
decreased O 0 2.929277709284861e-09
with O 0 3.2200500946211186e-12
increasing O 0 7.103669041885752e-11
duration O 0 1.77679504442807e-09
of O 0 3.3992708647900827e-10
use O 0 7.2943340256870215e-09
( O 0 3.050955488248519e-09
P O 0 8.367945270038035e-08
for O 0 7.481595898362059e-10
trend O 0 4.89845453088833e-09
, O 0 1.6699906735251346e-10
< O 0 1.4809626414091781e-08
0 O 0 1.6312532435946991e-09
. O 0 1.634444801723589e-10
001 O 0 4.230126293691683e-08
) O 0 3.6917652962431546e-11
; O 0 8.811867034663745e-12
use O 0 2.245045954696323e-10
for O 0 5.1648806759230226e-11
six O 0 1.4353802868516397e-10
or O 0 4.509669027097374e-11
more O 0 6.9430021627792105e-12
years O 0 1.4231612416315542e-11
was O 0 2.0248092091890157e-10
associated O 0 1.1877612782207336e-10
with O 0 7.45677131153144e-12
a O 0 4.660897778840933e-10
60 O 0 2.738189008866243e-09
percent O 0 2.3769558543662583e-10
reduction O 0 2.3336248489158606e-09
in O 0 4.018605892497362e-09
risk O 0 2.9524463229790854e-07
. O 0 4.29432049031675e-07

Oral O 0 0.031091487035155296
- O 0 9.15782293304801e-05
contraceptive O 0 0.0002553759841248393
use O 0 1.3787700936518377e-07
protected O 1 0.7776258587837219
against O 1 0.9995463490486145
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
both O 0 6.946137887098303e-09
for O 0 1.6383336354230948e-10
carriers O 0 6.912524441737844e-10
of O 0 9.777326726023716e-10
the O 0 3.739093035193264e-09
BRCA1 O 0 1.3977246737795213e-07
mutation O 0 1.762271883976041e-09
( O 0 3.37433608832427e-10
odds O 0 2.3344362887200987e-08
ratio O 0 2.936157983413068e-09
, O 0 1.1186431642107308e-10
0 O 0 3.420701777390178e-10
. O 0 2.4096750636526387e-11
5 O 0 3.81156550766093e-10
; O 0 1.1271050759376067e-10
95 O 0 2.0174519832494298e-08
percent O 0 6.218511261479875e-10
confidence O 0 1.1468065386210924e-09
interval O 0 1.2002119298415437e-09
, O 0 1.2212228450714235e-10
0 O 0 3.468564047093281e-10
. O 0 3.7846437789257337e-11
3 O 0 5.873234121267501e-10
to O 0 2.2267422628008404e-10
0 O 0 5.582312945229262e-10
. O 0 9.874363826600785e-11
9 O 0 3.0919398152917665e-09
) O 0 1.8332690920885852e-10
and O 0 8.245840815712668e-11
for O 0 9.241634540968491e-11
carriers O 0 9.533945855011439e-10
of O 0 1.8745480723225683e-09
the O 0 7.24629867221438e-09
BRCA2 O 0 4.2468124661354523e-07
mutation O 0 1.433826724017706e-09
( O 0 4.6215486992906563e-10
odds O 0 2.5204807130307927e-08
ratio O 0 4.091438299269612e-09
, O 0 7.62784349572776e-11
0 O 0 1.3517935382179047e-10
. O 0 1.9442293261451304e-11
4 O 0 3.7918060358244077e-10
; O 0 1.361504797792179e-10
95 O 0 2.0431961900158058e-08
percent O 0 6.877516334213851e-10
confidence O 0 1.1164354996040515e-09
interval O 0 6.654243822623584e-10
, O 0 6.153485360149702e-11
0 O 0 2.343374105873153e-10
. O 0 2.826690097268436e-11
2 O 0 7.054268835737787e-10
to O 0 2.592167314130478e-10
1 O 0 5.778730383099173e-09
. O 0 2.7128927992947638e-09
1 O 0 2.2817889089310484e-07
) O 0 1.855290179264557e-07
. O 0 9.670668532635318e-07

CONCLUSIONS O 0 2.2466183509095572e-05
Oral O 0 6.423820013878867e-05
- O 0 2.4373732685489813e-06
contraceptive O 0 2.7401554234529613e-06
use O 0 9.51274836680227e-10
may O 0 1.0129933003533154e-10
reduce O 0 2.322115139063996e-10
the O 0 6.415577513685378e-10
risk O 0 1.0690579301808611e-06
of O 1 0.9879509806632996
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 2.383898731750378e-07
women O 0 3.2950333572756563e-09
with O 0 2.4822619654196743e-11
pathogenic O 0 4.1623085533792903e-10
mutations O 0 1.4224128819240178e-10
in O 0 9.955287705309956e-10
the O 0 8.614245672333709e-08
BRCA1 O 0 3.9019428186293226e-06
or O 0 5.881876859348267e-06
BRCA2 O 0 0.00012215373863000423
gene O 0 1.2387278729875106e-05

A O 0 1.302000782743562e-06
Japanese O 0 3.600609488785267e-06
family O 0 2.4648848295782955e-08
with O 0 3.6009499826406e-09
adrenoleukodystrophy B-Disease 1 1.0
with O 0 4.312725288002639e-09
a O 0 1.4350232113713446e-08
codon O 0 1.2420468920026906e-07
291 O 0 4.707611722665206e-08
deletion O 0 9.004177314864137e-08
: O 0 2.005327903731313e-09
a O 0 2.742113869302898e-09
clinical O 0 5.112481815672254e-08
, O 0 4.4997219839082447e-10
biochemical O 0 7.425900605539937e-08
, O 0 2.2895230156194657e-09
pathological O 0 2.3782172320352402e-07
, O 0 1.5487404692038353e-09
and O 0 2.275136079532558e-09
genetic O 0 6.9352452669591e-08
report O 0 3.476694843129735e-08
. O 0 2.4621553507131466e-07

We O 0 3.29433156309733e-08
report O 0 1.7679547825721897e-09
a O 0 7.205829266609953e-10
Japanese O 0 7.891092224099339e-08
family O 0 4.147143517485574e-09
with O 0 5.6641065171447735e-09
adrenoleukodystrophy B-Disease 1 1.0
( O 0 0.007617005612701178
ALD B-Disease 1 1.0
) O 0 2.6488562454574094e-09
with O 0 1.3211846894289891e-10
a O 0 1.1383421982813502e-09
three O 0 4.1794126492966654e-10
base O 0 3.2132710714449786e-08
pair O 0 2.8544068442215575e-08
deletion O 0 7.704385041051864e-08
( O 0 3.3736364812853026e-09
delGAG O 0 2.115859558671218e-07
291 O 0 1.1816455369739742e-08
) O 0 4.868478398201148e-10
in O 0 2.3056896392148474e-09
the O 0 2.0027704294989235e-07
ALD B-Disease 1 1.0
gene O 0 2.660313612068421e-06
. O 0 5.520531431102427e-06

A O 0 5.279218271425634e-07
variety O 0 2.65312536384954e-08
of O 0 7.913245170243499e-09
phenotypes O 0 1.695239681964722e-08
were O 0 1.0821648022130148e-09
observed O 0 3.3457339676523645e-10
within O 0 2.1090938717716057e-10
this O 0 2.984283375973007e-10
family O 0 1.1262960342151018e-08
. O 0 1.5577897727325762e-07

While O 0 8.308512633448117e-08
the O 0 9.188598326659303e-09
proband O 0 1.3794759979646187e-05
( O 0 3.8196530383061145e-09
patient O 0 4.938110365060311e-08
1 O 0 2.4283973942829107e-08
) O 0 8.646153792923883e-10
was O 0 8.481838342788706e-09
classified O 0 1.2390863446398726e-08
as O 0 1.0955769624843015e-09
having O 0 1.0521179483191645e-09
a O 0 4.403256370633102e-10
rare O 0 1.2864218579267117e-09
intermediate O 0 4.445977808131829e-09
type O 0 4.9687662873054705e-09
of O 0 5.766112476379703e-09
adult O 0 3.532818837470586e-08
cerebral O 0 5.698785798813333e-08
and O 0 2.6346569370616635e-09
cerebello O 1 0.9923396110534668
- O 0 0.2927596867084503
brain O 1 0.9064370393753052
stem O 0 2.2854891312817927e-07
forms O 0 1.1890243234446984e-09
, O 0 1.0046519866024894e-10
his O 0 5.399429237051834e-10
younger O 0 1.0376162151715107e-08
brother O 0 7.536542767638821e-08
( O 0 1.4718661844881353e-09
patient O 0 1.356418088960254e-08
2 O 0 8.500657955323732e-09
) O 0 4.754974747278595e-10
and O 0 1.903414315052032e-09
nephew O 0 0.00029719527810811996
( O 0 8.324704481310619e-09
patient O 0 8.996158271656896e-07
3 O 0 1.5731400537788431e-07
) O 0 5.470252695261024e-09
had O 0 5.907304156949067e-08
a O 0 1.5312913603793277e-07
childhood O 0 0.0008391016162931919
ALD B-Disease 1 1.0
type O 1 0.973414957523346
. O 0 0.00012630547280423343

Another O 0 1.3150349786883453e-06
nephew O 0 0.00032029763679020107
( O 0 3.867393516543416e-08
patient O 0 1.8695291714720952e-07
4 O 0 2.4530844910941596e-08
) O 0 3.3471639349080817e-10
of O 0 2.2951458511499823e-09
patient O 0 8.287825892239198e-08
1 O 0 7.310187299935933e-08
was O 0 1.1254578424768624e-07
classified O 0 5.342864284330062e-08
as O 0 1.2424894890727955e-08
having O 0 1.6938434654889534e-08
an O 0 1.9182040400522737e-09
adolescent O 0 1.7821967901454627e-07
form O 0 1.4030300476974844e-08
. O 0 4.3981617636745796e-07

The O 0 1.8285186342836823e-07
tau O 0 1.0333860700484365e-07
level O 0 1.4379740065351143e-08
in O 0 7.551961833662801e-10
the O 0 3.290348216111738e-09
cerebrospinal O 0 1.2795824204658857e-06
fluid O 0 2.3499744372657005e-07
( O 0 3.277647309118947e-08
CSF O 1 0.9946887493133545
) O 0 1.6404451130824782e-09
in O 0 1.9579520227352987e-09
patient O 0 1.2760102663378348e-07
1 O 0 4.108597906338218e-08
was O 0 2.5919819179875958e-08
as O 0 1.657036619029384e-09
high O 0 5.001541403260035e-09
as O 0 3.793412250985284e-10
that O 0 2.551871040867848e-11
of O 0 7.096589982324986e-10
patients O 0 7.51804751786267e-09
with O 0 1.5266675701397503e-09
Alzheimers B-Disease 1 1.0
disease I-Disease 0 0.00046277689398266375
( O 0 3.858012576074543e-09
AD B-Disease 0 3.576421022444265e-06
) O 0 9.707374459821949e-08
. O 0 1.01513819572574e-06

His O 0 1.6171668448805576e-06
brain O 0 8.315601917274762e-06
magnetic O 0 6.923667115188437e-07
resonance O 0 5.652204890793655e-07
image O 0 1.1840747049518541e-07
( O 0 7.029991166973559e-08
MRI O 1 0.9999972581863403
) O 0 5.6484232402453927e-08
showed O 0 1.3314344471382356e-07
abnormalities B-Disease 0 1.4799792324993177e-06
in I-Disease 0 8.865621570208759e-10
the I-Disease 0 6.308014111056082e-09
bilateral I-Disease 0 9.104502169066109e-06
cerebellar I-Disease 1 1.0
hemispheres I-Disease 0 0.0002578377316240221
and O 0 1.2190712439519302e-08
brain O 0 3.9352512430923525e-06
stem O 0 1.7580694233743088e-08
, O 0 6.238204397490676e-11
but O 0 1.7236616647875458e-11
not O 0 4.0843391169165244e-11
in O 0 1.304771568566565e-10
the O 0 3.003551629632284e-09
cerebral O 0 5.53175732420641e-06
white O 0 2.7119100298733656e-09
matter O 0 1.6938166425006784e-09
, O 0 1.1253800669130953e-10
where O 0 4.603335768127437e-11
marked O 0 8.872129420023356e-11
reductions O 0 3.5157166067278922e-09
of O 0 1.3171846946491428e-09
the O 0 2.059565851197931e-09
cerebral O 0 2.614422669466876e-07
blood O 0 5.639614109043123e-09
flow O 0 6.787276074504689e-09
and O 0 7.131666368564993e-10
oxygen O 0 5.237945543967726e-08
metabolism O 0 8.681691809897529e-08
were O 0 3.995715314175641e-09
clearly O 0 1.749331790534825e-09
demonstrated O 0 1.3114614949572e-09
by O 0 2.614142791124152e-10
positron O 0 1.1555547629882312e-08
emission O 0 5.819547510554912e-08
tomography O 0 1.143436566053424e-05
( O 0 1.729579821585503e-07
PET O 0 5.200560190132819e-05
) O 0 1.405092575623712e-07
. O 0 9.005145216178789e-07

In O 0 4.131008424224092e-08
patients O 0 1.2959829653880206e-08
2 O 0 3.3511005081976464e-09
and O 0 4.375586282190369e-10
3 O 0 1.401256977118237e-08
, O 0 1.289057305342567e-09
the O 0 2.6982063250358124e-09
autopsy O 0 1.4480247045867145e-07
findings O 0 1.4046045215820868e-08
showed O 0 1.7363415594218168e-08
massive O 0 7.380996436268106e-08
demyelination B-Disease 1 1.0
of I-Disease 0 2.639291381001385e-07
the I-Disease 0 5.909298295136978e-08
cerebral I-Disease 0 0.000977699994109571
white I-Disease 0 3.613223942267041e-09
matter I-Disease 0 4.699756694925838e-10
with O 0 3.003778129007095e-11
sparing O 0 4.799563768642656e-08
of O 0 7.61448148978161e-08
the O 0 1.2492469636526948e-07
U O 0 0.002266749506816268
- O 0 7.787014510540757e-06
fibers O 0 2.6949217613037035e-07
, O 0 1.6968012550577782e-09
compatible O 0 3.7874876568366744e-08
with O 0 5.129851057827928e-11
the O 0 2.046705471769883e-09
findings O 0 7.957894787580244e-09
of O 0 1.3887095917652914e-07
childhood O 1 0.5648618936538696
ALD B-Disease 1 1.0
. O 0 8.619777509011328e-05

Oleic O 0 0.006223344709724188
and O 0 1.3046718549958314e-06
erucic O 1 0.6026137471199036
acids O 0 1.6635773363304907e-06
( O 0 1.6898644261686968e-08
Lorenzos O 0 3.2853633911145153e-06
Oil O 0 2.2217749062747316e-07
) O 0 8.712920385178791e-10
were O 0 1.5701467903639355e-09
administered O 0 1.2083799516560134e-09
to O 0 4.0257464029025414e-10
patients O 0 1.9397641271012844e-09
1 O 0 2.84081069779063e-09
and O 0 1.7482143510605397e-09
4 O 0 3.642391277480783e-08
, O 0 9.909424392162691e-10
but O 0 1.413892475321532e-10
sufficient O 0 3.0798619210514744e-09
effectiveness O 0 1.136967053838589e-08
was O 0 5.871187980233117e-09
not O 0 4.201137659975984e-09
obtained O 0 2.1025975627253501e-07
. O 0 8.36416177207866e-07

The O 0 1.7259777962408407e-07
findings O 0 2.1214660250734596e-08
in O 0 4.894697425150696e-10
this O 0 3.436959883362789e-10
family O 0 3.664826775384711e-10
suggest O 0 3.847810403634355e-10
that O 0 9.012270096864228e-12
delGAG291 O 0 5.777848421928411e-09
is O 0 9.477910643818088e-12
part O 0 8.381574601035169e-11
of O 0 7.690195147347367e-10
the O 0 1.0817603479651439e-09
cause O 0 8.193704381653788e-09
of O 0 2.5778025047884512e-08
Japanese O 0 0.0001376396685373038
ALD B-Disease 1 1.0
with O 0 1.5834618949384094e-08
phenotypic O 0 2.8540728180814767e-07
variations O 0 6.435805630644609e-07
. O 0 1.0236475418423652e-06

Moreover O 0 5.755808274443552e-07
, O 0 2.948920441170344e-09
although O 0 1.0556975432729487e-10
the O 0 4.124365432511823e-11
scale O 0 4.549256249486433e-10
of O 0 2.580141100771982e-10
the O 0 1.5882788140242354e-10
study O 0 2.1074370026852307e-10
is O 0 4.9597253387601015e-12
limited O 0 1.257134396581705e-10
, O 0 6.899626009415627e-11
there O 0 5.429944688328803e-11
is O 0 3.949551449777822e-11
a O 0 1.943362554213124e-10
possibility O 0 7.529944667794553e-09
that O 0 1.4058796349303293e-09
PET O 0 1.5842132370380568e-06
can O 0 1.8120646316788225e-08
detect O 0 6.792639624109142e-07
an O 0 1.627487478117473e-08
insidious B-Disease 0 0.00017520297842565924
lesion I-Disease 1 0.9996767044067383
which O 0 3.3409019994934397e-09
is O 0 1.5013247589568124e-10
undetectable O 0 3.3887919137498557e-09
by O 0 2.4915116844659302e-11
computed O 0 4.3839674113144156e-09
tomogram O 0 2.1848852611583425e-06
( O 0 1.5324447488751503e-08
CT O 1 0.9981855750083923
) O 0 6.205563618522092e-09
or O 0 1.779655001143965e-08
MRI O 0 7.523310159740504e-06
analysis O 0 3.5318874491707675e-09
, O 0 1.100964180933417e-10
and O 0 4.72549811780798e-11
that O 0 6.36173622461933e-12
the O 0 7.953001451843633e-11
higher O 0 2.8524080875058644e-09
level O 0 2.0705945846799523e-09
of O 0 4.0096001518996616e-10
tau O 0 1.1737447680459923e-09
reflects O 0 2.3535956517051204e-10
the O 0 7.153719283614635e-11
process O 0 9.607987738746715e-10
of O 0 2.3415712036012337e-08
neuronal B-Disease 0 0.0004218774556647986
degeneration I-Disease 1 1.0
in O 0 2.8012065740767866e-05
ALD B-Disease 1 1.0
. O 0 7.140880188671872e-05

Lorenzos O 0 3.2416115573141724e-05
Oil O 0 3.066639635562751e-07
should O 0 2.004135080113656e-09
be O 0 7.019917980244372e-11
given O 0 1.1153004908504016e-10
in O 0 5.890968962640741e-11
the O 0 2.174803115373436e-10
early O 0 1.0047009446623179e-08
stage O 0 6.5569327745151895e-09
. O 0 8.622492941867677e-09
. O 0 1.260379747236584e-07

Nonsense O 0 2.3997430616873316e-05
mutation O 0 1.9227879022309935e-07
in O 0 1.9172830434399657e-08
exon O 0 9.946355703505105e-07
4 O 0 2.617603627186327e-07
of O 0 6.109357997274856e-08
human O 0 4.644340911852396e-09
complement O 0 2.022213685393126e-08
C9 O 0 4.694360904977657e-05
gene O 0 1.5719276547088157e-08
is O 0 2.8457011747029526e-10
the O 0 4.492192728910993e-10
major O 0 6.309734956744251e-09
cause O 0 1.0086081303484207e-08
of O 0 2.1606402000884373e-08
Japanese O 0 8.546084245608654e-06
complement B-Disease 0 0.00010040131019195542
C9 I-Disease 1 1.0
deficiency I-Disease 1 0.6130594611167908
. O 0 9.745321221998893e-06

Deficiency B-Disease 0 0.003415978280827403
of I-Disease 0 6.521824502669915e-07
the I-Disease 0 6.412646769149433e-08
ninth I-Disease 0 1.4826521237409906e-06
component I-Disease 0 1.7482784997469025e-08
of I-Disease 0 8.82563577775386e-10
human I-Disease 0 1.0406654704642193e-10
complement I-Disease 0 1.1557707679799023e-08
( O 0 2.108951235868517e-08
C9 O 1 0.9999998807907104
) O 0 8.489736913475099e-09
is O 0 2.4353247196629013e-10
the O 0 5.66179214622764e-10
most O 0 6.46757314370916e-10
common O 0 4.3148826733840906e-08
complement B-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 1.9007948548477316e-09
Japan O 0 2.2362870666370327e-08
but O 0 2.4190982550464923e-10
is O 0 3.368315695806423e-11
rare O 0 1.497692525553873e-10
in O 0 7.303236487787856e-11
other O 0 2.1381067749626226e-10
countries O 0 3.111450652681924e-09
. O 0 9.386286592416582e-08

We O 0 1.1956842627114384e-07
studied O 0 1.0080815826540857e-07
the O 0 1.941829586016297e-09
molecular O 0 4.471115033766182e-09
basis O 0 1.2036283969507622e-08
of O 0 6.353648274171064e-08
C9 B-Disease 1 1.0
deficiency I-Disease 1 0.9054988026618958
in O 0 3.0328955347158626e-08
four O 0 1.2474072441648332e-08
Japanese O 0 1.336624222858518e-06
C9 B-Disease 1 0.8378217220306396
- I-Disease 0 3.861106597469188e-05
deficient I-Disease 0 6.753387424396351e-05
patients O 0 8.543881335754122e-07
who O 0 6.584579548274405e-09
had O 0 2.9875440787918706e-08
suffered O 0 0.1472465991973877
from O 1 0.5735093951225281
meningococcal B-Disease 1 1.0
meningitis I-Disease 1 1.0
. O 0 7.761509550618939e-06

Direct O 0 1.2677054428422707e-07
sequencing O 0 1.3499582962595014e-07
of O 0 1.4994796515566122e-07
amplified O 0 1.30358364458516e-06
C9 O 0 1.1352116416674107e-05
cDNA O 0 3.5167821010873013e-07
and O 0 7.945670787989911e-09
DNA O 0 2.7272758273966247e-08
revealed O 0 1.062287502406889e-08
a O 0 1.8550992963994872e-09
nonsense O 0 2.93394801786917e-08
substitution O 0 5.351747844883903e-08
( O 0 8.725679734311598e-09
CGA O 0 2.120826366081019e-06
- O 0 4.036363861814607e-06
- O 0 5.897835308132926e-06
> O 0 9.692647836345714e-06
TGA O 0 3.750373798538931e-05
) O 0 1.144138894737523e-09
at O 0 1.7566339494123895e-09
codon O 0 1.1473847649767777e-08
95 O 0 1.7903660776141805e-08
in O 0 1.9502925940884097e-09
exon O 0 1.8414613123240997e-07
4 O 0 4.491460359190569e-08
in O 0 7.2115806659667214e-09
the O 0 1.5681933973610285e-08
four O 0 5.84533417224975e-08
C9 B-Disease 0 0.0017342525534331799
- I-Disease 0 7.814208947820589e-05
deficient I-Disease 0 6.99930433256668e-06
individuals O 0 3.426791650440464e-08
. O 0 3.0660987704322906e-07

An O 0 1.2702480489679147e-07
allele O 0 8.996349265544268e-08
- O 0 6.059779877887195e-08
specific O 0 4.171593737112289e-09
polymerase O 0 1.8117646050086478e-07
chain O 0 1.1706532632160815e-08
reaction O 0 5.885917864212331e-10
system O 0 4.438299172626614e-10
designed O 0 4.4235792806546215e-09
to O 0 2.197210857701748e-09
detect O 0 1.043216268925562e-08
exclusively O 0 2.242710239741541e-09
only O 0 1.6832971128089014e-10
one O 0 4.767449976461613e-11
of O 0 2.629193807113239e-10
the O 0 2.672768673050996e-10
normal O 0 3.0005800066845723e-09
and O 0 5.794023594241082e-10
mutant O 0 7.042858740646807e-09
alleles O 0 7.652402045366102e-10
indicated O 0 1.2020584527761002e-09
that O 0 2.1771509942092315e-11
all O 0 1.2347158018233273e-10
the O 0 4.284698151835187e-10
four O 0 8.460280254141139e-10
patients O 0 1.0090772661897063e-09
were O 0 1.9262248740492538e-10
homozygous O 0 2.7696350768380285e-10
for O 0 1.044202641020675e-10
the O 0 8.439779430879923e-10
mutation O 0 1.0067798816848494e-09
in O 0 5.349486964512096e-10
exon O 0 5.985755535675708e-08
4 O 0 1.194995391529119e-08
and O 0 4.87449913766369e-10
that O 0 4.594756866649341e-11
the O 0 3.038398699306555e-10
parents O 0 3.104844992218858e-10
of O 0 9.266066802737782e-10
patient O 0 6.201978486330972e-09
2 O 0 3.742947995988288e-08
were O 0 3.685615297399636e-07
heterozygous O 0 7.490232860618562e-07
. O 0 2.5526233002892695e-06

The O 0 1.177570254640159e-07
common O 0 1.784348846456396e-08
mutation O 0 2.4296795686495898e-09
at O 0 1.2813698990754574e-09
codon O 0 1.796365722839255e-08
95 O 0 6.437610977627628e-08
in O 0 3.1557145785399143e-09
exon O 0 1.437371253132369e-07
4 O 0 2.39396555912208e-08
might O 0 2.3469624021998925e-09
be O 0 2.778169083672566e-10
responsible O 0 9.971422576526834e-10
for O 0 5.009893055962777e-10
most O 0 3.3585485503806467e-09
Japanese O 0 7.6082324085291475e-06
C9 B-Disease 1 0.9999996423721313
deficiency I-Disease 0 0.00012307331780903041
. O 0 1.9158579789291252e-07
. O 0 7.747960353299277e-07

BRCA1 O 0 3.4052425235131523e-06
required O 0 6.813817776674114e-08
for O 0 1.292314966150343e-08
transcription O 0 1.2674674962909194e-06
- O 0 2.3685213363933144e-06
coupled O 0 9.638545179768698e-07
repair O 0 2.784469870675821e-05
of O 0 3.3505691021673556e-07
oxidative O 0 5.80985943088308e-06
DNA O 0 9.358378747492679e-07
damage O 0 2.4403907445957884e-05
. O 0 7.205394467746373e-06

The O 0 4.3446383642731234e-05
breast B-Disease 1 1.0
and I-Disease 1 0.9999998807907104
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
susceptibility O 0 0.005442330148071051
gene O 0 6.607025682114909e-08
BRCA1 O 0 8.212546021013623e-08
encodes O 0 3.5398317610457752e-09
a O 0 2.431479551034954e-08
zinc O 0 1.3693129403691273e-05
finger O 0 5.838497827426181e-07
protein O 0 2.9183804262089552e-09
of O 0 2.3975834650968864e-09
unknown O 0 1.900295742984781e-08
function O 0 1.653592818229299e-08
. O 0 1.2072545985120087e-07

Association O 0 9.966428251573234e-07
of O 0 1.2255974013442028e-07
the O 0 1.565431873018497e-08
BRCA1 O 0 5.072780417947342e-09
protein O 0 1.2528113269016927e-10
with O 0 1.0105823296246985e-11
the O 0 6.631867277562264e-10
DNA O 0 1.0899208646719671e-08
repair O 0 6.113292556619854e-07
protein O 0 6.120295381606411e-09
Rad51 O 0 3.999140929522582e-08
and O 0 2.4560409261908944e-10
changes O 0 1.7092346982217066e-10
in O 0 8.912785093295739e-11
the O 0 1.119479856037664e-10
phosphorylation O 0 1.0028452512855779e-09
and O 0 4.077864990126301e-10
cellular O 0 1.3779309249173366e-08
localization O 0 1.3765917117325444e-07
of O 0 2.553489863998948e-09
the O 0 6.726058598971463e-10
protein O 0 5.488622889515682e-10
after O 0 6.455913581504547e-10
exposure O 0 6.894502302401406e-09
to O 0 3.765148193224377e-10
DNA O 0 7.034429927443853e-08
- O 0 9.822661013458855e-07
damaging O 0 2.2886365513841156e-07
agents O 0 1.69768590296826e-08
are O 0 9.000764716882159e-11
consistent O 0 4.793804242453348e-10
with O 0 2.6305357631734028e-12
a O 0 8.707283505327013e-11
role O 0 7.137190838335528e-10
for O 0 2.1727559751383296e-09
BRCA1 O 0 3.6023049432287735e-08
in O 0 2.1026211882713142e-08
DNA O 0 3.2250989079329884e-06
repair O 1 0.9997792840003967
. O 0 0.00027080377913080156

Here O 0 1.3319080949258932e-07
, O 0 2.5988713403535257e-09
it O 0 7.445376953851834e-11
is O 0 3.9695496889535775e-11
shown O 0 3.546169191626092e-10
that O 0 3.0957739149961583e-10
mouse O 0 9.476084983361943e-08
embryonic O 0 5.983067694614874e-07
stem O 0 2.896389901252405e-07
cells O 0 3.433366941862914e-07
deficient B-Disease 0 6.482145522568317e-07
in I-Disease 0 2.060871651110574e-08
BRCA1 I-Disease 0 4.8260471174899067e-08
are O 0 4.851514745496388e-10
defective O 0 1.2782143343770258e-08
in O 0 1.2870009502563562e-09
the O 0 2.1411767914258917e-09
ability O 0 1.1447632841665722e-09
to O 0 1.3294514378259237e-09
carry O 0 8.321339173278375e-09
out O 0 1.7528654083776019e-09
transcription O 0 3.3495723528176313e-07
- O 0 6.297642016761529e-07
coupled O 0 6.638522904722777e-07
repair O 0 1.1482425179565325e-05
of O 0 7.19361423762166e-08
oxidative O 0 3.055779700389394e-07
DNA O 0 3.9433928122889483e-08
damage O 0 1.7937880159024644e-07
, O 0 7.47500905617926e-09
and O 0 9.44886480169771e-09
are O 0 1.4092281119815198e-08
hypersensitive O 0 5.1718175200221594e-06
to O 0 9.670654321780603e-08
ionizing O 0 9.223218512488529e-05
radiation O 0 8.196753333322704e-05
and O 0 4.279948839780445e-08
hydrogen O 0 6.119159934314666e-07
peroxide O 0 1.6484667867189273e-05
. O 0 5.376663921197178e-06

These O 0 6.684907560838838e-08
results O 0 8.727943701103413e-09
suggest O 0 1.4153238581116057e-08
that O 0 6.544284558707147e-10
BRCA1 O 0 4.414133059071901e-08
participates O 0 1.7895185333571817e-09
, O 0 5.985544282438582e-10
directly O 0 2.295614365266374e-09
or O 0 2.8778079919078436e-09
indirectly O 0 8.974100573766464e-09
, O 0 3.054284325454404e-10
in O 0 1.121033821327444e-09
transcription O 0 5.840307721882709e-07
- O 0 1.8672392343432875e-06
coupled O 0 1.5825793298063218e-06
repair O 0 1.437498940504156e-05
of O 0 9.727131811132494e-08
oxidative O 0 2.649169061896828e-07
DNA O 0 4.463227654127877e-08
damage O 0 1.672364504656798e-07
. O 0 4.877126613678229e-08
. O 0 3.594940665152535e-07

Truncation O 0 2.321035208296962e-05
mutations O 0 1.2356858292150719e-07
in O 0 5.699892113852911e-09
the O 0 1.018230300076084e-08
transactivation O 0 1.4186869066179497e-06
region O 0 1.7312785871581582e-08
of O 0 1.819257455792922e-08
PAX6 O 0 8.596809493610635e-05
result O 0 9.115665555725627e-09
in O 0 3.553483063356566e-09
dominant O 0 5.315257922688943e-08
- O 0 3.254616842696123e-07
negative O 0 1.3189754177744817e-08
mutants O 0 6.309081186373078e-07
. O 0 4.314278498895874e-07

PAX6 O 0 0.0007654789951629937
is O 0 2.1815729667196138e-08
a O 0 4.250221508073082e-09
transcription O 0 4.6481094528871836e-08
factor O 0 8.265248041539053e-09
with O 0 3.974125542538509e-11
two O 0 2.656951048063405e-10
DNA O 0 4.9568389393073176e-09
- O 0 1.4732458808452975e-08
binding O 0 3.212999866164523e-09
domains O 0 4.279848919708229e-09
( O 0 6.94553858870961e-10
paired O 0 8.00008148615916e-09
box O 0 3.269810733286249e-08
and O 0 2.515503805256003e-09
homeobox O 0 1.2379250620142557e-06
) O 0 9.678710055638362e-10
and O 0 1.095882162793771e-09
a O 0 3.030933504177824e-09
proline O 0 1.8190878847690328e-07
- O 0 6.663240981197305e-08
serine O 0 1.283846842170533e-07
- O 0 9.060224783752346e-07
threonine O 0 1.891138708742801e-06
( O 0 1.6951426928812907e-08
PST O 0 0.000164266413776204
) O 0 5.5537608290023854e-08
- O 0 2.0192940155538963e-06
rich O 0 3.180533951763209e-07
transactivation O 0 3.117065716651268e-05
domain O 0 9.333529078503489e-07
. O 0 2.2545299316334422e-07

PAX6 O 1 0.9930579662322998
regulates O 0 7.068638296914287e-06
eye O 0 0.00015603263454977423
development O 0 5.523010315755528e-08
in O 0 4.59175630851405e-09
animals O 0 2.019456823987298e-09
ranging O 0 3.6116736268354543e-09
from O 0 1.1126981558362559e-09
jellyfish O 0 3.460721709203085e-09
to O 0 4.696228739220487e-09
Drosophila O 0 2.1414867035218776e-07
to O 0 4.14161185346984e-08
humans O 0 3.382726845302386e-07
. O 0 5.050222284808115e-07

Heterozygous O 0 4.349218727384141e-07
mutations O 0 7.142165081575058e-09
in O 0 7.788744094128219e-10
the O 0 2.4147293053999874e-09
human O 0 4.17558965182252e-09
PAX6 O 0 9.856275028141681e-06
gene O 0 3.2890683510089502e-09
result O 0 6.934829932525588e-10
in O 0 4.883833892854739e-10
various O 0 7.979565341820205e-10
phenotypes O 0 8.98208085686747e-09
, O 0 1.849509156937046e-10
including O 0 2.7680784331352015e-09
aniridia B-Disease 1 1.0
, O 0 2.162493899504625e-07
Peters B-Disease 1 1.0
anomaly I-Disease 1 1.0
, O 0 2.8192997092446603e-07
autosomal B-Disease 0 0.0012162181083112955
dominant I-Disease 0 6.94542495693895e-06
keratitis I-Disease 1 1.0
, O 0 1.5388415874895145e-08
and O 0 4.6598980674161794e-08
familial B-Disease 1 0.9999620914459229
foveal I-Disease 1 1.0
dysplasia I-Disease 1 1.0
. O 1 0.999990701675415

It O 0 1.1574607050590657e-08
is O 0 9.673192247205975e-10
believed O 0 6.910590766295854e-09
that O 0 5.702582850375393e-11
the O 0 9.370180187318056e-10
mutated O 0 2.9961952918711177e-08
allele O 0 3.946786009123571e-08
of O 0 3.178816854187971e-08
PAX6 O 0 0.00017628665955271572
produces O 0 3.2160409890735764e-09
an O 0 1.9600283895915283e-10
inactive O 0 2.746464922154246e-08
protein O 0 2.4242725604750603e-09
and O 0 3.524256442233309e-09
aniridia B-Disease 1 1.0
is O 0 1.9172674559087e-09
caused O 0 3.076140009383721e-09
due O 0 6.293292553749552e-09
to O 0 7.351712572045699e-09
genetic O 0 2.5514108870083874e-07
haploinsufficiency O 0 3.991717312601395e-05
. O 0 2.382065076744766e-06

However O 0 1.5624377169842774e-07
, O 0 3.575279183820612e-09
several O 0 1.7511934957692432e-10
truncation O 0 1.0037913966698397e-07
mutations O 0 1.2539738136752021e-09
have O 0 5.292548690971621e-11
been O 0 6.356427190157277e-11
found O 0 1.6315690118395842e-11
to O 0 1.3477766645786371e-11
occur O 0 4.431656777659221e-11
in O 0 9.193146938146768e-11
the O 0 1.0514900061764365e-09
C O 0 2.1649020709446631e-07
- O 0 2.1037244835042657e-08
terminal O 0 1.1848168668393555e-07
half O 0 3.153849181813939e-09
of O 0 2.4482360583277796e-09
PAX6 O 0 4.447627361514606e-06
in O 0 1.682020744908641e-09
patients O 0 3.542344417795107e-09
with O 0 6.922298151357253e-11
Aniridia B-Disease 1 1.0
resulting O 0 2.1158570007173694e-08
in O 0 1.2062914001020886e-09
mutant O 0 1.7968857513039893e-09
proteins O 0 8.25078061428286e-11
that O 0 2.6805885636194127e-11
retain O 0 9.340955564596243e-09
the O 0 2.3504759028014632e-08
DNA O 0 8.190988864953397e-08
- O 0 8.762893344282929e-08
binding O 0 3.4715044172628495e-09
domains O 0 2.612539073965081e-09
but O 0 2.4959173616778685e-10
have O 0 3.262830006178774e-10
lost O 0 9.944077561385711e-09
most O 0 1.3048794267334074e-09
of O 0 5.915972156600446e-09
the O 0 1.548758987723886e-08
transactivation O 0 8.410807822656352e-06
domain O 0 7.457865649485029e-07
. O 0 3.5979041967948433e-07

It O 0 1.0619957357960175e-08
is O 0 2.5491578292680117e-10
not O 0 1.929063297989586e-10
clear O 0 4.501249928345885e-10
whether O 0 1.9746816681820434e-10
such O 0 1.4772323364553586e-09
mutants O 0 8.370976161131694e-07
really O 0 3.4361310241592946e-08
behave O 0 1.1743785943707508e-09
as O 0 1.109678016142368e-09
loss O 0 4.399749009564857e-09
- O 0 3.703873829863369e-08
of O 0 6.045464573389836e-08
- O 0 6.87349697159334e-08
function O 0 4.000321407460206e-09
mutants O 0 1.1547175660098219e-08
as O 0 7.040746319297853e-10
predicted O 0 1.5421619536937214e-08
by O 0 6.80770950722831e-09
haploinsufficiency O 0 0.00017326684610452503
. O 0 3.3617502595006954e-06

Contrary O 0 5.154644213689608e-07
to O 0 2.3268600379822146e-09
this O 0 9.816113200056265e-11
theory O 0 2.7221604970151247e-09
, O 0 5.885128495641823e-11
our O 0 2.6786375895149206e-10
data O 0 2.447082980694404e-09
showed O 0 4.5903092438237536e-10
that O 0 2.34597532372538e-11
these O 0 1.4266515746541586e-10
mutants O 0 2.837855284099078e-08
are O 0 1.1509085906524774e-09
dominant O 0 1.1657335541315206e-08
- O 0 5.336723063464888e-08
negative O 0 1.7071828395387456e-09
in O 0 7.39795891213646e-10
transient O 0 2.3474875376905402e-08
transfection O 0 1.7397901785898284e-07
assays O 0 1.1775664887636594e-08
when O 0 5.398131941447559e-10
they O 0 8.420676933518223e-10
are O 0 9.556339053418128e-10
coexpressed O 0 6.767616014258238e-07
with O 0 1.8193051509740599e-09
wild O 0 6.422794740501558e-07
- O 0 5.208235506870551e-06
type O 0 4.435634036781266e-05
PAX6 O 1 0.9994844198226929
. O 0 2.406124804110732e-05

We O 0 1.1997552462617023e-07
found O 0 2.6110296147408008e-09
that O 0 5.641308600812245e-11
the O 0 6.292857346323899e-10
dominant O 0 1.5771622230431603e-08
- O 0 2.7961508664020585e-08
negative O 0 5.409283576618407e-10
effects O 0 3.0649243143443528e-09
result O 0 1.6788083423424638e-10
from O 0 2.6432023236822033e-10
the O 0 3.0850105803281735e-10
enhanced O 0 1.338448640808565e-08
DNA O 0 5.973594952024541e-09
binding O 0 5.434060978970479e-10
ability O 0 3.4282996441703517e-09
of O 0 1.4189566854838631e-08
these O 0 8.504192905434138e-09
mutants O 0 1.654669176787138e-06
. O 0 1.2211446573928697e-06

Kinetic O 0 9.280876724915288e-07
studies O 0 6.517446848874897e-08
of O 0 5.589624763047141e-09
binding O 0 1.960773543530081e-09
and O 0 1.068833244133316e-09
dissociation O 0 3.1138984724066177e-08
revealed O 0 2.390961650888812e-09
that O 0 2.2873775790133166e-11
various O 0 1.8284672387292034e-10
truncation O 0 1.2071429011939472e-07
mutants O 0 9.288473101776162e-09
have O 0 1.0543976108889908e-10
3 O 0 2.045328129085533e-09
- O 0 3.9627245485007734e-08
5 O 0 1.1303822589070478e-07
- O 0 7.369559398284764e-07
fold O 0 6.278571618167916e-08
higher O 0 1.614052536069721e-08
affinity O 0 2.130397858124411e-09
to O 0 3.67293029324145e-10
various O 0 2.642900065463749e-10
DNA O 0 3.6327383323708773e-09
- O 0 4.165789491139549e-09
binding O 0 9.03425723119966e-10
sites O 0 2.0079420348650956e-09
when O 0 1.3810870502783956e-10
compared O 0 2.2233385965630958e-10
with O 0 2.9985573052337955e-11
the O 0 2.6449586965071603e-09
wild O 0 8.888538616247388e-08
- O 0 1.535933506602305e-06
type O 0 7.547427230747417e-06
PAX6 O 0 0.11111132800579071
. O 0 1.6083131413324736e-05

These O 0 2.482298988581988e-08
results O 0 4.339558490329409e-09
provide O 0 8.576354737499514e-09
a O 0 7.429946102810447e-10
new O 0 6.726789680833178e-10
insight O 0 1.038412111853404e-08
into O 0 2.09987374710785e-10
the O 0 3.014374305720935e-10
role O 0 1.4800186631802603e-09
of O 0 1.0537311467828658e-08
mutant O 0 4.297876614600682e-07
PAX6 O 0 9.32612965698354e-05
in O 0 5.221556520496051e-08
causing O 0 7.623954729751858e-07
aniridia B-Disease 1 1.0
. O 0 4.940079065818281e-07
. O 0 1.2624575447262032e-06

Reversal O 0 1.452032392990077e-06
of O 0 3.58990121185343e-07
severe O 1 0.9929591417312622
hypertrophic B-Disease 1 1.0
cardiomyopathy I-Disease 1 1.0
and O 0 1.1118967222500942e-06
excellent O 0 4.0353492636313604e-07
neuropsychologic O 0 1.5102403949640575e-06
outcome O 0 5.323503859955281e-09
in O 0 2.140290833452241e-09
very B-Disease 0 2.931356934965379e-09
- I-Disease 0 2.3357684142411017e-07
long I-Disease 0 1.4810761683747842e-07
- I-Disease 0 1.7553875295561738e-06
chain I-Disease 0 3.31554048216276e-07
acyl I-Disease 0 3.5508267046679975e-06
- I-Disease 0 1.7111353827203857e-06
coenzyme I-Disease 0 6.051180207578e-06
A I-Disease 0 7.133140115911374e-06
dehydrogenase I-Disease 0 0.0009075579000636935
deficiency I-Disease 1 0.9996732473373413
. O 0 1.187947145808721e-05

Very B-Disease 0 1.473474213753434e-07
- I-Disease 0 1.6089369410110521e-06
long I-Disease 0 8.80197390529247e-08
- I-Disease 0 4.004713503036328e-07
chain I-Disease 0 7.140220503742967e-08
acyl I-Disease 0 3.6764353694707097e-07
- I-Disease 0 5.755676824037437e-08
coenzyme I-Disease 0 1.622505862997059e-07
A I-Disease 0 3.028987549669182e-08
dehydrogenase I-Disease 0 1.718730686661729e-07
( I-Disease 0 1.932025739392884e-08
VLCAD I-Disease 1 1.0
) I-Disease 0 3.5916065144192544e-07
deficiency I-Disease 1 0.9083683490753174
is O 0 4.1168637388011575e-09
a O 0 4.366711436887272e-08
disorder O 1 0.9975753426551819
of O 0 8.429859121861227e-07
fatty O 0 1.0734079296526033e-06
acid O 0 1.7906357285824015e-08
beta O 0 1.8248423216959964e-08
oxidation O 0 5.2601013322828294e-08
that O 0 9.90602266881524e-10
reportedly O 0 4.003193154744622e-08
has O 0 8.52045239918553e-11
high O 0 1.6406390690448802e-09
rates O 0 9.90614079654506e-09
of O 0 2.173800472959897e-09
morbidity O 0 4.557577995001338e-06
and O 0 2.0249926180326838e-08
mortality O 0 1.795849675545469e-05
. O 0 7.16171541625954e-07

We O 0 1.474716349036953e-08
describe O 0 8.126034067856835e-09
the O 0 2.0305446213342293e-10
outcome O 0 5.840257721878572e-10
of O 0 6.387360640403017e-10
a O 0 1.442642810767225e-10
5 O 0 3.869093934127932e-10
- O 0 4.989400004262734e-10
year O 0 1.6825973947476314e-10
- O 0 3.925283209582631e-09
old O 0 6.257277362919922e-09
girl O 0 5.850685269592759e-09
with O 0 1.1443375136366285e-09
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
who O 0 3.53482754178458e-08
was O 0 8.394990480553588e-09
first O 0 2.2279966760407888e-09
seen O 0 6.045920986075259e-10
at O 0 2.8566971010945963e-10
5 O 0 1.3634466888845509e-09
months O 0 2.724808434440007e-10
of O 0 2.8442356803104474e-10
age O 0 6.064815871731355e-10
with O 0 2.1669400995794064e-10
severe O 0 6.652872252743691e-05
hypertrophic B-Disease 1 1.0
cardiomyopathy I-Disease 1 1.0
, O 1 0.9999786615371704
hepatomegaly B-Disease 1 1.0
, O 1 0.9331212639808655
encephalopathy B-Disease 1 0.9999736547470093
, O 0 1.0591357835210147e-07
and O 0 3.8381540434784256e-07
hypotonia B-Disease 1 0.9997621178627014
. O 0 1.1662655197142158e-05

Biochemical O 0 2.354148091399111e-05
studies O 0 1.708369018160738e-05
indicated O 0 0.22455283999443054
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
caused O 0 3.177117093855486e-07
by O 0 6.933189578006704e-10
a O 0 2.1787482928914415e-09
stable O 0 1.0885189993814492e-07
yet O 0 1.0794194871266427e-08
inactive O 0 3.078331189954042e-07
enzyme O 0 2.3024809081562125e-07
. O 0 8.17381931028649e-07

Molecular O 0 6.775643441869761e-07
genetic O 0 3.011975024946878e-08
analysis O 0 3.2335953914497395e-09
of O 0 8.221287650655995e-09
her O 0 6.146054332134554e-09
VLCAD O 0 0.0320136733353138
gene O 0 2.86056014431324e-08
revealed O 0 1.1852142378643293e-08
a O 0 6.940894081708393e-09
T1372C O 0 5.16402542416472e-06
( O 0 1.3668063125749086e-08
F458L O 0 2.164432544304873e-06
) O 0 3.4267504389617898e-09
missense O 0 2.387354527400021e-07
mutation O 0 5.129973779105512e-09
and O 0 2.113947905613145e-09
a O 0 6.587735157381758e-08
1668 O 1 0.9999679327011108
ACAG O 1 0.9999914169311523
1669 O 0 0.0006146541563794017
splice O 0 2.1216828827164136e-05
site O 0 1.490247427682334e-06
mutation O 0 2.5565964278939646e-07
. O 0 2.6653165718926175e-07

After O 0 6.780239658610299e-08
initial O 0 5.247384748940931e-08
treatment O 0 2.0413602896951488e-07
with O 0 5.708026828976642e-10
intravenous O 0 8.461030631679023e-08
glucose O 0 9.320527993850192e-08
and O 0 1.3493933748165432e-09
carnitine O 0 9.415456929673383e-07
, O 0 2.2396666743418336e-09
the O 0 1.4151403604500956e-08
patient O 0 8.205145718420681e-07
has O 0 1.7123509554739513e-10
thrived O 0 1.2146815775437858e-09
on O 0 3.9696576581427223e-10
a O 0 7.946667213154512e-10
low O 0 9.104756770739186e-08
- O 0 4.6729820724067395e-07
fat O 0 7.053453714433999e-07
diet O 0 9.823057212088315e-08
supplemented O 0 5.573952854831532e-09
with O 0 1.5213647008849307e-10
medium O 0 7.997916213753342e-07
- O 0 2.963197857752675e-06
chain O 0 4.6339241066561954e-07
triglyceride O 0 6.184870358083572e-07
oil O 0 3.8623960563199944e-07
and O 0 1.8555176950485475e-08
carnitine O 0 9.610679398974753e-07
and O 0 3.1869502592485333e-09
avoidance O 0 5.278289791021962e-06
of O 0 4.886615556642937e-07
fasting O 0 7.839013051125221e-06
. O 0 1.8593834738567239e-07

Her O 0 4.5181532186688855e-06
ventricular O 1 1.0
hypertrophy O 1 0.99997878074646
resolved O 0 2.2078303629768925e-07
significantly O 0 6.232680149764747e-09
over O 0 1.5055746926950775e-10
1 O 0 3.028933992510474e-09
year O 0 5.26635013375909e-10
, O 0 2.0791893207139367e-10
and O 0 3.303249895836302e-10
cognitively O 0 9.237294307240518e-08
, O 0 4.813392462388322e-10
she O 0 1.1120526721697388e-10
is O 0 8.262650980084274e-12
in O 0 1.6401305660829202e-11
the O 0 7.553599412624123e-11
superior O 0 4.578315060399518e-09
range O 0 1.4382675495028252e-08
for O 0 4.073264836534918e-09
age O 0 1.1260365084808655e-07
. O 0 9.524081860945444e-07

Clinical O 0 1.3850824871042278e-05
recognition O 0 1.3256130841909908e-06
of O 1 0.9609184861183167
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
is O 0 2.3948412142260622e-09
important O 0 5.685187876025566e-10
because O 0 7.55221319509447e-12
it O 0 2.0490421425573002e-12
is O 0 1.2296288119661991e-12
one O 0 3.665731780622128e-12
of O 0 2.831170020645146e-10
the O 0 4.334297365460316e-09
few O 0 9.635797049156736e-09
directly O 0 4.68111505114166e-09
treatable O 0 4.1159833585879824e-07
causes O 0 1.918899261710294e-09
of O 0 1.4314420759831137e-08
cardiomyopathy B-Disease 1 1.0
in O 0 7.338686032198893e-07
children O 0 1.4718163576787902e-08
. O 0 4.208917214754138e-09
. O 0 5.4437141017160684e-08

Cloning O 0 1.8661140757103567e-06
of O 0 1.2160290552287734e-08
a O 0 1.2076610822475686e-09
novel O 0 5.108287570720904e-09
member O 0 1.1647195430342094e-09
of O 0 2.596527881593147e-09
the O 0 4.825198018920673e-09
low O 0 6.903874805175292e-08
- O 0 1.667620885825727e-08
density O 0 1.1305849589859918e-09
lipoprotein O 0 5.124685387158934e-08
receptor O 0 6.623277215567214e-08
family O 0 9.453699334471821e-08
. O 0 2.933033329099999e-06

A O 0 1.276569264518912e-06
gene O 0 4.165759648344647e-08
encoding O 0 7.513535393854909e-08
a O 0 1.2175608077313882e-08
novel O 0 2.4823556543651648e-08
transmembrane O 0 8.568081355520007e-09
protein O 0 4.902714900723026e-10
was O 0 8.96887730750251e-10
identified O 0 8.337090739996e-11
by O 0 1.4393273899127035e-11
DNA O 0 2.1472366940056276e-10
sequence O 0 3.5084782301630923e-11
analysis O 0 7.356278086678714e-11
within O 0 1.1765617646819493e-10
the O 0 1.078044542524026e-09
insulin B-Disease 0 0.00015040926518850029
- I-Disease 1 0.9987578392028809
dependent I-Disease 1 0.9999994039535522
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
( O 0 2.058098971247091e-07
IDDM B-Disease 0 0.00025887947413139045
) O 0 2.0761005359304363e-08
locus O 0 2.8866969614682603e-07
IDDM4 O 0 1.9239272660342976e-05
on O 0 1.9740251389066543e-07
chromosome O 0 1.3856711120752152e-06
11q13 O 0 8.781588257988915e-05
. O 0 2.013448238358251e-06

Based O 0 3.0612046231226486e-08
on O 0 8.784392768745874e-09
its O 0 3.2214111933548395e-10
chromosomal O 0 2.965957435208111e-08
position O 0 1.2473905464105428e-08
, O 0 2.311535962640221e-10
this O 0 2.4334151013660765e-11
gene O 0 4.2991856602503375e-11
is O 0 3.844461641394625e-12
a O 0 3.558023667360466e-11
candidate O 0 4.99750518745401e-10
for O 0 5.434289129802039e-10
conferring O 0 1.5535199793248466e-07
susceptibility O 0 1.488509587943554e-05
to O 0 8.949812126957113e-07
diabetes B-Disease 1 1.0
. O 0 2.200544986408204e-05

The O 0 5.877923854313849e-07
gene O 0 1.2564828466565814e-07
, O 0 9.663459366038296e-09
termed O 0 1.2723599240871408e-07
low O 0 7.253589728861698e-08
- O 0 5.988494145015011e-09
density O 0 5.966643151777973e-11
lipoprotein O 0 2.1544487027735926e-10
receptor O 0 6.093057308698135e-11
related O 0 5.289160776023039e-10
protein O 0 3.2356542445377556e-10
5 O 0 1.3918992181061185e-08
( O 0 8.32902458114404e-09
LRP5 O 0 1.4106948583503254e-05
) O 0 2.2473176652937354e-09
, O 0 5.908469824511542e-10
encodes O 0 3.6541053516359057e-10
a O 0 2.7026705873289814e-10
protein O 0 1.426372020496558e-09
of O 0 5.63135893472122e-09
1615 O 0 2.2836748030385934e-06
amino O 0 2.8322206802045002e-08
acids O 0 9.245082033260132e-09
that O 0 1.0071077999329603e-10
contains O 0 1.4522669178340664e-10
conserved O 0 3.400678072473795e-10
modules O 0 4.919324947394443e-09
which O 0 3.860106678743591e-11
are O 0 2.294605304375974e-11
characteristic O 0 1.0066819600140775e-09
of O 0 3.743402920974859e-09
the O 0 3.279215121665402e-09
low O 0 9.82080905487237e-08
- O 0 2.7142554870351887e-08
density O 0 2.3484758582270615e-09
lipoprotein O 0 3.430087147648919e-08
( O 0 5.27134735861523e-09
LDL O 0 1.2261110668987385e-06
) O 0 2.3215683597754833e-08
receptor O 0 2.2096818952377362e-07
family O 0 3.497339946534339e-07
. O 0 2.7683736334438436e-06

These O 0 2.852115699170099e-08
modules O 0 1.7501710658507363e-07
include O 0 1.3596143766392288e-08
a O 0 4.189926627873319e-09
putative O 0 2.946785393476148e-08
signal O 0 4.7857877660817394e-08
peptide O 0 7.652668720936617e-09
for O 0 4.2368403230241825e-10
protein O 0 3.6207833953305624e-10
export O 0 2.3361554468692702e-08
, O 0 1.9169019704889934e-09
four O 0 1.6282628578778713e-09
epidermal O 0 3.070455534270877e-08
growth O 0 2.179321834105963e-09
factor O 0 3.5944791587638747e-09
( O 0 1.3499364959201898e-09
EGF O 0 1.1379963780200342e-06
) O 0 1.0235787772927551e-09
repeats O 0 3.6161402761081263e-09
with O 0 1.9833974740368632e-10
associated O 0 4.218322757765236e-08
spacer O 0 9.19211402106157e-07
domains O 0 1.772010449485606e-08
, O 0 3.227887401813234e-10
three O 0 5.195569668936528e-11
LDL O 0 4.293732036586562e-09
- O 0 1.0271093309199841e-08
receptor O 0 9.568235093126987e-09
( O 0 8.123321570963071e-09
LDLR O 1 0.543657660484314
) O 0 6.113365369486701e-09
repeats O 0 1.2277564742646518e-08
, O 0 1.0908020042776911e-09
a O 0 1.2087281175965359e-09
single O 0 6.653904094378049e-09
transmembrane O 0 1.292093099181102e-08
spanning O 0 1.2977391605772937e-08
domain O 0 5.96089311244441e-09
, O 0 4.2719680570790786e-10
and O 0 8.412586183226267e-10
a O 0 7.581840932857631e-09
cytoplasmic O 0 1.4221978972273064e-07
domain O 0 7.265608132911439e-07
. O 0 3.9762437609169865e-07

The O 0 9.526028321715785e-08
encoded O 0 2.3575069008074934e-08
protein O 0 3.948764426553453e-09
has O 0 1.0432828906337122e-10
a O 0 1.4110744517292773e-10
unique O 0 6.99715674290502e-10
organization O 0 3.3215610262260498e-09
of O 0 1.2857111819641887e-08
EGF O 0 3.1657033105148e-05
and O 0 2.9719826599716725e-08
LDLR O 0 0.16415852308273315
repeats O 0 7.875225804809816e-09
; O 0 3.466454345790737e-10
therefore O 0 3.801758463595206e-09
, O 0 7.04450719979377e-10
LRP5 O 0 1.5217065083561465e-06
likely O 0 1.4838742457001786e-09
represents O 0 2.9071552457016203e-11
a O 0 2.0759864313713017e-11
new O 0 3.420334154791149e-11
category O 0 2.460665449177668e-09
of O 0 4.4120014308646205e-09
the O 0 1.6145850878501733e-08
LDLR O 0 0.25311383605003357
family O 0 1.7468543944687553e-07
. O 0 6.484247592197789e-07

Both O 0 2.0791128463315545e-07
human O 0 3.1548072598752697e-08
and O 0 2.9715744531699784e-08
mouse O 0 4.613759756466607e-06
LRP5 O 1 0.9922961592674255
cDNAs O 0 4.9384671001462266e-05
have O 0 8.82288020420674e-09
been O 0 3.9078700275752e-09
isolated O 0 3.6998757391160098e-09
and O 0 1.9298949938129084e-10
the O 0 1.005624472583122e-09
encoded O 0 1.475711552956227e-09
mature O 0 1.2873619947839643e-09
proteins O 0 5.5911119484219896e-11
are O 0 3.802291120846846e-11
95 O 0 4.915507556546572e-09
% O 0 1.1020608037259905e-10
identical O 0 1.5727118218844538e-10
, O 0 1.0140700085203846e-10
indicating O 0 9.468451578342751e-10
a O 0 1.8297093007380028e-10
high O 0 9.8111396784617e-10
degree O 0 1.532611371146686e-08
of O 0 3.728922504109278e-09
evolutionary O 0 1.4639879530875533e-08
conservation O 0 5.588601137418436e-09
. O 0 4.556787835952036e-09
. O 0 1.0675893236111733e-07

The O 0 1.4067313713894691e-06
APC B-Disease 0 4.447813807928469e-06
variants O 0 6.00654743720952e-07
I1307K O 0 9.640057214710396e-06
and O 0 8.958435770978213e-09
E1317Q O 0 2.175009967686492e-06
are O 0 6.427630094840708e-10
associated O 0 6.456843237856447e-08
with O 0 4.949878871229885e-07
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 8.4712034720269e-08
but O 0 1.577768332650109e-10
not O 0 1.0126281063671527e-10
always O 0 1.8376100641148696e-10
with O 0 8.266118692312752e-12
a O 0 1.6136946223710424e-09
family O 0 4.274847587026898e-09
history O 0 1.946952892240006e-07
. O 0 4.925444159198378e-07

Classical O 0 0.43544474244117737
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 0 1.6076592146418989e-06
FAP B-Disease 0 8.513141438015737e-06
) O 0 1.50833467937872e-09
is O 0 1.6367689148477638e-10
a O 0 2.5670559011814476e-09
high O 0 0.010247237980365753
- O 1 1.0
penetrance O 1 1.0
autosomal B-Disease 1 1.0
dominant I-Disease 1 0.9371033310890198
disease I-Disease 0 0.0007075128378346562
that O 0 5.381865439413325e-11
predisposes O 0 7.884469077623635e-09
to O 0 1.6600061603089244e-10
hundreds O 0 1.1488819895433267e-09
or O 0 1.511946567944733e-09
thousands O 0 6.2639074371873e-08
of O 0 0.006783490069210529
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 1.0
carcinoma I-Disease 1 1.0
and O 0 3.0548758189752334e-08
that O 0 1.3107080698571139e-10
results O 0 1.1523489801268383e-10
from O 0 4.893708771547267e-10
truncating O 0 1.695663165435235e-08
mutations O 0 5.736316421867116e-10
in O 0 1.072003930069343e-09
the O 0 2.3658135006598968e-08
APC B-Disease 0 3.157593937430647e-06
gene O 0 7.047523240544251e-07
. O 0 5.116431111673592e-06

A O 0 4.751851747641922e-07
variant O 0 4.5063399056743947e-07
of O 0 1.1464806703997965e-07
FAP B-Disease 0 1.0790110536618158e-05
is O 0 4.598761549345909e-08
attenuated B-Disease 1 0.9999996423721313
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 1.0
, O 0 7.523039968759804e-09
which O 0 7.655712175314022e-11
results O 0 9.209485951622298e-11
from O 0 2.572926871557968e-10
germ O 0 2.909323029598454e-06
- O 0 9.611625273464597e-08
line O 0 8.829141862065626e-09
mutations O 0 7.82383463571179e-11
in O 0 4.2090258361993094e-11
the O 0 1.7879549230048752e-10
5 O 0 1.8539532131711667e-09
and O 0 2.8900401516374075e-10
3 O 0 6.2419123203483196e-09
regions O 0 1.1315515191512304e-09
of O 0 7.86200349267574e-09
the O 0 2.8892383596712534e-08
APC B-Disease 0 1.3160160960978828e-06
gene O 0 3.0584649834963784e-07
. O 0 3.63383992407762e-06

Attenuated B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 1.0
patients O 0 1.4112788448983338e-05
have O 0 6.070521862966416e-10
" O 0 5.983926687491703e-09
multiple O 0 8.489060832062023e-08
" O 1 0.9999996423721313
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
( O 0 4.1158688901532514e-08
typically O 0 1.1907764774221619e-09
fewer O 0 1.3375286989081303e-10
than O 0 3.3753191214236367e-11
100 O 0 1.3627706740848566e-09
) O 0 2.464280723923906e-10
without O 0 4.1612469026119925e-09
the O 0 5.2387019167099425e-09
florid O 0 1.171534336208424e-06
phenotype O 0 4.8183672163304436e-08
of O 0 4.535736408683988e-08
classical O 0 4.213725787849398e-06
FAP B-Disease 0 2.255262734252028e-05
. O 0 1.541270194138633e-06

Another O 0 2.2002591038017272e-07
group O 0 5.32288479959675e-09
of O 0 1.1678031874851058e-08
patients O 0 2.711559687895715e-08
with O 0 7.325348660991438e-11
multiple O 0 1.3523859365704993e-07
adenomas B-Disease 1 0.9999998807907104
has O 0 3.5689426969298665e-09
no O 0 1.5067618264197336e-09
mutations O 0 4.1227943281541e-10
in O 0 2.5036320239202325e-10
the O 0 2.585157199419541e-09
APC B-Disease 0 5.455012086486022e-08
gene O 0 2.6588431456531225e-09
, O 0 3.2180705322737424e-10
and O 0 4.4454159797702175e-10
their O 0 1.1417692347137631e-09
phenotype O 0 3.0436202447248206e-09
probably O 0 5.063980901276466e-10
results O 0 5.3697248036943535e-11
from O 0 7.211366920278905e-11
variation O 0 5.46659884026468e-10
at O 0 6.859895429478513e-10
a O 0 2.005311749986305e-10
locus O 0 5.635334865417008e-09
, O 0 3.0458779942676983e-10
or O 0 4.889668669960656e-10
loci O 0 3.6684930648789305e-09
, O 0 2.0925490507028854e-10
elsewhere O 0 1.5176093715041361e-09
in O 0 6.057925272529019e-10
the O 0 7.274576940830002e-09
genome O 0 4.3809937011474176e-08
. O 0 1.8454979056059528e-07

Recently O 0 6.900516495988995e-07
, O 0 4.92662044493386e-09
however O 0 9.54253231988389e-10
, O 0 1.9614458668382184e-10
a O 0 2.7904950572477105e-10
missense O 0 2.441126412122685e-08
variant O 0 7.80935422994844e-08
of O 0 3.055080526337406e-07
APC B-Disease 0 2.8931019187439233e-05
( O 0 2.553267464122655e-08
I1307K O 0 0.0010410577524453402
) O 0 1.2002759897100646e-09
was O 0 5.208821374225181e-09
described O 0 5.31092558819779e-10
that O 0 6.5860017092744805e-12
confers O 0 8.8622059690735e-10
an O 0 1.6310213596382184e-11
increased O 0 6.428255150403572e-10
risk O 0 2.1903021263369737e-07
of O 0 0.06943982094526291
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 2.380679262614649e-07
including O 0 9.574021575531333e-09
multiple O 0 1.7508146044065143e-08
adenomas B-Disease 0 6.016090264893137e-05
, O 0 1.3545771615497415e-08
in O 0 4.145690013501735e-08
Ashkenazim O 0 0.0002987583284266293
. O 0 8.576633945267531e-07

We O 0 8.368695603166998e-08
have O 0 1.882057176771923e-09
studied O 0 1.3409656496321531e-08
a O 0 5.264642610747217e-10
set O 0 2.3217485711768404e-09
of O 0 1.7926613526952906e-09
164 O 0 1.4780419554938362e-08
patients O 0 1.9489985181309066e-09
with O 0 3.170542439701052e-10
multiple O 1 0.9999430179595947
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 1.0
/ I-Disease 1 1.0
or I-Disease 1 0.9997294545173645
carcinoma I-Disease 1 1.0
and O 0 9.333389527910185e-08
analyzed O 0 1.2702281004806082e-08
codons O 0 2.5687125315698722e-08
1263 O 0 1.5267229400706128e-06
- O 0 1.137016738539387e-06
1377 O 0 2.1105977793922648e-05
( O 0 5.841021177843686e-08
exon O 0 3.181108695571311e-06
15G O 0 1.4020493836142123e-05
) O 0 3.300291817609491e-09
of O 0 1.3549648514299406e-08
the O 0 1.0992614818405855e-08
APC B-Disease 0 2.9024954528722446e-07
gene O 0 1.0868153488274856e-08
for O 0 8.392045280913862e-09
germ O 1 0.9999836683273315
- O 0 0.013158215209841728
line O 0 7.317472864087904e-06
variants O 0 1.7179177120851818e-06
. O 0 6.801099061704008e-07

Three O 0 1.3034762957886414e-07
patients O 0 1.8373208732214152e-08
with O 0 7.637014631800554e-11
the O 0 4.726421920508983e-09
I1307K O 0 2.915224968091934e-06
allele O 0 6.574389477265186e-09
were O 0 2.109147079210061e-09
detected O 0 4.007866927224768e-09
, O 0 2.2077789596508524e-10
each O 0 1.3100558138301466e-10
of O 0 1.4858178687404688e-08
Ashkenazi O 0 6.75776755088009e-05
descent O 0 1.3820490494254045e-05
. O 0 1.105873138840252e-06

Four O 0 4.89189858399186e-07
patients O 0 3.6091623201173206e-07
had O 0 7.752880115674543e-09
a O 0 4.003557485532383e-09
germ O 0 0.2145725041627884
- O 0 3.839172495645471e-05
line O 0 3.862855919578578e-06
E1317Q O 0 2.672439040907193e-05
missense O 0 2.164167085538793e-07
variant O 0 5.1851433369165534e-08
of O 0 1.4744631293694965e-08
APC O 0 1.1782464781617819e-07
that O 0 1.8765790310570907e-10
was O 0 4.521481855590537e-09
not O 0 2.468260318355675e-10
present O 0 8.178176191808717e-11
in O 0 1.5136769615509138e-10
controls O 0 3.274053028690105e-09
; O 0 4.7204708891745994e-11
one O 0 3.7996304019793925e-11
of O 0 1.9131460304855352e-10
these O 0 3.9439052718082124e-11
individuals O 0 3.351915273119843e-11
had O 0 5.946751979735154e-10
an O 0 5.383261544866791e-11
unusually O 0 7.861175044254765e-10
large O 0 2.71885375324743e-10
number O 0 1.6698863403163955e-09
of O 0 3.345577681557188e-08
metaplastic B-Disease 0 8.9538429165259e-05
polyps I-Disease 0 1.8269147403771058e-06
of I-Disease 0 4.6280192123049346e-08
the I-Disease 0 9.215314378252515e-08
colorectum I-Disease 0 0.00011167224874952808
. O 0 7.275980919985159e-07

There O 0 4.5766409328962254e-08
is O 0 1.1788264808743065e-09
increasing O 0 1.0652654314213805e-09
evidence O 0 1.2748487820957166e-09
that O 0 2.926370951117363e-11
there O 0 6.891891918270332e-11
exist O 0 1.1307165204144098e-09
germ O 0 1.3314576108314213e-06
- O 0 5.911778799827516e-08
line O 0 2.1153526930106636e-08
variants O 0 1.264947790957649e-08
of O 0 4.680258403055859e-09
the O 0 3.8136760416307425e-09
APC B-Disease 0 2.7702137472829236e-08
gene O 0 9.719834936916527e-10
that O 0 8.505190302043886e-11
predispose O 0 1.0402834149658702e-08
to O 0 3.720303509702205e-10
the O 0 7.187655470808352e-10
development O 0 6.252326656408513e-09
of O 0 8.960438435678952e-08
multiple O 1 0.9999995231628418
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 1.0
carcinoma I-Disease 1 1.0
, O 0 4.975755807379301e-09
but O 0 1.2640155588883317e-10
without O 0 6.132023777638551e-10
the O 0 3.816898186403961e-10
florid O 0 8.473757162619222e-08
phenotype O 0 1.6984623707472224e-09
of O 0 1.1874060623640048e-09
classical O 0 5.267496021588158e-07
FAP B-Disease 0 1.3307641211213195e-07
, O 0 1.1569958879853459e-10
and O 0 2.6380031839523532e-11
possibly O 0 6.87175982783117e-10
with O 0 1.0608906982068067e-11
importance O 0 1.4252273103920743e-06
for O 1 0.9999972581863403
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
risk O 0 3.5338343877810985e-06
in O 0 1.015601491793916e-09
the O 0 1.2333936094677256e-09
general O 0 6.905794602829474e-09
population O 0 1.8189537376311904e-10
. O 0 1.5666199448816087e-09
. O 0 7.948357705345188e-08

Genomic O 0 8.249830898421351e-07
structure O 0 1.9002882822860556e-08
of O 0 2.257001341376963e-08
the O 0 3.52536062564468e-08
human O 0 2.234565954495338e-06
congenital B-Disease 1 1.0
chloride I-Disease 1 1.0
diarrhea I-Disease 1 1.0
( O 0 9.327765292255208e-05
CLD B-Disease 1 1.0
) O 0 3.6842024542238505e-07
gene O 0 3.681452653836459e-07
. O 0 2.812330876622582e-06

Congenital B-Disease 1 1.0
chloride I-Disease 1 1.0
diarrhea I-Disease 1 1.0
( O 0 8.216168680519331e-06
CLD B-Disease 1 1.0
) O 0 8.669078788159368e-09
is O 0 1.927819986979884e-10
caused O 0 5.954867154933652e-10
by O 0 9.300697018099768e-11
mutations O 0 2.40281933239217e-10
in O 0 4.016742216617075e-10
a O 0 1.4592981267824712e-09
gene O 0 7.168214355424141e-10
which O 0 8.623919911521227e-10
encodes O 0 2.263617737696677e-09
an O 0 3.0251119387258996e-09
intestinal O 0 2.3525940378021915e-06
anion O 0 2.3629728218566015e-07
transporter O 0 2.000324457185343e-06
. O 0 1.2923404710818431e-06

We O 0 1.4937292291961057e-07
report O 0 9.843966530809212e-09
here O 0 1.4101495526830377e-09
the O 0 6.872559743520412e-10
complete O 0 3.932941972095705e-09
genomic O 0 1.583045161623886e-08
organization O 0 1.7757684211971991e-09
of O 0 9.031724812480491e-10
the O 0 2.827879486133611e-09
human O 0 1.2059929943575298e-08
CLD B-Disease 0 0.00013546559785027057
gene O 0 1.6461127572142686e-08
which O 0 6.659424123256485e-10
spans O 0 4.151107901861906e-09
approximately O 0 3.7175440503744994e-10
39kb O 0 1.8922884237326798e-07
, O 0 2.353444328306864e-09
and O 0 8.048230526469524e-09
comprises O 0 9.873756567913006e-08
21 O 0 4.995209224034625e-07
exons O 0 3.911394742317498e-06
. O 0 6.736836439813487e-07

All O 0 2.0007155399071053e-06
exon O 0 4.107589484192431e-05
/ O 0 2.0153338482487015e-05
intron O 0 6.74608190820436e-06
boundaries O 0 1.8492853470775117e-08
conform O 0 8.307973331511675e-08
to O 0 2.745003868653839e-08
the O 0 1.079119371638626e-07
GT O 0 0.00027286363183520734
/ O 0 0.00015220533532556146
AG O 0 0.0002439070085529238
rule O 0 9.304936611442827e-06
. O 0 2.773550477286335e-06

An O 0 7.636658416743103e-09
analysis O 0 4.547644927299643e-09
of O 0 3.1636937514178953e-09
the O 0 2.6929518615048664e-09
putative O 0 3.8813748659549674e-08
promoter O 0 1.057044940466767e-07
region O 0 1.0637370984056815e-08
sequence O 0 1.616605738163912e-09
shows O 0 5.9329785528916545e-09
a O 0 1.3807828658229937e-08
putative O 0 2.4482569642714225e-06
TATA O 0 3.7949172110529616e-05
box O 0 1.2417287962307455e-06
and O 0 1.2587623388071734e-08
predicts O 0 5.1800128630929976e-08
multiple O 0 3.20923332353118e-09
transcription O 0 1.0536813022099523e-07
factor O 0 3.477251908634571e-08
binding O 0 3.136310056106595e-08
sites O 0 3.6044500006937596e-07
. O 0 5.572780423790391e-07

The O 0 3.315796845981822e-07
genomic O 0 2.989918641560507e-07
structure O 0 1.4995062969092032e-08
was O 0 1.154263884473039e-08
determined O 0 2.4775439477764394e-09
using O 0 3.373655577121326e-09
DNA O 0 1.813703498498853e-08
from O 0 1.4635350709113482e-09
several O 0 1.8572084148349433e-10
sources O 0 1.1817373746225712e-09
including O 0 1.761521623011575e-10
multiple O 0 5.252766555052801e-10
large O 0 2.4821318334034004e-09
- O 0 2.651977411005646e-07
insert O 0 2.9458803965098923e-06
libaries O 0 3.5594962355389725e-06
and O 0 3.6102274503235776e-09
genomic O 0 2.5976142126182822e-08
DNA O 0 2.042970237425834e-08
from O 0 1.3100397211474046e-08
Finnish O 0 2.6454692488186993e-05
CLD B-Disease 1 0.9999997615814209
patients O 0 2.3463995603378862e-05
and O 0 2.7550171921575384e-08
controls O 0 1.1232741599087603e-05
. O 0 3.4186225548182847e-06

Exon O 0 2.973883783852216e-05
- O 0 8.9582056261861e-07
specific O 0 1.3929242648202944e-08
primers O 0 3.1900694352771097e-07
developed O 0 4.6092090144611575e-09
in O 0 7.71337230198732e-11
this O 0 1.7458567577732786e-11
study O 0 2.622691647191644e-11
will O 0 9.454673155495641e-12
facilitate O 0 6.002602304100435e-10
mutation O 0 1.0302200759149116e-10
screening O 0 4.3466805155212285e-10
studies O 0 1.3448967495222064e-09
of O 0 8.951787089372942e-10
patients O 0 1.0462127830734858e-09
with O 0 3.2934280302931995e-11
the O 0 2.2578191760658228e-08
disease O 0 8.671164550833055e-07
. O 0 2.1309745079634013e-07

Genomic O 0 5.773333668912528e-07
sequencing O 0 1.3062974346667033e-07
of O 0 6.659112017359803e-08
a O 0 1.7227644377726392e-07
BAC O 1 0.9996199607849121
clone O 0 0.008570416830480099
H O 1 1.0
_ O 0 3.139836053378531e-07
RG364P16 O 0 2.291773625984206e-06
revealed O 0 6.387363971072091e-09
the O 0 1.9516684102161008e-10
presence O 0 3.503076995148291e-10
of O 0 4.2753101059389564e-10
another O 0 3.276887650116578e-10
, O 0 4.91983571937471e-11
highly O 0 2.944838539686856e-10
homologous O 0 3.454375951950084e-10
gene O 0 2.3560481343665174e-10
3 O 0 7.50237649782548e-09
of O 0 4.6263160413673177e-08
the O 0 2.136279135811492e-07
CLD B-Disease 1 0.9497304558753967
gene O 0 1.9606773093983065e-08
, O 0 6.459165424743674e-10
with O 0 5.241585290804984e-11
a O 0 6.379008432588762e-10
similar O 0 1.7335272106677735e-10
genomic O 0 5.819100756809803e-09
structure O 0 1.463719367933436e-09
, O 0 4.3896716817037884e-10
recently O 0 7.062683216041421e-10
identified O 0 2.8066418633621026e-10
as O 0 4.2410849832030806e-10
the O 0 1.9335001155695863e-08
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
gene O 0 6.646410355415355e-08
( O 0 7.966368897882603e-09
PDS B-Disease 0 1.355461517960066e-05
) O 0 7.1244641297596445e-09
. O 0 1.7356530435108652e-08
. O 0 2.02688681838481e-07

The O 0 1.76860021383618e-06
APCI1307K O 1 0.9999998807907104
allele O 0 6.342046162899351e-06
and O 0 4.866143754611585e-08
cancer B-Disease 0 1.1646593520708848e-05
risk O 0 8.626523495536276e-09
in O 0 1.9513483884292526e-10
a O 0 4.032263134501335e-10
community O 0 2.645320629213188e-10
- O 0 1.7723439382777428e-09
based O 0 3.175262830446002e-10
study O 0 7.300120508091368e-10
of O 0 2.9085669428496885e-09
Ashkenazi O 0 1.1662593806249788e-06
Jews O 0 7.335677310038591e-07
. O 0 2.5316111873507907e-07

Mutations O 0 5.825460902997293e-06
in O 0 1.8609267726787948e-07
APC O 0 1.5641508070984855e-06
are O 0 5.141787440265944e-09
classically O 0 6.067163667466957e-06
associated O 0 9.252088517541779e-08
with O 0 2.6005192665934374e-08
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 0 1.314836453047974e-07
FAP B-Disease 0 1.0599194411042845e-06
) O 0 3.968067818771459e-10
, O 0 1.0826720769907539e-10
a O 0 1.805791183251415e-09
highly O 0 0.0002800112124532461
penetrant O 1 1.0
autosomal B-Disease 1 1.0
dominant I-Disease 1 1.0
disorder I-Disease 1 1.0
characterized O 0 2.0589764915257547e-07
by O 0 1.0845824238714386e-09
multiple O 0 2.4039135837483627e-07
intestinal O 1 0.9999997615814209
polyps B-Disease 0 1.2167712384325569e-06
and O 0 6.16207418424608e-10
, O 0 1.6437140537561845e-10
without O 0 1.1259559951071196e-09
surgical O 0 0.0003200668725185096
intervention O 0 6.806777946621878e-06
, O 0 1.8310289395806478e-10
the O 0 1.6682778769538942e-10
development O 0 1.0423769403189453e-08
of O 1 0.9999977350234985
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 2.2209977032616735e-05
CRC B-Disease 0 0.004542349837720394
) O 0 6.97460436072106e-08
. O 0 7.275203870449332e-07

APC B-Disease 0 4.6752800699323416e-05
is O 0 2.06823518311694e-08
a O 0 2.4248706154139654e-08
tumour O 1 1.0
- O 0 9.491543096373789e-06
suppressor O 0 5.50835466128774e-05
gene O 0 2.482242145163127e-08
, O 0 5.88207926810469e-10
and O 0 1.6878568542821881e-09
somatic O 0 0.0003542494960129261
loss O 0 1.654636093917361e-06
occurs O 0 1.0243023496059322e-07
in O 0 1.5379342244159488e-07
tumours B-Disease 1 1.0
. O 0 2.194256376242265e-05

The O 0 1.2567793419293594e-06
germline O 0 1.4377827028511092e-05
T O 0 3.847491996111785e-07
- O 0 5.927619639578552e-08
to O 0 3.5311462642795277e-09
- O 0 3.969472572862287e-08
A O 0 1.987000430858643e-08
transversion O 0 1.3641815144183056e-07
responsible O 0 1.6772536692855056e-09
for O 0 4.853014656802657e-10
the O 0 5.6775295576017015e-09
APC O 0 1.9234992123529082e-06
I1307K O 0 1.9724495359696448e-05
allele O 0 3.0897954417241635e-08
converts O 0 7.138692303954031e-09
the O 0 6.369088034752224e-10
wild O 0 1.5925354368562239e-09
- O 0 1.4222182320722254e-09
type O 0 1.9165069531368317e-09
sequence O 0 4.5464371156711536e-10
to O 0 1.0862758470508993e-09
a O 0 7.058084605660042e-08
homopolymer O 1 0.9999954700469971
tract O 1 0.7241448163986206
( O 0 4.661595909283278e-08
A8 O 0 1.2263320058991667e-05
) O 0 1.2882093169963582e-09
that O 0 1.1900765095607113e-10
is O 0 1.297760093832423e-10
genetically O 0 7.456156581042706e-09
unstable O 0 9.628598007793698e-08
and O 0 2.967349388427465e-08
prone O 0 1.0793349929372198e-06
to O 0 6.565419852222476e-08
somatic O 0 3.136217128485441e-05
mutation O 0 1.251994035555981e-06
. O 0 1.3320304788067006e-06

The O 0 1.2710468126897467e-06
I1307K O 0 3.3678912586765364e-05
allele O 0 7.595782847147348e-08
was O 0 1.3604185333804253e-08
found O 0 1.7974547406041097e-09
in O 0 2.542720034526269e-09
6 O 0 2.4335593025170965e-06
. O 0 2.0467359718168154e-06

1 O 0 4.323918346926803e-06
% O 0 1.5004995645995223e-07
of O 0 2.0836822045566805e-07
unselected O 0 0.00027175789000466466
Ashkenazi O 0 2.1161522454349324e-05
Jews O 0 4.184597628409392e-07
and O 0 1.8632801968010426e-09
higher O 0 3.607611542832956e-09
proportions O 0 4.913220497115844e-09
of O 0 4.3912478098206975e-09
Ashkenazim O 0 2.153801460735849e-06
with O 0 2.3875426635733277e-10
family O 0 1.5099984596034233e-09
or O 0 1.6229484423035956e-09
personal O 0 5.8040505734879844e-08
histories O 0 6.163008947623894e-07
of O 0 6.100689233790035e-07
CRC B-Disease 1 0.5418761372566223
( O 0 4.40518412858637e-08
ref O 0 1.5800451365066692e-05
. O 0 9.56298062959604e-09
2 O 0 2.488324639671191e-07
) O 0 6.055620360712055e-08
. O 0 4.131553055231052e-07

To O 0 2.6183469614693422e-08
evaluate O 0 1.7106257743648712e-08
the O 0 2.1955601781087353e-09
role O 0 5.5395288356407946e-09
of O 0 2.702111601138313e-08
I1307K O 0 3.192854273947887e-05
in O 0 2.3658708325768885e-09
cancer B-Disease 0 2.5294770722439353e-08
, O 0 1.3129901332842309e-10
we O 0 3.0716590382340314e-10
genotyped O 0 4.078032986853941e-07
5 O 0 1.4148643856515264e-07
, O 0 3.0298831887876077e-08
081 O 0 4.940935832564719e-05
Ashkenazi O 0 9.51014499150915e-06
volunteers O 0 2.850566716006142e-07
in O 0 3.5665204123347394e-09
a O 0 6.865501500641358e-09
community O 0 1.58381538994945e-08
survey O 0 4.272746778610781e-08
. O 0 1.0730011013038165e-07

Risk O 0 2.8675744943029713e-06
of O 0 2.846627467079088e-07
developing O 1 0.5252707004547119
colorectal B-Disease 1 1.0
, I-Disease 0 0.0002550557837821543
breast I-Disease 1 0.9999991655349731
and I-Disease 0 6.73243079063468e-08
other I-Disease 0 1.0639506342613458e-07
cancers I-Disease 1 0.9992314577102661
were O 0 3.785898528008147e-08
compared O 0 8.903584536312792e-09
between O 0 5.76496628212908e-10
genotyped O 0 9.535023650641961e-07
I1307K O 0 1.9430129327702161e-07
carriers O 0 2.167234391947659e-09
and O 0 3.6027275607253273e-10
non O 0 3.339527410162191e-08
- O 0 1.3662171838291215e-08
carriers O 0 2.784871000471867e-09
and O 0 9.138810541653442e-11
their O 0 1.1838686975185198e-10
first O 0 2.6680129217027115e-09
- O 0 2.4588368674471894e-08
degree O 0 2.248168442520182e-07
relatives O 0 2.2359400020377507e-07
. O 0 1.769910085158699e-07

Sperm O 0 2.2456055148722953e-07
DNA O 0 4.4464716353331823e-08
analysis O 0 5.2260871186149416e-09
in O 0 4.3221870527077044e-09
a O 0 8.275757323872313e-08
Friedreich B-Disease 0 0.002570481738075614
ataxia I-Disease 1 0.9995879530906677
premutation O 1 0.9962730407714844
carrier O 0 2.990462689922424e-06
suggests O 0 1.442299435439054e-07
both O 0 2.207106719609442e-09
meiotic O 0 9.353730092698243e-07
and O 0 1.015561412742727e-08
mitotic O 0 2.536156387122901e-07
expansion O 0 2.1034679775766563e-07
in O 0 8.691181108133605e-09
the O 0 3.2470950372953666e-08
FRDA B-Disease 0 0.00015633883595000952
gene O 0 3.557469767656585e-07
. O 0 6.729086408086005e-07

Friedreich B-Disease 1 0.9999998807907104
ataxia I-Disease 1 0.9999992847442627
is O 0 6.812466324390698e-08
usually O 0 2.3943569349427207e-09
caused O 0 3.82578302371428e-10
by O 0 8.041927367086199e-12
an O 0 2.7978361814839925e-12
expansion O 0 6.305496680347744e-10
of O 0 1.9641686055393848e-09
a O 0 4.4967038981269525e-09
GAA O 0 4.192078861819937e-08
trinucleotide O 0 1.9050226001127157e-06
repeat O 0 3.5797299346995715e-08
in O 0 1.937103100146942e-08
intron O 0 1.0525881180001306e-06
1 O 0 1.221045096144735e-07
of O 0 1.0804085803783892e-07
the O 0 1.9171446297150396e-07
FRDA B-Disease 0 0.0010933652520179749
gene O 0 1.0058419093184057e-06
. O 0 2.6382797386759194e-06

Occasionally O 0 8.745926720621355e-07
, O 0 6.450698641913277e-09
a O 0 3.802440140532326e-09
fully O 0 4.154571442427368e-08
expanded O 0 2.522173581098741e-08
allele O 0 7.84636355888324e-09
has O 0 4.9625383663487455e-11
been O 0 4.5470675835712626e-11
found O 0 1.988866710211923e-11
to O 0 6.954323228391956e-11
arise O 0 3.1604835415421917e-10
from O 0 2.6730131996721695e-10
a O 0 4.686973587020304e-10
premutation O 0 6.213454639691918e-08
of O 0 3.2403870697805814e-09
100 O 0 2.2781200925692247e-08
or O 0 2.5804673953189194e-09
less O 0 3.285721916768125e-08
triplet O 0 1.2807176972273737e-06
repeats O 0 4.0432925629829697e-07
. O 0 1.3480225788953248e-06

We O 0 2.68451771034961e-07
have O 0 6.775816352444508e-09
examined O 0 2.516988217848848e-08
the O 0 2.357964490329323e-09
sperm O 0 9.91523307902753e-09
DNA O 0 1.4263373593337292e-08
of O 0 2.4349137817125666e-08
a O 0 7.627316023217645e-08
premutation O 0 5.506054367288016e-05
carrier O 0 3.825053681794088e-06
. O 0 2.269131755383569e-06

This O 0 6.653259276845347e-08
mans O 0 2.767006208159728e-06
leucocyte O 0 3.5959014894615393e-06
DNA O 0 1.4646255408479192e-07
showed O 0 5.88998627648607e-09
one O 0 2.1155523166616064e-10
normal O 0 3.037988749454712e-09
allele O 0 2.3375805735526e-09
and O 0 3.9225267478570913e-10
one O 0 4.92019536224575e-10
allele O 0 2.133764942513494e-09
of O 0 3.826843286702797e-09
approximately O 0 2.7267750279946767e-09
100 O 0 1.2814615502065863e-07
repeats O 0 1.1323016479991566e-07
. O 0 5.749131446464162e-07

His O 0 4.67011290083974e-07
sperm O 0 4.190192441910767e-07
showed O 0 1.839821273108555e-08
an O 0 2.3247961888905877e-10
expanded O 0 2.681547650595917e-09
allele O 0 1.9166970233186476e-09
in O 0 3.785230739961065e-10
a O 0 1.940867022653947e-09
tight O 0 3.6870279274126005e-08
range O 0 1.4886175847550476e-08
centering O 0 3.107109458611035e-09
on O 0 3.7273137354354446e-10
a O 0 1.4621392985247894e-10
size O 0 5.627039945110823e-10
of O 0 3.677327109485873e-09
approximately O 0 5.185802898211023e-09
320 O 0 1.8132095647160895e-07
trinucleotide O 0 3.1664072594139725e-05
repeats O 0 3.3446960969740758e-06
. O 0 4.571655608742731e-06

His O 0 6.05008494858339e-07
affected O 0 2.7776852107308514e-07
son O 0 1.8190530681749806e-06
has O 0 2.379197727719884e-09
repeat O 0 3.8786791556333355e-09
sizes O 0 1.0018935903133297e-08
of O 0 2.169328361389944e-08
1040 O 0 8.02781073616643e-07
and O 0 1.05161937824505e-07
540 O 0 1.0508806553843897e-05
. O 0 1.8374913679508609e-06

These O 0 5.504752920160172e-08
data O 0 4.7812079628783977e-08
suggest O 0 2.7927060664012515e-09
that O 0 1.4194959443991628e-11
expansion O 0 6.226498761030541e-10
occurs O 0 4.499547956449135e-11
in O 0 6.9560850135541585e-12
two O 0 7.834866436184917e-12
stages O 0 1.2568178442418088e-10
, O 0 2.4915116844659302e-11
the O 0 1.3592603431700212e-10
first O 0 6.738462565714087e-10
during O 0 1.6926250401283482e-09
meiosis O 0 4.0803564971270134e-09
followed O 0 7.888571462721927e-10
by O 0 4.468041908678444e-11
a O 0 4.965693967129425e-10
second O 0 1.0676030726131103e-08
mitotic O 0 1.548976797494106e-06
expansion O 0 8.274190804513637e-06
. O 0 3.5534285416360945e-06

We O 0 1.3955508393337368e-07
also O 0 4.821444576919021e-09
show O 0 8.021804887015094e-10
that O 0 2.8959758202606878e-11
in O 0 1.3793495512448573e-10
all O 0 1.0684678142247606e-10
informative O 0 2.389557440807266e-09
carrier O 0 2.464249027056553e-09
father O 0 2.3665882586954012e-09
to O 0 1.624385403964368e-09
affected O 0 4.559943977966441e-09
child O 0 5.681602743834446e-09
transmissions O 0 1.8935333301328683e-08
, O 0 1.516801267920087e-10
with O 0 3.271346735167491e-11
the O 0 1.3722912806102272e-09
notable O 0 2.660319520231269e-09
exception O 0 1.3547988286788382e-09
of O 0 1.0902861946604503e-09
the O 0 9.385742183454227e-10
premutation O 0 2.9438146498250717e-07
carrier O 0 1.2769618251695647e-08
, O 0 5.301402095092556e-10
the O 0 7.023377435189104e-10
expansion O 0 1.6460562690667757e-08
size O 0 3.3038942692797946e-09
decreases O 0 1.4415330262806947e-08
. O 0 7.588988104600958e-09
. O 0 4.367253154669015e-07

The O 0 3.1143801493271894e-07
R496H O 0 1.4533204193867277e-05
mutation O 0 4.813195531028214e-08
of O 0 1.9468073375605854e-08
arylsulfatase O 0 9.820283594308421e-06
A O 0 1.5003736564267456e-07
does O 0 5.18981035924071e-09
not O 0 1.3775894203149619e-08
cause O 0 1.8869191990233958e-05
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
. O 0 2.19221710722195e-05

Deficiency B-Disease 0 0.0015402825083583593
of I-Disease 0 4.889822321274551e-06
arylsulfatase I-Disease 1 0.6621251702308655
A I-Disease 0 2.40098361246055e-05
( O 0 3.023475869667891e-07
ARSA O 0 0.00023330506519414485
) O 0 8.017709163254949e-09
enzyme O 0 3.5777571127937335e-08
activity O 0 1.2794978943020396e-07
causes O 0 1.7909896996570751e-06
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
( O 0 2.5303970687673427e-06
MLD B-Disease 1 1.0
) O 0 7.5863994197789e-07
. O 0 1.7209333691425854e-06

A O 0 7.003317250564578e-07
number O 0 2.9723851824314806e-08
of O 0 6.224723136938337e-08
ARSA O 0 5.0815928261727095e-05
gene O 0 2.3350951394718322e-08
mutations O 0 4.71135486179719e-09
responsible O 0 9.049386129333925e-09
for O 0 1.3208364180172794e-07
MLD B-Disease 1 1.0
have O 0 3.6515180568130745e-07
been O 0 2.6853211210209338e-08
identified O 0 9.96249696072482e-08
. O 0 4.542775116078701e-07

Recently O 0 3.8001007851562463e-07
, O 0 4.467424208343118e-09
the O 0 3.5968248379703027e-09
R496H O 0 7.780360533615749e-07
mutation O 0 2.2271436250775878e-08
of O 0 1.6792359502915133e-08
ARSA O 0 8.295731095131487e-05
was O 0 2.6345377435177397e-08
proposed O 0 4.952810939151675e-10
to O 0 1.4158463290669943e-10
be O 0 1.0320648502482044e-10
a O 0 2.2487744999466486e-10
cause O 0 4.63260052541159e-09
of O 0 1.1819739853535793e-07
MLD B-Disease 1 1.0
( O 0 8.626626168961593e-08
Draghia O 0 4.960363639838761e-06
et O 0 5.250864205663675e-07
al O 0 4.4038611690666585e-07
. O 0 1.4648755541912806e-09
, O 0 1.2807443994233836e-09
1997 O 0 2.00824565865787e-08
) O 0 2.997115444713927e-08
. O 0 2.2287569834134047e-07

We O 0 2.4108194907057623e-07
have O 0 7.853985017902687e-09
investigated O 0 1.9761529301831615e-08
the O 0 4.556988120185679e-09
R496H O 0 2.2480815005110344e-06
mutation O 0 2.5566477823701916e-09
and O 0 7.750743102885593e-11
found O 0 6.221544807116786e-11
this O 0 2.7201180544111914e-11
mutation O 0 2.8608956870179725e-10
at O 0 2.747971572514274e-10
a O 0 1.2537101912180049e-10
relatively O 0 1.8278152602579922e-10
high O 0 9.46111800015359e-11
frequency O 0 2.7375607336566077e-10
in O 0 3.690399721922866e-11
an O 0 8.013665425687932e-11
African O 0 1.546001549002085e-09
American O 0 3.635310052985119e-09
population O 0 2.5759505639655345e-11
( O 0 2.8914997132756248e-11
f O 0 3.861443165220635e-09
= O 0 5.949602588373182e-09
0 O 0 1.9445205445833835e-09
. O 0 5.182013707027977e-10
09 O 0 4.1271498218975466e-08
, O 0 1.6770169697366555e-09
n O 0 1.6990236773040124e-08
= O 0 1.0870395783513231e-07
61 O 0 8.752103042297676e-08
subjects O 0 3.58234615305264e-07
) O 0 6.301234378724985e-08
. O 0 5.539357061934425e-07

The O 0 9.853587471297942e-06
ARSA O 0 0.00019973750750068575
enzyme O 0 5.307528283537977e-08
activity O 0 7.455516204402102e-09
in O 0 2.4456164871011765e-10
subjects O 0 3.6412086679149525e-09
with O 0 9.886646189227744e-12
and O 0 4.1559918700917464e-11
without O 0 4.5259573866474057e-10
the O 0 3.6446251572286315e-10
R496H O 0 8.349610425284482e-08
mutation O 0 1.3154867473108567e-10
was O 0 2.2376928088263526e-10
determined O 0 2.3310078867133655e-10
and O 0 2.9276003843392573e-10
found O 0 6.825778831043294e-10
to O 0 6.114924677724787e-10
be O 0 4.665515973556467e-09
normal O 0 8.229462764575146e-07
. O 0 9.125835163104057e-07

It O 0 1.1911472697079262e-08
is O 0 2.5823418403625453e-10
therefore O 0 4.782406692882546e-10
concluded O 0 3.3287150813521293e-09
that O 0 4.7049742574190034e-11
the O 0 8.261004658116633e-10
R496H O 0 1.161606178357033e-06
mutation O 0 1.5063946534610295e-08
of O 0 1.4589426555744467e-08
ARSA O 0 7.099759386619553e-05
does O 0 4.40847713889525e-09
not O 0 6.376186245660165e-10
negatively O 0 8.999361811312667e-10
influence O 0 1.832640594834345e-09
the O 0 7.136388147088724e-10
activity O 0 4.717343848881228e-09
of O 0 2.674024557336452e-09
ARSA O 0 1.1490092219901271e-05
and O 0 2.291607126281292e-09
is O 0 2.8296909260205894e-10
not O 0 3.7135966524104447e-10
a O 0 3.099905665493452e-09
cause O 0 2.5857266905404686e-07
of O 0 2.3540022084489465e-05
MLD B-Disease 1 1.0

Down O 0 2.830114681273699e-06
- O 0 7.39228767088207e-07
regulation O 0 3.603480820402183e-07
of O 0 8.363637249431122e-08
transmembrane O 0 7.558206789326505e-07
carbonic O 0 0.002887004753574729
anhydrases O 0 0.035179052501916885
in O 0 2.577604163889191e-06
renal B-Disease 1 1.0
cell I-Disease 1 1.0
carcinoma I-Disease 1 1.0
cell O 1 0.9999998807907104
lines O 0 7.472375784800533e-08
by O 0 3.893518396580475e-09
wild O 0 1.3372715557125048e-07
- O 0 1.1183411743331817e-06
type O 0 1.0875983207370155e-05
von B-Disease 1 0.9999957084655762
Hippel I-Disease 1 0.9993667006492615
- I-Disease 0 0.060698702931404114
Lindau I-Disease 0 0.0034172949381172657
transgenes O 0 0.0006832216749899089
. O 0 1.4991926946095191e-05

To O 0 2.413743516171962e-07
discover O 0 2.099577898206917e-07
genes O 0 9.472177708857998e-09
involved O 0 6.144249997674933e-09
in O 0 6.157177878662878e-09
von B-Disease 1 0.9998103976249695
Hippel I-Disease 1 0.9999951124191284
- I-Disease 1 0.9999595880508423
Lindau I-Disease 1 0.9999862909317017
( O 0 2.78262717756661e-07
VHL B-Disease 0 0.00010069363634102046
) O 0 1.7515594308292748e-08
- O 0 2.3971509222064924e-07
mediated O 0 1.93500611089803e-07
carcinogenesis O 0 0.0006722694961354136
, O 0 3.3090279405456613e-09
we O 0 7.102186394547516e-09
used O 0 2.47834759647958e-06
renal B-Disease 1 1.0
cell I-Disease 1 1.0
carcinoma I-Disease 1 1.0
cell O 1 1.0
lines O 0 1.534599732622155e-06
stably O 0 3.052324245800264e-06
transfected O 0 4.1263120920120855e-07
with O 0 1.4232793832391621e-09
wild O 0 1.6902747290714615e-07
- O 0 1.0112973996001529e-06
type O 0 7.958792593854014e-06
VHL O 1 0.5105432271957397
- O 0 0.014822586439549923
expressing O 0 2.7336980110703735e-06
transgenes O 0 7.411545084323734e-05
. O 0 3.469584726190078e-06

Large O 0 6.698270027527542e-08
- O 0 4.9035708826750124e-08
scale O 0 2.499569085046005e-08
RNA O 0 8.515071669989993e-08
differential O 0 9.696234570810702e-08
display O 0 4.851692825269538e-09
technology O 0 6.744460279151099e-08
applied O 0 3.392428027382266e-08
to O 0 1.116401304734893e-09
these O 0 4.1106473780416763e-10
cell O 0 2.9755788943930384e-08
lines O 0 2.337491533666025e-09
identified O 0 4.08418721065118e-09
several O 0 7.75024433519178e-10
differentially O 0 1.0126314720082519e-07
expressed O 0 1.5701918654187352e-09
genes O 0 5.852356932400937e-10
, O 0 2.0981362480743115e-10
including O 0 4.717845003554544e-10
an O 0 4.381407181508479e-10
alpha O 0 3.151577487869872e-08
carbonic O 0 1.5000246094132308e-06
anhydrase O 0 2.5174496840918437e-05
gene O 0 1.9040766119360342e-07
, O 0 6.446813927141193e-08
termed O 0 1.2546521247713827e-05
CA12 O 1 0.9957442879676819
. O 0 1.3170645615900867e-05

The O 0 1.0862147092893792e-07
deduced O 0 5.998624885705794e-08
protein O 0 3.6142905335267983e-10
sequence O 0 1.0907910685808986e-10
was O 0 9.875273931925221e-10
classified O 0 1.0615779366673905e-09
as O 0 3.9561429132639603e-10
a O 0 5.450898066250431e-10
one O 0 1.1222189844062314e-09
- O 0 1.9868208767093165e-07
pass O 0 5.133940703672124e-07
transmembrane O 0 6.55913652281015e-07
CA O 0 2.4564028535678517e-06
possessing O 0 2.59481453213084e-07
an O 0 2.600582194034473e-09
apparently O 0 7.896602483015158e-08
intact O 0 5.265270175414116e-08
catalytic O 0 1.9958086738824932e-08
domain O 0 2.3727544373741694e-08
in O 0 2.906808793667892e-09
the O 0 8.61626237025348e-09
extracellular O 0 7.221864848361292e-07
CA O 0 1.0250962077407166e-05
module O 0 6.95468406775035e-05
. O 0 5.073265583632747e-06

Reintroduced O 0 1.4946974260965362e-05
wild O 0 3.911588919436326e-06
- O 0 3.1990646220947383e-06
type O 0 1.4978189710745937e-06
VHL B-Disease 0 0.00028994461172260344
strongly O 0 2.965776246810492e-08
inhibited O 0 4.1465440858701186e-08
the O 0 2.5507154166604096e-09
overexpression O 0 4.6467178549391974e-08
of O 0 3.917369983952312e-09
the O 0 3.469829756852505e-09
CA12 O 0 6.366813977365382e-06
gene O 0 1.919781444925661e-09
in O 0 1.2349378186726767e-09
the O 0 1.9682234508877627e-08
parental O 1 0.5718753337860107
renal B-Disease 1 1.0
cell I-Disease 1 1.0
carcinoma I-Disease 1 1.0
cell O 1 1.0
lines O 0 4.045344394398853e-05
. O 0 1.1699405149556696e-05

Similar O 0 2.834836365650517e-08
results O 0 1.9348644908490087e-09
were O 0 2.2990847003967474e-09
obtained O 0 1.2743438304596566e-08
with O 0 4.317529667119402e-10
CA9 O 0 8.038081432459876e-05
, O 0 1.4084354127419374e-08
encoding O 0 7.187853867662852e-08
another O 0 3.3374643493289113e-08
transmembrane O 0 4.145485377193836e-07
CA O 0 2.8319075227045687e-06
with O 0 3.5135780951378592e-09
an O 0 4.908555784055579e-09
intact O 0 3.914489354883699e-07
catalytic O 0 4.1016221530298935e-07
domain O 0 9.096257826968213e-07
. O 0 5.658067721014959e-07

Although O 0 3.790060816299956e-07
both O 0 1.0293018881668559e-08
domains O 0 1.4555072702648886e-08
of O 0 9.457608918239657e-09
the O 0 4.628767591441374e-09
VHL B-Disease 0 8.592024869358283e-07
protein O 0 1.0260671201578475e-09
contribute O 0 1.4357368627315736e-09
to O 0 1.1841899683062707e-09
regulation O 0 2.7769252142206824e-07
of O 0 7.702194579906063e-07
CA12 O 1 0.9997250437736511
expression O 0 6.704047450512007e-08
, O 0 1.5782809503761541e-09
the O 0 2.3371795609961055e-09
elongin O 0 1.1802404031868718e-07
binding O 0 1.4406389414745036e-09
domain O 0 6.626762250050433e-09
alone O 0 2.0177282067379565e-09
could O 0 1.4147780724727e-09
effectively O 0 2.5808724046783027e-08
regulate O 0 2.519837494219246e-07
CA9 O 0 0.0023396769538521767
expression O 0 7.538665158790536e-06
. O 0 4.65942775917938e-06

We O 0 1.7713956594889169e-06
mapped O 0 4.828205874218838e-06
CA12 O 0 0.00039094360545277596
and O 0 4.184150839137146e-07
CA9 O 0 0.0015804801369085908
loci O 0 1.5826291246412438e-06
to O 0 9.024069669294477e-08
chromosome O 0 3.6447545426199213e-07
bands O 0 3.5516463867679704e-06
15q22 O 0 6.574879080289975e-05
and O 0 2.8033070975652663e-07
17q21 O 0 0.00040170690044760704
. O 0 2.7687033252732363e-06

2 O 0 2.1521689177461667e-06
respectively O 0 6.198220603437221e-07
, O 0 6.3181646581256246e-09
regions O 0 3.4669187520819378e-09
prone O 0 2.8750665848065182e-08
to O 0 7.909966015517966e-10
amplification O 0 6.38942537989351e-07
in O 0 2.8466049073472277e-08
some O 0 1.8067773055463476e-08
human O 0 8.860794764586899e-08
cancers B-Disease 0 1.2490338122006506e-05
. O 0 4.788490741702844e-07

Additional O 0 2.9023044589848723e-07
experiments O 0 1.1677836653234408e-07
are O 0 5.0236720339214e-10
needed O 0 9.347157714501009e-09
to O 0 5.148890203088285e-10
define O 0 1.4260482794625773e-09
the O 0 6.644262362520692e-10
role O 0 5.323635754450606e-09
of O 0 6.744576808159763e-08
CA O 0 2.9176530915719923e-06
IX O 1 0.9999699592590332
and O 0 1.3046731055510463e-06
CA O 0 4.145532147958875e-05
XII O 0 0.0005569293862208724
enzymes O 0 8.470360413070921e-09
in O 0 8.938735307495449e-10
the O 0 1.1088485685206706e-09
regulation O 0 1.7173045208096482e-08
of O 0 3.519017077735498e-09
pH O 0 1.2843925034644599e-08
in O 0 2.4843474499824936e-10
the O 0 6.388469198093105e-10
extracellular O 0 4.513330598143739e-09
microenvironment O 0 9.53173540096941e-08
and O 0 1.9112422755540592e-10
its O 0 5.0705314946775104e-11
potential O 0 4.2963188562339383e-10
impact O 0 6.03233196727615e-09
on O 0 4.7676934400442406e-08
cancer B-Disease 0 6.240902621357236e-07
cell O 0 7.753731665616215e-07
growth O 0 1.6848109396505606e-07
. O 0 4.3125012894051906e-07

A O 0 4.6845744350321183e-07
gene O 0 1.7413629649354334e-08
encoding O 0 4.8033005128900186e-08
a O 0 1.6530787405599767e-08
transmembrane O 0 3.185614971812356e-08
protein O 0 3.4198552878450528e-09
is O 0 6.779196648487584e-11
mutated O 0 6.825335852056469e-10
in O 0 6.636017291228313e-10
patients O 0 3.053670809549658e-07
with O 0 3.3166628554681665e-08
diabetes B-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 1 0.9999994039535522
optic B-Disease 1 1.0
atrophy I-Disease 1 1.0
( O 1 0.5563982129096985
Wolfram B-Disease 1 1.0
syndrome I-Disease 1 1.0
) O 0 1.287471178557098e-07
. O 0 4.841628538088116e-07

Wolfram B-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 2.4506070985808037e-06
WFS B-Disease 1 0.9138046503067017
; O 0 1.1078876838155338e-07
OMIM O 0 0.00010561320959823206
222300 O 0 3.2690647913113935e-06
) O 0 3.495363554151254e-09
is O 0 8.093886116888882e-10
an O 0 1.3435539791828432e-08
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
neurodegenerative I-Disease 1 1.0
disorder I-Disease 1 1.0
defined O 0 2.4091904027301325e-09
by O 0 4.361277658460061e-11
young O 0 3.4356623102027584e-10
- O 0 3.011676241726491e-08
onset O 1 0.9996825456619263
non O 1 0.9999080896377563
- O 0 0.008284896612167358
immune O 0 0.002316494472324848
insulin B-Disease 1 1.0
- I-Disease 1 1.0
dependent I-Disease 1 1.0
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 0 0.1894330233335495
progressive O 1 1.0
optic B-Disease 1 1.0
atrophy I-Disease 1 0.9999996423721313
. O 0 8.26358882477507e-05

Linkage O 0 7.718924280197825e-06
to O 0 4.1067490741397705e-08
markers O 0 1.1774893948768295e-07
on O 0 6.503923799527911e-08
chromosome O 0 6.674243309134908e-07
4p O 0 0.0002986213658004999
was O 0 3.873011067412335e-08
confirmed O 0 1.7921486517025187e-09
in O 0 8.963490505387028e-10
five O 0 4.3382430980898334e-09
families O 0 3.756248645458982e-09
. O 0 5.216071841118719e-08

On O 0 9.853832949602293e-08
the O 0 3.1493467833598743e-09
basis O 0 8.176063381881704e-09
of O 0 5.726283891505091e-09
meiotic O 0 0.012287463061511517
recombinants O 1 0.998873770236969
and O 0 8.893913872043413e-08
disease O 0 1.767595313140191e-05
- O 0 2.8825954245803587e-07
associated O 0 1.280580619322791e-07
haplotypes O 0 1.400671010287624e-07
, O 0 1.016780104556858e-09
the O 0 4.500290362585702e-09
WFS B-Disease 0 3.455346086411737e-05
gene O 0 3.256788394523369e-09
was O 0 3.350908661658991e-09
localized O 0 1.7283719344618476e-08
to O 0 7.852636763061582e-09
a O 0 2.435174621950864e-07
BAC O 1 0.9999791383743286
/ O 0 0.00041309333755634725
P1 O 0 1.823680941015482e-05
contig O 0 2.5166766135953367e-05
of O 0 9.258972966108558e-08
less O 0 3.1672033884433404e-08
than O 0 4.925202023997599e-09
250 O 0 1.4075094156851264e-07
kb O 0 6.274492989177816e-06
. O 0 1.7153375893030898e-06

Mutations O 0 2.305878297192976e-07
in O 0 4.096295302957742e-09
a O 0 1.9674306628303384e-09
novel O 0 1.8367041221267755e-08
gene O 0 4.55023041467939e-09
( O 0 4.520904095528522e-09
WFS1 O 0 0.0001807075022952631
) O 0 6.283349396341009e-09
encoding O 0 3.027820483225696e-08
a O 0 1.0183623722070934e-08
putative O 0 9.0173422506723e-08
transmembrane O 0 7.816176150754472e-09
protein O 0 7.847826832829696e-10
were O 0 4.379903106865868e-10
found O 0 6.908580651998619e-11
in O 0 4.3659884735314236e-11
all O 0 9.209889795247506e-11
affected O 0 1.2571726992760546e-10
individuals O 0 6.971851047865574e-12
in O 0 2.609320537416693e-10
six O 0 1.8678036894925754e-08
WFS B-Disease 0 6.660795042989776e-05
families O 0 5.593269181147775e-10
, O 0 1.5691402344142347e-10
and O 0 5.941092062755615e-11
these O 0 1.6098632149574854e-10
mutations O 0 2.677309485221713e-10
were O 0 3.509965651460334e-10
associated O 0 2.9359674691420423e-09
with O 0 2.968863488383988e-10
the O 0 1.2452586872768734e-07
disease O 0 2.8308327273407485e-06
phenotype O 0 1.6419352277807775e-07
. O 0 4.895589995612681e-07

WFS1 O 0 0.004458684008568525
appears O 0 1.2123160786359222e-07
to O 0 1.7077169678358928e-09
function O 0 1.955179129708995e-09
in O 0 8.335314105600844e-10
survival O 0 2.5860448658932e-05
of O 0 8.035717513621421e-08
islet O 0 1.4403204886548338e-06
beta O 0 3.1926501264933904e-07
- O 0 3.90092054658453e-07
cells O 0 1.611627595821119e-07
and O 0 7.725070361175312e-09
neurons O 0 5.527488724510476e-07
. O 0 3.382343152225076e-07
. O 0 2.2605784124607453e-06

Stable O 0 1.1714438414855977e-06
interaction O 0 1.6796867230439716e-09
between O 0 1.6857197582265115e-10
the O 0 2.5816526694200093e-10
products O 0 1.7525110251881415e-09
of O 0 3.95134902575478e-09
the O 0 8.03746136313066e-09
BRCA1 O 0 1.1581467163068737e-07
and O 0 2.1641996639232275e-08
BRCA2 O 0 1.5999232516605844e-07
tumor B-Disease 0 1.156266193902411e-07
suppressor O 0 2.3569096185838134e-07
genes O 0 2.8010493924313096e-09
in O 0 2.347490646315009e-09
mitotic O 0 7.92652372183511e-07
and O 0 1.3523654729397094e-07
meiotic O 0 0.00034361466532573104
cells O 0 9.066914935829118e-05
. O 0 4.314069883548655e-06

BRCA1 O 0 9.157526073977351e-05
and O 0 2.2585068393254915e-07
BRCA2 O 0 5.529028044293227e-07
account O 0 3.3641649466176204e-09
for O 0 1.2093963330794821e-10
most O 0 3.53816767550974e-11
cases O 0 1.1844101220626069e-11
of O 0 8.473825113819444e-11
familial O 0 5.186841622872862e-09
, O 0 1.6810255965005183e-10
early O 0 2.0125082755839685e-07
onset O 1 1.0
breast B-Disease 1 1.0
and I-Disease 1 0.9999852180480957
/ I-Disease 1 1.0
or I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 2.585366746643558e-05
encode O 0 1.1921360787425783e-08
products O 0 1.2468672316856555e-08
that O 0 8.171284482383356e-11
each O 0 4.293416663858629e-11
interact O 0 2.4479498983431824e-10
with O 0 7.217121900104928e-10
hRAD51 O 0 8.176039045793004e-06
. O 0 1.7899208160088165e-06

Results O 0 7.187991002410854e-08
presented O 0 4.189592672787512e-08
here O 0 6.9663852464429965e-09
show O 0 2.5470110465164453e-09
that O 0 4.5513565138932677e-10
BRCA1 O 0 6.43444337811161e-08
and O 0 2.133123011560656e-08
BRCA2 O 0 5.022690743317071e-07
coexist O 0 5.34524691175875e-09
in O 0 4.902527828143377e-10
a O 0 3.7012995446339403e-10
biochemical O 0 6.540145758293647e-09
complex O 0 2.2241509967102502e-08
and O 0 9.587910021480184e-09
colocalize O 0 0.00012354493082966655
in O 0 4.065148573317856e-08
subnuclear O 0 3.4713582863332704e-05
foci O 0 6.4392190779472e-07
in O 0 1.281895478655315e-09
somatic O 0 9.533589917509744e-08
cells O 0 1.0608296463487932e-08
and O 0 7.741143837058928e-10
on O 0 1.2387838310701227e-08
the O 0 3.2796967364134844e-09
axial O 0 6.982668221411359e-09
elements O 0 1.4074203136260621e-08
of O 0 3.849848084769292e-08
developing O 0 2.3399243787025625e-07
synaptonemal O 0 9.51320180320181e-06
complexes O 0 4.834799938180367e-07
. O 0 7.967115038809425e-07

Like O 0 9.385654266225174e-06
BRCA1 O 0 1.4925180039426778e-05
and O 0 3.7692336718464503e-07
RAD51 O 0 0.0013650597538799047
, O 0 5.716519240195339e-07
BRCA2 O 0 2.541158664826071e-06
relocates O 0 2.996249861553224e-07
to O 0 2.8747702884857063e-08
PCNA O 0 2.2487888600153383e-06
+ O 0 4.031659628367379e-08
replication O 0 2.9770985676691453e-09
sites O 0 1.176692410176372e-09
following O 0 3.158651395995804e-10
exposure O 0 8.71995631257505e-09
of O 0 2.429169754236682e-09
S O 0 4.986950585816885e-08
phase O 0 7.526860201778618e-08
cells O 0 3.409690805256105e-07
to O 0 2.1097582703077933e-07
hydroxyurea O 0 4.089867070433684e-05
or O 0 9.783096857063356e-07
UV O 0 0.33159101009368896
irradiation O 0 3.8246613257797435e-05
. O 0 3.892925633408595e-06

Thus O 0 3.8276485270216654e-07
, O 0 2.629557727118481e-08
BRCA1 O 0 2.5339807052660035e-07
and O 0 7.041246696815051e-09
BRCA2 O 0 2.529067728573864e-07
participate O 0 3.5748426441273295e-09
, O 0 5.113695578096156e-10
together O 0 1.2695341999879872e-10
, O 0 1.0774642983379934e-10
in O 0 7.009455516016061e-11
a O 0 3.318424979248391e-10
pathway O 0 1.5605666092710635e-08
( O 0 9.348579688150949e-10
s O 0 5.6641065171447735e-09
) O 0 1.115509004612214e-10
associated O 0 4.796786301497491e-10
with O 0 1.171359537144312e-11
the O 0 2.6031862776498826e-10
activation O 0 5.9179354749971935e-09
of O 0 3.346131371984029e-09
double O 0 2.1981549025440472e-08
- O 0 3.2208738787176117e-08
strand O 0 2.872961601951829e-08
break O 0 6.537740659950941e-08
repair O 0 2.5419926714675967e-06
and O 0 1.1546100608939014e-07
/ O 0 5.499570761458017e-06
or O 0 5.14016242902926e-08
homologous O 0 9.442904769230154e-08
recombination O 0 1.8491499531592126e-07
. O 0 9.204491675518511e-07

Dysfunction O 0 0.0004134154296480119
of O 0 1.1325857229849134e-07
this O 0 5.003647496337749e-10
pathway O 0 9.76983827172262e-09
may O 0 2.0120777266541268e-10
be O 0 3.436486165075969e-11
a O 0 6.843464683825573e-11
general O 0 5.314664819344728e-10
phenomenon O 0 1.083372946908412e-09
in O 0 8.064352137460151e-12
the O 0 1.851371660144263e-11
majority O 0 6.082116147526628e-12
of O 0 7.573970617347214e-11
cases O 0 3.387625249762216e-11
of O 0 1.7131945861947884e-09
hereditary B-Disease 1 1.0
breast I-Disease 1 1.0
and I-Disease 1 1.0
/ I-Disease 1 1.0
or I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.43658775091171265
. O 0 1.3948464584245812e-05

A O 0 8.363587653548166e-07
novel O 0 1.6984964190669416e-07
Arg362Ser O 0 3.196530315108248e-06
mutation O 0 5.683651327359485e-09
in O 0 3.140940563195471e-10
the O 0 1.0784105830552448e-09
sterol O 0 5.4265466786773686e-08
27 O 0 2.6746488401840907e-07
- O 0 2.8864465662081784e-07
hydroxylase O 0 6.953033334866632e-06
gene O 0 3.198131892645506e-08
( O 0 5.516922030324167e-09
CYP27 O 0 3.20968174492009e-05
) O 0 8.905923776225677e-10
: O 0 3.284691130200912e-10
its O 0 7.898037085452003e-11
effects O 0 2.27373897487837e-09
on O 0 4.195932490347332e-09
pre O 0 1.2242142588547722e-07
- O 0 3.701331507954819e-08
mRNA O 0 1.8022754844082556e-08
splicing O 0 1.1282013190339057e-07
and O 0 8.261749506743854e-09
enzyme O 0 1.2685526407096859e-08
activity O 0 1.3622158689940989e-07
. O 0 2.9489288522199786e-07

A O 0 5.321531943991431e-07
novel O 0 1.4766392553156038e-07
C O 0 7.901497269813262e-07
to O 0 1.5581923529239816e-09
A O 0 7.003435165131577e-09
mutation O 0 1.1203925565084205e-09
in O 0 6.456110646091417e-10
the O 0 1.8097184861787241e-09
sterol O 0 6.096426119484022e-08
27 O 0 2.073904568078433e-07
- O 0 4.074650803431723e-07
hydroxylase O 0 2.373833240199019e-06
gene O 0 2.1272560601914847e-08
( O 0 5.1860702399153524e-09
CYP27 O 0 2.4250099158962257e-05
) O 0 2.1417487783281786e-09
was O 0 7.258416534483558e-09
identified O 0 1.9210160129290443e-09
by O 0 3.031059014890758e-10
sequencing O 0 4.610213721889522e-08
amplified O 0 6.998123467383266e-07
CYP27 O 0 2.0403460439410992e-05
gene O 0 3.3497200568888275e-09
products O 0 3.4834102269343248e-09
from O 0 3.928958824950257e-10
a O 0 1.2880816413485263e-09
patient O 0 1.4010244520079596e-08
with O 0 1.0671730166222915e-09
cerebrotendinous B-Disease 1 1.0
xanthomatosis I-Disease 1 1.0
( O 0 9.270942769035173e-07
CTX B-Disease 1 0.8210752606391907
) O 0 2.7419383741289494e-07
. O 0 1.1104259556304896e-06

The O 0 3.602449965001142e-07
mutation O 0 8.016887420581043e-08
changed O 0 4.0341902263207885e-08
the O 0 1.6862584217847143e-08
adrenodoxin O 0 9.64658170232724e-07
cofactor O 0 4.510622275688547e-08
binding O 0 1.0353620183423118e-09
residue O 0 1.31934774216802e-08
362Arg O 0 3.32174003858654e-08
to O 0 2.3883182098671796e-09
362Ser O 0 8.867658607414342e-08
( O 0 6.708201993887997e-09
CGT O 0 1.3526765769711346e-06
362Arg O 0 8.446613151136262e-07
to O 0 1.8545765811950332e-08
AGT O 0 0.0001692969090072438
362Ser O 0 2.746104428297258e-07
) O 0 3.852267949078225e-10
, O 0 4.149908541806191e-11
and O 0 2.1729113300339442e-11
was O 0 5.755319554268112e-10
responsible O 0 7.41324224229345e-10
for O 0 4.4006722710321355e-09
deficiency O 0 0.1290464699268341
in O 0 6.53147154139333e-08
the O 0 8.44038297032057e-08
sterol O 0 1.9843157872401207e-07
27 O 0 2.7084539055977075e-07
- O 0 1.1747705030984434e-07
hydroxylase O 0 2.7502795774125843e-07
activity O 0 8.244684934766155e-09
, O 0 8.90371179562699e-11
as O 0 1.0019384627524275e-10
confirmed O 0 1.316405318085856e-10
by O 0 1.3340451139598475e-11
expression O 0 1.021166595727152e-09
of O 0 1.3725085512561463e-09
mutant O 0 3.4827591921526846e-09
cDNA O 0 2.7843148231454506e-08
into O 0 9.046177140703549e-09
COS O 0 8.654783414385747e-06
- O 0 6.170398592075799e-06
1 O 0 2.8083534289180534e-06
cells O 0 1.124484151659999e-05
. O 0 4.430185981618706e-06

Quantitative O 0 2.1564917460636934e-06
analysis O 0 4.609879766803715e-08
showed O 0 2.923896458284503e-09
that O 0 1.05877216716177e-11
the O 0 1.217160261468564e-10
expression O 0 5.684276938033861e-10
of O 0 6.273203623230472e-10
CYP27 O 0 7.44552934861531e-08
gene O 0 7.612901281595086e-11
mRNA O 0 4.913499052072723e-10
in O 0 4.3066727961615925e-10
the O 0 4.461548464007592e-09
patient O 0 3.223381384032109e-08
represented O 0 8.954899932689386e-09
52 O 0 8.159854019140766e-07
. O 0 1.0088007229569484e-06

5 O 0 2.527623621517705e-07
% O 0 3.591347441656012e-09
of O 0 3.4998464126800855e-09
the O 0 3.6833782690592898e-09
normal O 0 6.059364210386775e-08
level O 0 5.183842972655839e-07
. O 0 4.4861394599138293e-07

As O 0 3.8214622577470436e-08
the O 0 3.148301619404492e-09
mutation O 0 8.604696399849843e-10
occurred O 0 2.2323312087735303e-09
at O 0 5.794509871925868e-10
the O 0 1.8968823733978013e-10
penultimate O 0 1.9261534589531948e-08
nucleotide O 0 9.518760002436011e-09
of O 0 6.074752256779448e-09
exon O 0 1.2156387185768835e-07
6 O 0 4.305190515196955e-08
( O 0 1.1973081415206366e-09
- O 0 2.001480936542066e-08
2 O 0 5.846337458592643e-08
position O 0 4.727226965428599e-08
of O 0 2.8388512873789296e-08
exon O 0 4.849951551477716e-07
6 O 0 5.962038471807318e-07
- O 0 2.262182988488348e-06
intron O 0 1.1454339073679876e-05
6 O 0 3.70362727153406e-07
splice O 0 1.9639172421648254e-07
site O 0 1.4205435938663413e-08
) O 0 1.2848444530533243e-10
of O 0 6.882135417107804e-10
the O 0 6.349426540097625e-10
gene O 0 1.3514281915760762e-09
, O 0 4.98319885355869e-10
we O 0 1.0618249612903696e-09
hypothesized O 0 3.4169473916989546e-09
that O 0 2.4454473168677993e-11
the O 0 4.3355274925716003e-10
mutation O 0 9.453150484617368e-10
may O 0 7.690811876237547e-10
partially O 0 2.335735604930278e-09
affect O 0 1.6800062729860343e-10
the O 0 1.1398972737941548e-10
normal O 0 5.91256210658031e-10
splicing O 0 3.10005932036006e-09
efficiency O 0 7.0311276800794076e-09
in O 0 2.9436268977889313e-09
exon O 0 1.2749545419410424e-07
6 O 0 2.7976232885862373e-08
and O 0 1.3750737215545428e-09
cause O 0 3.003895576725313e-09
alternative O 0 9.24816845326859e-09
splicing O 0 1.88601099182506e-08
elsewhere O 0 7.2345880397506335e-09
, O 0 5.539311717650541e-11
which O 0 3.6040367738798817e-12
resulted O 0 4.3906572821938994e-11
in O 0 3.0367749981330405e-11
decreased O 0 9.864881134191705e-10
transcript O 0 2.47937803621312e-09
in O 0 5.576428208087236e-10
the O 0 1.4531716274746032e-08
patient O 0 1.1310600029901252e-06
. O 0 7.394494900836435e-07

Transfection O 0 3.968495730077848e-05
of O 0 3.2437651498185005e-07
constructed O 0 3.057041908505198e-07
minigenes O 0 2.5798444767133333e-06
, O 0 3.6736308439699883e-10
with O 0 1.1224876063364864e-11
or O 0 2.1247074932784216e-10
without O 0 1.1249513542921363e-09
the O 0 4.783118345841331e-10
mutation O 0 6.216542280945703e-10
, O 0 1.0706465575216484e-10
into O 0 1.8193710982217226e-09
COS O 0 3.17679155159567e-06
- O 0 7.332949394367461e-07
1 O 0 3.360902667282062e-07
cells O 0 1.8003828472501482e-07
confirmed O 0 3.024708039589541e-09
that O 0 5.289006732578372e-11
the O 0 8.564285947088024e-10
mutant O 0 2.7146437986402816e-08
minigene O 0 2.6537941266724374e-07
was O 0 3.2791211967975187e-09
responsible O 0 5.875217534700994e-10
for O 0 1.4569168094169527e-10
a O 0 2.2220753015389505e-10
mRNA O 0 3.324666986159741e-09
species O 0 2.771583483551776e-11
alternatively O 0 4.015570098658827e-10
spliced O 0 5.2333288813599665e-09
at O 0 5.262537072781015e-09
an O 0 1.4232115486123575e-09
activated O 0 1.1373062079655938e-05
cryptic O 0 6.751139949301432e-07
5 O 0 7.277508018432854e-08
splice O 0 9.481921665610571e-07
site O 0 5.857924278984683e-08
88 O 0 7.747473063091093e-08
bp O 0 1.5190408930720878e-08
upstream O 0 1.030403318225126e-09
from O 0 2.6677010600550943e-10
the O 0 5.995164920058471e-10
3 O 0 1.3547374777544974e-08
end O 0 5.436316286022702e-08
of O 0 1.2952212102845806e-07
exon O 0 3.815475793089718e-06
6 O 0 5.416255135060055e-06
. O 0 3.477797235973412e-06

Our O 0 1.0522091997700045e-07
data O 0 1.1115108833337217e-08
suggest O 0 7.851270189540571e-10
that O 0 8.412529353685194e-12
the O 0 8.513841714963277e-11
C O 0 4.8735934399246617e-08
to O 0 2.3850849073525637e-10
A O 0 2.8465165780033885e-09
mutation O 0 6.795952134375227e-10
at O 0 9.83551573519037e-10
the O 0 7.767247955925427e-10
penultimate O 0 2.156136424957822e-08
nucleotide O 0 1.1222623719220337e-08
of O 0 3.1843616632443172e-09
exon O 0 5.03960819742133e-08
6 O 0 1.1367502494863402e-08
of O 0 3.7817975417908656e-09
the O 0 2.7408644243109848e-09
CYP27 O 0 6.067660706321476e-06
gene O 0 2.056268932904004e-09
not O 0 2.500224471901902e-10
only O 0 3.55087959036382e-10
causes O 0 5.2490238822144875e-09
the O 0 5.141258085927802e-09
deficiency B-Disease 0 2.993638645421015e-06
in I-Disease 0 8.741021240155078e-09
the I-Disease 0 1.109653169351077e-08
sterol I-Disease 0 1.3127927900313807e-07
27 I-Disease 0 1.8241972554733366e-07
- I-Disease 0 9.287627023013556e-08
hydroxylase I-Disease 0 4.1886184476425115e-07
activity I-Disease 0 5.944226000309527e-09
, O 0 7.79355469049392e-11
but O 0 4.237816000896011e-11
also O 0 1.0432430613827037e-10
partially O 0 3.917444590939567e-09
leads O 0 2.6972685196469115e-10
to O 0 4.7949172410355345e-11
alternative O 0 1.476618161078136e-09
pre O 0 1.6435089733590758e-08
- O 0 2.343987448583107e-09
mRNA O 0 1.9865522560280624e-09
splicing O 0 1.0450983189969065e-08
of O 0 6.659325979541109e-09
the O 0 1.1845113334629787e-08
gene O 0 6.057618406885013e-08
. O 0 6.36292554645479e-07

To O 0 2.7400188784554302e-08
our O 0 9.110381782306831e-09
knowledge O 0 1.5862701374658172e-08
, O 0 4.096884984039484e-11
this O 0 2.794098069233697e-12
is O 0 1.3531542423020348e-12
the O 0 9.856482817427459e-12
first O 0 1.4171593065714916e-10
report O 0 3.5551336180494886e-11
regarding O 0 7.490758707762168e-11
effects O 0 6.415944442395016e-10
on O 0 3.24183152544677e-10
pre O 0 7.040575233929758e-09
- O 0 5.094614174971923e-10
mRNA O 0 3.9777828253484415e-10
splicing O 0 1.64128377555528e-09
of O 0 2.986823011141837e-10
a O 0 5.3694992896424765e-11
mutation O 0 5.4843084934530495e-11
at O 0 8.066418366592387e-11
the O 0 8.286581837380069e-11
- O 0 3.717432806027432e-09
2 O 0 2.0390034549677694e-08
position O 0 1.789819670250381e-08
of O 0 8.613896262943399e-09
a O 0 7.190662287825944e-09
5 O 0 1.154437185846291e-07
splice O 0 3.493160647849436e-06
site O 0 1.4914317034708802e-06
. O 0 7.934926316011115e-07

ATM O 0 0.00022353438544087112
germline O 0 0.00016642300761304796
mutations O 0 2.8374313387757866e-07
in O 0 4.05152498217376e-08
classical O 1 0.9999995231628418
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
patients O 1 0.9999991655349731
in O 0 6.8828081012384246e-09
the O 0 4.909866735403057e-09
Dutch O 0 1.4014381122251507e-06
population O 0 2.2017707657084884e-09
. O 0 1.9085812041907957e-08

Germline O 0 3.92976617149543e-05
mutations O 0 5.444440986934751e-08
in O 0 1.5374356232555897e-09
the O 0 9.5256935672694e-10
ATM O 0 9.475940032643848e-08
gene O 0 1.5586375246012807e-10
are O 0 4.465075011117481e-12
responsible O 0 6.41928316058582e-11
for O 0 5.545995884759236e-10
the O 1 0.9951568245887756
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 2.984860884680529e-06
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 1.6913435274545918e-06
. O 0 2.914143578891526e-06

In O 0 8.822846453426791e-09
our O 0 2.825474743062273e-09
study O 0 8.170727427980751e-10
, O 0 3.253847885575922e-11
we O 0 2.6163560901126814e-11
have O 0 1.2331854287728206e-11
determined O 0 5.3047372050585295e-11
the O 0 1.810750022146479e-10
ATM O 0 9.494735309090174e-07
mutation O 0 3.4204032939300077e-09
spectrum O 0 2.274519905753891e-09
in O 0 1.2404802185450592e-10
19 O 0 2.7270665725609433e-09
classical O 0 1.5465413980564335e-06
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 1.772008545231074e-05
, O 0 3.296571904343182e-10
including O 0 2.1242940739796268e-10
some O 0 2.0986035825787397e-11
immigrant O 0 2.2038958158443478e-10
populations O 0 2.2003118077540407e-11
, O 0 7.89851604260372e-12
as O 0 2.1794569621258475e-11
well O 0 1.6740567265749462e-10
as O 0 3.4892669309449786e-10
12 O 0 2.835505608089761e-09
of O 0 2.2838271274139288e-09
Dutch O 0 1.9191057276657375e-07
ethnic O 0 3.605300280540291e-09
origin O 0 8.49547490133773e-08
. O 0 2.9938018997199833e-07

Both O 0 2.8118959605194505e-08
the O 0 3.3457037140749435e-09
protein O 0 8.462459621938478e-10
truncation O 0 3.11336719960309e-07
test O 0 3.236188561572817e-08
( O 0 1.9556425812083944e-08
PTT O 0 2.2686904230795335e-06
) O 0 1.2430292350984473e-09
and O 0 4.4031384094367354e-10
the O 0 6.869977919876646e-10
restriction O 0 1.69217067025329e-08
endonuclease O 0 2.0541732226320164e-07
fingerprinting O 0 1.3401854630501475e-06
( O 0 1.7167348431712526e-08
REF O 0 2.0875397694908315e-06
) O 0 3.537737880421332e-10
method O 0 1.4603284137493233e-09
were O 0 3.040358242945018e-10
used O 0 6.546994613110257e-10
and O 0 2.258118553255528e-10
compared O 0 5.064599295501182e-10
for O 0 5.488525953167844e-11
their O 0 5.866983981972496e-11
detection O 0 1.0386854043531457e-08
efficiency O 0 2.9900051323750176e-09
, O 0 3.09171410695086e-10
identifying O 0 3.3789295805775055e-09
76 O 0 1.414363204332858e-08
% O 0 1.67750882629214e-10
and O 0 7.06480846046631e-11
60 O 0 9.435424663806202e-10
% O 0 6.020291209996032e-11
of O 0 3.0507676940239037e-10
the O 0 5.648266299118632e-10
mutations O 0 2.142488186862579e-09
, O 0 6.314116784977841e-09
respectively O 0 3.927075340470765e-07
. O 0 8.744166279939236e-07

Most O 0 7.393438039571265e-08
patients O 0 1.8922877487170808e-08
were O 0 1.086673750982925e-09
found O 0 1.7313991906853232e-10
to O 0 4.234408657044497e-10
be O 0 8.179525501361695e-09
compound O 0 1.1218941835977603e-05
heterozygote O 0 4.884287409367971e-05
. O 0 1.7452670135753579e-06

Seventeen O 0 4.917342721455498e-06
mutations O 0 2.7734385454891708e-08
were O 0 3.4208600396823385e-09
distinct O 0 4.589258695286702e-10
, O 0 1.8655124667255052e-10
of O 0 3.953879723628262e-10
which O 0 1.1315137195266889e-11
10 O 0 1.3022456724076648e-10
were O 0 2.417659128450822e-10
not O 0 5.530974567236058e-10
reported O 0 6.050469014695636e-09
previously O 0 6.283040221433112e-08
. O 0 3.968488897498901e-07

Mutations O 0 1.3100492424200638e-06
are O 0 1.2391690340507466e-08
small O 0 1.4875872089703535e-08
deletions O 0 2.5484880552539835e-06
or O 0 1.1624373428276158e-06
point O 0 2.851392537195352e-06
mutations O 0 1.1180325998338958e-07
frequently O 0 3.402783477213234e-08
affecting O 0 1.927384474242899e-08
splice O 0 1.0752521575341234e-06
sites O 0 4.495317114106001e-07
. O 0 3.7733411772933323e-07

Moreover O 0 7.139810804801527e-07
, O 0 1.8356150377485392e-08
a O 0 1.892879808451653e-08
16 O 0 4.7132991198850505e-07
. O 0 5.81058543502877e-07

7 O 0 4.27643453804194e-06
- O 0 2.1436926544993185e-06
kb O 0 3.5591397136158776e-06
genomic O 0 3.5557093269744655e-07
deletion O 0 4.7733806241012644e-08
of O 0 2.844204649576909e-09
the O 0 5.045162621009069e-10
3 O 0 3.3944131949681378e-09
end O 0 2.4857182978621495e-09
of O 0 6.682708830751949e-10
the O 0 1.945543448567122e-10
gene O 0 1.1363675278541763e-10
, O 0 3.612207408187906e-11
most O 0 4.7976435324503797e-11
likely O 0 1.4039977513924384e-10
a O 0 3.3805701293854185e-11
result O 0 3.972897705262213e-11
of O 0 2.215862215937392e-10
recombination O 0 3.0182170651649187e-10
between O 0 6.07006736541571e-11
two O 0 9.078524737526905e-11
LINE O 0 5.95479088261186e-09
elements O 0 9.886434781947173e-09
, O 0 2.366994600322414e-09
was O 0 2.2481764005988225e-08
identified O 0 7.052916828342859e-08
. O 0 4.406755920172145e-07

The O 0 1.0255357807409382e-07
most O 0 5.47559686481236e-09
frequently O 0 1.2520403602778174e-09
found O 0 4.8438933419880925e-11
mutation O 0 1.2508773183927957e-10
, O 0 3.005061477434623e-11
identified O 0 3.484351973614963e-10
in O 0 8.155371516993526e-11
three O 0 8.436684684198781e-11
unrelated O 0 5.270047176431092e-10
Turkish O 0 2.2761872386922732e-08
A B-Disease 1 1.0
- I-Disease 1 0.9999967813491821
T I-Disease 1 1.0
individuals O 0 3.8945263680645326e-10
, O 0 1.4634868317209282e-10
was O 0 1.0516705284402406e-09
previously O 0 2.687583211535838e-10
described O 0 3.281658278453392e-11
to O 0 1.1068507221878576e-11
be O 0 2.0400077460625e-11
a O 0 2.4393737030337093e-10
Turkish O 0 6.524548723518819e-08
A B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
founder O 0 7.181375985965133e-05
mutation O 0 8.963957611740625e-07
. O 0 7.068227887430112e-07

The O 0 1.2227896206695732e-07
presence O 0 3.129396475287649e-08
of O 0 2.155001510573129e-08
a O 0 1.55348676145195e-08
founder O 0 8.805077413853724e-07
mutation O 0 1.6572080596688465e-08
among O 0 2.570268442525503e-10
relatively O 0 2.8222199577321305e-10
small O 0 3.001893872367489e-11
ethnic O 0 1.2151832491646974e-11
population O 0 7.561837983040276e-13
groups O 0 4.696792542564776e-13
in O 0 3.8890219170029106e-12
Western O 0 1.2841394614326873e-09
Europe O 0 8.141205043443733e-09
could O 0 1.2960366113645705e-09
indicate O 0 9.519626198439823e-10
a O 0 3.167175688378876e-10
high O 0 1.793902915103729e-09
carrier O 0 1.2606550248150938e-09
frequency O 0 6.2714122783802395e-09
in O 0 1.0374098247112329e-09
such O 0 7.038990723629013e-09
communities O 0 8.48158379085362e-08
. O 0 5.467699111250113e-07

In O 0 6.265580054787279e-08
patients O 0 2.994606873585326e-08
of O 0 2.4324104952455627e-09
Dutch O 0 9.690891289437786e-08
ethnic O 0 1.830201545871546e-10
origin O 0 1.2024437001656452e-09
, O 0 9.212806212355318e-11
however O 0 1.3785025898549463e-10
, O 0 5.0900859915881114e-11
no O 0 1.4606564568975244e-10
significant O 0 4.685418164562805e-10
founder O 0 6.9428001125970695e-09
effect O 0 9.898393216190016e-10
could O 0 1.6586049200739694e-09
be O 0 4.320810376157169e-09
identified O 0 1.457861174003483e-07
. O 0 8.102587685243634e-07

The O 0 1.1808574384986059e-07
observed O 0 4.624384075668786e-08
genetic O 0 9.013693791359856e-09
heterogeneity O 0 3.6474365749938897e-09
including O 0 4.095511985102718e-10
the O 0 2.652798813951307e-10
relative O 0 2.1596060051365384e-08
high O 0 1.5708996770058548e-08
percentage O 0 3.1534279631983964e-09
of O 0 1.8287297232078004e-09
splice O 0 2.691839426915976e-07
- O 0 2.3482158439946943e-07
site O 0 3.408090520906626e-08
mutations O 0 2.654470421248334e-09
had O 0 3.32068683661646e-09
no O 0 1.973876839755917e-09
reflection O 0 3.16786206155939e-08
on O 0 2.924556063987893e-08
the O 0 2.473173310590937e-08
phenotype O 0 6.765641842321202e-07
. O 0 4.024096824650769e-07

All O 0 4.6185835600454084e-08
patients O 0 1.8047625616191e-08
manifested O 0 4.030219713513361e-09
classical O 0 3.2996459253809007e-07
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
and O 0 2.560031475695723e-07
increased O 0 5.442477686301572e-07
cellular O 0 7.909111445769668e-07
radioresistant O 0 7.335754048654053e-07
DNA O 0 9.284651270036193e-08
synthesis O 0 1.5219487750073313e-06
. O 0 1.133189016400138e-06

Determination O 0 3.607152905260591e-07
of O 0 8.827461783766921e-08
the O 0 3.1010825018995547e-09
genomic O 0 7.418111458434851e-09
structure O 0 8.788394456615833e-10
of O 0 1.7260979312538893e-09
the O 0 1.931715232217357e-09
COL4A4 O 0 4.688365152105689e-06
gene O 0 6.431676857765467e-10
and O 0 3.1883470863469654e-10
of O 0 1.015600226139668e-08
novel O 0 2.1494152235845831e-07
mutations O 0 3.6524969004858576e-07
causing O 0 3.177846110702376e-06
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 0.0003212563751731068

Autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
is O 0 5.44221601117556e-09
a O 0 5.785634193955502e-09
progressive O 0 0.03111046738922596
hematuric B-Disease 1 1.0
glomerulonephritis I-Disease 1 1.0
characterized O 0 3.91416615457274e-05
by O 0 2.800041443151713e-08
glomerular B-Disease 1 0.9999985694885254
basement I-Disease 1 1.0
membrane I-Disease 1 0.9999966621398926
abnormalities I-Disease 1 0.9982561469078064
and O 0 5.894683852147864e-09
associated O 0 1.934303242023816e-07
with O 0 4.787627516655846e-10
mutations O 0 2.4331392456389267e-09
in O 0 1.0688984142248614e-09
either O 0 4.471559122976032e-09
the O 0 2.0459181016008188e-08
COL4A3 O 0 6.9190158683341e-05
or O 0 7.623341957696539e-09
the O 0 7.900817777795055e-09
COL4A4 O 0 8.867107680998743e-06
gene O 0 2.104674434733056e-09
, O 0 3.1980554315858e-10
which O 0 9.390518224128286e-11
encode O 0 3.951740712437868e-09
the O 0 9.24041021477251e-09
alpha3 O 0 1.7367116015520878e-05
and O 0 3.604689879921352e-08
alpha4 O 0 6.304321868810803e-05
type O 0 1.9666042135213502e-05
IV O 1 1.0
collagen O 0 0.18968883156776428
chains O 0 6.187576218508184e-06
, O 0 5.5806150811577027e-08
respectively O 0 5.58905071557092e-07
. O 0 2.8016901865157706e-07

To O 0 1.8447547489586213e-08
date O 0 5.562061389241535e-08
, O 0 1.2581304886793987e-09
mutation O 0 3.514548096994474e-10
screening O 0 9.089237140713635e-10
in O 0 2.2903823282405256e-10
the O 0 1.053630072078704e-09
two O 0 4.709717615902775e-10
genes O 0 1.0581736598069824e-09
has O 0 5.687853313340874e-11
been O 0 1.2901463231074217e-10
hampered O 0 5.564647853617544e-09
by O 0 1.3236110818493074e-10
the O 0 1.662976423233431e-09
lack O 0 2.128262543976689e-08
of O 0 3.423862526830135e-09
genomic O 0 9.379339083182003e-09
structure O 0 4.28935331697744e-09
information O 0 2.0874963979622407e-08
. O 0 8.64901608110813e-08

We O 0 7.40242640517863e-08
report O 0 6.9200210006670204e-09
here O 0 9.61183688197309e-10
the O 0 3.0024677188933424e-10
complete O 0 1.812243466403629e-09
characterization O 0 6.109087902217425e-09
of O 0 2.0764281405405427e-09
the O 0 1.1694788470961726e-09
48 O 0 2.0374601561456984e-08
exons O 0 2.694289058524646e-08
of O 0 1.517725278787907e-09
the O 0 4.361232264216142e-09
COL4A4 O 0 3.336702866363339e-05
gene O 0 3.3654998787824297e-09
, O 0 3.547231119949146e-10
a O 0 2.84349821466634e-10
comprehensive O 0 9.072648410324291e-09
gene O 0 8.136358808918942e-10
screen O 0 1.5424083121828858e-09
, O 0 2.4691362843221043e-10
and O 0 8.896548081560596e-11
the O 0 2.043248764627137e-10
subsequent O 0 3.243947055420193e-10
detection O 0 1.1944416122844359e-08
of O 0 3.1676047895778936e-10
10 O 0 1.8592073713907808e-10
novel O 0 2.2058428694737842e-10
mutations O 0 8.581254457018517e-11
in O 0 1.6551088277694248e-10
eight O 0 1.2012499439606472e-08
patients O 0 6.919891575307702e-07
diagnosed O 0 1.9982442154287128e-06
with O 0 9.647495602393974e-08
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 0.00016973639139905572

Furthermore O 0 6.134515615485725e-07
, O 0 9.473009043858838e-09
we O 0 3.639889278872488e-09
identified O 0 2.821328060065298e-09
a O 0 1.3588592473467997e-09
glycine O 0 6.52820872915072e-08
to O 0 8.437949006179224e-09
alanine O 0 1.2644912317227863e-07
substitution O 0 4.772898023475136e-07
in O 0 3.028069173183212e-08
the O 0 3.7089428417402814e-08
collagenous O 0 1.955588686541887e-06
domain O 0 1.5420259513732049e-09
that O 0 1.4334589071296477e-11
is O 0 1.4544893935097836e-11
apparently O 0 6.654523043714278e-10
silent O 0 4.091079475188053e-09
in O 0 2.2119688025679096e-10
the O 0 1.0235260416990855e-09
heterozygous O 0 1.355442313943911e-09
carriers O 0 2.233413010088725e-09
, O 0 1.4357425248689992e-09
in O 0 6.904174121302731e-09
11 O 0 7.505900043724978e-07
. O 0 1.0885952406169963e-06

5 O 0 5.201254680287093e-07
% O 0 6.051438461440739e-09
of O 0 3.493390687836495e-09
all O 0 4.24903612294969e-10
control O 0 2.809380061918887e-09
individuals O 0 4.136332248938501e-11
, O 0 6.040557637421173e-11
and O 0 1.0193330207686202e-10
in O 0 3.7286504439570933e-10
one O 0 3.2646974013061936e-10
control O 0 1.6850518758104727e-09
individual O 0 3.3952338163167894e-10
homozygous O 0 1.419906303645746e-09
for O 0 3.4084185474014816e-10
this O 0 7.39577232788946e-10
glycine O 0 8.943449358866928e-08
substitution O 0 1.85386045359337e-06
. O 0 1.6881334659046843e-06

There O 0 3.9236457638480715e-08
has O 0 1.1755170170602014e-09
been O 0 2.5673288495120516e-10
no O 0 1.490414458515943e-10
previous O 0 3.0446176135789926e-10
finding O 0 7.701939086501852e-10
of O 0 2.3061720588746226e-10
a O 0 9.000902800870847e-11
glycine O 0 2.785439434660475e-09
substitution O 0 2.7687239168017186e-08
that O 0 2.589636838301601e-10
is O 0 7.90144200069065e-11
not O 0 9.368834874567966e-11
associated O 0 9.105113329965775e-10
with O 0 4.7468893399349454e-11
any O 0 2.9620155217457977e-09
obvious O 0 2.4929034836418396e-08
phenotype O 0 9.620866769921577e-09
in O 0 1.6923151768821754e-09
homozygous O 0 1.1429747814872826e-08
individuals O 0 1.8846793015114827e-09
. O 0 1.611822852964906e-07

Founder O 0 0.00014669877418782562
BRCA1 O 0 6.240014045033604e-06
and O 0 7.202208252010678e-08
BRCA2 O 0 5.030254897064879e-07
mutations O 0 2.5027162564583705e-09
in O 0 2.0239800946342257e-09
French O 0 3.853091584460344e-06
Canadian O 0 0.45152559876441956
breast B-Disease 1 1.0
and I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 4.076468485436635e-06
. O 0 2.339400680284598e-06

We O 0 1.0740247802232261e-07
have O 0 2.1488519852397303e-09
identified O 0 2.0326613725529796e-09
four O 0 1.380805192408019e-10
mutations O 0 2.1348303680390757e-10
in O 0 5.7748566345550145e-11
each O 0 4.6113324964069946e-11
of O 0 4.648905260751235e-09
the O 0 9.75228317656729e-07
breast B-Disease 1 1.0
cancer I-Disease 1 0.9130123853683472
- O 0 1.0534323337196838e-05
susceptibility O 0 1.3090988204567111e-06
genes O 0 9.086450702966431e-09
, O 0 7.910649912901135e-09
BRCA1 O 0 7.902629306499875e-08
and O 0 3.3432812074352114e-08
BRCA2 O 0 1.6054362106387998e-07
, O 0 5.723944651592205e-10
in O 0 4.419140886557926e-10
French O 0 2.333272703936018e-07
Canadian O 0 1.4517332829200313e-06
breast B-Disease 0 0.04765892028808594
cancer I-Disease 0 0.00014581988216377795
and O 0 0.2572331428527832
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 6.537865715472435e-07
from O 0 5.247544621056477e-08
Quebec O 0 1.1627466847130563e-06
. O 0 1.0028143151430413e-06

To O 0 3.429332195992174e-07
identify O 0 3.0771190040468355e-07
founder O 0 8.057854756771121e-07
effects O 0 6.712658660035231e-07
, O 0 4.273747133964889e-09
we O 0 3.5114811058889472e-09
examined O 0 1.7424527598564055e-08
independently O 0 7.0207821778467405e-09
ascertained O 0 1.565462497410408e-07
French O 0 5.612114364339504e-07
Canadian O 0 5.355832968234608e-07
cancer B-Disease 0 5.1137984513616175e-08
families O 0 1.0478212048026236e-11
for O 0 7.792332751277442e-12
the O 0 2.1786048659544477e-11
distribution O 0 8.480568330915261e-11
of O 0 6.259267548713865e-10
these O 0 5.962050297902977e-10
eight O 0 2.3486743216949435e-08
mutations O 0 5.678950643073222e-08
. O 0 6.602956545975758e-07

Mutations O 0 1.4284341887105256e-07
were O 0 1.4347002696979416e-08
found O 0 8.294239184358787e-10
in O 0 5.283282700219161e-10
41 O 0 2.6461611568606713e-08
of O 0 2.8220076941920524e-08
97 O 0 5.309499556460651e-06
families O 0 4.332018832542417e-08
. O 0 3.6357769772621396e-07

Six O 0 1.1820010570318118e-07
of O 0 1.0556099994118995e-08
eight O 0 1.8309040950015287e-09
mutations O 0 4.735307701508873e-10
were O 0 4.6308493151236974e-10
observed O 0 1.0397235294945517e-09
at O 0 3.2298845820122324e-09
least O 0 3.414588833905441e-09
twice O 0 7.518825384522643e-08
. O 0 3.0235045755944157e-07

The O 0 2.7943597160628997e-06
BRCA1 O 0 1.3436813787848223e-05
C4446T O 0 1.1581469152588397e-05
mutation O 0 4.8328178792189647e-08
was O 0 8.287743824553218e-09
the O 0 9.022461666674531e-10
most O 0 2.5798360669959663e-10
common O 0 3.399225345646073e-10
mutation O 0 1.8405915680475005e-10
found O 0 1.8375320362529202e-11
, O 0 2.0849624110530485e-11
followed O 0 2.6308391576357337e-10
by O 0 1.2812251259930463e-10
the O 0 1.0057592980672325e-08
BRCA2 O 0 5.281071366880496e-07
8765delAG O 0 1.2729695981761324e-06
mutation O 0 8.985185928622741e-08
. O 0 2.542426216223248e-07

Together O 0 4.8870905544617926e-08
, O 0 2.723791414638299e-09
these O 0 2.0971760439358889e-10
mutations O 0 2.0056711846905273e-10
were O 0 4.2322445548137466e-10
found O 0 1.1394495069705357e-10
in O 0 9.524488836509803e-11
28 O 0 8.166291642908163e-09
of O 0 4.368592154690987e-09
41 O 0 3.6037741679706414e-09
families O 0 3.975278092815948e-11
identified O 0 2.8722682565707203e-10
to O 0 3.325134612097713e-10
have O 0 2.3032939999723112e-09
a O 0 4.545791298937729e-08
mutation O 0 2.598947901333304e-07
. O 0 1.476660600019386e-06

The O 0 8.758031100342123e-08
odds O 0 1.7853540157375392e-07
of O 0 6.073083813618041e-09
detection O 0 2.403358791980281e-07
of O 0 1.3647503127600658e-09
any O 0 2.3069991750279684e-10
of O 0 1.781974123815644e-09
the O 0 2.3312092256588812e-09
four O 0 3.688925387379527e-09
BRCA1 O 0 2.57614107823656e-08
mutations O 0 4.353752025565427e-09
was O 0 5.7941512920933746e-08
18 O 0 7.841883871151367e-07
. O 0 1.7409946622137795e-06

7x O 0 0.00015729160804767162
greater O 0 1.33332136442732e-07
if O 0 2.850602420778614e-09
one O 0 2.6222926607921693e-10
or O 0 2.574306601221821e-10
more O 0 2.9612329949246785e-11
cases O 0 2.01042821279529e-10
of O 0 3.0501519177050795e-07
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
were O 0 4.866064955422189e-07
also O 0 9.59483936746608e-10
present O 0 9.720015764491663e-11
in O 0 5.139569325685045e-10
the O 0 1.550218975410189e-08
family O 0 5.1964004654792006e-08
. O 0 8.264698294624395e-07

The O 0 2.1046962217496912e-07
odds O 0 2.9344582230805827e-07
of O 0 7.187028749910951e-09
detection O 0 1.3646382512888522e-07
of O 0 3.4327425346702967e-09
any O 0 7.785565525608718e-10
of O 0 5.8872005048726805e-09
the O 0 5.290253124456967e-09
four O 0 1.5706419276284578e-08
BRCA2 O 0 1.0604375688672008e-07
mutations O 0 5.001856262509818e-09
was O 0 1.4916237489615014e-07
5 O 0 3.1204376682580914e-06
. O 0 4.067874215252232e-06

3x O 0 7.4831310485024e-05
greater O 0 4.1726622157511883e-08
if O 0 6.610927361094809e-10
there O 0 1.9126351891163296e-10
were O 0 3.825659233847034e-10
at O 0 3.889255861810881e-10
least O 0 3.56892571051759e-11
five O 0 1.8537144041985698e-11
cases O 0 2.8024575715601685e-11
of O 0 2.265332366135908e-09
breast B-Disease 1 0.9931127429008484
cancer I-Disease 0 3.2225473205471644e-06
in O 0 1.6155183857335942e-08
the O 0 7.362561973422999e-07
family O 0 3.355611966071592e-07
. O 0 3.101491756751784e-06

Interestingly O 0 2.5890329879985075e-07
, O 0 2.09736095158064e-09
the O 0 5.069992203843299e-10
presence O 0 1.1461046556249244e-09
of O 0 2.7945925573646946e-09
a O 0 9.50836565039026e-08
breast B-Disease 1 0.9999891519546509
cancer I-Disease 0 7.0400660661107395e-06
case O 0 1.8119703515395713e-09
< O 0 3.4521471548032423e-07
36 O 0 1.208779565331497e-08
years O 0 7.534639023809575e-10
of O 0 1.026936424786129e-09
age O 0 1.6342990294404558e-09
was O 0 1.667473825683885e-09
strongly O 0 6.819268760782649e-11
predictive O 0 1.022807949446758e-09
of O 0 2.2376928088263526e-10
the O 0 1.309940905747098e-10
presence O 0 1.1819463463513813e-10
of O 0 1.8322622585831283e-10
any O 0 1.0079322099176835e-10
of O 0 7.67009733504409e-10
the O 0 1.0632192903869964e-09
eight O 0 8.290020225842909e-09
mutations O 0 6.256048123987057e-09
screened O 0 1.6098026378585928e-07
. O 0 1.3521993196263793e-06

Carriers O 0 2.85651566400702e-07
of O 0 2.0642824338779064e-08
the O 0 1.5443276657478577e-09
same O 0 8.589396971458996e-10
mutation O 0 3.195055886529019e-10
, O 0 2.013543151657693e-11
from O 0 3.27576750447367e-11
different O 0 1.0730195378061413e-11
families O 0 4.6992524455058415e-11
, O 0 3.175237156538557e-11
shared O 0 1.3622813987979043e-10
similar O 0 7.062895407417003e-11
haplotypes O 0 1.0080677625978751e-08
, O 0 2.534293885858574e-10
indicating O 0 3.4049050245954504e-09
that O 0 5.27362459257219e-11
the O 0 2.430197432179426e-10
mutant O 0 2.266680843021618e-09
alleles O 0 1.9636993420224513e-10
were O 0 5.050881379808914e-10
likely O 0 6.735147439762557e-10
to O 0 1.1958080359253387e-10
be O 0 6.492189424944783e-11
identical O 0 6.228538518282534e-11
by O 0 2.7623370604801245e-11
descent O 0 2.625106354514628e-09
for O 0 8.759555580883926e-11
a O 0 1.617126016428827e-10
mutation O 0 1.6173110073403052e-10
in O 0 1.8347556807185583e-10
the O 0 5.248053103201755e-09
founder O 0 6.737093372066738e-07
population O 0 2.832845957811969e-09
. O 0 5.5746149030255765e-08

The O 0 5.827878979403067e-08
identification O 0 2.2696114854170446e-07
of O 0 1.6022242732560699e-07
common O 0 5.615856366603111e-07
BRCA1 O 0 1.9166652691637864e-06
and O 0 6.412427211444083e-08
BRCA2 O 0 4.414255556639546e-07
mutations O 0 1.4557729466346814e-09
will O 0 2.542214494472006e-10
facilitate O 0 4.463600156157099e-09
carrier O 0 3.6240805911802454e-09
detection O 0 7.107460220368012e-08
in O 0 1.556748618902759e-09
French O 0 1.1429483492975123e-06
Canadian O 0 9.949211744242348e-06
breast B-Disease 1 0.9999393224716187
cancer I-Disease 1 0.8540418148040771
and O 1 0.9812670946121216
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 1.3994980690767989e-05
. O 0 5.98598944634432e-06

Are O 0 1.2924944030601182e-06
Dp71 O 0 0.0002517153916414827
and O 0 5.349360208128928e-07
Dp140 O 0 0.00027076966944150627
brain O 0 1.6317153495037928e-05
dystrophin O 0 1.1829533832496963e-06
isoforms O 0 3.74904942646026e-08
related O 0 2.3117941339023673e-08
to O 0 7.822395176049213e-09
cognitive B-Disease 0 0.001036925707012415
impairment I-Disease 1 0.9999986886978149
in O 0 0.11410578340291977
Duchenne B-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
? O 1 1.0

Molecular O 0 2.854385456885211e-06
study O 0 4.0434343873130274e-08
and O 0 7.820779579503778e-10
neuropsychological O 0 7.75664048546787e-08
analysis O 0 2.9245992294590906e-09
were O 0 2.360277528978827e-09
performed O 0 8.39984348743883e-09
concurrently O 0 3.2240619063372833e-09
on O 0 4.4593790882174744e-09
49 O 0 2.1403367966854603e-08
patients O 0 1.248118763896855e-08
with O 0 5.192176466550791e-09
Duchenne B-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.996746301651001
DMD B-Disease 1 1.0
) O 0 2.9667139855860114e-09
in O 0 4.510738449425844e-10
order O 0 8.364171022456901e-10
to O 0 2.8541699559347933e-10
find O 0 3.682596727561105e-10
a O 0 1.2074485855606554e-10
molecular O 0 4.790367547080621e-10
explanation O 0 4.182299229160691e-10
for O 0 4.196544500789656e-11
the O 0 8.134713458396448e-10
cognitive B-Disease 0 5.284194912746898e-07
impairment I-Disease 0 1.8756189490432007e-07
observed O 0 8.520505967446468e-10
in O 0 1.3697128986578377e-09
most O 0 7.065141716111611e-08
DMD B-Disease 1 1.0
patients O 0 0.024073665961623192
. O 0 1.6878115047802567e-06

Complete O 0 1.0220580293207604e-07
analysis O 0 1.2460874110331588e-08
of O 0 3.3918958752821027e-09
the O 0 1.7505467075906722e-09
dystrophin O 0 1.0437441488875265e-07
gene O 0 4.535456898935308e-09
was O 0 1.8185533079417837e-08
performed O 0 3.581143559472366e-08
to O 0 3.1525859700565206e-09
define O 0 1.4308169760113287e-08
the O 0 5.359427124318472e-09
localization O 0 1.0287639270245563e-05
of O 0 1.287557154228125e-07
deletions O 0 5.120435844219173e-07
and O 0 4.905261086207702e-09
duplications O 0 9.746892004613983e-08
in O 0 9.22385279267246e-10
relation O 0 1.7263876994633165e-09
to O 0 6.774752980831522e-10
the O 0 5.19280041189063e-09
different O 0 4.447387524919577e-08
DMD B-Disease 1 1.0
promoters O 0 0.06857302784919739
. O 0 1.944069481396582e-05

Qualitative O 0 1.1637762327154633e-06
analysis O 0 7.136598867418797e-08
of O 0 1.1777124164780162e-08
the O 0 7.502462651132191e-09
Dp71 O 0 3.209325768693816e-06
transcript O 0 4.371995032670384e-08
and O 0 3.863555586569589e-10
testing O 0 3.9153361108823503e-10
for O 0 6.381341982608646e-11
the O 0 1.5019291366158427e-10
specific O 0 3.7039832312402154e-10
first O 0 2.415586175530393e-09
exon O 0 8.610778934325936e-08
of O 0 1.16117995219156e-08
Dp140 O 0 4.199227532808436e-06
were O 0 2.0793619270875752e-08
also O 0 2.986494163081943e-09
carried O 0 9.72300995272235e-09
out O 0 1.3033105261683886e-08
. O 0 4.1004020090440463e-07

Neuropsychological O 0 2.059731923509389e-05
analysis O 0 1.3091320738567447e-07
assessed O 0 2.058807666571738e-07
verbal O 0 8.64261764377261e-08
and O 0 6.551432285561987e-09
visuospatial O 0 6.713812126690755e-06
intelligence O 0 1.3413396970918257e-07
, O 0 3.6421115012785776e-09
verbal O 0 1.4015991922633475e-08
memory O 0 8.780156690590957e-07
, O 0 5.948603831740229e-09
and O 0 7.2096550951528116e-09
reading O 0 7.89758087194059e-06
skills O 0 9.169733675662428e-05
. O 0 3.901128366123885e-06

Comparison O 0 8.906218909032759e-07
of O 0 8.001732965112751e-08
molecular O 0 1.2976518348750687e-07
and O 0 4.9352353315157416e-09
psychometric O 0 3.4068571039824747e-06
findings O 0 1.5731902891502614e-08
demonstrated O 0 9.329684580450248e-09
that O 0 2.7549199033138905e-10
deletions O 0 2.86097492363524e-08
and O 0 2.871557214234599e-09
duplications O 0 2.0861557459284086e-07
that O 0 3.3327665627247427e-10
were O 0 1.5019899768375922e-09
localized O 0 4.905167827473633e-09
in O 0 3.0054872479645667e-10
the O 0 9.053179872431372e-10
distal O 0 6.134486341125012e-08
part O 0 2.8361764048412397e-09
of O 0 9.516313070889737e-08
the O 0 7.790921330297351e-08
gene O 0 1.1113984399457877e-08
seemed O 0 3.78347309037963e-08
to O 0 1.1515959297270228e-09
be O 0 1.0576611808588154e-09
preferentially O 0 3.491838596048069e-09
associated O 0 2.050152581034581e-08
with O 0 5.655470314280819e-09
cognitive B-Disease 1 0.9995480179786682
impairment I-Disease 1 0.9995169639587402
. O 0 8.20390778244473e-06

Two O 0 1.2509995883647207e-07
altered O 0 2.976439645863138e-07
Dp71 O 0 1.4269886378315277e-05
transcripts O 0 5.57271164325357e-07
and O 0 4.071851300579965e-09
two O 0 1.523822290572241e-09
deleted O 0 2.6774042538590948e-08
Dp140 O 0 1.2559209494611423e-07
DNA O 0 3.4668661275105705e-09
sequences O 0 2.689901357211255e-10
were O 0 5.105353362289122e-10
found O 0 2.4904012185800184e-10
in O 0 2.271189070146562e-10
four O 0 2.0275734424757275e-09
patients O 0 3.82253917408093e-09
with O 0 2.8392654893849567e-10
severe O 0 0.01890658773481846
cerebral B-Disease 1 1.0
dysfunction I-Disease 1 0.9999998807907104
. O 0 5.555749521590769e-05

These O 0 1.50128258269433e-07
findings O 0 6.639061211899389e-08
suggest O 0 9.535314760000801e-09
that O 0 1.4785846158549276e-10
some O 0 9.649157861613133e-11
sequences O 0 1.9748964963373083e-10
located O 0 3.845161966609112e-10
in O 0 1.547062616902295e-10
the O 0 1.2562768603174845e-09
distal O 0 1.1011756839707232e-07
part O 0 4.09908551546323e-09
of O 0 1.7427584708684662e-08
the O 0 2.6859088286812494e-09
gene O 0 3.683039151436418e-10
and O 0 1.7003479180210945e-10
, O 0 1.0142982981298232e-10
in O 0 6.977388805617935e-11
particular O 0 4.6165798961439464e-10
, O 0 1.766760626686903e-10
some O 0 6.114761474940167e-10
DMD B-Disease 1 1.0
isoforms O 0 2.212958527536557e-08
expressed O 0 2.6978705380820145e-10
in O 0 1.1352951911902665e-10
the O 0 8.848761168245289e-10
brain O 0 2.0678690759723395e-07
may O 0 3.642276202864281e-10
be O 0 7.597206197473838e-11
related O 0 9.025318825628403e-10
to O 0 5.681393688838909e-10
the O 0 7.627443565638714e-09
cognitive B-Disease 0 1.7705389836919494e-05
impairment I-Disease 0 1.1544630069693085e-06
associated O 0 2.6168391897840593e-08
with O 0 9.759631325323426e-09
DMD B-Disease 1 1.0
. O 0 1.2515199159679469e-05
. O 0 3.782726707868278e-06

I1307K O 0 0.000532418314833194
APC O 0 1.0598450899124146e-05
and O 0 1.235145763445189e-08
hMLH1 O 0 6.211700451785873e-07
mutations O 0 2.9742834861679057e-09
in O 0 1.78337067335832e-10
a O 0 4.3547132566601476e-10
non O 0 3.415065918943583e-08
- O 0 2.1999376542680693e-08
Jewish O 0 1.25187140653793e-08
family O 0 1.819585315754324e-10
with O 0 3.417817071027507e-11
hereditary B-Disease 1 1.0
non I-Disease 1 1.0
- I-Disease 1 1.0
polyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 1 0.9991390705108643

We O 0 8.20935071033091e-08
describe O 0 3.3894917095267374e-08
a O 0 5.344798381656801e-09
French O 0 3.339502541166439e-07
Canadian O 0 7.671127377761877e-07
hereditary B-Disease 1 1.0
non I-Disease 1 1.0
- I-Disease 1 1.0
polyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 0.0001369944220641628
HNPCC B-Disease 1 1.0
) O 0 6.155968623744457e-09
kindred O 0 1.7060288826087344e-07
which O 0 2.1314534859318002e-10
carries O 0 3.717700036709459e-10
a O 0 3.3073477290201936e-10
novel O 0 4.45832482043329e-09
truncating O 0 1.271341147912608e-07
mutation O 0 2.9071693941062904e-09
in O 0 8.505328885632935e-09
hMLH1 O 0 7.725818250037264e-06
. O 0 9.518678893982724e-07

Interestingly O 0 1.934361762323533e-06
, O 0 2.6253982099433415e-08
the O 0 2.509065133438071e-08
I1307K O 0 1.4196074516803492e-05
APC O 0 5.672141583090706e-07
polymorphism O 0 3.002476773872331e-07
, O 0 2.859564252055691e-10
associated O 0 2.548204980357127e-10
with O 0 6.429916061395646e-12
an O 0 9.604717195188517e-12
increased O 0 3.9292361031506573e-10
risk O 0 3.979349827432088e-08
of O 0 0.03688948601484299
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 7.773435584113031e-08
is O 0 8.717187388596059e-11
also O 0 2.8835302201546398e-11
present O 0 1.0475374907781276e-11
in O 0 1.5704486322487554e-10
this O 0 8.063714695971669e-10
family O 0 1.9118820304697692e-08
. O 0 2.167800658980923e-07

The O 0 7.193071951405727e-07
I1307K O 0 5.144476017449051e-05
polymorphism O 0 8.207789505831897e-06
has O 0 2.4079132021626037e-09
previously O 0 1.3864190906431872e-09
only O 0 4.788455743032216e-11
been O 0 6.67608052173918e-11
identified O 0 7.13955700115676e-11
in O 0 2.3080983305168168e-11
individuals O 0 1.5227749616819608e-11
of O 0 1.315449749128561e-09
self O 0 1.8867777384912188e-07
- O 0 4.392515222662041e-07
reported O 0 1.6959996074206174e-08
Ashkenazi O 0 1.1269157766946591e-06
Jewish O 0 2.673763788152428e-07
origins O 0 7.217252573354926e-07
. O 0 2.626974264785531e-07

In O 0 8.20776602239448e-09
addition O 0 3.7412473119502465e-09
, O 0 1.4030232531325737e-10
in O 0 2.991097300397705e-11
this O 0 2.1850719150728892e-11
family O 0 6.489812853782695e-11
, O 0 3.394073216922422e-11
there O 0 1.7892708148448122e-11
appears O 0 2.257257158966297e-10
to O 0 9.732556427444194e-11
be O 0 4.660871133488342e-10
no O 0 2.175177593599642e-09
relationship O 0 2.9636643139596686e-10
between O 0 5.396135205337771e-10
the O 0 3.152321514932055e-09
I1307K O 0 1.590431963904848e-07
polymorphism O 0 7.338711416338128e-09
and O 0 1.2424952733347538e-10
the O 0 3.763855616067957e-10
presence O 0 2.4498194584055e-09
or O 0 3.127622827392429e-09
absence O 0 6.035786270786048e-08
of O 0 3.4894235056981415e-08
cancer B-Disease 0 3.1720247761768405e-07
. O 0 1.4254127655988214e-08
. O 0 1.8145398428259796e-07

Identification O 0 6.074164389247017e-07
of O 0 4.9688818393178735e-08
a O 0 1.395904947187887e-09
novel O 0 1.0279750384256658e-09
mutation O 0 2.4256360808827537e-10
of O 0 6.693194332108021e-10
the O 0 3.163935113903449e-09
CPO O 0 1.8948539945995435e-06
gene O 0 1.2715971609011945e-09
in O 0 9.77561143145067e-10
a O 0 9.25353216274516e-09
Japanese O 0 1.638373578316532e-05
hereditary B-Disease 1 0.9999994039535522
coproporphyria I-Disease 1 0.9989417195320129
family O 0 2.265312701865696e-07
. O 0 3.918691504622984e-07

Hereditary B-Disease 1 0.9999990463256836
coproporphyria I-Disease 1 0.9999967813491821
( O 0 8.609972041995206e-07
HCP B-Disease 1 0.9999947547912598
) O 0 3.8400720825393364e-08
is O 0 4.018736454725058e-09
an O 0 1.8173430760271003e-08
autosomal B-Disease 1 1.0
dominant I-Disease 1 0.9999998807907104
disease I-Disease 1 0.9999879598617554
characterized O 0 2.177680702430962e-09
by O 0 7.825700504282551e-11
a O 0 2.613635530224201e-09
deficiency B-Disease 0 3.3332852922285383e-07
of I-Disease 0 2.2317633465718245e-06
coproporphyrinogen I-Disease 0 0.0003864493337459862
oxidase I-Disease 0 1.808717371432067e-07
( O 0 5.748849840614412e-09
CPO O 0 4.5929502334729477e-07
) O 0 4.3356182533038634e-10
caused O 0 7.851239658407394e-10
by O 0 3.541381424221335e-11
a O 0 2.5429031103030297e-10
mutation O 0 5.052288032381114e-10
in O 0 1.8429180403956025e-09
the O 0 9.886269225489741e-08
CPO O 0 4.990505476598628e-05
gene O 0 5.958349333923252e-07
. O 0 3.0585106287617236e-06

Only O 0 3.5965587841246816e-08
11 O 0 1.742738575671865e-08
mutations O 0 1.6870199681662257e-09
of O 0 2.15493889399454e-09
the O 0 1.8713186555885386e-09
gene O 0 1.5894463523125069e-09
have O 0 3.8870162644144557e-10
been O 0 1.4907506340477994e-09
reported O 0 1.6950318926234331e-09
in O 0 9.121126964828363e-09
HCP B-Disease 1 0.9999998807907104
patients O 0 0.08339942246675491
. O 0 5.694820174539927e-06

We O 0 9.338998552266276e-08
report O 0 3.4993925535076187e-09
another O 0 6.33967267571478e-10
mutation O 0 5.117149481925765e-10
in O 0 3.4279909466583547e-10
a O 0 2.0963852875865996e-09
Japanese O 0 1.3856076748197665e-06
family O 0 4.576632406383396e-08
. O 0 2.167792274576641e-07

Polymerase O 0 1.0540704352024477e-05
chain O 0 3.981028555699595e-07
reaction O 0 1.2070814570108723e-08
- O 0 5.007203895956991e-08
single O 0 9.733456707294863e-09
strand O 0 1.1894604412532317e-08
conformational O 0 1.4564229822155994e-09
polymorphism O 0 1.5740539982544988e-09
and O 0 4.650195506439303e-11
direct O 0 2.4792681796448335e-10
sequence O 0 4.837559519632606e-11
analyses O 0 1.0163089259052072e-09
demonstrated O 0 2.5132018688367452e-09
a O 0 1.430952689673859e-09
C O 0 1.3406298648988013e-07
to O 0 1.0153555773939615e-09
T O 0 1.376155367438514e-08
substitution O 0 8.937580453505234e-09
in O 0 1.3215180061365572e-09
exon O 0 3.768550271843196e-08
1 O 0 1.4963919880983667e-08
of O 0 1.6672139224738203e-08
the O 0 1.8173951232824948e-08
CPO O 0 2.0881548152829055e-06
gene O 0 7.174278060517736e-09
at O 0 9.20726428432772e-09
nucleotide O 0 6.5004265081825e-08
position O 0 5.2068472200517135e-08
85 O 0 1.5441375467162288e-07
, O 0 1.2250284120440824e-09
which O 0 1.4230641665058386e-10
lies O 0 5.691719318079436e-10
in O 0 1.292814050257718e-10
the O 0 1.556131223878765e-09
putative O 0 9.945541989964113e-08
presequence O 0 1.2561226867546793e-06
for O 0 8.384269278849388e-09
targeting O 0 1.8079360586398252e-07
to O 0 9.182714677535841e-08
mitochondria O 0 1.2086353308404796e-05
. O 0 2.4245343865914037e-06

This O 0 9.310467952161616e-09
mutation O 0 2.4096820094854365e-09
changes O 0 5.249321533007389e-10
the O 0 1.309714225961045e-09
codon O 0 1.70494818263478e-08
for O 0 9.791136790227029e-10
glutamine O 0 4.73375934006981e-08
to O 0 1.8977446281098764e-09
a O 0 2.894206430070767e-09
termination O 0 4.870052805472369e-08
codon O 0 1.0005877015828446e-07
at O 0 2.6230756233758257e-08
amino O 0 1.3128511611171234e-08
acid O 0 2.9159339831608122e-08
position O 0 1.1650760711745534e-07
29 O 0 3.0875269203534117e-06
. O 0 2.2132660433271667e-06

MaeI O 0 7.45352590456605e-05
restriction O 0 4.6820196075714193e-07
analysis O 0 1.9035605092199148e-08
showed O 0 5.220309073905582e-09
two O 0 9.510384146871331e-11
other O 0 4.736561143303675e-11
carriers O 0 5.574865014068564e-10
in O 0 5.09770503587248e-10
the O 0 1.313835706895361e-08
family O 0 5.256109858464697e-08
. O 0 5.463482466439018e-07

The O 0 1.5536487580902758e-06
C O 1 0.8010531663894653
- O 0 0.00028494902653619647
T O 0 7.4980544013669714e-06
mutation O 0 5.685385939813159e-09
is O 0 6.824733139731975e-11
located O 0 1.3765530382237046e-10
within O 0 2.2943087707449905e-10
a O 0 3.7009326159243017e-10
recently O 0 4.843858647518573e-10
proposed O 0 7.63267504755305e-11
putative O 0 9.528237088218816e-10
alternative O 0 3.6527278979292532e-09
translation O 0 1.1479714068229896e-08
initiation O 0 6.644659045207391e-09
codon O 0 3.168617013216135e-08
( O 0 2.4523534314369044e-09
TIC O 0 1.7118685491368524e-07
- O 0 7.600289819720274e-08
1 O 0 8.797291428663812e-08
) O 0 8.487595626327504e-10
, O 0 2.9984331684218546e-10
supporting O 0 5.650658274625187e-10
that O 0 7.147759467640569e-11
TIC O 0 8.523554129169497e-08
- O 0 1.2035921770348068e-07
1 O 0 3.246773587761709e-07
is O 0 1.2080988431861783e-09
the O 0 2.173643043335005e-09
real O 0 3.418122318521455e-08
TIC O 0 1.3224008625911665e-06
rather O 0 7.049362871214271e-09
than O 0 5.099701549937663e-09
TIC O 0 7.922412805783097e-07
- O 0 6.896016770951974e-07
2 O 0 7.728565378783969e-07
. O 0 2.4363174588870606e-07
. O 0 8.58349096688471e-07

Human B-Disease 0 3.842079365767859e-08
complement I-Disease 0 5.143654107087059e-07
factor I-Disease 0 2.7988247893517837e-05
H I-Disease 1 1.0
deficiency I-Disease 1 0.9794924259185791
associated O 0 7.905650818429422e-06
with O 0 7.855805961298756e-07
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 1 0.9999908208847046

This O 0 4.503863060278945e-09
study O 0 4.636083072995234e-09
reports O 0 3.2054386922553135e-10
on O 0 3.4065336662614243e-10
six O 0 3.3854696823709673e-10
cases O 0 1.2219240896893524e-10
of O 0 1.4965053640736414e-09
deficiency B-Disease 0 1.0659025662107524e-07
in I-Disease 0 2.561646228471659e-09
the I-Disease 0 3.6810534620457247e-09
human I-Disease 0 2.5756963228928953e-10
complement I-Disease 0 2.096544049479121e-10
regulatory I-Disease 0 5.393397950470558e-10
protein I-Disease 0 1.0762652991047617e-09
Factor I-Disease 0 1.2639324253882478e-08
H I-Disease 1 0.5040110945701599
( O 0 8.310981236547832e-09
FH O 0 1.385918267260422e-06
) O 0 2.5104410217302586e-10
in O 0 7.300395704623597e-11
the O 0 6.611983183191228e-11
context O 0 8.584140065437396e-10
of O 0 2.979375079981139e-10
an O 0 5.203962261113304e-10
acute B-Disease 1 0.9997155070304871
renal I-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 6.423440936487168e-05

Five O 0 6.487494630391666e-08
of O 0 4.965942768109244e-09
the O 0 4.2974412917118343e-10
cases O 0 3.7136727720765705e-11
were O 0 9.034407943975253e-11
observed O 0 1.2765562218408633e-10
in O 0 5.7024739097411015e-11
children O 0 2.5123092495249466e-10
presenting O 0 2.3637642954099647e-09
with O 0 1.2775196900349783e-08
idiopathic O 1 1.0
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 0.9795370101928711
HUS B-Disease 1 1.0
) O 0 1.998183279283694e-06
. O 0 3.0475105177174555e-06

Two O 0 5.903797895001617e-09
of O 0 4.809779241554679e-09
the O 0 2.054402870044214e-09
children O 0 7.933264045689725e-10
exhibited O 0 2.659030995388889e-09
a O 0 1.9375685056388647e-08
homozygous O 0 3.4582010357553372e-06
deficiency O 0 6.449568559219188e-07
characterized O 0 3.918685376191888e-09
by O 0 1.6054353679795241e-10
the O 0 3.1404749911700947e-09
absence O 0 1.4190758790277869e-08
of O 0 3.805037618320739e-09
the O 0 6.84221568292287e-10
150 O 0 3.5745972848388874e-09
- O 0 4.98547381155845e-09
kD O 0 2.418146323179826e-07
form O 0 1.2595013920702058e-09
of O 0 1.0077544132514049e-08
Factor O 0 8.621362468375082e-08
H O 1 0.999915599822998
and O 0 5.532177493883239e-10
the O 0 5.70125946453004e-10
presence O 0 5.43059985869121e-10
, O 0 4.411122161984693e-11
upon O 0 5.474779518621631e-10
immunoblotting O 0 6.609395342138669e-08
, O 0 1.8366955178983346e-10
of O 0 4.916629881002166e-10
the O 0 4.912431017523033e-10
42 O 0 6.277935060694517e-09
- O 0 1.8652759337101088e-08
kD O 0 1.473507950322528e-06
Factor O 0 1.1609412098323446e-07
H O 0 0.00014727101370226592
- O 0 2.9593628880775213e-08
like O 0 5.291925786465868e-10
protein O 0 2.284483713310692e-10
1 O 0 7.980543337282597e-09
( O 0 3.3993698966838792e-09
FHL O 0 3.617160700741806e-06
- O 0 9.621252274882863e-07
1 O 0 4.213482043269323e-07
) O 0 4.420728672016594e-09
and O 0 1.7640711114097485e-09
other O 0 1.5835124322904903e-09
FH O 0 7.29461476112192e-07
- O 0 7.660075596049865e-08
related O 0 1.840544250342191e-08
protein O 0 3.400615122828299e-09
( O 0 2.8598385881650756e-09
FHR O 0 1.2307220458751544e-05
) O 0 2.069340077071047e-08
bands O 0 7.988258403202053e-06
. O 0 2.347184363316046e-06

Southern O 0 7.255682248796802e-06
blot O 0 3.137967269140063e-06
and O 0 5.538588698783542e-09
PCR O 0 4.94621659186123e-08
analysis O 0 8.57284965238847e-10
of O 0 1.7403452290398747e-10
DNA O 0 1.4598020570133485e-09
of O 0 6.944995134539056e-10
one O 0 1.955622053184669e-10
patient O 0 7.597475537579612e-09
with O 0 1.247632663847753e-09
homozygous O 0 0.006374977994710207
deficiency O 0 0.22201699018478394
ruled O 0 1.5509189665863232e-07
out O 0 2.9752935670757097e-09
the O 0 2.5120614477458503e-09
presence O 0 9.743110762627794e-10
of O 0 1.1888927620162804e-09
a O 0 2.1583561327087608e-10
large O 0 2.1342562439574664e-10
deletion O 0 1.242138747414856e-08
of O 0 5.691939364282916e-09
the O 0 1.671346616660685e-08
FH O 0 1.5233125850500073e-05
gene O 0 7.051353723142029e-09
as O 0 2.0290629176855646e-09
the O 0 4.778515805270445e-09
underlying O 0 1.8492764866095968e-06
defect O 0 7.55003725316783e-07
for O 0 1.3096998152661854e-08
the O 0 2.622351303216419e-06
deficiency O 1 0.9999995231628418
. O 0 0.00023709122615400702

The O 0 4.6511157592021846e-08
other O 0 1.3384838792873666e-09
four O 0 3.963832040376758e-10
children O 0 1.4186739283328365e-10
presented O 0 7.842185234530064e-10
with O 0 7.838462101616983e-10
heterozygous O 0 8.759799925428524e-07
deficiency O 0 2.0362731447676197e-06
and O 0 4.986443702392762e-09
exhibited O 0 4.666826569632576e-08
a O 0 1.9333923351183557e-09
normal O 0 9.397156830459608e-09
immunoblotting O 0 9.519762755871852e-08
pattern O 0 4.284142485211362e-10
of O 0 8.758256897500871e-10
proteins O 0 1.3189764558330097e-10
of O 0 5.353001153451942e-09
the O 0 7.88215643865442e-08
FH O 0 0.06514899432659149
family O 0 3.5048458357778145e-07
. O 0 1.6562195241931477e-06

Factor B-Disease 1 0.9992735981941223
H I-Disease 1 1.0
deficiency I-Disease 1 0.6190023422241211
is O 0 9.978995407777802e-10
the O 0 1.0078884393749377e-09
only O 0 5.26812060641646e-09
complement B-Disease 1 1.0
deficiency I-Disease 1 1.0
associated O 0 2.2516990156873362e-06
with O 0 3.539577164701768e-08
HUS B-Disease 1 1.0
. O 0 0.00028903436032123864

These O 0 6.841307964577936e-08
observations O 0 5.542596426266755e-08
suggest O 0 2.834943169105486e-09
a O 0 3.9259176465300527e-10
role O 0 1.7968514454125284e-09
for O 0 3.591765329602481e-09
FH O 1 0.8985324501991272
and O 0 1.7968097836273955e-06
/ O 1 0.9999343156814575
or O 0 9.78458956524264e-07
FH O 0 1.5242440895235632e-05
receptors O 0 1.1083691298097165e-08
in O 0 2.507131169338095e-09
the O 0 1.0876012090932363e-08
pathogenesis O 0 0.0001672577200224623
of O 0 2.8957160225218104e-07
idiopathic O 1 0.9994152784347534
HUS B-Disease 1 1.0
. O 0 1.2829499382860376e-06
. O 0 1.4850819525236147e-06

Further O 0 7.348813824137324e-08
evidence O 0 6.285518772131127e-09
for O 0 5.194145114018056e-10
a O 0 7.045004579708802e-10
major O 0 3.90994259191757e-09
ancient O 0 1.4791552302995115e-06
mutation O 0 6.304892394837225e-06
underlying O 1 0.837932288646698
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
from O 0 2.5594701469344727e-07
linkage O 0 2.928037190486066e-07
disequilibrium O 0 6.72274211410695e-07
studies O 0 7.924179534768427e-09
in O 0 2.006945581944919e-10
the O 0 6.663756768610085e-10
Japanese O 0 6.689511877766563e-08
population O 0 6.179446399023902e-10
. O 0 5.796613411490625e-09

The O 0 8.671321847941726e-05
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 2.55945651588263e-05
DM B-Disease 1 1.0
) O 0 2.450624592142958e-08
mutation O 0 6.235177707480943e-09
is O 0 1.0403022887572888e-10
an O 0 8.953609381689986e-11
unstable O 0 6.348523839960762e-08
( O 0 9.703983394615534e-09
CTG O 0 1.2170846730441554e-06
) O 0 7.109745570055281e-10
n O 0 1.7820692699288543e-09
repeat O 0 1.947898509158108e-09
, O 0 1.7272233643339518e-10
present O 0 5.537748384853991e-11
at O 0 2.809202037656888e-10
a O 0 9.598055683568418e-11
copy O 0 3.365949075018193e-09
number O 0 1.976373509293694e-10
of O 0 2.5773572165377345e-10
5 O 0 1.8558636849519417e-09
- O 0 2.1128524707592078e-08
37 O 0 1.2518380110293492e-08
repeats O 0 1.3307910329274364e-09
on O 0 6.915386596695328e-10
normal O 0 1.5898041771933435e-09
chromosomes O 0 4.772346962056417e-10
but O 0 1.932071724830564e-10
amplified O 0 3.5819837762574025e-08
to O 0 3.231597656139229e-09
50 O 0 5.63538051778778e-08
- O 0 1.4034736750545562e-07
3000 O 0 2.2351916584284481e-07
copies O 0 9.937085110323096e-08
on O 0 2.5421451255169814e-07
DM B-Disease 1 0.9999994039535522
chromosomes O 0 2.8635029138968093e-06
. O 0 3.939178895961959e-06

Previous O 0 2.863492341020901e-07
findings O 0 2.5673021042393884e-08
in O 0 6.2672717016099e-10
Caucasian O 0 2.2108658015440597e-08
populations O 0 7.048687189481484e-10
of O 0 9.57659174183334e-10
a O 0 9.333511741260736e-09
DM B-Disease 1 1.0
founder O 0 2.9720547900069505e-05
chromosome O 0 1.9266683182195266e-07
raise O 0 4.925878371864201e-09
a O 0 2.1859871690566024e-09
question O 0 2.14174478152529e-09
about O 0 6.614809394678289e-11
the O 0 1.1100859814705544e-10
molecular O 0 5.191708729590516e-10
events O 0 7.549250113925154e-11
involved O 0 7.597235340828234e-11
in O 0 3.8606681740382953e-10
the O 0 4.144636633895971e-09
expansion O 0 4.044106276523962e-07
mutation O 0 2.1611063516502327e-07
. O 0 2.950866928586038e-07

To O 0 7.861017081722821e-08
investigate O 0 1.4243853208029122e-08
whether O 0 2.045511315884596e-09
a O 0 4.8923483042528915e-09
founder O 0 1.647080836164605e-07
chromosome O 0 2.356077644094512e-08
for O 0 1.758967527187849e-09
the O 0 2.5184526464272494e-08
DM B-Disease 1 1.0
mutation O 0 7.370892340929913e-09
exists O 0 2.1097093516608822e-10
in O 0 3.2484282624922756e-11
the O 0 1.2200353227687089e-10
Japanese O 0 2.099523399579084e-08
population O 0 7.718464062334007e-11
, O 0 6.050624584696962e-11
we O 0 2.906990204110116e-10
genotyped O 0 3.447935270628477e-08
families O 0 2.4578311608181025e-10
using O 0 6.033099575475376e-10
polymorphic O 0 1.842771446547431e-08
markers O 0 2.1878735267932825e-08
near O 0 1.0789052851123415e-07
the O 0 3.013428795384243e-08
( O 0 3.575362583774222e-08
CTG O 0 5.724125003325753e-06
) O 0 6.378878314450276e-09
n O 0 3.298695006037633e-08
repeat O 0 5.3873474570309554e-08
region O 0 9.017978896963541e-08
and O 0 2.1685918838443285e-08
constructed O 0 2.231541884611943e-06
haplotypes O 0 1.4286360965343192e-05
. O 0 1.4655270206276327e-06

Six O 0 1.8131905221707711e-07
different O 0 2.950085065123176e-09
haplotypes O 0 1.4023216010627948e-07
were O 0 8.330232503794832e-09
found O 0 1.8270144286347545e-09
and O 0 8.57381987628969e-09
DM B-Disease 1 1.0
alleles O 0 9.971545722464725e-08
were O 0 8.523927874648507e-08
always O 0 9.951519786000063e-08
haplotype O 0 1.5088812688190956e-06
A O 0 1.3308393818078912e-06
. O 0 1.856388735177461e-06

To O 0 4.439776901676851e-08
find O 0 5.322377205629891e-09
an O 0 7.114123179441378e-11
origin O 0 4.430298072843897e-10
of O 0 1.4538583670287153e-09
the O 0 3.901911238557432e-09
( O 0 1.207606548092599e-08
CTG O 0 2.521712758607464e-06
) O 0 2.5506570189293143e-09
n O 0 9.221535535175462e-09
repeat O 0 1.046628295142682e-08
mutation O 0 2.1298451891027526e-09
and O 0 3.288552485880558e-10
to O 0 1.1185583570494373e-09
investigate O 0 2.147884980985282e-09
the O 0 8.859028510777023e-10
mechanism O 0 3.0015947061201587e-08
of O 0 2.7627826693077395e-09
the O 0 3.5169353540531745e-10
expansion O 0 2.0429185010328865e-09
mutation O 0 6.173894728789264e-11
in O 0 1.0316490717254823e-11
the O 0 1.9660894440276522e-11
Japanese O 0 1.6393253421398413e-09
population O 0 4.003482875075681e-12
we O 0 8.86696532170772e-12
have O 0 1.676030321473565e-11
studied O 0 1.6617714981848053e-09
90 O 0 7.772690935325954e-09
Japanese O 0 1.3668516203324543e-06
DM B-Disease 1 1.0
families O 0 9.481849083670113e-09
comprising O 0 3.934142789319139e-09
190 O 0 9.974089998365798e-09
affected O 0 1.5523424767849292e-09
and O 0 1.87101889537189e-09
130 O 0 1.5272456721504568e-07
unaffected O 0 3.1722004223411204e-07
members O 0 4.450705759495577e-08
. O 0 5.068170594313415e-07

The O 0 1.6229763843966794e-07
results O 0 1.0045342335729401e-08
suggest O 0 4.817657384137419e-09
that O 0 6.360526688675705e-11
a O 0 4.899452510365165e-10
few O 0 1.1559334600619309e-09
common O 0 2.2847550518179105e-09
ancestral O 0 1.7725950485214526e-08
mutations O 0 1.4960545025033412e-09
in O 0 2.2747874417472502e-10
both O 0 7.414925340398781e-10
Caucasian O 0 4.1820001683845476e-08
and O 0 3.617216304263593e-09
Japanese O 0 4.823190238312236e-07
populations O 0 1.3193715564518982e-10
have O 0 2.5362012837093495e-12
originated O 0 1.0976465396328461e-11
by O 0 6.228983258013687e-13
expansion O 0 3.0388044858220553e-10
of O 0 4.198115466369501e-10
an O 0 3.1613985734813e-11
ancestral O 0 2.4534483333837898e-09
n O 0 1.1753420459115205e-09
= O 0 2.1000190475461977e-09
5 O 0 1.7547052699740107e-09
repeat O 0 3.333594511545357e-09
to O 0 1.901629076428435e-09
n O 0 1.2802199300665507e-08
= O 0 6.276093245105585e-08
19 O 0 9.501024322844387e-08
- O 0 7.019110626060865e-07
37 O 0 3.860127719690354e-07
copies O 0 1.9623630578280427e-06
. O 0 1.8608856180435396e-06

These O 0 4.2565677205175234e-08
data O 0 1.7204913049795323e-08
support O 0 2.5576136764016155e-09
multistep O 0 3.229947864724636e-08
models O 0 1.1553211720638501e-08
of O 0 1.6085358822692797e-08
triplet O 0 3.5399290254645166e-07
repeat O 0 1.904791879780987e-08
expansion O 0 1.3901082951406352e-08
that O 0 7.587243333606608e-11
have O 0 1.884102596161341e-11
been O 0 1.1652760353864089e-11
proposed O 0 2.161514890686167e-11
for O 0 1.1773967911743455e-10
both O 0 4.518352358928723e-09
DM B-Disease 1 1.0
and O 0 3.04262925965304e-06
Friedreichs B-Disease 1 0.9999735355377197
ataxia I-Disease 1 0.811882734298706
. O 0 2.150070486095501e-06
. O 0 3.151243618049193e-06

The O 0 2.6334426195262495e-08
molecular O 0 2.9249019206645244e-08
basis O 0 2.9775033993928446e-08
of O 0 1.723055106594984e-06
C6 B-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 2.7832580684616914e-08
the O 0 4.043339885129171e-09
western O 0 3.965817185758169e-08
Cape O 0 8.780544646924682e-08
, O 0 7.088703513069561e-10
South O 0 1.8962186487669896e-08
Africa O 0 5.678366221673059e-08
. O 0 3.278616489410524e-08

Deficiency B-Disease 0 0.0032755641732364893
of I-Disease 0 6.100596579017292e-07
the I-Disease 0 6.062462176714689e-08
sixth I-Disease 0 1.8161497905566648e-07
component I-Disease 0 4.867050762413783e-09
of I-Disease 0 3.497755973747019e-10
human I-Disease 0 1.2496127396732781e-11
complement I-Disease 0 1.5736217884310122e-09
( O 0 6.962294296641858e-09
C6 O 1 1.0
) O 0 5.665262481358013e-09
has O 0 1.4828605010563933e-10
been O 0 4.119216079345733e-11
reported O 0 1.2013742431427055e-11
in O 0 5.21630004815532e-12
a O 0 1.699685704681375e-11
number O 0 2.955071604082704e-11
of O 0 2.091853773533714e-11
families O 0 6.043401022670647e-12
from O 0 9.493288967432623e-12
the O 0 9.501518322130309e-11
western O 0 6.878608793670082e-09
Cape O 0 1.3421649214251374e-07
, O 0 2.4746678040088455e-09
South O 0 4.903056094462954e-08
Africa O 0 1.512526353053545e-07
. O 0 1.1710702807476991e-07

Meningococcal B-Disease 1 1.0
disease I-Disease 0 0.3304431736469269
is O 0 6.593071644189763e-10
endemic O 0 1.9928585170969626e-10
in O 0 1.876449169657679e-11
the O 0 4.429486777368652e-10
Cape O 0 8.74594547894958e-08
and O 0 3.306527829316508e-10
almost O 0 3.202187681683455e-10
all O 0 3.5190808600482626e-11
pedigrees O 0 1.514602110397334e-09
of O 0 1.2347611821894589e-09
total O 0 3.9285549746637116e-07
C6 B-Disease 1 1.0
deficiency I-Disease 1 1.0
( O 0 1.5411393405884155e-07
C6Q0 O 1 0.6104652285575867
) O 0 1.0288342400244233e-09
have O 0 1.1343969513744057e-10
been O 0 9.268961292940858e-11
ascertained O 0 5.499041666467974e-09
because O 0 2.339890226021879e-10
of O 0 1.1378652686744317e-08
recurrent O 0 0.3643355071544647
disease O 0 0.0007775142439641058
. O 0 4.951238565809035e-07

We O 0 7.805780199987566e-08
have O 0 3.0371603010337367e-09
sequenced O 0 1.970195384615181e-08
the O 0 3.5951785992693885e-09
expressed O 0 3.878479315488903e-09
exons O 0 2.5487469912377492e-08
of O 0 2.0739621131582453e-09
the O 0 2.426317369241815e-09
C6 O 0 1.5678613635827787e-05
gene O 0 2.6762796423440705e-09
from O 0 3.510869928113891e-10
selected O 0 7.870296081513573e-10
cases O 0 8.706220466780934e-11
and O 0 7.205028934587077e-11
have O 0 1.5277853981920941e-10
found O 0 8.289901404223698e-11
three O 0 4.1184385762838005e-11
molecular O 0 2.752485528390025e-08
defects O 0 4.2214739437440585e-07
leading O 0 1.913381453277907e-08
to O 0 1.8801482593033825e-09
total O 0 1.2619167932825803e-07
deficiency O 0 0.005255389958620071
879delG O 0 3.349434791743988e-07
, O 0 2.4973934031891076e-10
which O 0 1.165087123999875e-11
is O 0 3.160667257431915e-12
the O 0 4.115093335532727e-11
common O 0 1.2245097158469775e-09
defect O 0 2.992083381059274e-08
in O 0 4.3792014459143047e-10
the O 0 4.064200531672668e-09
Cape O 0 7.777104542583402e-07
and O 0 1.0854018794859144e-09
hitherto O 0 7.57901048586973e-08
unreported O 0 6.89271395515334e-09
, O 0 3.3341763377991995e-11
and O 0 3.526673744702613e-11
1195delC O 0 1.0724217069935094e-08
and O 0 1.3241691076970596e-10
1936delG O 0 1.2576464314406621e-08
, O 0 4.091871633193911e-11
which O 0 3.3776746590635787e-12
have O 0 4.569165792250862e-12
been O 0 1.2924854762841331e-11
previously O 0 7.228401904812998e-11
reported O 0 2.6778699049878618e-11
in O 0 1.1621890949609082e-10
African O 0 4.520311236433372e-08
- O 0 1.1642057415883755e-06
Americans O 0 8.225743499679083e-07
. O 0 8.272646709883702e-07

We O 0 2.168183073081309e-07
also O 0 9.331197148298997e-09
show O 0 1.4276866355800166e-09
that O 0 4.539234266243142e-11
the O 0 5.795040558531639e-10
879delG O 0 1.604675503585895e-07
and O 0 3.95668120489745e-09
1195delC O 0 1.0620382226989022e-06
defects O 0 2.189047023648527e-07
are O 0 9.791319144358823e-11
associated O 0 1.8617704045098549e-09
with O 0 2.918590646938668e-10
characteristic O 0 8.470591637887992e-06
C6 O 1 1.0
/ O 1 0.9999998807907104
C7 O 1 0.9975873231887817
region O 0 8.529276556146215e-07
DNA O 0 7.110578508218168e-07
marker O 0 3.1903095987217966e-07
haplotypes O 0 9.300744352458423e-08
, O 0 5.434869221332406e-10
although O 0 1.8667048462539526e-10
small O 0 2.2132094767979282e-10
variations O 0 4.36944169734943e-09
were O 0 1.1054556381395741e-08
observed O 0 3.5002219789248556e-08
. O 0 2.7225470944358676e-07

The O 0 1.1467704297274395e-07
1936delG O 0 2.7001490252587246e-06
defect O 0 1.7218657148987404e-06
was O 0 1.2341991428854726e-08
observed O 0 1.4768716249946579e-09
only O 0 6.203404456783801e-11
once O 0 8.463891393306611e-11
in O 0 3.6388999452574566e-11
the O 0 2.750719096944465e-10
Cape O 0 1.8920674804689952e-08
, O 0 7.057508744079399e-11
but O 0 1.8547966981752317e-11
its O 0 3.6611359777172225e-11
associated O 0 3.53285778409429e-09
haplotype O 0 4.6266954711882136e-08
could O 0 3.413468618873594e-09
be O 0 7.931650003456525e-09
deduced O 0 1.288659404963255e-06
. O 0 1.3702409660254489e-06

The O 0 9.781290088994865e-08
data O 0 3.960208516673447e-08
from O 0 2.4045720969922968e-09
the O 0 5.229417787688817e-09
haplotypes O 0 1.4962583350097702e-07
indicate O 0 3.128386660833371e-09
that O 0 1.158866058670327e-11
these O 0 2.085217068459322e-11
three O 0 7.997601886300387e-11
molecular O 0 2.7353390663620303e-09
defects O 0 2.8595987799917566e-09
account O 0 7.477183455728564e-11
for O 0 8.543447893583078e-11
the O 0 2.0426964564279615e-09
defects O 0 9.744501312525244e-07
in O 0 2.043873514878669e-09
all O 0 1.1266949595523101e-09
the O 0 2.746840754852542e-09
38 O 0 2.4397392550667973e-08
unrelated O 0 8.5141413919132e-09
C6Q0 O 0 2.7691287414199905e-06
individuals O 0 9.532340194962075e-11
we O 0 6.380919126414142e-10
have O 0 2.785374431102383e-10
studied O 0 1.345497846472199e-08
from O 0 3.5392919706112025e-09
the O 0 2.8333067447761096e-08
Cape O 0 9.71114423009567e-06
. O 0 1.3145660204827436e-06

We O 0 1.1514991626881965e-07
have O 0 5.278681491915904e-09
also O 0 7.321482864419693e-10
observed O 0 7.449514338730978e-10
the O 0 5.467026276129161e-10
879delG O 0 1.7551286646266817e-07
defect O 0 9.454673488562548e-08
in O 0 1.4481351673367726e-09
two O 0 4.483207138861189e-09
Dutch O 1 0.9999997615814209
C6 B-Disease 1 1.0
- I-Disease 1 1.0
deficient I-Disease 1 1.0
kindreds O 0 2.174668225052301e-05
, O 0 9.210210927257378e-10
but O 0 2.9188006178682e-11
the O 0 1.4301607120792426e-10
879delG O 0 2.3654433078945658e-08
defect O 0 1.5165452893484144e-08
in O 0 1.75598993679138e-10
the O 0 9.345940688021415e-10
Cape O 0 2.419569682388101e-07
probably O 0 5.818090897946604e-09
did O 0 2.94310881221449e-10
not O 0 2.790978038957892e-11
come O 0 1.690220602368342e-10
from O 0 1.9622241331784807e-10
The O 0 2.1903818758772786e-09
Netherlands O 0 2.080586511965521e-07
. O 0 3.20314370583219e-08
. O 0 3.608322458603652e-07

Complement B-Disease 1 1.0
C7 I-Disease 1 1.0
deficiency I-Disease 1 1.0
: O 0 2.156881322434856e-07
seven O 0 1.151361495033143e-08
further O 0 2.3004795846048864e-09
molecular O 0 1.713280539661355e-08
defects O 0 5.543040870747973e-08
and O 0 5.629487431768609e-10
their O 0 7.432614079760924e-09
associated O 0 3.146909875795245e-06
marker O 0 1.6313233572873287e-05
haplotypes O 0 2.001650136662647e-05
. O 0 3.817648575932253e-06

Seven O 0 2.456882555179618e-07
further O 0 1.1265515631464496e-08
molecular O 0 3.967701189822037e-08
bases O 0 2.987572997881216e-07
of O 0 7.36732818040764e-06
C7 B-Disease 1 1.0
deficiency I-Disease 1 1.0
are O 0 1.9490744307404384e-07
described O 0 5.21026493061072e-07
. O 0 5.068518476036843e-07

All O 0 8.875611712255704e-08
these O 0 3.405184134663841e-09
new O 0 4.714330703592395e-09
molecular O 0 5.99479292873184e-08
defects O 0 4.2862392746201294e-08
involve O 0 1.8820285330178876e-09
single O 0 4.8769939198223256e-09
- O 0 2.7604453833873777e-08
nucleotide O 0 1.0077317114109974e-07
events O 0 9.48852463267258e-09
, O 0 2.3155173334288293e-09
deletions O 0 5.6900429257211727e-08
and O 0 1.5624481708442772e-09
substitutions O 0 7.353006026278308e-08
, O 0 7.713597538483441e-10
some O 0 1.7844049848836363e-10
of O 0 1.464040333409855e-09
which O 0 8.019750835641659e-11
alter O 0 6.404235364243505e-09
splice O 0 2.504822020910069e-07
sites O 0 1.8574015214767314e-08
, O 0 1.5237234807230493e-09
and O 0 6.021009468781813e-09
others O 0 1.1662777410492708e-07
codons O 0 3.860627657559235e-06
. O 0 1.7868865143100265e-06

They O 0 6.658095941247666e-08
are O 0 6.478709790869175e-10
distributed O 0 7.717202432644399e-10
along O 0 8.405240392583835e-10
the O 0 3.4592038122838176e-09
C7 O 0 3.915103297913447e-05
gene O 0 7.233815324525494e-09
, O 0 6.173119793118076e-10
but O 0 7.265694990099547e-11
predominantly O 0 8.883491858791004e-11
towards O 0 5.721019213922318e-10
the O 0 5.936144353846373e-10
3 O 0 1.7507611360656483e-08
end O 0 5.424062692327425e-07
. O 0 1.1367349088686751e-06

All O 0 7.823233971748778e-08
were O 0 3.4038354357335265e-08
found O 0 5.3266830946085975e-09
in O 0 2.1350026191413463e-09
compound O 0 5.011522716813488e-07
heterozygous O 0 2.8333662527302295e-08
individuals O 0 2.6235498218341036e-09
. O 0 2.2828946555364382e-07

The O 0 1.132877696363721e-05
C6 O 1 1.0
/ O 1 0.9999938011169434
C7 O 1 0.9997557997703552
marker O 0 9.657456757850014e-06
haplotypes O 0 1.3301187209435739e-06
associated O 0 4.516605400795015e-08
with O 0 9.764523634103739e-10
most O 0 3.956025906859395e-08
C7 B-Disease 1 1.0
defects I-Disease 0 0.12354899197816849
are O 0 2.1725954368889688e-08
tabulated O 0 5.24502361543e-08
. O 0 3.20975495071707e-08
. O 0 3.8349122633007937e-07

A O 0 7.350705573117011e-07
genome O 0 5.8942145386708944e-08
- O 0 8.632304826505788e-08
wide O 0 5.032939398574854e-09
search O 0 2.814115829252728e-09
for O 0 1.7503221094727905e-10
chromosomal O 0 7.247379585351155e-08
loci O 0 3.802790260465372e-08
linked O 0 7.91968020052991e-08
to O 0 5.0936548312563446e-09
mental O 1 0.9992519021034241
health O 0 4.964259403550386e-08
wellness O 0 3.621146049681556e-08
in O 0 6.847529765430238e-10
relatives O 0 5.9317675216163934e-09
at O 0 3.1255835697407974e-09
high O 0 2.843217146164534e-07
risk O 0 1.5900066500762478e-05
for O 0 0.00037098664324730635
bipolar B-Disease 1 1.0
affective I-Disease 1 1.0
disorder I-Disease 1 0.9999992847442627
among O 0 4.7087858057182075e-09
the O 0 3.858078745366811e-09
Old O 0 1.5585624169034418e-07
Order O 0 4.4431658352550585e-07
Amish O 0 2.2736894607078284e-05
. O 0 1.1398547030694317e-06

Bipolar B-Disease 1 1.0
affective I-Disease 1 1.0
disorder I-Disease 1 1.0
( O 0 2.3639743176318007e-06
BPAD B-Disease 1 1.0
; O 1 0.7664486765861511
manic B-Disease 1 1.0
- I-Disease 1 1.0
depressive I-Disease 1 1.0
illness I-Disease 1 1.0
) O 0 1.4166303685669845e-09
is O 0 3.9843413290885366e-11
characterized O 0 6.350186348980102e-11
by O 0 1.6041307171477115e-11
episodes O 0 2.6669138009083326e-09
of O 0 1.2649044478507676e-08
mania B-Disease 0 1.3504595699487254e-06
and O 0 2.405096211077762e-08
/ O 0 0.33050522208213806
or O 0 1.0898646678469959e-06
hypomania B-Disease 0 9.26475549931638e-05
interspersed O 0 5.898215249544592e-09
with O 0 3.597136477573315e-11
periods O 0 6.278931152792211e-08
of O 0 4.3925066250949385e-08
depression B-Disease 0 6.071180450817337e-06
. O 0 1.1162298818589989e-07

Compelling O 0 5.0891117098217364e-06
evidence O 0 1.8487321540305857e-07
supports O 0 1.0488625967752796e-08
a O 0 7.902411502946904e-10
significant O 0 1.357828072201528e-09
genetic O 0 4.749574511464516e-09
component O 0 6.218905834742827e-09
in O 0 4.323107982706631e-10
the O 0 2.397418930044637e-09
susceptibility O 0 3.082432158407755e-07
to O 0 4.474897252748633e-08
develop O 0 3.593319343053736e-05
BPAD B-Disease 1 1.0
. O 0 0.001575932838022709

To O 0 2.8682856978434756e-08
date O 0 7.11581620294055e-08
, O 0 2.5099156086838548e-09
however O 0 1.0813847595159132e-09
, O 0 2.9217545050030935e-10
linkage O 0 2.2829963697290623e-08
studies O 0 2.0639623343754465e-09
have O 0 7.536905821670103e-11
attempted O 0 5.122356760978164e-09
only O 0 2.1516727288783954e-10
to O 0 9.326637240292257e-10
identify O 0 1.4448692908786143e-08
chromosomal O 0 1.098886173167557e-06
loci O 0 5.897509325336614e-08
that O 0 4.021341593052341e-10
cause O 0 3.1447426884767538e-09
or O 0 1.624774897956982e-10
increase O 0 2.714765356959248e-10
the O 0 6.279788355989524e-10
risk O 0 6.423674481226271e-09
of O 0 2.3957014150255418e-08
developing O 0 4.147824256506283e-06
BPAD B-Disease 1 1.0
. O 0 2.59267781075323e-05

To O 0 3.464620235149596e-08
determine O 0 6.4630873986004644e-09
whether O 0 1.356945222852346e-09
there O 0 8.117447825028989e-10
could O 0 2.687856159866442e-09
be O 0 1.5921345353220318e-09
protective O 0 1.0199042321801244e-07
alleles O 0 5.134199732026445e-10
that O 0 1.658169955509603e-11
prevent O 0 1.8162080173134143e-10
or O 0 6.981941413908288e-11
reduce O 0 5.777162082054588e-10
the O 0 2.498451168175819e-10
risk O 0 1.4189613928294875e-09
of O 0 4.999135549965672e-10
developing O 0 1.139389826931847e-08
BPAD B-Disease 1 1.0
, O 0 1.9599760703314928e-10
similar O 0 3.747628596340036e-11
to O 0 5.569887606693413e-11
what O 0 3.6245749457375354e-11
is O 0 4.6553047874930975e-12
observed O 0 5.667829053312978e-11
in O 0 6.91589771562029e-11
other O 0 9.280398671762669e-09
genetic B-Disease 1 1.0
disorders I-Disease 1 1.0
, O 0 8.404326679034568e-10
we O 0 4.692662369798484e-10
used O 0 3.095977874068012e-08
mental O 0 5.460442480398342e-06
health O 0 9.567139969135496e-09
wellness O 0 2.8745290592269157e-08
( O 0 3.488494770831352e-10
absence O 0 4.837601430551786e-09
of O 0 2.7956479353719033e-09
any O 0 1.0741371347933182e-08
psychiatric B-Disease 1 1.0
disorder I-Disease 0 1.1897555850737263e-05
) O 0 1.2658708803403584e-10
as O 0 2.510738006389346e-10
the O 0 5.680981796096773e-10
phenotype O 0 3.196325204513073e-09
in O 0 5.889286835980556e-10
our O 0 5.721436657779577e-09
genome O 0 8.30565660692173e-09
- O 0 1.1352166495726124e-07
wide O 0 3.323469854876748e-08
linkage O 0 5.748314606535132e-07
scan O 0 7.833729114281596e-07
of O 0 1.5955402332679114e-08
several O 0 1.7479908631656826e-09
large O 0 3.86607856839305e-09
multigeneration O 0 2.46482022703276e-06
Old O 0 1.08729047099132e-07
Order O 0 7.905237708882851e-08
Amish O 0 1.933159182954114e-06
pedigrees O 0 2.6895352789324534e-07
exhibiting O 0 1.5599923131048854e-08
an O 0 2.9310420757155953e-10
extremely O 0 6.0107621102645226e-09
high O 0 8.376472493409892e-08
incidence O 0 2.8166627998871263e-06
of O 0 4.533013452601153e-06
BPAD B-Disease 1 1.0
. O 0 0.00020748980750795454

We O 0 2.924389832514862e-07
have O 0 5.9221472170634115e-09
found O 0 6.413007902494883e-10
strong O 0 6.262372842513741e-10
evidence O 0 1.1100018681986512e-09
for O 0 1.542542898969046e-10
a O 0 1.1408375355514977e-09
locus O 0 3.3603317461938786e-08
on O 0 1.614846922848301e-08
chromosome O 0 6.186475047798012e-07
4p O 0 0.00017572044453117996
at O 0 1.1687529166692912e-07
D4S2949 O 0 1.3393753306445433e-06
( O 0 1.4209059484571185e-09
maximum O 0 3.607681975381638e-08
GENEHUNTER O 0 3.0628975764557254e-06
- O 0 1.983715804954045e-07
PLUS O 0 4.706628828898829e-07
nonparametric O 0 3.265336374624894e-07
linkage O 0 2.7919087486338867e-08
score O 0 3.761338795982283e-09
= O 0 4.4448924541029555e-09
4 O 0 3.39917516356536e-09
. O 0 3.2238267611006677e-10
05 O 0 2.1925382043264108e-07
, O 0 1.784630443424362e-09
P O 0 4.698049949070082e-08
= O 0 6.119945439309049e-09
5 O 0 1.806321647812581e-09
. O 0 2.294229944910242e-10
22 O 0 1.9080161894891035e-09
x O 0 1.488989465059376e-08
10 O 0 3.2433673524678852e-09
( O 0 7.631951182140995e-10
- O 0 6.808763686194652e-08
4 O 0 7.037033356027678e-08
) O 0 2.219543215886688e-09
; O 0 3.214348343050233e-09
SIBPAL O 0 5.3585172281600535e-06
Pempirical O 0 1.3675057175532856e-07
value O 0 1.1839347280329093e-09
< O 0 2.094387951956378e-08
3 O 0 3.6246612378221243e-09
x O 0 1.6261378021908968e-08
10 O 0 3.867103970378594e-09
( O 0 7.624952336193758e-10
- O 0 3.28952189931897e-08
5 O 0 2.4836486645085643e-08
) O 0 2.1820005802197784e-09
) O 0 9.30130417131636e-10
and O 0 7.366446896917012e-10
suggestive O 0 2.4862933045710633e-08
evidence O 0 6.735764168652736e-10
for O 0 1.1116242648601116e-10
a O 0 1.113959591236835e-09
locus O 0 2.4234280360246885e-08
on O 0 1.3060128978281682e-08
chromosome O 0 3.9421973951903055e-07
4q O 0 1.3783286476609646e-06
at O 0 1.927888249042553e-08
D4S397 O 0 1.2465674217310152e-06
( O 0 3.5439327028541356e-09
maximum O 0 6.822843090503738e-08
GENEHUNTER O 0 3.822989583568415e-06
- O 0 2.9742972174062743e-07
PLUS O 0 8.412046099692816e-07
nonparametric O 0 3.8033056171116186e-07
linkage O 0 2.687088773711821e-08
score O 0 5.501412214670154e-09
= O 0 3.4197311649108997e-09
3 O 0 1.5203965864074576e-09
. O 0 2.0229061481469301e-10
29 O 0 6.849178557644109e-09
, O 0 5.767253341559808e-10
P O 0 2.4282815758169818e-08
= O 0 4.753788918065993e-09
2 O 0 2.476419513897099e-09
. O 0 2.7657970358418993e-10
57 O 0 2.984011704398881e-09
x O 0 1.1432538471467524e-08
10 O 0 2.7671758218161813e-09
( O 0 5.364496624693516e-10
- O 0 3.013411387087217e-08
3 O 0 2.651425567989918e-08
) O 0 1.6371692890260192e-09
; O 0 1.44751377550989e-09
SIBPAL O 0 3.7204392810963327e-06
Pempirical O 0 1.4376756496403686e-07
value O 0 8.481139124327797e-10
< O 0 1.4210584708962415e-08
1 O 0 3.0033109332805452e-09
x O 0 2.553637479252302e-08
10 O 0 2.6985049750294365e-09
( O 0 3.1381142129305317e-10
- O 0 2.373460539217831e-08
3 O 0 1.6044085171529332e-08
) O 0 6.199479818391751e-10
) O 0 1.4771976697414146e-10
that O 0 2.116007195851477e-11
are O 0 1.0058139043866987e-10
linked O 0 3.616155552776945e-08
to O 0 2.0852320758990572e-08
mental O 1 0.9997217059135437
health O 0 7.0535879785893485e-06
wellness O 0 2.168242099287454e-05
. O 0 9.19127273846243e-07

These O 0 2.9503398835117878e-08
findings O 0 1.2350562350604832e-08
are O 0 2.0443792492219615e-10
consistent O 0 3.5675475906771226e-09
with O 0 3.652111252305801e-11
the O 0 8.455134370422002e-10
hypothesis O 0 3.658989333743534e-09
that O 0 5.20872407705486e-12
certain O 0 1.1169418168144318e-10
alleles O 0 2.450028513401037e-10
could O 0 4.934198050143834e-10
prevent O 0 4.31455982052853e-09
or O 0 1.919305603337307e-09
modify O 0 3.909892143383331e-08
the O 0 8.609494450695365e-09
clinical O 0 1.8542924351550027e-07
manifestations O 0 4.5278444105179005e-08
of O 0 1.810665395396427e-08
BPAD B-Disease 1 1.0
and O 0 9.170284087645086e-09
perhaps O 0 9.56644718996813e-09
other O 0 1.021729700845242e-09
related O 0 2.653295325671934e-07
affective B-Disease 0 0.0005329631385393441
disorders I-Disease 1 0.999995231628418
. O 0 3.159867901558755e-06

Segregation O 0 0.00011963780707446858
distortion O 0 0.0009558575693517923
in O 0 1.3665811820828822e-05
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 0.00034529200638644397

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.04070127382874489
DM B-Disease 1 1.0
) O 0 2.2838636937194678e-07
is O 0 8.86031781277552e-09
an O 0 1.3401526111067597e-08
autosomal B-Disease 1 0.9999991655349731
dominant I-Disease 1 0.9713720679283142
disease I-Disease 1 0.6215954422950745
which O 0 2.2498372956314405e-11
, O 0 7.0338799888769454e-12
in O 0 1.4505165298051015e-11
the O 0 1.1901378493828219e-10
typical O 0 2.23572294011376e-09
pedigree O 0 1.7417873809932871e-09
, O 0 8.768364506694937e-11
shows O 0 2.0715297532891697e-10
a O 0 4.92334950585871e-10
three O 0 1.0515341930528166e-09
generation O 0 5.819025545861223e-07
anticipation O 0 1.8093850258082966e-06
cascade O 0 4.552604423224693e-06
. O 0 1.2821279824493104e-06

This O 0 1.5063170266671477e-08
results O 0 1.2611823585473303e-08
in O 0 1.800035498433772e-08
infertility B-Disease 1 0.9999988079071045
and O 0 0.0014918638626113534
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 3.543765458857706e-08
CDM B-Disease 0 1.7533301388539257e-07
) O 0 9.268624756586519e-11
with O 0 1.7477224528716917e-11
the O 0 2.9966165104866604e-09
disappearance O 0 1.0032516684077564e-07
of O 0 8.559297270949173e-08
DM B-Disease 1 1.0
in O 0 4.167528686593869e-07
that O 0 2.591729852952085e-08
pedigree O 0 1.2787796777047333e-06
. O 0 4.7160867211459845e-07

The O 0 1.56567097064908e-08
concept O 0 6.491133319741493e-08
of O 0 9.297087544268834e-09
segregation O 0 1.0235972780492375e-07
distortion O 0 3.1875666195446684e-07
, O 0 3.876391985180305e-10
where O 0 1.1864004223482993e-10
there O 0 1.3706052785777967e-11
is O 0 5.712050624162579e-12
preferential O 0 1.5711054679456993e-09
transmission O 0 3.1109403941798064e-09
of O 0 1.3873766580019264e-09
the O 0 4.2446296477649526e-10
larger O 0 4.412436804823727e-10
allele O 0 1.4523312552583434e-09
at O 0 1.331621257705251e-09
the O 0 2.001469567858294e-08
DM B-Disease 1 1.0
locus O 0 3.971612443365302e-07
, O 0 6.581374889513825e-10
has O 0 1.6930720714292136e-11
been O 0 1.1089934526253842e-11
put O 0 1.6772784550145303e-10
forward O 0 2.7102966537739803e-09
to O 0 2.9233497844671774e-09
explain O 0 1.0133169858761448e-08
partially O 0 2.47080649273812e-08
the O 0 6.372939953536161e-10
maintenance O 0 5.461965884023812e-07
of O 0 3.7781771311529155e-07
DM B-Disease 1 1.0
in O 0 4.405394093964787e-08
the O 0 2.7084221088102822e-08
population O 0 1.5240142481331986e-09
. O 0 1.9837550269130588e-08

In O 0 1.9418306962393217e-08
a O 0 6.667840946050774e-09
survey O 0 5.260229141157424e-09
of O 0 6.150839393370688e-09
DM B-Disease 1 1.0
in O 0 2.339651494764894e-08
Northern O 0 7.618665165409766e-08
Ireland O 0 1.841524088774804e-08
, O 0 2.2180366432422716e-09
59 O 0 6.268652441576705e-08
pedigrees O 0 3.8369245203284663e-07
were O 0 6.527785245680207e-08
ascertained O 0 2.869785248549306e-06
. O 0 8.647900244795892e-07

Sibships O 0 1.3730710634263232e-05
where O 0 3.263709302814277e-09
the O 0 1.7733170487588268e-10
status O 0 6.509552341604774e-10
of O 0 4.502400396955153e-10
all O 0 4.554958146774091e-11
the O 0 8.279203711492045e-11
members O 0 2.8632360371538823e-11
had O 0 8.679857527171819e-11
been O 0 1.2849468017384069e-11
identified O 0 3.118125202483668e-11
were O 0 1.4500525780114515e-10
examined O 0 7.881307273471805e-10
to O 0 1.7313132871787928e-10
determine O 0 7.066887630635676e-10
the O 0 1.551226702645181e-09
transmission O 0 6.322471080011383e-08
of O 0 1.5807341213758264e-08
the O 0 5.199781227815947e-08
DM B-Disease 1 1.0
expansion O 0 3.6873450426355703e-07
from O 0 9.111529308825084e-09
affected O 0 1.339111932452397e-09
parents O 0 3.7938319152885924e-10
to O 0 4.87428541973145e-10
their O 0 3.895553657429218e-09
offspring O 0 4.6705227418897266e-07
. O 0 1.0855959544642246e-06

Where O 0 1.1876677064037722e-07
the O 0 2.3834138218603584e-08
transmitting O 0 2.1136884242878295e-06
parent O 0 7.652492861609517e-09
was O 0 1.4626532163219963e-07
male O 0 4.369893957800741e-08
, O 0 2.8975051691304543e-08
58 O 0 1.2558914477267535e-06
. O 0 9.44517182688287e-07

3 O 0 4.113330760446843e-07
% O 0 4.743545112262382e-09
of O 0 2.3517932046246415e-09
the O 0 5.096091881817699e-10
offspring O 0 1.4800779490897753e-09
were O 0 7.338750163121688e-10
affected O 0 3.90330157085117e-10
, O 0 3.090674938199811e-11
and O 0 3.9253988948217966e-11
in O 0 3.903768627799842e-11
the O 0 1.8748545771440916e-10
case O 0 1.2544180971740815e-10
of O 0 1.5107638751121755e-10
a O 0 4.879159853921067e-10
female O 0 9.705699577367e-10
transmitting O 0 3.66628434278482e-08
parent O 0 5.294068294858789e-09
, O 0 4.355598193228616e-08
68 O 0 1.9165179764968343e-05
. O 0 1.6417707229265943e-05

7 O 0 2.8809733976231655e-06
% O 0 5.646203504738878e-08
were O 0 6.365948479469807e-08
affected O 0 6.359758941698601e-08
. O 0 3.828064905064821e-07

Studies O 0 3.0360186542566225e-07
on O 0 2.815395205857385e-08
meiotic O 0 1.6248794736384298e-06
drive O 0 1.8412734448247647e-07
in O 0 1.7119216266792137e-08
DM B-Disease 1 1.0
have O 0 2.7315121275961474e-09
shown O 0 1.1813694467122104e-10
increased O 0 7.209167290911367e-11
transmission O 0 3.1216496054753406e-10
of O 0 1.367086444048482e-10
the O 0 2.066671556111288e-10
larger O 0 3.827804739842122e-10
allele O 0 4.0125631706189324e-09
at O 0 6.450944223246324e-09
the O 0 4.2904925834363894e-08
DM B-Disease 1 1.0
locus O 0 2.821857947310491e-07
in O 0 1.7373752214666638e-08
non O 0 2.3614738893229514e-05
- O 0 0.0002507106401026249
DM O 1 1.0
heterozygotes O 0 0.00018225153326056898
for O 0 6.548998499056324e-07
CTGn O 0 0.00042042770655825734
. O 0 2.3099200916476548e-06

This O 0 3.027248851594777e-08
study O 0 1.2633083024127245e-08
provides O 0 7.532914847452332e-10
further O 0 1.8431210724312308e-10
evidence O 0 8.328782663546974e-10
that O 0 1.0544096151754445e-10
the O 0 1.19798952979977e-08
DM B-Disease 1 1.0
expansion O 0 4.583499503496569e-06
tends O 0 1.074481801310867e-07
to O 0 4.534471020889441e-09
be O 0 7.0566676946270945e-09
transmitted O 0 1.0078181844619394e-07
preferentially O 0 8.736809320453176e-08
. O 0 6.688631515316956e-07

Diagnosis O 1 0.9999998807907104
of O 0 0.04772098362445831
hemochromatosis B-Disease 1 1.0
. O 1 0.6929975748062134

If O 0 2.7129310637974413e-06
untreated O 1 0.9896048307418823
, O 0 1.1367117025429252e-07
hemochromatosis B-Disease 1 1.0
can O 0 7.20902519901756e-08
cause O 0 1.843568043113919e-06
serious O 0 3.9040097021825204e-07
illness O 0 2.556723188718024e-07
and O 0 3.020300676226384e-11
early B-Disease 0 1.0365242886223314e-08
death I-Disease 0 1.3588462577374116e-09
, O 0 2.138423813025092e-11
but O 0 1.2848265854015217e-11
the O 0 4.5222472988548645e-10
disease O 0 6.180568945524101e-09
is O 0 9.504159612094831e-12
still O 0 6.397343071951056e-11
substantially O 0 2.550900157771707e-09
under O 0 1.1009506124537438e-06
- O 1 1.0
diagnosed O 1 0.999488353729248
. O 0 4.550182438833872e-06

The O 0 1.928506634385485e-07
cornerstone O 0 4.121118763578124e-06
of O 0 5.3314632708634235e-08
screening O 0 3.17794395243709e-08
and O 0 3.1635410957520094e-10
case O 0 1.8301246629270906e-10
detection O 0 6.501393556845869e-08
is O 0 6.801563479097439e-11
the O 0 2.2570548208200591e-10
measurement O 0 1.7086202674931883e-08
of O 0 1.3400170750799134e-08
serum O 0 5.222224075396298e-08
transferrin O 0 1.3747471427905111e-07
saturation O 0 2.0628877450690197e-07
and O 0 4.360233951672399e-09
the O 0 2.493198181241496e-08
serum O 0 4.2658740539991413e-07
ferritin O 0 1.4034040987098706e-06
level O 0 1.840186655499565e-06
. O 0 1.166712195299624e-06

Once O 0 1.0333067166357068e-06
the O 0 3.67655736965844e-08
diagnosis O 0 1.3761334230366629e-05
is O 0 3.6011063575536184e-10
suspected O 0 1.7639340654795888e-08
, O 0 2.0681711898618005e-09
physicians O 0 2.9707879889429023e-07
must O 0 1.149128081578965e-08
use O 0 2.4169059997802833e-07
serum O 0 4.289676780899754e-06
ferritin O 0 1.2051134035573341e-05
levels O 0 1.357131850454607e-06
and O 0 9.961717495343692e-08
hepatic O 1 0.9933565258979797
iron O 1 0.853283703327179
stores O 0 3.0194464670785237e-06
on O 0 3.361498954745912e-07
liver O 0 1.2953181794728152e-05
biopsy O 0 1.3171636510378448e-06
specimens O 0 6.766439852867734e-09
to O 0 5.048319540179591e-10
assess O 0 3.705258677655365e-08
patients O 0 7.56753770758678e-09
for O 0 3.2241587177850306e-10
the O 0 2.1342208000874052e-09
presence O 0 1.716253450467775e-08
of O 0 3.497429759136139e-07
iron B-Disease 1 0.9999881982803345
overload I-Disease 1 0.9986931681632996
. O 0 1.2939686712343246e-05

Liver O 1 1.0
biopsy O 1 0.9999325275421143
is O 0 1.2771365076602592e-09
also O 0 8.539195045509373e-11
used O 0 8.613263574597241e-11
to O 0 7.262951351449942e-11
establish O 0 1.5086539795206022e-09
the O 0 1.236974633833654e-09
presence O 0 2.6901796346123774e-09
or O 0 9.51088363621011e-09
absence O 0 2.0969827119188267e-07
of O 0 3.121569491781884e-08
cirrhosis B-Disease 0 0.17409832775592804
, O 0 1.4352215249591183e-10
which O 0 5.938460227034037e-12
can O 0 1.2756915315770279e-11
affect O 0 5.881967135579202e-10
prognosis O 0 4.3411982915131375e-06
and O 0 5.655753554378862e-08
management O 0 4.0341628846363164e-06
. O 0 2.2410131350625306e-06

A O 0 3.642030321771017e-07
DNA O 0 1.0400577821201296e-07
- O 0 6.441037214699463e-08
based O 0 2.945446775370897e-09
test O 0 1.8015665625981114e-09
for O 0 5.213142140192417e-10
the O 0 4.336182968245339e-09
HFE O 0 0.00033257316681556404
gene O 0 7.034132387673253e-09
is O 0 9.29736218568955e-11
commercially O 0 3.0759932378998656e-09
available O 0 2.0846144810349188e-09
, O 0 9.899482622532929e-11
but O 0 1.763867524262608e-11
its O 0 5.9634766742810985e-12
place O 0 1.0495058988535533e-10
in O 0 1.1424963058948023e-10
the O 0 9.638456699434528e-10
diagnosis O 0 1.5332085467889556e-06
of O 0 3.3660661813428305e-08
hemochromatosis B-Disease 1 1.0
is O 0 5.861072516211152e-09
still O 0 3.7000802421971457e-09
being O 0 4.141673226598641e-09
evaluated O 0 1.5474884662580735e-07
. O 0 5.453460971693858e-07

Currently O 0 1.1625820661720354e-07
, O 0 1.597665111319202e-09
the O 0 5.561079929883306e-10
most O 0 6.659928164509665e-11
useful O 0 2.4100163531493024e-10
role O 0 3.3355755657549224e-11
for O 0 1.3825674979872637e-11
this O 0 8.290449923786802e-12
test O 0 1.0022480761984198e-10
is O 0 1.5269971702022711e-12
in O 0 2.2406716239375957e-12
the O 0 3.66341297575179e-11
detection O 0 2.0191478142805863e-06
of O 0 2.0856165861005138e-07
hemochromatosis B-Disease 1 1.0
in O 0 5.263965263679893e-08
the O 0 1.969733354201253e-08
family O 0 2.1860985244259723e-10
members O 0 3.769536766062842e-11
of O 0 5.580024220463997e-10
patients O 0 7.816365332757869e-10
with O 0 5.859409745595512e-12
a O 0 1.0736531663724236e-09
proven O 0 5.676340819604775e-08
case O 0 1.3405763166218776e-09
of O 0 5.357692245411272e-08
the O 0 1.165397634395049e-06
disease O 0 8.863133552949876e-05
. O 0 1.1867454077219008e-06

It O 0 1.77862684580532e-08
is O 0 2.0563237779214205e-09
crucial O 0 1.988747015957415e-07
to O 0 4.793873245034774e-07
diagnose O 1 1.0
hemochromatosis B-Disease 1 1.0
before O 1 0.9999998807907104
hepatic B-Disease 1 1.0
cirrhosis I-Disease 1 1.0
develops O 0 1.2885934097539575e-08
because O 0 1.1553977774525492e-09
phlebotomy O 0 0.003680892987176776
therapy O 0 0.0001313112152274698
can O 0 2.2829689250158935e-09
avert O 0 3.652078930826974e-06
serious O 0 0.02106304280459881
chronic O 1 1.0
disease O 0 5.00690703120199e-06
and O 0 1.6741494301975024e-10
can O 0 1.491347184634506e-10
even O 0 2.068012289191401e-10
lead O 0 2.265721388283737e-09
to O 0 1.0889311674588953e-09
normal O 0 1.9289622343876545e-08
life O 0 1.0785489834574946e-08
expectancy O 0 2.395143994249338e-08
. O 0 3.4430243101013502e-09
. O 0 1.7019598885781306e-07

Prevalence O 0 1.742475069477223e-05
of O 0 1.3627368389279582e-07
the O 0 6.98845354918376e-08
I1307K O 0 1.927239827637095e-05
APC B-Disease 0 4.742118449030386e-07
gene O 0 4.9409338842565376e-09
variant O 0 2.4390136132979023e-08
in O 0 9.666588640655505e-10
Israeli O 0 5.4765191492833765e-08
Jews O 0 2.7427377702338163e-08
of O 0 3.534972314866991e-10
differing O 0 2.759240926020201e-11
ethnic O 0 1.0673918346415512e-11
origin O 0 1.1601913180170342e-10
and O 0 1.2933616677646143e-10
risk O 0 3.2078212086616986e-08
for O 0 1.6355522802768974e-06
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 1 0.999982476234436

BACKGROUND O 0 2.3743838028167374e-05
& O 0 6.01676902078907e-06
AIMS O 0 4.5349230504143634e-07
Israeli O 0 3.9579735044981135e-08
Jews O 0 1.972274610295699e-08
of O 0 1.3242935636981201e-09
European O 0 1.4819536708898795e-09
birth O 0 5.0179385091553286e-09
, O 0 2.112028468781446e-10
i O 0 5.406106673433442e-10
. O 0 8.53437598369311e-11
e O 0 2.4089927830317492e-09
. O 0 1.677995242754804e-10
, O 0 4.857941271474431e-10
Ashkenazim O 0 6.874288942526618e-07
, O 0 2.8003321883574017e-10
have O 0 1.1312250441930516e-10
the O 0 2.5025539418521703e-09
highest O 1 0.9998824596405029
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
incidence O 0 7.283145464498375e-07
of O 0 3.909204515650799e-09
any O 0 4.4201356463879904e-10
Israeli O 0 4.402064064379374e-07
ethnic O 0 8.25450374719594e-09
group O 0 5.5179665281457346e-08
. O 0 3.718704419952701e-07

The O 0 3.5431276046438143e-06
I1307K O 0 0.00019396981224417686
APC B-Disease 0 4.548455308395205e-06
gene O 0 2.4207855275903967e-08
variant O 0 9.985972582171598e-08
was O 0 5.4647905756155524e-08
found O 0 3.6218210652805283e-09
in O 0 6.1668510298318324e-09
6 O 0 5.037114078731975e-06
. O 0 1.4573276985174743e-06

1 O 0 3.344436265706463e-07
% O 0 2.6564761501646217e-09
of O 0 2.0101762476798513e-09
American O 0 2.0410761969458235e-09
Jews O 0 5.202992703345899e-09
, O 0 4.822046581476336e-11
28 O 0 4.819373233821977e-10
% O 0 1.196636262301709e-10
of O 0 1.0895357949181061e-09
their O 0 3.36867387318307e-08
familial O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
cases O 0 4.0589316085970495e-07
, O 0 5.175079809127681e-10
but O 0 6.519899203860646e-11
not O 0 1.5976581169141468e-10
in O 0 4.4004855315193936e-10
non O 0 2.469808180194377e-07
- O 0 4.764775383137021e-07
Jews O 0 1.9854753645631718e-06
. O 0 5.132976070854056e-07

We O 0 1.7938855023658107e-07
assessed O 0 4.00873318540107e-07
the O 0 2.870485715789073e-08
I1307K O 0 1.1439601621532347e-05
prevalence O 0 3.5040695678389966e-08
in O 0 2.9704481929737625e-11
Israeli O 0 2.3014188332837193e-09
Jews O 0 4.31520996713175e-09
of O 0 1.9598901668249624e-10
differing O 0 1.9583197910510997e-11
ethnic O 0 4.147635360163271e-12
origin O 0 7.475343954954639e-11
and O 0 5.364933844398401e-11
risk O 0 4.952409682346115e-08
for O 0 2.4768778530415148e-06
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 1 0.999972939491272

METHODS O 0 9.339876669400837e-06
DNA O 0 1.0280754167979467e-06
samples O 0 6.946829955722933e-08
from O 0 2.5353104060599208e-09
500 O 0 2.0604234762799933e-08
unrelated O 0 9.016130619876606e-10
Jews O 0 7.93782461983028e-09
of O 0 1.530218396439409e-09
European O 0 2.242239727223705e-09
or O 0 7.395264400855694e-10
non O 0 1.7568023480407646e-08
- O 0 3.7488621096315455e-09
European O 0 3.531030190462303e-10
origin O 0 1.5628229266262395e-10
, O 0 6.795608346876758e-12
with O 0 6.332436203008995e-13
or O 0 1.651418585213449e-11
without O 0 5.217397000545354e-11
a O 0 3.578031620987687e-11
personal O 0 8.568468712333299e-10
and O 0 4.997181002330819e-10
/ O 0 6.863402177259559e-06
or O 0 1.2124578674388431e-08
family O 0 4.875512771285173e-10
history O 0 1.6394942070618868e-09
of O 0 9.91373538816731e-10
neoplasia B-Disease 0 1.6848395034685382e-06
, O 0 5.791018220513422e-10
were O 0 7.384087230555281e-10
examined O 0 4.283834620366633e-09
for O 0 4.0842632054172157e-10
the O 0 2.0596995220500958e-09
I1307K O 0 1.065262296151559e-07
variant O 0 4.557491717349649e-09
by O 0 6.957825982034649e-11
the O 0 7.148962533065628e-10
allele O 0 1.6602887953354184e-09
- O 0 8.119154237817838e-09
specific O 0 4.211069271065071e-09
oligonucleotide O 0 1.7762590687198099e-06
( O 0 6.737170821224936e-08
ASO O 0 1.6394520571338944e-05
) O 0 8.479736024469275e-09
method O 0 2.495677620117931e-07
. O 0 2.0118461918627872e-07

RESULTS O 0 2.074976919175242e-07
In O 0 2.8540461105563963e-09
persons O 0 8.834072362517986e-10
at O 0 2.008098132222358e-10
average O 0 2.078531097238212e-10
risk O 0 7.464462936646044e-10
for O 0 1.531924631592574e-08
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 1.1818640359706478e-06
I1307K O 0 8.048944437177852e-06
was O 0 1.8005986035518617e-08
found O 0 5.092904431514e-10
in O 0 1.4158146877107924e-09
5 O 0 3.878570566939743e-07
. O 0 1.0660229463610449e-06

0 O 0 6.306958084678627e-07
% O 0 3.319078345498383e-09
of O 0 2.672596588482179e-09
120 O 0 1.3999505554807001e-08
European O 0 6.2787606225356285e-09
and O 0 9.465134453989776e-09
1 O 0 3.6460653518588515e-06
. O 0 3.354234195285244e-06

6 O 0 2.1743546767538646e-06
% O 0 1.7134176744093566e-08
of O 0 7.120578793262666e-09
188 O 0 2.983830782454788e-08
non O 0 1.9814905272141914e-07
- O 0 1.904140134456611e-07
European O 0 1.2414377970060286e-08
Jews O 0 1.351269531824073e-07
( O 0 1.883608602426534e-09
P O 0 4.447998236400963e-08
= O 0 1.009643746385791e-08
0 O 0 5.7957065813241115e-09
. O 0 2.063407444907739e-09
08 O 0 2.868931971988786e-07
) O 0 3.1818196077892935e-08
. O 0 3.1043956028042885e-07

It O 0 6.8829919541713025e-09
occurred O 0 2.7318677098264743e-08
in O 0 5.95825611071632e-09
15 O 0 2.0094685737603868e-07
. O 0 4.6051695790083613e-07

4 O 0 6.588407472918334e-07
% O 0 7.667219747986564e-09
of O 0 8.39768077298686e-09
52 O 0 3.164178252745842e-08
Ashkenazi O 0 3.574306504106062e-07
Israelis O 0 1.0055198629288498e-07
with O 0 7.251659828177992e-10
familial O 1 0.7449647784233093
cancer B-Disease 1 0.9999980926513672
( O 0 6.208523473105743e-09
P O 0 4.3728960008593276e-07
= O 0 1.7761825787943053e-08
0 O 0 3.4353886402271883e-09
. O 0 4.3490855361483227e-10
02 O 0 1.0858397558877186e-07
) O 0 1.6376150435704062e-10
and O 0 1.9262468009539901e-10
was O 0 2.9921387589837423e-09
not O 0 3.902690948187626e-10
detected O 0 2.875448767980515e-09
in O 0 3.308994744877225e-10
51 O 0 7.553837555462906e-09
non O 0 1.7250266637347522e-07
- O 0 3.385221702956187e-07
European O 0 3.22732454094421e-08
Jews O 0 1.5060722091675416e-07
at O 0 9.739733464186884e-09
increased O 0 1.1662494969755244e-08
cancer B-Disease 0 3.987296892660197e-08
risk O 0 1.8559353165414905e-08
. O 0 1.3678044297193992e-07

Colorectal B-Disease 1 0.999997615814209
neoplasia I-Disease 0 0.008814550004899502
occurred O 0 5.167922608961817e-06
personally O 0 9.229175645941723e-08
or O 0 5.012990023089969e-10
in O 0 8.171658488764777e-11
the O 0 1.095881510537744e-10
families O 0 1.6393050111807028e-11
of O 0 1.3460894898731368e-10
13 O 0 1.1468546112780587e-09
of O 0 2.557881906284365e-09
20 O 0 2.4975102874691402e-08
Ashkenazi O 0 4.361733942914725e-07
I1307K O 0 2.1681375983462203e-07
carriers O 0 1.259744086823389e-09
, O 0 9.600985284574648e-11
8 O 0 2.3896578049686923e-09
of O 0 2.8785216432680727e-09
whom O 0 7.416725011921699e-09
also O 0 1.0856296972505675e-09
had O 0 6.263137231066196e-10
a O 0 4.241877682442663e-10
personal O 0 1.8491018494160016e-08
or O 0 2.0959494140271318e-09
family O 0 2.7993604656550986e-10
history O 0 4.762946925751521e-09
of O 0 2.559762357634554e-08
noncolonic O 0 2.7303518436383456e-05
neoplasia B-Disease 1 0.6535782814025879
. O 0 1.9545408576959744e-05

CONCLUSIONS O 0 1.0888229553529527e-05
The O 0 7.025138302196865e-07
I1307K O 0 6.830982601968572e-05
APC O 0 1.509212324890541e-06
variant O 0 4.7577015038768877e-07
may O 0 5.747950559964465e-09
represent O 0 1.0767006175527172e-09
a O 0 1.670956817356739e-09
susceptibility O 0 4.8195346380452975e-08
gene O 0 9.558129399067639e-09
for O 0 9.180438098610466e-08
colorectal B-Disease 1 1.0
, I-Disease 0 0.024129293859004974
or I-Disease 0 2.2275316950981505e-06
other I-Disease 0 6.911727012948177e-08
, I-Disease 0 7.784233702068377e-09
cancers I-Disease 0 1.0165555295316153e-06
in O 0 1.4227338196448613e-09
Ashkenazi O 0 5.891224077458901e-07
Jews O 0 4.303819522988306e-08
, O 0 2.113612340703952e-10
and O 0 2.1384247150812996e-10
partially O 0 7.329562734526007e-09
explains O 0 6.016253606411226e-10
the O 0 1.4324155750422563e-10
higher O 0 1.720832720764065e-08
incidence O 0 1.5801076642674161e-06
of O 0 6.4755768107716e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 1.1244305824220646e-06
European O 0 8.970714020506421e-07
Israelis O 0 6.163928901514737e-06
. O 0 8.217353979489417e-07

Systematic O 0 5.344984970179212e-07
analysis O 0 6.398681762220804e-08
of O 0 5.351247622797928e-08
coproporphyrinogen O 0 1.4965429727453738e-05
oxidase O 0 9.99721305561252e-06
gene O 0 9.101394766730664e-07
defects O 0 2.526432399463374e-05
in O 0 2.767832256722613e-07
hereditary B-Disease 1 0.9999998807907104
coproporphyria I-Disease 1 0.9999691247940063
and O 0 1.7191013057527016e-07
mutation O 0 1.4349649291034439e-07
update O 0 8.441302270512097e-06
. O 0 2.2651406652585138e-06

Hereditary B-Disease 1 1.0
coproporphyria I-Disease 1 0.9999996423721313
( O 0 4.7444615347558283e-07
HC B-Disease 1 0.9995032548904419
) O 0 2.699525580851514e-08
is O 0 1.1470734362362123e-09
an O 0 1.2167059582068873e-09
acute O 1 0.9999998807907104
hepatic B-Disease 1 1.0
porphyria I-Disease 1 1.0
with O 0 4.000718763563782e-05
autosomal O 1 1.0
dominant O 0 0.00010554203618085012
inheritance O 0 7.692959798077936e-07
caused O 0 6.110057171326844e-08
by O 0 1.7549520170412336e-10
deficient B-Disease 0 5.090032395571598e-09
activity I-Disease 0 1.7970502863562388e-09
of I-Disease 0 6.587871137497814e-09
coproporphyrinogen I-Disease 0 1.5134396562643815e-06
III I-Disease 1 0.9924160242080688
oxidase I-Disease 0 3.2727239158703014e-06
( O 0 1.3790081254683173e-07
CPO O 0 4.3136333260918036e-05
) O 0 2.017687421584924e-07
. O 0 1.1757225593100884e-06

Clinical O 0 2.8498176106950268e-05
manifestations O 0 9.021330811265216e-07
of O 0 6.611576708337452e-08
the O 0 6.086212778200206e-08
disease O 0 2.9332971962503507e-07
are O 0 2.4872666426478673e-11
characterized O 0 5.3172573982740445e-11
by O 0 1.1878533746900732e-11
acute O 0 4.944490683556069e-08
attacks O 0 2.616390126775059e-08
of O 0 0.00013012955605518073
neurological B-Disease 1 1.0
dysfunction I-Disease 1 1.0
often O 0 1.4661648783942383e-08
precipitated O 0 8.736438239509425e-09
by O 0 1.140567154611638e-10
drugs O 0 1.6023962601252606e-08
, O 0 7.804656365628659e-10
fasting O 0 9.395726152661155e-08
, O 0 4.181280210957539e-09
cyclical O 0 1.468578375352081e-06
hormonal O 0 4.033016466564732e-06
changes O 0 1.9822836705429836e-08
, O 0 2.5388443347651446e-08
or O 0 5.708309345209273e-07
infectious B-Disease 1 0.9999375343322754
diseases I-Disease 0 0.05173134803771973
. O 0 4.1656730331851577e-07

Skin O 1 1.0
photosensitivity O 1 0.9999808073043823
may O 0 8.483232250000583e-07
also O 0 1.285745465651189e-08
be O 0 1.6308178141244412e-09
present O 0 7.853071082308816e-09
. O 0 3.5762741390499286e-07

The O 0 3.8288388282126107e-07
seven O 0 1.001827101276831e-07
exons O 0 2.70609660901755e-07
, O 0 2.8575051214119185e-09
the O 0 6.055745238597865e-09
exon O 0 1.045760200213408e-06
/ O 0 1.5059371207826189e-06
intron O 0 1.6750219629102503e-06
boundaries O 0 1.2066941890154226e-09
and O 0 2.2015136935671364e-10
part O 0 5.43806277786274e-10
of O 0 4.357290972478722e-09
3 O 0 1.1405987265789008e-08
noncoding O 0 1.1665275856387325e-08
sequence O 0 5.032975147756247e-10
of O 0 4.1711483156348095e-09
the O 0 1.1904773167259464e-08
CPO O 0 1.1206386716366978e-06
gene O 0 3.5936771336508855e-09
were O 0 4.853534907311996e-09
systematically O 0 3.2843163744189496e-09
analyzed O 0 7.354148956473239e-10
by O 0 1.0418869239581241e-10
an O 0 2.6111526829630805e-10
exon O 0 2.8916639749354545e-08
- O 0 7.013503733332982e-08
by O 0 1.1243513675651684e-08
- O 0 1.3370463420869783e-06
exon O 0 3.3358849123032996e-06
denaturing O 0 4.911208179692039e-06
gradient O 0 1.9711582410764095e-07
gel O 0 3.377279540472955e-07
electrophoresis O 0 2.74970446412226e-08
( O 0 2.7270039559823545e-09
DGGE O 0 2.2566778170585167e-06
) O 0 3.996109554371685e-10
strategy O 0 1.1262352161978129e-09
followed O 0 2.5630964017864244e-10
by O 0 6.2295927964750586e-12
direct O 0 6.947933200995848e-11
sequencing O 0 1.366602275787443e-09
in O 0 3.6573688522167913e-10
seven O 0 2.4680355537043397e-09
unrelated O 0 3.154524463866437e-08
heterozygous O 0 4.810570786162316e-08
HC B-Disease 0 2.1957888748147525e-05
patients O 0 1.2085118896720815e-06
from O 0 1.704720631323653e-08
France O 0 1.0968072672312701e-07
, O 0 2.918235653126544e-09
Holland O 0 1.432255061217802e-07
, O 0 2.1384503057220172e-09
and O 0 2.3673196736240243e-09
Czech O 0 6.676592647636426e-07
Republic O 0 2.8901122277602553e-06
. O 0 6.312147888820618e-06

Seven O 0 3.0806364748059423e-07
novel O 0 5.82567807327905e-08
mutations O 0 9.183271032497942e-09
and O 0 8.656450556365769e-10
two O 0 4.4141371113859407e-10
new O 0 1.885632094911216e-09
polymorphisms O 0 5.019443847231742e-07
were O 0 2.0755528851168492e-07
detected O 0 6.786501671740552e-07
. O 0 6.62206389279163e-07

Among O 0 8.359953085346206e-08
these O 0 1.4200931541807904e-09
mutations O 0 1.7230257221001466e-09
two O 0 2.2440099778364697e-10
are O 0 3.375192070276256e-10
missense O 0 1.8050367600608297e-07
( O 0 9.650750421030807e-09
G197W O 0 9.173957550956402e-06
, O 0 5.550761184025532e-09
W427R O 0 1.509318849457486e-06
) O 0 7.026137449628322e-10
, O 0 3.0623109603666876e-10
two O 0 1.3030033996219714e-10
are O 0 6.991670437050956e-11
nonsense O 0 9.691557067981194e-08
( O 0 6.598182888950532e-09
Q306X O 0 7.60031298341346e-06
, O 0 5.841452654919976e-09
Q385X O 0 1.6257582728940179e-06
) O 0 8.163079101564108e-10
, O 0 3.301159068325177e-10
two O 0 7.946632935018627e-11
are O 0 9.608514678349778e-11
small O 0 1.0078308187999596e-09
deletions O 0 2.8753413516824367e-07
( O 0 1.6187819085189403e-08
662de14bp O 0 4.0582026485935785e-06
; O 0 3.1105249487239917e-09
1168del3bp O 0 3.511205761697056e-07
removing O 0 3.714429297474453e-08
a O 0 1.412076677809182e-09
glycine O 0 2.941035681658377e-08
at O 0 1.1178657111088341e-08
position O 0 1.154246298540329e-08
390 O 0 1.841959651471825e-08
) O 0 1.2550643857522914e-10
, O 0 3.783359042719425e-11
and O 0 2.927096759419712e-11
one O 0 1.071802455815396e-11
is O 0 2.0587143101380434e-12
a O 0 2.1332500002579913e-11
splicing O 0 2.273948318531893e-08
mutation O 0 8.706710907802062e-09
( O 0 3.170157025778053e-09
IVS1 O 0 1.253733535122592e-05
- O 0 7.820353289389459e-07
15c O 0 1.0506711987545714e-05
- O 0 9.762927675183164e-07
- O 0 7.879373242758447e-07
> O 0 6.66442929286859e-07
g O 0 6.022619913892413e-08
) O 0 2.5630134126153337e-10
which O 0 4.7770710998040755e-11
creates O 0 2.9225735720395107e-10
a O 0 7.713685246102386e-10
new O 0 2.7442854655390647e-09
acceptor O 0 8.4640007003145e-08
splice O 0 4.327841907070251e-06
site O 0 2.063599367829738e-06
. O 0 1.0564297099335818e-06

The O 0 1.4116000102148973e-07
pathological O 0 3.640426200490765e-07
significance O 0 3.565379103065425e-08
of O 0 1.0742067679814227e-08
the O 0 2.880905514146548e-09
point O 0 3.92284498218487e-08
mutations O 0 2.133634824375008e-09
G197W O 0 1.5315482926325785e-07
, O 0 6.333435997873949e-10
W427R O 0 3.146880942495045e-07
, O 0 2.164440848773097e-10
and O 0 8.048682553774e-11
the O 0 4.4898115780789283e-10
in O 0 3.83367920742117e-10
- O 0 1.0582549059279245e-08
frame O 0 3.283403771092708e-08
deletion O 0 3.0179325705148585e-08
390delGly O 0 9.572944215108237e-09
were O 0 2.3953974914725507e-10
assessed O 0 5.616510034833766e-10
by O 0 1.858961769241052e-11
their O 0 1.9165134756971014e-10
respective O 0 4.813881737675274e-09
expression O 0 1.7193554358030383e-09
in O 0 1.390141335377848e-10
a O 0 1.7913068250940967e-10
prokaryotic O 0 4.629365502051286e-10
system O 0 1.090968537731385e-09
using O 0 3.3317510972352693e-09
site O 0 1.2814121319593141e-08
- O 0 2.2772905339252247e-08
directed O 0 1.6595423701915024e-08
mutagenesis O 0 2.0905858946207445e-06
. O 0 9.565032996761147e-07

These O 0 2.7034932514879984e-08
mutations O 0 4.56640192325608e-09
resulted O 0 1.8094699072435105e-09
in O 0 1.2362594281611905e-10
the O 0 3.7658592910716493e-10
absence O 0 2.8297786336395347e-09
or O 0 2.952357802676886e-10
a O 0 2.3263177495458365e-10
dramatic O 0 3.2339038114059804e-09
decrease O 0 9.081755791839896e-09
of O 0 2.1960013896205055e-07
CPO O 0 0.00011326203093631193
activity O 0 2.0901672996842535e-06
. O 0 1.7250313248950988e-06

The O 0 2.413524669009348e-07
two O 0 1.2118290371176954e-08
polymorphisms O 0 3.70468711707872e-07
were O 0 8.43736902567116e-09
localized O 0 1.9642856230461803e-08
in O 0 1.0074079348498799e-09
noncoding O 0 2.392564368847161e-08
part O 0 1.921887982092585e-09
of O 0 4.724276969625407e-09
the O 0 1.0340081013637814e-09
gene O 0 2.9694469105834287e-10
1 O 0 7.175605443165978e-09
) O 0 9.685561241923324e-10
a O 0 5.956346971203175e-09
C O 0 2.841817604348762e-06
/ O 0 4.056195734847279e-07
G O 0 1.89732261901554e-07
polymorphism O 0 3.307843243760544e-08
in O 0 1.7645792604881194e-09
the O 0 6.6325660519339635e-09
promotor O 0 9.46286763792159e-06
region O 0 7.177018090942511e-08
, O 0 2.972769141962317e-09
142 O 0 2.0010116230650965e-08
bp O 0 1.4088061384143202e-08
upstream O 0 1.635936386357173e-09
from O 0 2.86128870596869e-10
the O 0 2.9002891754892346e-10
transcriptional O 0 2.1181050247065514e-09
initiation O 0 1.454685794044508e-08
site O 0 1.0233470071341344e-08
( O 0 9.409186763065236e-10
- O 0 5.8436619099211384e-08
142C O 0 2.049923978120205e-06
/ O 0 1.737695782821902e-07
G O 0 4.6639705431061884e-08
) O 0 1.497772461611646e-10
, O 0 2.5169892212129064e-11
and O 0 3.2614532602393e-11
2 O 0 1.821419681746761e-09
) O 0 2.9363916853597516e-10
a O 0 8.918401572799439e-10
6 O 0 3.832864337027786e-08
bp O 0 4.5936594972317835e-08
deletion O 0 4.000015874083829e-09
polymorphism O 0 3.0323155097988774e-09
in O 0 1.7560704279606654e-10
the O 0 5.891488408238388e-10
3 O 0 6.851791134465657e-09
noncoding O 0 2.2855843440083845e-08
part O 0 2.044431068881636e-09
of O 0 6.879343317223174e-09
the O 0 2.3757163347681853e-08
CPO O 0 5.495843197422801e-06
gene O 0 1.987326214702989e-08
, O 0 6.549458309024203e-09
574 O 0 1.030235239340982e-07
bp O 0 5.848523798590577e-08
downstream O 0 3.5213674198786293e-09
of O 0 1.014000883259314e-09
the O 0 3.7534533814387316e-10
last O 0 4.1614514612042797e-10
base O 0 1.6370569344559271e-09
of O 0 1.733322096963974e-10
the O 0 5.719859655362036e-11
normal O 0 6.833802967953773e-10
termination O 0 4.014959475995283e-09
codon O 0 2.937156473592495e-08
( O 0 5.684366310987343e-09
+ O 0 3.115083870852686e-07
574 O 0 7.500834158236103e-07
delATTCTT O 0 5.8863779486273415e-06
) O 0 9.044903492849699e-08
. O 0 4.427118369676464e-07

Five O 0 1.3881550557925948e-06
intragenic O 0 4.7359037125715986e-05
dimorphisms O 0 1.747134047036525e-05
are O 0 1.541449634601122e-09
now O 0 6.018973652821558e-10
well O 0 3.032597506447132e-10
characterized O 0 1.5073847725588507e-10
and O 0 2.8527152862167782e-11
the O 0 1.1459116988632445e-10
high O 0 1.5456507185263035e-09
degree O 0 1.664658988431711e-08
of O 0 8.670467899207779e-09
allelic O 0 8.756394009878932e-08
heterogeneity O 0 1.443717767557473e-08
in O 0 1.2608641908329332e-09
HC B-Disease 0 2.0891027816105634e-05
is O 0 1.407381988727252e-09
demonstrated O 0 4.149453669555214e-09
with O 0 3.302164791607609e-11
seven O 0 2.0522163135527904e-10
new O 0 3.855323699175628e-11
different O 0 1.474539587653645e-11
mutations O 0 1.1309899544675872e-10
making O 0 2.0705068215498557e-10
a O 0 2.0986405668832475e-10
total O 0 7.650869382480607e-10
of O 0 5.068718333944844e-09
nineteen O 0 1.4155987173580797e-06
CPO O 0 3.685558840516023e-05
gene B-Disease 0 1.5575179190818744e-07
defects I-Disease 0 1.115392933570547e-06
reported O 0 8.014009900136898e-09
so O 0 1.6479277942238468e-09
far O 0 4.074834691891738e-09
. O 0 1.0923954185670937e-08
. O 0 2.628189577080775e-07

Coincidence O 0 1.260389581148047e-06
of O 0 9.047094096104047e-08
two O 0 1.589046227934432e-09
novel O 0 9.034657466600038e-09
arylsulfatase O 0 3.5826539601657714e-07
A O 0 1.5807341213758264e-08
alleles O 0 1.0773826275567444e-09
and O 0 1.693096440824604e-09
mutation O 0 1.84142923131958e-08
459 O 0 1.2914615865611268e-07
+ O 0 6.09283404173766e-07
1G O 0 4.768476173921954e-06
> O 0 1.4206959519924567e-07
A O 0 6.814633746188292e-09
within O 0 9.32781185625231e-10
a O 0 1.0789290572077448e-09
family O 0 1.216086342736844e-09
with O 0 3.1833418123738966e-09
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
: O 0 8.35363689333235e-09
molecular O 0 9.53573309203648e-09
basis O 0 4.785055018885487e-09
of O 0 7.639061827546811e-09
phenotypic O 0 4.1107188053501886e-07
heterogeneity O 0 2.638325213411008e-06
. O 0 4.070361683261581e-06

In O 0 1.8486645103621413e-08
a O 0 4.9285566738888065e-09
family O 0 3.431680217769184e-10
with O 0 3.7431564792189675e-11
three O 0 6.158654697330235e-10
siblings O 0 1.4619677912719453e-08
, O 0 2.2695913204362483e-10
one O 0 4.2544592848692275e-11
developed O 0 5.784130396868647e-10
classical O 0 3.212303738564515e-07
late O 0 0.0008113825460895896
infantile O 1 0.9999921321868896
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
( O 0 3.0116709126559726e-07
MLD B-Disease 1 1.0
) O 0 2.356462802666215e-09
, O 0 2.2304659508254332e-10
fatal O 0 3.0325293387534202e-09
at O 0 1.0819500850800523e-09
age O 0 1.0201230971063069e-09
5 O 0 3.709308638022435e-09
years O 0 6.855880307909956e-10
, O 0 2.605550775136578e-10
with O 0 1.3530368492276068e-10
deficient O 0 4.1165762354467006e-07
arylsulfatase O 0 1.297530070587527e-05
A O 0 1.0590201782179065e-06
( O 0 6.784728867614831e-08
ARSA O 0 2.9027523851254955e-05
) O 0 8.314291477518054e-10
activity O 0 2.1682931006239414e-09
and O 0 2.6353691451319605e-10
increased O 0 1.1218300066673237e-08
galactosylsulfatide O 0 5.309307198331226e-06
( O 0 7.621193987006336e-08
GS O 1 0.9997449517250061
) O 0 3.574538425255014e-07
excretion O 0 2.7114101612824015e-06
. O 0 5.496967219187354e-07

The O 0 1.0917563031398458e-07
two O 0 2.4870037140800605e-09
other O 0 5.436217032084301e-10
siblings O 0 1.0204155742599141e-08
, O 0 5.322637885996073e-10
apparently O 0 8.460187217451676e-09
healthy O 0 1.6147383430364926e-09
at O 0 8.636067971856676e-10
12 O 0 5.1636250830711106e-09
( O 0 5.900563926353186e-10
1 O 0 3.807362602969988e-08
/ O 0 2.12964778256719e-07
2 O 0 3.307136964281199e-08
) O 0 3.6495642619094326e-10
and O 0 1.3269528531534291e-10
15 O 0 8.732585210502464e-10
years O 0 1.7014964437400693e-10
, O 0 1.0392730426245222e-10
respectively O 0 4.190827407324349e-10
, O 0 2.563681905654036e-11
and O 0 2.0558197505460285e-11
their O 0 6.958543463664313e-11
father O 0 2.187217296167887e-09
, O 0 2.973924717597498e-10
apparently O 0 3.3231959406521128e-09
healthy O 0 7.277681790540669e-10
as O 0 1.2540783689285462e-10
well O 0 3.9426140130416343e-10
, O 0 1.3343187665881828e-09
presented O 0 1.3585922431502695e-07
ARSA O 0 0.00038561763358302414
and O 0 1.2026134754705708e-07
GS O 1 0.8519959449768066
values O 0 7.472044316614301e-09
within O 0 7.406034119306071e-10
the O 0 4.0239656051710426e-10
range O 0 9.194629058129067e-09
of O 0 5.2043056086858996e-08
MLD B-Disease 1 1.0
patients O 0 0.00022395895211957395
. O 0 2.8480362743721344e-06

Mutation O 0 7.521435918533825e-08
screening O 0 3.872057874332313e-08
and O 0 1.001048799409432e-09
sequence O 0 3.124461245285204e-10
analysis O 0 7.734280993432208e-10
disclosed O 0 3.1313356352313804e-09
the O 0 5.012263382120352e-10
involvement O 0 4.950366783162963e-09
of O 0 3.2114373382796657e-09
three O 0 2.930315434745978e-10
different O 0 2.485603389779101e-10
ARSA O 0 3.3414662539144047e-06
mutations O 0 1.9558432651223256e-09
being O 0 6.559331411359892e-10
the O 0 4.0112602128772323e-10
molecular O 0 7.2102741555113425e-09
basis O 0 9.483747120953012e-09
of O 0 2.6032784816720778e-08
intrafamilial O 0 1.9065573724219576e-05
phenotypic O 0 1.3527745750252507e-06
heterogeneity O 0 4.226753844704945e-06
. O 0 2.8120546176069183e-06

The O 0 1.7217215031450905e-07
late O 0 9.0718713181559e-06
infantile O 0 1.7079861208912916e-05
patient O 0 1.6587408424584282e-07
inherited O 0 8.678429708197655e-08
from O 0 2.4995404857008907e-08
his O 0 3.978636442525385e-08
mother O 0 2.7347558884116552e-08
the O 0 6.992877388256602e-09
frequent O 0 6.093795690276238e-09
0 O 0 7.811540747582058e-09
- O 0 3.35531069595163e-08
type O 0 2.548920292611001e-07
mutation O 0 1.7813452757309278e-07
459 O 0 1.5973253653100983e-07
+ O 0 3.900217677710316e-07
1G O 0 2.270344111821032e-06
> O 0 8.291098652080109e-08
A O 0 5.787719636884958e-09
, O 0 1.1422870982435995e-10
and O 0 1.0780151771250246e-10
from O 0 4.372524287088453e-10
his O 0 1.7239066840701867e-09
father O 0 6.308266797816486e-09
a O 0 3.579780916140862e-10
novel O 0 1.0641768577457356e-09
, O 0 8.649349986233901e-11
single O 0 1.1077346817600642e-09
basepair O 0 2.601770177079743e-07
microdeletion O 0 2.656222193309077e-07
of O 0 5.950987258529494e-09
guanine O 0 5.07871753541167e-08
at O 0 7.1256192057944645e-09
nucleotide O 0 1.594694509776673e-08
7 O 0 3.073537513387237e-08
in O 0 2.8909348248618016e-09
exon O 0 2.1644210335125535e-07
1 O 0 1.2593920928338775e-07
( O 0 2.8389759876290555e-08
7delG O 0 2.263805981783662e-06
) O 0 6.938818586377238e-08
. O 0 3.6942861925126635e-07

The O 0 3.1885576845525065e-07
two O 0 3.938551884630215e-08
clinically O 0 2.2358224669005722e-05
unaffected O 0 1.3332373782759532e-07
siblings O 0 2.2330732818431898e-08
carried O 0 3.461157360717948e-09
the O 0 2.677178256860202e-09
maternal O 0 2.8916533665324096e-06
mutation O 0 5.077061615565981e-08
459 O 0 8.14409801819238e-08
+ O 0 2.48952574111172e-07
1G O 0 2.1990667846694123e-06
> O 0 1.1944648292683269e-07
A O 0 1.315698838766366e-08
and O 0 8.231859083274173e-10
, O 0 3.390820124682392e-10
on O 0 2.2953998701780165e-09
their O 0 1.0400964534085233e-09
paternal O 0 4.6870050596226065e-07
allele O 0 1.443756314500888e-08
, O 0 6.291333565222601e-10
a O 0 1.0703694597324898e-09
novel O 0 9.898170283406671e-09
cytosine O 0 5.16173734865788e-08
to O 0 1.3369094720161456e-09
thymidine O 0 3.6803959346798365e-07
transition O 0 1.6718286133254878e-07
at O 0 9.492365649066414e-08
nucleotide O 0 5.22615493991907e-07
2435 O 0 9.186161150864791e-06
in O 0 1.5325120727993635e-08
exon O 0 3.260544474414928e-07
8 O 0 2.3772798840582254e-08
, O 0 8.661801831344462e-10
resulting O 0 3.486665400842526e-10
in O 0 1.2632032919679403e-10
substitution O 0 1.003595873072527e-08
of O 0 5.871467756435322e-09
alanine O 0 8.306309950967261e-08
464 O 0 8.188582967250113e-08
by O 0 1.189210863117296e-08
valine O 0 2.6713842089520767e-05
( O 0 1.030704979143593e-07
A464V O 0 0.00011396937043173239
) O 0 1.1947723521643638e-07
. O 0 4.0800244960337295e-07

The O 0 4.664958055400348e-07
fathers O 0 6.674682708762703e-07
genotype O 0 9.545507850816648e-08
thus O 0 4.8591786594442965e-08
was O 0 3.178887482135906e-07
7delG O 0 1.5646457541151904e-05
/ O 0 0.0001483540254412219
A464V O 0 0.0007599695818498731
. O 0 6.145228780951584e-06

Mutation O 0 2.862699830075144e-06
A464V O 0 6.72457736072829e-06
was O 0 3.485006772052657e-08
not O 0 6.2525379318501e-10
found O 0 2.1484329593146612e-10
in O 0 2.563199097416202e-10
18 O 0 9.56701207144306e-09
unrelated O 0 5.682878168045136e-07
MLD B-Disease 1 1.0
patients O 0 1.6916930690058507e-05
and O 0 1.5593943913927433e-08
50 O 0 4.7052327545316075e-07
controls O 0 3.7960471672704443e-06
. O 0 3.0499209060508292e-06

A464V O 0 9.275009506382048e-05
, O 0 5.6058350850207717e-08
although O 0 1.2687196182525895e-08
clearly O 0 3.261775560758906e-08
modifying O 0 2.030196355917724e-06
ARSA O 1 0.99964439868927
and O 0 4.853843051932927e-07
GS O 1 1.0
levels O 0 2.1116313746460946e-06
, O 0 1.319905851282499e-09
apparently O 0 8.192172273879805e-09
bears O 0 7.775049049030258e-09
little O 0 6.196453350426623e-10
significance O 0 3.4402540816103055e-09
for O 0 8.559288833254186e-10
clinical O 0 2.3743481847304793e-08
manifestation O 0 5.922669998881247e-08
of O 0 1.0443813636129562e-07
MLD B-Disease 1 1.0
, O 0 9.343310125586868e-08
mimicking O 0 1.1264590966675314e-06
the O 0 1.8020902814441797e-07
frequent O 0 1.7602792468096595e-06
ARSA O 0 0.0023483068216592073
pseudodeficiency O 0 0.0005733020370826125
allele O 0 1.0316080079064704e-05
. O 0 2.3554384824819863e-06

Our O 0 2.1053284626759705e-07
results O 0 8.384908767311572e-09
demonstrate O 0 3.2690921081268698e-09
that O 0 2.3972882706724263e-11
in O 0 2.8180232453101084e-11
certain O 0 1.7338711022496511e-10
genetic O 0 4.536391262632833e-09
conditions O 0 1.0879647049932828e-07
MLD B-Disease 1 1.0
- O 0 0.47287270426750183
like O 0 2.170960897274199e-06
ARSA O 1 0.9998449087142944
and O 0 1.844480976842533e-07
GS O 1 0.9999998807907104
values O 0 1.1137901267943562e-08
need O 0 2.7605175922928993e-09
not O 0 8.643841198363589e-11
be O 0 5.094165020369523e-11
paralleled O 0 1.5634259442620646e-09
by O 0 2.579176872075095e-10
clinical O 0 3.768802230297297e-07
disease O 0 9.58421697561107e-09
, O 0 9.759770769335319e-11
a O 0 2.427760492640374e-10
finding O 0 2.1404458205864785e-09
with O 0 1.8620960329229774e-10
serious O 0 1.1877379080260653e-07
diagnostic O 0 7.33134729671292e-05
and O 0 2.2021357892754168e-07
prognostic O 0 0.23832853138446808
implications O 0 3.7766351397294784e-06
. O 0 1.0941585060209036e-06

Moreover O 0 3.048754706469481e-06
, O 0 7.883510022566043e-08
further O 0 8.766905779111767e-08
ARSA O 0 3.782087878789753e-05
alleles O 0 3.1659528332284026e-08
functionally O 0 2.983688673907636e-08
similar O 0 1.3636027862418132e-09
to O 0 1.880137601162346e-09
A464V O 0 8.775134006100416e-07
might O 0 1.910197111598677e-09
exist O 0 4.826024024850994e-10
which O 0 3.268964265945584e-11
, O 0 3.332853784621115e-11
together O 0 3.413400118112975e-11
with O 0 4.204003117846966e-11
0 O 0 7.291246717500144e-09
- O 0 5.369364686202971e-08
type O 0 1.4907918455264735e-07
mutations O 0 2.0376855758286183e-08
, O 0 1.899896018286995e-09
may O 0 1.674722760469649e-08
cause O 0 1.2058570746376063e-06
pathological O 0 0.001911761937662959
ARSA O 0 0.42730411887168884
and O 0 8.1562546938585e-08
GS O 1 1.0
levels O 0 2.180720741762343e-07
, O 0 1.537778099303111e-10
but O 0 3.057366165792885e-11
not O 0 6.285884313061985e-11
clinical O 0 1.3389842568045651e-09
outbreak O 0 3.422372385486483e-10
of O 0 2.500539497685139e-10
the O 0 2.9851161542637783e-09
disease O 0 9.573130910212058e-08
. O 0 9.562068470359009e-09
. O 0 1.6387157586450485e-07

Human O 0 0.00030139347654767334
MLH1 O 1 1.0
deficiency O 1 1.0
predisposes O 0 0.011274155229330063
to O 0 2.3252500795933884e-06
hematological B-Disease 1 1.0
malignancy I-Disease 1 0.9999998807907104
and O 0 7.621339648267167e-08
neurofibromatosis B-Disease 0 0.05042240023612976
type I-Disease 0 5.278716344037093e-05
1 I-Disease 1 0.8677378296852112
. O 0 3.4441934985807166e-05

Heterozygous O 0 2.212059143857914e-06
germ O 0 9.221222717314959e-05
- O 0 3.3303665532002924e-06
line O 0 1.0359595137288125e-07
mutations O 0 2.473096394339791e-09
in O 0 3.268766368691445e-10
the O 0 4.830102984243467e-10
DNA O 0 4.650980489628864e-09
mismatch O 0 2.0577398629484378e-07
repair O 0 8.040628927119542e-06
genes O 0 4.9205659991002904e-08
lead O 0 5.144316332916787e-07
to O 0 7.090372378115717e-07
hereditary B-Disease 1 1.0
nonpolyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.017385395243763924

The O 0 1.3047676930000307e-06
disease O 0 4.897121016256278e-06
susceptibility O 0 1.4440144013860845e-07
of O 0 1.3536474163799994e-08
individuals O 0 9.892843211289915e-10
who O 0 1.444582675702577e-08
constitutionally O 0 1.1407704505472793e-06
lack O 0 3.354780062636564e-07
both O 0 4.216566651393805e-09
wild O 0 1.5622880766841263e-08
- O 0 3.407180315662117e-08
type O 0 2.6896167071299715e-08
alleles O 0 2.7924715872984507e-09
is O 0 5.251444279430473e-10
unknown O 0 1.3208186544488854e-07
. O 0 2.6037980660476023e-07

We O 0 8.240130000558565e-08
have O 0 2.156328671176766e-09
identified O 0 1.8575706528523028e-09
three O 0 2.2098771423895158e-10
offspring O 0 2.69932343144319e-09
in O 0 6.013488595968397e-10
a O 0 3.002499227022781e-08
hereditary B-Disease 1 1.0
nonpolyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 0 0.0009441943257115781
who O 0 8.44118730469745e-08
developed O 0 1.495338324275508e-06
hematological B-Disease 1 1.0
malignancy I-Disease 0 0.41252103447914124
at O 0 6.029628352166583e-09
a O 0 1.8038864846303682e-10
very O 0 3.147169677641948e-11
early O 0 4.8740558256099575e-09
age O 0 5.588715601412275e-10
, O 0 6.291293874749471e-11
and O 0 5.547241832548622e-11
at O 0 3.626160482994578e-10
least O 0 3.4881139643339054e-11
two O 0 2.4670730736087165e-11
of O 0 2.458112324799089e-10
them O 0 3.6796618529955083e-10
displayed O 0 1.7069069713215868e-08
signs O 0 2.917669839064274e-08
of O 0 3.279898663777203e-08
neurofibromatosis B-Disease 0 2.0241070160409436e-05
type I-Disease 0 1.3797595102005289e-06
1 I-Disease 0 9.865011634246912e-06
( O 0 5.381467076404078e-07
NF1 B-Disease 0 0.0006251848535612226
) O 0 8.808185611997033e-07
. O 0 2.4363366719626356e-06

DNA O 0 9.552192636874679e-08
sequence O 0 4.0099772391499755e-09
analysis O 0 3.3345994854272476e-09
and O 0 4.422859578578908e-10
allele O 0 1.5046450752009832e-09
- O 0 1.867321852699888e-09
specific O 0 1.982727870775136e-10
amplification O 0 1.617701528289217e-08
in O 0 6.03792293940586e-10
two O 0 4.860322699862252e-10
siblings O 0 1.9390473227076654e-08
revealed O 0 9.381880161640765e-09
a O 0 9.074206275272445e-09
homozygous O 0 3.679104452203319e-07
MLH1 O 0 0.000142325006891042
mutation O 0 7.013503733332982e-08
( O 0 8.352793123833635e-09
C676T O 0 1.4587178156943992e-05
- O 0 1.5263884051819332e-05
- O 0 3.725638453033753e-05
> O 0 5.8363737480249256e-05
Arg226Stop O 0 0.00013512541772797704
) O 0 9.264078215664995e-08
. O 0 2.657542097495025e-07

Thus O 0 3.3124590004263155e-07
, O 0 2.589452030576922e-08
a O 0 1.396387716567915e-08
homozygous O 0 1.7153674036762823e-07
germ O 0 0.2210252285003662
- O 0 0.00016942368529271334
line O 0 1.1079802789026871e-05
MLH1 O 0 0.0005698601016774774
mutation O 0 1.672762550697371e-08
and O 0 6.954447018259202e-10
consequent O 0 4.955064696332556e-07
mismatch O 1 0.7364300489425659
repair O 1 1.0
deficiency O 1 0.9971626400947571
results O 0 7.344732821934485e-09
in O 0 1.257830506418145e-09
a O 0 2.0217501006669636e-09
mutator O 0 7.154962077038363e-06
phenotype O 0 1.2565051221713475e-08
characterized O 0 3.792920144629619e-10
by O 0 8.096166098647828e-11
leukemia B-Disease 1 0.9999997615814209
and O 0 0.004991874098777771
/ O 1 1.0
or O 1 1.0
lymphoma B-Disease 1 1.0
associated O 1 0.9999998807907104
with O 0 3.5199452241840845e-08
neurofibromatosis B-Disease 1 0.9999927282333374
type I-Disease 0 0.0132902842015028
1 I-Disease 1 0.7389244437217712
. O 0 3.7566910577879753e-06
. O 0 4.452575922186952e-06

Missense O 0 6.938970909686759e-05
mutations O 0 2.0169716208329191e-07
in O 0 7.1664953971151135e-09
the O 0 4.495434691165201e-09
most O 0 5.395476287972656e-10
ancient O 0 5.376022738090569e-09
residues O 0 3.346093180311982e-09
of O 0 2.5502386868936355e-09
the O 0 1.669199356513218e-08
PAX6 O 0 9.017241245601326e-05
paired O 0 1.4199008546711411e-07
domain O 0 2.5886718546530574e-08
underlie O 0 1.655479167084195e-07
a O 0 1.540356286966471e-09
spectrum O 0 4.312924417604336e-08
of O 0 3.525663316850114e-08
human O 0 5.357403279049322e-05
congenital B-Disease 1 1.0
eye I-Disease 1 1.0
malformations I-Disease 1 1.0
. O 1 0.9130372405052185

Mutations O 0 3.7484926451725187e-07
of O 0 5.3317886994364017e-08
the O 0 1.0197015676283172e-08
human O 0 1.2900271073590375e-08
PAX6 O 0 0.0006056400015950203
gene O 0 1.3948432524557575e-06
underlie O 1 0.9999998807907104
aniridia B-Disease 1 1.0
( O 1 0.9999120235443115
congenital B-Disease 1 1.0
absence I-Disease 0 0.001689376076683402
of I-Disease 0 3.4515218771957734e-07
the I-Disease 0 2.226536288674197e-08
iris I-Disease 0 8.653865393171145e-07
) O 0 3.5902292250256096e-10
, O 0 2.6580762590988627e-10
a O 0 4.061457392623424e-09
rare O 0 7.031691893644165e-06
dominant O 1 0.9099283218383789
malformation B-Disease 1 1.0
of I-Disease 1 1.0
the I-Disease 1 1.0
eye I-Disease 1 1.0
. O 0 0.4819389581680298

The O 0 4.5744548060611123e-07
spectrum O 0 1.9507810975483153e-06
of O 0 4.269231794751249e-07
PAX6 O 1 0.9921483993530273
mutations O 0 9.699440397525905e-07
in O 0 9.553522772876022e-08
aniridia B-Disease 1 1.0
patients O 0 6.730106747454556e-07
is O 0 3.7650674244993354e-11
highly O 0 2.766182283231444e-10
biased O 0 6.514445649585809e-10
, O 0 6.562681648114577e-11
with O 0 1.9590818550740963e-11
92 O 0 5.1126576749993546e-08
% O 0 2.0542215151131415e-10
of O 0 2.904795293190432e-10
all O 0 6.565986643281008e-11
reported O 0 2.1588419940599124e-10
mutations O 0 2.351702166336622e-10
leading O 0 1.4414084370528712e-09
to O 0 7.688553127493947e-10
premature O 0 6.264432528269026e-08
truncation O 0 1.8015816749539226e-07
of O 0 2.0245371601390616e-08
the O 0 4.331909053689742e-09
protein O 0 1.7283349196262066e-09
( O 0 1.024657025894271e-09
nonsense O 0 3.973858397898766e-08
, O 0 7.940031410136328e-10
splicing O 0 2.5648645873843634e-08
, O 0 1.8807437829337914e-09
insertions O 0 3.722031749475718e-08
and O 0 4.857746427333609e-10
deletions O 0 2.1764194002571458e-08
) O 0 1.6385211243363784e-10
and O 0 8.530746248291976e-11
just O 0 2.95771768188402e-10
2 O 0 6.367427474174292e-09
% O 0 6.020053344713006e-10
leading O 0 5.100350697340161e-10
to O 0 3.487728161832848e-11
substitution O 0 3.766866818466497e-09
of O 0 4.202267422925843e-09
one O 0 2.6379140538601575e-10
amino O 0 1.4646681090191294e-10
acid O 0 1.9438593790166436e-10
by O 0 7.243886740448957e-11
another O 0 4.50408599306229e-09
( O 0 1.3837832213425827e-08
missense O 0 3.1978900096873986e-06
) O 0 1.815150767470186e-07
. O 0 9.843516863838886e-07

The O 0 8.563559816820998e-08
extraordinary O 0 4.540401477015621e-08
conservation O 0 3.165868633914215e-08
of O 0 7.855048167471068e-09
the O 0 7.748134578378085e-09
PAX6 O 0 3.45306989402161e-06
protein O 0 8.640949289429045e-09
at O 0 1.0819651841131872e-08
the O 0 6.81490686105235e-09
amino O 0 4.6753974913826823e-08
acid O 0 1.7706022958918766e-07
level O 0 2.7929908696933126e-07
amongst O 0 8.896713410422308e-08
vertebrates O 0 9.398142992722569e-07
predicts O 0 2.0641524045572623e-08
that O 0 3.317538743718984e-10
pathological O 0 1.7902880244946573e-07
missense O 0 4.621985567609954e-07
mutations O 0 6.583122935666097e-09
should O 0 6.124239448901392e-10
in O 0 2.4811983023731443e-10
fact O 0 2.659759912315707e-10
be O 0 1.5645408579789688e-10
common O 0 2.566393486613805e-10
even O 0 5.454639517843418e-11
though O 0 2.5670581979553297e-11
they O 0 2.3672090329607265e-11
are O 0 7.865895434999715e-11
hardly O 0 1.0257447335959569e-08
ever O 0 3.3883782446508803e-09
seen O 0 9.330912043026274e-09
in O 0 2.008494703886754e-08
aniridia B-Disease 1 1.0
patients O 0 2.8910968467243947e-05
. O 0 9.273232421946886e-07

This O 0 1.038776531459007e-08
indicates O 0 1.1890022300065084e-08
that O 0 6.13481695999063e-11
there O 0 5.2401256944722974e-11
is O 0 1.6226620741521813e-11
a O 0 7.208163232963472e-11
heavy O 0 1.3594437575648044e-07
ascertainment O 0 2.6798961698659696e-05
bias O 0 4.561312039186305e-08
in O 0 9.871431450036994e-10
the O 0 1.7390253681526247e-09
selection O 0 4.193708047495193e-09
of O 0 2.1510910830357943e-09
patients O 0 1.090648127366478e-09
for O 0 1.1341892702798617e-10
PAX6 O 0 3.287860295131395e-07
mutation O 0 7.858101946922602e-10
analysis O 0 4.1807518558201195e-10
and O 0 1.6914590561523113e-10
that O 0 1.477564043339541e-10
the O 0 6.514722539208151e-09
missing O 0 1.8385605926596327e-06
PAX6 O 0 0.005126996897161007
missense O 0 1.2875764696218539e-05
mutations O 0 9.248788757076909e-08
frequently O 0 1.398194804380637e-08
may O 0 1.2901427481892824e-08
underlie O 0 1.2328224556767964e-06
phenotypes O 0 9.302359416096806e-08
distinct O 0 6.014317488478582e-09
from O 0 2.777700203182576e-08
textbook O 0 7.316820119740441e-05
aniridia B-Disease 1 1.0
. O 0 3.360522441653302e-06

Here O 0 2.815903314967727e-07
we O 0 1.3171250756727204e-08
present O 0 2.1547745809868957e-09
four O 0 1.9133477024979584e-09
novel O 0 1.5692764421260108e-08
PAX6 O 0 1.2147527741035447e-05
missense O 0 7.46379896554572e-07
mutations O 0 1.0062370492391892e-08
, O 0 5.7528393160311e-10
two O 0 1.932606158439043e-10
in O 0 6.30051955052835e-10
association O 0 2.1874175804015294e-09
with O 0 1.243147251805965e-10
atypical O 0 4.2156565882578434e-07
phenotypes O 0 1.7448643347961479e-06
ectopia B-Disease 0 0.00015680388605687767
pupillae I-Disease 0 1.3952775589132216e-05
( O 0 1.327049692356752e-09
displaced B-Disease 0 1.2255805259542285e-08
pupils I-Disease 0 1.3813413524133011e-08
) O 0 1.9022639019539156e-09
and O 0 1.2587207720571314e-07
congenital B-Disease 1 1.0
nystagmus I-Disease 1 1.0
( O 0 6.530522789205406e-09
searching B-Disease 0 1.0680923168138179e-07
gaze I-Disease 0 1.3701844636671012e-07
) O 0 4.4614700822620534e-10
, O 0 2.575558932793598e-10
and O 0 2.867134030193341e-10
two O 0 5.383264389813291e-10
in O 0 1.164888407956255e-09
association O 0 3.549026406091116e-09
with O 0 2.465780635230175e-10
more O 0 8.629518433167505e-09
recognizable O 0 2.2800168153480627e-06
aniridia B-Disease 1 0.9999996423721313
phenotypes O 0 1.2348968084552325e-05
. O 0 1.7113948160840664e-06

Strikingly O 0 7.73702504375251e-06
, O 0 2.6346784309794202e-08
all O 0 2.557452694063045e-09
four O 0 1.426739282273104e-09
mutations O 0 5.934401303697712e-10
are O 0 7.829701470507544e-11
located O 0 1.0295133634485865e-09
within O 0 2.5172941509055136e-09
the O 0 2.3743572441503602e-08
PAX6 O 0 0.00025457184528931975
paired O 0 2.361238244930064e-07
domain O 0 4.797879427087537e-08
and O 0 1.916967695692051e-09
affect O 0 4.062294056694782e-09
amino O 0 1.63399038743961e-09
acids O 0 1.0017249252314286e-09
which O 0 1.4798422903750108e-11
are O 0 2.0937617958849408e-11
highly O 0 5.655122481407204e-10
conserved O 0 1.7602764801338822e-09
in O 0 1.9071064727427256e-09
all O 0 5.532792002327369e-09
known O 0 4.600384428954385e-08
paired O 0 6.77967122442169e-08
domain O 0 7.259360756961541e-08
proteins O 0 1.6859047491379897e-08
. O 0 2.3714430597010505e-07

Our O 0 3.4575936069813906e-07
results O 0 1.6891169352106772e-08
support O 0 7.061744078384891e-09
the O 0 8.011896146520314e-10
hypothesis O 0 8.107714499772101e-10
that O 0 1.2674351585612031e-12
the O 0 1.562521119435889e-11
under O 0 2.500510631886499e-10
- O 0 5.867806240900109e-09
representation O 0 1.295977214432753e-09
of O 0 1.03013659824569e-08
missense O 0 1.4914816404143494e-07
mutations O 0 1.2223863032900795e-09
is O 0 4.34667822568624e-11
caused O 0 4.06412126174871e-10
by O 0 2.959263945001567e-10
ascertainment O 0 4.2001767724286765e-05
bias O 0 1.098440236546594e-07
and O 0 1.8898558273861e-09
suggest O 0 4.821076871053265e-09
that O 0 2.592521856914498e-11
a O 0 5.395638102978495e-11
substantial O 0 2.199642690214887e-09
burden O 0 3.2560822660343547e-07
of O 0 7.255387686200265e-07
PAX6 B-Disease 1 1.0
- I-Disease 1 0.8451669216156006
related I-Disease 0 0.002538023516535759
disease I-Disease 0 2.429806045256555e-05
remains O 0 1.918899261710294e-09
to O 0 9.140379425565115e-11
be O 0 6.995234946849394e-10
uncovered O 0 1.6363543409170234e-07
. O 0 7.494571008237472e-08
. O 0 1.1881643331435043e-06

The O 0 1.28659237930151e-07
chromosomal O 0 5.254620987216185e-07
order O 0 3.406017512475046e-08
of O 0 3.911458534844314e-08
genes O 0 7.995780038072553e-09
controlling O 0 1.9467925937988184e-08
the O 0 2.016355615808152e-08
major O 0 1.1384490790078416e-06
histocompatibility O 1 0.9998420476913452
complex O 0 5.256009671938955e-07
, O 0 1.311244002266676e-09
properdin O 0 7.099317258507654e-07
factor O 0 2.6501410843593476e-08
B O 0 8.661328934067569e-07
, O 0 1.2080844657980094e-10
and O 0 3.9419220665415367e-10
deficiency B-Disease 0 4.294997779652476e-06
of I-Disease 0 3.599935371312313e-05
the I-Disease 0 2.2678336790704634e-06
second I-Disease 0 2.8263712010812014e-06
component I-Disease 0 7.006444207036111e-07
of I-Disease 0 2.1923939641510515e-07
complement I-Disease 0 4.042219188704621e-06
. O 0 4.662481387640582e-06

The O 0 3.1267060052186935e-08
relationship O 0 4.351408677827351e-10
of O 0 2.317280145547329e-09
the O 0 6.069757474413962e-10
genes O 0 3.2835006935627575e-10
coding O 0 2.7890985521139555e-08
for O 0 2.79550937953843e-09
HLA O 0 2.4279404442495434e-06
to O 0 6.806982089102576e-09
those O 0 3.3717708625147225e-09
coding O 0 1.4913806012373243e-07
for O 0 1.9041441756684208e-09
properdin O 0 7.726782200734306e-07
Factor O 0 6.029596022472106e-08
B O 0 2.833361634202447e-07
allotypes O 0 8.065353540587239e-08
and O 0 2.4431548450998264e-10
for O 0 1.1184986270507125e-09
deficiency B-Disease 0 1.504792948026079e-07
of I-Disease 0 6.501220184418344e-08
the I-Disease 0 1.4855173979810843e-08
second I-Disease 0 7.670159618555772e-09
component I-Disease 0 2.114883379533694e-09
of I-Disease 0 1.33251298883863e-09
complement I-Disease 0 5.0039293597592405e-08
( O 0 9.81687264811626e-09
C2 O 0 9.578932076692581e-05
) O 0 2.702263690590456e-10
was O 0 2.005932531190524e-09
studied O 0 6.097039317864983e-09
in O 0 1.86633458687524e-10
families O 0 1.7368434468423288e-10
of O 0 2.857962977387274e-09
patients O 0 9.168469006226587e-08
with O 0 1.585311437679593e-08
connective O 1 1.0
tissue O 1 1.0
disorders O 1 1.0
. O 0 0.00022618276125285774

Patients O 0 9.320960430159175e-07
were O 0 2.4596988890124294e-09
selected O 0 9.871996553556528e-10
because O 0 1.0775876024826658e-10
they O 0 3.9513994853912493e-10
were O 0 3.1438791570082003e-09
heterozygous O 0 1.61190509828657e-08
or O 0 3.9711384403062766e-08
homozygous O 0 6.286886218731524e-06
for O 0 0.0001237195247085765
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 8.799198985798284e-05

12 O 0 4.6850701096445846e-07
families O 0 3.894060629505702e-09
with O 0 2.0379010978732737e-10
15 O 0 3.6220370702721993e-08
matings O 0 9.028130421029346e-07
informative O 0 2.4645853500260273e-06
for O 0 7.164986072893953e-06
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
were O 0 1.5598427580698626e-06
found O 0 8.977836785106774e-08
. O 0 2.0617490292806906e-07

Of O 0 2.2100537080405047e-06
57 O 0 1.171919848275138e-06
informative O 0 1.917470200396565e-07
meioses O 0 2.254612581964466e-06
, O 0 1.0444023423872295e-09
two O 0 7.583337430228099e-11
crossovers O 0 1.948820216313152e-09
were O 0 5.837774152972486e-10
noted O 0 6.871301860833512e-10
between O 0 3.9541062091252854e-10
the O 0 7.409852059936384e-06
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
gene O 0 1.4672868253740035e-08
and O 0 2.3545445593242675e-09
the O 0 3.171120255274218e-08
HLA O 0 9.112359839491546e-05
- O 0 0.0001276460534427315
B O 0 7.634649227838963e-05
gene O 0 1.427735707437705e-09
, O 0 6.76929831633366e-11
with O 0 1.175825235788519e-11
a O 0 3.040700469192359e-10
recombinant O 0 2.107602981027412e-09
fraction O 0 7.2809762663439415e-09
of O 0 2.458743253441753e-08
0 O 0 4.0568767190052313e-07
. O 0 8.115378591355693e-07

035 O 0 0.023014629259705544
. O 0 0.00013248100003693253

A O 0 2.751310432813625e-07
lod O 0 8.182116289390251e-06
score O 0 1.265091924551598e-07
of O 0 1.6588019846608404e-08
13 O 0 8.84900241970854e-09
was O 0 1.5526386842878992e-09
calculated O 0 4.957734778265888e-10
for O 0 3.1759656016205895e-10
linkage O 0 1.6548490748391487e-05
between O 1 0.9684087038040161
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
and O 0 2.5166912109853e-07
HLA O 0 0.00015101458120625466
- O 0 2.095979652949609e-05
B O 0 7.726156582066324e-06
at O 0 1.1918989129000579e-09
a O 0 5.710855052742936e-11
maximum O 0 4.777611084527678e-10
likelihood O 0 1.4970698292149365e-10
value O 0 4.739690306898581e-10
of O 0 1.3363180562109278e-09
the O 0 1.4135210779642193e-09
recombinant O 0 8.756055436265342e-09
fraction O 0 1.983342734490634e-08
of O 0 2.968572054840024e-08
0 O 0 6.660959570581326e-07
. O 0 1.1327308584441198e-06

04 O 0 0.004576853010803461
. O 0 8.153083035722375e-05

18 O 0 2.1382989245921635e-07
families O 0 1.9580976839961295e-09
with O 0 1.0885444629016305e-10
21 O 0 1.7964341125775718e-08
informative O 0 1.8010384295052972e-08
matings O 0 2.543584720626768e-08
for O 0 2.0351829110865083e-09
both O 0 3.4857829955825537e-09
properdin O 0 7.090878625604091e-06
Factor O 0 8.427801390098466e-07
B O 0 7.0938131102593616e-06
allotype O 0 1.918669795486494e-06
and O 0 1.557925699557927e-08
HLA O 0 8.527441968908533e-05
- O 0 0.0006843352457508445
B O 0 0.05716979131102562
were O 0 9.509471965429839e-08
found O 0 2.7278273861952584e-08
. O 0 1.5662554631035164e-07

Of O 0 5.491258889378514e-06
72 O 0 5.4543843361898325e-06
informative O 0 1.4673786381536047e-06
meioses O 0 5.561245416174643e-06
, O 0 6.361624560469181e-09
three O 0 1.1509854180857815e-09
recombinants O 0 3.411004456665978e-07
were O 0 3.361189104822415e-09
found O 0 5.203525943464626e-10
, O 0 1.1898586282921286e-10
giving O 0 3.664994419061429e-10
a O 0 1.9732433742536415e-10
recombinant O 0 3.423666461443986e-09
fraction O 0 1.4076566579035443e-08
of O 0 8.134473006293774e-08
0 O 0 1.6794174371170811e-06
. O 0 1.2643685067814658e-06

042 O 0 0.008123124949634075
. O 0 6.740404205629602e-05

A O 0 6.086213488742942e-07
lod O 0 2.5043538698810153e-05
score O 0 2.523242415009008e-07
of O 0 6.520219386629833e-08
16 O 0 6.440165378762686e-08
between O 0 2.7928979129399067e-09
HLA O 0 4.1165854781866074e-05
- O 0 1.7972288333112374e-05
B O 0 2.306052192579955e-05
and O 0 7.315090200243901e-10
Factor O 0 3.005089155294627e-08
B O 0 3.4303101870136743e-07
allotypes O 0 6.987826850490819e-08
was O 0 1.2958834005871722e-09
calculated O 0 8.307253218653443e-10
at O 0 4.079436510817658e-10
a O 0 9.23701670707544e-11
maximum O 0 4.611739601312337e-10
likelihood O 0 1.830393475676928e-10
value O 0 3.8562816828680013e-10
of O 0 1.1145758760378044e-09
the O 0 1.7462514767530024e-09
recombinant O 0 9.73080194199838e-09
fraction O 0 1.2077770783491815e-08
of O 0 2.6134374664366078e-08
0 O 0 7.634497478647972e-07
. O 0 8.664782171763363e-07

04 O 0 0.0043931077234447
. O 0 4.621416883310303e-05

A O 0 4.592599722741397e-08
crossover O 0 1.9671427153866716e-08
was O 0 7.154068004666669e-09
shown O 0 4.664553188149512e-10
to O 0 1.694610701763466e-10
have O 0 4.4575294844140245e-11
occurred O 0 3.245630431081281e-10
between O 0 7.391365297593211e-12
genes O 0 3.6744000203592364e-11
for O 0 8.702867593246566e-11
Factor O 0 7.363795795356509e-09
B O 0 3.529586933836981e-07
and O 0 1.1578088487951277e-09
HLA O 0 3.1265144571079873e-06
- O 0 2.0048175429110415e-05
D O 0 2.0302608390920796e-05
, O 0 3.169878803888082e-09
in O 0 4.111713747256829e-10
which O 0 1.2619030820282262e-10
HLA O 0 4.42085735130604e-07
- O 0 1.173532609755057e-06
D O 0 1.248924218089087e-05
segregared O 0 2.190081613662187e-05
with O 0 2.200347681835524e-09
HLA O 0 4.74124972242862e-05
- O 0 1.6747642803238705e-05
A O 0 6.619729447265854e-06
and O 0 4.3796237036985985e-07
B O 0 0.0010030174162238836
. O 0 2.4127007236529607e-07

These O 0 1.0381982384899402e-08
studies O 0 4.082216786827075e-09
suggest O 0 6.45933750931249e-10
that O 0 6.853637449233396e-12
the O 0 3.3760466644494613e-11
genes O 0 1.1654077702871746e-10
for O 0 3.1602664929408775e-10
Factor O 0 1.5764607042001444e-06
B O 1 1.0
and O 1 0.5907264947891235
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
are O 0 1.6395630408894135e-09
located O 0 1.5762945115849192e-10
outside O 0 2.4948035304284133e-10
those O 0 3.601578410505901e-11
for O 0 1.8211754326813434e-10
HLA O 0 2.4994312752824044e-07
, O 0 2.8826135922699336e-10
that O 0 2.0047408177958914e-11
the O 0 8.99668048393032e-11
order O 0 6.501920113421988e-10
of O 0 2.684633626515165e-09
genese O 0 4.5710226004302967e-07
is O 0 1.6553521053896958e-10
HLA O 0 5.1900507003210805e-08
- O 0 5.587666151996018e-08
A O 0 8.68742304760417e-08
, O 0 1.4482263166470943e-09
- O 0 3.354120181597864e-08
B O 0 3.4613185562193394e-07
, O 0 1.794045745295847e-10
- O 0 7.1186234684716965e-09
D O 0 8.897137604435557e-08
, O 0 8.420323882596392e-10
Factor O 0 1.0227073943269716e-07
B O 0 7.27778096916154e-05
allotype O 0 0.0004948948626406491
, O 0 7.117084805940976e-07
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
, O 0 7.324695294741446e-10
that O 0 8.951795034406462e-12
the O 0 1.0535371880449063e-10
genes O 0 7.231383825079263e-10
coding O 0 8.569458259444218e-06
for O 0 4.2932701035169885e-05
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
and O 0 1.4511469359490548e-08
Factor O 0 2.1002168182349124e-07
B O 0 4.0268761836159683e-07
allotypes O 0 3.7090348570245624e-08
are O 0 1.6779015676871012e-11
approximately O 0 2.941367982511878e-11
3 O 0 4.591377555929199e-10
- O 0 1.1988123382877802e-08
- O 0 2.968776868783607e-07
5 O 0 1.8274550939167966e-07
centimorgans O 0 2.1003820620535407e-06
from O 0 3.287199623613901e-09
the O 0 2.6604816127928643e-09
HLA O 0 8.833321203383093e-07
- O 0 9.099632620745979e-07
A O 0 2.5417668325644627e-07
and O 0 1.1801251531551316e-08
HLA O 0 1.7615269825910218e-05
- O 0 3.6545075090543833e-06
B O 0 2.1848684355063597e-06
loci O 0 1.975209995563887e-09
, O 0 1.7059994042445403e-11
and O 0 3.6237850827708362e-12
that O 0 5.728173469408959e-13
the O 0 2.3038937077557442e-11
apparent O 0 1.5428025523789302e-09
lack O 0 2.015982580871878e-08
of O 0 2.8889958869626753e-08
recombinants O 0 9.738359949551523e-07
between O 0 5.449256046397011e-10
the O 0 5.169715322494994e-09
Factor O 0 6.758496624570398e-07
B O 0 0.20658721029758453
gene O 0 6.462067290158302e-07
and O 0 0.0018063163151964545
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
gene O 0 1.272954648356972e-07
suggests O 0 3.5754565974599473e-09
that O 0 1.5250072038508478e-11
these O 0 3.028122197434868e-11
two O 0 8.434561382664185e-11
genes O 0 5.060524221889295e-10
lie O 0 1.2459346887538914e-09
in O 0 1.3226268691379772e-10
close O 0 8.98296770301954e-10
proximity O 0 7.8234991818249e-09
to O 0 3.190404829211957e-09
one O 0 7.094198561929943e-09
another O 0 1.2026833928757696e-07
. O 0 1.2432597031875048e-06

Distribution O 0 3.5026396005832794e-08
of O 0 6.274454023014187e-08
emerin O 0 1.5021251783764455e-05
and O 0 1.1543277445014155e-08
lamins O 0 9.744279850565363e-06
in O 0 4.086829097360578e-09
the O 0 7.745312835538698e-09
heart O 0 5.395902462623781e-07
and O 0 1.4550790572442907e-09
implications O 0 2.2814466760223695e-08
for O 0 1.4244397661400399e-08
Emery B-Disease 1 0.9901129007339478
- I-Disease 1 1.0
Dreifuss I-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 0.0017880190862342715

Emerin O 0 0.001204584608785808
is O 0 2.735804649489637e-08
a O 0 1.3644196883433324e-09
nuclear O 0 2.167260504393198e-08
membrane O 0 1.0725280219503475e-08
protein O 0 2.4381272001328114e-10
which O 0 7.76627720466827e-12
is O 0 1.518381080589659e-11
missing O 0 3.4468090603922974e-09
or O 0 1.33750388542353e-09
defective O 0 1.7817169464251492e-06
in O 0 6.181803655636031e-07
Emery B-Disease 1 1.0
- I-Disease 1 1.0
Dreifuss I-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 4.663584149966482e-06
EDMD B-Disease 1 1.0
) O 0 5.197579753257742e-07
. O 0 9.312989845966513e-07

It O 0 5.421412652140134e-09
is O 0 2.1448298692661183e-10
one O 0 5.30546578891844e-11
member O 0 3.1341662598549647e-10
of O 0 4.310110046645832e-09
a O 0 6.481568171068375e-09
family O 0 2.0867627625875684e-09
of O 0 1.5640949868611642e-08
lamina O 1 0.9990691542625427
- O 0 0.0001268244523089379
associated O 0 3.5371215290069813e-07
proteins O 0 4.0073142026919584e-10
which O 0 5.7347598891865914e-11
includes O 0 1.140472050131791e-09
LAP1 O 0 4.09602616855409e-05
, O 0 1.9500033587860344e-08
LAP2 O 0 0.00044272522791288793
and O 0 1.3418117816854647e-07
lamin O 0 6.056944403098896e-05
B O 0 2.358293158977176e-06
receptor O 0 2.6428018884416815e-08
( O 0 4.5428791395352164e-08
LBR O 0 0.00011690730025293306
) O 0 3.5530993613974715e-07
. O 0 2.850370265150559e-06

A O 0 2.560649818406091e-06
panel O 0 1.4673740622583864e-07
of O 0 2.3147503469544972e-08
16 O 0 2.2638737107172346e-08
monoclonal O 0 8.563261211236295e-09
antibodies O 0 2.628092188317055e-09
( O 0 6.5647789426748204e-09
mAbs O 0 2.2825668111181585e-06
) O 0 5.318541163035206e-09
has O 0 8.303355780725497e-10
been O 0 8.16895107114135e-10
mapped O 0 2.455583070215539e-09
to O 0 9.548978274764863e-10
six O 0 7.494392328943889e-10
specific O 0 6.707661648341912e-10
sites O 0 1.6685174353270327e-09
throughout O 0 6.49177156475389e-10
the O 0 4.937794062520595e-10
emerin O 0 2.2175132841084633e-08
molecule O 0 3.011650373530017e-10
using O 0 4.185669144618487e-09
phage O 0 3.720016295005735e-08
- O 0 2.9156556280440782e-08
displayed O 0 1.7451601053153354e-08
peptide O 0 2.2178474168299545e-08
libraries O 0 1.6044880979393383e-08
and O 0 4.812676923648951e-10
has O 0 4.1254194504958264e-11
been O 0 6.303714494837465e-11
used O 0 5.539547154320701e-10
to O 0 2.2746196037815025e-09
localize O 0 6.818874567215971e-07
emerin O 0 7.2192319748864975e-06
in O 0 7.338851304439231e-09
human O 0 1.556948525660573e-08
and O 0 5.870831998322501e-08
rabbit O 0 2.7146828870172612e-05
heart O 0 0.06120536848902702
. O 0 6.958652193134185e-06

Several O 0 3.821834582140582e-07
mAbs O 0 4.9782725000113714e-06
against O 0 9.354684138429548e-09
different O 0 1.6454589912839879e-09
emerin O 0 2.212829031122965e-06
epitopes O 0 2.567909973549831e-07
did O 0 2.417315769775996e-08
not O 0 2.4869466486165948e-09
recognize O 0 5.515575551839902e-09
intercalated O 0 9.660990372140077e-07
discs O 0 3.0843807508063037e-06
in O 0 2.3161090823009545e-09
the O 0 5.138826697503873e-09
heart O 0 1.418452825419081e-06
, O 0 8.010002106040304e-10
though O 0 1.8564823289768384e-10
they O 0 1.6142077952085998e-10
recognized O 0 2.323888415034503e-09
cardiomyocyte O 0 8.305961785026739e-08
nuclei O 0 3.1634300512450864e-08
strongly O 0 3.435401740858879e-09
, O 0 6.646708738955454e-10
both O 0 1.001404070777312e-09
at O 0 1.878106381525413e-08
the O 0 1.1988123382877802e-08
rim O 0 4.899775376543403e-07
and O 0 8.588431077427572e-10
in O 0 2.3200663612499284e-09
intranuclear O 0 4.318573701311834e-06
spots O 0 5.0313293087356215e-08
or O 0 1.3343321114689388e-08
channels O 0 1.5285847609902703e-07
. O 0 2.2986678516190295e-07

A O 0 2.0057394067407586e-05
polyclonal O 0 9.197283361572772e-05
rabbit O 0 1.1793794328696094e-05
antiserum O 0 1.0294941603206098e-05
against O 0 9.525737709736859e-08
emerin O 0 3.820331039605662e-05
did O 0 2.481913838892069e-07
recognize O 0 2.6270813080486732e-08
both O 0 3.0500129089006123e-09
nuclear O 0 1.0194024469001306e-07
membrane O 0 1.3815012778195523e-07
and O 0 1.4437885331730627e-09
intercalated O 0 2.379396875085149e-07
discs O 0 1.603305008757161e-07
but O 0 2.7338509234198227e-10
, O 0 1.2479842159685006e-10
after O 0 1.9012652563432653e-10
affinity O 0 3.1826177804283873e-10
purification O 0 9.904912445790615e-09
against O 0 2.7160290683170274e-10
a O 0 5.793736601589217e-10
pure O 0 6.996963008987223e-08
- O 0 1.5845985501528048e-07
emerin O 0 3.2286841360473773e-06
band O 0 3.0573190201721445e-07
on O 0 6.142129027608689e-09
a O 0 1.0600280653250138e-09
western O 0 1.624187895288287e-08
blot O 0 2.6950041842610517e-07
, O 0 1.2245284786160937e-09
it O 0 1.3288802003241784e-10
stained O 0 6.131011787147145e-08
only O 0 1.298146923289778e-09
the O 0 3.604488929553895e-09
nuclear O 0 8.497199246448872e-07
membrane O 0 7.31263844500063e-06
. O 0 1.5053527704367298e-06

These O 0 5.824719373492826e-09
results O 0 1.045026065682464e-09
would O 0 3.6013536597323537e-10
not O 0 7.810698615662304e-11
be O 0 7.370012933272108e-11
expected O 0 9.181025384386032e-10
if O 0 7.769900278731257e-10
immunostaining O 0 6.285126232796756e-07
at O 0 1.3160351031160644e-08
intercalated O 0 3.0913403747945267e-07
discs O 0 5.489679892889399e-07
were O 0 4.024190314311227e-09
due O 0 2.8884323821642965e-09
to O 0 3.2085645251811457e-10
a O 0 1.7073414904089645e-10
product O 0 1.2275117033944127e-10
of O 0 4.849026735698203e-10
the O 0 5.246689194216003e-10
emerin O 0 1.7065643476144032e-07
gene O 0 5.743476250152924e-10
and O 0 2.8263680285078863e-10
, O 0 2.782596930650527e-10
therefore O 0 8.432040066175261e-10
, O 0 7.310734656540419e-11
cast O 0 5.235772371214864e-10
some O 0 1.0941563627353545e-10
doubt O 0 1.9157762043420234e-09
upon O 0 7.763071296906787e-10
the O 0 9.711051962568717e-10
hypothesis O 0 8.253810968028574e-09
that O 0 9.695352159999615e-11
cardiac B-Disease 1 0.9999631643295288
defects I-Disease 0 1.9551898731151596e-05
in O 0 9.257701805154284e-08
EDMD B-Disease 1 1.0
are O 0 1.731736865018263e-09
caused O 0 1.889192580151189e-09
by O 0 1.0709284153920251e-10
absence O 0 1.505673807855601e-08
of O 0 5.407071768104288e-08
emerin O 0 2.339270395168569e-05
from O 0 4.854342705584713e-08
intercalated O 0 3.745138019439764e-05
discs O 0 0.0007301285513676703
. O 0 3.74141404790862e-06

Although O 0 7.59097304126044e-07
emerin O 0 2.8355743779684417e-05
was O 0 6.44440447672423e-08
abundant O 0 2.3144986371903542e-08
in O 0 4.3275133476683436e-10
the O 0 9.17110165588042e-10
membranes O 0 2.8317074907135975e-08
of O 0 2.1725319321319603e-09
cardiomyocyte O 0 3.7607094327540835e-08
nuclei O 0 3.1781728360158468e-09
, O 0 2.244836261322547e-10
it O 0 6.237026867195183e-11
was O 0 1.3452053693185917e-08
absent O 0 1.2462115250855277e-07
from O 0 2.9695785830341492e-09
many O 0 8.388871819420274e-10
non O 0 1.0465888067301421e-07
- O 0 9.419285618150752e-08
myocyte O 0 2.1371156435634475e-06
cells O 0 1.7717297851049807e-08
in O 0 1.734599575087259e-09
the O 0 1.6854254880627195e-08
heart O 0 1.840874938352499e-05
. O 0 2.380943215030129e-06

This O 0 4.210121584691251e-09
distribution O 0 2.4632291761861325e-09
of O 0 5.107537504045467e-09
emerin O 0 9.826052291828091e-07
was O 0 6.93485979752495e-09
similar O 0 2.0558363345024588e-10
to O 0 1.8494315801032002e-10
that O 0 5.123661217520947e-11
of O 0 3.928923408835772e-09
lamin O 0 8.676408924657153e-07
A O 0 9.13120601353512e-09
, O 0 2.5780458323687583e-10
a O 0 2.582938307682525e-10
candidate O 0 3.5922428920365235e-10
gene O 0 2.666068199541627e-10
for O 0 2.964354040013717e-10
an O 0 6.81594336526814e-10
autosomal O 0 6.596146562287686e-08
form O 0 4.074572501622242e-08
of O 0 0.2303486317396164
EDMD B-Disease 1 1.0
. O 0 4.8622823669575155e-05

In O 0 1.6843257810705836e-07
contrast O 0 1.2508074576089712e-07
, O 0 6.14094872730675e-08
lamin O 0 0.002039563376456499
B1 O 1 0.8561233282089233
was O 0 1.1508365105328267e-06
absent O 0 9.987303428715677e-07
from O 0 1.352274558996669e-08
cardiomyocyte O 0 4.284898977857665e-07
nuclei O 0 7.365217413735081e-08
, O 0 6.526637452708428e-09
showing O 0 5.657069834796857e-08
that O 0 4.199263159421207e-09
lamin O 0 0.00016199312813114375
B1 O 0 7.665975135751069e-05
is O 0 1.1761629448159283e-09
not O 0 3.23625903853042e-10
essential O 0 3.2036631125720305e-08
for O 0 1.0901302083254905e-09
localization O 0 5.196066013013478e-06
of O 0 7.527922463168579e-08
emerin O 0 3.822927737928694e-06
to O 0 5.138512726432509e-09
the O 0 1.2694966855519851e-08
nuclear O 0 5.377642992243636e-06
lamina O 1 0.9979729056358337
. O 0 1.3219470019976143e-05

Lamin O 1 0.999984860420227
B1 O 1 0.9964145421981812
is O 0 2.6115637652424084e-08
also O 0 5.8605587049953556e-09
almost O 0 3.798996672799149e-09
completely O 0 1.2923598546876747e-07
absent O 0 7.842728564355639e-07
from O 0 5.578082351576086e-08
skeletal O 0 1.5037190678413026e-05
muscle O 0 1.6029791822802508e-06
nuclei O 0 8.454691851511598e-06
. O 0 2.0756922822329216e-05

In O 0 3.2275838179884886e-07
EDMD B-Disease 1 1.0
, O 0 6.045508982310821e-09
the O 0 6.939778196546342e-10
additional O 0 5.126588931148035e-09
absence O 0 6.516340533835319e-08
of O 0 3.4438969009897846e-07
lamin O 1 0.9999996423721313
B1 O 1 1.0
from O 0 8.962914535004529e-07
heart O 1 0.9999998807907104
and O 0 7.499303364966181e-07
skeletal O 1 0.9999947547912598
muscle O 0 1.995275624722126e-06
nuclei O 0 1.0581418337096693e-06
which O 0 1.0368287561846046e-08
already O 0 2.4648990404330107e-08
lack O 0 6.170877782096795e-07
emerin O 0 8.319798325828742e-06
may O 0 3.4251688152409088e-09
offer O 0 5.822295423563162e-10
an O 0 2.406712329428018e-11
alternative O 0 3.133151960099667e-09
explanation O 0 2.8622832992653002e-09
of O 0 1.5609707970654085e-09
why O 0 3.73572861533944e-09
these O 0 5.100759259413223e-10
tissues O 0 6.854068601569452e-08
are O 0 1.8198351159348647e-10
particularly O 0 3.0270050910274904e-09
affected O 0 2.820897737620953e-09
. O 0 9.104302201023984e-09
. O 0 2.441583433210326e-07

Genetic O 0 3.3988794712058734e-07
mapping O 0 1.31109629819548e-07
of O 0 3.042600482672242e-08
the O 0 7.124874912278756e-08
copper B-Disease 0 0.4061174988746643
toxicosis I-Disease 1 0.9999966621398926
locus O 0 8.875296657606668e-07
in O 0 1.860464848846277e-08
Bedlington O 0 5.84007966608624e-06
terriers O 0 9.64760261012998e-07
to O 0 1.47000394079555e-08
dog O 0 8.679953111823124e-08
chromosome O 0 1.9483712421219934e-08
10 O 0 4.145711773873018e-09
, O 0 2.0265904232541487e-10
in O 0 2.6049248869064456e-10
a O 0 9.132263278921471e-10
region O 0 1.1034206437443572e-08
syntenic O 0 9.331446904070617e-07
to O 0 2.3179034247533536e-09
human O 0 2.679047650389066e-09
chromosome O 0 3.0922240767949916e-08
region O 0 1.010588093208753e-07
2p13 O 0 0.00010611340985633433
- O 0 3.0433715437538922e-05
p16 O 0 2.465848228894174e-05
. O 0 3.32851845996629e-06

Abnormal O 1 0.9984264373779297
hepatic B-Disease 1 0.9999995231628418
copper I-Disease 0 8.867343422025442e-05
accumulation I-Disease 0 1.2743683328153566e-05
is O 0 2.3944471405634715e-10
recognized O 0 5.285378801289653e-10
as O 0 2.3167487372965923e-10
an O 0 4.850200796546744e-10
inherited B-Disease 1 1.0
disorder I-Disease 1 1.0
in O 0 7.679415148231783e-08
man O 0 6.466468960297789e-08
, O 0 3.0232083503278773e-09
mouse O 0 4.0260582068185613e-07
, O 0 4.2929240606781605e-08
rat O 0 0.03462390974164009
and O 0 4.17751471104566e-06
dog O 1 0.8844178915023804
. O 0 0.00018160638865083456

The O 0 7.210662289480751e-08
major O 0 6.674790853367085e-08
cause O 0 1.5989866142263054e-07
of O 0 2.8817268571401655e-07
hepatic B-Disease 1 1.0
copper I-Disease 1 0.9944394826889038
accumulation I-Disease 1 0.9934737086296082
in O 0 6.89930672592709e-08
man O 0 1.680745924659277e-07
is O 0 3.732357756192073e-10
a O 0 1.8051644623540142e-09
dysfunctional O 0 1.623018022200995e-07
ATP7B O 1 0.9995111227035522
gene O 0 2.9270674772874372e-08
, O 0 6.9629315646579926e-09
causing O 0 6.378430157383264e-07
Wilson B-Disease 0 4.9259182560490444e-05
disease I-Disease 0 1.0204835234617349e-05
( O 0 3.568304762779917e-08
WD B-Disease 0 0.00019995510228909552
) O 0 7.317077574953146e-07
. O 0 3.6167848520562984e-06

Mutations O 0 9.800226052902872e-08
in O 0 7.359148401775428e-09
the O 0 1.1092341267726624e-08
ATP7B O 0 0.0002571741060819477
genes O 0 6.261157370346382e-09
have O 0 3.906951151488869e-10
also O 0 1.9163817754908052e-10
been O 0 1.0413107875972827e-10
demonstrated O 0 1.7832831877839794e-09
in O 0 5.731167984635022e-09
mouse O 0 1.2117744745410164e-06
and O 0 2.5211161869265197e-07
rat O 0 0.00328875333070755
. O 0 1.0011926860897802e-05

The O 0 1.0171897883992642e-06
ATP7B O 0 0.14372292160987854
gene O 0 1.1296666713178638e-07
has O 0 4.423914290452302e-10
been O 0 1.8629629783273316e-10
excluded O 0 1.2781355973601194e-09
in O 0 9.851375964986531e-11
the O 0 7.969435666943525e-10
much O 0 3.1270024347662684e-09
rarer O 0 2.663296527316561e-06
human O 0 1.0934214600410996e-07
copper B-Disease 1 0.9995794892311096
overload I-Disease 1 1.0
disease O 1 0.9794466495513916
non B-Disease 0 6.362142448779196e-05
- I-Disease 0 4.930293926008744e-06
Indian I-Disease 0 9.971488879045864e-08
childhood I-Disease 0 1.8704793092183536e-06
cirrhosis I-Disease 0 1.3500781278708018e-05
, O 0 4.602813685750107e-09
indicating O 0 4.073150705607986e-08
genetic O 0 3.1790474253057255e-08
heterogeneity O 0 1.2537816473923158e-06
. O 0 1.2668258477788186e-06

By O 0 8.694381214979785e-09
investigating O 0 1.24559784708822e-08
the O 0 1.6632245802838952e-08
common O 0 3.5343803119758377e-06
autosomal O 1 0.9994662404060364
recessive O 1 0.9810614585876465
copper B-Disease 1 1.0
toxicosis I-Disease 1 1.0
( O 0 1.8959842407184624e-07
CT B-Disease 1 0.9999899864196777
) O 0 2.8464839374464646e-09
in O 0 1.1087815110499832e-08
Bedlington O 0 3.6936406104359776e-05
terriers O 0 3.5897376164939487e-06
, O 0 2.780714991601485e-09
we O 0 8.787572891577611e-10
have O 0 1.674488048220013e-10
identified O 0 3.3903416185587787e-10
a O 0 8.197009737642702e-11
new O 0 2.0621433727274763e-10
locus O 0 5.213522502600654e-09
involved O 0 3.403585191463776e-10
in O 0 3.825996408579613e-09
progressive O 1 1.0
liver B-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 3.653043904705555e-06

We O 0 2.3294262518902542e-07
examined O 0 3.5868998793375795e-07
whether O 0 1.328336818318121e-08
the O 0 4.836764588844744e-08
WD B-Disease 0 0.0022765558678656816
gene O 0 3.1382965062221047e-06
ATP7B O 1 0.9998965263366699
was O 0 5.928908421992674e-07
also O 0 3.757179900532037e-09
causative O 0 1.380435321607365e-08
for O 0 1.721435771706581e-09
CT B-Disease 0 1.808302477002144e-05
by O 0 1.9802195438956005e-09
investigating O 0 6.0544405044993255e-09
the O 0 1.1113328035605718e-08
chromosomal O 0 1.528877874079626e-06
co O 0 3.581567398214247e-07
- O 0 3.680080453705159e-06
localization O 1 0.9024521112442017
of O 0 1.7556386637807009e-06
ATP7B O 0 0.000573628640267998
and O 0 6.1902194481433526e-09
C04107 O 0 5.130876843395527e-07
, O 0 4.4558232104030537e-10
using O 0 1.2295673368356574e-09
fluorescence O 0 1.1711960290483603e-08
in O 0 4.423343025194981e-09
situ O 0 1.7748401432982064e-06
hybridization O 0 1.838799192910301e-07
( O 0 2.8850642763700307e-08
FISH O 0 6.7816827140632086e-06
) O 0 8.694716768786748e-08
. O 0 1.0642119150361395e-06

C04107 O 0 0.00015806984447408468
is O 0 1.7693659870587908e-08
an O 0 1.7684066433432122e-09
anonymous O 0 6.403968910717595e-08
microsatellite O 0 7.725647606093844e-07
marker O 0 5.715701831832121e-07
closely O 0 2.9037957816058224e-08
linked O 0 4.3581084696597827e-07
to O 0 2.492150770194712e-07
CT B-Disease 1 1.0
. O 0 0.0012838696129620075

However O 0 1.6380843135266332e-06
, O 0 2.564451904163434e-07
BAC O 0 9.455462713958696e-05
clones O 0 1.779918534339231e-06
containing O 0 3.6025596727995435e-07
ATP7B O 0 0.00011144045129185542
and O 0 3.3534167442894613e-08
C04107 O 0 9.596769814379513e-06
mapped O 0 9.433417602622285e-08
to O 0 7.57334284173794e-09
the O 0 1.5903356853641526e-08
canine O 0 1.1651210343188723e-06
chromosome O 0 2.6934728225569415e-07
regions O 0 1.224213885819836e-08
CFA22q11 O 0 1.3048547771177255e-06
and O 0 3.2196190158373383e-09
CFA10q26 O 0 6.2775334299658425e-06
, O 0 2.3810589055983655e-09
respectively O 0 4.047568058496154e-09
, O 0 3.474397436420418e-10
demonstrating O 0 3.4646712165908866e-09
that O 0 5.52742816795071e-11
WD B-Disease 0 1.8605683749228774e-07
cannot O 0 1.1772542940491348e-08
be O 0 2.8675399832422954e-09
homologous O 0 2.953706967900871e-08
to O 0 3.6374902379066043e-07
CT B-Disease 1 0.9999898672103882
. O 0 5.748893090640195e-05

The O 0 6.803596193094563e-07
copper O 0 1.5460930171684595e-06
transport O 0 2.7825370807477157e-07
genes O 0 4.337459102998764e-08
CTR1 O 0 5.060324110672809e-05
and O 0 1.7799944629359743e-08
CTR2 O 0 0.1240902692079544
were O 0 5.836065852804495e-08
also O 0 3.824559335896538e-09
excluded O 0 3.7694323218318004e-09
as O 0 4.6250939189640405e-10
candidate O 0 3.882392740628404e-10
genes O 0 4.749463600184356e-10
for O 0 1.086425061025409e-09
CT B-Disease 0 0.01004912331700325
since O 0 5.701112471001579e-08
they O 0 3.2833520346997602e-09
both O 0 5.389595880700426e-09
mapped O 0 6.599922386385515e-08
to O 0 3.1287822110925845e-08
canine O 0 4.51302048531943e-06
chromosome O 0 2.04969319383963e-06
region O 0 2.6738173346529948e-06
CFA11q22 O 0 0.0019232770428061485
. O 0 6.914706318639219e-06

2 O 0 1.1799756975960918e-05
- O 0 6.7215456510894e-05
22 O 0 1.1478220585559029e-05
. O 0 4.238600467942888e-06

5 O 0 9.808798495214432e-05
. O 0 2.3841404981794767e-05

A O 0 3.251322482356045e-07
transcribed O 0 9.718175419948238e-08
sequence O 0 7.80266184996492e-10
identified O 0 2.4580761870396373e-09
from O 0 4.394329067292091e-10
the O 0 1.2921810288446522e-09
C04107 O 0 5.201765702622652e-07
- O 0 4.48231176619629e-08
containing O 0 1.0143224926650873e-08
BAC O 0 9.273586556446389e-07
was O 0 2.484054739682051e-09
found O 0 9.016710295073338e-11
to O 0 3.7748970616036104e-11
be O 0 6.278503411616398e-11
homologous O 0 6.236363647715848e-10
to O 0 3.5989361490962324e-10
a O 0 2.4158901545945355e-09
gene O 0 7.327745521479301e-09
expressed O 0 1.2415531935872082e-09
from O 0 1.8181569583219925e-09
human O 0 1.5563449418110054e-09
chromosome O 0 6.343135350306284e-09
2p13 O 0 2.644491701175866e-07
- O 0 1.1907161479030037e-07
p16 O 0 9.739440542944067e-08
, O 0 5.16167331099382e-10
a O 0 3.4974287355105105e-10
region O 0 1.4351839716653103e-09
devoid O 0 1.7324447654232245e-08
of O 0 6.590217260793452e-10
any O 0 3.2274935501952484e-10
positional O 0 8.837736800160201e-07
candidate O 0 2.0958870550202846e-07
genes O 0 2.1453624299283547e-07
. O 0 1.0737662705651019e-06

Molecular O 0 1.2134323412738013e-07
analysis O 0 4.097560957205815e-09
of O 0 2.9893665320912532e-09
the O 0 3.287375038851792e-09
APC B-Disease 0 7.974825422252252e-08
gene O 0 1.8891495034978334e-09
in O 0 8.827824027335396e-10
205 O 0 1.3854205782592999e-08
families O 0 1.1034370084317402e-09
: O 0 1.2593908138569532e-09
extended O 0 6.421986142868263e-08
genotype O 0 1.37767671049005e-07
- O 0 5.784102654615708e-07
phenotype O 0 1.9171734422229747e-08
correlations O 0 3.5757703464867063e-09
in O 0 1.7609009805852338e-09
FAP B-Disease 0 4.078257731521262e-08
and O 0 3.8869640839322983e-10
evidence O 0 9.049623272971985e-10
for O 0 1.2666027948693426e-10
the O 0 5.77169922966192e-10
role O 0 5.484168230651676e-09
of O 0 4.191295488453761e-08
APC B-Disease 0 2.6597936653161014e-07
amino O 0 1.606953503596742e-08
acid O 0 2.8664372209163957e-08
changes O 0 5.377399858730314e-08
in O 1 0.7064194679260254
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
predisposition O 1 0.9999982118606567
. O 0 1.231159876624588e-05

BACKGROUND O 0 4.8959878768073395e-05
/ O 0 1.0505410500627477e-05
AIMS O 0 4.771205226461461e-07
The O 0 3.2769205127181067e-09
development O 0 1.5425177579686533e-08
of O 0 0.00016374267579521984
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 3.3998754922492935e-09
a O 0 3.1806454692251407e-10
variable O 0 9.492828745294446e-10
range O 0 2.44284392714178e-09
of O 0 2.8687874298327642e-09
extracolonic O 0 1.6134988527483074e-06
manifestations O 0 5.644249085889896e-07
in O 0 4.77193282222288e-07
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 0 1.438753685079064e-07
FAP B-Disease 0 1.3944202237325953e-06
) O 0 2.022520345645873e-10
is O 0 1.8909427842994653e-11
the O 0 3.2809324701510434e-11
result O 0 1.2137385541066692e-10
of O 0 2.6628068638956393e-09
the O 0 4.3152263984325145e-09
dominant O 0 1.999416809894683e-08
inheritance O 0 6.633669045186252e-07
of O 0 6.166518869576976e-05
adenomatous B-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 0.9999996423721313
( O 0 7.342971031221168e-08
APC B-Disease 0 4.847930767937214e-07
) O 0 1.6517740064614372e-08
gene O 0 6.367697125142513e-08
mutations O 0 3.380430939614598e-07
. O 0 5.977740329399239e-06

In O 0 1.6707282668448897e-08
this O 0 4.5803216774942257e-10
study O 0 5.295701654972618e-10
, O 0 1.521567073725638e-11
direct O 0 9.233917103168565e-11
mutation O 0 2.9301634035805435e-11
analysis O 0 1.0969438551944322e-10
of O 0 5.118945822779608e-10
the O 0 2.518951047747464e-09
APC B-Disease 0 7.421171233090718e-08
gene O 0 4.8275730080149515e-09
was O 0 2.010890476356053e-08
performed O 0 4.03272863991333e-08
to O 0 2.868245640996747e-09
determine O 0 2.737353677062515e-09
genotype O 0 3.9181490052442314e-08
- O 0 3.077359735925711e-07
phenotype O 0 2.0922717780536004e-08
correlations O 0 7.025337200872173e-09
for O 0 2.544316313191075e-09
nine O 0 1.6479976494565562e-08
extracolonic O 0 3.9889178538032866e-07
manifestations O 0 2.234645535281743e-08
and O 0 3.477301224741325e-10
to O 0 5.571377803548216e-10
investigate O 0 1.0197418465196506e-09
the O 0 1.97000282753379e-09
incidence O 0 2.4346616100956453e-07
of O 0 7.101417054400372e-08
APC B-Disease 0 2.816730386712152e-07
mutations O 0 4.693256006049751e-09
in O 0 4.6565393319042414e-08
non O 1 1.0
- O 1 1.0
FAP O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.00010316348925698549

METHODS O 0 1.0230805855826475e-05
The O 0 3.507333588004258e-07
APC B-Disease 0 3.1233109893946676e-06
gene O 0 6.115793382832635e-08
was O 0 1.1375890807130418e-07
analysed O 0 5.608840325521669e-08
in O 0 1.796751969429522e-09
190 O 0 1.677577721181933e-08
unrelated O 0 8.79643202722491e-09
FAP B-Disease 0 1.1083167095193858e-07
and O 0 1.4491021715912211e-09
15 O 0 2.2489382445201045e-07
non O 1 0.9999709129333496
- O 1 1.0
FAP O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 1.6858456319823745e-06
using O 0 2.315129954411077e-08
denaturing O 0 1.2055879778927192e-06
gradient O 0 7.345744990061576e-08
gel O 0 1.1345662187522976e-07
electrophoresis O 0 1.5951810539149847e-08
, O 0 1.1083475248696573e-09
the O 0 1.6015152537462995e-09
protein O 0 9.73686908878335e-10
truncation O 0 7.421567715937272e-08
test O 0 2.7673077163115067e-09
, O 0 4.491027827402405e-10
and O 0 8.142226337604086e-10
direct O 0 2.5762886934899143e-08
sequencing O 0 2.424105787213193e-07
. O 0 7.178235250648868e-07

RESULTS O 0 1.8599062059365679e-06
Chain O 0 2.0266124067802593e-07
terminating O 0 4.296552802429687e-08
signals O 0 6.924447149003754e-08
were O 0 5.7004569953278406e-09
only O 0 5.825950277760228e-10
identified O 0 1.0287379836881883e-09
in O 0 3.389488134608598e-10
patients O 0 1.9251753524685e-09
belonging O 0 8.389592354163256e-10
to O 0 7.374854060770986e-10
the O 0 1.1455697723761205e-08
FAP B-Disease 0 1.9994299691461492e-06
group O 0 2.3229855372619568e-08
( O 0 4.8104951133609575e-09
105 O 0 2.5850854399322998e-06
patients O 0 1.2554507975437446e-06
) O 0 4.888722315854466e-08
. O 0 1.4088767557041137e-06

Amino O 0 3.208121484021831e-07
acid O 0 1.6714071904289085e-08
changes O 0 3.8933081758507626e-10
were O 0 1.0481501222514567e-09
identified O 0 7.465516538296413e-10
in O 0 8.415695224028852e-11
four O 0 3.4489247568991743e-10
patients O 0 4.1821796026297875e-10
, O 0 9.025206797186325e-12
three O 0 2.2844519678710817e-11
of O 0 7.860199713327631e-10
whom O 0 2.9217501751332975e-09
belonged O 0 1.45890169278573e-07
to O 0 5.0568602638634275e-09
the O 0 1.1760551643646977e-07
non O 1 0.9999804496765137
- O 0 0.09054054319858551
FAP O 0 8.673132106196135e-05
group O 0 2.378949943704356e-07
of O 0 0.004927963018417358
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 1 0.9999810457229614
. O 0 2.0431552911759354e-06

Genotype O 0 5.901637632632628e-05
- O 0 2.8110891435062513e-05
phenotype O 0 3.613874071106693e-07
correlations O 0 2.981828473025416e-08
identified O 0 3.491112732234569e-09
significant O 0 1.2046428299328227e-09
differences O 0 4.556689747747811e-10
in O 0 3.667504910875863e-10
the O 0 6.17244866329969e-10
nature O 0 5.719142381899189e-10
of O 0 1.5535984720926876e-09
certain O 0 3.8128109558499546e-09
extracolonic O 0 4.272207206668099e-06
manifestations O 0 1.5671504627334798e-07
in O 0 5.585809148556109e-09
FAP B-Disease 0 9.34474257974216e-07
patients O 0 2.1708348896254392e-08
belonging O 0 3.675833415428542e-09
to O 0 2.8355164882754025e-09
three O 0 1.6080297982057346e-08
mutation O 0 1.393846957853384e-07
subgroups O 0 1.2363157111394685e-06
. O 0 6.612566494368366e-07

CONCLUSIONS O 0 1.3775343177258037e-05
Extended O 0 1.2213262152727111e-06
genotype O 0 2.290644033564604e-06
- O 0 9.360681474390731e-07
phenotype O 0 3.069038356784404e-08
correlations O 0 6.812437280956374e-09
made O 0 6.06072192432805e-10
in O 0 1.247413006222331e-10
this O 0 3.00724029012045e-11
study O 0 1.0973854464024768e-10
may O 0 3.2133216226748473e-11
have O 0 9.791239000134233e-12
the O 0 3.824460539925134e-11
potential O 0 6.006607711217526e-11
to O 0 1.0552908547012407e-10
determine O 0 8.735833723072517e-10
the O 0 1.2328996712440699e-09
most O 0 8.372598725436831e-10
appropriate O 0 8.862109268648055e-09
surveillance O 0 4.1473199985375686e-07
and O 0 5.365215827168868e-09
prophylactic O 0 0.02541649341583252
treatment O 0 1.2063241001669667e-06
regimens O 0 5.2864024269183574e-08
for O 0 3.3797015186465273e-10
those O 0 2.518219799352295e-10
patients O 0 7.473865415441594e-10
with O 0 6.7545925450107624e-12
mutations O 0 2.8196053825091383e-10
associated O 0 9.446770032894847e-10
with O 0 1.2042011832136268e-10
life O 0 7.193985140929726e-08
threatening O 0 8.505819693027661e-08
conditions O 0 7.416388712044863e-07
. O 0 1.1638949217740446e-06

This O 0 2.51600411615982e-08
study O 0 1.4853134722159211e-08
also O 0 3.592167396870849e-10
provided O 0 5.864737584460045e-10
evidence O 0 3.1787289467288815e-10
for O 0 1.3680698240925437e-10
the O 0 1.0415496243254552e-09
pathological O 0 1.371823969975594e-07
nature O 0 1.276469152600157e-09
of O 0 1.5233923011948036e-09
amino O 0 1.696759177605145e-09
acid O 0 2.4728039615951047e-09
changes O 0 6.228493831805793e-10
in O 0 3.1600391192654342e-09
APC O 0 2.0368233322187734e-07
associated O 0 2.9492145614540277e-08
with O 0 2.0411415613263983e-10
both O 0 5.407388314893069e-09
FAP B-Disease 0 3.9097213289096544e-07
and O 0 1.8061296458427023e-08
non O 1 0.9999978542327881
- O 1 1.0
FAP O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 3.82334110327065e-05
. O 0 1.0353387480677156e-08
. O 0 6.190789036963906e-08

Inherited B-Disease 1 1.0
colorectal I-Disease 1 1.0
polyposis I-Disease 1 1.0
and O 0 2.5465067665209062e-05
cancer B-Disease 1 0.9865191578865051
risk O 0 2.1429310947951308e-07
of O 0 2.2169513158587506e-07
the O 0 7.939672741485992e-07
APC O 0 3.221758015570231e-05
I1307K O 0 0.000591280753724277
polymorphism O 0 1.4416394151339773e-05
. O 0 3.025514160981402e-06

Germ O 0 0.0014812849694862962
- O 0 1.413559220964089e-05
line O 0 2.6449660595062596e-07
and O 0 5.4410538297133826e-09
somatic O 0 3.2946209671536053e-07
truncating O 0 1.5030174438379618e-07
mutations O 0 2.594809922484842e-09
of O 0 5.4051714215574975e-09
the O 0 1.298288854201246e-08
APC B-Disease 0 1.7165014298825554e-07
gene O 0 4.943714770888619e-09
are O 0 6.178043632232288e-10
thought O 0 9.060267203153671e-09
to O 0 6.856864409598984e-09
initiate O 0 4.132319645577809e-06
colorectal B-Disease 1 1.0
tumor I-Disease 1 0.6323586702346802
formation O 0 2.541994945204351e-06
in O 0 1.7743324178809416e-06
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
syndrome I-Disease 1 1.0
and O 0 2.2592507775698323e-06
sporadic O 1 0.9999963045120239
colorectal O 1 1.0
carcinogenesis O 1 1.0
, O 0 0.00013388198567554355
respectively O 0 7.67653837101534e-05
. O 0 3.7460554267454427e-06

Recently O 0 1.0184282928094035e-06
, O 0 9.421905922124552e-09
an O 0 1.3487089223218618e-09
isoleucine O 0 1.576015733917302e-06
- O 0 7.962610766298894e-07
- O 0 1.0689304872357752e-06
> O 0 1.0365776006437954e-06
lysine O 0 4.794961583343138e-08
polymorphism O 0 1.8928220768543724e-08
at O 0 2.6319548762643308e-09
codon O 0 5.355096988068908e-08
1307 O 0 2.033876171481097e-06
( O 0 1.3433079537605863e-08
I1307K O 0 2.1278744952724082e-06
) O 0 1.5526919749930812e-09
of O 0 6.269451180429542e-09
the O 0 1.0512700043818768e-08
APC B-Disease 0 5.168333245819667e-07
gene O 0 8.804589057831436e-09
has O 0 9.287259850054852e-11
been O 0 5.57422406843866e-11
identified O 0 1.1397016663750037e-10
in O 0 4.7097870742307535e-11
6 O 0 8.116801453184053e-09
% O 0 3.2317007403470654e-10
- O 0 5.2274229389581706e-09
7 O 0 9.15027964509818e-09
% O 0 2.8206273428033057e-10
of O 0 4.5020054351141425e-10
the O 0 1.0246550274928268e-09
Ashkenazi O 0 1.9945971985180222e-07
Jewish O 0 8.31569479942118e-08
population O 0 6.935808594121795e-10
. O 0 1.4406809079048344e-08

To O 0 7.228369724998629e-08
assess O 0 1.8653332745088846e-07
the O 0 5.864729590854267e-09
risk O 0 1.7833382770504613e-08
of O 0 2.7805242552858545e-09
this O 0 3.1598385019648845e-10
common O 0 6.341247971164421e-09
APC B-Disease 0 1.1851332715195895e-07
allelic O 0 1.5426010691044212e-07
variant O 0 4.1580841525501455e-07
in O 0 5.444565687184877e-08
colorectal O 1 1.0
carcinogenesis O 1 1.0
, O 0 1.6346801245958886e-08
we O 0 2.183257796772864e-09
have O 0 2.687439715209905e-10
analyzed O 0 9.900072983626274e-10
a O 0 2.124512926693356e-10
large O 0 8.484422608923126e-10
cohort O 0 3.9187628431136545e-07
of O 0 1.8570283089047734e-07
unselected O 0 7.849236862966791e-05
Ashkenazi O 0 5.172685632715002e-06
Jewish O 0 1.766038906225731e-07
subjects O 0 2.324772623296667e-07
with O 0 2.579719549089532e-09
adenomatous B-Disease 1 0.9930360913276672
polyps I-Disease 0 3.858798663713969e-05
and O 0 4.192156843885186e-09
. O 0 8.539924323258674e-08
or O 1 0.9999984502792358
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, I-Disease 0 1.2988585318396417e-08
for O 0 3.897820732845503e-09
the O 0 4.654150842497984e-08
APC O 0 3.886404556396883e-06
I1307K O 0 0.00010109165305038914
polymorphism O 0 9.166016752715223e-06
. O 0 2.1487564936251147e-06

The O 0 5.15101601195056e-06
APC O 0 3.1910276447888464e-05
I1307K O 0 3.2586925954092294e-05
allele O 0 1.1035747604637436e-07
was O 0 8.001607376684206e-09
identified O 0 1.811054750611163e-09
in O 0 2.828903222784618e-10
48 O 0 3.507705681471407e-09
( O 0 1.3688920830201567e-10
10 O 0 4.0750888774532257e-10
. O 0 6.60039106703536e-11
1 O 0 3.946784232766731e-09
% O 0 3.1910665776457847e-10
) O 0 3.5045072399597643e-10
of O 0 2.385313502273334e-09
476 O 0 5.507152422978834e-07
patients O 0 2.701411574435042e-07
. O 0 4.7212887466230313e-07

Compared O 0 1.287087592061198e-08
with O 0 4.310820797548409e-11
the O 0 1.6872316044302949e-10
frequency O 0 1.4488091837350225e-09
in O 0 2.7667769117445395e-11
two O 0 8.88955489081189e-12
separate O 0 1.6222658633102682e-11
population O 0 3.27397939488272e-12
control O 0 1.4250578495023092e-10
groups O 0 7.735413004583691e-11
, O 0 3.888247224193009e-10
the O 0 8.865861822471288e-09
APC O 0 2.063290367004811e-06
I1307K O 0 1.1503907444421202e-05
allele O 0 1.3122353870187453e-08
is O 0 4.0722664823578114e-11
associated O 0 1.256429543738946e-10
with O 0 3.034862508868863e-12
an O 0 7.670294954742474e-12
estimated O 0 1.5400403174936628e-11
relative O 0 2.2938535793048942e-10
risk O 0 9.598316585979205e-10
of O 0 4.599952418971043e-09
1 O 0 3.279397105870885e-06
. O 0 4.822707069251919e-06

5 O 0 6.122754712123424e-06
- O 0 2.0187653717584908e-05
1 O 0 1.97763856704114e-05
. O 0 7.213086973933969e-06

7 O 0 3.552134103301796e-06
for O 0 4.5944744897497003e-07
colorectal B-Disease 1 1.0
neoplasia I-Disease 1 1.0
( O 0 4.5766498146804224e-07
both O 0 3.383510360777109e-08
P O 0 1.2883054978374275e-06
= O 0 9.108769205568024e-08
. O 0 8.385037553182428e-09
01 O 0 1.7393152802469558e-06
) O 0 3.659954472823301e-08
. O 0 3.893765949669614e-07

Furthermore O 0 9.071584941011679e-07
, O 0 7.212130448408516e-09
compared O 0 1.8706549642644177e-09
with O 0 2.620452743684609e-10
noncarriers O 0 1.3345250408747233e-05
, O 0 3.381510182975944e-08
APC O 0 9.62712647378794e-07
I1307K O 0 3.0389610401471145e-06
carriers O 0 1.053425702224331e-08
had O 0 9.976920400944778e-10
increased O 0 3.9292510911614897e-10
numbers O 0 8.042027044297129e-10
of O 0 5.6562252659375645e-09
adenomas B-Disease 1 0.9999990463256836
and O 0 1.1395068213460036e-05
colorectal B-Disease 1 1.0
cancers I-Disease 1 1.0
per O 0 2.4705337864361354e-07
patient O 0 4.797413453161425e-07
( O 0 1.9949779606065476e-09
P O 0 1.6811083014545147e-07
= O 0 1.4163825667878882e-08
. O 0 6.907530103461568e-10
03 O 0 1.188889271475091e-07
) O 0 2.484129568713911e-10
, O 0 7.695620529712954e-11
as O 0 4.229353672835501e-11
well O 0 1.0841599840105687e-10
as O 0 9.86698431293398e-11
a O 0 4.3896128398834833e-10
younger O 0 4.170241485468296e-09
age O 0 4.030834777069003e-09
at O 0 4.0399267930979477e-08
diagnosis O 0 7.629157607880188e-06
. O 0 6.152890250632481e-07

We O 0 4.4042177904657365e-08
conclude O 0 2.406390819942317e-07
that O 0 2.588077974152725e-09
the O 0 1.4616555077395788e-08
APC O 0 3.393203087398433e-06
I1307K O 0 3.1782419682713225e-05
variant O 0 6.280287834670162e-06
leads O 0 2.1705286457063266e-08
to O 0 1.6480848907818313e-09
increased O 0 2.0574728409883392e-07
adenoma B-Disease 1 1.0
formation O 0 2.7522867185325595e-07
and O 0 6.550254227910557e-10
directly O 0 2.846232971531748e-10
contributes O 0 1.2395531823194972e-10
to O 0 1.8834772283482515e-11
3 O 0 8.580407495628606e-10
% O 0 1.2513735880848031e-10
- O 0 4.630039018849175e-09
4 O 0 7.264441048704384e-09
% O 0 3.813259707996508e-10
of O 0 6.984795519748843e-10
all O 0 1.2858649700575597e-09
Ashkenazi O 0 1.0881170965149067e-05
Jewish O 0 0.0007357905269600451
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.3778220818494447e-05

The O 0 4.888013549475545e-08
estimated O 0 4.547575205293697e-09
relative O 0 1.5712711132209733e-08
risk O 0 4.345265036675983e-09
for O 0 2.5089955113521967e-10
carriers O 0 4.4199359727770116e-09
may O 0 1.6479591025131413e-09
justify O 0 1.0570606612247957e-08
specific O 0 1.4738318898643854e-10
clinical O 0 6.401728591676203e-10
screening O 0 1.881912681245268e-10
for O 0 5.90755361296047e-11
the O 0 2.124253689617106e-10
360 O 0 7.58678808665536e-09
, O 0 2.2136063815292317e-10
000 O 0 6.210205238943445e-09
Americans O 0 6.229943783075953e-10
expected O 0 2.574340740579828e-10
to O 0 3.0127075834052164e-10
harbor O 0 5.602179342645286e-08
this O 0 8.466705114784645e-10
allele O 0 3.8161429571914596e-09
, O 0 1.455011805484574e-10
and O 0 1.9635382209060026e-10
genetic O 0 5.316306839198148e-10
testing O 0 8.970874043612298e-11
in O 0 8.240930507441568e-12
the O 0 4.474386833264177e-11
setting O 0 7.957465797403529e-10
of O 0 2.654134689805687e-10
long O 0 1.0782454790136953e-10
- O 0 1.3893998174197009e-09
term O 0 3.2478242317779404e-09
- O 0 2.220745809466962e-09
outcome O 0 2.945181043489953e-10
studies O 0 3.1838137681816647e-10
may O 0 4.0751412661022e-11
impact O 0 4.4529174791918535e-10
significantly O 0 1.7245454841940955e-08
on O 0 0.00024328760628122836
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
prevention O 0 0.000278642401099205
in O 0 6.121623208343863e-10
this O 0 3.73159614319718e-10
population O 0 6.858875689630395e-10
. O 0 3.38747518924265e-08

Localization O 0 2.18552268052008e-05
of O 0 1.8559467207523994e-07
human O 0 2.1689972484750797e-08
BRCA1 O 0 2.919284014524237e-08
and O 0 4.1699291242203174e-10
its O 0 2.3014178063274215e-10
loss O 0 4.373385653622108e-09
in O 0 1.346513789357573e-09
high O 0 3.134259074499823e-08
- O 0 5.1822759417063935e-08
grade O 0 8.372062438866124e-07
, O 0 8.232145631836829e-09
non B-Disease 0 0.10017474740743637
- I-Disease 1 0.9998618364334106
inherited I-Disease 1 1.0
breast I-Disease 1 1.0
carcinomas I-Disease 1 1.0
. O 0 0.01102360524237156

Although O 0 7.248790012681638e-08
the O 0 5.9539160268684554e-09
link O 0 2.6949571463319444e-08
between O 0 6.847346023519663e-10
the O 0 9.448792859245714e-09
BRCA1 O 0 5.289529667606985e-07
tumour B-Disease 1 1.0
- O 0 7.384420769085409e-06
suppressor O 0 0.009409620426595211
gene O 0 9.169063730496418e-08
and O 0 7.367592047557991e-08
hereditary B-Disease 1 1.0
breast I-Disease 1 1.0
and I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
is O 0 5.277997150443525e-09
established O 0 1.2859655562635908e-09
, O 0 3.7001190306140685e-11
the O 0 3.6832550898147076e-11
role O 0 1.5629958438623248e-10
, O 0 5.1490249564078994e-11
if O 0 3.594585046284848e-11
any O 0 3.514494528733536e-10
, O 0 8.339671730972498e-10
of O 0 1.3002565246722497e-08
BRCA1 O 0 9.300141101675763e-08
in O 0 1.635540947120262e-08
non B-Disease 1 0.9992675185203552
- I-Disease 1 0.9923700094223022
familial I-Disease 0 0.00022994127357378602
cancers I-Disease 1 0.9999921321868896
is O 0 2.100211338174063e-09
unclear O 0 4.380876816867385e-08
. O 0 1.677437495573031e-07

BRCA1 O 0 9.571464033797383e-05
mutations O 0 2.9466966111613146e-07
are O 0 2.443593993817217e-09
rare O 0 2.1404021666171502e-08
in O 0 3.3443001701272124e-09
sporadic B-Disease 0 1.26034751701809e-06
cancers I-Disease 0 9.03500313143013e-06
, O 0 3.802829717791667e-10
but O 0 2.5001958836590177e-10
loss O 0 1.6937724112153774e-08
of O 0 5.577869046646811e-07
BRCA1 O 0 6.60507311067704e-08
resulting O 0 1.8713508520562527e-09
from O 0 2.961093314990393e-10
reduced O 0 3.039460905185365e-09
expression O 0 3.247589086541325e-09
or O 0 1.229595536500483e-09
incorrect O 0 1.2396489168509106e-08
subcellular O 0 2.0701342862139427e-07
localization O 0 1.1176342695762287e-06
is O 0 3.4268077264698604e-10
postulated O 0 6.452790302091671e-09
to O 0 1.863794674150654e-10
be O 0 2.3175530938779332e-10
important O 0 9.10742370408002e-10
in O 0 1.8406276502958008e-09
non B-Disease 1 0.6349637508392334
- I-Disease 1 0.9998992681503296
familial I-Disease 1 1.0
breast I-Disease 1 1.0
and I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancers I-Disease 1 1.0
. O 1 1.0

Epigenetic O 0 4.337108111940324e-05
loss O 0 1.4755568145119469e-06
, O 0 7.2324359834397e-09
however O 0 1.2931328230436634e-09
, O 0 2.0197755967732434e-10
has O 0 3.6741456231614844e-12
not O 0 1.878489551410123e-12
received O 0 3.185925828708136e-11
general O 0 3.1168184699836843e-10
acceptance O 0 4.199887548850256e-09
due O 0 1.1018869150447586e-09
to O 0 6.338294333829708e-10
controversy O 0 1.1606301475453051e-09
regarding O 0 1.6610300912489606e-09
the O 0 8.092496117662051e-10
subcellular O 0 2.2768327312405745e-07
localization O 0 2.8511178697954165e-06
of O 0 4.3647212066844077e-08
BRCA1 O 0 2.195862869314169e-08
proteins O 0 1.6694842730480275e-10
, O 0 1.3087571304470913e-10
reports O 0 1.1811282507601106e-10
of O 0 1.922444287094649e-10
which O 0 2.2195452073492383e-11
have O 0 1.249946500470056e-11
ranged O 0 1.3491282535582627e-09
from O 0 2.0407318196413726e-11
exclusively O 0 1.2465567467145888e-10
nuclear O 0 3.3517908448743583e-09
, O 0 3.1935326605392333e-10
to O 0 6.019203468987655e-10
conditionally O 0 1.2914821212461902e-08
nuclear O 0 2.88667152403832e-08
, O 0 1.4966652361891875e-09
to O 0 2.065880577717394e-09
the O 0 1.582100317421009e-08
ER O 0 0.0003385863674338907
/ O 0 2.0602190488716587e-05
golgi O 0 3.32864947267808e-05
, O 0 3.018985950120623e-08
to O 0 1.78300503250739e-08
cytoplasmic O 0 5.398631230946194e-08
invaginations O 0 2.83354211205733e-06
into O 0 2.314617830734278e-08
the O 0 2.919696129310978e-08
nucleus O 0 8.424747193203075e-07
. O 0 1.8040744862446445e-06

In O 0 1.0570767372541923e-08
an O 0 5.363811061975809e-10
attempt O 0 9.198839023838445e-09
to O 0 1.0167704456165438e-09
resolve O 0 3.1507887410242574e-09
this O 0 3.4275590699017755e-10
issue O 0 4.283376764391278e-09
, O 0 3.2768815438899423e-10
we O 0 8.530815498453137e-10
have O 0 6.971725419191444e-10
comprehensively O 0 5.789953050339136e-08
characterized O 0 2.5787516122477427e-08
19 O 0 2.1280196449424693e-07
anti O 0 5.4740826271881815e-06
- O 0 4.1273793613072485e-05
BRCA1 O 0 1.980990873562405e-06
antibodies O 0 1.9589097632888297e-07
. O 0 1.6090212966446416e-06

These O 0 9.357042785040903e-08
reagents O 0 1.3520549373424728e-06
detect O 0 1.56783954707862e-07
a O 0 7.861553186216952e-09
220 O 0 3.695081929322441e-08
- O 0 1.5366309469300177e-07
kD O 0 1.3633248272526544e-06
protein O 0 6.94407154000487e-09
localized O 0 2.123955944455247e-08
in O 0 1.3495015105391417e-09
discrete O 0 1.024882312350428e-08
nuclear O 0 3.5634764117276063e-07
foci O 0 1.6199484207390924e-06
in O 0 9.03462371582009e-09
all O 0 5.174845441047182e-09
epithelial O 0 2.9786333470838144e-06
cell O 0 5.982457196296309e-07
lines O 0 5.213224518740844e-09
, O 0 2.7830696081032613e-10
including O 0 2.2933460686047624e-10
those O 0 3.0251853799789785e-10
derived O 0 2.3296589546362156e-08
from O 0 6.658133600012661e-08
breast B-Disease 0 9.570596012054011e-05
malignancies I-Disease 0 0.0003243922255933285
. O 0 3.0282769785117125e-06

Immunohistochemical O 0 0.00045604584738612175
staining O 0 1.2985041394131258e-05
of O 0 3.368700163264293e-07
human O 0 2.2588193360206787e-07
breast O 0 9.539758138998877e-06
specimens O 0 1.637003776977508e-07
also O 0 6.128262342031121e-09
revealed O 0 2.1949750461658368e-08
BRCA1 O 0 1.3295692724568653e-07
nuclear O 0 4.24999507231405e-06
foci O 0 0.00019944577070418745
in O 0 1.4225820450519677e-06
benign O 1 1.0
breast O 1 1.0
, O 0 1.561905628477689e-05
invasive B-Disease 1 1.0
lobular I-Disease 1 1.0
cancers I-Disease 1 0.9999996423721313
and O 0 1.244761620000645e-06
low B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
grade I-Disease 1 1.0
ductal I-Disease 1 1.0
carcinomas I-Disease 1 1.0
. O 0 0.0001325316698057577

Conversely O 0 1.794366198737407e-06
, O 0 3.449665086918685e-08
BRCA1 O 0 1.2566277973746764e-07
expression O 0 7.876141516760526e-09
was O 0 3.8647147704296e-09
reduced O 0 4.223263516678344e-09
or O 0 1.4775027867841573e-09
undetectable O 0 3.260954528627735e-08
in O 0 8.21270620954273e-11
the O 0 1.828498741307527e-10
majority O 0 3.2115567150103885e-11
of O 0 6.604046753899695e-10
high O 0 2.7928994228432202e-08
- O 0 4.4805767629441107e-07
grade O 0 0.00027758016949519515
, O 0 4.3907897406825214e-07
ductal B-Disease 1 1.0
carcinomas I-Disease 1 1.0
, O 0 3.4613092392277167e-09
suggesting O 0 1.7524909301513958e-09
that O 0 1.7248258377122738e-11
absence O 0 1.793978299247101e-09
of O 0 7.201422569380611e-09
BRCA1 O 0 2.541722388116341e-08
may O 0 5.726346619105982e-10
contribute O 0 1.0316559828638106e-09
to O 0 4.3400863458664674e-10
the O 0 3.4732727804964725e-09
pathogenesis O 0 0.09873083233833313
of O 0 7.038105209744572e-09
a O 0 4.960373778395422e-10
significant O 0 1.5897677618781358e-09
percentage O 0 6.707780109138639e-09
of O 0 1.2154772299766137e-08
sporadic B-Disease 0 0.0001592067419551313
breast I-Disease 1 0.999991774559021
cancers I-Disease 1 0.99997878074646
. O 0 3.6280880522099324e-06
. O 0 9.44457406149013e-06

